Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download American Society of Clinical Oncology 47th Annual Meeting
Document related concepts
no text concepts found
Transcript
American Society of Clinical Oncology 47th Annual Meeting Meeting Program Note: Sessions in which Special Awards are presented are shaded in gray Friday, June 3, 2011 FRIDAY 1:00 PM - 2:15 PM EDUCATION SESSIONS Customized Cancer Treatment: A Systems Biology Approach to Drug Selection Location: E354b CME credit: 1.25 Track(s): Developmental Therapeutics, Cancer Genetics, Clinical Trials John Mendelsohn, MD—Chair University of Texas M. D. Anderson Cancer Center Customized Cancer Medicine: Are We Ready for What It Will Take? Jeffrey M. Trent, PhD TGen Large-scale, Multidimensional Genomics Data: Making Sense for Patients Andrea Califano, PhD Columbia University Cancer’s Complexity: Are We Looking at the Wrong Levels to Develop Effective Interventions? Endometrial Cancer: Present State and Future Promise Location: E354a CME credit: 1.25 Track(s): Gynecologic Cancer Don S. Dizon, MD—Chair Warren Alpert Medical School of Brown University Options in the Treatment of Relapsed Endometrial Cancer: Beyond First-line Therapy Karen H. Lu, MD University of Texas M. D. Anderson Cancer Center Molecular Characterization of Endometrial Cancer: Going beyond Histology David Scott Miller, MD University of Texas Southwestern Medical Center Incorporation of Adjuvant Chemotherapy into Endometrial Cancer Treatment Neoadjuvant Therapy in Operable Breast Cancer: Who, What, When, Why, and How? Location: Hall D1 CME credit: 1.25 Track(s): Breast Cancer Luca Gianni, MD—Chair Fondazione IRCCS Istituto Nazionale dei Tumori Neoadjuvant Assumptions and Application to Chemotherapy, Endocrine Therapy, and Biologic Therapy-based Regimens David W. Ollila, MD University of North Carolina at Chapel Hill Surgical Implications of the Neoadjuvant Approach: Facilitating Research Biopsies, Breast Conservation in Previously T3– 4 Tumors, and Axillary Staging—Before or After? Thomas A. Buchholz, MD University of Texas M. D. Anderson Cancer Center Radiation in the Setting of Marked Cytoreduction: Do We Radiate a Cleared Nodal Basin or Breast? 58 Friday, June 3, 2011 FRIDAY Pediatric Bone Sarcomas: Converging Progress on the Biologic and Clinical Fronts? Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology, Sarcoma Stephen L. Lessnick, MD, PhD—Chair Huntsman Cancer Institute Recent Progress in Understanding the Biology of Bone Tumors Holcombe E. Grier, MD Dana-Farber Cancer Institute Advances in the Treatment of Ewing’s Sarcoma Neyssa Marina, MD Stanford University School of Medicine Update on the Management of Children, Adolescents, and Young Adults with Osteosarcoma Radiation Therapy Updates for Primary Brain Tumors: Clinical Role for Proton Therapy, Stereotactic Radiosurgery, and Hypofractionated Schedules Location: S100bc CME credit: 1.25 Track(s): Central Nervous System Tumors John H. Suh, MD—Chair Cleveland Clinic Radiosurgery Applications for Primary Brain Tumors Eugen Hug, MD Paul Scherrer Institut Proton Therapy for Primary Brain Tumors: When to Refer Eric L. Chang, MD University of Texas M. D. Anderson Cancer Center Abbreviated Course of Radiation Therapy in Older Patients with Glioblastoma Survivorship Care: Whose Job Is It? Location: S406 CME credit: 1.25 Track(s): Patient and Survivor Care, Health Services Research Julia Howe Rowland, PhD—Chair National Cancer Institute/National Institutes of Health Overview of This Emerging Challenge in Survivors’ Care Paul Han, MD, MA, MPH Maine Medical Center Research Institute Presentation of Data from the National Cancer Institute– and American Cancer Society–funded Study: Survey of Physician Attitudes Regarding Care of Cancer Survivors James Ross Waisman, MD Breastlink Medical Group Inc. How to Implement Survivorship Care in Practice 59 Friday, June 3, 2011 FRIDAY The Identification and Treatment of the “High Risk” Patient with Non-Hodgkin Lymphoma and Myeloma Location: Arie Crown Theater CME credit: 1.25 Track(s): Lymphoma and Plasma Cell Disorders Francine M. Foss, MD—Chair Yale Cancer Center High-risk Peripheral T-cell Lymphoma Michael Pfreundschuh, MD Saarland University Hospital High-risk B-cell Non-Hodgkin Lymphoma Rafael Fonseca, MD Mayo Clinic High-risk Myeloma 60 Friday, June 3, 2011 FRIDAY 1:00 PM - 2:15 PM MEET THE PROFESSOR SESSION Implementing a Quality Research Program in a Community Setting (M05)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Clinical Trials, Practice Management and Information Technology, Professional Development Patrick J. Flynn, MD Metro Minnesota Community Clinical Oncology Project Practical Aspects of Clinical Trial Implementation in the Community Setting Lidia Schapira, MD Massachusetts General Hospital Talking to Patients about Clinical Trials 61 Friday, June 3, 2011 FRIDAY 1:00 PM - 3:15 PM EXTENDED EDUCATION SESSIONS How to Participate in Clinical Research across Borders Location: S100a CME credit: 2.25 Track(s): Clinical Trials, International Eduardo L. Cazap, MD—Chair Latin American-Caribbean Society of Medical Oncology Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute The BIG Experience: Challenges and Opportunities Edward Lloyd Trimble, MD National Cancer Institute Promoting Independent Research at the U.S. National Cancer Institute Jean-Yves Blay, MD, PhD Centre Léon Bérard How to Participate in European Organisation for Research and Treatment of Cancer Trials Henry Leonidas Gomez, MD Instituto Nacional de Enfermedades Neoplasicas Leading Clinical Research in Low-resource Scenarios Role of Nutrition, Supplements, and Integrative Medicine in Cancer Prevention, Treatment, and Survivorship Location: E353 CME credit: 2.25 Track(s): Cancer Prevention/Epidemiology, General Oncology, Patient and Survivor Care Charles L. Loprinzi, MD—Chair Mayo Clinic Nutrition Recommendations for Patients with Far-advanced Disease Heather Greenlee, ND, PhD Columbia University Lifestyle Modification and Dietary Supplements in Cancer Prevention: What Is the Role? Kimberly Robien, PhD, RD University of Minnesota Approaches to Nutrition Interventions during Cancer Treatment Wendy Demark-Wahnefried, PhD, RD University of Alabama at Birmingham Nutrition and Physical Activity Recommendations for Cancer Survivorship: What Do We Tell Our Patients and Their Families after Treatment? Lorenzo Cohen, PhD University of Texas M. D. Anderson Cancer Center Improving Patient Outcomes: The Role of Integrative Medicine in Cancer Care 62 Friday, June 3, 2011 FRIDAY 1:00 PM - 3:30 PM EXTENDED EDUCATION SESSIONS Grant Writing Workshop I: Basic Grant Writing Location: S106 CME credit: 2.5 Track(s): Professional Development, Clinical Trials Charles M. Rudin, MD, PhD—Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Developing Hypothesis and Stating Aims Lei Ming, PhD National Cancer Institute National Cancer Institute Training and Career Development Grants Kathleen A. Cooney, MD University of Michigan Medical School, University of Michigan Comprehensive Cancer Center Conquer Cancer Foundation of ASCO (formerly The ASCO Cancer Foundation) Grants Program Susan Blaney, MD Texas Children’s Cancer Center Choosing a Mentor and Obtaining Letters of Support Heidi Nelson, MD Mayo Clinic Tips for Grant Writing in the New National Institutes of Health Format Donna S. Neuberg, ScD Dana-Farber Cancer Institute Statistical Considerations Mary L. Disis, MD University of Washington Grant Writing Pearls On the Shoulders of Giants: Historical Perspectives on Biomarkers and Colorectal Carcinoma Location: E350 CME credit: 2.5 Track(s): Professional Development, Gastrointestinal (Colorectal) Cancer Jill Gilbert, MD—Chair Vanderbilt University Robert J. Mayer, MD Dana-Farber Cancer Institute History of Systemic Treatment for Colorectal Cancer S. Gail Eckhardt, MD University of Colorado School of Medicine, Anschutz Medical Campus History of the Development of Novel Agents and Integration of Biomarkers in Colorectal Cancer Katherine Elizabeth Reeder-Hayes, MD University of North Carolina Hospital Case Study: Colorectal Carcinoma Jae Hong Park, MD Memorial Sloan-Kettering Cancer Center Case Study: Colorectal Carcinoma 63 Friday, June 3, 2011 FRIDAY 1:00 PM - 4:00 PM EXTENDED EDUCATION SESSION Maintenance of Certification and Lifelong Learning Workshop (MOC)—Ticketed Session Location: E451b Track(s): Professional Development Alexandria T. Phan, MD—Chair University of Texas M. D. Anderson Cancer Center ABIM 2010 Update in Medical Oncology Gregory A. Masters, MD Thomas Jefferson University Medical School and Medical Oncology Hematology Consultants ABIM 2010 Update in Medical Oncology Anne Moore, MD Weill Cornell Medical College ABIM 2010 Update in Medical Oncology 64 Friday, June 3, 2011 FRIDAY 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Central Nervous System Tumors Display Time: 2:00 PM - 6:00 PM Display Location: S102 Discussion Time: 5:00 PM - 6:00 PM Discussion Location: S100a CME credit: 1 Track(s): Central Nervous System Tumors Mark R. Gilbert, MD—Co-Chair University of Texas M. D. Anderson Cancer Center John L. Villano, MD—Co-Chair University of Illinois Discussion 5:00 PM Martin Kelly Nicholas, MD, PhD (Abstracts #2012–2017) The University of Chicago Discussion 5:30 PM Jeffrey J. Raizer, MD (Abstracts #2025–2030) Northwestern University Feinberg School of Medicine Discussion 5:45 PM David M. Peereboom, MD (Abstracts #2031–2036) Cleveland Clinic Brd. 1 A population-based study of glioblastoma multiforme (GBM) in the new Stupp paradigm: Have we improved outcome? (Abstract #2012) Z. Lwin, D. MacFadden, A. AL-Zahrani, E. Atenafu, B. Miller, C. Menard, N. Laperriere, W. P. Mason Brd. 2 Improved survival time trends for glioblastoma using the SEER 17 population-based registries. (Abstract #2013) M. Koshy, J. L. Villano, T. A. Dolecek, A. Howard, S. Chmura, R. R. Weichselbaum, B. J. McCarthy Brd. 3 Real-life survival in unselected adult glioblastoma patients: A populationbased study. (Abstract #2014) M. Preusser, A. Woehrer, N. Zielonke, H. Heinzl, C. Auer, T. Waldhoer, K. Roessler, C. Marosi, J. A. Hainfellner Brd. 4 Effects of surgery with BCNU wafer placement on neurocognitive function in patients with one to three brain metastases. (Abstract #2015) M. G. Ewend, C. A. Meyers, E. Silva, M. Booth-Jones, S. Jain, S. Brem Brd. 5 Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. (Abstract #2016) T. S. Armstrong, J. S. Wefel, M. Wang, M. Won, A. Bottomley, T. R. Mendoza, C. Coens, M. Werner-Wasik, D. Brachman, A. K. Choucair, M. R. Gilbert Brd. 6 Variation over time and interdependence between disease progression and death among patients with glioblastoma (GBM) on RTOG 0525. (Abstract #2017) M. Wang, J. Dignam, M. Won, W. J. Curran Jr., M. P. Mehta, M. R. Gilbert Brd. 7 Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ). (Abstract #2018) B. E. Sanchez, J. Munoz, H. Y. Ali, J. M. Anderson, P. Kuriakose 65 Friday, June 3, 2011 Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR). (Abstract #2019) S. Anderson, J. M. Lafky, X. W. Carrero, T. K. Kimlinger, T. M. Halling, S. Kumar, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. Galanis Brd. 9 Detection of IDH1 mutations in a series of 91 oligodendrogliomas: Comparison of immunohistochemistry, DNA sequencing, and allele-specific PCR. (Abstract #2020) D. Loussouarn, A. Le Loupp, J. Frenel, F. Leclair, A. Von Deimling, M. Aumont, S. Martin, M. Campone, M. G. Denis Brd. 10 The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). (Abstract #2021) C. S. Nangia, D. Wang, L. Scarpace, L. Schultz, A. Khanshour, T. Mikkelsen Brd. 11 Clinical use of personalized molecular biomarkers in patients with glioblastoma. (Abstract #2022) M. Holdhoff, J. O. Blakeley, C. Carson, C. H. Ferrigno, L. Blair, A. S. Balmanoukian, P. Burger, S. A. Grossman, L. A. Diaz Jr. Brd. 12 Triple-negative, low-grade gliomas: A highly aggressive tumor with dismal prognosis. (Abstract #2023) P. Metellus, B. Coulibaly, C. Colin, A. Maues de Paula, A. Barlier, A. Loundou, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, D. Figarella-Branger Brd. 13 The role of amide proton transfer imaging in detecting active malignant glioma. (Abstract #2024) J. O. Blakeley, X. Ye, M. Lim, H. Zhu, L. Blair, A. Quinones-Hinojosa, C. Eberhart, P. Barker, J. Laterra, P. C. van Zijl, J. Zhou Brd. 14 Methotrexate (MTX) rechallenge for recurrent primary CNS lymphoma (PCNSL). (Abstract #2025) E. Pentsova, L. M. DeAngelis, A. M. Omuro Brd. 15 Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial. (Abstract #2026) A. Korfel, L. Fischer, P. Martus, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, H. Mergenthaler, T. Hundsberger, M. Leithäuser, T. Birnbaum, A. Florschütz, K. Jahnke, U. Herrlinger, M. Weller, E. Thiel Brd. 16 Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neurooncology). (Abstract #2027) R. Soffietti, E. Trevisan, R. Ruda, L. Bertero, C. Bosa, M. Fabrini, I. Lolli Brd. 17 Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). (Abstract #2028) A. M. Omuro, K. Beal, S. Karimi, D. Correa, T. A. Chan, L. M. DeAngelis, I. T. Gavrilovic, C. Nolan, A. Hormigo, A. B. Lassman, T. J. Kaley, I. K. Mellinghoff, C. Grommes, K. Panageas, A. S. Reiner, R. Barradas, L. E. Abrey, P. H. Gutin Brd. 18 Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group. (Abstract #2029^) B. Chauffert, L. Feuvret, F. Bonnetain, L. Taillandier, H. Taillia, D. Frappaz, R. Schott, J. Honnorat, M. Fabbro, I. Tennevet, F. Ghiringhelli, J. S. Guillamo, X. Durando, D. Castera, M. Frenay, C. Campello, R. Guillevin, J. Skrzypski, T. S. Dabakuyo, O. L. Chinot, Association des Neuro-Oncologues d’Expression Francaise FRIDAY Brd. 8 66 Brd. 19 Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. (Abstract #2030) D. A. Reardon, J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, H. S. Friedman Brd. 20 Phase II study of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. (Abstract #2031) J. Welsh, A. Amini, E. S. Kim, P. Allen, J. Y. Chang, L. L. Garland, J. Holt, D. Erdman, R. Komaki, B. Stea Brd. 21 Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. (Abstract #2032) P. Y. Wen, V. K. Puduvalli, J. G. Kuhn, J. M. Reid, K. Lamborn, T. F. Cloughesy, S. M. Chang, J. Drappatz, W. A. Yung, M. R. Gilbert, H. Robins, F. S. Lieberman, A. B. Lassman, R. M. McGovern, S. Desideri, X. Ye, M. M. Ames, I. J. Espinoza-Delgado, S. A. Grossman, M. Prados Brd. 22 NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study. (Abstract #2033) K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn, J. N. Sarkaria, B. W. Scheithauer, B. J. Erickson, J. C. Buckner, NCCTG Brd. 23 TEMOBIC: An ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG). (Abstract #2034) O. L. Chinot, K. Hoang-Xuan, M. Fabbro, L. Taillandier, J. Honnorat, M. Barrie, M. Sanson, C. Kerr, P. Beauchesne, S. Cartalat-Carel, D. Autran, A. Loundou, R. Guillevin, K. Mokhtari, D. Figarella-Branger, J. Delattre, Association des Neuro-Oncologues d’Expression Francaise Brd. 24 Open-label, dose-confirmation study of interstitial 131I-chTNT-1/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: Interim results. (Abstract #2035) W. R. Shapiro, D. Gupta, A. K. Mahapatra, S. Gopal, K. Judy, S. J. Patel, J. Shan Brd. 25 A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas. (Abstract #2036) S. A. Jeyapalan, M. Goldmann, J. Donahue, H. Elinzano, D. L. Evans, B. M. O’Connor, M. A. Puthawala, A. Oyelese, D. Cielo, M. Blitstein, M. Dargush, A. Santaniello, M. Constantinou, T. Dipetrillo, H. Safran, Brown University Oncology Group 67 FRIDAY Friday, June 3, 2011 Friday, June 3, 2011 FRIDAY 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Gynecologic Cancer Display Time: 2:00 PM - 6:00 PM Display Location: E450a Discussion Time: 5:00 PM - 6:00 PM Discussion Location: E354b CME credit: 1 Track(s): Gynecologic Cancer Daniela Matei, MD—Co-Chair Indiana University Simon Cancer Center Seiko Diane Yamada, MD—Co-Chair The University of Chicago Discussion 5:00 PM Paul J. Goodfellow, PhD (Abstracts #5012–5016) Washington University School of Medicine Discussion 5:15 PM David R. Spriggs, MD (Abstracts #5017–5024) Memorial Sloan-Kettering Cancer Center Discussion 5:30 PM Beth Karlan, MD (Abstracts #5025–5031) Cedars-Sinai Medical Center Discussion 5:45 PM Patricia J. Eifel, MD (Abstracts #5032–5036) University of Texas M. D. Anderson Cancer Center Brd. 1 A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. (Abstract #5012) B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman Brd. 2 Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. (Abstract #5013) H. Mackay, S. Welch, M. S. Tsao, J. J. Biagi, L. Elit, P. Ghatage, L. Martin, K. S. Tonkin, S. Ellard, S. K. Lau, L. McIntosh, E. A. Eisenhauer, A. M. Oza Brd. 3 Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. (Abstract #5014) G. F. Fleming, V. L. Filiaci, P. Hanjani, J. J. Burke II, S. A. Davidson, K. K. Leslie, R. J. Zaino, Gynecologic Oncology Group Brd. 4 A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II and California Cancer (CCCP) N01 Consortia NCI#8233. (Abstract #5015) R. Morgan, A. M. Oza, R. Qin, K. M. Laumann, H. Mackay, E. L. Strevel, S. Welch, D. Sullivan, R. M. Wenham, H. X. Chen, L. A. Doyle, D. R. Gandara, C. Erlichman Brd. 5 The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. (Abstract #5016) L. A. Meyer, B. M. Slomovitz, B. Djordjevic, J. M. Galbincea, T. A. Johnston, M. Munsell, J. K. Burzawa, M. Huang, R. Broaddus, D. A. Iglesias, R. L. Coleman, D. M. Gershenson, T. W. Burke, J. Wolf, K. H. Lu Brd. 6 Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. (Abstract #5017) R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, M. Garcia, A. Sood 68 Brd. 7 The role of bevacizumab incombination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers. (Abstract #5018) H. Kouta, K. Kudoh, M. Takano, R. Kikuchi, T. Kita, T. Goto, K. Furuya, Y. Kikuchi Brd. 8 A phase II study of intermittent sorafenib with bevacizumab in patients with bevacizumab-naive epithelial ovarian cancer (EOC). (Abstract #5019) E. C. Kohn, J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz, J. Squires, N. D. Houston, H. X. Chen, J. J. Wright Brd. 9 A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer. (Abstract #5020) R. E. Swensen, J. Childs, D. Higgins, T. Gooley, B. A. Goff, P. A. Fintak, B. Buening, M. L. Disis Brd. 10 A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. (Abstract #5021) U. Matulonis, W. P. Tew, D. Matei, K. Behbakht, G. F. Fleming, A. M. Oza Brd. 11 Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC). (Abstract #5022) G. Scambia, D. Lorusso, G. Amadio, N. Trivellizzi, A. Pietragalla, R. De Vincenzo, V. Salutari, M. Di Stefano, G. Mangili, S. Montoli, G. Citterio, A. Lambiase, C. Bordignon Brd. 12 Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (Abstract #5023) R. A. Burger, M. F. Brady, J. Rhee, M. A. Sovak, H. Nguyen, M. A. Bookman Brd. 13 A single-center experience of EMA/CO chemotherapy for high-risk gestational trophoblastic neoplasia: Induction low-dose cisplatin and etoposide chemotherapy. (Abstract #5024) C. Alifrangis, R. Agarwal, D. Short, P. Savage, M. Seckl Brd. 14 Sequence-specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin. (Abstract #5025) J. L. Hays, G. Kim, J. Mariani, R. F. Murphy, M. Angelos, A. McCollum, J. Lu, B. C. Widemann, J. Lee, E. C. Kohn Brd. 15 Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer. (Abstract #5026) K. Alsop, S. Fereday, C. Meldrum, A. deFazio, P. Webb, M. J. Birrer, M. Friedlander, S. B. Fox, D. Bowtell, G. Mitchell, The Australian Ovarian Cancer Study (AOCS) Group Brd. 16 Loss of heterozygosity (LOH) as a measure of whole-genome instability in ovarian cancer correlates with clinical outcomes. (Abstract #5027) G. Korpanty, K. Timms, V. Abkevich, M. Carey, A. Gutin, Y. Li, J. Li, M. Markman, R. Broaddus, J. S. Lanchbury, K. H. Lu, G. B. Mills, B. Hennessy Brd. 17 A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triplenegative breast cancer. (Abstract #5028) J. Liu, G. F. Fleming, S. M. Tolaney, M. J. Birrer, R. T. Penson, S. T. Berlin, C. Whalen, K. Tyburski, K. Matijevich, E. Kasparian, M. Roche, H. Lee, E. P. Winer, S. P. Ivy, U. Matulonis Brd. 18 Effect of WBC BRCA1 promoter methylation on ovarian cancer risk. (Abstract #5029) P. Lonning, M. Bjornslett, S. Knappskog, L. Vatten, P. Romundstad, U. Axcrona, D. G. Evans, A. Howell, A. Dørum , R. Chrisanthar Brd. 19 Associations between MDM2 SNP309 and SNP285C haplotypes and ovarian cancer risk in BRCA1 mutation carriers. (Abstract #5030) M. Bjørnslett, S. Knappskog, P. Lonning, A. Dørum 69 FRIDAY Friday, June 3, 2011 Friday, June 3, 2011 FRIDAY Brd. 20 A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarkers. (Abstract #5031) Z. Zhang, S. J. Skates, L. J. Sokoll, Z. Lu, C. H. Clarke, M. A. Hernandez, K. H. Lu, R. C. Bast Brd. 21 A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) for women with locally advanced cervical cancer (CXCA): A GOG study. (Abstract #5032) K. N. Moore, M. Sill, D. S. Miller, P. Disilvestro, K. De Geest, P. G. Rose, H. R. Cardenes, R. S. Mannel, J. H. Farley, R. J. Schilder, P. M. Fracasso Brd. 22 INCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy in untreated patients with locally advanced squamous cell cervical carcinoma—Final report of a phase II trial. (Abstract #5033) A. N. Rodrigues, I. A. Small, C. C. Carmo, G. M. Moralez, F. Erlich, R. Grazziotin, M. H. Lewer, C. C. Camisao, F. V. Alves, C. G. Ferreira Brd. 23 Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer. (Abstract #5034) C. Kunos, S. E. Waggoner, K. M. Zanotti, R. DeBernardo, N. Fusco, A. Heugel, J. Knazek, R. Adams, T. Radivoyevitch, A. Dowlati Brd. 24 Utility of preoperative ferumoxtran-10 enhanced MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. (Abstract #5035) M. Atri, Z. Zhang, H. Marques, J. Gorelick, M. Harisinghani, A. Sohaib, D. Koh, S. Raman, M. S. Gee, H. Choi, L. M. Landrum, R. S. Mannel, L. T. Chuang, J. Q. Yu, C. K. McCourt, M. Gold, ACRIN/GOG Brd. 25 Estimation of expectedness: How reliable are the predictions for the outcome of standard therapy in randomized phase III studies (RP3) in epithelial ovarian cancer (EOC)? (Abstract #5036) V. Castonguay, I. Diaz-Padilla, L. Wang, A. M. Oza 70 Friday, June 3, 2011 FRIDAY 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Head and Neck Cancer Display Time: 2:00 PM - 6:00 PM Display Location: S403 Discussion Time: 5:00 PM - 6:00 PM Discussion Location: S406 CME credit: 1 Track(s): Head and Neck Cancer Quynh-Thu Le, MD—Co-Chair Stanford University Medical Center Barbara A. Murphy, MD—Co-Chair Vanderbilt Medical Center Discussion 5:00 PM Quynh-Thu Le, MD (Abstracts #5507–5515^) Stanford University Medical Center Discussion 5:15 PM Bonnie S. Glisson, MD (Abstracts #5516 –5520) University of Texas M. D. Anderson Cancer Center Discussion 5:30 PM Barbara A. Murphy, MD (Abstracts #5521–5526) Vanderbilt Medical Center Discussion 5:45 PM Lisa F. Licitra, MD (Abstracts #5527–5529) Fondazione IRCCS Istituto Nazionale dei Tumori Brd. 1 Genetic sequence variants (GSV) in relation to acute and late toxicities in head and neck cancer (HNC) patients treated with radiation therapy (RT). (Abstract #5507) F. Meyer, I. Bairati, W. Xu, A. Azad, G. Liu Brd. 2 Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment. (Abstract #5508) I. Tinhofer, K. F. Klinghammer, W. Weichert, M. Knoedler, A. Stenzinger, T. C. Gauler, V. Budach, U. Keilholz Brd. 3 MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in patients with advanced squamous cell carcinoma of head and neck (SCCHN). (Abstract #5509) M. Gasco, D. Vivenza, M. Monteverde, L. Lattanzio, I. Colantonio, G. Natoli, E. Miraglio, A. Comino, N. Syed, T. Crook, M. C. Merlano, C. Lo Nigro Brd. 4 Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC). (Abstract #5510) V. Papadimitrakopoulou, J. Heymach, S. J. Frank, J. Myers, H. Lin, H. T. Tran, C. Chen, F. R. Hirsch, P. B. Langmuir, J. R. Vasselli, S. M. Lippman, D. Raben Brd. 5 Correlation of circulating tumor cells in SCCNH patients to cancer reoccurrence using a negative enrichment technology. (Abstract #5511) K. Jatana, P. Balasubramanian, J. C. Lang, T. N. Teknos, D. E. Schuller, J. J. Chalmers Brd. 6 Predictive value of human papillomavirus (HPV) 16 in situ hybridization (ISH) and p16 immunohistochemistry (IHC) for HPV oncogene expression in paraffin-embedded oropharynx squamous cell carcinoma (OPSCC). (Abstract #5512) M. L. Gillison, R. Jordan, M. Lingen, B. Perez-Ordonez, X. He, R. Pickard, A. Inman, M. Koluder, B. Jiang, P. Wakely, W. Xiao 71 Friday, June 3, 2011 FRIDAY Brd. 7 H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC). (Abstract #5513) T. Rampias, A. Giagini, K. Florou, P. Gouveris, E. Vaja, N. Haralambakis, P. Katsaounis, D. G. Pectasides, T. Economopoulos, A. Psyrri Brd. 8 Molecular prognostic prediction by support vector machine integrated approach for local advanced nasopharyngeal carcinoma. (Abstract #5514) X. Wan, X. Wu, X. Fan, H. Cai, M. Chen, J. Xu, M. Hong, Q. Liu Brd. 9 Exosomal-miRNA profiles as diagnostic and prognostic biomarkers in head and neck squamous cell carcinoma (HNSCC). (Abstract #5515^) G. Rabinowits, C. G. Taylor, G. H. Kloecker, A. Patel, M. B. Hall, D. D. Taylor Brd. 10 Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615. (Abstract #5516) N. Y. Lee, Q. Zhang, A. S. Garden, J. J. Kim, D. G. Pfister, J. Mechalakos, K. Hu, Q. Le, B. S. Glisson, A. T. Chan, K. Ang Brd. 11 Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent and/or metastatic squamous cell carcinoma of the head and neck. (Abstract #5517) C. A. Perez, H. Song, L. E. Raez, M. Agulnik, T. A. Grushko, A. Dekker, K. Stenson, E. A. Blair, O. I. Olopade, T. Y. Seiwert, E. E. Vokes, E. E. Cohen Brd. 12 Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: Preliminary outcome results. (Abstract #5518) P. M. Harari, D. Khuntia, A. M. Traynor, T. Hoang, D. T. Yang, G. K. Hartig, T. M. McCulloch, R. Jeraj, M. J. Nyflot, P. A. Wiederholt, L. R. Gentry Brd. 13 A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). (Abstract #5519) T. Y. Seiwert, D. J. Haraf, E. E. Cohen, E. A. Blair, K. Stenson, J. K. Salama, M. Kocherginsky, V. M. Villaflor, M. Witt, R. Williams, A. Dekker, E. E. Vokes Brd. 14 Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes. (Abstract #5520) W. N. William Jr., R. S. Weber, J. Lee, J. Myers, L. E. Ginsberg, A. K. El-Naggar, E. M. Sturgis, A. L. Sabichi, M. S. Kies, E. Y. Hanna, A. C. Hessel, C. Lu, S. Y. Lai, R. Ayuste, S. M. Lippman, E. S. Kim Brd. 15 A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer. (Abstract #5521) J. S. Kuk, S. Parpia, S. M. Sagar, T. Tsakiridis, D. Kim, D. I. Hodson, C. Zywine, J. R. Wright Brd. 16 Neurocognitive function (NCF) in patients (pts) treated with chemo/bioradiotherapy (C/B-RT) for head and neck cancers (HNC). (Abstract #5522) A. R. Abdul Razak, L. L. Siu, A. Chan, G. R. Pond, K. M. Tirona, E. X. Chen, A. J. Hope, J. Ringash, B. O’Sullivan, J. N. Waldron, K. Chan, H. K. Gan, L. J. Bernstein Brd. 17 Patient-reported fatigue in head and neck cancer survivors. (Abstract #5523) G. B. Gunn, T. R. Mendoza, A. S. Garden, X. S. Wang, W. H. Morrison, S. J. Frank, E. Y. Hanna, C. Lu, B. M. Beadle, K. Ang, C. S. Cleeland, D. I. Rosenthal 72 Brd. 18 Phase III trial of low-level laser therapy to prevent induced oral mucositis in head and neck cancer patients submitted to concurrent chemoradiation. (Abstract #LBA5524) H. S. Antunes, D. Herchenhorn, C. M. Araujo, E. Cabral, E. M. D. S. Ferreira, I. A. Small, M. P. Rampini, N. Teich, P. C. Rodrigues, T. G. P. D. Silva, L. F. Dias, C. G. M. Ferreira Brd. 19 The utility of using area under the curve to analyze symptom burden during radiation/chemoradiation for head and neck cancer. (Abstract #5525) T. R. Mendoza, G. B. Gunn, C. D. Fuller, X. S. Wang, D. I. Rosenthal, C. S. Cleeland Brd. 20 Toxicity in combined modality treatment of HNSCC: Cisplatin versus cetuximab. (Abstract #5526) A. Chew, J. Hay, J. J. Laskin, J. Wu, C. Ho Brd. 21 Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (Abstract #5527) M. E. Trinkaus, R. J. Hicks, R. J. Young, L. J. Peters, B. J. Solomon, M. Bressel, J. Corry, R. Fisher, D. Binns, G. A. McArthur, D. Rischin Brd. 22 Human papillomavirus (HPV)–related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT. (Abstract #5528) B. Pajares, J. Trigo Perez, M. D. Toledo, M. Alvarez, L. Perez-Villa, C. Gonzalez-Hermoso, A. Rueda, J. A. Medina, B. Jimenez, J. Jerez, L. Perez, E. Alba Brd. 23 Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States. (Abstract #5529) A. Chaturvedi, E. Engels, R. Pfeiffer, B. Y. Hernandez, W. Xiao, E. Kim, B. Jiang, M. Goodman, M. Sibug-Saber, W. Cozen, L. Liu, C. Lynch, N. Wentzensen, R. Jordan, S. Altekruse, W. F. Anderson, P. Rosenberg, M. L. Gillison 73 FRIDAY Friday, June 3, 2011 Friday, June 3, 2011 FRIDAY 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Leukemia, Myelodysplasia, and Transplantation Display Time: 2:00 PM - 6:00 PM Display Location: E450b Discussion Time: 5:00 PM - 6:00 PM Discussion Location: Arie Crown Theater CME credit: 1 Track(s): Leukemia, Myelodysplasia, and Transplantation Jane Liesveld, MD—Co-Chair University of Rochester Medical Center Harry Paul Erba, MD, PhD—Co-Chair University of Michigan Medical Center Discussion 5:00 PM Olatoyosi Odenike, MD (Abstracts #6509 – 6515) The University of Chicago Discussion 5:15 PM Farhad Ravandi, MD (Abstracts #6516 – 6522) University of Texas M. D. Anderson Cancer Center Discussion 5:30 PM Joseph P. Uberti, MD (Abstracts #6523– 6528) Karmanos Cancer Institute, Wayne State University Discussion 5:45 PM Guido Marcucci, MD (Abstracts #6529 – 6533) The Ohio State University Comprehensive Cancer Center Brd. 1 Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: Eighteen-month follow-up. (Abstract #6509) C. Gambacorti-Passerini, J. E. Cortes, D. Kim, H. Kantarjian, N. Khattry, J. H. Lipton, C. Powell, P. Harris, A. M. Countouriotis, T. H. Brummendorf Brd. 2 Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. (Abstract #6510) H. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. Bradley-Garelik, C. Zhu, A. Hochhaus Brd. 3 Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. (Abstract #6511) R. A. Larson, D. Kim, G. Rosti, L. Stenke, R. Pasquini, A. Hoenekopp, R. E. Blakesley, N. J. Gallagher, A. Hochhaus, T. P. Hughes, G. Saglio, H. Kantarjian Brd. 4 Five-year follow-up of patients with imatinib-resistant or -intolerant chronicphase chronic myeloid leukemia (CML-CP) receiving dasatinib. (Abstract #6512) N. P. Shah, J. E. Cortes, C. A. Schiffer, F. Guilhot, T. H. Brummendorf, A. C. Chen, D. Healey, A. Lambert, G. Saglio Brd. 5 A survey of current practices in the management of chronic myeloid leukemia (CML). (Abstract #6513) M. J. Mauro, J. E. Cortes, R. A. Larson, P. M. Herout, V. K. Bollu, A. Niyazov, H. Kantarjian Brd. 6 Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. (Abstract #6514) A. D. Pardanani, D. Caramazza, G. George, T. L. Lasho, W. J. Hogan, M. R. Litzow, K. Begna, C. A. Hanson, R. F. McClure, L. M. Bavisotto, G. Smith, M. Kowalski, S. Sirhan, A. W. Roberts, V. Gupta, J. Gotlib, A. Tefferi 74 Brd. 7 Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. (Abstract #6515) H. J. Deeg, O. Odenike, B. L. Scott, Z. Estrov, J. E. Cortes, D. A. Thomas, H. J. Zhu, H. Kantarjian, S. Verstovsek Brd. 8 Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab; anti-CD33; HuM195) in acute myeloid leukemia (AML). (Abstract #6516) J. G. Jurcic, T. L. Rosenblat, M. R. McDevitt, N. Pandit-Taskar, J. A. Carrasquillo, S. M. Chanel, C. Ryan, M. G. Frattini, D. Cicic, S. M. Larson, D. A. Scheinberg Brd. 9 Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML. (Abstract #6517) E. J. Feldman, K. W. Yee, D. Rizzieri, A. S. Advani, A. Charman, A. Richardson, M. J. Toal, J. E. Cortes Brd. 10 Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. (Abstract #6518) M. Talpaz, N. P. Shah, M. W. Deininger, M. J. Mauro, I. W. Flinn, S. Lustgarten, W. Lindmark, J. M. Gozgit, T. Clackson, C. D. Turner, F. G. Haluska, H. Kantarjian, J. E. Cortes Brd. 11 CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60 –75: Safety and efficacy in secondary AML (sAML). (Abstract #6519) J. E. Lancet, J. E. Cortes, T. Kovacsovics, D. Hogge, J. E. Kolitz, M. S. Tallman, M. Chiarella, A. C. Louie, E. J. Feldman Brd. 12 A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). (Abstract #6520) R. M. Stone, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, L. E. Damon, J. Jang, M. S. Tallman, K. Warzocha, T. Masszi, M. A. Sekeres, E. Miklos, H. Horst, D. L. Selleslag, S. R. Solomon, P. Venugopal, A. S. Lundberg, B. L. Powell Brd. 13 A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies. (Abstract #6521) O. Odenike, L. A. Godley, J. Madzo, T. Karrison, M. Green, A. S. Artz, R. J. Mattison, K. W. Yee, M. Bennett, N. Fulton, G. Koval, G. Malnassy, R. A. Larson, M. J. Ratain, W. Stock Brd. 14 Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q. (Abstract #6522) A. F. List, A. Giagounidis, J. T. Backstrom, T. Fu, P. Fenaux Brd. 15 Relapse incidence and leukemia-free survival (LFS) in patients (pts) older than age 60 with AM undergoing stem cell transplantation: A report of the East German Study Group Hematology and Oncology (OSHO). (Abstract #6523) D. Niederwieser, G. Maschmeyer, T. Fischer, L. Uharek, R. Kortmann, U. Hegenbart, P. Dreger, M. Herold, H. G. Sayer, H. Wolf, U. Kreibich, D. Hähling, C. Junghanss, N. Grobe, R. Krahl, T. Lange, H. Al-Ali, W. Pönisch, C. Nehring, G. Doelken Brd. 16 A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen. (Abstract #6524) S. Kim, J. Lee, Y. Joo, H. Kim, H. Ryoo, M. Kim, G. Lee, W. Lee, J. Park, S. Bae, M. Hyun, D. Kim, Y. Min, Cooperative Study Group A for Hematology (COSAH) Brd. 17 Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions. (Abstract #6525) K. Van Besien, H. Liu, E. S. Rich, L. A. Godley, O. Odenike, L. Joseph, J. P. Kline, V. H. Nguyen, J. M. Cunningham, R. A. Larson, W. Stock, A. Wickrema, A. S. Artz 75 FRIDAY Friday, June 3, 2011 Friday, June 3, 2011 Mechanism of thymic renewal after infusion of suicide gene-modified donor T cells after hematopoietic stem cell transplantation (HSCT) in adult patients. (Abstract #6526) C. Bordignon, L. Vago, G. Oliveira, M. Noviello, C. Soldati, D. Ghio, I. Brigida, A. Aiuti, M. Lupo-Stanghellini, J. Peccatori, A. Lambiase, A. Bondanza, A. Del Maschio, F. Ciceri, C. Bonini Brd. 19 Vincristine sulfate liposomes injection (VSLI) “bridging” to potentially curative hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome–negative (Ph-) acute lymphoblastic leukemia (ALL). (Abstract #6527) G. J. Schiller, S. E. Coutre, M. L. Larson, D. Ben Yehuda, P. Venugopal, S. Goldberg, G. L. Messerschmidt, J. Silverman, S. R. Deitcher, H. Kantarjian Brd. 20 A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL). (Abstract #6528) J. E. Castro, L. S. Schwartzberg, J. Pinilla-Ibarz, T. J. Kipps, M. J. Cantwell Brd. 21 High-throughput mutation analysis in acute myeloid leukemia (AML). (Abstract #6529) J. Dunlap, C. L. Corless, W. H. Fleming, R. Braziel, N. Leeborg, K. Gatter, M. Loriaux, K. Kelemen, T. Kovacsovics, G. Fan Brd. 22 Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1␣ and VEGF-A expression. (Abstract #6530) M. Smonskey, P. Starostik, G. Deeb, K. Demock, R. Vargas, D. Lal, S. N. Sait, M. Wetzler, E. S. Wang Brd. 23 PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. (Abstract #6531) F. P. Duhoux, G. Ameye, K. Bahloula, M. Mozziconacci, S. Laibe, I. Wlodarska, L. Michaux, P. Talmant, S. Richebourg, E. Lippert, F. Speleman, C. Herens, S. Struski, S. Raynaud, N. Nadal, M. Lafage, N. Auger, J. Libouton, J. Demoulin, H. A. Poirel, Groupe Francophone de Cytogenetique Hematologique (GFCH) and Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO) Brd. 24 The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1positive acute lymphoblastic leukemia (ALL). (Abstract #6532) I. Iacobucci, A. Ferrari, A. Lonetti, C. Papayannidis, F. Paoloni, M. Abbenante, V. Guadagnuolo, E. Ottaviani, F. Cattina, A. Vitale, S. Paolini, S. Soverini, S. Parisi, M. Vignetti, M. Baccarani, G. Martinelli Brd. 25 Novel jumping translocations (JT) associated with genetic instability and aggressive disease in chronic lymphocytic leukemia (CLL). (Abstract #6533) C. Miller, F. Racke, G. Lozanski, A. McFaddin, J. C. Byrd, N. A. Heerema FRIDAY Brd. 18 76 Friday, June 3, 2011 FRIDAY 2:45 PM - 4:00 PM EDUCATION SESSIONS Acute Myeloid Leukemia: Update on Therapy and Molecular Basis Location: Arie Crown Theater CME credit: 1.25 Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric Oncology Martin S. Tallman, MD—Chair Memorial Sloan-Kettering Cancer Center Therapy of the Elderly Patient with Acute Myeloid Leukemia Sami N. Malek, MD University of Michigan Comprehensive Cancer Center Update on the Molecular Biology of Acute Myeloid Leukemia: Clinical Implications Alan Burnett, MD University of Wales College of Medicine Therapy of Acute Myeloid Leukemia in Patients Younger Than Age 55 Challenges in HER2-positive Breast Cancer Location: Hall D1 CME credit: 1.25 Track(s): Breast Cancer Mark D. Pegram, MD—Chair University of Miami Sylvester Comprehensive Cancer Center Overview and Discussion of HER2 Biology: De Novo and Acquired Resistance to Targeting Giuseppe Viale, MD European Institute of Oncology Controversies in Testing for HER2 Eric P. Winer, MD Dana-Farber Cancer Institute Therapeutic Implications of HER2 Targeting in Very Small Clinical Low-risk Tumors and HER2 Targeting after Progression Targeting ALK in Pediatric Malignancies Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology, Lymphoma and Plasma Cell Disorders Stephan Morris, MD—Chair St. Jude Children’s Research Hospital The Role of ALK Signaling in Anaplastic Large Cell Lymphoma Yael P. Mosse, MD The Children’s Hospital of Philadelphia “Driver” ALK Mutations in Neuroblastoma Pasi A. Janne, MD, PhD Dana-Farber Cancer Institute Developing Drugs That Taget ALK and Other Genomic Aberrations 77 Friday, June 3, 2011 When Adults Are Diagnosed with Children’s Sarcomas FRIDAY Location: S406 CME credit: 1.25 Track(s): Sarcoma, Pediatric Oncology Karen H. Albritton, MD—Chair Cooks Children’s Medical Center The Unique Issues of the Adolescent and Young Adult (AYA) with Sarcoma David Parham, MD University of Oklahoma Health Sciences Center Pathologic Differences between Adult and Pediatric Sarcomas Robert G. Maki, MD, PhD Mount Sinai School of Medicine The Management of the Adult with Children’s Sarcoma 78 Friday, June 3, 2011 FRIDAY 2:45 PM - 4:00 PM MEET THE PROFESSOR SESSION Setting Up a Cancer Genetics Program (M02)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Cancer Genetics, Cancer Prevention/Epidemiology Jeffrey N. Weitzel, MD City of Hope The Academic Perspective Therese M. Mulvey, MD Southcoast Hospitals Group Community Practice Perspective 79 Friday, June 3, 2011 FRIDAY 3:00 PM - 4:30 PM CLINICAL SCIENCE SYMPOSIUM Personalized Medicine Location: E354b CME credit: 1.5 Track(s): Developmental Therapeutics James L. Gulley, MD, PhD—Chair National Cancer Institute 3:00 PM Personalized medicine in a phase I clinical trials program: The University of Texas M. D. Anderson Cancer Center Initiative. (Abstract #CRA2500) A. M. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock Discussion 3:15 PM Paula M. Fracasso, MD, PhD (Abstract #CRA2500) University of Virginia 3:30 PM Progression-free survival (PFS) from a phase I study of crizotinib (PF02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). (Abstract #2501) D. R. Camidge, Y. Bang, E. L. Kwak, A. T. Shaw, A. J. Iafrate, R. G. Maki, B. J. Solomon, S. I. Ou, R. Salgia, K. D. Wilner, D. B. Costa, G. Shapiro, P. LoRusso, P. Stephenson, Y. Tang, K. Ruffner, J. W. Clark Discussion 3:45 PM Nasser H. Hanna, MD (Abstract #2501) Indiana University 4:00 PM The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience. (Abstract #2502) T. Shimizu, A. W. Tolcher, K. P. Papadopoulos, M. Beeram, D. W. Rasco, L. S. Smith, S. Gunn, L. Smetzer, T. A. Mays, B. Kaiser, C. Alvarez, G. L. Mangold, A. Patnaik Discussion 4:15 PM James L. Gulley, MD, PhD (Abstract #2502) National Cancer Institute 80 3:30 PM - 4:45 PM SPECIAL SESSION ASCO/Society of Nuclear Medicine (SNM) Joint Session: Molecular Imaging in Cancer Clinical Trials Location: S100a CME credit: 1.25 Track(s): Clinical Trials, Special Session George W. Sledge Jr., MD—Co-Chair Indiana University Simon Cancer Center Introduction and Overview David A. Mankoff, MD, PhD—Co-Chair University of Washington The Imaging Perspective Anthony Frank Shields, MD, PhD Karmanos Cancer Institute/Wayne State University The Medical Oncology Perspective 81 FRIDAY Friday, June 3, 2011 Friday, June 3, 2011 FRIDAY 3:30 PM - 6:00 PM EXTENDED EDUCATION SESSION Career Choices: Options in Academia, Private Practice, Industry, and Government Location: S404 Track(s): Professional Development John E. Pippen, MD—Chair Baylor Sammons Cancer Center and Texas Oncology/US Oncology Hybrid: Academia and Private Practice Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute Academia Johanna C. Bendell, MD Sarah Cannon Research Institute Private Practice Barbara L. McAneny, MD New Mexico Oncology Hematology Consultants Hybrid: Public Policy and Private Practice Sandra J. Horning, MD Genentech Inc. Industry Richard Pazdur, MD U.S. Food and Drug Administration Government 82 Friday, June 3, 2011 FRIDAY 3:45 PM - 6:00 PM EXTENDED EDUCATION SESSIONS An Update on Biomarkers for the Early Detection of Cancer, Prediction of Prognosis, and as Surrogate Endpoints for Cancer Prevention Trials Location: E354a CME credit: 2.25 Track(s): Cancer Prevention/Epidemiology, Cancer Genetics Dean E. Brenner, MD—Chair University of Michigan Medical Center Overview and Fundamental Concepts of Biomarker Development and Validation Carol J. Fabian, MD University of Kansas Medical Center Biomarkers as Surrogate Endpoints for Cancer Prevention Trials: Where Are We? Sanford D. Markowitz, MD, PhD Case Western Reserve University Biomarkers for the Early Detection of Colon Cancer Harvey I. Pass, MD New York University School of Medicine Early Detection and Prognostic Biomarkers for Lung Cancer Ian Thompson, MD University of Texas Health Science Center at San Antonio Prostate Cancer and Prostate-specific antigen: Our “Perfect Biomarker”—Fact or Fantasy? Robert C. Bast, MD University of Texas M. D. Anderson Cancer Center Ovarian Cancer: CA-125 as a Prototype for an Early-diagnosis Biomarker—Do We Have Reasonable Expectations? Biologic, Clinical, and Psychosocial Correlates at the Interface of Aging and Cancer: Report from the National Institute on Aging (NIA)/National Cancer Institute (NCI) Conference on Geriatric Oncology Research to Improve Clinical Care Location: S100bc CME credit: 2.25 Track(s): Geriatric Oncology William Dale, MD, PhD—Chair The University of Chicago Medical Center Psychosocial Factors at the Interface of Cancer and Aging Arti Hurria, MD City of Hope Improving Geriatric Oncology Clinical Care through Research Harvey Jay Cohen, MD Duke University Medical Center Biologic Factors at the Interface of Cancer and Aging Supriya Gupta Mohile, MD, MS University of Rochester Medical Center Clinical Factors at the Interface of Cancer and Aging 83 Friday, June 3, 2011 Second Malignant Neoplasms: Epidemiology, Genetics, and Risk Prediction FRIDAY Location: E353 CME credit: 2.25 Track(s): Cancer Prevention/Epidemiology, Cancer Genetics, Patient and Survivor Care Lois B. Travis, MD, ScD—Chair University of Rochester School of Medicine and Dentistry Epidemiology of Second Malignant Neoplasms: An Overview Sophie D. Fossa, MD Oslo University Hospital, The Norwegian Radium Hospital Second Malignant Neoplasms in Survivors of Testicular Cancer M. Eileen Dolan, PhD The University of Chicago Genomics and Late Effects of Treatment: Cisplatin as a Paradigm Margaret R. Spitz, MD University of Texas M. D. Anderson Cancer Center Risk Prediction Models for Second Cancers: Synopsis of Ongoing Research and Genetic Predictors Andrea K. Ng, MD, MPH Brigham and Women’s Hospital and Harvard Medical School Screening for Second Cancers: Evidence-based Recommendations to Date Scott Michael Lippman, MD University of Texas M. D. Anderson Cancer Center Chemoprevention and Interventional Strategies in Second Cancers: A Review of Evidencebased Recommendations 84 Friday, June 3, 2011 FRIDAY 4:00 PM - 6:00 PM EXTENDED EDUCATION SESSION Grant Writing Workshop II: Improving Your Grant Writing Skills (Mock Study Section and Small Group Discussions) Location: S106 CME credit: 2 Track(s): Professional Development, Clinical Trials Bruce E. Johnson, MD—Chair Dana-Farber Cancer Institute Eric Jay Small, MD University of California, San Francisco Small Group Roundtable Discussant Alex A. Adjei, MD, PhD Roswell Park Cancer Institute Small Group Roundtable Discussant Fabrice Andre, MD, PhD Institut Gustave-Roussy Small Group Roundtable Discussant Dawn L. Hershman, MD, MS Columbia University Medical Center Small Group Roundtable Discussant J. Jack Lee, PhD, DDS University of Texas M. D. Anderson Cancer Center Small Group Roundtable Discussant Wells A. Messersmith, MD University of Colorado Cancer Center Small Group Roundtable Discussant Gary K. Schwartz, MD Memorial Sloan-Kettering Cancer Center Small Group Roundtable Discussant Lillian L. Siu, MD Princess Margaret Hospital Small Group Roundtable Discussant 85 Friday, June 3, 2011 FRIDAY 4:30 PM - 5:45 PM EDUCATION SESSIONS Cancer Predisposition in Children, Adolescents, and Young Adults Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology, Cancer Genetics David Malkin, MD—Chair The Hospital for Sick Children, University of Toronto Familial Cancer Syndromes: Moving past p53 Stephen J. Chanock, MD National Cancer Institute Cancer Susceptibility: Methods for Identifying the Key Mutations Kenan Onel, MD, PhD The University of Chicago Medical Center Genetic Predisposition to Secondary Cancers in Survivors of Pediatric Cancer Updates in Triple-negative Breast Cancer Location: Hall D1 CME credit: 1.25 Track(s): Breast Cancer, General Oncology, Tumor Biology Lisa A. Carey, MD—Chair University of North Carolina at Chapel Hill Clinical and Molecular Biology of Triple-negative Breast Cancer William Foulkes, PhD McGill University Triple-negative Disease: Basal-like and BRCAness Findings and Implications of Epidemiologic Risk Factor Studies Andrew Nicholas James Tutt, PhD, MBChB Guy’s Hospital Breakthrough Breast Cancer Research Unit, Guy’s Hospital PARP Inhibitors and DNA Damage Repair as a Therapeutic Target 86 4:30 PM - 5:45 PM MEET THE PROFESSOR SESSION Cancer Epidemiology for the Clinical Oncologist: When Should We Have Confidence in Studies and What Should We Tell Our Patients and Colleagues? (M03)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Cancer Prevention/Epidemiology Christine B. Ambrosone, PhD Roswell Park Cancer Institute 87 FRIDAY Friday, June 3, 2011 Friday, June 3, 2011 FRIDAY 4:45 PM - 6:00 PM CLINICAL PROBLEMS IN ONCOLOGY SESSION Liver-directed Therapy in Colorectal Cancer: What Are the Options and When Should They Be Used? (C01)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Gastrointestinal (Colorectal) Cancer Alan Paul Venook, MD—Chair University of California, San Francisco Under- and Overutilization of Liver-focused Treatments: The Medical Oncologist Perspective of When to Use and When Not to Use Kenneth Tanabe, MD Massachusetts General Hospital Cancer Center Which Patients Should Undergo Hepatic Metastasectomy and Which Should Not? Stephen Barnett Solomon, MD Memorial Sloan-Kettering Cancer Center Radiofrequency Ablation, Cryoablation, Stereotactic Radiosurgery, External Beam Radiation: Lots of Choices, but Which to Use? 88 Saturday, June 4, 2011 7:30 AM - 8:15 AM EDUCATION SESSION How to Navigate the Annual Meeting (Fellows and Junior Faculty Only) Location: S501 Track(s): Professional Development John E. Pippen, MD—Chair Baylor Sammons Cancer Center and Texas Oncology/US Oncology SATURDAY Clifford Hudis, MD Memorial Sloan-Kettering Cancer Center 89 Saturday, June 4, 2011 8:00 AM - 9:15 AM EDUCATION SESSIONS ASCO/Children’s Oncology Group (COG) Joint Session: Designing Trials to Test Novel Treatment Strategies for “Go” or “No Go” Decisions Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology, Clinical Trials, Special Session Mark J. Ratain, MD—Chair The University of Chicago Designing Early-phase Studies with “Go” versus “No Go” Rules SATURDAY Frank M. Balis, MD The Children’s Hospital of Philadelphia Early-phase Pediatric Studies: Identifying Valid Endpoints Susan Blaney, MD Texas Children’s Cancer Center Challenges of Conducting Early-phase Studies in Pediatrics Biomarkers in Genitourinary Cancers: Relevance to Clinical Practice Location: Hall D2 CME credit: 1.25 Track(s): Genitourinary Cancer, Clinical Trials, Tumor Biology Nancy Ann Dawson, MD—Chair Georgetown University Hospital Lombardi Comprehensive Cancer Center Circulating Tumor Cells in Prostate Cancer Mark Garzotto, MD Portland Veterans Affairs Medical Center Prostate-specific Antigen Kinetics in Biochemically Recurrent Prostate Cancer (Castration-naive or -resistant): Does It Guide Management? Kimryn Rathmell, MD, PhD University of North Carolina at Chapel Hill Renal Cell Cancer Biomarkers: Relevance to Clinical Practice Contemporary Topics in Ovarian Cancer Management Location: E354a CME credit: 1.25 Track(s): Gynecologic Cancer, Cancer Genetics, General Oncology Gottfried E. Konecny, MD—Chair University of California, Los Angeles Molecular Characterization of Ovarian Cancer: Where Are We Headed? Deborah Kay Armstrong, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Doctor, I’m Confused: What Is the Best Treatment for My Advanced Ovarian Cancer? Martin Eric Gore, PhD Royal Marsden Hospital Bevacizumab Incorporation into Ovarian Cancer Treatment: Practical Considerations 90 Saturday, June 4, 2011 Etiology and Treatment of HPV-related Oropharyngeal Cancer Location: E354b CME credit: 1.25 Track(s): Head and Neck Cancer Andy Trotti, MD—Chair H. Lee Moffitt Cancer Center and Research Institute Current Therapy and Modifications in HPV-related Oropharyngeal Cancer Maura L. Gillison, MD, PhD The Ohio State University Epidemiology and Etiology of HPV-related Oropharyngeal Cancer Identification of Molecular Signatures for Classification, Response, Outcomes, and Novel Targets Location: S406 CME credit: 1.25 Track(s): Sarcoma Paul S. Meltzer, MD, PhD—Chair National Cancer Institute Identification of Novel Targets through Genomics, Proteomics, and Metabolomics Matt Van De Rijn, MD, PhD Stanford University Molecular Signatures for Classification, Response, and Outcomes George D. Demetri, MD Dana-Farber Cancer Institute Molecular Translation: Bench to Bedside in Sarcomas PARP Inhibitors, DNA Repair, and Beyond: Theory Meets Reality in the Clinic Location: S100a CME credit: 1.25 Track(s): Tumor Biology, Developmental Therapeutics Michael B. Kastan, MD, PhD—Chair St. Jude Children’s Research Hospital DNA Damage Response: Opportunities for Therapeutic Targeting Elizabeth R. Plummer, MD, DPhil Northern Centre for Cancer Care Development of PARP Inhibitors and Potential Roles in Chemotherapy Potentiation Judy Ellen Garber, MD, MPH Dana-Farber Cancer Institute Clinical Development of PARP Inhibitors: Current Status 91 SATURDAY Sara Pai, MD, PhD The Johns Hopkins University School of Medicine Biology and Immune Therapy of HPV-related Oropharyngeal Cancer Saturday, June 4, 2011 Running an Oncology Practice in 2011: Finance, Resourcing, and Ancillary Opportunities Location: E353 CME credit: 1.25 Track(s): Practice Management and Information Technology Dee Anna Smith—Chair Sarah Cannon Research Institute How to Understand the Financial Position of Your Practice: Financial Statements 101 Jeffrey Patton, MD Tennessee Oncology How Do You Assess and Implement Ancillary Services That Will Enhance Your Practice? SATURDAY John Emmett Hennessy, CMPE Kansas City Cancer Center How Do You Manage the Resources in Your Office and How Does Technology Enable Efficient Formulary Management and Related Reimbursement Issues? 92 Saturday, June 4, 2011 8:00 AM - 9:15 AM MEET THE PROFESSOR SESSION Mechanisms of Metastasis (M04)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Breast Cancer SATURDAY Larry Norton, MD Memorial Sloan-Kettering Cancer Center 8:00 AM - 9:15 AM CLINICAL PROBLEMS IN ONCOLOGY SESSION How to Manage Challenging Cases of Urothelial Cancer (C02)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Genitourinary Cancer, Geriatric Oncology Joaquim Bellmunt, MD, PhD—Chair University Hospital del Mar-IMIM Treatment Options for a Patient with Locally Advanced but Unresectable Bladder Cancer and for a Patient with Muscle-invasive but with Mixed Histology or Predominantly Nontransitional Cell Theresa M. Koppie, MD University of California, Davis Palliative Surgery in Patients with Advanced Bladder Cancer and Management of Upper Tract Tumors Daniel Peter Petrylak, MD Columbia University College of Physicians and Surgeons Systemic Therapy for Select Patient Subsets: Renal Dysfunction, Impaired Performance Status, Frail Elderly, or Platinum-refractory Disease 93 Saturday, June 4, 2011 8:00 AM - 9:30 AM CLINICAL SCIENCE SYMPOSIUM Emerging Novel Targets for Lung Cancer Location: Hall D1 CME credit: 1.5 Track(s): Lung Cancer George R. Simon, MD—Co-Chair Medical University of South Carolina Neeta Somaiah, MD—Co-Chair Fox Chase Cancer Center SATURDAY 8:00 AM An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7500) K. Wong, M. Koczywas, J. W. Goldman, E. H. Paschold, L. Horn, J. M. Lufkin, R. K. Blackman, F. Teofilovici, G. Shapiro, M. A. Socinski Discussion 8:15 AM Suresh S. Ramalingam, MD (Abstract #7500) Winship Cancer Institute of Emory University Heat Shock Protein Inhibitors: Shock and Awe? 8:30 AM Open-label, randomized multicenter phase II clinical trial of a toll-like receptor-2 (TLR2) agonist mycobacterium w (Cadi-05) in combination with paclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced nonsmall cell lung cancer (NSCLC). (Abstract #7501) C. P. Belani, D. Desai, B. M. Khamar, for the Cadi-05 Investigators Study Group Discussion 8:45 AM Raffit Hassan, MD (Abstract #7501) National Cancer Institute Chemoimmunotherapy: A Light in the Darkness? 9:00 AM Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC). (Abstract #7502) P. Lara, J. Douillard, K. Nakagawa, J. Von Pawel, M. J. McKeage, I. Albert, G. Losonczy, M. Reck, D. S. Heo, X. Fan, A. Fandi, G. Scagliotti Discussion 9:15 AM Jean-Charles Soria, MD, PhD (Abstract #7502) Institut Gustave-Roussy Vascular Disrupting Agents: Is There a Future? 94 Saturday, June 4, 2011 8:00 AM - 9:30 AM CLINICAL SCIENCE SYMPOSIUM Patient and Survivor Care and Health Services Research Session: Survivorship—Care Plans, Quality of Care, and Barriers to Care Location: S100bc CME credit: 1.5 Track(s): Patient and Survivor Care, Health Services Research 8:00 AM Quality of care for comorbid conditions during the transition to survivorship. (Abstract #9004) C. F. Snyder, K. D. Frick, R. J. Herbert, A. L. Blackford, B. A. Neville, A. C. Wolff, M. A. Carducci, C. Earle 8:15 AM Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (Abstract #9005) E. Grunfeld, M. N. Levine, J. A. Julian, G. R. Pond, E. Maunsell, A. Folkes, S. F. Dent, A. Joy, L. F. Paszat, K. I. Pritchard, G. A. Porter, D. Rayson, A. Robidoux, S. Smith, J. Sussman, L. Provencher, J. Wiernikowski, J. J. Sisler, FUPII Trial Investigators, Ontario Clinical Oncology Group Discussion 8:30 AM Lynne I. Wagner, PhD (Abstract #CRA9006) Northwestern University 8:45 AM Barriers in providing breast and colorectal cancer survivorship care: Perceptions of U.S. primary care physicians (PCPs) and medical oncologists (MOs). (Abstract #CRA9006) K. S. Virgo, C. C. Lerro, C. N. Klabunde, C. Earle, P. A. Ganz 9:00 AM Long-term consequences of treatment on paid work after diagnosis of breast cancer. (Abstract #9007) R. Jagsi, S. T. Hawley, P. Abrahamse, J. J. Griggs, A. S. Hamilton, S. J. Katz Discussion 9:15 AM Wendy Demark-Wahnefried, PhD, RD (Abstract #9007) University of Texas M. D. Anderson Cancer Center 95 SATURDAY Wendy Demark-Wahnefried, PhD, RD—Co-Chair University of Alabama at Birmingham Lynne I. Wagner, PhD—Co-Chair Northwestern University Saturday, June 4, 2011 8:00 AM - 11:00 AM SPECIAL SESSION Designing Clinical Trials for Older Patients: Nuts and Bolts Location: S106 CME credit: 3 Track(s): Geriatric Oncology, Clinical Trials, Professional Development Harvey Jay Cohen, MD—Co-Chair Duke University Medical Center Hyman Bernard Muss, MD—Co-Chair University of North Carolina Lineberger Comprehensive Cancer Center SATURDAY Martine Extermann, MD H. Lee Moffitt Cancer Center & Research Institute Defining Eligibility Criteria: Healthy, Vulnerable, Frail Lazzaro Repetto, MD, PhD Istituto Nazionale Riposo E Cura Per Anziani Clinical Trial Recruitment Heidi D. Klepin, MD, MS Wake Forest University Acute Myeloid Leukemia: Bringing Theory to Practice William Thomas Barry, PhD Duke University Medical Center Novel Design of Clinical Trials for Vulnerable Patients 96 Saturday, June 4, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Central Nervous System Tumors Location: Hall A Track(s): Central Nervous System Tumors Objective responses to chemotherapy in recurrent glioma: A prospective analysis from the German Glioma Network. (Abstract #2037) O. Baehr, B. Hentschel, E. Hattingen, S. Nussbaum, H. Berger, M. Tatagiba, J. Tonn, O. Schnell, M. Simon, T. Reithmeier, D. Krex, T. Pietsch, G. Reifenberger, O. Heese, M. Weller, J. Steinbach, M. Loeffler, German Glioma Network Brd. 1B Phase II study of dose-intense temozolomide in recurrent glioblastoma. (Abstract #2038) S. Hammond, A. D. Norden, G. J. Lesser, J. Drappatz, C. E. Fadul, T. Batchelor, E. C. Quant, R. Beroukhim, A. Muzikansky, A. S. Ciampa, L. M. Doherty, D. C. LaFrankie, S. Ruland, C. A. Bochacki, K. Griffin, M. Gerard, C. Sceppa, M. R. Rosenfeld, P. Y. Wen Brd. 1C Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. (Abstract #2039) L. Nayak, L. E. Abrey, J. Drappatz, M. R. Gilbert, D. A. Reardon, K. Lamborn, P. Y. Wen, M. Prados, L. M. DeAngelis, A. M. Omuro Brd. 1D Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. (Abstract #2040) A. D. Norden, S. Hammond, J. Drappatz, S. Phuphanich, D. A. Reardon, E. Wong, S. R. Plotkin, G. J. Lesser, J. J. Raizer, T. Batchelor, E. C. Quant, R. Beroukhim, T. J. Kaley, A. Muzikansky, A. S. Ciampa, L. M. Doherty, K. H. Smith, M. Gerard, C. Sceppa, P. Y. Wen Brd. 1E AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome. (Abstract #2041) B. Adamo, A. M. Deal, C. Livasy, E. Burrows, K. Fritchie, K. L. Blackwell, E. P. Hamilton, J. Geradts, L. Thorne, A. Ugolkov, C. R. Miller, M. G. Ewend, L. A. Carey, C. M. Perou, V. L. Cryns, C. K. Anders Brd. 1F Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma. (Abstract #2042) S. Phuphanich, C. J. Wheeler, J. Rudnick, M. Mazer, M. Nuno, X. Fan, J. Bender, E. S. Hawkins, K. L. Black, J. Yu Brd. 1G Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. (Abstract #2043) J. F. De Groot, T. Cloughesy, F. S. Lieberman, S. M. Chang, A. M. Omuro, J. Drappatz, T. Batchelor, L. M. DeAngelis, M. R. Gilbert, W. A. Yung, J. D. Fisher, X. Ye, K. Lamborn, A. P. Chen, S. A. Grossman, M. Prados, P. Y. Wen Brd. 2A Circulating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan. (Abstract #2044) M. Eoli, A. Calleri, L. Cuppini, E. Anghileri, S. Pellegatta, E. Prodi, M. Bruzzone, F. Bertolini, G. Finocchiaro Brd. 2B Effect of standard therapy on lymphocyte subsets and cytokines in newly diagnosed high-grade gliomas (HGG). (Abstract #2045) A. S. Balmanoukian, S. A. Grossman, C. Thoburn, F. Kos, M. Holdhoff, A. Hess Brd. 2C A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma. (Abstract #2046) S. A. Grimm, M. C. Chamberlain, J. Chandler, K. Muro, L. Rice, K. McCarthy, A. Rademaker, I. B. Helenowski, S. K. Johnston, M. M. Mrugala, J. J. Raizer SATURDAY Brd. 1A 97 Saturday, June 4, 2011 SATURDAY Brd. 2D Vascular hemodynamic profiles of vestibular schwannomas and glioblastoma using MRI. (Abstract #2047) S. R. Plotkin, D. Jennings, K. Mouridsen, K. E. Emblem, A. G. Sorensen Brd. 2E FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM). (Abstract #2048) C. Grommes, S. Karimi, K. Beal, T. A. Chan, L. E. Abrey, P. H. Gutin, A. M. Omuro Brd. 2F CD44 as a prognostic and predictive marker for GBM. (Abstract #2049) B. D. Vaillant, K. Bhat, E. P. Sulman, V. Balasubramaniyan, S. Wang, K. D. Aldape, H. Colman Brd. 2G A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). (Abstract #2050) J. Drappatz, J. J. Raizer, D. Schiff, A. S. Chi, T. Batchelor, S. M. Snodgrass, E. C. Quant, A. D. Norden, R. Beroukhim, S. A. Grimm, L. M. Doherty, A. S. Ciampa, D. C. LaFrankie, S. Ruland, M. Gerard, S. Hammond, P. Y. Wen Brd. 3A Concurrent temozolomide and radiation as the initial treatment for anaplastic glioma. (Abstract #2051) C. Tham, S. See, S. Tan, W. Ng, K. H. Lim, J. Thomas, E. Chua Brd. 3B Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme. (Abstract #2052) K. F. Hofland, S. Hansen, M. Sorensen, H. P. Schultz, A. Muhic, S. Engelholm, A. Ask, C. Kristiansen, C. Thomsen, H. Skovgaard Poulsen, U. N. Lassen Brd. 3C Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland Clinic experience. (Abstract #2053) N. Hashemi-Sadraei, H. S. Bawa, A. Satra, G. Rahmathulla, M. Patel, G. Stevens, T. M. Tekautz, L. A. Rybicki, D. M. Peereboom, J. H. Suh, R. Weil, M. A. Vogelbaum, G. Barnett, M. S. Ahluwalia Brd. 3D Phase l study of sorafenib in combination with radiation therapy and temozolomide for the first-line treatment of patients with high-grade glioma. (Abstract #2054) A. F. Hottinger, A. Ben Aissa, A. Bodmer, D. Squiban, N. Dunkel, N. Maradan, M. I. Vargas, D. C. Weber, E. Brendel, P. Dietrich Brd. 3E Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. (Abstract #2055) E. Lou, D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, A. L. Sumrall, L. Bailey, H. S. Friedman, J. J. Vredenburgh Brd. 3F Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. (Abstract #2056) D. A. Bota, Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins, M. E. Linskey, K. Peters, H. S. Friedman, J. J. Vredenburgh Brd. 3G Temozolomide-based chemoradiation in naive pure and mixed anaplastic astrocytoma: Long-term results of a phase II study. (Abstract #2057) S. Chiesa, G. Chiloiro, S. Manfrida, A. Mangiola, G. R. D’Agostino, G. Mantini, A. Albanese, P. De Bonis, C. Anile, M. Balducci Brd. 3H Prognostic factors in newly diagnosed glioblastoma: Have we missed gender? (Abstract #2058) E. Franceschi, A. Tosoni, S. Bartolini, L. Scopece, L. Lombardo, R. Poggi, V. Mazzocchi, L. La Torre, M. Ermani, A. A. Brandes Brd. 4A Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. (Abstract #2059) F. Bach, M. Westphal, OSAG-101 Study Group 98 Brd. 4B Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: A pooled analysis. (Abstract #2060) A. Paccapelo, I. Lolli, S. Scoccianti, B. Detti, G. Silvano, M. Fabrini, F. Perrone, G. Savio, S. Cascinu Brd. 4C Use of exosome analysis to reveal glioma-specific genetic changes in patient serum. (Abstract #2061) B. Carter, F. Hochberg, X. Breakefield, L. Balaj, S. Sivaraman, W. Curry, S. N. Kalkanis, L. Loguidice, L. M. Russo, M. Noerhelm, J. Skog Brd. 4D Neurotoxicity of intra-CSF liposomal cytarabine in the treatment of leptomeningeal metastases. (Abstract #2062) M. C. Chamberlain, S. K. Johnston Brd. 4E Glioblastoma in the elderly: Treatment planning, toxicity, and efficacy in an ambulatory practice. (Abstract #2063) W. P. Mason, Z. Lwin, D. MacFadden, A. AL-Zahrani, N. Laperriere, C. Menard, B. Millar, A. Sahgal, C. Massey, L. E. Coate Brd. 4F A phase I trial of laromustine (VNP40101M) and temozolomide for patients with malignant gliomas in first relapse or progression. (Abstract #2064) J. J. Raizer, L. Rice, A. Rademaker, J. Chandler, K. Muro, R. M. Levy, S. A. Grimm Brd. 4G A mathematical model of diffuse low-grade gliomas treated with PCV chemotherapy. (Abstract #2065) F. Ducray, M. Peyre, D. Ricard, B. Cajavec-Bernard, E. Grenier, M. Tod, V. Calvez, D. Frappaz, M. Sunyach, A. Vasiljevic, J. Pallud, S. Cartalat-Carel, J. Honnorat, B. Ribba Brd. 4H Glioblastoma in the elderly: The Cleveland Clinic experience (1992–2010). (Abstract #2066) H. S. Bawa, N. Hashemi-Sadraei, J. H. Suh, G. Stevens, G. Rahmathulla, S. T. Chao, T. M. Tekautz, P. Elson, D. M. Peereboom, L. Angelov, R. Weil, M. A. Vogelbaum, G. Barnett, M. S. Ahluwalia Brd. 5A The effect of surgery in determining pseudoprogression and predicting outcome in adults with glioblastoma. (Abstract #2067) I. Melguizo, K. R. Hess, D. Blas-Boria, J. Bruner, N. Guha-Thakurta, V. K. Puduvalli Brd. 5B Survival after recurrence of medulloblastoma in the contemporary era. (Abstract #2068) C. Koschmann, K. L. Schmidt, J. R. Geyer, S. Leary Brd. 5C Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). (Abstract #2069) E. C. Quant, T. Batchelor, A. B. Lassman, D. Schiff, T. J. Kaley, E. Wong, T. Mikkelsen, J. Drappatz, A. D. Norden, R. Beroukhim, S. E. Weiss, B. M. Alexander, C. Sceppa, M. Gerard, S. D. Hallisey, C. A. Bochacki, K. H. Smith, A. Muzikansky, P. Y. Wen Brd. 5D A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzymeinducing antiepileptic drug (EIAED). (Abstract #2070) A. Desjardins, D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, M. Gardner, A. Brickhouse, J. E. Herndon, H. S. Friedman Brd. 5E Novel use of MR spectroscopy in detecting CSF lactate for diagnosis of neoplastic meningitis. (Abstract #2071) C. L. Weston, O. Zalatimo, J. Sheehan, R. Harbaugh, D. A. Bota, A. Shedden, M. J. Glantz Brd. 5F Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. (Abstract #2072) A. S. Chi, E. L. Kwak, J. W. Clark, D. L. Wang, D. N. Louis, A. J. Iafrate, T. Batchelor 99 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 5G Concurrent, 3-times daily ultrafractionated radiation therapy and temozolomide for newly inoperable glioblastoma: TEMOFRAC—A phase II trial. (Abstract #2073) P. D. Beauchesnes, G. Faure, G. Noel, T. Schmitt, L. Martin, L. Taillandier, C. D. Carnin Brd. 5H Efficacy of radiation therapy on epileptic seizures of grade 2 and 3 gliomas: A retrospective study. (Abstract #2074) R. Ruda, E. Trevisan, U. Magliola, C. Mantovani, U. Ricardi, R. Soffietti Brd. 6A Value of CA 15–3 detection in cerebrospinal fluid (CSF) of breast cancer leptomeningeal metastases. (Abstract #2075) S. Salingue, M. Girot, I. Rodrigues, S. Taillibert, N. Kotecki, F. Zairi, M. Baranzelli, M. Faivre-Pierret, P. Devos, J. Bonneterre, F. Dubois, E. Le Rhun Brd. 6B Prognostic relevance of promoter methylation-associated loss of ID4 expression in glioblastoma multiforme. (Abstract #2076) M. Martini, T. Cenci, N. Montano, V. Cesarini, R. Pallini, L. Larocca Brd. 6C Stereotactic volumetric resection, intracavitary carmustine wafers, and radiation therapy for brain metastases: The Moffitt Cancer Center experience. (Abstract #2077) S. Brem, R. Sampath, D. Yu, A. Staller, M. Obadia, M. G. Ewend Brd. 6D IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma. (Abstract #2078) P. Metellus, C. Colin, D. Taieb, E. Guedj, I. Nanni-Metellus, B. Coulibaly, C. Colavolpe, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, D. Figarella-Branger Brd. 6E Is cerebrospinal fluid cytology a useful test? (Abstract #2079) C. M. Zoccoli, O. Zalatimo, M. J. Glantz Brd. 6F Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: A phase II study. (Abstract #2080) F. Zustovich, L. Landi, G. Lombardi, L. Galli, C. Porta, D. Amoroso, A. Fontana, M. Andreuccetti, C. Galli, A. Falcone, V. Zagonel Brd. 6G Feasibility pilot of attenuated maintenance chemotherapy for adolescents and adults with newly diagnosed localized medulloblastoma and other primitive neuroectodermal tumors. (Abstract #2081) J. N. Dagri, A. Evans, J. Torkildson, J. Portnow, L. S. Ashby, B. Zakotnik, R. J. Brown, G. Dhall, J. L. Finlay Brd. 6H Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. (Abstract #2082) K. C. Cuneo, A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburgh, K. Peters, Z. Chang, J. E. Herndon, A. Desjardins, D. A. Reardon, J. Kirkpatrick Brd. 7A Chemotherapy plus concomitant low-dose fractionated radiotherapy as second-line treatment for recurrent or progressive glioblastoma after temozolomide-based chemoradiation: A pilot study. (Abstract #2083) G. R. D’Agostino, B. Diletto, S. Manfrida, A. Mangiola, S. Chiesa, L. De Filippo, V. Frascino, F. Miccichè, C. Anile, M. Balducci Brd. 7B Use of Tegwondo, a near-continuous temozolomide regimen, in high- and low-grade gliomas. (Abstract #2084) H. M. Strik, H. C. Bock, C. Marosi Brd. 7C Baseline and long-term cognition and neuroimaging in patients with primary CNS lymphoma (PCNSL) treated with enhanced chemotherapy (CHT) delivery. (Abstract #2085) N. D. Doolittle, M. A. Lubow, D. F. Kraemer, E. Dosa, N. A. Hedrick, R. Tyson, C. Lacy, L. M. Maron, R. W. Butler, E. A. Neuwelt 100 Brd. 7D Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): Results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire. (Abstract #2086) F. Grude, M. Campone, J. Frenel, P. Soulie, E. Vauleon, Y. Hadjarab, G. Ganem, F. Denis, J. Egreteau, A. Lortholary, M. Porneuf, H. Simon, P. DAM Hieu, V. Klein, B. Dominique, P. Deguiral, H. Desclos, P. Menei, S. Traoré Brd. 7E Functional and survival effect of bevacizumab and irinotecan administered at recurrence in a cohort of patients with GBM. (Abstract #2087) E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, A. Loundou, O. L. Chinot Brd. 7F Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab. (Abstract #2088) L. J. Kim, M. C. Chamberlain, J. Zhu, J. J. Raizer, S. A. Grimm, S. Phuphanich, C. E. Fadul, S. Rosenfeld, A. H. Balch, C. C. Pope, M. Brulotte, A. A. Beelen, L. D. Recht Brd. 7G Prospective follow-up of 96 patients with breast cancer with leptomeningeal metastasis recruited from 2007 to 2010. (Abstract #2089) E. Le Rhun, N. Kotecki, F. Zairi, I. Rodrigues, A. Mailliez, M. Baranzelli, M. Faivre-Pierret, P. Devos, J. Cazin, J. Bonneterre, F. Dubois Brd. 8A Radiographic pattern of progression of recurrent GBM treated with bevacizumab with or without irinotecan. (Abstract #2091) P. Dory-Lautrec, E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, N. Girard, O. L. Chinot Brd. 8B Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia (RedLANO registry). (Abstract #2092) L. D. Ortiz, A. F. Cardona, C. E. Fadul, A. Londono, H. A. Becerra, E. Jimenez-Hakim, C. J. Yepes, H. Carranza, R. E. Bruges Maya, C. J. Castro, C. A. Vargas Brd. 8C Prognostic factors in elderly patients with grade 3 gliomas. (Abstract #2093) A. Satra, N. Hashemi-Sadraei, H. S. Bawa, D. M. Peereboom, G. Stevens, L. A. Rybicki, J. H. Suh, M. A. Vogelbaum, R. Weil, G. Barnett, M. S. Ahluwalia Brd. 8D Photodynamic therapy (PDT) in the multidisciplinary treatment of brain tumors: A feasibility study. (Abstract #2094) M. S. Gonzalez, V. Vanaclocha, I. Azinovic, J. Rebollo, R. Cañon, E. Calvo, A. Brugarolas Brd. 8E The role of plasma GFAP as a biomarker for glioblastoma. (Abstract #2095) H. Husain, W. Savage, A. Everett, X. Ye, C. Blair, K. E. Romans, C. Bettegowda, P. Burger, S. A. Grossman, M. Holdhoff Brd. 8G O(6)-methylguanine DNA-methyltransferase (MGMT) in glioblastoma: Analysis on first and following surgeries. (Abstract #2097) F. Bertolini, C. Baraldi, E. Zunarelli, A. Valentini, R. Depenni, A. Falasca, F. Bertoni, F. Cavalleri, A. Chiari, A. Fontana, P. F. Conte, G. Pinna, Gruppo Neuro-Oncologico Modena (GNO-MO) Brd. 8H Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). (Abstract #2098) J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, A. D. Coan, L. Bailey, D. Janney, C. Lu, H. S. Friedman Brd. 9A A review of how antineoplastic treatments impact the sexuality, fertility, and sexual function of adult patients with brain cancer: Implications for real-time treatment planning. (Abstract #2099) E. M. Dunbar, S. Savona, N. Ferree, P. A. Pumphrey 101 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 Brd. 9B Treatment of patients with advanced neurofibromatosis type 2 (NF2) with novel molecularly targeted therapies. (Abstract #2100) V. Subbiah, J. M. Slopis, D. S. Hong, L. S. Angelo, I. E. McCutcheon, R. Kurzrock Brd. 9C A comparative study of pediatric CNS tumor activity as assessed by [18F]FDG PET imaging and proton magnetic resonance spectroscopic imaging. (Abstract #2101) S. J. Hipp, E. A. Steffen-Smith, P. Herscovitch, N. J. Patronas, J. M. Solomon, R. Bent, S. M. Steinberg, K. E. Warren SATURDAY 102 Saturday, June 4, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Gastrointestinal (Colorectal) Cancer Brd. 10A The biology of early-onset colorectal cancer: An examination of tumor markers, pathology, and survival in a large cohort of patients. (Abstract #3537) S. A. Khan, M. Morris, K. Idrees, M. Gimbel, S. Rosenberg, Z. Zeng, J. Shia, M. P. La Quaglia, P. Paty Brd. 10B Colorectal cancer cases with de novo germ-line mutations in MLH1, MSH2, and MSH6 from the Colon Cancer Family Registry. (Abstract #3538) A. Win, M. A. Jenkins, D. D. Buchanan, J. P. Young, S. N. Thibodeau, J. L. Hopper, N. M. Lindor Brd. 10C Incidence and characteristics of BRAF V600E mutation in colorectal cancer (CRC) with mismatch repair (MMR) protein defect due to loss of MLH1: A prospective evaluation of 104 consecutive patients. (Abstract #3539) S. A. Mahesh, E. Hanna, M. Khan, P. Ravichandran, F. Slezak Brd. 10D The effect of screening on stage of disease and tumor characteristics in patients with operable colorectal cancer. (Abstract #3540) M. J. Proctor, E. Chrighton, C. H. Richards, D. C. Mcmillan, P. G. Horgan Brd. 10E Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. (Abstract #3541) M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. Alberts Brd. 10F The final results of the SWOG S9304 phase III intergroup trial’s pharmacogenetic analysis: Association of polymorphisms with survival and toxicity in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation (RT). (Abstract #3542) P. M. Wilson, P. O. Bohanes, C. J. Rankin, J. K. Benedetti, C. M. Ulrich, S. R. Smalley, K. W. Makar, W. Zhang, T. Winder, Y. Ning, A. Gerger, L. Benhaim, R. El-Khoueiry, M. J. Labonte, C. D. Blanke, H. Lenz Brd. 10G Accuracy of endorectal ultrasonography in evaluation of response to chemoradiation in locally advanced rectal cancer. (Abstract #3543) B. Farnault, L. Moureau-Zabotto, C. de Chaisemartin, M. Giovannini, G. Monges, J. Delpero, P. Viens, M. Resbeut Brd. 10H Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer. (Abstract #3544) M. Cukier, H. Soliman, A. Smith, S. Wong Brd. 11A Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: Establishing oncologic benchmarks. (Abstract #3545) G. J. Chang, I. Park, Y. You, C. Hu, S. R. Hamilton, C. Eng, B. W. Feig, P. Das, S. Krishnan, C. H. Crane, S. T. Nguyen, M. A. Rodriguez-Bigas, J. M. Skibber Brd. 11B Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07). (Abstract #3546) D. Helbling, G. Bodoky, O. Gautschi, H. Sun, F. Bosman, B. Gloor, R. Burkhard, R. C. Winterhalder, A. Madlung, D. Rauch, P. Saletti, L. A. Widmer, M. M. Borner, D. Baertschi, P. Yan, D. Koeberle Brd. 11C Factors influencing histopathology-assessed TME quality after low anterior rectal resection: Results of a prospective multicenter observational trial. (Abstract #3547) B. Garlipp, H. Ptok, U. Schmidt, P. Stuebs, F. Meyer, I. Gastinger, H. Lippert 103 SATURDAY Location: Hall A Track(s): Gastrointestinal (Colorectal) Cancer Saturday, June 4, 2011 SATURDAY Brd. 11D Morbidity and mortality results from a prospective randomized trial comparing mesorectal excision with or without lateral lymph node dissection for clinical stage II and III lower rectal cancer: Japan Clinical Oncology Group study JCOG0212. (Abstract #3548) S. Fujita, S. Saito, Y. Moriya, J. Mizusawa, K. Nakamura, N. Saito, Y. Kinugasa, Y. Kanemitsu, M. Ohue, S. Fujii, Y. Akazai, M. Shiozawa, T. Yamaguchi, H. Bandou, T. Aoki, K. Murata, K. Shirouzu, N. Takiguchi, Y. Saida, Colorectal Cancer Study Group of Japan Clinical Oncology Group Brd. 11E Prospective analysis of KRAS, BRAF, and PIK3CA mutational status and EGFR copy number in patients (pts) with locally advanced rectal cancer: A translational substudy of a clinical trial (SAKK 41/07) evaluating the effect of neoadjuvant chemoradiation (CRT) with or without panitumumab. (Abstract #3549) D. Koeberle, S. Bougel, J. Benhattar, F. Bosman, O. Gautschi, H. Sun, G. Bodoky, R. von Moos, D. Helbling, for the Swiss Group for Clinical Cancer Research (SAKK) Brd. 11F Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node–positive rectal cancer. (Abstract #3550) T. E. Seery, A. Ziogas, B. S. Lin, C. G. Pan, M. J. Stamos, J. A. Zell Brd. 11G Results of a nationwide Japanese study on lateral pelvic lymph node metastasis in low rectal cancer: Is it regional or distant disease? (Abstract #3551) T. Akiyoshi, T. Watanabe, S. Miyata, K. Kotake, T. Muto, K. Sugihara Brd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. (Abstract #3552) C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, R. Vera, M. P. Escudero, J. Maurel, J. Aparicio Brd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. (Abstract #3552) C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, R. Vera, M. P. Escudero, J. Maurel, J. Aparicio Brd. 12A Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer. (Abstract #3553) I. Park, C. Hu, M. A. Rodriguez-Bigas, Y. You, J. M. Skibber, C. Eng, R. A. Wolff, P. Das, C. H. Crane, G. J. Chang Brd. 12B Adherence to NCCN treatment guidelines for rectal cancer: Analysis of national practice patterns. (Abstract #3554) R. Chagpar, J. N. Cormier, B. W. Feig, G. J. Chang, Y. You, Y. Chiang, M. A. Rodriguez-Bigas, J. M. Skibber, Y. Xing Brd. 12C Comparison of outcomes of intensity-modulated radiotherapy and 3-D conformal radiotherapy for anal squamous cell carcinoma using a propensity score analysis. (Abstract #3555) D. A. Rothenstein, T. Dasgupta, J. F. Chou, Z. Zhang, J. L. Wright, L. K. Temple, L. Saltz, K. A. Goodman Brd. 12D Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. (Abstract #3556) Q. Shi, J. M. Hubbard, G. A. Yothers, T. Andre, L. Saltz, G. Francini, B. M. Bot, C. Twelves, M. E. Buyse, A. Grothey, D. J. Sargent, for the ACCENT Collaborative Group 104 Brd. 12E Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. (Abstract #3557) M. Morse, D. Niedzwiecki, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu, T. S. Crocenzi, D. J. Cole, S. Dessureault, A. Hobeika, T. Osada, B. M. Clary, S. D. Hsu, G. Devi, A. Bulusu, R. Annechiarico, V. Chadaram, T. M. Clay, H. K. Lyerly Brd. 12F Independent validation of a prognostic classifier (Predictor-C) in a set of 292 patients with colorectal cancer of UICC stage II. (Abstract #3558) H. Adams, T. Mayr, B. Hinzmann, A. Rosenthal Brd. 12G External validation of a tumor derived 5-gene prognostic signature (OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC). (Abstract #3559) P. F. Lenehan, L. A. Boardman, D. W. Fry, E. R. Heyman, J. Ohrnberger, W. P. Worzel Brd. 12H Microsatellite instability to predict the efficacy of adjuvant chemotherapy for stage II colon cancer. (Abstract #3560) J. Kim, H. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. Kim Brd. 13A Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase III trial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer. (Abstract #3561) A. Takagane, H. Takiuchi, K. Ikejiri, I. Mochizuki, H. Mochizuki, K. Kotake, S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, Y. Matsubara, K. Sugihara Brd. 13B Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC). (Abstract #3562) H. Baba, K. Muro, H. Yasui, Y. Shimada, A. Tsuji, S. Sameshima, T. Satoh, T. Denda, K. Ina, K. Sugihara Brd. 13C Carcinoma of unknown primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy. (Abstract #3563) F. A. Greco, W. J. Lennington, D. R. Spigel, G. R. Varadhachary, J. D. Hainsworth Brd. 13D Role of surgical resection among chemotherapy-treated patients with colorectal cancer with stage IV disease: A survival analysis. (Abstract #3564) B. S. Lin, A. Ziogas, T. E. Seery, M. J. Stamos, J. A. Zell Brd. 13E A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. (Abstract #3565) E. E. Voest, N. Snoeren, S. B. Schouten, A. M. Bergman, E. van Werkhoven, O. J. Loosveld, T. M. van Gulik, J. M. Smit, A. Cats, E. Boven, E. Hesselink, A. Rijken, M. Tol, O. Dalesio, H. M. Verheul, R. A. Tollenaar, J. van der Sijp, I. Borel Rinkes, R. van Hillegersberg Brd. 13F Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (Abstract #3566) G. W. Middleton, S. J. Gwyther, S. R. Brown, T. S. Maughan, C. Olivier, S. Richman, N. R. Maisey, M. Hill, S. Gollins, S. Myint, S. Slater, J. Wagstaff, J. A. Bridgewater, R. Glynne-Jones, G. Hemmings, H. Marshall, D. Blake, V. Napp, P. Quirke, M. T. Seymour, UK NCRI Colorectal Clinical Studies Group Brd. 13G Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). (Abstract #3567^) S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, D. Cunningham, F. Xu, K. Krishnan, J. Douillard 105 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 13H FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report. (Abstract #3568) D. Morton, L. Magill, K. Handley, G. Brown, D. R. Ferry, Z. b. Gray, P. Quirke, M. T. Seymour, B. Warren, R. G. Gray, on behalf of the FOxTROT Collaborative Group Brd. 14A Initial change in tumor size as an imaging surrogate of outcomes in patients with metastatic colorectal cancer (mCRC) treated with first-line irinotecan and 5-FU combination chemotherapy. (Abstract #3569) C. Suzuki, L. Blomqvist, A. Sundin, P. Bystrom, A. Berglund, H. Jacobsson, P. Nygren, B. Glimelius Brd. 14B Can patients be cured after cytoreductive surgery plus intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis? (Abstract #3570) D. Goéré, D. Tzanis, V. G. Gava, L. Maggiori Jr., F. Dumont, M. Ducreux, D. Elias Brd. 14C Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG’s phase III trials N9741 and N9841. (Abstract #3571) J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg, H. C. Pitot, A. Grothey, S. R. Alberts, D. J. Sargent Brd. 14D Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. (Abstract #3572) H. Piessevaux, E. Van Cutsem, C. Bokemeyer, M. Schlichting, S. Heeger, S. Tejpar Brd. 14E Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study. (Abstract #3573) B. Chibaudel, C. Tournigand, M. Mabro, M. Bennamoun, P. Artru, S. Nguyen, J. Bachet, N. Aissat, H. Blons, P. Laurent-Puig, A. De Gramont, T. Andre, GERCOR Brd. 14F Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. (Abstract #3574^) M. Peeters, T. J. Price, A. H. Strickland, T. E. Ciuleanu, W. Scheithauer, S. O’Reilly, M. M. Keane, D. R. Spigel, Y. Tian, K. Krishnan Brd. 14G FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306. (Abstract #3575) S. Stintzing, J. Neumann, A. Jung, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jaeger, T. Heintges, C. Stoll, D. P. Modest, T. Kirchner, W. Scheithauer, V. Heinemann Brd. 14H Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies. (Abstract #3576) C. Kohne, C. Bokemeyer, S. Heeger, U. Sartorius, P. Rougier, E. Van Cutsem Brd. 15A A multicenter, multinational retrospective analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (mCRC). (Abstract #3577) R. Ferrarotto, K. K. Machado, M. P. Mak, V. A. Vieira, T. K. Takahashi, D. Saragiotto, S. Kopetz, M. J. Overman, P. Hoff Brd. 15B Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial): Final results. (Abstract #3578) E. Mitry, O. Bouche, J. Seitz, P. Etienne, J. Legoux, T. Aparicio, G. Breysacher, C. Lecaille, T. Lecomte, J. Jouve, FFCD 106 Brd. 15C Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial. (Abstract #3579) S. Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Buyukunal, S. Buyukberber, C. Camci, O. Sencan, S. Kilickap Brd. 15D Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). (Abstract #3580) T. Ciuleanu, V. Nikolic, E. Shmueli, D. Vrbanec, S. Plate, Z. M. Krmpotic, M. Dank, G. Purkalne, T. Brodowicz, C. Zielinski Brd. 15E Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ⴞ bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). (Abstract #3581) A. D. Baron, C. L. O’Bryant, Y. Choi, A. Ashkenazi, S. Royer-Joo, C. C. Portera Brd. 15F Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. (Abstract #3582) A. Bessudo, J. C. Bendell, N. Gabrail, M. V. Kopp, L. Mueller, L. L. Hart, V. I. Vladimirov, A. U. Pande, I. Gorbatchevsky, C. Eng Brd. 15G Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205. (Abstract #3583) G. von Wichert, T. Hoehler, C. C. Schimanski, M. H. Moehler, R. Hofheinz, S. Kanzler, A. Hinke, T. Seufferlein, J. Siebler, A. Hochhaus, D. Arnold, M. Hallek, U. T. Hacker, Arbeitsgemeinschaft Internistische Onkologie (AIO) Brd. 15H A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recurrent colorectal cancer. (Abstract #3584) E. H. Lin, H. Lenz, M. N. Saleh, S. Badarinath, J. A. Knost, M. J. MacKenzie, B. N. Polite, P. Kavan, E. X. Chen, L. P. Leichman, K. Pathiraja, B. D. Lu Brd. 16A Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer. (Abstract #3585) B. Schultheis, G. Folprecht, J. Kuhlmann, R. Ehrenberg, U. T. Hacker, C. Kohne, M. Kornacker, O. Boix, T. Lin, J. Krauss, R. Fischer, S. Hamann, D. Strumberg, K. B. Mross Brd. 16B Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. (Abstract #3586) J. H. Strickler, A. L. Cohn, C. Arrowood, S. Haley, M. Morse, H. Uronis, G. C. Blobe, S. D. Hsu, Y. Zafar, H. Hurwitz Brd. 16C Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05–102—Final report. (Abstract #3587) S. Shahda, M. Yu, J. Picus, J. A. Bufill, W. A. Harb, M. Burns, A. J. Spittler, J. Flynn, Y. Zeng, G. H. Vance, J. Wu, C. R. Currie, P. J. Loehrer, E. G. Chiorean Brd. 16D The relationship between the development of rash and clinical and healthrelated quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. (Abstract #3588) C. J. O’Callaghan, D. Tu, C. S. Karapetis, H. Au, M. J. Moore, N. C. Tebbutt, M. G. Trudeau, T. J. Price, D. Yip, D. J. Jonker 107 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 16E Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. (Abstract #3589) V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H. Hass, H. F. Dietzfelbinger, D. V. Oruzio, S. Klein, K. Zellmann, T. Decker, M. Schulze, W. Abenhardt, G. Puchtler, H. W. Kappauf, J. Mittermueller, C. Haberl, C. A. Giessen, N. Moosmann, S. Stintzing Brd. 16F Association of baseline CEA, VEGF, and soluble VEGF receptor 2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC). (Abstract #3590^) H. Schmoll, P. M. Hoff, J. D. Robertson, L. Pike, S. Morgan, D. Wilson, J. M. Jürgensmeier Brd. 16G Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations. (Abstract #3591) C. Hoh, J. R. Infante, H. A. Burris III, J. C. Tarazi, S. Kim, B. Rosbrook, T. R. Reid Brd. 16H Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy. (Abstract #3592) A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, M. J. Labonte, P. M. Wilson, L. Benhaim, R. El-Khoueiry, G. Absenger, A. B. El-Khoueiry, S. Iqbal, H. Lenz Brd. 17A Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. (Abstract #3593) A. Hendlisz, V. Golfinopoulos, C. Garcia, P. Emonts, A. Covas, L. Ameye, M. Paesmans, A. Deleporte, G. Machiels, E. Toussaint, B. Vanderlinden, A. Awada, M. Piccart, P. Flamen Brd. 17B Evaluation of the association between tagging polymorphisms of the MACC1 locus and overall survival in patients with colorectal cancer. (Abstract #3594) A. Lang, S. Geller-Rhomberg, T. Winder, B. L. Hartmann, K. Gasser, B. Kohler, I. Grizelj, N. Stark, P. Tschann, H. Drexel, A. Muendlein Brd. 17C CpG island methylator phenotype and KRAS mutation status as prognostic markers in patients with resected colorectal cancer. (Abstract #3595) D. H. Koo, Y. Hong, K. Kim, J. Lee, H. Chang, Y. Kang, C. Yu, J. Kim, M. Kim, S. Jang, T. Kim Brd. 17D The prognostic influence and interrelationships of CD8ⴙ T-cell infiltration in malignant colorectal tumors. (Abstract #3596) C. H. Richards, A. Powell, S. Platt, C. S. Roxburgh, D. C. Mcmillan, P. G. Horgan Brd. 17E Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (Abstract #3597) A. Sartore-Bianchi, S. Fieuws, S. Veronese, M. Moroni, N. Personeni, M. Frattini, V. Torri, F. Cappuzzo, S. Vander Borght, V. Martin, M. Skokan, A. Santoro, M. Gambacorta, S. Tejpar, M. Varella-Garcia, S. Siena Brd. 17F Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer. (Abstract #3598) T. J. George, H. Liu, L. V. Duckworth, J. E. Sullivan, J. Dong, C. Liu, L. H. Dang, K. Slentz-Kesler, C. J. Allegra Brd. 17G Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan. (Abstract #3599) N. Pallisgaard, K. G. Spindler, I. S. Vogelius, A. K. Jakobsen 108 Brd. 17H The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. (Abstract #3600) T. Hansen, R. D. Christensen, R. F. Andersen, K. G. Spindler, A. Johnsson, A. K. Jakobsen Brd. 18A The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. (Abstract #3601) M. M. Vickers, C. S. Karapetis, D. Tu, C. J. O’Callaghan, T. J. Price, N. C. Tebbutt, G. Van Hazel, J. D. Shapiro, N. Pavlakis, P. Gibbs, J. Blondal, U. J. Yu Min Lee, J. M. Meharchand, R. L. Burkes, S. H. Rubin, J. Simes, J. R. Zalcberg, M. J. Moore, L. Zhu, D. J. Jonker Brd. 18B Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. (Abstract #3602) G. A. Van Hazel, D. Tu, N. C. Tebbutt, D. J. Jonker, T. J. Price, C. O’Callaghan, J. R. Zalcberg, M. Taylor, A. H. Strickland, A. T. Tomiak, D. Yip, J. Simes, S. K. Yadav, M. Links, M. J. Burnell, M. Jefford, C. S. Karapetis Brd. 18C The role of KRAS, BRAF, and PI3K mutations as markers of resistance to cetuximab in metastatic colorectal cancer. (Abstract #3603) A. Passardi, P. Ulivi, M. Valgiusti, E. Scarpi, R. Moscati, E. Chiadini, P. Rosetti, L. Saragoni, L. Capelli, A. Casadei Gardini, A. Ragazzini, M. Monti, S. Calpona, W. Zoli, C. Milandri, L. Frassineti Brd. 18D Prediction of tumor recurrence in stage II colon cancer through genetic variants in formyl peptide receptor 2 (FPR2). (Abstract #3604) R. D. Ladner, W. Zhang, M. J. Labonte, D. Yang, Y. Ning, A. Gerger, P. O. Bohanes, T. Winder, A. B. El-Khoueiry, S. Iqbal, N. Petasis, H. Lenz Brd. 18E Clinicopathological features of patients with colorectal cancer among KRAS wild-type p.G13D and other mutations: Results from a multicenter, crosssectional study by the Japan Study Group of KRAS Mutation in Colorectal Cancer. (Abstract #3605) H. Uetake, T. Watanabe, T. Yoshino, K. Yamazaki, M. Ishiguro, K. Sugihara, Y. Ohashi Brd. 18F Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. (Abstract #3606) M. J. Deenen, A. Cats, M. K. Sechterberger, J. L. Severens, P. H. Smits, R. Bakker, C. M. Mandigers, M. Soesan, J. H. Beijnen, J. H. Schellens Brd. 18G Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. (Abstract #3607) S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. Nair Brd. 18H CpG island methylation in PTEN, MGMT, and E/H cadherin promoters, mutations of K-ras and B-raf may indicate how progression in the colorectal adenocarcinoma sequence occurs. (Abstract #3608) B. Metzger, M. Dicato, G. Mahon Brd. 19A Genome-wide association study (GWAS) of the efficacy of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 trial of the Dutch Colorectal Cancer Group (DCCG). (Abstract #3609) H. Guchelaar, J. Pander, S. Bohringer, T. van der Straaten, Y. Ariyurek, J. Houwing-Duistermaat, H. Gelderblom, C. J. Punt 109 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 19B A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. (Abstract #3610) G. Della Vittoria Scarpati, C. Carlomagno, S. Marchini, P. Ubezio, F. Falcetta, M. D’Incalci, S. De Placido, F. Sabbatino, C. Fusciello, S. Pepe Brd. 19C Clinical and prognostic relevance of methylation of circulating HLTF and HPP1 tumor DNA and CEA in serum of patients with colorectal carcinoma (CRC). (Abstract #3611) F. T. Kolligs, A. B. Philipp, D. Nagel, F. Spelsberg, A. Herbst, P. Stieber Brd. 19D Cancer stem cell gene variants associated with colon cancer recurrence. (Abstract #3612) L. Benhaim, A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, M. J. Labonte, P. M. Wilson, R. El-Khoueiry, A. B. El-Khoueiry, S. Iqbal, H. Lenz Brd. 19E Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib. (Abstract #3613^) J. M. Jürgensmeier, P. M. Hoff, L. Pike, J. D. Robertson, S. Morgan, G. McWalter, D. Wilson, J. Smith Brd. 19F Effects of a neurokinin-1 receptor (NK-1R) antagonist on colon cancer through suppression of colon tumor–initiating cells. (Abstract #3614) C. Polytarchou, J. M. Bugni, S. Dry, C. Pothoulakis, D. Iliopoulos Brd. 19G Effect of body mass index (BMI) and body surface area (BSA) on outcomes in early-stage colon cancer (CC). (Abstract #3615) S. Alipour, R. Woods, H. J. Lim, S. Gill, H. F. Kennecke, C. Speers, C. J. Brown, W. Y. Cheung Brd. 19H Comparison of innovative estimation of efficacy to standard using the ACCENT database. (Abstract #3616) J. W. Chapman, C. O’Callaghan, N. Hu, K. Ding, G. A. Yothers, P. J. Catalano, Q. Shi, R. G. Gray, M. J. O’Connell, D. J. Sargent, for the ACCENT collaborative group Brd. 20A Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #3617) R. Sidhu, A. Rong, S. Dahlberg Brd. 20B Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). (Abstract #3618) H. M. Hassabo, M. Hassan, B. George, S. Wen, V. Baladandayuthapani, S. Kopetz, D. R. Fogelman, B. K. Kee, C. Eng, C. R. Garrett Brd. 20C Predictive and prognostic value of gender in early-stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database. (Abstract #3619) W. Y. Cheung, Q. Shi, M. O’Connell, J. Cassidy, C. D. Blanke, D. J. Kerr, E. Van Cutsem, S. R. Alberts, G. A. Yothers, D. J. Sargent, for the ACCENT Collaborative Group Brd. 20D Effect of VTE on mortality in patients with stage III colon cancer. (Abstract #3620) C. D. Mullins, K. A. Bikov, D. L. McNally, N. C. Onwudiwe, M. R. Dalal, N. Hanna Brd. 20E Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). (Abstract #3621) T. J. Price, D. Zannino, K. Wilson, J. Simes, G. A. Van Hazel, B. A. Robinson, A. Broad, V. Ganju, S. P. Ackland, N. C. Tebbutt Brd. 20F Short-term outcomes after colorectal cancer among the oldest old patients: A cross-national comparative study. (Abstract #3622) A. Syse, J. P. Bynum, H. G. Welch, S. Tretli, S. S. Soneji 110 Brd. 20G Allergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer: A comparative analysis between Asian and Western patients (pts). (Abstract #3623) K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P. Lee, A. De Gramont, R. M. Goldberg, M. L. Rothenberg, T. Andre, S. Brienza Brd. 20H Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. (Abstract #3624) E. Elimova, C. J. O’Callaghan, D. Tu, C. S. Karapetis, T. J. Price, L. Zhu, J. R. Zalcberg, J. Simes, D. J. Jonker Brd. 21A Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). (Abstract #3625) M. Kozloff, T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, N. Roach, H. Tezcan, S. Fish, E. D. Flick, Y. Mun, D. Dalal, A. Grothey Brd. 21B The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study. (Abstract #3626) I. Griebsch, I. Lang, U. Sartorius, E. Van Cutsem Brd. 21C Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer. (Abstract #3627) J. Cassidy, J. O’Shaughnessy, H. Schmoll, C. Twelves, T. H. Cartwright, A. Buzdar, E. McKenna, F. Gilberg, N. Scotto, D. G. Haller Brd. 21D An analysis of the effect of stage at diagnosis of bowel cancer on survival: Findings from the South Australian Clinical Registry (SACR) for metastatic colorectal cancer (mCRC). (Abstract #3628) K. Jain, T. J. Price, C. Beeke, R. Padbury, G. P. Young, D. Roder, A. R. Townsend, S. Bishnoi, C. S. Karapetis Brd. 21E Surgical treatment of colorectal cancer in the advanced elderly: Does outcome justify treatment? (Abstract #3629) J. D. Cull, S. Kukreja, T. J. Hieken Brd. 21F Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), oxaliplatin (Ox), and bevacizumab (Bev) in patients with locally advanced rectal cancer (RC): Effects on pathological complete response (pCR) and surgical complications. (Abstract #3630) T. Hoehler, K. Dellas, D. Riesenbeck, T. Reese, F. Wuerschmidt, C. Roedel, W. Wagner, H. Zuehlke, M. Richter, J. Dunst Brd. 21G Colorectal cancer in African American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. (Abstract #3631) E. P. Mitchell, A. Topham, R. Singla, S. Maron, J. Schoenfeld, F. Guiles, S. Goldstein, P. R. Anne, G. Isenberg, P. J. Maxwell IV, J. Palazzo Brd. 21H Could baseline health-related quality of life (QoL) improve prognostication of overall survival in metastatic colorectal cancer? Results from GERCOR OPTIMOX 1 study. (Abstract #3632) M. Diouf, F. Bonnetain, B. Chibaudel, C. Tournigand, L. Teixeira, H. Marijon, N. Perez-Staub, A. De Gramont Brd. 22A Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies. (Abstract #3633^) D. Wilson, P. M. Hoff, H. Schmoll, J. D. Robertson, A. Stone Brd. 22B The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314. (Abstract #3634) M. Karthaus, J. Thaler, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, E. Fernebro, E. Gamelin, A. Baños, C. Kohne 111 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 Brd. 22C Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR. (Abstract #3635) E. Canestrari, A. Ruzzo, B. Vincenzi, N. Galluccio, G. Perrone, F. Andreoni, P. Lorenzini, E. Rulli, S. d’Emidio, V. Catalano, F. Loupakis, R. Bisonni, I. Floriani, M. De Nictolis, D. Santini, L. Salvatore, G. Tonini, A. Falcone, M. Magnani, F. Graziano Brd. 22D miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy. (Abstract #3636) L. Landi, F. Biagioni, V. Ludovini, A. Sacconi, A. Destro, G. Blandino, M. Roncalli, L. Crinò, F. Cappuzzo SATURDAY 112 Saturday, June 4, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Gastrointestinal (Noncolorectal) Cancer Brd. 23A Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma (HCC): A multicenter study of over 200 patients. (Abstract #4033) N. Williet, A. Zaanan, M. Hebbar, V. Boige, L. Fartoux, T. Mansourbakht, O. Dubreuil, O. Rosmorduc, F. Bonnetain, J. Taı̈eb Brd. 23B Phase II trial of concurrent chemoradiotherapy consisting of two courses with S-1 and cisplatin for locally advanced esophageal cancer. (Abstract #4034) H. Iwase, M. Shimada, T. Tsuzuki, N. Ryuge, H. Goto Brd. 23C Clinical significance of tumor markers as prognostic factors in patients with metastatic gastric cancer receiving first-line chemotherapy. (Abstract #4035) J. Jo, M. Ryu, D. Koo, B. Ryoo, H. Kim, J. Lee, H. Chang, T. Kim, K. Choi, G. Lee, H. Jung, K. Kim, J. Yook, S. Oh, B. Kim, J. Kim, Y. Kang Brd. 23D Effect of neoadjuvant chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicentric comparative study. (Abstract #4036) C. Mariette, M. Messager, J. H. Lefevre, V. Pichot, A. Souadka, T. Thibot, D. Brachet, N. Carrere, M. Fernandez, J. Guiramand, B. Tsilividis, R. Flamein, K. Kraft, J. Balon, F. Borie, A. Glaise, X. d’Journo, F. Peschaud, F. Vandois, G. Piessen, FRENCH Brd. 23E Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. (Abstract #4037) S. Lorenzen, S. Blank, K. Becker, R. Langer, F. Lordick, D. Jaeger, J. R. Siewert, K. Ott Brd. 23F C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). (Abstract #4038) N. Galluccio, A. Ruzzo, E. Canestrari, P. Lorenzini, S. d’Emidio, V. Sisti, V. Catalano, F. Andreoni, C. Zingaretti, M. De Nictolis, C. Ligorio, F. Cappuzzo, M. Magnani, F. Graziano Brd. 23G Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer. (Abstract #4039) H. Fensterer, C. Schade-Brittinger, H. Mueller, B. Schupfner, J. Fass, U. Lindig, U. Settmacher, M. P. Ebert, M. Kornmann, R. Hofheinz, E. Endlicher, C. Brendel, P. J. Barth, D. K. Bartsch, T. M. Gress, Arbeitsgemeinschaft Internistische Onkologie (AIO) Brd. 23H The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study. (Abstract #4040) H. Isayama, Y. Nakai, T. Sasaki, N. Sasahira, K. Hirano, T. Tsujino, M. Tada, M. Omata, K. Koike, GEMSAP study group Brd. 24A Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). (Abstract #4041) I. McCaffery, Y. Tudor, H. Deng, R. Tang, S. Badola, H. L. Kindler, C. S. Fuchs, E. Loh, S. D. Patterson, L. Chen, J. L. Gansert 113 SATURDAY Location: Hall A Track(s): Gastrointestinal (Noncolorectal) Cancer Saturday, June 4, 2011 SATURDAY Brd. 24B Adjuvant treatments in pancreatic cancer: Preliminary data of a pooled analysis. (Abstract #4042) F. Drudi, D. Tassinari, C. Castellani, F. Carloni, C. Santelmo, E. Tamburini, M. Fantini, M. Papi, L. Gianni, A. Ravaioli Brd. 24C Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC). (Abstract #4043) G. K. Abou-Alfa, B. Gansukh, J. F. Chou, J. Shia, M. Capanu, M. Kalin, H. X. Chen, N. J. Zojwalla, S. Katz, D. L. Reidy, D. P. Kelsen, L. Saltz Brd. 24E Screening for pancreatic cancer in a high-risk cohort: A 7-year experience. (Abstract #4045) W. Al-Sukhni, A. Borgida, H. Rothenmund, S. Holter, S. Wilson, M. J. Moore, S. Narod, K. Jhaveri, M. A. Haider, S. Gallinger Brd. 24F Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). (Abstract #4046) B. E. Phillips, R. R. Tubbs, T. W. Rice, L. A. Rybicki, T. Plesec, C. P. Rodriguez, G. M. Videtic, J. P. Saxton, D. I. Ives, D. J. Adelstein Brd. 24G Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial. (Abstract #4047) S. H. Boeck, A. Jung, R. P. Laubender, J. Neumann, R. Egg, C. Goritschan, U. Vehling-Kaiser, C. Winkelmann, L. Fischer von Weikersthal, M. R. Clemens, T. C. Gauler, A. Marten, S. Klein, G. Kojouharoff, M. Barner, M. Geissler, T. F. Greten, U. Mansmann, T. Kirchner, V. Heinemann Brd. 24H Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. (Abstract #4048) H. Safran, K. Charpentier, A. Kaubisch, G. Dubel, G. Soares, K. E. Faricy-Anderson, T. J. Miner, Y. Eng, I. Ribizzi-Akhtar, A. M. Plette, N. J. Espat, D. Berz, A. Schumacher, D. Luppe, P. Bakalarski, P. Wingate, J. Victor, K. Rosati, D. Isdale Brd. 25A Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). (Abstract #4049) J. Lu, H. Deng, R. Tang, C. Hsu, H. L. Kindler, C. S. Fuchs, J. L. Gansert, S. Bray, S. S. Suzuki, E. Loh, M. Zhu Brd. 25B Adjuvant therapy in the treatment of biliary tract cancer (BTC): A systematic review and meta-analysis. (Abstract #4050) A. M. Horgan, E. Amir, T. Walter, J. J. Knox Brd. 25C An evaluation of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on patients with peritoneal carcinomatosis: Final results of a phase II prospective and randomized clinical trial. (Abstract #4051) Y. Li, X. Yang, G. Yang, Y. Zhou, Y. Yonrmura Brd. 26A Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type 1 receptor (IGF-1R) targeted therapy in pancreatic cancer. (Abstract #4052) R. T. Shroff, M. M. Javle, D. Li, R. A. Wolff, D. J. Mauro, G. Naumov, M. Nebozhyn, T. Zhang, Y. Li, S. Sathyanarayanan Brd. 26B Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4053) P. C. Thuss-Patience, R. Hofheinz, D. Arnold, A. Florschütz, S. Daum, A. Kretzschmar, L. Mantovani-Löffler, D. Bichev, B. Gahn, G. Schumacher, M. Kneba 114 Brd. 26C Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients. (Abstract #4054) M. Kudo, N. Izumi, N. Kokudo, M. Sakamoto, Y. Matsuyama, T. Ichida, O. Nakashima, O. Matsui, Y. Ku, M. Makuuchi, for the Liver Cancer Study Group of Japan Brd. 27A Prognostic significance of post-treatment standardized uptake value (pSUV) of positron emission tomography (PET) to predict overall survival (OS) and relapse-free survival (RFS) in patients with esophageal or gastroesophageal cancer treated with definitive chemoradiotherapy. (Abstract #4055) A. Suzuki, L. Xiao, Y. Hayashi, J. Welsh, S. H. Lin, D. Maru, W. L. Hofstetter, R. J. Mehran, J. H. Lee, M. S. Bhutani, H. A. Macapinlac, Z. X. Liao, J. A. Ajani Brd. 27B Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. (Abstract #4056) E. C. Smyth, P. C. Enzinger, J. Li, M. Vincitore, J. Lacy, B. F. El-Rayes, P. L. Kunz, J. M. Ford, E. Robinson, D. P. Kelsen, M. A. Shah Brd. 27C A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced gastric cancer. (Abstract #4057) H. Ohnuma, Y. Sato, T. Takayama, T. Sagawa, M. Hirakawa, K. Harada, T. Nobuoka, K. Hirata, Y. Takahashi, S. Katsuki, S. Takahashi, M. Hirayama, M. Takahashi, M. Maeda, T. Sato, K. Miyanishi, M. Kobune, R. Takimoto, J. Kato Brd. 28A Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC). (Abstract #4058) S. L. Chan, A. K. Chan, E. P. Hui, S. Yu, L. Leung, H. H. Loong, B. Ma, T. Mok, A. T. Chan, W. Yeo Brd. 28B Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study. (Abstract #4059) D. Takahari, A. Takashima, J. Mizusawa, Y. Yamada, T. Yoshino, K. Yamazaki, W. Koizumi, Y. Suzuki, N. Boku, A. Ohtsu Brd. 28C Final results of feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma. (Abstract #4060) H. Hara, H. Daiko, K. Kato, H. Igaki, S. Kadowaki, Y. Tanaka, Y. Hamamoto, H. Matsushita, M. Nagase, Y. Hosoya, M. Tahara Brd. 29A Prognostic microRNAs in patients operated for pancreatic cancer. (Abstract #4061) N. A. Schultz, K. K. Andersen, A. Roslind, H. Willenbrock, M. Wøjdemann, J. S. Johansen Brd. 29B An evaluation of microRNA signature and response of patients with gastric cancer to cisplatin and fluorouracil. (Abstract #4062) H. K. Kim, C. H. Kim, J. Kim, I. J. Choi, D. J. Munroe, J. E. Green Brd. 29C Effect of metformin on survival of diabetic patients with pancreatic adenocarcinoma. (Abstract #4063) N. Sadeghi, J. L. Abbruzzese, S. J. Yeung, M. Hassan, D. Li Brd. 30A Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. (Abstract #4064) F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu, The Western Cooperative Gastrointestinal Oncology Group of China Brd. 30B Phase II single-arm, single institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC). (Abstract #4065) E. M. O’Reilly, W. R. Jarnagin, M. F. Brennan, C. Winston, L. H. Tang, M. Capanu, M. Schattner, L. Y. Chen, R. P. DeMatteo, C. J. DiMaio, M. I. D’Angelica, R. C. Kurtz, D. S. Klimstra, M. A. Lowery, D. G. Coit, D. L. Reidy, P. J. Allen 115 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 30C Correlation of HER2 and PTEN status with clinical outcome in esophageal (E), gastric (G), and gastroesophageal junction (GEJ) adenocarcinomas (ACs). (Abstract #4066) K. Linos, C. E. Sheehan, J. S. Ross Brd. 31A A new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): The Hong Kong Combined Liver Cancer (HKCLC) classification. (Abstract #4067) Y. Tang, T. Yao, C. C. Yau, S. Fan, R. Poon Brd. 31B Quality of lymphadenectomy for esophageal cancer in the United States: An analysis of the SEER database. (Abstract #4068) B. M. Stiles, A. Nasar, F. Mirza, J. L. Port, P. C. Lee, S. Paul, N. K. Altorki Brd. 31C A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer. (Abstract #4069) A. H. Ko, M. A. Tempero, Y. Shan, W. Su, Y. Lin, E. Dito, A. Ong, Y. Wang, G. Yeh, L. Chen Brd. 31D Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4070) S. Al-Batran, R. Hofheinz, N. Homann, G. Illerhaus, U. M. Martens, J. Stoehlmacher-Williams, H. Schmalenberg, K. B. Luley, N. Prasnikar, M. Egger, S. Probst, J. T. Hartmann, M. H. Moehler, D. Arnold, W. Fischbach, C. Pauligk, S. P. Moenig, P. Piso, E. Jaeger Brd. 31E CA19-9 for the prediction of efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials. (Abstract #4071) T. M. Bauer, T. S. Bekaii-Saab, X. Li, M. A. Villalona-Calero, P. A. Philip, A. F. Shields, M. M. Zalupski, N. Hammad, B. F. El-Rayes Brd. 31F Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). (Abstract #4072) L. Dahan, B. Chibaudel, F. Di Fiore, P. Artru, L. Mineur, M. Galais, O. Dupuis, V. Blondin, S. Abdiche, M. Attia, A. De Gramont, G. Lledo, GERCOR Brd. 31G Prognostic values of microRNAs in phase III clinical trial gastric cancer patients treated with S-1/oxaliplatin or doxifluridine/oxaliplatin. (Abstract #4073) J. Jiang, C. Wu, X. Zheng, Q. Zhou, X. Zhang, X. Xu, B. Lu, J. Ju Brd. 31H Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4074) R. S. Finn, R. Poon, T. Yau, H. Klumpen, L. Chen, Y. Kang, T. Kim, C. Gomez-Martin, C. Rodriguez-Lope, T. Kunz, T. Paquet, K. Asubonteng, R. E. Winkler, O. Anak, D. B. Sellami, J. Bruix Brd. 32A Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2. (Abstract #4075) E. M. Wolin, N. Fazio, S. Saletan, R. E. Winkler, A. Panneerselvam, L. Kvols Brd. 32B Use of MTHFR A1298C polymorphism to predict response in a phase II international clinical trial of patients with advanced gastric (GC) or gastroesophageal junction (GEJ) adenocarcinoma treated with first-line lapatinib plus capecitabine. (Abstract #4076) M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, A. Gerger, P. O. Bohanes, Y. Ning, L. Benhaim, R. El-Khoueiry, Y. M. Nagarwala, A. M. Kemner, M. J. Pishvaian, R. K. Hsieh, O. Gladkov, S. Urba, S. Y. Rha, D. Sakaeva, S. Iqbal, A. B. El-Khoueiry, H. Lenz 116 Brd. 32C A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data. (Abstract #4077) M. H. Moehler, C. C. Schimanski, S. Kanzler, M. A. Woerns, U. Denzer, F. T. Kolligs, M. P. Ebert, A. Distelrath, M. Geissler, S. Zeuzem, F. Lammert, A. W. Lohse, M. M. Dollinger, U. Lindig, E. M. Duerr, N. Lubomierski, S. Zimmermann, M. Kabisch, S. Schadmann-Fischer, P. R. Galle, German AIO Brd. 32D Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. (Abstract #4078) L. B. Anthony, M. Peeters, J. D. Hainsworth, E. Baudin, D. Hoersch, J. Klimovsky, K. Grouss, V. Jehl, M. E. Pavel, J. C. Yao Brd. 32E Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. (Abstract #4079) A. J. Zurita, J. Heymach, M. Khajavi, L. Tye, X. Huang, M. Kulke, H. Lenz, N. J. Meropol, W. Carley, S. E. DePrimo, C. S. Harmon Brd. 32F The role of cytoreductive surgery in patients with carcinomatosis from high-grade appendix cancer in the era of modern systemic chemotherapy. (Abstract #4080) H. M. El Halabi, P. Ledakis, V. Gushchin, J. Francis, N. Athas, R. Macdonald, K. Studeman, A. Sardi Brd. 32G Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. (Abstract #4081) M. Aglietta, C. Barone, M. B. Sawyer, M. J. Moore, W. H. Miller Jr., C. Bagalà, D. A. Ferraro, F. Colombi, C. Cagnazzo, L. Gioeni, K. D. Fly, B. Huang, F. Leone Brd. 32H Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: A prospective, open-label, phase II study. (Abstract #4082) T. Yau, R. C. Leung, H. Wong, J. Chiu, P. Chan, R. Pang, S. Fan, R. Poon Brd. 33A The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. (Abstract #4083) J. Chiu, Y. Tang, T. Yao, A. Wong, H. Wong, R. C. Leung, P. Chan, T. Cheung, R. Poon, S. Fan, C. C. Yau Brd. 33B HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. (Abstract #4084) Y. Park, M. Ryu, H. Park, H. Kim, B. Ryoo, J. Yook, B. Kim, S. Jang, Y. Kang Brd. 33C A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4085) A. X. Zhu, P. J. Gold, A. B. El-Khoueiry, T. A. Abrams, H. Morikawa, T. Ohtomo, P. A. Philip Brd. 33D C-reactive protein as a biomarker to predict outcomes after liver transplantation for hepatocellular carcinoma. (Abstract #4086) H. An, J. Jang, M. Lee, S. Bae, J. Choi, S. Yoon, Y. You, D. Kim, E. Jeon, K. Park, S. Chun Brd. 33E Combination of exposure-response and case-control analyses in regulatory decision making. (Abstract #4087) J. Yang, Y. Wang, H. Zhao, C. Garnett, J. Gobburu, W. Pierce, G. Schechter, J. Summers, P. Keegan, B. Booth, N. Rahman 117 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 33F Fluoropyrimidine/platinum-based first-line chemotherapy in metastatic esophageal squamous cell carcinoma: Prognostic factor analysis in 239 patients. (Abstract #4088) H. Jung, J. Lee, H. Ahn, S. Park, Y. Park, Y. Im Brd. 33G Clinical/pathologic features and survival of patients with fibrolamellarhepatocellular carcinoma (FLL-HCC): Data from the FibrolamellarHepatocellular (FLL-HCC) Consortium. (Abstract #4089) C. Ang, A. P. Venook, M. A. Choti, R. P. DeMatteo, R. K. Kelley, D. Cosgrove, J. P. McGuire, M. S. Torbenson, T. M. Pawlik, W. R. Jarnagin, M. I. D’Angelica, Y. Fong, J. F. Chou, E. M. O’Reilly, D. S. Klimstra, A. C. Griffin, G. P. Vallarapu, M. Capanu, D. P. Kelsen, G. K. Abou-Alfa Brd. 33H The association between body mass index and baseline clinical stage of esophageal carcinoma. (Abstract #4090) Y. Hayashi, A. M. Correa, W. L. Hofstetter, A. A. Vaporciyan, D. C. Rice, G. L. Walsh, R. J. Mehran, A. Suzuki, J. H. Lee, M. S. Bhutani, S. H. Lin, J. Welsh, D. Maru, S. Swisher, J. A. Ajani Brd. 34A Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial. (Abstract #4091) J. J. Knox, R. Wong, G. E. Darling, J. Lister, M. Guindi, G. Liu, W. Xu, J. J. Kim, D. J. Jonker, J. Wells, W. Kendal, H. Mackay, A. Visbal, R. E. Dinniwell, A. Pierre, R. Feld, S. Sundaresan, A. Bayley, Y. Shargall, A. M. Horgan Brd. 34B Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma. (Abstract #4092) A. F. Okines, R. E. Langley, L. C. Thompson, S. P. Stenning, L. Stevenson, S. Falk, M. T. Seymour, F. Y. Coxon, G. W. Middleton, D. Smith, L. Evans, S. Slater, J. S. Waters, D. Ford, M. Hall, T. Iveson, R. D. Petty, C. Plummer, W. Allum, D. Cunningham, The National Cancer Research Institute (NCRI) Upper Gastrointestinal Cancers Clinical Studies Group Brd. 34C Utility of routine endoscopy in the follow-up of resected gastric carcinoma. (Abstract #4093) M. Satolli, W. Evangelista, C. Mecca, R. Napoletano, A. Giacobino, A. Novarino, F. Brusa, J. Fiore, L. Pomba, M. Garino, G. Fronda, L. Ciuffreda Brd. 34D Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer. (Abstract #4094) J. Kwon, E. Chie, J. Kim, S. Im, D. Oh, Y. Kim, S. Han, K. Lee, J. Jang, T. Kim, H. S. Han, S. Kim, Y. Yoon, Y. Bang, S. Ha Brd. 34E Progression-free survival as surrogate endpoint of overall survival in patients with advanced/recurrent gastric cancer: Individual patient data analysis on 4,102 patients from 20 randomized trials. (Abstract #4095) K. Shitara, T. Burzykowski, on behalf of GASTRIC project Brd. 34F Mature long-term outcome using a continuous 50-Gy shrinking field chemoradiation schedule for squamous cell carcinoma of the anus. (Abstract #4096) R. Cooper, K. Spindler, R. Prestwich, P. Byrnes, D. Sebag-Montefiore Brd. 34G Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer. (Abstract #4097) J. Lee, I. Petrini, J. Hwang, E. Giovannetti, J. Voortman, Y. Wang, S. M. Steinberg, N. Funel, P. S. Meltzer, G. Giaccone Brd. 34H Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. (Abstract #4098) E. Deutsch, C. Lemanski, E. Paris, A. Delarochefordiere, I. Martel-Lafay, E. Rio, L. Miglianico, Y. Becouarn, J. Pignon, J. Berille, P. Ezra, D. Azria 118 Brd. 35A Impact of prior procedures on overall survival following radioembolization in patients with unresectable hepatocellular carcinoma (HCC). (Abstract #4099) G. M. Ettorre, B. Sangro, R. Cianni, D. Gasparini, R. Golfieri, S. Ezzidin, F. T. Kolligs, F. Izzo, on behalf of European Network for Radioembolization using Y90 microspheres (ENRY) Brd. 35B Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma. (Abstract #4100) D. Ilson, Y. Y. Janjigian, M. A. Shah, D. P. Kelsen, L. H. Tang, J. Campbell, L. Fuqua, M. Capanu Brd. 35C Marker driven systemic treatment of inoperable cholangiocarcinomas: Panitumumab and combination chemotherapy in KRAS wild-type tumors. (Abstract #4101) L. H. Jensen, J. Lindebjerg, J. Ploen, T. Hansen, A. K. Jakobsen Brd. 35D Pancreatic cancer and diabetes mellitus: A retrospective cohort study. (Abstract #4102) A. Yacoub, E. Siegel, I. Makhoul Brd. 35E Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial. (Abstract #4103) R. F. Pommier, E. M. Wolin, A. Panneerselvam, S. Saletan, R. E. Winkler, E. Van Cutsem Brd. 35F Epidemiology, treatment outcome, and survival of primary gallbladder cancer in the United States: A period prevalence SEER database study 1973–2007. (Abstract #4104) A. M. Hossain, R. F. Khozouz, R. N. Rahman Brd. 35G Clinical factors and outcomes in HPV-associated anal canal cancer. (Abstract #4105) J. Nair, Y. Hu, W. M. Mendenhall, C. Liu, C. G. Morris, R. Zlotecki, J. Kirwan, L. H. Dang, S. Tan, E. Huang, C. J. Allegra, T. J. George Brd. 35H Oxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer. (Abstract #4106) S. Lee, K. Kim, H. Kim, S. Kim, S. Bae, C. Kim, N. Lee, K. Lee, S. Park, J. Won, J. Moon, D. Hong, H. Park Brd. 36A TACE plus sorafenib for the treatment of hepatocellular carcinoma: Final results of the multicenter SOCRATES trial. (Abstract #4107) A. Erhardt, F. T. Kolligs, M. M. Dollinger, E. Schott, H. Wege IV, M. Bitzer, C. Gog, J. Raedle, M. Schuchmann, C. Walter, D. Blondin, C. Ohmann, D. Haeussinger Brd. 36B FOLFIRI followed by radiochemotherapy and surgery in locally advanced gastric cancer: FFCD 0308 phase II trial. (Abstract #4108) P. Michel, G. Breysacher, F. Desseigne, L. Dahan, C. Petorin, D. Moussata, J. Grenier, S. Nguyen, F. Viret, N. Carrere, C. Mariette, C. Garnier Tixidre, K. Bouhier Leporrier, M. Galais, F. Fein, I. Iwanicki-Caron, E. Maillard, B. Dousset, F. Mornex, L. Bedenne Brd. 36C Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. (Abstract #4109) H. Bleiberg, D. J. Sargent, GASTRIC Brd. 36D Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer. (Abstract #4110) J. S. Baker, A. Qureshi, L. Itri, W. Sun, M. F. Mulcahy, J. A. Ajani Brd. 36E Outcomes following sequential trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). (Abstract #4111) A. Bujold, C. Massey, J. J. Kim, J. D. Brierley, R. Wong, C. Cho, Z. Kassam, R. E. Dinniwell, J. Ringash, B. Cummings, J. J. Knox, M. Sherman, L. A. Dawson 119 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 36F Association of the expression of the glioma-associated oncogene homolog (GLI) 1 with nuclear expression of NF-B and unfavorable overall survival of patients with pancreatic cancer. (Abstract #4112) S. Yang, S. H. Kuo, C. Hsu, J. Lee, Y. Tien, A. Cheng Brd. 36G Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). (Abstract #4113) D. E. Castellano, J. Capdevila, R. Salazar, J. Sastre, V. Alonso, M. Llanos, R. Garcia-Carbonero, A. Abad, I. Sevilla, I. Duran, Spanish Neuroendocrine Tumor Group (GETNE) Brd. 36H The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. (Abstract #4114) J. Stephenson, D. A. Richards, B. M. Wolpin, C. R. Becerra, J. T. Hamm, W. A. Messersmith, S. Devens, J. Cushing, J. Goddard, T. Schmalbach, C. S. Fuchs Brd. 37A Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. (Abstract #4115) T. Pressiani, L. Rimassa, C. Boni, R. Labianca, S. Fagiuoli, A. Ardizzoni, P. Foa, E. Cortesi, C. Porta, F. Artioli, L. Latini, C. Carnaghi, R. Lutman, G. Torzilli, M. Tommasini, R. Ceriani, G. Covini, L. Giordano, N. Locopo, A. Santoro Brd. 37B Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745. (Abstract #4116) J. M. Hubbard, S. R. Alberts, W. S. Loui, M. R. Mahoney, L. R. Roberts, T. C. Smyrk, Z. Gatalica, S. Kumar, S. R. Dakhil, P. J. Flynn, J. M. Lafky, M. J. Bury, NCCTG Brd. 37C Influence of tumor infiltrating Foxp3ⴙ regulatory T cells on prognosis in resectable gastric cancer. (Abstract #4117) J. Kwon, M. Cho, E. Nam, J. Jo, S. Lee Brd. 37D S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704. (Abstract #4118) M. A. Tempero, K. A. Winter, G. E. Kim, S. Kakar, T. S. Hyun, W. Regine, R. B. Mowat, K. Charpentier, W. Small Jr., C. Guha, D. K. Chang, A. V. Biankin, RTOG Brd. 37E Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC). (Abstract #4119) Y. Kang, A. Ohtsu, E. Van Cutsem, L. Roman, J. Nunes, C. Li, D. Otero, F. Rivera, G. Aprile, P. R. Pimentel Alvarez, M. H. Moehler, J. Wu, B. Langer, M. A. Shah Brd. 37F Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). (Abstract #4120) J. A. Chan, D. P. Ryan, C. S. Fuchs, A. X. Zhu, T. A. Abrams, B. M. Wolpin, P. Malinowski, E. Regan, M. Kulke Brd. 37G Polymorphisms in EGF aⴙ61G, GSTP1 Ile105Val, and MTHFR A1298C to predict response and survival in a phase II study for patients with metastatic or unresectable gastric (G) or gastroesophageal junction (GEJ) cancer treated with capecitabine, oxaliplatin (XELOX), and cetuximab. (Abstract #4121) S. Iqbal, M. J. Labonte, D. Yang, W. Zhang, P. O. Bohanes, Y. Ning, L. Benhaim, R. El-Khoueiry, P. M. Wilson, A. Gerger, A. B. El-Khoueiry, H. Lenz 120 Brd. 37H Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. (Abstract #4122) M. Alsina, A. H. Ko, M. Garcia De Paredes, F. Rivera, L. S. Schwartzberg, A. Fattaey, L. A. Kunkel, J. Tabernero, J. A. Ajani Brd. 38A Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: Clinicopathologic features and survival data. (Abstract #4123) H. R. Carlson, S. Karanth, M. A. Zarzour, R. Lenzi, M. N. Raber, G. R. Varadhachary Brd. 38B A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC). (Abstract #4124) A. B. El-Khoueiry, S. Iqbal, H. Lenz, B. J. Gitlitz, D. Yang, S. Cole, V. Duddalwar, A. Garcia Brd. 38C BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. (Abstract #4125) J. A. Bridgewater, C. Stubbs, J. N. Primrose, National Cancer Research Institute (UK) Upper Gastrointestinal Studies Group Brd. 38E A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC). (Abstract #4127) Z. Meng, L. Liu, Y. Shen, P. Yang, L. Cohen, Y. Huo, Q. Zhao, C. S. Ng, D. Z. Chang, C. R. Garrett Brd. 38F Inactivation of BRCA2 cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer. (Abstract #4128) G. Feldmann, C. Karikari, M. dal Molin, S. Duringer, P. Volkmann, D. K. Bartsch, S. Bisht, J. Koorstra, P. Brossart, A. Maitra, V. Fendrich Brd. 38G Prevention of Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) in the levrat rat model of EAC by treatment with a smoothened (SMO) inhibitor. (Abstract #4129) M. K. Gibson, A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell, T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy, C. Smith, J. D. Luketich, B. A. Jobe, Pittsburgh Esophageal Neoplasia Group Brd. 38H Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. (Abstract #4130) J. K. Lennerz, E. L. Kwak, M. Michael, S. B. Fox, A. Ackerman, K. Bergethon, G. Y. Lauwers, J. G. Christensen, K. D. Wilner, D. A. Haber, R. Salgia, Y. Bang, J. W. Clark, B. J. Solomon, A. J. Iafrate Brd. 39A REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II. (Abstract #4131) I. Chau, A. F. Okines, D. Gonzalez de Castro, C. Saffery, Y. Barbachano, A. Wotherspoon, L. Puckey, S. Hulkki Wilson, F. Y. Coxon, G. W. Middleton, D. R. Ferry, T. D. Crosby, S. Madhusudan, J. Wadsley, J. S. Waters, M. Hall, D. Swinson, A. Robinson, D. Smith, D. Cunningham, UK National Cancer Research Institute Upper Gastrointestinal Cancer Clinical Studies Group Brd. 39B FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum-salts: A retrospective series of 70 patients. (Abstract #4132) C. Neuzillet, O. Hentic, B. Rousseau, V. Rebours, L. Bengrine-Lefèvre, F. Bonnetain, E. Raymond, P. Ruszniewski, C. Louvet, P. Hammel 121 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Health Services Research Location: Hall A Track(s): Health Services Research SATURDAY Brd. 40A Comparative analysis of lung cancer in a public hospital versus private hospitals in New York. (Abstract #6037) V. Gotlieb, V. Verma, J. Fogel, A. Multz, R. J. Gralla Brd. 40B The development of a value-based pricing index for new drugs in metastatic colorectal cancer. (Abstract #6038) G. Dranitsaris, I. Truter, M. Lubbe Brd. 40C The influence of self-reported conflicts of interest on the conclusions of editorial authors of phase III cancer trials. (Abstract #6039) M. C. Miranda, A. T. Lera, A. Ueda, B. Briones, T. Lerner, A. Del Giglio, R. P. Riechelmann Brd. 40D Perceptions of caregivers on the participation of cancer patients into clinical trials. (Abstract #6040) A. T. Lera, M. C. Miranda, P. Santi, G. Brito, P. Prestes, M. Oliveira, A. Del Giglio, R. P. Riechelmann Brd. 40E Factors influencing patient preferences for outpatient treatment of febrile neutropenia. (Abstract #6041) N. Lathia, P. K. Isogai, C. De Angelis, S. Walker, M. C. Cheung, N. Mittmann Brd. 40F Analysis of dermatologist density and melanoma mortality. (Abstract #6042) S. Aneja, J. S. Bordeaux Brd. 40G Changes in Medicaid reimbursements for cancer screening: Keeping pace with inflation? (Abstract #6043) M. T. Halpern, S. G. Haber, F. K. Tangka, D. H. Howard, L. C. Richardson, S. A. Sabatino, S. Sujha Brd. 40H Preferences of patients with metastatic breast cancer. (Abstract #6044) M. Smith, C. B. White, E. Railey, A. M. Storniolo, G. W. Sledge Jr. Brd. 41A A predictive model to identify cancer patients at risk for in-hospital mortality based on admission criteria. (Abstract #6045) K. Ramchandran, J. Shega, M. Schumacher, A. Rademaker, b. Weitner, E. Szmuilowicz, S. A. Weitzman Brd. 41B Discordance between conclusions in the abstract and conclusions stated in the body of the article: An analysis of randomized controlled trials (RCTs) of lung cancer. (Abstract #6046) A. K. Altwairgi, C. Booth, W. Hopman, T. D. Baetz Brd. 41C Assessing 2-month clinical prognosis in patients with solid tumors: First results of PRONOPALL study. (Abstract #6047) H. P. Bourgeois, S. Traoré, P. Solal-Celigny, O. Dupuis, P. Maillart, O. Capitain, R. Delva, P. Soulie, M. Marcq, E. Boucher, G. Ganem, E. Bourbouloux, J. Baudon, M. Kaassis, M. Zinger, C. Lafond, V. Berger, P. Mussault, P. Ingrand, F. Grude Brd. 41D Factors associated with histologic versus cytologic diagnosis of lung cancer. (Abstract #6048) C. S. Lathan, A. Cronin, J. C. Weeks Brd. 41E Randomized controlled trials (RCTs) in the era of molecular oncology: Methodology, biomarkers, and endpoints. (Abstract #6049) A. Kay, J. Higgins, A. G. Day, R. M. Meyer, C. M. Booth Brd. 41F Socioeconomic position, stage of lung cancer, and time between referral and diagnosis in Denmark, 2001–2008. (Abstract #6050) S. O. Dalton, B. L. Frederiksen, E. Jakobsen, M. Steding-Jessen, K. Oesterlind, J. Schuz, M. Osler, C. Johansen 122 Brd. 41G Are breast cancer quality metrics being met? (Abstract #6051) A. Murphy, G. Rauscher, D. Dupuy, R. Alvarez, T. Macarol, E. Knightly, D. Ansell, P. Grabler, P. A. Robinson, E. A. Marcus Brd. 41H Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI-designated cancer center. (Abstract #6052) K. H. Lethert, S. K. Cheng, D. J. Nauman, D. M. Dilts, A. Sandler, S. Y. Chui Brd. 42A Predictive markers of utilization of chemotherapy in patients with advanced colorectal cancer (CRC): A population-based study. (Abstract #6053) S. Ahmed, T. Zhu, R. Lee-Ying, C. Ubhi, V. Kundapur, R. Alvi, K. Haider Brd. 42B Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)—Are there differences of concern? (Abstract #6054) E. Bria, R. J. Gralla, H. Raftopoulos, I. Sperduti, M. Milella, F. Cognetti, D. Giannarelli Brd. 42C Defining indicators for measuring the quality of systemic cancer therapy using administrative data. (Abstract #6055) M. K. Krzyzanowska, C. M. Booth, K. K. Chan, K. Enright, M. E. Trudeau Brd. 42D Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC). (Abstract #6056) D. Giannarelli, M. Milella, F. Loupakis, F. Cuppone, V. Vaccaro, I. Sperduti, P. Carlini, A. Falcone, F. Cognetti, E. Bria Brd. 42E SBRT for early NSCLC: Markov model insight for optimal patient selection. (Abstract #6057) A. V. Louie, G. Rodrigues, M. Hannouf, D. Palma, G. Zaric, S. Senan Brd. 42F Pathways of care for adolescents with cancer in France. (Abstract #6058) E. Desandes, S. Bonnay, C. Berger, L. Brugieres, F. Isfan, V. Laurence, L. Mignot, D. Olive-Sommelet, I. Tron, J. Clavel, B. Lacour Brd. 42G Screening for hepatitis B virus (HBV) prior to chemotherapy: A cost-effectiveness analysis. (Abstract #6059) U. Zurawska, L. K. Hicks, G. Woo, C. M. Bell, M. Krahn, K. K. Chan, J. J. Feld Brd. 42H The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer. (Abstract #6060) A. J. Montero, S. Gluck, G. D. Lopes Jr. Brd. 43A Prognostic significance of QOL deterioration during early lung cancer survivorship: Secondary analysis of RTOG 0212 and 0214. (Abstract #6061) V. Gondi, R. Paulus, D. Bruner, C. A. Meyers, E. Gore, A. H. Wolfson, M. Werner-Wasik, H. Choy, B. Movsas, Radiation Therapy Oncology Group (RTOG) Brd. 43B Smaller, faster trials: The right way to assess new targeted agents? A simulation study. (Abstract #6062) M. Le Deley, K. V. Ballman, D. J. Sargent Brd. 43C Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC). (Abstract #6063) P. Ravdin, S. Martino, M. D. Pegram, N. J. Robert, S. M. Swain, D. Janssen, A. Bowser, J. A. Mortimer, R. W. Carlson Brd. 43D Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) in colorectal cancer: A population-based analysis of adherence and nonreceipt. (Abstract #6064) D. Rayson, R. Urquhart, E. Grunfeld, M. Cox, C. Kendell, M. Jorgensen, B. Colwell, G. A. Porter Brd. 43E Understanding patients’ attitudes toward communication about the cost of cancer care. (Abstract #6065) A. J. Bullock, E. W. Hofstatter, M. Yushak, M. K. Buss 123 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 43F Are African American men adequately represented in prostate cancer randomized controlled trials? A systematic review. (Abstract #6066) S. Galeb, T. Reljic, B. Djulbegovic, C. Gwede, N. B. Kumar, A. Kumar Brd. 43G Costs and utilization of oncology health care services at the end of life. (Abstract #6067) B. Chastek, C. R. Harley, J. D. Kallich, L. N. Newcomer, C. J. Paoli, A. Teitelbaum Brd. 43H Willingness to pay to prevent chemotherapy-induced nausea and vomiting. (Abstract #6068) P. Miller, S. Balu, D. Buchner, M. Walker, E. J. Stepanski, L. S. Schwartzberg Brd. 44A Meta analysis of behavioral interventions to reduce cancer pain. (Abstract #6069) S. S. Gorin, H. Badr, P. B. Jacobsen, E. Janke, H. S. Jim, P. Krebs Brd. 44B Analysis of minority-based community clinical oncology program (MBCCOP) accrual activity. (Abstract #6070) E. H. Williams, W. J. McCaskill-Stevens, T. E. Lad Brd. 44C Surgical treatment of colon cancer in patients older than age 80. (Abstract #6071) H. B. Neuman, E. S. O’Connor, J. Weiss, N. K. LoConte, D. Y. Greenblatt, M. Smith Brd. 44D Cancer in the adolescent and young adult (AYA) population in the United States: Current statistics and projections. (Abstract #6072) R. S. Go, J. D. Gundrum Brd. 44E A review of medical malpractice claims related to clinical genetic testing. (Abstract #6073) R. A. Lindor, G. E. Marchant Brd. 44F ASCO Quality Oncology Practice Initiative (QOPI) quality measures for smoking cessation and survival in metastatic NSCLC. (Abstract #6074) I. T. Lennes, J. S. Temel, J. A. Greer, J. O. Jacobson, E. R. Park, V. A. Jackson, E. R. Gallagher, H. Bemis, W. F. Pirl Brd. 44G A clinical trial with culturally tailored video to increase participation of African Americans in cancer clinical trials. (Abstract #6075) D. R. Banda, M. Mete, R. Kapoor, S. M. Swain Brd. 44H Quantifying the personal financial impact of a career choice in academic hematology/oncology (AHO). (Abstract #6076) M. Palmeri, E. Stansfield, A. Stansfield, A. D. Fuld, J. M. Pipas, B. A. Arrick, E. Wadsworth, T. H. Davis Brd. 45A Comparison of beliefs of lung cancer providers and minority patients. (Abstract #6077) C. B. Smith, N. Bickell, E. Halm, A. R. Berman, C. A. Powell, J. Salazar-Schicchi, J. E. Nelson, J. P. Wisnivesky Brd. 45B Impact of early prostate cancer diagnosis in the United States. (Abstract #6078) Y. Zhang, B. K. Hollenbeck, J. E. Montie, J. T. Wei Brd. 45C Predictors of successful breast-conserving surgery (BCS) in patients with ductal carcinoma in situ (DCIS). (Abstract #6079) J. J. Griggs, M. E. Sorbero, G. M. Ahrendt, L. M. Schiffhauer, A. Stark, A. W. Dick Brd. 45D Accelerated partial-breast irradiation using brachytherapy (APBIb) for breast cancer: Predictors of use and guideline concordance. (Abstract #6080) J. A. Hattangadi, N. Taback, B. A. Neville, J. R. Harris, R. S. Punglia Brd. 45E Cost-effectiveness of intraoperative radiation therapy for breast conservation. (Abstract #6081) M. Alvarado, E. Ozanne, A. Mohan, L. Esserman 124 Brd. 45F Cost effectiveness of a survivorship care plan for breast cancer survivors. (Abstract #6082) D. Coyle, E. Grunfeld, K. Coyle, J. A. Julian, G. R. Pond, A. Folkes, M. N. Levine, FUPII Trial Investigators, Ontario Clinical Oncology Group Brd. 45G Clinical outcome of advanced colorectal cancer patients pre and post bevacizumab therapy using the SEER database. (Abstract #6083) M. Choi, G. Dyson, P. A. Philip, A. F. Shields Brd. 45H How often are opioids prescribed for cancer patients reporting pain? Results of a population-based analysis. (Abstract #6084) L. C. Barbera, H. Seow, A. Husain, D. Howell, C. Atzema, C. Earle, Y. Liu, J. Sussman, R. Sutradhar, D. J. Dudgeon Brd. 46A Validation of a claims-based predicted performance status measure in SEER-Medicare. (Abstract #6085) F. Hendrick, I. H. Zuckerman, N. B. Pandya, X. Ke, M. J. Edelman, A. J. Davidoff Brd. 46B The cost-effectiveness of primary prophylaxis with granulocyte colonystimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: The impact of risk of febrile neutropenia and its mortality. (Abstract #6086) K. K. Chan, M. E. Trudeau, A. Eisen, J. L. Verreault, C. A. Freedman, S. Dent Brd. 46C Correlates of poor surgical margins following initial surgery for ductal carcinoma in situ and receipt of additional surgery. (Abstract #6087) M. E. Sorbero, J. J. Griggs, G. M. Ahrendt, L. M. Schiffhauer, A. Stark, A. W. Dick Brd. 46D A year in the life of oncology health services research. (Abstract #6088) M. Brundage, C. F. Snyder, B. H. Bass Brd. 46E Changing prognosis of glioblastoma multiforme (GBM) in the 21st century: The influence of age and regional income. (Abstract #6089) M. V. Mishra, A. Dicker, M. Werner-Wasik, D. W. Andrews, X. Shen, T. N. Showalter, J. Glass, Z. Symon, Y. R. Lawrence Brd. 46F Reporting of cancer clinical trial adverse drug events: A RADAR report. (Abstract #6090) S. M. Belknap, C. H. Georgopoulos, S. A. Weitzman, L. Qualkenbush, A. T. Samaras, J. M. McKoy, B. J. Edwards, S. T. Rosen, D. P. West Brd. 46G A national evaluation of response and factors affecting response to neoadjuvant therapy in breast and rectal cancer. (Abstract #6091) S. B. Edge, D. Gress, D. P. Winchester, A. Stewart Brd. 46H Evaluation of cancer trial eligibility criteria (with focus on non-AIDS– defining cancers) for inclusion of persons with HIV infection. (Abstract #6092) S. A. Weiss, S. Gajavelli, A. Negassa, J. A. Sparano, M. Haigentz Jr. Brd. 47A Predictors of accrual to clinical trials in an integrated health care delivery system. (Abstract #6093) C. P. Somkin, L. M. Ackerson, G. Husson, T. Kolevska, D. Goldstein, L. Fehrenbacher Brd. 47B Emerging trends in radiation therapy use among women older than age 70 with stage I breast cancer from 2000 –2007: A population-based analysis. (Abstract #6094) X. Shen, A. P. Wojcieszynski, M. V. Mishra, P. R. Anne, T. N. Showalter Brd. 47C Assessment of clinical trials in oncology: An evaluation of 40,696 trials on ClinicalTrials.gov. (Abstract #6095) B. R. Hirsch, R. M. Califf, A. Tasneem, K. Chiswell, J. Bolte, K. A. Schulman, A. P. Abernethy Brd. 47D Therapeutic clinical trial enrolment among young adults diagnosed with cancer. (Abstract #6096) P. S. Blanchette, M. Crump, A. A. Gupta 125 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 47E Use of radiation therapy after breast-conserving surgery among Medicaid recipients with early-stage breast cancer. (Abstract #6097) S. B. Wheeler, Y. Wu, A. Meyer, W. R. Carpenter, L. C. Richardson, J. L. Smith, M. A. Lewis, B. Weiner Brd. 47F Risks and benefits of phase I trials: Twelve-years experience from a single institution. (Abstract #6098) U. Swami, M. H. Ghalib, I. Chaudhary, J. Y. Hou, S. Aparo, M. H. Einstein, G. L. Goldberg, T. N. Elrafei, S. Gajavelli, B. Cohen, L. Rajdev, A. Kaubisch, M. Haigentz Jr., S. Mani, S. Goel Brd. 47G Framing the benefits of cancer treatment: How survival is described influences preferences for care. (Abstract #6099) P. Lin, T. W. Concannon, D. Greenberg, G. P. Rossi, J. Hille, C. Fang, H. R. Auerbach, P. J. Neumann Brd. 47H Doctor, what do I have? Limited-English–proficient patients and cancer diagnosis knowledge. (Abstract #6100) J. C. Leng, L. Yogendran, D. Massie, J. Ramirez, T. Lee, I. Lobach, F. Gany Brd. 48A The ASCO Breast Cancer Registry pilot: Implementation of a multisite community practice registry and treatment plan/summary program. (Abstract #6101) A. H. Partridge, V. W. Norris, V. S. Blinder, B. A. Cutter, M. T. Halpern, J. Malin, M. N. Neuss, A. C. Wolff, ASCO Breast Cancer Registry Pilot Steering Group Brd. 48B Health-related quality-of-life (HRQoL) reporting by randomized cancer trials (RCT): Pitfalls for interpretation. (Abstract #6102) L. Testa, C. C. Barbosa, A. C. Chaves, P. M. Hoff, R. P. Riechelmann Brd. 48C Prospective validation of risk prediction models for acute and delayed chemotherapy-induced nausea and vomiting (CINV). (Abstract #6103) N. Bouganim, G. Dranitsaris, L. Vandermeer, S. Hopkins, S. Dent, P. Wheatley-Price, S. Verreault, C. Young, M. J. Clemons Brd. 48D Pharmaceutical involvement in phase II breast cancer clinical trials. (Abstract #6104) A. Schneider, T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, J. M. Peppercorn Brd. 48E Shifting patterns in the interpretation of phase III clinical trial outcomes in the treatment of advanced NSCLC. (Abstract #6105) A. G. Sacher, N. B. Leighl Brd. 48F Relationship between physician characteristics and the use of newer chemotherapy for the treatment of colon cancer. (Abstract #6106) D. J. Becker, D. L. Hershman, B. J. Insel, A. I. Neugut Brd. 48G Uptake of bevacizumab for the treatment of colon cancer. (Abstract #6107) A. I. Neugut, D. J. Becker, B. J. Insel, D. L. Hershman Brd. 48H Population-based health care cost estimates related to breast cancer by staging. (Abstract #6108) N. Mittmann, P. K. Isogai, R. Saskin, N. Liu, J. Hoch, N. B. Leighl, M. C. Cheung, M. E. Trudeau, W. K. Evans, K. Dainty, C. Earle Brd. 49A Oncology appointment compliance in navigated and non-navigated patients receiving radiation therapy in an urban public hospital. (Abstract #6109) E. A. Marcus, N. Holloway, C. Galligan, R. Cheng, M. McDunn, P. A. Robinson, K. Devine Brd. 49B Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). (Abstract #6110) S. S. Grubbs, R. S. Go, M. Z. Berger, M. Gonzalez, M. A. Thompson, R. Enos, D. C. St. Germain, A. Denicoff, C. Servididio, J. D. Bearden, H. Zaren, K. Wilkinson, M. Krasna, W. McCaskill-Stevens, M. Bell, R. K. Freeman, S. Miesfeldt, T. S. Ravikumar, S. G. Nair, A. Bashey 126 Brd. 49C A cost benefit analysis of the 21-gene breast cancer assay within a Canadian health care system. (Abstract #6111) S. Hassan, N. Mittmann Brd. 49D Use of high-cost imaging in elderly patients with metastatic cancer. (Abstract #6112) Y. Hu, A. C. Kwok, W. Jiang, N. Taback, S. R. Lipsitz, G. V. Ting, E. T. Loggers, J. C. Weeks, C. C. Greenberg Brd. 49E The Cancer Therapy Evaluation Program’s (CTEP) implementation of the Operational Efficiency Working Group (OEWG) recommendations. (Abstract #6113) K. DiPiazza, E. Souhan, S. Finnigan, A. Denicoff, S. Friedman, M. Montello, M. M. Mooney, P. Schettino, J. A. Zwiebel, J. H. Doroshow, J. S. Abrams Brd. 49F Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. (Abstract #6114) V. C. Tam, Y. Ko, N. Mittmann, K. Kumar, S. Hassan, M. C. Cheung, K. K. Chan Brd. 49G Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries. (Abstract #6115) M. A. Dinan, T. J. Robinson, T. M. Zagar, C. D. Scales Jr., L. H. Curtis, S. D. Reed, K. A. Schulman, W. Lee Brd. 49H The 2010 National Comprehensive Cancer Network (NCCN) research benchmarking survey (RBS): Clinical trials in the academic cancer center. (Abstract #6116) S. L. Sherman, M. B. Waldinger, D. E. Paul Brd. 50A Survivorship care plan assessment checklist (SCPAC): A tool to evaluate breast cancer survivorship care plans. (Abstract #6117) C. T. Stricker, L. A. Jacobs, A. DeMichele, A. Jones, B. C. Risendal, S. C. Palmer Brd. 50B Survival trends and patterns of chemotherapy use in elderly metastatic colorectal cancer (mCRC) patients. (Abstract #6118) V. Shankaran, S. J. Beck, D. K. Blough, L. Koepl, Y. Yim, E. Yu, S. D. Ramsey Brd. 50C Clinical trial availability compared to incidence rates for adolescent and young adult cancer. (Abstract #6119) D. J. Indelicato, A. Bleyer, LIVESTRONG Young Adult Alliance Brd. 50D Conflict of interest in economic analyses of targeted therapies in oncology. (Abstract #6120) A. D. Nearchou, A. Valachis, N. P. Polyzos, D. Mauri, P. A. Lind Brd. 50E Long-term surveillance and preventive practices among healthy young adult cancer survivors. (Abstract #6121) E. M. Del Giudice, L. F. Paszat, L. Rabeneck, R. Sutradhar, D. Urbach, D. Wilton, N. N. Baxter Brd. 50F Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. (Abstract #6122) J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. Alberts Brd. 50G Perspectives on electronic health information exchange among people affected by cancer. (Abstract #6123) E. B. Beckjord, R. Rechis, L. N. Shulman, B. Hesse Brd. 50H Does insurance coverage affect pancreatic cancer survival? The Medicare age threshold. (Abstract #6124) J. K. Smith, J. Dimick, E. R. Witkowski, E. Ragulin-Coyne, T. P. McDade, S. Ng, Z. Zhou, J. F. Tseng Brd. 51A The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. (Abstract #6125) M. Raphael, J. J. Biagi, W. J. Mackillop, W. Kong, W. D. King, C. M. Booth 127 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 51B Two decades of oncology randomized controlled trials: Factors associated with CONSORT clinical trial reporting checklist compliance. (Abstract #6126) G. Rodrigues, I. Arra, V. Velker, B. Rotenberg, T. Sexton Brd. 51C Palliative chemotherapy: Does aggressive care beget aggressive care? (Abstract #6127) A. A. Wright, H. G. Prigerson Brd. 51D Appointment (appt) access for new cancer patients (pts). (Abstract #6128) K. Gogineni, K. Armstrong Brd. 51E Impact of travel distance on early diagnosis of prostate cancer (CaP) and receipt of curative treatment. (Abstract #6129) J. A. Holmes, W. R. Carpenter, Y. Wu, S. P. Hinton, M. Massing, A. P. Schenck, A. Meyer, S. B. Wheeler, P. A. Godley, R. C. Chen Brd. 51F Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. (Abstract #6130) A. C. Dueck, D. J. Sargent, P. J. Novotny, P. A. Decker, H. Nelson, R. Qin, J. A. Sloan Brd. 51G Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study. (Abstract #6131) M. Walker, A. Szeto, Z. Meng, B. E. Chen, R. M. Meyer Brd. 51H Managing specialty medication services through a network of specialty pharmacies: A case of oral oncology medications. (Abstract #6132) S. Aslam, S. Tschida, L. S. Lal, T. T. Khan, W. H. Shrank, G. R. Bhattarai, J. C. Montague- Clouse, L. N. Newcomer Brd. 52A Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. (Abstract #6133) L. P. Garrison, D. Lalla, M. G. Brammer, B. Wang, J. Babigumira, E. A. Perez Brd. 52B Rapid improvement in evidence-based, quality care of cancer patients with initiation of ASCO’s Quality Oncology Practice Initiative (QOPI). (Abstract #6134) M. A. Amin, M. H. Hashmi, S. A. Taylor Brd. 52C The effect of process engineering on the performance of a chemotherapy outpatient clinic (CC). (Abstract #6135) J. Latreille, C. Mimeault, N. Moreau, S. Parent, J. Savaria, J. Bastien, J. Lafreniere, C. C. Prady, O. Blaizel, G. Pie, M. Gannon Brd. 52D Computer-assisted outreach by patient care navigators using laptop wireless communication. (Abstract #6136) M. Castaldi, T. N. Elrafei, M. Broderick, H. Delany, Albert Einstein College of Medicine 128 Saturday, June 4, 2011 8:00 AM - 1:00 PM POSTER DISCUSSION SESSION Developmental Therapeutics—Clinical Pharmacology and Immunotherapy Display Time: 8:00 AM - 12:00 PM Display Location: S403 Discussion Time: 12:00 PM - 1:00 PM Discussion Location: S406 CME credit: 1 Track(s): Developmental Therapeutics SATURDAY Jeffrey R. Infante, MD—Chair The Sarah Cannon Cancer Center Discussion 12:00 PM Janet Dancey, MD (Abstracts #2515–2523) Ontario Institute for Cancer Research Discussion 12:15 PM S. Percy Ivy, MD (Abstracts #2524 –2529) National Cancer Institute Discussion 12:30 PM George Coukos, MD, PhD (Abstracts #2530 –2535) University of Pennsylvania, Abramson Cancer Center Discussion 12:45 PM Jeffrey R. Infante, MD (Abstracts #2536 –2539) The Sarah Cannon Cancer Center Brd. 1 First-in-human trial focusing on the immunologic effects of the survivinderived multiepitope vaccine EMD640744. (Abstract #2515) S. Gross, V. Lennerz, E. Gallerani, C. Sessa, N. Mach, S. Boehm, D. Hess, L. von Boehmer, A. Knuth, A. Ochsenbein, U. Gnad-Vogt, J. Zieschang, U. Forssmann, T. Woelfel, E. Kaempgen Brd. 2 The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors. (Abstract #2516) T. Nishina, T. Hirashima, K. Sugio, K. Muro, S. Akinaga, H. Maeda, T. Takahashi, T. Naito, H. Murakami, H. Yasui, N. Boku, N. Yamamoto Brd. 3 Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. (Abstract #2517) C. Sessa, E. Gallerani, G. Del Conte, A. Christinat, A. Perotti, P. Lardelli, C. M. Kahatt, A. Florez, C. Fernandez, M. Miani, L. Gianni Brd. 4 A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. (Abstract #2518) M. Puglisi, L. van Doorn, M. Blanco-Codesido, M. J. De Jonge, K. Moran, J. Yang, T. Busman, C. Franklin, M. Mabry, A. Krivoshik, R. Humerickhouse, L. R. Molife, F. Eskens Brd. 5 A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). (Abstract #2519) B. Neyns, S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, C. Heirman, I. Van Riet, A. Bonehill, J. Corthals, K. Thielemans Brd. 6 Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). (Abstract #2520) J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz, J. Squires, N. D. Houston, J. J. Ji, M. Yu, J. H. Doroshow, E. C. Kohn 129 Saturday, June 4, 2011 SATURDAY Brd. 7 Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors. (Abstract #2521) M. Simonelli, P. A. Zucali, R. De Sanctis, E. Lorenzi, F. De Vincenzo, L. Rimassa, M. C. Tronconi, N. Personeni, G. Masci, M. Zuradelli, M. Perrino, M. Bertossi, L. Giordano, A. Santoro Brd. 8 Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. (Abstract #2522) P. A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, V. Quagliuolo, A. Lambiase, C. Bordignon, A. Santoro Brd. 9 Is there a therapeutic benefit for patients participating in modern phase I trials? (Abstract #2523) M. N. Stein, A. R. Tan, J. M. Mehnert, D. Gibbon, R. S. DiPaola, R. A. Moss, E. Poplin, E. H. Rubin, B. Saraiya, M. P. Kane, P. Scott, M. LaRosiliere, H. Camisa, P. Kirin, C. M. Thomas, J. Aisner Brd. 10 Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors. (Abstract #2524) G. A. Daniels, W. E. Carson III, A. C. Mita, K. L. Kendra, M. H. Rahimy, D. W. Inman, J. R. Appleman, J. L. Freddo, D. G. McNeel Brd. 11 Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR)–positive advanced breast carcinoma resistant to standard endocrine therapies. (Abstract #2525) B. Basu, J. Ang, D. Crawley, E. Folkerd, D. Sarker, M. Blanco-Codesido, K. Moran, S. Wan, N. Dobbs, F. Raynaud, S. R. Johnston, M. Dowsett, A. N. Tutt, J. F. Spicer, C. Swanton, J. S. De Bono Brd. 12 High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations. (Abstract #2526) I. Jawed, L. Amiri-Kordestani, M. Velarde, K. Adams, S. Balasubramaniam, J. Reynolds, K. Pacak, A. T. Fojo Brd. 13 Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and decay using data from phase II and phase III clinical trials in metastatic breast cancer (MBC) patients (Pts). (Abstract #2527) L. Amiri-Kordestani, I. Jawed, J. Wilkerson, W. D. Stein, A. T. Fojo, S. M. Swain, S. E. Bates Brd. 14 Survival of 1,181 patients in a phase I clinic: The University of Texas University of Texas M. D. Anderson Cancer Center experience. (Abstract #2528) B. Stephen, J. J. Wheler, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, G. S. Falchook, S. A. Piha-Paul, S. Fu, F. Janku, S. L. Moulder, R. Kurzrock Brd. 15 Bevacizumab changes in patients with naive, stage II-III breast cancer assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT. (Abstract #2529) V. Boni, I. Dominguez, M. J. Garcia Velloso, J. Lopez Vega, P. Martinez, A. Plazaola, B. Hernando, A. Llombart Cussac, J. Lao, R. S. Gomez, I. Alvarez, J. J. Illarramendi, E. G. Calvo, S. Morales Murillo, T. Puertolas, L. J. Pina, E. Bernedo, G. Palacios, S. J. Scherer, J. Garcia-Foncillas Brd. 16 Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. (Abstract #2530) C. R. Heery, P. A. Pinto, J. Schlom, K. Y. Tsang, R. A. Madan, D. Poole, M. Vergati, B. Walter Rodriguez, M. Merino, J. L. Gulley 130 Brd. 17 A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma. (Abstract #2531) T. K. Eigentler, B. Weide, G. Spitaleri, F. G. De Braud, A. Romanini, R. Gonzales-Inglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. Trachsel, D. Neri, H. D. Menssen, C. Garbe Brd. 18 Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell– based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. (Abstract #2532) R. A. Figlin, A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, M. DeBenedette, S. K. Pal, V. Master, I. Y. Tcherepanova, R. Jain, W. L. Williams, T. Monesmith, F. Miesowicz, C. A. Nicolette Brd. 19 A dendritic cell– based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. (Abstract #2533) H. K. Lyerly, A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu, T. S. Crocenzi, D. J. Cole, S. Dessureault, S. D. Hsu, A. Bulusu, B. M. Clary, R. Annechiarico, G. Devi, V. Chadaram, T. M. Clay, M. Morse Brd. 20 Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. (Abstract #2534) R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna, M. G. Frattini, M. Sadelain Brd. 21 A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2ⴙ metastatic breast cancer. (Abstract #2535) L. A. Emens, R. Gupta, S. Petrik, M. Laiko, J. M. Leatherman, J. Levi, J. M. Asquith, M. M. Daphtary, E. Garrett-Mayer, B. J. Kobrin, N. E. Davidson, T. Dauses, S. Atay-Rosenthal, X. Ye, A. C. Wolff, V. Stearns, E. M. Jaffee Brd. 22 An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. (Abstract #2536) J. Fok, R. Kurzrock, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, F. Janku, G. S. Falchook, S. A. Piha-Paul, R. Katz, S. Fu, S. L. Moulder, J. J. Wheler Brd. 23 Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. (Abstract #2537) P. A. Cohen, D. W. Northfelt, G. J. Weiss, D. D. Von Hoff, K. Manjarrez, G. Dietsch, R. M. Hershberg, R. K. Ramanathan Brd. 24 Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients (pts) with advanced cancer: Updated results and assessment of human CSF distribution. (Abstract #2538) E. G. Chiorean, E. A. Sausville, E. I. Heath, A. Weise, J. Gomez-Navarro, K. Venkatakrishnan, S. Sankoh, J. Wu, M. Corvez, P. LoRusso Brd. 25 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a pharmacodynamic (PD) biomarker in phase I trials of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). (Abstract #2539) J. Fredrickson, I. Chang, M. Friesenhahn, E. Ashton, P. N. Munster, M. S. Gordon, D. S. Chen, L. Naumovski, A. de Crespigny, L. S. Rosen 131 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 8:00 AM - 1:00 PM POSTER DISCUSSION SESSION Lymphoma and Plasma Cell Disorders Display Time: 8:00 AM - 12:00 PM Display Location: E450b Discussion Time: 12:00 PM - 1:00 PM Discussion Location: E354a CME credit: 1 Track(s): Lymphoma and Plasma Cell Disorders SATURDAY John Leonard, MD—Co-Chair Weill Cornell Medical College Sonali M. Smith, MD—Co-Chair The University of Chicago Discussion 12:00 PM Ann S. LaCasce, MD (Abstracts #8015– 8016, 8023) Dana-Farber Cancer Institute Discussion 12:15 PM David G. Maloney, MD, PhD (Abstracts #8017– 8019) Fred Hutchinson Cancer Research Center Discussion 12:30 PM Suzanne Lentzsch, MD, PhD (Abstracts #8021– 8022, 8024) University of Pittsburgh Discussion 12:45 PM Jonathan L. Kaufman, MD (Abstracts #8025– 8027) Emory University Brd. 1 Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study. (Abstract #8015) G. S. Nowakowski, C. B. Reeder, B. LaPlant, T. M. Habermann, C. Rivera, W. R. Macon, D. J. Inwards, I. N. Micallef, P. B. Johnston, L. F. Porrata, S. M. Ansell, T. E. Witzig Brd. 2 Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. (Abstract #8016) J. D. Hainsworth, E. Arrowsmith, M. McCleod, L. Fayad, O. Hamid, L. Davis, B. K. Lin Brd. 3 Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell nonHodgkin lymphoma (NHL). (Abstract #8017) B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir Brd. 4 Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma. (Abstract #8018) L. F. Porrata, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston, W. J. Hogan, S. Markovic Brd. 5 Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20ⴙ NHL not eligible for standard ASCT: Five-year results. (Abstract #8019) L. Devizzi, A. Guidetti, C. Carlo-Stella, C. Tarella, E. Seregni, M. Magni, M. A. Di Nicola, E. Schiavello, P. Matteucci, S. Viviani, E. Bombardieri, A. M. Gianni 132 Brd. 6 Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. (Abstract #8020) M. Boccadoro, F. Cavallo, A. Nagler, D. Ben Yehuda, P. Omedè, M. Cavalli, A. Levi, C. Crippa, A. Siniscalchi, P. Brasca, A. M. Carella, B. Zanetti, F. Patriarca, S. Pezzati, V. Montefusco, A. Stanevsky, B. Lupo, T. Caravita, F. Di Raimondo, A. P. Palumbo Brd. 7 Survival outcomes in elderly patients with plasma cell myeloma: The threedecade Eastern Cooperative Oncology Group (ECOG) experience. (Abstract #8021) E. L. Campagnaro, S. J. Jacobus, H. Uno, M. M. Oken, R. A. Kyle, S. V. Rajkumar, P. R. Greipp, D. H. Vesole, M. Weiss, R. Fonseca, H. M. Lazarus Brd. 8 Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance versus observation in previously untreated mantle cell lymphoma (MCL). (Abstract #8022) C. Grant, K. Dunleavy, M. Tweito, S. M. Steinberg, S. Pittaluga, E. S. Jaffe, A. Wiestner, W. H. Wilson Brd. 9 Activity of vorinostat (SAHA), cladribine (2-CdA), and rituximab in previously untreated mantle cell lymphoma: A phase I/II study. (Abstract #8023) S. E. Spurgeon, A. I. Chen, B. Ratterree, C. Okada, G. Palmbach, K. Diaz, N. Subbiah, C. Capper, E. E. Epner Brd. 10 Generation of an automated tool for querying myeloma transcriptomics for multiple gene expression signatures used in risk stratification. (Abstract #8024) R. Fonseca, E. Braggio, J. J. Keats, G. J. Ahmann, J. Mantei, A. K. Stewart, P. L. Bergsagel Brd. 11 Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (Abstract #8025) M. Wang, W. Bensinger, T. Martin, M. Alsina, D. S. Siegel, N. Y. Gabrail, P. Hari, S. Singhal, R. A. Vescio, S. E. Assouline, L. A. Kunkel, M. Vallone, A. Wong, R. Niesvizky Brd. 12 The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171– 004 study. (Abstract #8026) A. K. Stewart, J. L. Kaufman, A. J. Jakubowiak, S. Jagannath, V. Kukreti, K. T. McDonagh, M. Alsina, N. J. Bahlis, A. Belch, N. Y. Gabrail, F. J. Reu, J. Matous, D. H. Vesole, R. Z. Orlowski, L. A. Kunkel, M. Le, P. Lee, M. Sebag, M. Wang, R. Vij, The Multiple Myeloma Research Consortium (MMRC) Brd. 13 PX-171– 003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. (Abstract #8027) D. S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, V. Kukreti, N. J. Bahlis, M. Alsina, G. Somlo, F. Buadi, F. J. Reu, K. W. Song, L. A. Kunkel, A. Wong, M. Vallone, R. Z. Orlowski, A. K. Stewart, S. Singhal, S. Jagannath, A. J. Jakubowiak, The Multiple Myeloma Research Consortium (MMRC) Brd. 14 Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM). (Abstract #8028) J. Szymonifka, S. Z. Usmani, R. Sexton, S. Panozzo, B. P. Nair, S. Waheed, Y. Alsayed, J. Crowley, B. Barlogie 133 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 8:00 AM - 1:00 PM POSTER DISCUSSION SESSION Sarcoma Display Time: 8:00 AM - 12:00 PM Display Location: E450a Discussion Time: 12:00 PM - 1:00 PM Discussion Location: E354b CME credit: 1 Track(s): Sarcoma SATURDAY Robin L. Jones, MD—Co-Chair University of Washington Christian Frederick Meyer, MD, PhD—Co-Chair The Johns Hopkins University Discussion 12:00 PM Jayesh Desai, MBBS (Abstracts #10009 –10017) Royal Melbourne Hospital Discussion 12:15 PM Richard F. Riedel, MD (Abstracts #10019 –10023) Duke University Medical Center Discussion 12:30 PM Warren Allen Chow, MD (Abstracts #10024 –10028) City of Hope Discussion 12:45 PM Leo Mascarenhas, MBBS, MD, MS (Abstracts #10029 –10033) Children’s Hospital Los Angeles Brd. 1 Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. (Abstract #10009) H. L. Kindler, N. P. Campbell, K. Wroblewski, R. G. Maki, D. R. D’Adamo, W. A. Chow, D. R. Gandara, C. Antonescu, W. M. Stadler, E. E. Vokes Brd. 2 A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study. (Abstract #10010) M. Ryu, S. Park, B. Ryoo, S. Im, H. Kwon, S. Lee, B. Kang, Y. Kang Brd. 3 An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. (Abstract #10011) G. D. Demetri, M. C. Heinrich, B. Chmielowski, J. A. Morgan, S. George, R. Bradley, R. K. Blackman, F. Teofilovici, J. A. Fletcher, W. D. Tap, M. von Mehren Brd. 4 The effect of crenolanib (CP-868596) on phosphorylation of the imatinibresistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. (Abstract #10012) M. C. Heinrich, D. Griffith, A. McKinley, A. Presnell, A. Ramachandran Brd. 5 Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST). (Abstract #10013) M. Molimard, S. Bouchet, S. Poulette, E. Chauzit, K. Titier, N. Moore, R. Lassalle, A. Abouelfath, A. Italiano, C. Chevreau, F. Duffaud, M. Rios, D. Cupissol, A. Adenis, I. L. Ray-Coquard, O. Bouche, A. Le Cesne, J. Blay, B. Bui Nguyen Brd. 6 Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study. (Abstract #10014) K. Eechoute, M. N. Fransson, U. De Giorgi, A. K. Reyners, F. A. de Jong, L. E. Friberg, W. Van Der Graaf, A. Sparreboom, J. Verweij, W. J. Loos, R. Mathijssen 134 Brd. 7 Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. (Abstract #10015) A. Le Cesne, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci, F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, A. Cioffi, S. Chabaud, D. Perol, J. Blay Brd. 8 Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KITⴙ gastrointestinal stromal tumors (GIST). (Abstract #10016) M. von Mehren, M. C. Heinrich, H. Joensuu, C. D. Blanke, E. Wehrle, G. D. Demetri Brd. 9 An analysis of arterial hypertension and mutational status as predictive factors for results of sunitinib (SU) therapy in gastrointestinal stromal tumors (GIST). (Abstract #10017) P. Rutkowski, E. Bylina, T. Switaj, A. Klimczak, S. Falkowski, J. Kroc, I. A. Lugowska, M. Brzeskwiniewicz, A. Wozniak, J. Siedlecki, J. Limon Brd. 11 Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). (Abstract #10019) S. Stacchiotti, P. Verderio, A. Messina, C. Morosi, A. Ferraro, V. Quagliuolo, J. Martin, A. Comandone, G. Grignani, P. Picci, S. Frustaci, A. Gronchi, P. G. Casali Brd. 12 Preoperative chemoradiation therapy for localized retroperitoneal soft tissue sarcoma (RSTS): A phase II study from the Italian Sarcoma Group. (Abstract #10020) A. Gronchi, A. De Paoli, C. Dani, F. Merlo, V. Quagliuolo, G. Grignani, G. Bertola, P. Navarria, A. P. Dei Tos, P. G. Casali, Italian Sarcoma Group Brd. 13 Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III study. (Abstract #10021) R. D. Issels, R. P. Laubender, L. Lindner, U. Mansmann, E. Kampmann, J. Verweij, P. Reichardt, B. Schem, S. Daugaard, M. Niederhagen, Z. Vujaskovic, R. Wessalowski, C. M. Wendtner, K. Jauch, H. Duerr, R. Windhager, W. Hiddemann, J. Blay, P. Hohenberger Brd. 14 A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients. (Abstract #10022) P. Pautier, A. Floquet, L. Gladieff, D. Berton-Rigaud, S. Piperno-Neumann, F. Selle, C. Guillemet, I. Ray-Coquard, B. Weber, P. Duvillard, C. Haie-Meder, A. Rey Brd. 15 Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions. (Abstract #10023) R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr, C. Morosi, S. Pilotti, I. R. Judson, P. G. Casali Brd. 16 A phase II dose expansion of TH-302 in combination with doxorubicin in soft tissue sarcoma. (Abstract #10024) L. D. Cranmer, K. N. Ganjoo, D. Adkins, D. R. Reed, S. H. Okuno, J. E. Butrynski, D. A. Rushing, G. A. Lorente, S. Kroll, S. P. Chawla Brd. 17 A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST). (Abstract #10025) D. R. D’Adamo, M. Keohan, R. D. Carvajal, M. L. Hensley, C. Hirst, L. Qin, C. Antonescu, R. A. Lefkowitz, G. K. Schwartz, R. G. Maki 135 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 18 A dose-finding study of temsirolimus and liposomal doxorubicin for patients with advanced soft tissue or bone sarcoma. (Abstract #10026) D. M. Loeb, K. A. DeLorenzo, A. R. Chen, C. F. Meyer, J. Powell Brd. 19 Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas. (Abstract #10027) S. Movva, T. Bocklage, B. Schmit, R. Quinn, B. J. Liem, C. F. Verschraegen Brd. 20 Phase II AIDS Malignancy Consortium trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS). (Abstract #10028) H. B. Koon, K. Honda, J. Y. Lee, A. Noy, AIDS Malignancy Consortium Brd. 21 Use of cellular context to determine sarcoma phenotype in a new mouse sarcoma model. (Abstract #10029) S. Hettmer, J. Liu, C. M. Miller, R. T. Bronson, D. M. Langenau, A. J. Wagers Brd. 22 Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas. (Abstract #10030) K. A. Robertson, D. C. Bowers, F. Yang, T. Vik, C. Ho, J. Croop, L. E. Walsh, C. Hingtgen, K. R. Pradhan, G. Hutchins, J. W. Fletcher, M. Cohen, M. Edwards-Brown, J. B. Travers, M. Yu, G. Nalepa, S. Denne, D. Ingram, W. Clapp Brd. 23 Cixutumumab combined with temsirolimus in patients with refractory Ewing’s sarcoma. (Abstract #10031) A. Naing, P. LoRusso, S. Fu, D. S. Hong, P. M. Anderson, R. S. Benjamin, J. A. Ludwig, H. X. Chen, L. A. Doyle, R. Kurzrock Brd. 24 Preliminary safety and outcome report of the metronomic therapy from the Latin American osteosarcoma treatment protocol 2006. (Abstract #10032) A. S. Petrilli, C. R. Macedo, S. R. Toledo, P. C. Pavoni-Ferreira, M. Grings, M. Scopinaro, S. Ferman, E. Boldrini, M. A. Almeida, C. T. de Oliveira, G. L. Rey, L. A. Castillo, M. Borsato, J. Barreto, V. L. Morais, A. L. Brunetto, D. Lustosa, Grupo Latino Americano para Tratamento de Osteosarcoma GLATO/GALOP Brd. 25 Activity of toremifene in sporadic desmoid-type fibromatosis. (Abstract #10033) M. Fiore, C. Colombo, S. Radaelli, P. Prestianni, R. Sanfilippo, C. Morosi, F. Perrone, S. Stacchiotti, P. G. Casali, A. Gronchi 136 Saturday, June 4, 2011 9:30 AM - 12:00 PM SPECIAL SESSION Opening Session with Presidential Address, NCI Director’s Address, David A. Karnofsky Memorial Award and Lecture, ASCO Humanitarian Award, and the Conquer Cancer Foundation Donor Recognition Awards Location: Hall B1 CME credit: 1.5 Track(s): Special Session SATURDAY Kenneth Carl Anderson, MD—Karnofsky Award Recipient Dana-Farber Cancer Institute Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma 137 Saturday, June 4, 2011 9:45 AM - 11:00 AM MEET THE PROFESSOR SESSION The Role of Prevention Services in U.S. Health Care Reform (M01)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Cancer Prevention/Epidemiology, Health Services Research Steven Stranne, MD, JD Polsinelli Shughart The Role of Prevention in the New Health Care Reform Bill SATURDAY 138 Saturday, June 4, 2011 9:45 AM - 11:00 AM CLINICAL PROBLEMS IN ONCOLOGY SESSION Practical Approaches to the Patient with Complex Gynecologic Cancer (C03)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Gynecologic Cancer SATURDAY Nadeem Abu-Rustum, MD—Chair Memorial Sloan-Kettering Cancer Center Practical Management of Late-stage Complications of Ovarian Cancer Krishnansu Sujata Tewari, MD University of California, Irvine Medical Center Treatment Challenges in the Management of the Advanced Cervical Cancer Patient Linda R. Duska, MD University of Virginia Health System Conservative Management of a Young Patient with Endometrial Cancer: Fertility-sparing Options 139 Saturday, June 4, 2011 1:00 PM - 4:00 PM ORAL ABSTRACT SESSION Gastrointestinal (Colorectal) Cancer Location: Hall D1 CME credit: 3 Track(s): Gastrointestinal (Colorectal) Cancer Michael J. Hall, MD—Co-Chair Fox Chase Cancer Center John S. Kauh, MD—Co-Chair Winship Cancer Institute of Emory University SATURDAY 1:00 PM The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. (Abstract #3503) M. S. Roh, G. A. Yothers, M. J. O’Connell, R. W. Beart, H. C. Pitot, A. F. Shields, D. S. Parda, S. Sharif, C. J. Allegra, N. J. Petrelli, J. C. Landry, D. P. Ryan, A. Arora, T. L. Evans, G. S. Soori, L. Chu, R. V. Landes, M. Mohiuddin, S. Lopa, N. Wolmark 1:15 PM Capecitabine (Cape) versus 5-fluorouracil (5-FU)– based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Longterm results of a randomized, phase III trial. (Abstract #3504) R. Hofheinz, F. K. Wenz, S. Post, A. Matzdorff, S. Laechelt, J. T. Hartmann, L. Müller, H. Link, M. H. Moehler, E. Kettner, E. Fritz, U. Hieber, H. Lindemann, M. Grunewald, S. Kremers, C. Constantin, M. Hipp, D. Gencer, I. Burkholder, A. Hochhaus 1:30 PM Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial. (Abstract #LBA3505) C. Roedel, H. Becker, R. Fietkau, U.Graeven, W. Hohenberger, T. Hothorn, M. Lang-Welzenbach, T. Liersch, L. Staib, H. Christiansen, C. Wittekind, R. Sauer 1:45 PM An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3– 4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? (Abstract #3506) F. Bonnetain, J. Bosset, J. Gerard, G. Calais, T. Conroy, L. Mineur, O. Bouche, P. Maingon, O. Chapet, L. Radosevic-Jelic, N. Methy, L. Collette Discussion 2:00 PM Robert Glynne-Jones, MD (Abstracts #3503–3506) Mount Vernon Centre for Cancer Treatment 2:15 PM The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. (Abstract #3507) G. A. Yothers, C. J. Allegra, M. J. O’Connell, T. J. George, S. Sharif, N. J. Petrelli, S. Lopa, N. Wolmark 2:30 PM Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. (Abstract #3508) C. J. Allegra, G. A. Yothers, M. J. O’Connell, S. Sharif, N. J. Petrelli, L. H. Colangelo, N. Wolmark 2:45 PM A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (Abstract #3509) T. Andre, E. Van Cutsem, H. Schmoll, J. Tabernero, S. Clarke, M. J. Moore, D. Cunningham, T. H. Cartwright, J. R. Hecht, F. Rivera, S. Im, G. Bodoky, R. Salazar, F. Maindrault-Goebel, E. Shmueli, E. Bajetta, M. Makrutzki, A. Shang, A. De Gramont, P. M. Hoff 140 Saturday, June 4, 2011 Discussion 3:00 PM Howard S. Hochster, MD (Abstracts #3507–3509) Yale Cancer Center 3:15 PM Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). (Abstract #3510^) J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, D. Cunningham, F. Xu, K. Krishnan 3:30 PM Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. (Abstract #3511) S. Tejpar, C. Bokemeyer, I. Celik, M. Schlichting, U. Sartorius, E. Van Cutsem SATURDAY Discussion 3:45 PM Tanios S. Bekaii-Saab, MD (Abstracts #3510^–3511) The Ohio State University Medical Center 141 Saturday, June 4, 2011 1:15 PM - 2:30 PM SPECIAL SESSION Pediatric Oncology Award and Lecture Location: S504 CME credit: 1.25 Track(s): Special Session, Pediatric Oncology Lee J. Helman, MD Center for Cancer Research, National Cancer Institute Pathways to New Targets for Pediatric Sarcomas SATURDAY 142 Saturday, June 4, 2011 1:15 PM - 2:30 PM EDUCATION SESSIONS Direct-to-Consumer Genetic Testing for Cancer: What Physicians Need to Know Location: E353 CME credit: 1.25 Track(s): Cancer Genetics, General Oncology Daniel B. Vorhaus, JD Robinson, Bradshaw, & Hinson, P.A. A Guide to the (Current) Direct-to-Consumer Genetic Testing Landscape Stacy W. Gray, MD Dana-Farber Cancer Institute Direct-to-Consumer Genetic Testing: What We Know about Consumer Attitudes and Behavior Angela R. Bradbury, MD Fox Chase Cancer Center Direct-to-Consumer Genetic Testing for Cancer: Clinical Implications and Challenges Management of Prostate Cancer in Older Adults: To Treat or Not to Treat Location: S100bc CME credit: 1.25 Track(s): Geriatric Oncology, Genitourinary Cancer Anthony Victor D’Amico, MD, PhD—Chair Dana-Farber Cancer Institute/Brigham and Women’s Hospital Localized Disease William Dale, MD, PhD The University of Chicago Medical Center Screening Shabbir M. H. Alibhai, MD, MSc University Health Network Biochemical Recurrence Newer Techniques and Controversies in Breast and Lung Imaging for Cancer Screening and Prevention Location: S100a CME credit: 1.25 Track(s): Cancer Prevention/Epidemiology, Breast Cancer, Lung Cancer Denise R. Aberle, MD—Chair University of California, Los Angeles David Geffen School of Medicine Lung Cancer Screening and CT Imaging Constance D. Lehman, MD, PhD University of Washington Breast Cancer Screening: Magnetic Resonance Imaging, Ultrasound, Mammography—Where Do We Stand? 143 SATURDAY Sancy Ann Leachman, MD—Chair University of Utah Hospitals and Clinics Direct-to-Consumer Genetic Testing for Cancer: The Consumer Perspective Saturday, June 4, 2011 Post–Health Care Reform: Facing the New Reality Location: E354b CME credit: 1.25 Track(s): Practice Management and Information Technology, Health Services Research Tom Main, MBA—Chair Oliver Wyman Preparing Your Practice for Post–Health Care Reform: How Do Accountable Care Organizations Work? How Do We Define and Manage Risk? Lee Nisley Newcomer, MD United Health Group Payer Perspectives in Oncology SATURDAY Cecil Wilson, MD American Medical Association Response from the Medical Community The Therapy of High-risk Patients with Lung Cancer Location: Hall B1 CME credit: 1.25 Track(s): Lung Cancer, Geriatric Oncology Jeffrey Bogart, MD—Chair State University of New York Upstate Medical University Tailoring Radiotherapy for High-risk/Compromised Patients with Early-stage or Locally Advanced Non-small Cell Lung Cancer Cesare Gridelli, MD SG Moscati Hospital Therapy of Elderly Patients with Advanced Lung Cancer Rogerio Lilenbaum, MD Cleveland Clinic Florida Implications of Comorbidities and Performance Status in Patients with Advanced Lung Cancer 144 Saturday, June 4, 2011 1:15 PM - 2:30 PM MEET THE PROFESSOR SESSION Circulating Tumor Cells: We Have the Technology, But What Do We Do with the Information? (M06)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Developmental Therapeutics, Breast Cancer, Genitourinary Cancer SATURDAY Daniel F. Hayes, MD University of Michigan Medical Center 1:15 PM - 2:30 PM CLINICAL PROBLEMS IN ONCOLOGY SESSION Subsequent Therapy after Treatment of Lung Cancer: Consensus? (C04)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Lung Cancer Kenneth Rosenzweig, MD—Chair Mount Sinai Medical Center The Role of Postoperative Radiation Therapy in the Patient with Resected Lung Cancer: When, Why, and How? Jessica S. Donington, MD New York University School of Medicine Surgical Concerns for Adjuvant Therapy Joan H. Schiller, MD University of Texas Southwestern Medical Center Adjuvant Therapy: Who, What, When, and Why? 145 Saturday, June 4, 2011 1:15 PM - 2:45 PM CLINICAL SCIENCE SYMPOSIUM Ovarian Cancer: Novel Approaches to Improve Treatment Outcomes Location: E354a CME credit: 1.5 Track(s): Gynecologic Cancer Amit M. Oza, MD—Chair Princess Margaret Hospital 1:15 PM SATURDAY Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens. (Abstract #5000) C. Gourley, C. O. Michie, K. E. Keating, S. Deharo, E. J. O’Brien, A. Winter, F. A. McDyer, J. M. Mulligan, L. A. Hill, T. S. Davison, T. Halsey, L. McCoy, C. Wilson, A. Williams, D. J. Harrison, D. P. Harkin, R. D. Kennedy Discussion 1:30 PM Patricia Shaw, MD (Abstract #5000) University Health Network 1:45 PM Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial. (Abstract #5001) S. S. Buys, E. Partridge, A. Black, C. Johnson, L. Lamerato, C. Isaacs, D. Reding, R. Greenlee, B. Kessel, M. Fouad, D. Chia, L. Ragard, J. Rathmell, P. Hartge, P. Pinsky, G. Izmirlian, J. Xu, P. Prorok, C. D. Berg Discussion 2:00 PM Usha Menon, PhD, RN (Abstract #5001) UCL Elizabeth Garrett Institute of Women’s Health 2:15 PM Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) Trial. (Abstract #LBA5002) J. Pfisterer, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska, E. Pujade-Lauraine, G. Scambia, J. B. Vermorken, C. Simonelli, M. Bertolotti, A. Capriati, P. Sabbatini, AGO-OVAR, COGI, GEICO, GINECO Discussion 2:30 PM George Coukos, MD, PhD (Abstract #LBA5002) University of Pennsylvania, Abramson Cancer Center 146 Saturday, June 4, 2011 1:15 PM - 2:45 PM CLINICAL SCIENCE SYMPOSIUM Translational Science Advancing AR Targeting in Prostate Cancer Location: Hall D2 CME credit: 1.5 Track(s): Genitourinary Cancer 1:15 PM Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study. (Abstract #4500) C. J. Ryan, A. L. Harzstark, A. M. Lin, L. Fong, K. Grycz, R. Z. Szmulewitz, V. K. Weinberg, A. Molina, E. J. Small Discussion 1:30 PM Mary-Ellen Taplin, MD (Abstract #4500) Dana-Farber Cancer Institute 1:45 PM MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. (Abstract #4501) E. Efstathiou, M. A. Titus, D. Tsavachidou, A. Hoang, M. Karlou, S. Wen, P. Troncoso, R. Ashe, C. J. Berman, J. Mohler, C. Logothetis Discussion 2:00 PM Christopher P. Evans, MD (Abstract #4501) University of California, Davis 2:15 PM An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model. (Abstract #4502) H. Matsumoto, H. Kuruma, A. Zoubeidi, L. Fazli, M. E. Gleave Discussion 2:30 PM Peter Nelson, MD (Abstract #4502) Fred Hutchinson Cancer Research Center 147 SATURDAY Mark Garzotto, MD—Co-Chair Portland Veterans Affairs Medical Center William Kevin Kelly, DO—Co-Chair Thomas Jefferson University Hospital Saturday, June 4, 2011 1:30 PM - 4:00 PM ORAL ABSTRACT SESSION Lymphoma Location: S406 CME credit: 2.5 Track(s): Lymphoma and Plasma Cell Disorders Myron Stefan Czuczman, MD—Co-Chair Roswell Park Cancer Institute Gilles A. Salles, MD, PhD—Co-Chair Hospices Civils de Lyon and Universite de Lyon SATURDAY 1:30 PM R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. (Abstract #8000) D. Cunningham, P. Smith, P. Mouncey, W. Qian, A. S. Jack, C. Pocock, K. Ardeshna, J. A. Radford, A. J. Davies, A. McMillan, M. D. Linch 1:45 PM Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOPⴞR for eight cycles to CHOP with or without R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (Abstract #8001) P. J. Stiff, J. M. Unger, J. Cook, L. S. Constine, S. Couban, T. C. Shea, J. N. Winter, T. P. Miller, R. R. Tubbs, D. C. Marcellus, J. W. Friedberg, K. Barton, G. M. Mills, M. L. LeBlanc, L. Rimsa, S. J. Forman, R. I. Fisher 2:00 PM Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). (Abstract #8002) N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel, P. Borchmann, C. Schmidt, A. Viardot, M. Bentz, N. Peter, G. Ehninger, G. Doelken, L. H. Truemper, M. Loeffler, M. Pfreundschuh, B. Glass 2:15 PM First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. (Abstract #8003) S. Le Gouill, N. Milpied, T. Lamy, V. Delwail, R. Gressin, D. Guyotat, G. Damaj, C. Foussard, G. Cartron, H. Maisonneuve, E. Deconinck, F. Dreyfus, E. Gyan, L. Sutton, N. Morineau, M. Alexis, F. Perry, M. Sauvezie Discussion 2:30 PM Julie Vose, MD (Abstracts #8000 – 8003) University of Nebraska Medical Center 2:45 PM Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. (Abstract #8004) C. Gisselbrecht, B. Glass, G. Laurent, D. S. Gill, M. D. Linch, M. Trneny, D. Bron, O. Shpilberg, H. Hagberg, M. Bargetzi, D. Ma, J. Briere, C. Moskowitz, N. Schmitz 3:00 PM Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: A potentially curative approach? (Abstract #8005) L. Fischer, M. Haenel, R. Moehle, R. Schroers, T. Elter, M. Reiser, M. H. Dreyling, G. Illerhaus, J. Eucker, C. W. Scholz, B. Metzner, A. Roeth, J. Birkmann, U. Schlegel, P. Martus, E. Thiel, A. Korfel Discussion 3:15 PM James L. Rubenstein, MD, PhD (Abstracts #8004 – 8005) University of California, San Francisco 148 Saturday, June 4, 2011 3:30 PM Predictors of early response and event-free survival in Hodgkin lymphoma (HL): PET versus CT imaging. (Abstract #8006) C. L. Schwartz, D. L. Friedman, K. McCarten, S. L. Wolden, S. Voss, L. S. Constine, L. Chen, Children’s Oncology Group SATURDAY Discussion 3:45 PM Bruce D. Cheson, MD (Abstract #8006) Georgetown University Medical Center 149 Saturday, June 4, 2011 1:30 PM - 4:30 PM ORAL ABSTRACT SESSION Melanoma/Skin Cancers Location: Arie Crown Theater CME credit: 3 Track(s): Melanoma/Skin Cancers Paolo Antonio Ascierto, MD—Co-Chair Istituto Nazionale Tumori Caroline Robert, MD, PhD—Co-Chair Institute Gustave-Roussy SATURDAY 1:30 PM A population-based, case-control study of MC1R variants, ultraviolet light exposure, and melanoma. (Abstract #8504) E. Ng, E. Vega-Saenz de Miera, B. Tan, W. Gai, J. D. Goldberg, I. Osman, M. Berwick, D. Lazovich, D. Polsky 1:45 PM Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). (Abstract #8505) S. S. Agarwala, S. J. Lee, L. E. Flaherty, M. Smylie, R. F. Kefford, W. E. Carson III, G. Cohen, J. M. Kirkwood 2:00 PM Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial (ISRCTN75125874). (Abstract #8506) V. Chiarion-Sileni, M. Guida, A. Romanini, R. Ridolfi, M. Mandala, P. Del Bianco, B. Silvestri, M. Medici, M. Michiara, M. Dalla Palma, O. Puccetti, J. Pigozzo, F. Laveder, G. De Salvo, Italian Melanoma Intergroup 2:15 PM EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-a2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. (Abstract #8506b) A. M. Eggermont, S. Suciu, M. Santinami, W. Kruit, A. Testori, J. Marsden, C. J. A. Punt, M. E. Gore, R. MacKie, R. Dummer, D. Schadendorf, P. Patel, A. Spatz, and U. Keilholz Discussion 2:30 PM Helen Gogas, MD (Abstracts #8504 – 8506b) Hellenic Cooperative Oncology Group (HeCOG) 2:45 PM Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients. (Abstract #8510) R. Shapira-Frommer, M. Besser, I. Kuchuk, R. Nave, D. Zippel, A. Treves, A. Nagler, S. Apter, A. Shimoni, R. Yerushalmi, E. Ben-Ami, A. Ben-Nun, G. Markel, O. Itzhaki, R. Catane, J. Schachter 3:00 PM A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. (Abstract #8511) F. S. Hodi, P. A. Friedlander, M. B. Atkins, D. F. McDermott, D. P. Lawrence, N. Ibrahim, X. Wu, J. Zhou, A. Giobbie-Hurder, G. Murphy, T. Hollman, E. Velazquez, S. Russell, P. Dipiro, J. T. Yap, A. D. Van Den Abbeele Discussion 3:15 PM Mario Sznol, MD (Abstracts #8510 – 8511) Yale Cancer Center 3:30 PM 150 BRAF mutation by age-decade and body mass index in metastatic melanoma. (Abstract #8507) A. M. Menzies, L. Visintin, M. D. Chatfield, M. S. Carlino, J. R. Howle, R. A. Scolyer, J. F. Thompson, R. F. Kefford, G. V. Long Saturday, June 4, 2011 Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. (Abstract #8508) W. H. Sharfman, F. S. Hodi, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, S. Kakar, Z. Tang, O. Krieter, M. B. Atkins 4:00 PM BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (Abstract #8509) A. Ribas, K. B. Kim, L. M. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, G. A. McArthur, T. E. Hutson, K. T. Flaherty, S. J. Moschos, D. P. Lawrence, P. Hersey, R. F. Kefford, B. Chmielowski, I. Puzanov, J. Li, K. B. Nolop, R. J. Lee, A. K. Joe, J. A. Sosman SATURDAY 3:45 PM Discussion 4:15 PM Gary K. Schwartz, MD (Abstracts #8507– 8509) Memorial Sloan-Kettering Cancer Center 151 Saturday, June 4, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Breast Cancer—Triple-negative/Cytotoxics/Local Therapy Display Time: 2:00 PM - 6:00 PM Display Location: E450b Discussion Time: 5:00 PM - 6:00 PM Discussion Location: Hall B1 CME credit: 1 Track(s): Breast Cancer SATURDAY Fatima Cardoso, MD—Co-Chair Champalimaud Cancer Center Karen A. Gelmon, MD—Co-Chair British Columbia Cancer Agency Discussion 5:00 PM Reshma Jagsi, MD, DPhil (Abstracts #1011–1014) University of Michigan Discussion 5:15 PM George Somlo, MD (Abstracts #1015–1021) City of Hope Discussion 5:30 PM Stephen K. L. Chia, MD (Abstracts #1022–1027) British Columbia Cancer Agency Discussion 5:45 PM Ian E. Krop, MD, PhD (Abstracts #1028 –1033) Dana-Farber Cancer Institute Brd. 1 Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. (Abstract #1011) T. B. Julian, J. P. Costantino, F. A. Vicini, J. R. White, K. A. Winter, D. W. Arthur, R. R. Kuske, R. Rabinovitch, D. S. Parda, E. P. Mamounas, W. J. Curran Jr., N. Wolmark Brd. 2 Observation or standard axillary dissection after sentinel-node biopsy in breast cancer: Final results from the German KISS study. (Abstract #1012) C. Schem, W. Jonat, H. Ostertag, on behalf of the German KISS study group Brd. 3 Contralateral breast cancer risk in patients with familial breast cancer tested negative for BRCA1 and BRCA2. (Abstract #1013) K. Rhiem, C. Engel, M. Graeser, W. Janni, M. Kiechle, N. Ditsch, C. Mundhenke, R. Kreienberg, J. Tio, M. Golatta, A. Honig, D. Gadzicki, D. Speiser, K. Kast, S. Briest, A. Meindl, R. Schmutzler Brd. 4 Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study. (Abstract #1014) M. J. Junqueira, M. Morrow, A. S. Reiner, K. Malone, C. Lynch, J. L. Bernstein, The WECARE Study Collaborative Group Brd. 5 Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer. GEICAM 2006-03: A multicenter, randomized phase II study. (Abstract #1015) E. Alba, J. Chacon, A. Lluch, L. Garcia-Estevez, A. Anton, B. Cirauqui, J. Lopez Garcia-Asenjo, E. M. Carrasco, C. Rodriguez, M. Escudero, A. Sanchez, N. Ribelles, C. Romero, J. Alvarez, J. Albanell, on behalf of Spanish Breast Cancer Research Group (GEICAM) 152 Brd. 6 Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptornegative breast cancer (TNBC). (Abstract #1016) A. M. Gonzalez-Angulo, M. C. Green, J. L. Murray, S. L. Palla, K. H. Koenig, A. M. Brewster, V. Valero, N. K. Ibrahim, S. L. Moulder, J. K. Litton, D. J. Crawford, P. R. Flores, M. J. Dryden, W. F. Symmans, S. H. Giordano, L. Pusztai, A. Buzdar, G. B. Mills, G. N. Hortobagyi, F. Meric-Bernstam Brd. 7 A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer. (Abstract #1017) H. Lindman, M. Andersson, P. Edlund, K. D. Bjerre, T. Hatschek, H. T. Mouridsen, H. Anderson, B. Ejlertsen, S. Møller, E. Lidbrink, C. Kamby, J. Ahlgren, J. Bergh, C. Blomqvist Brd. 8 Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (> 3ⴙLN): Eight-year follow-up analysis. (Abstract #1018) V. Moebus, C. Thomssen, H. Lueck, W. Kuhn, A. Junker-Stein, C. M. Kurbacher, U. Nitz, R. Kreienberg, M. Untch, C. Jackisch, J. B. Huober, A. Hinke, A. Du Bois, A. Schneeweiss Brd. 9 Anthracyline (A) use among women with breast cancer (BC). (Abstract #1019) S. H. Giordano, Y. Lin, Y. Kuo, G. N. Hortobagyi, J. S. Goodwin Brd. 10 Final multivariate analysis of obesity and survival in patients with nodalpositive primary breast cancer: The ADEBAR trial. (Abstract #1020) J. W. Janni, P. G. Hepp, U. Andergassen, N. Harbeck, B. K. Rack, J. K. Neugebauer, K. Annecke, A. Wischnik, W. Simon, M. Rezai, T. N. Fehm, A. Schneeweiss, P. A. Fasching, B. Gerber, T. Zwingers, H. L. Sommer, K. Friese, M. Kiechle Brd. 11 Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): Pooled analysis from the WSG AM-01 and -02 trials. (Abstract #1021) O. Gluz, C. Liedtke, R. E. Kates, J. B. Huober, S. Mohrmann, A. Hartmann, C. Thomssen, V. Moebus, U. Nitz, N. Harbeck, West German Study Group Brd. 12 Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts). (Abstract #1022) M. Ruiz-Borrego, C. H. Barrios, A. Lluch, J. Bines, J. Segalla, A. Ruiz, L. Torrecillas, A. Llombart-Cussac, R. Torres, J. Garcia Saenz, J. Lopez Garcia-Asenjo, H. L. Gomez, J. De la Haba, S. Reyes, E. Martinez, J. Baena, L. Perez-Michell, A. Rodriguez-Lescure, A. Anton, M. Martin, on behalf of CIBOMA/GEICAM Brd. 13 Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. (Abstract #1023) K. P. Raghav, L. F. Hernandez-Aya, X. Lei, M. Chavez-Mac Gregor, F. Meric-Bernstam, T. A. Buchholz, A. A. Sahin, K. Do, G. N. Hortobagyi, A. M. Gonzalez-Angulo Brd. 14 Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer. (Abstract #1024) T. M. Abdel-Fatah, P. D. Dickinson, P. Moseley, J. S. Reis-Filho, A. R. Green, I. O. Ellis, S. Chan 153 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 15 TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. (Abstract #1025) S. J. Isakoff, P. E. Goss, E. L. Mayer, T. A. Traina, L. A. Carey, K. Krag, H. S. Rugo, M. C. Liu, V. Stearns, S. E. Come, D. R. Borger, C. A. Quadrino, D. Finkelstein, J. E. Garber, P. D. Ryan, E. P. Winer, L. W. Ellisen, on behalf of the Translational Breast Cancer Research Consortium Brd. 16 Foxp3 expression in breast cancer cells: A new predictor of response to anthracycline versus docetaxel in primary breast cancer treated with adjuvant chemotherapy in the phase III trial FNCLCC/PACS-01. (Abstract #1026) F. Ghiringhelli, P. Fumoleau, L. Arnould, G. Mignot, C. Dalban, F. Bonnetain, H. H. Roche, M. Spielmann, C. Levy, A. Lortholary, F. Eichler, C. Mesleard, S. Ladoire Brd. 17 Use of topoisomerase 2 alpha (TOP2A) protein overexpression to predict response to anthracycline-based chemotherapy. (Abstract #1027) S. Chan, J. S. Reis-Filho, P. D. Dickinson, P. Moseley, A. R. Green, I. O. Ellis, T. M. Abdel-Fatah Brd. 18 Correlation of various pathological complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. (Abstract #1028) G. Von Minckwitz, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann, J. U. Blohmer, S. D. Costa, J. Hilfrich, C. Jackisch, B. Gerber, A. Du Bois, J. B. Huober, C. A. Hanusch, G. E. Konecny, W. Fett, E. Stickeler, N. Harbeck, K. Mehta, S. Loibl, M. Untch, GBG and AGO-B study groups Brd. 19 Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial. (Abstract #1029) K. Shen, G. Tang, J. P. Costantino, S. J. Anderson, C. Kim, K. L. Pogue-Geile, N. Song, M. J. Gabrin, C. E. Geyer, N. Wolmark Brd. 20 Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy ⴙ/- endocrine therapy. (Abstract #1030) W. F. Symmans, F. Andre, M. C. Liu, J. Delacruz, F. Peintinger, S. Borstnar, H. Wang, P. Regitnig, M. Ota, S. Seevaratnam, S. Delaloge, C. Hatzis Brd. 21 Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. (Abstract #1031) A. Rocca, A. Paradiso, P. Sismondi, E. Scarpi, A. Mangia, L. Medri, S. Bravaccini, D. Casadei Giunchi, D. Amadori, R. Silvestrini Brd. 22 The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. (Abstract #1032) M. Cheang, D. Voduc, D. Tu, S. Jiang, S. Leung, S. K. Chia, L. E. Shepherd, M. N. Levine, K. I. Pritchard, T. Vickery, S. Davies, I. J. Stijleman, C. Davis, J. S. Parker, M. J. Ellis, P. S. Bernard, C. M. Perou, T. O. Nielsen Brd. 23 Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer patients: Results of the German SUCCESS trial. (Abstract #1033) J. K. Jueckstock, B. K. Rack, T. Zwingers, P. G. Hepp, A. Schneeweiss, M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Pantel, H. Tesch, H. Forstbauer, R. Lorenz, M. Rezai, J. K. Neugebauer, U. Andergassen, K. Friese, W. Janni, SUCCESS Study Group 154 Saturday, June 4, 2011 Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). (Abstract #1034) A. Awada, S. Chan, G. H. Jerusalem, R. E. Coleman, M. T. Huizing, A. Mehdi, S. M. O’Reilly, J. T. Hamm, P. J. Barrett-Lee, V. Cocquyt, K. Sideras, D. E. Young, M. Brown, C. Zhao, A. L. Hannah, L. K. Masuoka, A. Garcia, E. A. Perez, NKTR-102 Study Group Brd. 25 Relationship between OS and PFS in metastatic breast cancer (MBC): Review of FDA submission data. (Abstract #1035) P. Cortazar, J. J. Zhang, R. Sridhara, R. L. Justice, R. Pazdur SATURDAY Brd. 24 155 Saturday, June 4, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Developmental Therapeutics—Experimental Therapeutics Display Time: 2:00 PM - 6:00 PM Display Location: S403 Discussion Time: 5:00 PM - 6:00 PM Discussion Location: S406 CME credit: 1 Track(s): Developmental Therapeutics SATURDAY R. Donald Harvey, PharmD—Co-Chair Winship Cancer Institute at Emory University Jan H. M. Schellens, MD, PhD—Co-Chair Netherlands Cancer Institute Discussion 5:00 PM Patrick Schoffski, MD, MPH (Abstracts #3011–3016) University Hospitals Leuven Discussion 5:15 PM Lillian L. Siu, MD (Abstracts #3017–3024) Princess Margaret Hospital Discussion 5:30 PM Carlos L. Arteaga, MD (Abstracts #3025–3029) Vanderbilt-Ingram Cancer Center Discussion 5:45 PM Mark J. Ratain, MD (Abstracts #3030 –3032) The University of Chicago Brd. 1 First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. (Abstract #3011) J. Rodon Ahnert, J. Baselga, E. Calvo, J. Seoane, I. Brana, E. Sicart, I. Gueorguieva, A. Cleverly, M. M. Lahn, S. Pillay, M. Holdhoff, J. O. Blakeley, M. A. Carducci Brd. 2 A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors. (Abstract #3012) T. Doi, H. Murakami, K. Wan, M. Miki, H. Kotani, N. Sakamoto, N. Yamamoto, A. Ohtsu Brd. 3 MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. (Abstract #3013) J. S. Kauh, G. Shapiro, R. B. Cohen, J. W. Clark, R. Harvey, J. M. Cleary, D. Mahalingam, S. Kuan, A. McDonald, A. Berger, B. Dezube, J. Sarantopoulos Brd. 4 A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. (Abstract #3014) C. M. Rudin, A. Jimeno, W. H. Miller Jr., B. J. Eigl, S. N. Gettinger, A. L. Chang, K. Faia, J. Sweeney, G. Loewen, R. W. Ross, G. J. Weiss Brd. 5 Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. (Abstract #3015) D. Mahadevan, E. G. Chiorean, W. Harris, D. D. Von Hoff, A. Younger, D. M. Rensvold, F. Cordova, W. Qi, C. F. Shelton, M. D. Becker, J. R. Garlich, R. K. Ramanathan Brd. 6 Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S). (Abstract #3016) M. L. Maitland, T. Karrison, G. L. Bakris, K. Fox, L. A. Janisch, S. Karovic, M. R. Levine, L. House, J. J. Wright, E. E. Cohen, G. F. Fleming, T. Y. Seiwert, V. M. Villaflor, W. M. Stadler, M. J. Ratain 156 Brd. 7 Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor. (Abstract #3017) S. Leijen, M. R. Middleton, P. Tresca, F. Kraeber-Bodere, V. Dieras, M. E. Scheulen, J. Tessier, Z. X. Xu, E. Shochat, A. Walz, J. Deutsch, S. Blotner, V. Lopez Valverde, V. M. Naegelen, J. H. Schellens, W. E. Eberhardt Brd. 8 Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). (Abstract #3018) P. N. Munster, R. van der Noll, E. E. Voest, E. C. Dees, A. R. Tan, J. M. Specht, G. S. Falchook, A. Daud, M. P. Lolkema, J. E. Grilley-Olson, E. Y. Yu, S. Fu, E. K. Bergsland, J. Kleha, S. Peng, D. A. Smith, T. A. Lampkin, J. H. Schellens, S. R. Morris, R. Kurzrock Brd. 9 Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. (Abstract #3019) N. Houede, S. J. Faivre, A. Awada, E. Raymond, A. Italiano, T. Besse-Hammer, M. Donica, N. Rejeb, C. Luepfert, S. Ongarello, J. Delord Brd. 10 A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. (Abstract #3020) A. J. Wagner, J. C. Bendell, S. Dolly, J. A. Morgan, J. A. Ware, J. Fredrickson, K. E. Mazina, J. O. Lauchle, H. A. Burris III, J. S. De Bono Brd. 11 A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. (Abstract #3021) V. Moreno Garcia, R. D. Baird, K. J. Shah, B. Basu, N. Tunariu, M. Blanco, P. A. Cassier, J. V. Pedersen, M. Puglisi, D. Sarker, D. Papadatos-Pastos, A. G. Omlin, A. Biondo, J. A. Ware, H. Koeppen, G. G. Levy, K. E. Mazina, J. S. De Bono Brd. 12 First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068. (Abstract #3022) J. Tabernero, C. Saura, D. Roda Perez, R. Dienstmann, S. Rosello, L. Prudkin, J. A. Perez-Fidalgo, B. Graña, C. Jones, L. Musib, Y. Yan, P. H. Patel, J. Baselga, A. Cervantes Brd. 13 Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. (Abstract #3023) H. A. Henary, R. Kurzrock, G. S. Falchook, A. Naing, S. L. Moulder, J. J. Wheler, A. M. Tsimberidou, J. Durand, P. Yang, M. Johansen, R. Newman, R. Khan, U. Patel, D. S. Hong Brd. 14 A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity. (Abstract #3024) R. D. Baird, B. Venugopal, R. S. Kristeleit, J. Charlton, M. Blanco-Codesido, E. Saunders, K. J. Shah, D. Crawford, P. Stephens, D. Wilkins, L. Sweeting, A. Forslund, J. W. Smit, P. A. Palmer, N. Fourneau, P. Hellemans, J. S. De Bono, R. Plummer, U. Banerji, T. Evans Brd. 15 Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. (Abstract #3025) A. Cervantes, M. Alsina, J. Tabernero, J. R. Infante, P. LoRusso, G. Shapiro, L. G. Paz-Ares, R. Falzone, J. Hill, J. Cehelsky, A. White, I. Toudjarska, D. Bumcrot, R. Meyers, G. Hinkle, N. Svrzikapa, D. W. Sah, A. Vaishnaw, J. Gollob, H. A. Burris III Brd. 16 A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. (Abstract #3026) J. Berlin, V. L. Keedy, P. A. Janne, L. Yee, N. A. Rizvi, X. Jin, C. Copigneaux, T. Hettmann, D. M. Beaupre, P. LoRusso 157 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 17 Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors. (Abstract #3027) L. Gandhi, R. Bahleda, J. M. Cleary, A. Hollebecque, E. L. Kwak, S. Pandya, S. Tolaney, R. Abbas, R. Ananthakrishnan, A. Berkenblit, J. Boni, J. Clancy, K. W. Turnbull, M. VoVan, G. Shapiro, J. Soria Brd. 18 A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors. (Abstract #3028) H. S. Han, C. Swanton, Y. Y. Janjigian, S. C. Sutherland, S. Chandarlapaty, R. Lehman, N. Hamilton, J. Knowles, R. Lee, L. Yan, D. Sullivan, C. Hudis Brd. 19 A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors. (Abstract #3029) C. Mamot, R. Ritschard, B. Vogel, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz Brd. 20 A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. (Abstract #3030) L. H. Brail, J. E. Gray, H. Burris, G. R. Simon, J. Cooksey, S. F. Jones, D. Farrington, T. Lam, K. Jackson, K. Chow, J. T. Brandt, J. R. Infante Brd. 21 Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors. (Abstract #3031) A. Deleporte, H. Dumez, A. Awada, J. Costermans, M. Meeus, T. Berghmans, M. Ould Kaci, N. Juhel, A. Berge, T. Taube, P. Schöffski Brd. 22 Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel. (Abstract #3032) D. W. Rasco, A. Patnaik, R. K. Amaravadi, K. P. Papadopoulos, N. B. Haas, A. W. Tolcher, M. Beeram, K. Harlacker, M. A. Drouin, M. Tawashi, J. Wang, A. Karam, C. R. Maroun, C. Bonfils, M. Mehran, J. M. Besterman, P. J. O’Dwyer 158 Saturday, June 4, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Genitourinary (Prostate) Cancer Display Time: 2:00 PM - 6:00 PM Display Location: E450a Discussion Time: 5:00 PM - 6:00 PM Discussion Location: Hall D2 CME credit: 1 Track(s): Genitourinary Cancer SATURDAY Leonard Joseph Appleman, MD, PhD—Co-Chair University of Pittsburgh Iwona Anna Skoneczna, MD—Co-Chair Institute of Oncology Discussion 5:00 PM Daniel W. Lin, MD (Abstracts #4521– 4524) University of Washington Discussion 5:15 PM William K. Oh, MD (Abstracts #4525^– 4530) Mount Sinai Medical Center Discussion 5:30 PM Charles J. Ryan, MD (Abstracts #4531– 4535) University of California, San Francisco Discussion 5:45 PM Philip W. Kantoff, MD (Abstracts #4536 – 4545) Dana-Farber Cancer Institute Brd. 1 Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). (Abstract #4521) B. M. Dubray, V. Beckendorf, S. Guerif, E. Le Prise, A. Reynaud-Bougnoux, J. Hannoun Levi, T. D. Nguyen, C. Hennequin, J. Cretin, M. Fayolle-Campana, J. Lagrange, J. Bachaud, D. Azria, A. Grangirard, P. Pommier, J. Simon, V. Harter, M. Habibian, Groupe d’Etude des Tumeurs Uro-Genitales Brd. 2 A phase II study of pomegranate extract for men with rising prostate-specific antigen following primary therapy. (Abstract #4522^) C. J. Paller, X. Ye, P. Wozniak, B. Gillespie, P. Sieber, R. Greengold, B. Stockton, B. Hertzman, M. Efros, R. Roper, H. Liker, M. A. Carducci Brd. 3 Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival (Abstract #4523) S. Oudard, I. Latorzeff, P. Beuzeboc, E. Banu, A. Caty, E. Sevin, R. Delva, F. Rolland, F. Priou, R. Elaidi, S. Culine Brd. 4 PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (Abstract #4524) G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, I. Latorzeff, R. Delva, B. Esterni, M. Habibian, M. Soulie Brd. 5 Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. (Abstract #4525^) A. O. Sartor, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, J. S. De Bono, For the TROPIC investigators 159 Saturday, June 4, 2011 SATURDAY Brd. 6 A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4526^) J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, A. O. Sartor, for the TROPIC investigators Brd. 7 Phase III, randomized, open-label study of triweekly versus biweekly docetaxel (T) as a treatment for advanced hormone-refractory prostate cancer (HRPC): Final analysis of the Finnish Uro-oncological Group Study 1-2003. (Abstract #4527) P. Kellokumpu-Lehtinen, U. Harmenberg, T. K. Joensuu, R. McDermott, P. Hervonen, C. Ginman, M. Luukkaa, P. Nyandoto, T. Luukkaala, H. Joensuu, Prosty study group Brd. 8 A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) (Abstract #4528) G. Sonpavde, V. B. Matveev, J. M. Burke, J. R. Caton, M. T. Fleming, P. A. Karlov, J. Holmlund, B. A. Wood, M. Brookes, L. H. Leopold Brd. 9 Final results on phase II study of a weekly schedule of ixabepilone in patients with metastatic castrate-refractory prostate cancer (E3803): A trial of the Eastern Cooperative Oncology Group. (Abstract #4529) G. Liu, Y. Chen, R. S. DiPaola, M. A. Carducci, G. Wilding, Eastern Cooperative Oncology Group Brd. 10 Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (Abstract #4530) B. Seruga, A. M. Horgan, G. R. Pond, S. M. Alibhai, E. Amir, R. De Wit, M. A. Eisenberger, I. Tannock Brd. 11 Safety, efficacy, and pharmacodynamics of the investigational agent TAK700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (Abstract #4531) D. B. Agus, W. M. Stadler, D. H. Shevrin, L. Hart, G. R. MacVicar, O. Hamid, J. D. Hainsworth, M. E. Gross, J. Wang, L. de Leon, D. MacLean, R. Dreicer Brd. 12 A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial. (Abstract #4532) E. S. Antonarakis, E. I. Heath, D. C. Smith, D. E. Rathkopf, A. L. Blackford, D. C. Danila, S. King, A. Frost, M. A. Carducci, Prostate Cancer Clinical Trials Consortium (PCCTC) Brd. 13 Effect of denosumab versus zoledronic acid in patients with castrateresistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain. (Abstract #4533) N. D. Shore, M. R. Smith, M. Jievaltas, K. Fizazi, R. Damião, J. Chin, K. Miller, J. P. Maroto, Y. Qian, A. Feng, K. Chung, C. D. Goessl Brd. 14 Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies. (Abstract #4534) L. G. Gomella, C. Nabhan, J. B. Whitmore, M. W. Frohlich, D. J. George Brd. 15 Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. (Abstract #4535) H. Kübler, T. Maurer, A. Stenzl, S. Feyerabend, U. Steiner, M. Schostak, W. Schultze-Seemann, F. vom Dorp, L. Pilla, G. Viatali, C. Hampel, S. Wedel, L. Trojan, K. Hiller, M. Sommerauer, D. Jocham, B. Scheel, T. Lander, K. Kallen, K. Miller Brd. 16 Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. (Abstract #4536) H. Beltran, D. Rickman, K. Park, A. Sboner, T. Macdonald, S. T. Tagawa, M. B. Gerstein, F. Demichelis, D. M. Nanus, M. A. Rubin 160 Brd. 17 Validation of NF-kappaB p65 as a prostate cancer prognostic marker on a large European cohort. (Abstract #4537) P. O. Gannon, L. Lessard, V. Forest, L. R. Begin, T. Schlomm, S. Minner, M. Graefen, A. Mes-Masson, F. Saad Brd. 18 Association of angiotensin II blockers with survival among men with prostate cancer: Results from CaPSURE. (Abstract #4538) A. Bardia, J. E. Cowan, P. Carroll, A. V. D’Amico, M. A. Carducci Brd. 19 A six-gene panel that predicts survival in men with castration-resistant prostate cancer. (Abstract #4539) S. K. Subudhi, G. Heller, A. Anand, D. C. Danila, M. Fleisher, H. I. Scher Brd. 20 Genomic analysis of circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) as predictive biomarkers. (Abstract #4540) D. C. Danila, A. Anand, J. Yao, M. Gierszewska, M. Kramer, S. Muller, M. Fleisher, W. R. McCombie, H. I. Scher Brd. 21 Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy. (Abstract #4541) S. M. Falzarano, C. Magi-Galluzzi, W. F. Novotny, T. Maddala, D. B. Cherbavaz, C. Millward, E. A. Klein Brd. 22 Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort. (Abstract #4542) J. M. Cuzick, G. Fisher, D. Berney, D. Mesher, H. Møller, J. E. Reid, A. Gutin, J. S. Lanchbury, S. Stone Brd. 23 Risk of second primary malignancy in U.S. men diagnosed with prostate cancer from 1992 to 2007. (Abstract #4543) E. Davis, C. A. Salinas, L. A. Okoth, K. A. Cooney Brd. 24 Racial disparities in prostate cancer treatment: The contribution of inappropriate care. (Abstract #4544) C. J. Presley, A. C. Raldow, L. D. Cramer, P. R. Soulos, J. B. Long, D. V. Makarov, J. B. Yu, C. P. Gross Brd. 25 PARP inhibition reverses radiation resistance conferred by ETS fusions in prostate cancer. (Abstract #4545) F. Y. Feng, S. Han, C. Brenner, A. Sabolch, D. A. Hamstra, T. S. Lawrence, A. Chinnaiyan 161 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Tumor Biology Display Time: 2:00 PM - 6:00 PM Display Location: S103 Discussion Time: 5:00 PM - 6:00 PM Discussion Location: S100bc CME credit: 1 Track(s): Tumor Biology SATURDAY Charles D. Lopez, MD, PhD—Co-Chair Oregon Health Science University Joseph A. Sparano, MD—Co-Chair Albert Einstein College of Medicine Discussion 5:00 PM Matthew James Ellis, MB, BChir, PhD (Abstracts #10509 –10516) Washington University Medical Center Discussion 5:15 PM Robert Arthur Kratzke, MD (Abstracts #10517–10521) University of Minnesota Discussion 5:30 PM David B. Solit, MD (Abstracts #10522–10527) Memorial Sloan-Kettering Cancer Center Discussion 5:45 PM Ravi Salgia, MD, PhD (Abstracts #10528 –10533) The University of Chicago Brd. 1 Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). (Abstract #10509) J. M. Balko, R. S. Cook, T. W. Miller, N. E. Bhola, M. Sanders, N. M. Granja-Ingram, V. Sanchez, I. M. Meszoely, J. Salter, M. Dowsett, K. Stemke-Hale, A. M. Gonzalez-Angulo, G. B. Mills, C. L. Arteaga Brd. 2 Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1. (Abstract #10510) J. Pierga, F. Bidard, F. Andre, T. Petit, F. Dalenc, T. Delozier, G. Romieu, J. Bonneterre, J. Ferrero, P. Kerbrat, A. Martin, P. Viens Brd. 3 Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response. (Abstract #10511) J. M. Mulligan, L. A. Hill, S. Deharo, F. A. McDyer, T. S. Davison, M. Bylesjo, N. M. Lindor, L. Galligan, T. Delaney, I. A. Halfpenny, V. Farztdinov, N. Goffard, V. Proutski, K. E. Keating, P. B. Mullan, J. E. Quinn, P. G. Johnston, F. J. Couch, D. P. Harkin, R. D. Kennedy Brd. 4 Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC). (Abstract #10512) M. J. Higgins, D. Jelovac, E. Barnathan, B. Blair, S. Slater, P. Powers, J. Zorzi, S. C. Jeter, G. R. Oliver, F. Diehl, P. Angenendt, P. Huang, P. Argani, K. Murphy, A. C. Wolff, B. H. Park Brd. 5 Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness, and as such treatment response. (Abstract #10513) E. H. Lips, L. Mulder, S. A. Joosse, S. Savola, M. A. Vollebergh, L. F. Wessels, J. Wesseling, P. M. Nederlof, S. Rodenhuis 162 Brd. 6 Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. (Abstract #10514) J. Budczies, C. Denkert, B. Mueller, S. F. Brockmoeller, M. Dietel, C. Radke, S. Loibl, G. Von Minckwitz, J. L. Griffin, M. Oresic, G. Wohlgemut, O. Fiehn Brd. 7 Global gene expression analysis of heterotypic interaction between cancer cells and osteoblasts in vitro to detect signaling pathways relevant for bone metastasis in breast cancer patients. (Abstract #10515) M. Buess, M. Rajski, B. Vogel, C. Rochlitz Brd. 8 Targeting -catenin/CBP interaction in breast cancer. (Abstract #10516) A. Ring, O. Evgrafov, J. Knwoles, M. Kahn Brd. 9 Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. (Abstract #10517) J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. Wu Brd. 10 Changes in molecular profile following platinum chemotherapy in NSCLC. (Abstract #10518) W. Huang, M. Skokan, Y. Chang, C. Wu, J. Lee, W. Feser, A. E. Barón, P. A. Bunn, M. Varella-Garcia Brd. 11 Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor receptor (EGFR) amplification and expression in surgically resected NSCLC. (Abstract #10519) V. Ludovini, A. Flacco, F. Bianconi, F. R. Tofanetti, M. Ragusa, J. Vannucci, G. Bellezza, M. G. Mameli, R. Chiari, V. Minotti, L. Pistola, A. Siggillino, E. Baldelli, A. Sidoni, F. Puma, M. Varella-Garcia, L. Crinó Brd. 12 Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays. (Abstract #10520) T. Li, P. C. Mack, S. Desai, K. Kelly, J. Cooc, P. V. Danenberg, K. D. Danenberg, D. R. Gandara Brd. 13 Blind prediction of response to erlotinib in early-stage non-small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles. (Abstract #10521) R. Hilhorst, E. Schaake, R. van Pel, P. M. Nederlof, L. Houkes, M. Mommersteeg, R. de Wijn, M. van den Heuvel, P. Baas, R. Ruijtenbeek, H. M. Klomp Brd. 14 Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer. (Abstract #10522) A. H. Calvert, J. C. Jackson, C. Hutton, A. Swart, W. Qian, C. Kwakye, R. Fossati, A. Lissoni, P. G. Harper, N. Colombo, R. J. Edmondson, J. Lunec Brd. 15 Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma. (Abstract #10523) K. J. Bloom, S. M. Anderson, R. C. Schilling, J. Lee, H. Halait, S. Cheng, R. A. Langland, H. Lawrence Brd. 16 Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. (Abstract #10524) M. Del Re, F. Loupakis, A. Michelucci, A. Di Paolo, A. Falcone, P. Simi, G. Bocci, M. Cantore, R. Bordonaro, A. Di Leo, C. Barbara, F. Cappuzzo, F. G. De Braud, R. Danesi Brd. 17 Circulating protein biomarkers of sunitinib (SU) and interferon-␣ (IFN-␣) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #10525) C. S. Harmon, R. A. Figlin, T. E. Hutson, M. D. Michaelson, S. Négrier, S. T. Kim, X. Huang, J. A. Williams, R. J. Motzer Brd. 18 RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. (Abstract #10526) C. Denkert, R. Kronenwett, S. Loibl, V. Nekljudova, S. Darb-Esfahani, B. Gerber, B. Sinn, C. Petry, I. Bauerfeind, J. Budczies, M. Rezai, M. Dietel, I. Schrader, G. Kunz, G. Von Minckwitz, GBG and AGO-B study groups 163 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 19 Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results. (Abstract #10527) E. Baudin, E. M. Wolin, D. E. Castellano, G. Kaltsas, J. Lebrec, Z. Tsuchihashi, J. Klimovsky, S. Saletan, J. C. Yao, D. Gross Brd. 20 A hepatocyte growth factor antagonist engineered by site-directed mutagenesis. (Abstract #10528) F. Cecchi, D. Pajalunga, A. Fowler, D. C. Rabe, B. Peruzzi, N. J. MacDonald, D. K. Blackman, S. J. Stahl, A. Byrd, D. P. Bottaro Brd. 21 Activity of the cancer metabolism inhibitor MPC-9528 in xenograft models: Comparison of different dosing schedules. (Abstract #10529) V. R. Baichwal, J. A. Willardsen, J. W. Lockman, B. R. Murphy, R. Gordillo, T. C. Fleischer, C. Bradford, D. I. Papac, G. G. Mather, R. O. Carlson Brd. 22 In vivo tumor growth inhibition by novel PKM2 cancer metabolism modulators. (Abstract #10530) O. M. Becker, V. Behar, O. Bohana-Kashtan, A. Shitrit, D. Sherman, E. Ben-Zeev, R. Ozeri, N. C. Schutz, A. Yacovan Brd. 23 New microRNA-based diagnostic test for lung cancer classification. (Abstract #10531) T. B. Edmonston, H. Gibori, M. Kushnir, G. Lithwick Yanai, H. Benjamin, M. Bibbo, C. Thurm, L. Horowitz, Y. Huang, M. Feinmesser, I. Barshack, S. J. Hou, S. Gilad, S. Benjamin, K. Ashkenazi, M. Ezagouri, Y. Goren, C. Hogan, A. Chajut Brd. 24 The effect of fish oil on chemotherapy activity in mice: Clinical implications. (Abstract #10532) L. G. Daenen, J. M. Roodhart, E. C. Stigter, M. G. Gerritsen, R. H. Medema, A. B. Brenkman, E. E. Voest Brd. 25 The effects of targeting stromal and tumor cell platelet-derived growth factor receptor (PDGFR) in non-small cell lung cancer (NSCLC). (Abstract #10533) D. E. Gerber, P. Gupta, M. T. Dellinger, J. Toombs, I. Valencia, M. Peyton, N. Loizos, R. A. Brekken 164 Saturday, June 4, 2011 2:00 PM - 6:00 PM GENERAL POSTER SESSION Cancer Prevention/Epidemiology Brd. 1A Gender, age, and ethnic representation in non-small cell lung cancer (NSCLC) U.S. registration trials: FDA review. (Abstract #1530) S. M. Malik, A. T. Farrell, Q. Xu, R. Sridhara, R. Pazdur Brd. 1B Recruitment in the Internet era: An efficient strategy for a study of breast cancer risk. (Abstract #1531) L. M. Yackowski, F. R. Schnabel, R. Oratz, D. Roses, R. Wieder, C. Kowalczyk, H. Ostrer Brd. 1C Clinical characteristics of affected BRCA1 and BRCA2 mutation carriers in an underserved population. (Abstract #1532) M. El-Masry, C. Ricker, D. V. Spicer, D. Tripathy Brd. 1D Prophylactic oophorectomy for patients with breast cancer with BRCA results. (Abstract #1533) J. C. Schink, K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, T. J. Fallen, W. J. Gradishar Brd. 1E Prevalence of recognized bone metastases in the U.S. adult population. (Abstract #1534) S. Li, Y. Peng, E. D. Weinhandl, A. H. Blaes, K. Cetin, V. M. Chia, S. Stryker, J. J. Pinzone, J. F. Acquavella, T. J. Arneson Brd. 1F Suicide in patients with cancer in California: 2000 –2005. (Abstract #1535) H. R. Mirshahidi, K. Nasseri, P. K. Mills Brd. 1G Perceptions and practices of dietary cancer prevention: Comparison between physicians and patients. (Abstract #1536) V. W. Li, J. Ko, W. W. Li Brd. 2A Cancer in young adults: Characteristics of a cohort of Brazilian patients. (Abstract #1537) C. S. Souza, A. V. Melo Mendes, S. D. Simon Brd. 2B Gestational diabetes and risk of incident primary cancer: A large populationbased cohort study in Israel. (Abstract #1538) T. Sella, G. Chodick, M. Barchana, A. D. Heymann, A. Porath, E. Kokia, V. Shalev Brd. 2C Antioxidant supplement use after diagnosis and breast cancer outcomes. (Abstract #1539) H. Greenlee, M. L. Kwan, L. Kushi, J. Song, A. Castillo, E. Weltzien, C. Quesenberry, B. J. Caan Brd. 2D Outcome of effective intervention to improve screening colonoscopy in a downtown Brooklyn community hospital. (Abstract #1540) K. Veerabhadrappa, Z. M. Bo, K. T. Lyar, R. Sultana, G. M. Villani Brd. 2E Diagnosis of breast cancer metastases with PET/TC in patients with elevation of tumor markers: First data update. (Abstract #1541) A. Mafodda, A. Prestifilippo, D. Aricò, A. Vadalà, M. Mare, C. Fornito, D. Giuffrida Brd. 2F Cancer with diabetes: Prevalence, metabolic control, and survival in a general oncology practice. (Abstract #1542) N. J. Karlin, A. C. Dueck, C. Cook Brd. 2G The prevalence of human papillomavirus types 52 and 58 in uterine cervical lesions from Japanese women. (Abstract #1543) K. Takehara, T. Nishimura, J. Sakane, Y. Kawakami, T. Mizunoe, M. Nishiwaki, K. Taniyama Brd. 3A Gender disparities in colorectal cancer screening. (Abstract #1544) S. Yager, W. Y. Cheung 165 SATURDAY Location: Hall A Track(s): Cancer Prevention/Epidemiology Saturday, June 4, 2011 SATURDAY Brd. 3B Environmental organochlorine pesticide pollutants in patients with benign and malignant breast disease. (Abstract #1545) K. S. Sodhi, I. D. Sharma, A. Chaturvedi Brd. 3C Early adulthood obesity, cumulative smoking, and esophageal cancer survival. (Abstract #1546) L. E. Coate, R. Zhai, W. Xu, Z. Chen, K. Asomaning, M. Kulke, R. S. Heist, D. Christiani, G. Liu Brd. 3D Breast cancer survival: The association of age within stage of disease. (Abstract #1547) C. Parise, K. Bauer, V. Caggiano Brd. 3E Trends in survival by race for stomach cancer patients from the U.S. SEER cancer registry. (Abstract #1548) L. Chu, L. Wang, M. Shing, W. Dong Brd. 3F Long-term history of fasting blood glucose level and the risk of pancreatic cancer: A nested case-control study. (Abstract #1549) K. Stefani, H. Kim, S. Ahn, K. Choi, I. Suh Brd. 3G Does breast cancer in Asian geriatric patients have the same biological characteristics as in their Western counterparts? A comparison between Shanghai and Vienna. (Abstract #1550) M. M. Tea, L. Tang, G. Di, Z. Shao, C. F. Singer Brd. 3H Stroger Hospital of Cook County (CCH) AIDS malignancy project: The CHAMP study—A 13-year, single-institution retrospective study of cancers in patients infected with HIV. (Abstract #1551) S. Gupta, H. Poola, K. K. Batra, J. M. Orsi, S. Velinova, S. Jain, S. B. Sreenivasappa, M. C. Telfer, M. R. Mullane, A. L. French, P. G. Rubinstein Brd. 4B The influence of sociodemographic factors on breast cancer tumor biology. (Abstract #1553) K. A. Dookeran, K. Ferrer, M. Sekosan, N. Holloway, W. J. McCaskill-Stevens, S. J. Gehlert Brd. 4C Multicenter, prospective, case-control, observational study on the influence of venous thromboembolism on patient outcome. (Abstract #1554) M. Mandala, R. Labianca, G. Agnelli, L. Crino, E. Maiello, A. Santoro, D. Fagnani, for the MASTER ONCOLOGY Investigators Brd. 4D Compliance to adjuvant hormone therapy for black and white women with breast cancer. (Abstract #1555) S. Bhatta, N. Hou, D. Huo, B. N. Polite, G. F. Fleming, O. I. Olopade, S. Hong Brd. 4E The accuracy of tobacco assessment during definitive radiotherapy or chemoradiotherapy in patients with head and neck cancer. (Abstract #1556) M. R. Kudrimoti, S. M. Arnold, J. Valentino, T. Gal, A. Hyland, A. Singh, V. Rangnekar, K. M. Cummings, J. R. Marshall, G. W. Warren Brd. 4F Prospective structured smoking behavior assessment at diagnosis and long-term cancer survival. (Abstract #1557) G. W. Warren, K. Kasza, M. E. Reid, K. M. Cummings, J. R. Marshall Brd. 4G Factors associated with on-time regular screening among the Korean population eligible to be screened for gastric cancer: A nationwide retrospective cohort study based on National Cancer Screening Program (NCSP) data. (Abstract #1558) M. Hahm, K. Choi, H. Lee, J. Jun, E. Park Brd. 4H Gynecological cancer screening in women at high risk of Lynch syndrome. (Abstract #1559) C. Guillen-Ponce, C. Martinez-Sevila, R. Perea, M. Arenas, M. Molina-Garrido, M. Goicoechea, D. Salas, A. Carrato, Hereditary Cancer Group of the Comunindad Valenciana (Spain) 166 Brd. 5A An analysis of colorectal cancer (CRC) following a diagnosis of prostate cancer (CaP): Is it due to earlier diagnosis or increased incidence? (Abstract #1560) S. Bae, M. Asadi, J. L. Millar, I. Jones, S. McLaughlin, A. Bui, M. Steele, M. W. Chao, D. English, P. Gibbs Brd. 5B The role of HPV genotypes and persistence in follow-up of cervical intraepithelial neoplasia after treatment. (Abstract #1561) Y. Huang, L. Wu, J. Zuo, N. Li, J. An, J. Hu, M. Huang Brd. 5C Multidisciplinary high-risk program: A community hospital’s experience. (Abstract #1562) H. Lowry, N. Dekhne, D. Fend, R. Lerman, N. Gregory, J. Boura Brd. 5D Results from a longitudinal breast MRI surveillance study: Psychological impact for high-risk women. (Abstract #1563) L. J. Patrick-Miller, A. R. Bradbury, R. Pius, K. Wroblewski, M. S. Verp, S. Jackson, C. Gulden, G. Newstead, H. Abe, O. I. Olopade Brd. 5E Racial differences in early-stage colorectal cancer outcomes and prognostic factors. (Abstract #1564) J. D. Acoba, C. D. Chong Brd. 5F Isolation of equol-producing bacterium to realize chemoprevention of prostate cancer. (Abstract #1565) H. Tsuji, K. Moriyama, K. Nomoto, N. Miyanaga, H. Akaza Brd. 5G Management of breast cancer after childhood cancer and Hodgkin lymphoma. (Abstract #1566) M. Terenziani, S. Viviani, M. Massimino, A. Moliterni, M. Gennaro, L. Gandola, L. Boschetti, S. Catania, G. Cefalo, A. Di Russo, G. Goisis, G. Mariani, F. Spreafico, M. Zambetti, P. Valagussa, G. Bonadonna Brd. 5H Impact of dietary habits on epidermal growth factor receptor (EGFR) mutation status of Japanese patients with lung adenocarcinomas. (Abstract #1567) Y. Yamane, M. Iwasaki, A. Kawase, K. Tsuchihara, G. Ishii, H. Ohmatsu, S. Niho, K. Yoh, K. Nagai, Y. Ohe, S. Tsugane, A. Ochiai, H. Esumi, K. Goto Brd. 6A Metachronous contralateral breast cancer: An analysis of risk factors and prognosis in 42,670 women in Sweden. (Abstract #1568) V. Vichapat, H. Garmo, M. Holmqvist, L. Holmberg, G. Liljegren, F. Warnberg, M. Lambe, T. Fornander, J. Adolfsson, M. Lüchtenborg Brd. 6B The burden of cancer in Japan, the United States, France, Germany, Italy, Spain, Sweden, and the United Kingdom. (Abstract #1569) N. Koinuma, N. E. Wilking, B. Jonsson, D. Hogberg Brd. 6C Preventing cancer in the colon: Effect of ginger root extract on markers of inflammation in colon mucosa in people at high risk for colorectal cancer. (Abstract #1570) S. M. Zick, D. K. Turgeon, S. Vareed, M. T. Ruffin IV, Z. Djuric, A. J. Litzinger, B. Wright, D. P. Normolle, D. E. Brenner Brd. 6D The new generation of combined hormone contraceptives and risk of gynecologic cancers. (Abstract #1571) R. Haque, G. Inzhakova, J. M. Shi, J. Chung, F. Niu, C. T. Cheetham Brd. 6E Disparities of incidence and survival in lung cancer: A SEER-based analysis on Asian living in the United States 1973–2007. (Abstract #1572) R. N. Rahman, S. Rastogi, A. M. Hossain Brd. 6F Determining the impact of the U.S. mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital. (Abstract #1573) I. Habtes, C. Raskind-Hood, K. Adams, E. R. Becker, C. D’Orsi, G. Birdsong II, K. Gundry, R. O’Regan, S. G. Gabram 167 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 6G Fetal microchimerism in breast and colon cancer. (Abstract #1574) M. Kamper-Jørgensen, R. J. Biggar, C. L. Stamper, H. Hjalgrim, A. Tjønneland, A. Olsen, A. N. Andersen, K. Rostgaard, N. Kroman, V. K. Gadi Brd. 7A Global cancer mortality: The effect of health care system resources on survival from cancer. (Abstract #1576) A. Batouli, P. Jahanshahi, J. B. Yu Brd. 7B Observations on cancer of the breast among Arab-American women. (Abstract #1577) O. R. Signori, K. A. Schwartz, H. Dakhlallah, R. M. Pandit, E. E. Signori Brd. 7C Association between contralateral prophylactic mastectomy and breast cancer outcomes. (Abstract #1578) A. M. Brewster, P. A. Parker, I. Bedrosian, W. Dong, S. K. Peterson, S. B. Cantor, M. Crosby, Y. Shen Brd. 7D Impact on stage distribution of gastric cancer by the National Cancer Screening Program (NCSP) in Korea. (Abstract #1579) J. Jun, K. Choi, H. Lee, E. Park Brd. 7E A combination of fecal tests for the detection of colon cancer: A new strategy for appropriate prioritization of referrals to colonscopy—A prospective Italian study. (Abstract #1580) A. Ardizzoia, F. Parente, B. Marino, A. Ilardo, F. Perna, I. Saracino, A. Zullo, C. Hassan, P. Fracasso, R. A. Moretti, M. Cremaschini, D. Vaira, G. Ucci Brd. 7F Knowledge and perceptions of breast cancer risk in adolescent girls at high risk and population risk for breast cancer. (Abstract #1581) A. R. Bradbury, L. J. Patrick-Miller, L. Tuchman, C. Moore, P. Rauch, C. B. Sands, R. Shorter, B. Rowan, S. Malhotra, S. Van Decker, L. Bealin, H. Schmidheiser, M. B. Daly Brd. 7G A dose-finding clinical trial of mushroom powder in postmenopausal breast cancer survivors for secondary breast cancer prevention. (Abstract #1582) M. R. Palomares, J. Rodriguez, S. Phung, F. Z. Stanczyk, S. F. Lacey, T. W. Synold, S. Denison, P. H. Frankel, S. Chen Brd. 7H Peripheral blood eosinophil counts and risk of colorectal cancer mortality in a large general population-based cohort study. (Abstract #1583) N. Taghizadeh, J. M. Vonk, H. M. Boezen Brd. 8A Meta-analysis of insulin glargine and cancer risk. (Abstract #1584) P. Boyle, A. Koechlin, P. Boffetta, M. Boniol, G. Bolli, J. Rosenstock Brd. 8B Healthcare service barriers to breast cancer screening among Egyptian females. (Abstract #1585) H. M. El-Mansy, H. M. Ismail, I. F. Kharboush, M. M. Tawfik, O. G. El Sharkawy, H. Mamdouh, H. Sallam Brd. 8C Prospective analysis of association between use of statins or other lipid lowering agents and melanoma risk in the Women’s Health Initiative. (Abstract #1586) D. B. Jagtap, C. A. Rosenberg, L. Martin, M. Pettinger, P. Greenland, J. D. Khandekar, R. Levy, D. Lane, M. S. Simon Brd. 8D Breast ductal lavage (DL) and P16 immunocytochemistry. (Abstract #1587) C. Casadio, S. Di Vincenzo Jr., L. Chiapparini, B. Bonanni, M. Cazzaniga Brd. 8E Risk of lymphoma in women with breast implants: Analysis of clinical studies. (Abstract #1588) J. A. Largent, M. Oefelein, H. M. Kaplan, T. Okerson, P. Boyle Brd. 8F Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviral therapy: A prospective multicohort study from southern Africa. (Abstract #1589) J. Bohlius, F. Valeri, M. Maskew, H. Prozesky, C. Chimbetete, P. Lumano-Mulenga, T. Gsponer, M. Egger, International epidemiologic Database to Evaluate AIDS (IeDEA) 168 Brd. 8G Racial variation of leptin levels in women with breast cancer. (Abstract #1590) T. P. Avery, K. R. Sexton, A. Brewster, R. El-Zein, M. Bondy Brd. 8H Time since last pregnancy and breast cancer survival: A systematic review and meta-analysis. (Abstract #1591) A. Valachis, A. D. Nearchou, D. Mauri, P. A. Lind, N. P. Polyzos Brd. 9A Aristolochic acid nephropathy in Taiwan: Harbinger of a global iatrogenic disease. (Abstract #1592) A. P. Grollman, C. Chen, M. Moriya, K. Dickman, L. Wu, G. Mihalyne, K. L. Edwards, K. Snappin, Y. Pu Brd. 9B Classification of the components of the MedDietScore in relation to colorectal cancer prevalence. (Abstract #1593) N. Kontou, D. B. Panagiotakos, T. Psaltopoulou, N. Soupos, E. Polychronopoulos, D. Xynopoulos, D. Dimitroulopoulos, A. Linos, E. Paraskevas, M. A. Dimopoulos Brd. 9D What we know from the semiannually repeated CT screening in a high-risk cohort over 15 years: Update of the Anti-lung Cancer Association Project. (Abstract #1595) N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, M. Kusumoto, T. Tsuchida, H. Nishiyama, N. Moriyama Brd. 9E MRI characteristics of BRCA-associated breast cancers. (Abstract #1596) A. K. Kelekar, S. Mukherjee, C. Mitri, F. Khan, W. Ducaine, L. Dohany, D. Zakalik Brd. 9F Do cancer survivors follow screening guidelines better? (Abstract #1597) A. B. Chagpar, T. B. Sanft, C. P. Gross Brd. 9G The impact of screening mammography in breast cancer patients age 40 – 49 at an urban city hospital. (Abstract #1598) C. Checka, S. Dhage, S. Adams, E. Samii, T. Shah, S. Shaylor, K. P. Joseph Brd. 9H Body mass index: A potential risk factor for breast cancer in minority patients. (Abstract #1599) V. Sharma, D. Patel, A. Abichandani, P. Saraf, A. J. Cohen Brd. 10A Breast cancer characteristics among Hispanic women from a Southwestern county hospital. (Abstract #1600) M. N. Kundranda, S. Amar Brd. 10B Patterns of treatment in young women with early-stage cervical cancer. (Abstract #1601) S. Grover, L. L. Lin, G. Suneja Brd. 10C A survey of suspected familial breast cancer in Iraqi Kurdish women. (Abstract #1602) A. M. Saaed, A. K. Sheikha, S. S. Mohammed, H. A. Ameen, S. Y. Sheet, M. Khasraw Brd. 10D Clinical and pathological profile of breast cancer in a tertiary cancer center in Saudi Arabia. (Abstract #1603) S. AlShehri, O. A. Abulkhair, A. Al Kushi, S. Musaad, A. Al Olayan, A. R. Jazieh Brd. 10E Pattern of malignant diseases in Lagos, Nigeria. (Abstract #1604) O. F. Adetayo 169 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 2:00 PM - 6:00 PM GENERAL POSTER SESSION Head and Neck Cancer Location: Hall A Track(s): Head and Neck Cancer SATURDAY Brd. 11A Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5530) J. B. Vermorken, E. Remenar, C. Van Herpen, M. Degardin, J. S. Stewart, R. Karra Gurunath, C. Fortpied Brd. 11B Prognostic factors of overall survival in head and neck cancer: Post-hoc exploratory results from the SPINNAKER trial—A phase III randomized clinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy. (Abstract #5531) S. Urba, J. Gatz, W. Shen, A. Hossain, K. Winfree, A. Koustenis, P. Peterson Brd. 11C The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. (Abstract #5532) H. H. Loong, B. Ma, F. Mo, S. Leung, E. P. Hui, M. K. Kam, S. L. Chan, A. T. Chan Brd. 11D Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of disparities in care. (Abstract #5533) B. A. Murphy, A. Y. Chen, W. J. Curran Jr., A. S. Garden, P. M. Harari, S. J. Wong, L. A. Bellm, M. Schwartz, J. Newman, D. Adkins, D. N. Hayes, U. Parvathaneni, D. Brachman, B. Ghabach, C. Schneider, M. Greenberg, A. Abitbol, P. R. Anne, K. Ang Brd. 11E Concomitant chemoradiation in locally advanced head and neck squamous cell carcinoma: A literature-based metanalysis on the platinum concomitant chemotherapy. (Abstract #5534) M. G. Ghi, A. Paccagnella, I. Floriani, D. Garavaglia Brd. 11F Long-term toxicity: A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oropharyngeal cancer patients. (Abstract #5535) L. Raimondo, M. Garzaro, G. Riva, G. Pecorari, C. Giordano, M. Airoldi Brd. 11G Neoadjuvant chemotherapy and prognostic subgroups defined by survival benefit in paitents with locoregionally advanced nasopharyngeal carcinoma. (Abstract #5536) X. Ji, Y. Zhong, Y. Zhou, F. Zhou, G. Zhang, G. Chen, D. Deng, H. Liu, J. Zhang, C. Xie Brd. 11H Quality of life, physical, and psychologic functioning in patients affected by end-stage head and neck cancer. (Abstract #5537) M. Airoldi, M. Garzaro, L. Raimondo, G. Riva, G. Pecorari, C. Giordano Brd. 12A A phase II study of pemetrexed combined with cisplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma. (Abstract #5538) A. W. Lee, T. Yau, T. C. Shum, W. Ng, L. L. Chan, R. M. Yeung Brd. 12B Long-term symptom burden after radiation treatment for oropharynx cancer: A comparison of 3D and IMRT techniques. (Abstract #5539) D. I. Rosenthal, G. B. Gunn, T. R. Mendoza, A. S. Garden, B. M. Beadle, W. H. Morrison, X. S. Wang, S. J. Frank, R. S. Weber, K. Ang, C. S. Cleeland Brd. 12C Clinical characteristics of an incident cohort of patients with resected squamous cell carcinoma of the head and neck (SCCHN) in the United Kingdom. (Abstract #5540) K. Kim, M. Amonkar, D. Högberg, F. Kasteng 170 Brd. 12D Pretreatment PET and posttreatment pathologic nodal status as a predictor for distant metastasis in locally advanced head and neck squamous cell carcinoma treated with definitive concurrent chemoradiotherapy. (Abstract #5541) K. Hu, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, T. Tran, S. P. Schantz, P. Costantino, L. B. Harrison Brd. 12E Comparison of two schedules in locally advanced nasopharyngeal carcinoma observed in a nonendemic population. (Abstract #5542) M. Garzaro, L. Raimondo, G. Pecorari, F. Pedani, C. Giordano, M. Airoldi Brd. 12F A phase II trial of induction chemotherapy with cisplatin, docetaxel, and capecitabine followed by concurrent cisplatin-radiotherapy in advanced nasopharyngeal carcinoma. (Abstract #5543) M. Yamouni, Y. Beldjilali, K. Benhadji, H. Khellafi, F. Betkaoui, Y. Kaid, L. Benchlef, F. Z. Daim, S. Toubal, A. Boukerche, A. Abdelaoui, L. Djellali Brd. 12G Exploring factors in diagnostic delays of head and neck cancer at a public hospital. (Abstract #5544) D. W. Lai, S. A. Buckley, B. L. Schmidt, C. Viet, F. Muggia, I. Belitskaya-Levy, R. F. Cohen, M. D. DeLacure, N. Sanfilippo, D. Myssiorek, D. Hirsch, N. Seetharamu Brd. 12H Incidence of esophageal cancers among oral cavity and pharynx cancer patients: A review of the SEER database (1973–2007). (Abstract #5545) E. Kim, N. Chandra, J. Kim Brd. 13A Chemoselection with induction chemotherapy followed by chemoradiation or surgery versus chemoradiation for patients (pts) with locally advanced squamous cell carcinoma of the oropharynx (LASCCOP). (Abstract #5546) I. Y. Dobrosotskaya, E. Light, J. M. Maxwell, S. A. Byrd, M. E. Spector, B. Kumar, F. Y. Feng, A. Eisbruch, G. T. Wolf, M. Prince, J. Moyer, T. N. Teknos, D. B. Chepeha, H. M. Walline, J. B. McHugh, K. G. Cordell, S. Urba, C. R. Bradford, T. Carey, F. P. Worden Brd. 13B Measurement of distress in patients with nasopharyngeal carcinoma. (Abstract #5547) Y. Jiang, Y. Deng Brd. 13C Concomitant chemoradiation using weekly cisplatin for advanced squamous cell carcinoma of head and neck: Experience from a tertiary cancer center in India. (Abstract #5548) A. Sharma, B. K. Mohanti, A. Thakar, S. P. Chaudhary, S. Bhasker, S. Bahadur Brd. 13D Paclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). (Abstract #5549) P. Ceruse, E. Lavergne, G. Buiret, B. Pham, S. Chabaud, B. Favier, D. Girodet, P. Zrounba, J. Fayette Brd. 13E Recurrence of T1N0 oral tongue squamous cell carcinoma in Stockholm, Sweden 2000 –2009. (Abstract #5550) M. Ryott Brd. 13F Comprehensive volume hyperfractionated (HFx) re-irradiation (Re-RT) of recurrent head and neck (H/N) cancer is feasible. (Abstract #5551) P. Kumar, U. K. Sinha Brd. 13G Survival, tumor control, and toxicity with TPF before accelerated radiotherapy potentiated with cetuximab for stage III-IV unresectable head and neck cancer: A phase II study. (Abstract #5552^) C. Mercke, H. Sjödin, H. Haugen, G. Adell, G. Wickart-Johansson, E. M. Munck-Wikland, G. von Dobeln, J. Nyman Brd. 13H Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer. (Abstract #5553) J. J. Caudell, S. Spencer, R. Meredith, L. Nabell, J. A. Bonner 171 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 14A Kinetic analysis of 18f-fluoroerythronitroimidazole PET/CT during radiotherapy correlates with outcome in head and neck cancer. (Abstract #5554) M. Hu, J. Yu, L. Kong, Z. Fu Brd. 14B Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. (Abstract #5555) V. Espeli, E. Zucca, M. E. Ghielmini, A. Richetti, O. Giannini, F. Martucci Brd. 14C Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning. (Abstract #5556) A. D. Colevas, A. Quon, A. McMillan, Q. Le Brd. 14D Multiple cases of squamous cell carcinoma of the tongue and oral cavity in patients treated with long-term pegylated liposomal doxorubicin (PLD) for ovarian cancer. (Abstract #5557) T. L. Cannon, F. Muggia, D. Hirsch, E. A. Andreopoulou, A. R. Kerr, M. D. DeLacure Brd. 14E Influence of induction chemotherapy on patient’s compliance to radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. (Abstract #5558) B. Atassi, O. Ozgursoy, G. H. Yoo, J. R. Jacobs, N. Bhatti, M. Mal, H. Kim, H. Lin, A. Sukari Brd. 14F Use of buccal fat pad to correct defects in the oral cavity after excision of cheek cancer: A prospective study. (Abstract #5559) S. K. Agrawala, S. Gosh Brd. 14G Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF ⴙ C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). (Abstract #5560) D. Adkins, J. Ley, B. Nussenbaum, J. Diaz, R. Paniello, W. L. Thorstad, H. A. Gay, J. Subramanian, T. M. Wildes, J. Mathai, T. Rachocki, D. I. Kuperman Brd. 14H Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5561) L. L. Siu, S. J. Hotte, S. A. Laurie, S. Singh, E. Winquist, S. K. Chia, E. X. Chen, K. K. Chan, T. Wang, I. Taylor, A. Ruiz-Garcia, C. Mormont, D. Soulieres Brd. 15A Phase II trial of sorafenib in patients with advanced thyroid cancer. (Abstract #5562) S. M. Keefe, A. B. Troxel, S. Rhee, K. Puttaswamy, P. J. O’Dwyer, L. A. Loevner, S. J. Mandel, M. S. Brose Brd. 15B A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). (Abstract #5563) M. G. Fury, E. J. Sherman, D. M. Lisa, N. Agarwal, K. M. Algazy, B. Brockstein, C. J. Langer, D. Lim, R. Mehra, S. K. Rajan, N. Jafri, S. Korte, B. Lipson, F. Yunus, T. Tanvetyanon, S. Smith-Marrone, K. K. Ng, H. Xiao, S. Haque, D. G. Pfister Brd. 15C Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. (Abstract #5564) A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson, G. R. Blumenschein Jr., H. X. Chen, J. R. Grandis, M. S. Kies Brd. 15D Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. (Abstract #5565) A. W. Gramza, S. A. Wells, S. Balasubramaniam, A. T. Fojo 172 Brd. 15E A phase II study of VEGF trap in patients with radioactive iodine (RAI)–refractory thyroid carcinoma. (Abstract #5566) E. J. Sherman, A. L. Ho, S. Haque, R. M. Tuttle, R. A. Ghossein, H. Schöder, M. S. Baum, K. Kelly, A. P. Chen, A. R. Shaha, D. G. Pfister Brd. 15F Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03. (Abstract #5567) J. Guigay, J. Fayette, A. Dillies, C. Sire, J. N. Kerger, I. Tennevet, J. H. Machiels, S. Zanetta, Y. Pointreau, L. Bozec Le Moal, L. Brugel Ribere, S. Henry, S. Temam, GORTEC Brd. 15G Pilot study to evaluate the effect of erlotinib (E) administered before surgery in operable patients with squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5568) M. Porosnicu, J. D. Waltonen, C. Sullivan, L. McWilliams, G. L. Kucera, A. Thomas, R. Plasser, J. D. Browne Brd. 15H Prospective phase II study of tumor response assessment by CT and FDGPET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). (Abstract #5569) J. Ley, B. A. Siegel, F. Dehdashti, J. Subramanian, G. Ansstas, T. Rachocki, J. Mathai, T. M. Wildes, D. I. Kuperman, D. Adkins Brd. 16A Treatment (T) of T2 N0-1 larynx cancer (LC) with hyperfractionated radiotherapy (HRT) and cetuximab (C): Final report. (Abstract #5570) R. E. Giglio, A. Navigante, M. D. Pereira, L. Califano, B. M. Roth, P. Saco, M. A. Castro, P. Menendez, P. Aguerre, R. Adan, C. Brosio, C. Pogany Brd. 16B Human papillomavirus (HPV)–related, p16 positive head and neck squamous cell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solid organ transplantation (SOT). (Abstract #5571) C. P. Rodriguez, D. Chute, R. Seth, B. Burkey, J. Scharpf, A. P. Hoschar, D. I. Ives, D. J. Adelstein Brd. 16C Different cellular p16 localization may signal different survival outcomes in head and neck cancer. (Abstract #5572) D. N. Hayes, N. Zhao, M. Ang, M. Patel, M. D. Wilkerson, X. Yin, M. C. Hayward, W. K. Funkhouser Jr., A. Olshan Brd. 16D Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers (OPCs). (Abstract #5573) P. Bossi, F. Perrone, R. Miceli, L. Locati, C. Bergamini, A. Mirabile, R. Granata, C. Resteghini, B. Cortelazzi, M. Orsenigo, C. Fallai, E. Orlandi, S. Pilotti, L. F. Licitra Brd. 16E HPV prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced squamous cell carcinoma of the head and neck treated with chemoradiation therapy at Centre Hospitalier de l’Université de Montréal: A single-center experience. (Abstract #5574) E. Thibaudeau, D. Soulieres, B. Fortin, F. Coutlee, P. Nguyen-Tan, X. Weng, M. Audette, O. Abboud, L. Guertin, A. Christopoulos, J. Tabet Brd. 16F Factors predicting survival outcomes for patients with HPV-positive base of tongue cancer. (Abstract #5575) P. Attner Brd. 16G Lymph node density and response to induction TPF in patients with HPVrelated head and neck cancer. (Abstract #5576) H. C. Agbahiwe, S. Marur, A. A. Forastiere, G. Sanguineti Brd. 16H Effects of human papillomavirus (HPV) and other potential risk factors on survival in patients with oropharyngeal cancer. (Abstract #5577) M. Knoedler, A. Zakarneh, U. Zimmermann, K. Woelke, O. Kaschke, U. Keilholz 173 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 17A Association of p16 and pEGFR expression with high-risk HPV in head and neck squamous cell carcinoma. (Abstract #5578) R. Altaha Brd. 17B Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. (Abstract #5579) L. J. Wirth, V. Nardi, D. Juric, A. K. Cosper, K. Bergethon, V. Scialabba, D. R. Borger, A. J. Iafrate, L. W. Ellisen, D. Deschler, D. Zhao, P. M. Sadow, D. Dias-Santagata Brd. 17C Adenoid cystic carcinoma of the head and neck (ACCHN) incidence and survival trends. (Abstract #5580) C. L. Ellington, S. A. Kono, T. K. Owonikoko, S. S. Ramalingam, F. R. Khuri, D. M. Shin, N. F. Saba Brd. 17D High-grade transformation in acinic cell carcinoma of the salivary glands: A rare but important clinical entity. (Abstract #5581) K. A. Price, W. Shon, J. A. Davidson, J. E. Lewis, D. L. Price, J. J. Garcia Brd. 17E 17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma. (Abstract #5582) J. F. Moley, D. Adkins, K. C. Bible, A. M. Traynor, J. R. Molina, G. Colon-Otero, T. J. Pluard, M. H. Shah, R. Suresh, C. Erlichman, S. P. Ivy, V. Suman, S. M. Geyer, P. M. Fracasso, M. S. Cohen, H. Tang, E. Fialkowski, A. Traugott, R. C. Smallridge, P2C Brd. 17F Preoperative recombinant adeno-viral human p53 gene (rAd-p53) therapy in treatment of locally advanced locally advanced papillary thyroid cancer (PTC) and folliculary thyroid cancer (FTC). (Abstract #5583) J. Zhu Brd. 17G Prognostic factors of adenoid cystic carcinoma of head and neck. (Abstract #5584) Y. Choi, S. Kim, S. Nam, S. Choi, J. Roh, J. Lee, S. Lee, K. Cho Brd. 17H Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer. (Abstract #5585) S. Hossain, C. Bhimani, Z. Chen, S. S. Ramalingam, D. M. Shin, C. Cohen, F. R. Khuri, E. Waller, T. K. Owonikoko Brd. 18A Pharmacogenetic variations in ABCG2 are associated with cisplatin toxicity in patients with head and neck squamous cell carcinoma. (Abstract #5586) B. Lee, R. Slack, J. J. Hwang, K. Steadman, W. Harter, B. J. Davidson, K. A. Newkirk, P. G. Shields, R. Goldman, J. F. Deeken Brd. 18B ERCC1 and XPF protein expression in patients with nasopharyngeal carcinoma (NPC) undergoing curative intent radiation with or without platinum chemotherapy. (Abstract #5587) A. Jagdis, T. Phan, A. C. Klimowicz, J. J. Laskin, H. Lau, S. K. Petrillo, J. E. Siever, T. A. Thomson, A. M. Magliocco, D. Hao Brd. 18C Association of increased lymphocyte infiltration with outcome in patients with head and neck cancer treated with the IRX-2 regimen. (Abstract #5588) P. Naylor Brd. 18D Gene expression profiling predicts nonresponders to chemoradiation in HPV16-positive head and neck squamous cell carcinoma. (Abstract #5589) B. J. Thibodeau, T. J. Geddes, S. Ahmed, B. L. Pruetz, P. Y. Chen, G. D. Wilson, J. A. Akervall Brd. 18E Serum C18-ceramide as a biomarker for response: Phase II trial of gemcitabine plus doxorubicin in patients with HNSCC. (Abstract #5590) K. Shirai, S. Saddoughi, P. E. O’Brien, L. Afrin, E. Garrett-Mayer, G. R. Simon, U. B. Chaudhary, B. Ogretmen 174 Brd. 18F Identification of signaling pathways involved in the mechanism of action of the immunomodulatory peptide gamma-D-glutamyl-L-tryptophan. (Abstract #5591) J. Papkoff, H. Lee, G. Singh, S. Singh, S. Chitta, K. Andrew, P. Quintel, J. S. Rosenberg, B. A. Watkins, S. T. Sonis, C. W. Tuthill Brd. 18G The effect of the immunomodulatory peptide gamma-D-glutamyl-L-tryptophan in leukemia, lymphoma, and head and neck cancer xenograft models. (Abstract #5592) C. W. Tuthill, J. Papkoff, B. A. Watkins, S. T. Sonis Brd. 18H High dose rate intraoperative radiation therapy for recurrent head and neck cancer: The importance of in-field control on survival. (Abstract #5593) L. B. Harrison, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, T. Tran, S. P. Schantz, P. Costantino, K. Hu Brd. 19A Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. (Abstract #5594) B. Jimenez, J. Trigo Perez, M. Saez Medina, C. Quero Blanco, B. Pajares, A. Rueda, E. Alba 175 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 2:00 PM - 6:00 PM GENERAL POSTER SESSION Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell Location: Hall A Track(s): Lung Cancer SATURDAY Brd. 20A Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFRmutant lung cancers that recur after adjuvant TKI. (Abstract #7029) G. R. Oxnard, Y. Y. Janjigian, M. E. Arcila, M. G. Kris, M. Ladanyi, C. G. Azzoli, V. A. Miller Brd. 20B Tumor response and toxicity in neoadjuvant erlotinib in early-stage NSCLC patients. (Abstract #7030) H. M. Klomp, E. Schaake, NEL Study group Brd. 20C Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer. (Abstract #7031) J. Wang, K. Chen, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang, M. Wu, Q. Guo, X. Liu, S. Wang, Y. Wang Brd. 20D The role of EGFR mutation status in patients with stage III nonsquamous non-small cell lung cancer treated with chemoradiotherapy. (Abstract #7032) F. Li, G. y. Zhu, X. N. Li, R. Yu, A. Shi, L. Yin Brd. 20E Mutations of EGFR, K-ras, and EML-4ALK genes in resected lung adenocarcinoma and their clinical significance. (Abstract #7033) T. Ohba, K. Sugio, T. Kometani, M. Yamaguchi, M. Hamatake, K. Nosaki, H. Takeoka, H. Kitajima, F. Hirai, T. Seto, Y. Ichinose Brd. 20F The association of epidermal growth factor receptor (EGFR) mutation and survival in N2(ⴙ) non-small cell lung cancer patients treated with platinumbased neoadjuvant concurrent chemoradiotherapy. (Abstract #7034) H. Ahn, Y. Choi, J. Sun, Y. Ahn, K. Kim, J. Kim, Y. Shim, J. Ahn, K. Park, M. Ahn Brd. 20G Detection of EGFR mutations with mutation-specific antibodies in primary lesions of non-small cell lung cancer. (Abstract #7035) X. Zhang, L. Yin, X. Yang, J. Yang, Q. Zhou, J. Xu, Z. Xie, S. An, S. Chen, R. Wang, G. Zhu, Y. Gu, Y. Wu Brd. 20H Impact of EGFR mutation status in patients with completely resected lung adenocarcinoma treated with adjuvant platinum-based chemotherapy. (Abstract #7036) K. Yoh, K. Goto, S. Niho, H. Ohmatsu, K. Nagai, Y. Ohe Brd. 21A Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts). (Abstract #7037) E. Felip, M. Salcedo, N. Murtra-Garrell, A. Navarro, C. Teixido, J. Hernandez-Losa, S. Cedres, P. Martinez, E. Lopez, M. Montero, V. Freixinos, G. Argiles, I. Nuñez, V. Peg, E. Pallisa, M. Canela, J. Tabernero, S. Ramon y Cajal, N. Tallada Brd. 21B Initial experience with erlotinib in advanced non-small cell lung cancer in the kingdom of Saudi Arabia. (Abstract #7038) A. A. Alolayan, S. Musaad, H. Bamefleh, M. Nounou, A. R. Jazieh Brd. 21C SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. (Abstract #7039) J. Maguire, R. McMenemin, N. O’Rourke, C. Peedell, M. Snee, S. McNee, V. Kelly Brd. 21D Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). (Abstract #7040) Y. Chen, J. Moon, K. J. Pandya, K. Kelly, L. E. Gaspar, D. Lau, F. R. Hirsch, D. R. Gandara 176 Brd. 21E Predictive factors for symptomatic radiation pneumonitis in 293 consecutively treated non-small cell lung cancer (NSCLC) patients receiving definitive radiation therapy. (Abstract #7041) A. Orisamolu, E. Xanthopoulos, A. Fernandes, J. P. Christodouleas, S. Apisarnthanarax, N. Mitra, F. Wan, C. J. Langer, T. L. Evans, J. Stevenson, D. Sterman, A. Vachani, A. R. Haas, R. Rengan Brd. 21F Long-term survival (LTS) and competing risks within a prospective multicenter German randomized trial comparing induction chemotherapy (CTx) followed by concurrent (cc) chemoradiation (CTx/RTx) plus surgery (SURG) (ⴝ TRIMODALITY) supplemented by PCI versus local treatment (Tx) alone (SURG ⴙ RTx) in operable IIIA NSCLC. (Abstract #7042) T. C. Gauler, C. Poettgen, H. Wagner, S. Korfee, R. Hepp, G. Stamatis, J. Von Pawel, B. Passlick, V. Budach, H. Wilke, S. Seeber, M. Stuschke, W. E. Eberhardt Brd. 21G Endostar in combination with radiotherapy and paclitaxel/carboplatin in patients with unresectable non-small cell lung cancer of stage III: Preliminary results of a phase II study. (Abstract #7043) S. Ma, Y. Xu, X. Sun, Y. Ji, Y. Zheng, S. Wang, J. Chen Brd. 21H Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657. (Abstract #7044) J. Zhang, S. M. Russo, H. A. Gay, T. Parent, Z. Nelson, S. Eubanks, P. R. Walker Brd. 22A Oral vinorelbine (NVBo) at 3 weekly flat-dose intakes (FDI) as single agent or with cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stage III NSCLC: Escalation-dose phase I trial results. (Abstract #7045) D. M. Kowalski, M. J. Krzakowski, K. Zajda, C. Lucas Brd. 22B A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC. (Abstract #7046) V. L. Keedy, B. Lu, L. Horn, Y. Shyr, C. F. Winkler, D. P. Carbone, A. Sandler Brd. 22C Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG): Phase II results (CISTAXOL). (Abstract #7047) W. E. Eberhardt, T. C. Gauler, C. Le Pechoux, R. Hepp, S. Welter, B. Fischer, S. Bildat, D. Grunenwald, G. Stamatis, M. Stuschke, C. Poettgen Brd. 22D Long-term follow-up of phase III trial of docetaxel and cisplatin (DP) versus mitomycin, vindesine, and cisplatin (MVP) with concurrent thoracic radiation therapy (TRT) for locally advanced non-small cell lung cancer (OLCSG 0007). (Abstract #7048) K. Kiura, N. Takigawa, K. Matsuo, S. Kuyama, S. Hosokawa, K. Fujiwara, A. Hisamoto, T. Kozuki, H. Ueoka, M. Tanimoto, Okayama Lung Cancer Study Group Brd. 22E Stereotactic body radiation therapy versus high-dose conventional radiation therapy in early-stage NSCLC: A retrospective study on local failure and survival rates. (Abstract #7049) S. Jeppesen, T. Schytte, H. R. Jensen, C. Brink, O. Hansen Brd. 22F Fiducial-less stereotactic radiotherapy for early-stage lung cancer: Efficacy and toxicity evaluation. (Abstract #7050) J. Bibault, B. Prevost, E. Dansin, X. Mirabel, T. Lacornerie, F. Dubus, E. Lartigau Brd. 22G Outcomes of stereotactic body radiotherapy in patients with clinical stage I non-small cell lung cancer who are fit to undergo surgery. (Abstract #7051) S. Senan, N. E. Verstegen, C. J. Haasbeek, B. J. Slotman, F. J. Lagerwaard Brd. 22H Clinical outcome of cN0 non-small cell lung cancer patient staged by thin slice CT, FDG-PET, and EBUS-TBNA. (Abstract #7052) Y. Sakairi, H. Hoshino, T. Nakajima, T. Fujiwara, F. Ishibashi, H. Tamura, H. Wada, T. Iwata, T. Okamoto, T. Mizobuchi, Y. Moriya, S. Yoshida, K. Yasufuku, I. Yoshino 177 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 23A Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC). (Abstract #7053) K. A. Gold, J. Lee, Y. Ping, C. Behrens, D. Liu, H. Lee, J. S. Koo, R. Lotan, L. Solis, W. Rinsurongkawong, D. J. Stewart, W. L. Hofstetter, S. Swisher, S. M. Lippman, I. I. Wistuba, W. K. Hong, E. S. Kim Brd. 23B Survival analysis of patients with/without lymph node examination after lung cancer resection. (Abstract #7054) R. U. Osarogiagbon, R. A. Ramirez, C. Wang, L. E. Miller, M. Ul-Haq, A. Farooq, J. W. Allen, D. Spencer, A. Berry, A. B. Weir III, H. Cole, T. O’Brien Brd. 23C Final results of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomized study by the European Lung Cancer Working Party. (Abstract #7055) T. Berghmans, J. Lafitte, V. Giner, M. Berchier, A. Scherpereel, M. Paesmans, A. Meert, T. Bosschaerts, N. Leclercq, J. P. Sculier Brd. 23D BRCA1 mRNA expression patterns in a large lung cancer cohort. (Abstract #7056) K. Kelly, P. Mack, X. Huang, P. Lara Jr., P. V. Danenberg, K. D. Danenberg, D. R. Gandara Brd. 23E PI3K pathway and downstream signaling analysis in malignant pleural mesothelioma (MPM). (Abstract #7057) S. Cedres Perez, M. Montero, D. Torrejon, P. Martinez, V. Freixinos, N. Mulet-Margalef, G. Argiles, I. Nuñez, E. Lopez, L. Prudkin, M. Salcedo, N. Tallada, S. Ramon y Cajal, E. Felip Brd. 23F Role of solid tumor size compared with whole tumor size to predict pathological malignant grade or prognosis in clinical stage IA lung adenocarcinoma: A multicenter study. (Abstract #7058) Y. Tsutani, Y. Ibuki, T. Ikeda, Y. Miyata, H. Nakayama, M. Okada Brd. 23G Molecular studies support the association between germline genetic variants in the vascular endothelial growth factor (VEGF) pathway and survival in non-small cell lung cancer (NSCLC) patients. (Abstract #7059) D. M. Glubb, W. Zhang, K. Owzar, C. Jiang, O. Mirza, S. Kashyap, W. Rzyman, J. Jassem, F. R. Hirsch, R. Dziadziuszko, F. Innocenti Brd. 23H Characteristics of the ground-glass opacity nodules showing growth during follow-up. (Abstract #7060) H. Matsuguma, A. Ui, N. Oohata, R. Nakahara, T. Kasai, Y. Kamiyama, S. Igarashi, K. Mori, T. Kodama, K. Yokoi Brd. 24A Incomplete intrapulmonary lymph node retrieval with routine pathology evaluation of resected lung cancer. (Abstract #7061) R. A. Ramirez, C. Wang, L. E. Miller, C. A. Adair, T. O’Brien, A. Berry, R. U. Osarogiagbon Brd. 24B A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC). (Abstract #7062) K. H. Dragnev, T. Ma, F. Galimberti, C. P. Erkmen, V. Memoli, W. Nugent, J. R. Rigas, D. Johnstone, A. Frandsen, S. Simeone, J. Czum, H. Li, J. DiRenzo, S. Freemantle, E. Dmitrovsky Brd. 24C Induction chemotherapy with gemcitabine-carboplatin-paclitaxel (GEMCAP) in stage III non-small cell lung cancer (NSCLC). (Abstract #7063) G. L. Banna, H. Lipari, C. Buscarino, A. Seca, A. Basile, M. Ippolito, G. Novello, R. Condorelli, S. Cavallaro, G. Squadrito, M. D’Arrigo, V. Gebbia, A. Terminella, S. Saita Brd. 24D Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC). (Abstract #7064) L. Toschi, P. Colombo, C. Soldani, L. Giordano, G. Finocchiaro, L. Siracusano, L. Gianoncelli, M. Incarbone, A. Destro, M. Alloisio, L. Terracciano, M. Varella-Garcia, F. Cappuzzo, M. Roncalli, A. Viola, A. Santoro 178 Brd. 24E Hedgehog inhibition and radiation therapy in non-small cell lung cancer. (Abstract #7065) J. Zeng, K. Aziz, M. Armour, B. Aftab, R. Gajula, S. Chettair, T. Salih, C. M. Rudin, P. T. Tran, R. Hales Brd. 24F Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. (Abstract #7066) G. C. Connolly, M. R. Dalal, J. Lin, A. A. Khorana Brd. 24G Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer (NSCLC). (Abstract #7067) R. G. Salloum, T. J. Smith, J. Elston-Lafata, G. Jensen Brd. 24H Examination of 12-lipoxygenase (12-LOX) as a therapeutic target in nonsmall cell lung cancer (NSCLC): Mechanisms controlling survival and induction of apoptosis following selective inhibition. (Abstract #7068) M. Cathcart, V. Campbell, K. Gately, E. Kay, G. P. Pidgeon, K. J. O’Byrne Brd. 25A Smoking, passive smoking and lung cancer cell types among women in Morocco: Analysis of epidemiological profiling of 101 cases. (Abstract #7069) H. Errihani, S. Ouaouch, H. Abahssain, R. Razine, H. Mrabti, R. Abouqal, M. Ichou, N. Benjaafar, F. Zakkouri Brd. 25B Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations. (Abstract #7070) S. P. D’Angelo, B. J. Park, L. M. Krug, C. Crevar, C. E. Medina, D. K. Sumner, J. Richman, C. Coeshott, D. Apelian, A. Cohn, M. G. Kris, C. G. Azzoli Brd. 25C Prognostic role of integrin 1, E-cadherin, and rac1 expression in small cell lung cancer. (Abstract #7071) M. Chang, K. Lee, Y. Kim, J. Kang Brd. 26A Liposomal cisplatin in cancer patients with renal failure. (Abstract #7072) G. Stathopoulos, S. Rigatos, J. Stathopoulos, S. Batzios Brd. 26B Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients (pts) with advanced solid tumors. (Abstract #7073) N. Chen, S. P. Chawla, E. G. Chiorean, W. L. Read, M. Gorbaty, A. C. Mita, L. Yung, R. McNally, M. F. Renschler, S. Sharma Brd. 26C Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis. (Abstract #7074) S. E. Schild, N. R. Foster, J. P. Meyers, K. R. Olivier, H. J. Ross, J. R. Molina, P. J. Stella, L. R. Past, Y. I. Garces, A. A. Adjei, North Central Cancer Treatment Group Brd. 27A Retrospective review of extrapulmonary small cell carcinoma and prognostic factors. (Abstract #7075) J. E. Brammer, P. D. Lulla, M. A. Bilen, G. R. Lynch Brd. 27B A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for high-grade pulmonary neuroendocrine carcinona (large cell neuroendocrine carcinoma and small cell lung cancer). (Abstract #7076) H. Kenmotsu, S. Niho, T. Ito, Y. Ishikawa, H. Tada, I. Sekine, S. Watanabe, M. Yoshimura, N. Yamamoto, F. Oshita, K. Kubota, K. Nagai Brd. 27C Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). (Abstract #7077) M. G. Viganò, R. Cavina, S. Novello, F. Grossi, A. Santoro, V. Gregorc, G. Scagliotti, I. M. Garassino, G. Rossoni, M. G. Levra, C. Genova, F. Caligaris-Cappio, A. Lambiase, C. Bordignon 179 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 28A Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose (70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies. (Abstract #7078) J. K. Salama, L. Hodgson, H. Pang, M. R. Green, J. J. Urbanic, A. W. Blackstock, J. Crawford, J. Bogart, E. E. Vokes, CALGB Brd. 28B Phase II study of NK012 in relapsed small cell lung cancer. (Abstract #7079) E. Raefsky, D. R. Spigel, J. R. Infante, J. C. Bendell, S. F. Jones, A. J. Lipman, D. Trent, S. Kawamura, F. A. Greco, J. D. Hainsworth, H. A. Burris III Brd. 28C Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small cell lung cancer (SCLC) cells. (Abstract #7080) Z. Wang Brd. 29A A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC). (Abstract #7081) E. Kontopodis, L. Vamvakas, K. Kalbakis, N. K. Vardakis, G. Sfakiotaki, V. Georgoulias, S. Agelaki Brd. 29B A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. (Abstract #7082) S. I. Jalal, J. A. Bufill, G. A. Masters, N. Somaiah, K. Koneru, J. McClean, R. E. Sanborn, J. Wu, Z. Yu, L. H. Einhorn Brd. 29C Determinants of chemotherapy administration and effects of chemotherapy on survival in elderly patients with small cell lung cancer (SCLC): A SEERMedicare analysis. (Abstract #7083) L. C. Caprario, D. M. Kent, T. A. Trikalinos, G. M. Strauss Brd. 30A Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC). (Abstract #7084) J. Han, K. Lim, H. Kim, S. Oh, T. Yun, J. Lee Brd. 30B Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada. (Abstract #7085) A. Hasani, B. Sun, G. Liu, W. Xu, R. Feld, N. B. Leighl Brd. 30C Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in malignant pleural mesothelioma. (Abstract #7086) K. Hollevoet, K. Nackaerts, R. Gosselin, W. De Wever, L. Bosquée, P. De Vuyst, P. R. Germonpre, E. Kellen, C. Legrand, Y. Kishi, J. R. Delanghe, J. P. Van Meerbeeck Brd. 31A Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients (Italian SoMe Study). (Abstract #7087) V. Mutri, C. Pinto, S. Giaquinta, P. Di Tullio, V. Torri, B. Melotti, F. Sperandi, F. Di Fabio, F. L. Rojas Llimpe, S. Pini, F. Massari, A. Martoni Brd. 31B Repeated ambulatory intrapleural chemotherapy for malignant pleural mesothelioma. (Abstract #7088) J. Javidfar, J. R. Sonett, M. E. Ginsburg, J. Miller, E. Hare, M. Bacchetta, R. Fawwaz, R. N. Taub Brd. 31C NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM). (Abstract #7089) F. De Vincenzo, G. Rossoni, A. Santoro, V. Gregorc, P. A. Zucali, G. Citterio, M. Simonelli, G. Petrella, F. Caligaris-Cappio, A. Lambiase, C. Bordignon Brd. 31D Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of malignant pleural mesothelioma (MPM). (Abstract #7090) F. Rea, A. G. Favaretto, G. Marulli, L. Spaggiari, T. M. De Pas, A. Ceribelli, A. Paccagnella, G. Crivellari, F. Russo, M. Ceccarelli, F. Facciolo 180 Saturday, June 4, 2011 Imatinib mesylate in thymic epithelial malignancies. (Abstract #7091) C. Buonerba, M. Marino, S. Sioletic, S. Conti, L. Petillo, P. Federico, V. Damiano, G. Merola, A. Evoli, M. Lalle, A. Ceribelli, M. Milella, G. Palmieri SATURDAY Brd. 31E 181 Saturday, June 4, 2011 2:00 PM - 6:00 PM GENERAL POSTER SESSION Lung Cancer—Metastatic/Non-small Cell Location: Hall A Track(s): Lung Cancer SATURDAY Brd. 32A Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis. (Abstract #7537) K. E. Bickel, J. C. Niland, R. Mamet, C. C. Zornosa, D. S. Ettinger, K. Pisters, G. A. Otterson, M. Koczywas, M. E. Reid, M. S. Rabin, T. A. D’Amico, C. Earle, T. M. Pini, G. P. Kalemkerian Brd. 32B Guideline adherence rates and costs of chemotherapy treatment for NSCLC patients treated in U.S. community oncology practices. (Abstract #7538) Z. Wang, I. Aksamit, L. Tuscher, B. S. Tom, C. B. Del Buono, U. Campbell, S. Shields, T. Lam, K. B. Whitlock, M. Mayo, J. Huang, A. M. Christman, K. A. Bergstrom Brd. 32C The effect of 3 months of integrative cancer treatment on quality of life for patients with lung cancer. (Abstract #7539) E. D. Staren, D. Gupta, J. F. Grutsch, D. P. Braun Brd. 32D Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of moleculartargeted agents for advanced non-small cell lung cancer (NSCLC). (Abstract #7540) K. Hotta, K. Kiura, E. Suzuki, N. Takigawa, Y. Fujiwara, E. Ichihara, M. Tabata, M. Tanimoto Brd. 32E Factors influencing a specific histological diagnosis of non-small cell lung cancer. (Abstract #7541) J. A. Sulpher, S. P. Owen, H. Hon, K. Tobros, F. A. Shepherd, E. Sabri, G. Liu, C. M. Canil, P. Wheatley-Price Brd. 32F Surgical, histopathologic, and patient-related factors associated with isolated brain metastases (IBM) in patients with stages I-IIIA non-small cell carcinoma (NSCLC) undergoing surgical resection in comparison to patients developing other distal metastases (ODM). (Abstract #7542) J. M. Varlotto, L. N. Medford-Davis, J. Shelkey, J. C. Flickinger, A. Recht, M. Nikolov, M. Reed, J. Toth, M. M. DeCamp Brd. 32G Retrospective review of MRIs in lung cancer patients with brain metastases: An assessment of early response. (Abstract #7543) R. Zinner, M. Debnam, G. W. Gladish, B. Konda, J. M. Hanneken, D. J. Stewart, R. F. Munden, L. Chi Brd. 32H Clinical outcome of patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. (Abstract #7544) S. Umemura, K. Kiura, K. Tsubouchi, N. Takigawa, K. Fujiwara, N. Horita, Y. Segawa, N. Hamada, I. Takata, M. Tanimoto Brd. 33A Prospective study on incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer (CSPHOR13). (Abstract #7545) N. Katakami, A. Hata, H. Kunikane, K. Takeda, K. Eguchi, K. Takayama, T. Sawa, H. Saito, M. Harada, S. Yokota, K. Ando, Y. Ohashi Brd. 33B Can we really treat patients over 70 years old with a chemotherapy doublet for non-small cell lung cancer (NSCLC)? (Abstract #7546) M. G. Zauderer, C. S. Sima, B. Korc-Grodzicki, M. G. Kris, L. M. Krug Brd. 33C Meta-analysis of efficacy and safety of single-agent and doublet chemotherapy with or without platinum in advanced non-small cell lung cancer in the elderly. (Abstract #7547) G. Des Guetz, B. Uzzan, P. Nicolas, K. Chouahnia, G. Sebbane, J. F. Morere 182 Brd. 33D Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC). (Abstract #7548) H. Borghaei, R. Mehra, M. M. Millenson, H. Tuttle, K. Ruth, A. J. Magdalinski, D. M. Mintzer, J. Lee, J. Stevenson, C. J. Langer Brd. 33E Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients. (Abstract #7549) C. Reynolds, A. I. Spira, W. L. Gluck, R. E. Pluenneke, K. A. Boehm, F. Zhan, L. Asmar Brd. 33F Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. (Abstract #7550) A. S. Tsao, S. Liu, J. Lee, C. M. Alden, E. S. Kim, G. R. Blumenschein Jr., R. S. Herbst, S. M. Lippman, I. I. Wistuba, W. K. Hong Brd. 33G Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. (Abstract #7551) M. A. Socinski, I. N. Bondarenko, N. A. Karaseva, A. Makhson, I. Vynnychenko, I. Okamoto, J. K. Hon, V. Hirsh, P. Bhar, G. I. Berk, J. L. Iglesias Brd. 33H Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605). (Abstract #7552) T. Hirashima, I. Okamoto, H. Yoshioka, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto, H. Saka, K. Asami, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto, T. Sawa, M. Miyazaki, K. Tamura, T. Kurata, M. Fukuoka, K. Nakagawa, West Japan Oncology Group Brd. 34A Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis. (Abstract #7553) M. Behera, T. K. Owonikoko, Z. Chen, S. A. Kono, F. R. Khuri, C. P. Belani, S. S. Ramalingam Brd. 34B Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC. (Abstract #7554) J. D. Patel, C. G. Azzoli, G. A. Weems, A. Koutsoukos, P. Zatloukal, K. Kelly Brd. 34C Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials. (Abstract #7555) A. Ardizzoni, L. Boni, M. Tiseo, A. Vincent, R. Passalacqua, A. Camerini, R. Labianca, G. Genestreti, F. Zanelli, L. Ciuffreda, F. Di Costanzo, F. De Marinis, L. Crinò, A. Santo, A. Pazzola, F. Barbieri, N. Zilembo, I. Colantonio, C. Tibaldi, E. F. Smit Brd. 34D Prognostic score for second-line chemotherapy of advanced non-small cell lung cancer (NSCLC): External validation in a phase III trial comparing vinflunine with docetaxel. (Abstract #7556) M. J. Krzakowski, M. Di Maio, K. Perraud, D. M. Kowalski, C. Gridelli Brd. 34E The role of gender in predicting for reduced drug clearance and increased toxicity in non-small cell lung cancer (NSCLC) patients receiving carboplatin and paclitaxel. (Abstract #7557) V. H. Phan, C. Tan, J. L. Vardy, A. Rittau, H. Xu, F. Zhang, A. J. McLachlan, P. J. Beale, S. J. Clarke Brd. 34F Standard chemotherapy strategy versus changing chemotherapy strategy as to FDG-PET response after first cycle of standard chemotherapy for advanced NSCLC. (Abstract #7558) S. Kim, J. Kim, K. Kim, D. Lee, C. Choi, D. Moon, J. Ryu, S. Oh, C. Suh, J. Lee 183 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 34G A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial. (Abstract #7559) E. B. Garon, F. F. Kabbinavar, J. A. Neidhart, J. D. Neidhart, N. Y. Gabrail, M. R. Oliveira, S. Lu, J. Balkissoon Brd. 34H Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment and progression-free and overall survival (PFS, OS). (Abstract #7560) J. Aisner, J. Manola, S. R. Dakhil, P. J. Stella, J. H. Schiller, PrECOG, LLC Brd. 35A Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinumbased chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05. (Abstract #7561) F. Zappa, C. Droege, D. C. Betticher, R. von Moos, M. H. Brutsche, F. Baty, L. Bubendorf, A. Ochsenbein, E. Oppliger Leibundgut, O. Gautschi, P. Froesch, R. A. Stahel, D. Rauch, P. Schmid, M. Mayer, S. Crowe, P. Brauchli, K. Ribi, M. Pless Brd. 35B AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)pem: Interim safety data. (Abstract #7562) F. Barlesi, A. Scherpereel, R. Gervais, V. A. Gorbunova, A. Vikström, M. J. Ahn, J. H. Kim, A. Chella, J. Aerts, N. Ferrer, J. M. Trigo Perez, B. Lutiger, A. Rittmeyer Brd. 35C Phase II study of topotecan and bevacizumab in advanced refractory nonsmall cell lung cancer (NSCLC). (Abstract #7563) S. F. Powell, A. Beitinjaneh, R. L. Bliss, R. A. Kratzke, J. W. Leach, A. Dudek Brd. 35D Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). (Abstract #7564) S. M. Gadgeel, J. C. Ruckdeschel, A. J. Wozniak, W. Chen, D. Hackstock, C. Galasso, A. Burger, S. P. Ivy, P. LoRusso, M. J. Edelman Brd. 35E Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7565) G. R. Blumenschein, J. R. Molina, C. D. Lathia, T. J. Ong, D. Roth, P. Rajagopalan, F. V. Fossella, M. S. Kies, R. S. Marks, A. A. Adjei, P. R. Sundaresan Brd. 35F ALK rearrangement in a selected population of advanced non-small cell lung cancer patients: FISH and inmunohistochemistry diagnostic methods, prevalence and clinical outcomes. (Abstract #7566) P. Martinez, J. Hernandez-Losa, J. Castellvi, N. Tallada, S. Cedres, M. Montero, V. Rodriguez-Freixinos, I. Nuňez, G. Argiles, N. Mulet-Margalef, D. Torrejon, S. Ramon y Cajal, E. Felip Brd. 35G Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study. (Abstract #7567) M. W. Jones, C. Zhang, K. R. Oettel, J. H. Blank, E. G. Robinson, H. G. Ahuja, R. J. Kirschling, P. H. Johnson, M. S. Huie, J. Kolesar, M. Wims, H. Hernan, T. C. Campbell, A. M. Traynor, T. Hoang Brd. 35H Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapynaive patients with non-small cell lung cancer (NSCLC): Preliminary results. (Abstract #7568) V. Gregorc, N. Zilembo, F. Grossi, G. Rossoni, F. Pietrantonio, E. Rijavec, A. Bulotta, M. Vitali, G. Barletta, L. Bergamaschi, M. Platania, F. Caligaris-Cappio, A. Lambiase, C. Bordignon 184 Brd. 36A The effect of talactoferrin on overall survival in prognostically important NSCLC subsets in a randomized, placebo-controlled phase II trial. (Abstract #7569) P. M. Parikh, A. Ranade, A. K. Vaid, S. H. Advani, A. Bapna, J. Zhu, Y. Wang, P. M. Ismail, R. K. Malik Brd. 36B A phase IB trial of iniparib (BSI-201) in combination with carboplatin (C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC). (Abstract #7570) A. C. Mita, M. M. Mita, C. Rocha, C. R. Bradley, J. Sarantopoulos, P. O’Rourke, S. M. Gadgeel, A. J. Wozniak, E. I. Heath Brd. 36C Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. (Abstract #7571) E. Tan, K. Park, W. T. Lim, M. Ahn, Q. Ng, J. Ahn, D. S. Tan, J. Sun, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava, W. Slichenmyer Brd. 36D A phase I study of MM-10 – 001 in advanced non-small cell lung cancer. (Abstract #7572) M. C. Cristea, M. Koczywas, K. L. Reckamp, S. F. Lacey, A. Rotter, P. H. Frankel, S. Fouladi Rad, X. Liu, V. Tran, E. Reorizo, M. Kalos Brd. 36E Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). (Abstract #7573) P. C. Mack, N. Farneth, C. Mahaffey, P. Lara Jr., D. R. Gandara Brd. 36F Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC). (Abstract #7574) G. R. Simon, S. Saddoughi, A. Mukhopadhyay, Y. Peterson, C. E. Senkal, J. Oaks, D. Perrotti, Y. Hannun, B. Ogretmen Brd. 36G DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A catalogue of clinically relevant somatic mutations in lung cancer. (Abstract #7575) L. Horn, H. Chen, C. M. Lovly, J. Andrews, P. Yeh, M. A. Levy, W. Pao Brd. 36H My Cancer Genome: Web-based clinical decision support for genome directed lung cancer treatment. (Abstract #7576) M. A. Levy, C. M. Lovly, L. Horn, R. Naser, W. Pao Brd. 37A Screening for mutations in Colombian metastatic non-small cell lung cancer (NSCLC) patients (ONCOLGroup). (Abstract #7577) A. F. Cardona, P. L. Ramos, R. Duarte, H. Carranza, C. J. Castro, M. Lema, C. A. Vargas, A. Jimenez, H. A. Becerra, R. Rosell Brd. 37B Development of prognostic biomarker in pathologic stage I NSCLC patients: Protein expressions involving in DNA damage response. (Abstract #7578) J. Ryu, C. Choi, S. Yang, H. Nam, H. Kim, M. H. Lee Brd. 37C Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. (Abstract #7579) J. Sun, J. Ahn, K. Park, J. Han, M. Ahn Brd. 37D Clinical outcome of KRAS mutated advanced non-small cell lung cancer (NSCLC) patients (pts): A mono-institutional analysis. (Abstract #7580) R. Chiari, V. De Angelis, C. Bennati, C. Molica, G. Metro, S. Duranti, F. R. Tofanetti, V. Ludovini, V. Minotti, L. Crino Brd. 37F Role of basal inflammatory status as a predictor of survival in bevacizumab treated advanced non-small cell lung cancer (NSCLC) patients. (Abstract #7582) C. Botta, A. Guglielmo, E. Bestoso, S. Apollinari, A. Licchetta, P. Blardi, P. Tassone, G. Chiriaco, V. Barbieri, G. Mantovani, P. Tagliaferri, P. Correale 185 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 37G Circulating endothelial cells, endothelial progenitor cells, microparticles, and markers of inflammation and coagulation in advanced non-small cell lung cancer. (Abstract #7583) T. Fleitas, G. Reynes, V. Martinez-Sales, V. Vila, E. Reganon, D. Mesado, M. Martin, J. Gómez-Codina, J. Montalar Brd. 37H Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy. (Abstract #7584) K. Habben, P. Delmar, C. M. Brownstein, W. Koehler, K. Kuenkele, O. Splesis, S. S. Ramalingam, J. A. Engelman, D. Chen Brd. 38A Influence of expression of estrogen (ERS-1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC). (Abstract #7585) W. M. Brueckl, C. Eschbach, G. H. Wiest, J. H. Ficker, S. Zirlik, R. Hake, S. Eidt, A. Hartmann, R. M. Wirtz Brd. 38B The nuclear factor kb (NFkB) and Notch signalling pathways and BRCA1 mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients (p). (Abstract #7586) M. Santarpia, M. Sanchez-Ronco, I. Magri, S. Viteri, C. Costa, A. Gasco, M. Gonzalez Cao, N. Mederos, F. Salazar, J. Bertran-Alamillo, A. Gimenez Capitan, G. Altavilla, S. Benlloch, Z. Yeste, E. Aldeguer, M. Taron, R. Rosell Brd. 38C Clinical, pathological, and molecular characteristics of patients with nonsmall cell lung cancer harboring mutations in PIK3CA. (Abstract #7587) M. Pietanza, M. E. Arcila, J. E. Chaft, M. F. Zakowski, M. Ladanyi, G. J. Riely, M. G. Kris Brd. 38D Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #7588) E. Carcereny, M. A. Molina, J. Sanchez, J. Bertran-Alamillo, C. Mayo, E. Aldeguer, A. Gimenez Capitan, Z. Yeste, C. Costa, S. Benlloch, A. Martinez, C. Buges, J. Bosch, D. Isla, M. Domine, M. Provencio, C. Camps, M. Taron, R. Rosell Brd. 38E Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling. (Abstract #7589) M. Taron, S. Benlloch, R. Rosell, J. Sanchez, C. Costa, A. Gimenez Capitan, C. Mayo, J. Bertran-Alamillo, M. A. Molina, B. Massuti, C. Camps, M. Majem, D. Isla, M. Santarpia, S. Viteri, A. Gasco, T. Moran, E. Carcereny, C. Queralt, I. de Aguirre Brd. 38F Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib. (Abstract #7590) T. Moran, J. Sanchez, M. A. Molina, J. Bertran-Alamillo, A. Gimenez Capitan, S. Benlloch, M. Taron, B. Massuti, C. Camps, R. Porta, D. Isla, G. Lopez-Vivanco, I. Bover, M. Garcia-Campelo, C. D. Rolfo, F. Salazar, E. Carcereny, F. Cardenal, I. Magri, R. Rosell Brd. 38G [18F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced nonsmall cell lung cancer (NSCLC) treated first-line with erlotinib. (Abstract #7591) M. Scheffler, T. Zander Jr., L. Nogova, C. Kobe, D. Kahraman, M. Dietlein, I. Papachristou, S. Querings, E. Stoelben, W. Engel-Riedel, B. Neumaier, J. Wolf Brd. 38H Association of CA repeat number and R497K with PFS to EGFR TKIs in NSCLC patients having sensitive mutation of EGFR. (Abstract #7592) J. Kang, E. Jeon, J. Shin, J. Kim, M. Lee, Y. Kim, K. Lee, Y. Wang, E. Cho 186 Saturday, June 4, 2011 DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #7593) J. Wei, J. Ramirez, M. Taron, J. Sanchez, S. Benlloch, R. Rosell, M. Botia, M. Perez-Cano, P. Mendez, M. Tierno, C. Queralt, I. de Aguirre, B. Sanchez, A. Martinez, C. Buges, J. Bosch, B. Massuti, C. Camps, T. Moran Brd. 39B Quantitative detection of the T790M EGFR mutation in circulating tumor DNA of lung cancer patients subjected to EGFR-TKI treatment. (Abstract #7594) J. Uchida, K. Taniguchi, F. Imamura, K. Nishino, T. Kumagai, Y. Akazawa, T. Okuyama, K. Kato Brd. 39C Circulating tumor cells and detection of EGFR mutation in cell-free tumor DNA in blood plasma in metastatic non-small cell lung cancer with EGFR mutation. (Abstract #7595) K. Isobe, Y. Hata, S. Sakaguchi, K. Sato, K. Sugino, G. Sano, S. Sakamoto, Y. Takai, K. Shibuya, K. Takagi, S. Homma Brd. 39D The surfactant protein B (SFTPB) as a surrogate of circulating tumor cells (CTC) with prognostic value in advanced-stage NSCLC. (Abstract #7596) R. Sirera, E. Jantus-Lewintre, A. Timon, M. Usó, A. Berrocal, S. Borrego, G. Marcaida, E. Sanmartin, R. Rosell, C. Camps Brd. 39E First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in caucasian patients (pts) (NCT00339586)—FIELT study group. (Abstract #7597) J. De Greve, J. P. Van Meerbeeck, J. F. Vansteenkiste, E. Teugels, C. Geers, A. Meert, P. Vuylsteke, C. N. Focan, J. Canon, Y. Humblet, G. J. Berchem, B. Colinet, D. Galdermans, L. Bosquée, C. A. Dooms, L. Decoster, J. Vermeij, A. Dewaele, D. C. Schallier Brd. 39F Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7598) G. Lopes, J. Segel, D. S. Tan, Y. Do, T. Mok, E. Finkelstein Brd. 39G Targeting therapies influence survival of refractory patients with lung advanced adenocarcinoma: A phase III randomized trial. (Abstract #7599) K. Zarogoulidis, E. Boutsikou, T. Kontakiotis, P. Zarogoulidis, E. Eleftheriadou, L. Sacas, G. Galaktidou Brd. 39H Meta-analysis of the chemotherapy versus EGFR-TKI in different selections of patients. (Abstract #7600) C. Xu, Q. Zhou, Y. Wu Brd. 40A Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC. (Abstract #7601) L. L. Waller, A. A. Miller, N. P. Streer, J. F. Lovato, W. J. Petty Brd. 40B Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC. (Abstract #7602) T. K. Owonikoko, M. Behera, H. N. Tran, Z. Chen, R. P. Chowdry, N. F. Saba, S. S. Ramalingam, F. R. Khuri Brd. 40C Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01). (Abstract #7603) M. Ahn, J. Sun, J. Ahn, S. Kim, K. Lee, Y. Min, H. Yun, H. Kim, H. Song, Y. H. Kim, B. Kim, I. Hwang, I. S. Woo, H. Ryoo, H. Yi, J. Jang, J. Kwon, K. Park Brd. 40D Safety data and patterns of progression in met diagnostic subgroups in OAM4558g: A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC. (Abstract #7604) A. Vashishtha, P. H. Patel, W. Yu, J. G. Bothos, J. Simpson, T. Maneatis, L. Doessegger, A. C. Peterson, C. Clement-Duchene, G. Robinet, M. Krzakowski, G. R. Blumenschein Jr., J. H. Goldschmidt Jr., D. B. Daniel, D. R. Spigel SATURDAY Brd. 39A 187 Saturday, June 4, 2011 SATURDAY Brd. 40E A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT). (Abstract #7605) Y. Wu, C. Zhou, Y. Cheng, S. Lu, G. Chen, C. Huang, Y. Huang, H. Yan, J. Yang, Chinese Thoracic Oncology Group Brd. 40F Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations. (Abstract #7606) K. Kim, D. Lee, J. Lee, C. Suh, S. Kim, C. Choi, S. Jang, J. Choi Brd. 40G Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy. (Abstract #7607) S. Heon, B. Y. Yeap, N. I. Lindeman, M. S. Rabin, D. M. Jackman, B. E. Johnson Brd. 40H Cerebral penetration of gefitinib in patients with lung adenocarcinoma. (Abstract #7608) M. Wang, Z. Jing, C. Minjiang Brd. 41A How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor gene sensitive mutations? (Abstract #7609) A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, Y. Imai, K. Tomii, M. Iwasaku, A. Nishiyama, T. Ishida Brd. 41B Time course of skin toxicity (tox) secondary to erlotinib (E) therapy in patients (pts) with non-small cell lung cancer (NSCLC) enrolled in the SATURN study. (Abstract #7610) R. Perez-Soler, F. Cappuzzo, L. Leon, S. Wojtowicz-Praga Brd. 41C Implementation of adherence to erlotinib by a treatment-monitoring program. (Abstract #7611) V. Gebbia, M. Bellavia, P. Russo, G. L. Banna, F. Ferraù, P. Tralongo, N. Borsellino 188 Saturday, June 4, 2011 2:00 PM - 6:00 PM GENERAL POSTER SESSION Patient and Survivor Care Location: Hall A Track(s): Patient and Survivor Care Incidence and predictors of delayed congestive heart failure (CHF) after hematologic malignancies treated with autologous hematopoietic cell transplantation (aHCT). (Abstract #9042) S. Armenian, C. Sun, T. Shannon, M. Shangguan, G. MIlls III, L. Francisco, F. L. Wong, S. J. Forman, S. Bhatia Brd. 42B The risk of subsequent malignancies in cervical cancer survivors as compared with breast and colorectal cancer survivors: United States 1992–2007. (Abstract #9043) J. Underwood, S. Rim, E. Tai, T. Fairley Brd. 42C Prevalence and correlates of suicidal ideation among outpatients at a comprehensive cancer center. (Abstract #9044) J. M. Randall, L. Bazhenova, M. White, A. A. Bharne, K. A. Shimabukuro, Y. Matusov, K. Messer, A. Lowery, M. Loscalzo, K. Clark, W. Bardwell Brd. 42D Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors. (Abstract #9045) P. H. Morrow, A. C. Broxson, M. Munsell, K. Basen-Engquist, C. K. Rosenblum, L. H. Nguyen, L. R. Schover, K. Hahn, J. K. Litton, G. N. Hortobagyi Brd. 42E An evaluation of serum cytokine levels and fatigue and depression in ECOG E4Z02. (Abstract #9046) T. A. Rich, J. Manola, D. Cella, R. A. Cruciani, M. Fisch, Eastern Cooperative Oncology Group Brd. 42F Paclitaxel-associated acute pain syndrome (P-APS) and its association on the development of peripheral neuropathy: NCCTG trial N08C1. (Abstract #9047) B. Reeves, S. R. Dakhil, J. A. Sloan, K. N. Burger, N. A. Le-Lindqwister, G. S. Soori, A. J. Jaslowski, J. Kelaghan, D. H. Lachance, C. L. Loprinzi Brd. 42G Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. (Abstract #9048) R. Delarue, C. Haioun, B. Coiffier, L. Fornecker, M. Fournier, N. Mounier, T. J. Molina, S. Bologna, C. Fruchart, S. Picard, H. Tilly, A. Bosly Brd. 42H Randomized, multicenter, phase II trial of compound Chinese herbal extract LC09 versus placebo for external treatment of hand-foot syndrome induced by anticancer therapy. (Abstract #9049) L. Jia, Y. Lou, A. Tian, S. Zhu, X. Zhang Brd. 43A Structural and functional MRI of the brain as biomarker for postcancer fatigue. (Abstract #9050) H. Prinsen, A. Heerschap, G. Bleijenberg, M. Zwarts, M. van der Graaf, M. Rijpkema, H. Van Laarhoven Brd. 43B Long-term survival rates of older breast cancer patients: Population-based estimates over three decades. (Abstract #9051) B. Kanapuru, A. Jemal, C. S. Hesdorffer, W. B. Ershler, J. W. Yates Brd. 43C A risk stratification schema for predicting diabetes mellitus in cancer survivors. (Abstract #9052) A. Moghaddamjou, A. Y. Tashakkor, P. Birks, W. Y. Cheung Brd. 43D Quality-of-life concordance between patients with malignant gliomas and their caregivers: Updated data. (Abstract #9053) B. V. Stell, D. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, M. A. Schwartz, K. Muro, M. H. Marymont, J. Chandler, I. B. Helenowski, L. I. Wagner, J. J. Raizer, C. L. Bennett SATURDAY Brd. 42A 189 Saturday, June 4, 2011 SATURDAY Brd. 43E Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. (Abstract #9054) F. L. Day, J. Karnon, D. Rischin Brd. 43F A prospective, observational study of medication use among outpatients with common solid tumors. (Abstract #9055) M. Weiss, J. Manola, M. A. Thompson, M. L. Thomas, M. Fisch Brd. 43G Reactivation of hepatitis B infection among patients with cancer. (Abstract #9056) J. Hwang, M. Fisch, H. Zhang, M. Kallen, M. Routbort, L. S. Lal, J. Vierling, M. Suarez-Almazor Brd. 43H Analysis of overall survival and self-reported fatigue in patients with locally advanced esophageal cancer: A Mayo Clinic Esophageal Adenocarcinoma and Barrett’s Esophagus Registry Consortium study. (Abstract #9057) M. C. Stauder, Y. Romero, B. Kabat, P. J. Atherton, M. B. Fredericksen, C. Deschamps, A. Jatoi, J. A. Sloan, M. Botros, R. C. Miller Brd. 44A Accrual of underrepresented minority women to breast cancer clinical trials in the Inland Empire, California. (Abstract #9058) Y. Yuan, P. Uppala, S. S. Lum, C. Garberoglio, H. R. Mirshahidi, R. Cassady, J. Morgan, C. Chen Brd. 44B Incidence and risk factors predictive of recurrent venous thromboembolism in patients with cancer at a comprehensive cancer center. (Abstract #9059) S. Vadhan-Raj, X. Zhou, R. S. Benjamin, G. W. Gladish Brd. 44C Achievement of personalized pain goal (PPG) in cancer patients referred to a supportive care clinic. (Abstract #9060) S. Dalal, D. Hui, L. M. Nguyen, R. Chacko, E. Bruera Brd. 44D Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic. (Abstract #9061) A. Soni, A. Brufsky, R. C. Jankowitz, P. Rastogi, V. G. Vogel, S. Puhalla Brd. 44E Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study. (Abstract #9062) M. A. van der Kaaij, N. Heutte, P. Meijnders, J. M. Raemaekers, E. Abeilard-Lemoisson, A. Allgeier, B. Meulemans, A. H. Simons, N. Mounier, M. Henry-Amar, J. C. Kluin-Nelemans, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d’Etude des Lymphomes de l’Adulte (GELA) Brd. 44F Is there an advantage to adding inferior vena cava filter (IVCF) placement to anticoagulation with fondaparinux in patients with cancer and venous thromboemboli (VTE): Results of the Cancer and Thrombosis (CAT) prospective randomized clinical trial (RCT). (Abstract #9063) M. F. Barginear, R. J. Gralla, M. Akerman, M. Lesser, T. P. Bradley, I. Shapira, N. J. Nier-Shoulson, C. R. Greben, D. R. Budman Brd. 44G Symptom burden and change among adolescent/young adult (AYA) patients with breast, lung, colorectal, or prostate cancer. (Abstract #9064) V. T. Chang, F. Zhao, L. I. Wagner, S. D. Sanford, J. Salsman, M. Fisch Brd. 44H Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP). (Abstract #9065) U. Basso, C. Falci, A. Brunello, V. Zafferri, P. Fiduccia, G. Sergi, S. Lonardi, E. Lamberti, E. Castegnaro, C. Soldà, F. Cossutta, V. Chiarion-Sileni, S. Monfardini, V. Zagonel Brd. 45A OVERcome: An intervention study to improve sexual function in women with breast cancer. (Abstract #9066) I. Juraskova, S. Jarvis, K. Mok, M. Peate, B. Meiser, S. Mireskandari, M. Friedlander 190 Brd. 45B Recalling breast cancer presentation and therapy: Associations between patient inaccuracy and demographic characteristics. (Abstract #9067) W. C. Mertens, C. Loke, D. Katz, R. Barham, G. Makari-Judson Brd. 45C Understanding the psychosocial needs of young adults with cancer: Identifying targets for clinical intervention. (Abstract #9068) K. M. Trevino, K. Fasciano, A. H. Partridge, P. Maciejewski, E. Kacel, R. Jimenez, S. Block, H. G. Prigerson Brd. 45D Sleep disturbance in patients with advanced cancer: Frequency and factors associated with response to specialist-based outpatient supportive care. (Abstract #9069) S. Yennurajalingam, G. Chisholm, S. L. Palla, E. Bruera Brd. 45E Quality-of-life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (Abstract #9070) Y. Ohashi, M. Tanaka, N. Boku, H. Ueno, T. Okusaka Brd. 45F Predicting the risk of cardiovascular comorbidity in cancer survivors. (Abstract #9071) A. Y. Tashakkor, A. Moghaddamjou, W. Y. Cheung Brd. 45G Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link? (Abstract #9072) K. Webber, K. Mok, B. K. Bennett, I. Juraskova, D. Goldstein, M. Friedlander, A. R. Lloyd, FOLCAN study group Brd. 45H Clinical trial participation among patients with advanced cancer: What characteristics most influence enrollment? (Abstract #9073) R. Jimenez, B. Zhang, M. E. Nilsson, S. Joffe, C. Lathan, H. G. Prigerson Brd. 46A Stage I lung cancer survivorship: Incidence of secondary malignancies and need for individualized care plan. (Abstract #9074) R. Surapaneni, K. Rajagopalan, A. Hageboutros Brd. 46B Zoledronic acid inhibits adjuvant letrozole-associated bone loss in postmenopausal Japanese women with early breast cancer. (Abstract #9075) S. Takahashi, T. Iwase, N. Kohno, T. Ishikawa, T. Taguchi, M. Takahashi, J. Horiguchi, S. Nakamura, M. Fukunaga, S. Noguchi Brd. 46C Does time-to-antibiotics predict outcome of febrile neutropenia in pediatric cancer? (Abstract #9076) M. B. Fletcher, H. Hodgkiss, R. Browning, T. Hoffman, C. Hadden, N. J. Winick, T. L. McCavit Brd. 46D Health-related quality of life (HRQOL) of patients 3 years after radiation therapy (RT) for early head and neck cancer (HNC). (Abstract #9077) I. Bairati, F. Meyer Brd. 46E Aprepitant is active in biologic therapies induced severe pruritus: Proof of concept study. (Abstract #9078) D. Santini, B. Vincenzi, F. Guida, A. Frezza, O. Venditti, M. Silletta, G. Tonini Brd. 46F Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin. (Abstract #9079) M. A. Blazer, J. Reardon, D. Efries, Y. T. Smith, L. M. Weatherby, K. Juergens, T. Criswell, J. S. Rose, G. S. Phillips, N. Griffith, T. S. Bekaii-Saab Brd. 46G A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. (Abstract #9080) A. Buchner, P. Bias, M. Kaufmann Brd. 46H Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients (pts) with advanced cancer. (Abstract #9081) L. M. Nguyen, M. De la Cruz, D. Hui, J. L. Palmer, H. A. Parsons, E. Bruera 191 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 47A A population-based study of metastatic colorectal cancer (mCRC) in people age 80 or older: Findings from the South Australian Clinical Registry (SACR) for mCRC. (Abstract #9082) C. Beeke, K. Jain, T. J. Price, R. Padbury, D. Roder, G. P. Young, M. Ly, M. A. Khattak, A. Richards, A. R. Townsend, C. S. Karapetis Brd. 47B A randomized, noninferiority study of recombinant human G-CSF/human serum albumin fusion (CG-10639) and pegfilgrastim in patients with breast cancer receiving myelosuppressive therapy. (Abstract #9083) O. Gladkov, V. Moiseyenko, I. N. Bondarenko, J. V. Shparyk, S. Barash, J. M. Herpst Brd. 47C Cancer-related memory problems, demographic, and socioeconomic backgrounds: A cross-sectional study of the United States population. (Abstract #9084) P. Jean-Pierre, P. Winters, T. Ahles, M. Antoni, D. Armstrong, F. Penedo, S. E. Lipshultz, T. L. Miller, K. Fiscella Brd. 47D Prospective cohort study of depression during androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. (Abstract #9085) N. Timilshina, H. Breunis, S. M. Alibhai Brd. 47E Mammography-detected breast cancer over time among patients age 75 and older at a community-based cancer center: 1990 –2008. (Abstract #9086) J. A. Malmgren, M. K. Atwood, H. G. Kaplan Brd. 47F CD4ⴙ T-cell count to predict the response to new H1N1 vaccination in pediatric patients with cancer. (Abstract #9087) A. M. Mavinkurve-Groothuis, M. van der Flier, F. Stelma, C. van Leer-Buter, F. Preijers, P. Hoogerbrugge Brd. 47G Age-dependent effects of intensive chemotherapy (IC) on quality of life (QOL) and physical function in patients with acute myeloid leukemia (AML). (Abstract #9088) H. Z. Mohamedali, H. Breunis, J. Brandwein, M. Li, N. Timilshina, M. Minden, G. A. Tomlinson, S. M. Alibhai Brd. 47H Survivors’ perspectives on cancer: Results from a LIVESTRONG survey. (Abstract #9089) R. Rechis, E. B. Beckjord, S. Nutt, B. M. Hayes-Lattin Brd. 48A Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. (Abstract #9090) A. L. Sumrall, D. A. Reardon, A. Desjardins, K. Peters, E. Lou, S. G. Turner, L. Bailey, H. S. Friedman, J. J. Vredenburgh Brd. 48B Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). (Abstract #9091) S. Y. Barbour, G. R. Morrow, R. Ahmed, G. Ballinari, M. D. Thorn, D. Cox, L. S. Schwartzberg Brd. 48C Developing a community-based screening instrument that measures problem-related distress. (Abstract #9092) M. Golant, J. S. Buzaglo, M. Miller, K. Clark, M. Loscalzo, V. Kennedy, K. R. Dougherty, J. Taylor Brd. 48D An analysis of the prognostic value of handgrip strength and its incorporation into the comprehensive geriatric assessment (CGA) in elderly Asian patients with cancer. (Abstract #9093) R. Kanesvaran, K. Koo, W. Chen, D. Poon Brd. 48E Inflammatory cytokines and toxic effects of oxaliplatin-based chemotherapy in patients with colorectal cancer. (Abstract #9094) X. S. Wang, C. S. Cleeland, V. E. Johnson, J. M. Reuben, D. R. Fogelman, M. Malekifar, K. E. Liao, P. Liu, E. N. Cohen, K. R. Gilmore, C. Eng 192 Brd. 48F Barriers to care faced by newly diagnosed patients with cancer. (Abstract #9095) S. K. Hendren, P. C. Raich, P. Winters, W. Thorland, S. Loader, S. Rousseau, P. Valverde, E. Whitley, K. Fiscella Brd. 48G Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial. (Abstract #9096) A. Pickard, D. Cella, M. S. Duh, A. Guerin, N. Mishagina, L. Antràs, M. Neary, L. McCann, R. Hodge, C. Sternberg Brd. 48H Effect of a nurse practitioner (ARNP)– directed intervention on the quality of life of patients with metastatic cancer: Results of a randomized pilot study. (Abstract #9097) S. H. Dyar, M. Lesperance, R. P. Shannon, J. A. Sloan, G. Colon-Otero Brd. 49A To follow up or not? A new model of supportive care for early breast cancer. (Abstract #9098) J. Dent, A. Topping, C. Ferguson, J. Stephenson, M. McCoy, V. Allinson, S. Brayford Brd. 49B The influence of age on intensity of care at the end of life among older patients with advanced cancer. (Abstract #9099) J. A. Zerillo, A. K. Smith, M. A. Schonberg, E. P. McCarthy Brd. 49C Functional impairment (FI) after hematopoietic cell transplantation (HCT) and impact on quality of life (QOL). (Abstract #9100) A. Bosworth, F. L. Wong, H. Kim, R. Ferrer Danao, J. Gyorffy, S. Patel, S. J. Forman, S. Bhatia Brd. 49D Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and prophylaxis practices reported by patients with cancer. (Abstract #9101) F. R. Rickles, E. Varga, A. Brownstein, R. J. Friedman, G. A. Maynard, J. Ansell Brd. 49E Bupropion for hot flashes control in breast cancer survivors: A prospective, double-blind, randomized cross-over pilot phase II trial. (Abstract #9102) G. R. Nuňez, A. Del Giglio, H. Pinczowski, R. M. Zanellato, L. C. Tateyama, F. Schindler, F. A. Fonseca Brd. 49F Preventive skin care among cancer survivors. (Abstract #9103) S. C. Lau, W. Y. Cheung Brd. 49G Quality of life in patients with dermatologic toxicities: Experience from the SERIES clinic. (Abstract #9104) J. Gordon, Y. Balagula, S. W. Dusza, D. Chen, S. Berg, D. P. West, M. E. Lacouture Brd. 49H The effect of a 3-day oral aprepitant regimen on the prevention of CINV over standard therapy in Chinese patients receiving high-dose cisplatin. (Abstract #9105) Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. Chang, X. Song, J. Liang, H. Liang, J. Hu, S. Yu, J. Chen, J. Wang, H. Pan, A. Carides, D. Chitkara Brd. 50A Agreement between breast cancer survivors and oncologists on treatments received. (Abstract #9106) T. B. Sanft, V. Northrup, A. B. Chagpar, M. Irwin Brd. 50B What topics do patients and caregivers consider most important for support groups? An evidence-based analysis of 3,728 participants. (Abstract #9107) R. J. Gralla, K. D. Morse, C. N. Rittenberg, J. A. Petersen, K. Burg, B. J. Davis, C. Sison, L. M. Rosen, M. Lesser Brd. 50C Assessing patients’ values when standard-of-care options are exhausted. (Abstract #9108) R. D. Pentz, Z. L. Farmer, M. J. Green, C. Daugherty, F. J. Hlubocky, S. K. Peterson, C. C. Sun, C. M. Lewis, T. K. Owonikoko, F. R. Khuri, R. D. Harvey 193 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 50D Fertility preservation treatment options: What do patients actually understand about their choices? (Abstract #9109) J. Mersereau, L. Kondapalli, U. Balthazar Brd. 50E Predictors of quality of life (QOL) and mental health (MH) in caregivers of patients with advanced cancer. (Abstract #9110) D. Wadhwa, D. Burman, N. Swami, C. Zimmermann Brd. 50F Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 2001– 02 phase III study comparing a first-line chemotherapy of LV5FU2 or FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly patients. (Abstract #9111) T. Aparicio, J. Jouve, L. Teillet, D. Gargot, V. Le Brun Ly, J. Cretin, C. Locher, O. Bouche, G. Breysacher, J. Charneau, J. Seitz, M. Gasmi, F. Ricard, F. Subtil, E. Mitry, Federation Francophone de Cancerologie Digestive Brd. 50G Association between a validated symptom assessment tool and nurse clinical impression in patients with cancer admitted to a palliative care unit. (Abstract #9112) W. Rhondali, D. Hui, S. Kim, K. L. Kilgore, J. Kang, L. M. Nguyen, E. Bruera Brd. 50H Quality-of-life assessment in patients with malignant ascites: Results of a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. (Abstract #9113) A. Gonschior, M. M. Heiss, M. H. Moehler, S. L. Parsons, H. Gilet Brd. 51A Prevalence of psychosocial distress in a rural community oncology practice and impact of interventions. (Abstract #9114) J. S. Smith, D. L. Limesand, M. A. Alikhan Brd. 51B Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. (Abstract #9115) G. E. Richardson, T. E. Ciuleanu, L. Costa, S. J. Gans, J. Garcia Saenz, V. Hirsh, V. Hungria, M. Krzakowski, C. Manegold, H. Nahi, S. Novello, A. L. Petzer, M. E. Rader, P. Solal-Celigny, S. Vadhan-Raj, J. F. Vansteenkiste, P. J. Woll, C. Ke, K. Chung, H. Yeh Brd. 51C Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON). (Abstract #9116) C. Lhomme, D. Berton-Rigaud, F. Joly, J. Baurain, F. Rolland, A. Stenzl, T. Schmelter, M. Campone Brd. 51D The impact of less than 8% weight loss on overall survival in subjects with non-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024. (Abstract #9117) S. Dodson, A. Dobs, M. L. Hancock, M. A. Johnston, M. S. Steiner Brd. 51E A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy. (Abstract #9118) J. Kim, K. Oktay, C. Gracia, S. Lee, C. Morse, J. Mersereau Brd. 51F Cognitive difficulties among patients with cancer receiving chemotherapy affects quality of life: A University of Rochester Clinical Community Oncology Program study of 439 patients. (Abstract #9119) M. C. Janelsins, K. Devine, K. M. Mustian, S. G. Mohile, L. J. Peppone, L. Sprod, M. Weiss, V. Vinciguerra, A. Jacobs, G. R. Morrow Brd. 51G Sexual side effects (SSE) reported by adolescent/young adult (AYA) versus older cancer survivors. (Abstract #9120) C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, G. A. Di Lullo, J. M. Metz Brd. 51H Serum 25-hydroxyvitamin D testing at Memorial Sloan-Kettering Cancer Center. (Abstract #9121) K. M. Wesa, K. Yeung, G. Jacobs, M. Coleton, B. R. Cassileth 194 Brd. 52A Impact of geriatric vulnerability parameters on pegylated liposomal doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic breast cancer: Results of the DOGMES multicenter phase II GINECO trial. (Abstract #9122) C. Falandry, E. Brain, M. Bonnefoy, F. Mefti, A. Savoye, O. Rigal, S. Oddou-Lagranière, C. El Kouri, L. Uwer, S. Abadie-Lacourtoisie, J. Cretin, J. Jacquin, G. Freyer Brd. 52B The status of oncofertility resources at NCI-designated comprehensive cancer centers. (Abstract #9123) M. L. Clayman, M. Harper, G. P. Quinn, S. Shah, J. Reinecke Brd. 52C Safety and efficacy of implanted central venous catheters during adjuvant treatment of breast cancer and in a general oncology population. (Abstract #9124) M. Wilson, D. J. Porter, A. Maher Brd. 52D Quality of life in male patients with hormone-independent cancers: The role of testosterone. (Abstract #9125) P. Homel, S. B. Fleishman, M. Suhail, V. Rosenwald Brd. 52F Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening. (Abstract #9127) J. Sussman, H. Seow, D. Bainbridge, G. R. Pond, L. Martelli-Reid Brd. 52G Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of the American Academy of Family Physicians (AAFP). (Abstract #9128) T. O. Henderson, P. C. Nathan, M. Kigin, F. J. Hlubocky, K. Wroblewski, T. V. Stewart, J. M. Galliher, K. C. Oeffinger, C. Daugherty Brd. 52H The trajectory of physical functioning during breast cancer treatment of older women. (Abstract #9129) C. Owusu, M. D. Schluchter, S. M. Koroukian, N. A. Berger Brd. 53A Documenting the complete resolution rates of venous thromboemboli (VTE) with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer. (Abstract #9130) D. R. Budman, M. F. Barginear, R. J. Gralla, T. P. Bradley, I. Shapira, N. J. Nier-Shoulson, C. R. Greben, M. Akerman, M. Lesser Brd. 53B Survivorship care plans for colorectal cancer survivors: What do primary care providers want and need? (Abstract #9131) T. Salz, K. C. Oeffinger, P. R. Lewis, R. Rhyne, R. L. Williams, M. W. Yeazel Brd. 53C Intensity of end-of-life cancer care among seniors: Variations by principal health care provider. (Abstract #9132) K. Murray, L. Lucas, S. Miesfeldt Brd. 53D Comparison of patient-reported symptoms and health behaviors to clinician documentation among patients with breast cancer in follow-up care. (Abstract #9133) M. E. Melisko, M. Bock, D. H. Moore, D. Hamolsky, M. Mendelsohn, L. Lawson, H. Orlando, H. S. Rugo, A. J. Chien, J. W. Park, M. M. Moasser, P. N. Munster, A. Goga, L. Esserman Brd. 53E Geriatric assessment (GA) of older patients with cancer in Australia: A national, multicenter audit. (Abstract #9134) S. S. Joshi, C. B. Steer, J. Yoong, R. Lakhanpal, S. Kirsop, T. Dunlop, L. R. Mileshkin, D. Yip, G. M. Marx, E. J. Hovey, S. Della-Fiorentina, Clinical Oncology Society of Australia Brd. 53F Aggressiveness of end-of-life care before and after the utilization of a palliative care service. (Abstract #9135) W. Gonsalves, T. Tashi, T. Davies, S. Ortman, R. Thota, J. Krishnamurthy, I. T. Aldoss, M. Kalaiah, A. Ganta, N. Didwaniya, C. Eberle, A. Ganti, S. Subbiah, P. T. Silberstein 195 SATURDAY Saturday, June 4, 2011 Saturday, June 4, 2011 SATURDAY Brd. 53G Patient experience with survivorship care plans: Findings from an online registry of breast cancer survivors. (Abstract #9136) J. S. Buzaglo, K. R. Dougherty, M. Amsellem, M. Golant Brd. 53H Prospective assessment of symptom burden among cancer survivors with common solid tumors: Results from ECOG trial E2Z02. (Abstract #9137) L. I. Wagner, L. Zickl, M. Smith, D. Cella, C. Coles, L. J. Patrick-Miller, J. Manola, M. Fisch Brd. 54A Hodgkin lymphoma of the elderly veterans: Veterans Affairs Cancer Registry analysis. (Abstract #9138) J. Krishnamurthy, T. Tashi, W. Gonsalves, R. Thota, P. T. Silberstein, S. Subbiah Brd. 54B BRCA mutation carriers: Risk factors for psychosocial and physiologic disruption. (Abstract #9139) L. B. Wenzel, K. Osann, J. Gross, R. Kurz, E. L. Nelson, B. Y. Karlan Brd. 54C The effectiveness of a structured exercise and education program on clinical and quality-of-life outcomes in patients with cancer who are actively undergoing therapy compared with patients not currently receiving therapy. (Abstract #9140) L. M. Leach, A. Kleski, K. Spencer, J. Anthony, M. LaLonde, T. J. Sweeney, T. Caulin-Glaser 196 Saturday, June 4, 2011 3:00 PM - 4:15 PM SPECIAL SESSION ASCO/Radiological Society of North America (RSNA) Joint Session: Cancer Screening—Can We See Clearly Now? Location: E354b CME credit: 1.25 Track(s): Practice Management and Information Technology, Cancer Prevention/Epidemiology, Special Session N. Reed Dunnick, MD—Co-Chair University of Michigan Denise R. Aberle, MD University of California, Los Angeles David Geffen School of Medicine Lung Cancer Screening: Results and Implications of the National Lung Screening Trial (NLST) Mark Helvie, MD University of Michigan Breast Cancer Screening: U.S. Preventive Services Task Force Recommendations—Why the Controversy? Elizabeth Burnside, MD, MPH University of Wisconsin Evaluating Screening Studies: Translating the Science to Practice 197 SATURDAY George W. Sledge Jr., MD—Co-Chair Indiana University Simon Cancer Center Saturday, June 4, 2011 3:00 PM - 4:15 PM EDUCATION SESSIONS Immunologics and Biologics for Sarcomas: Is There a Role? Location: S100a CME credit: 1.25 Track(s): Sarcoma, Pediatric Oncology Peter Houghton, PhD—Chair Nationwide Children’s Hospital Emerging Biologic Strategies for Sarcomas SATURDAY Paul Robbins, PhD National Cancer Institute Center for Cancer Research Adoptive Immunotherapy of Synovial-cell Sarcoma Targeting Cancer/Testis Antigens Crystal Mackall, MD National Cancer Institute The Future of Immunotherapy for Sarcomas Lung Cancer Whole-genome Sequencing: What a Clinician Should Know Location: Hall D2 CME credit: 1.25 Track(s): Lung Cancer, Tumor Biology Ramaswamy Govindan, MD—Chair Washington University School of Medicine Whole-genome Sequencing of Lung Cancer: Update and Implications for Clinical Research Elaine Mardis, PhD Washington University Whole-genome Sequencing: A Primer for the Clinicians Neil Caporaso, MD National Cancer Institute Lung Cancer Whole-genome Sequencing: Insights into Lung Cancer Biology Next-generation Sequencing in Cancer Genetics Location: E353 CME credit: 1.25 Track(s): Cancer Genetics Stephen B. Gruber, MD, PhD, MPH—Chair University of Michigan Next-generation Sequencing: What Are the Clinical Implications? Veda N. Giri, MD Fox Chase Cancer Center Beyond Genome-wide Association Studies in Cancer Susceptibility Arul Chinnaiyan, MD, PhD University of Michigan Medical Center Next-generation Sequencing and Susceptibility to Prostate Cancer 198 Saturday, June 4, 2011 Prediction, Prevention, and Treatment of Chemotherapy Toxicity in Older Patients Location: S100bc CME credit: 1.25 Track(s): Geriatric Oncology, General Oncology Supriya Gupta Mohile, MD, MS—Chair University of Rochester Medical Center Prevention and Management of Nonhematologic Toxicity in Elderly Patients Receiving Chemotherapy SATURDAY Arti Hurria, MD City of Hope Prediction of Chemotherapy Toxicity in Elderly Patients Gary H. Lyman, MD, MPH Duke University Prevention and Management of Hematologic Toxicity in Elderly Patients Receiving Chemotherapy 199 Saturday, June 4, 2011 3:00 PM - 4:15 PM MEET THE PROFESSOR SESSION Issues in Therapy for Rectal Cancer (M07)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Gastrointestinal (Colorectal) Cancer Blase N. Polite, MD, MPH The University of Chicago Which Chemotherapy and When: Understanding the Timing and Type of Chemotherapy in Patients with Rectal Cancer SATURDAY Claus Roedel, MD University of Frankfurt Radiation Therapy for Rectal Cancer: When Can It Be Omitted or Shortened? 200 Saturday, June 4, 2011 3:00 PM - 4:15 PM CLINICAL PROBLEMS IN ONCOLOGY SESSION Integrative Oncology: A Mainstream Look at Approaches for Patients with Advanced Cancer (C06)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Professional Development, Cancer Prevention/Epidemiology, Patient and Survivor Care SATURDAY Nancy E. Davidson, MD—Chair University of Pittsburgh Cancer Institute Clinical Trial Design in Integrative Oncology: Advanced Cancer Edith P. Mitchell, MD Kimmel Cancer Center at Thomas Jefferson University Evidence-based Interventions in Integrative Oncology for Patients with Metastatic Cancer Brent Bauer, MD Mayo Clinic What Alternative Therapies Are Hot for Advanced Cancer Patients? 201 Saturday, June 4, 2011 3:00 PM - 4:30 PM CLINICAL SCIENCE SYMPOSIUM Host Genomics and Treatment Outcomes in Breast Cancer Location: Hall B1 CME credit: 1.5 Track(s): Breast Cancer Christos Sotiriou, MD, PhD—Chair Jules Bordet Institute SATURDAY Discussion 3:00 PM Mark J. Ratain, MD The University of Chicago 3:15 PM Genetic associations with taxane-induced neuropathy by genome-wide association study (GWAS) in E5103. (Abstract #1000) B. P. Schneider, L. Li, K. Miller, D. Flockhart, M. Radovich, B. A. Hancock, N. Kassem, T. Foroud, D. L. Koller, S. S. Badve, Z. Li, A. H. Partridge, A. M. O’Neill, J. A. Sparano, C. T. Dang, D. W. Northfelt, M. Smith, E. Railey, G. W. Sledge Jr. Discussion 3:30 PM Howard L. McLeod, PharmD (Abstract #1000) University of North Carolina Eshelman School of Pharmacy 3:45 PM Genes regulating estradiol and estrone-conjugate levels in postmenopausal women with resected early-stage breast cancer detected by a genome-wide association study (GWAS). (Abstract #1001) J. N. Ingle, B. L. Fridley, A. Buzdar, M. E. Robson, M. Kubo, M. Liu, I. Ibrahim-Zada, A. Batzler, G. D. Jenkins, M. P. Goetz, D. W. Northfelt, E. A. Perez, C. V. Williard, L. Wang, D. J. Schaid, Y. Nakamura, R. M. Weinshilboum 4:00 PM ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. (Abstract #1002) M. Bouzyk, K. P. Gray, M. M. Regan, O. Pagani, W. Tang, R. Kammler, R. Maibach, G. Viale, P. Dell’Orto, B. J. Thurlimann, E. Hitre, M. Lyng, H. J. Ditzel, P. Neven, G. MacGrogan, K. N. Price, R. D. Gelber, A. S. Coates, A. Goldhirsch, B. Leyland-Jones, BIG 1-98 Collaborative and International Breast Cancer Study Groups Discussion 4:15 PM James M. Rae, MD (Abstracts #1001–1002) University of Michigan 202 Saturday, June 4, 2011 3:00 PM - 5:30 PM ORAL ABSTRACT SESSION Pediatric Oncology I Location: S504 CME credit: 2.5 Track(s): Pediatric Oncology 3:00 PM Results of a prospective clinical trial for VAMP alone without irradiation for pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an early complete response. (Abstract #9503) M. Metzger, H. J. Weinstein, M. M. Hudson, A. Billett, E. C. Larsen, A. M. Friedmann, S. S. Donaldson, M. J. Krasin, L. E. Kun, K. C. Marcus, T. I. Yock, N. Tarbell, C. Billups, J. Wu, M. P. Link 3:15 PM Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group Study AALL0232. (Abstract #9504) N. J. Winick, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh, N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood, C. L. Willman, S. Hunger, W. L. Carroll, E. C. Larsen Discussion 3:30 PM Andrea Biondi, MD (Abstract #9504) University of Milano-Bicocca 3:45 PM Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children’s Oncology Group. (Abstract #9505) I. Chen, R. Harvey, C. G. Mullighan, M. L. Loh, M. Devidas, M. J. Borowitz, S. K. Tasian, D. Payne-Turner, W. Wharton, J. Pullen, A. J. Carroll, W. L. Carroll, B. M. Camitta, S. Hunger, N. J. Winick, C. L. Willman 4:00 PM Treatment outcomes in older adolescent and young adult (AYA) patients with newly diagnosed AML. (Abstract #9506) J. A. Canner, T. A. Alonzo, J. Franklin, D. R. Freyer, A. S. Gamis, R. B. Gerbing, B. Lange, S. Meshinchi, W. G. Woods, J. P. Perentesis, J. Horan 4:15 PM Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9507) G. T. Armstrong, Y. Chen, T. Kawashima, C. A. Sklar, D. A. Mulrooney, E. J. Chow, W. Border, J. Durand, A. Mertens, M. Stovall, W. Leisenring, Y. Yasui, L. L. Robison, K. C. Oeffinger, L. Meacham 4:30 PM Impact of HFE mutations on cardiac status in survivors of childhood highrisk ALL: Dana-Farber Cancer Institute Childhood ALL 05–159. (Abstract #9508) S. E. Lipshultz, S. R. Lipsitz, J. Kutok, T. L. Miller, S. D. Colan, D. S. Neuberg, S. E. Dahlberg, L. B. Silverman, J. M. Henkel, V. I. Franco, S. E. Sallan, Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium 4:45 PM Cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia (ALL). (Abstract #9509) K. C. Oeffinger, P. G. Snell, C. S. Moskowitz, J. F. Chou, D. A. Kent, E. S. Tonorezos, A. L. Dunn, S. M. Smith, T. S. Church 203 SATURDAY Paul C. Nathan, MD, MSc—Co-Chair The Hospital for Sick Children Jennifer Lynn McNeer, MD—Co-Chair The University of Chicago Saturday, June 4, 2011 5:00 PM Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9510) A. S. Pappo, G. T. Armstrong, W. Liu, D. K. Srivastava, W. Leisenring, S. Hammond, M. Stovall, J. P. Neglia, L. L. Robison Discussion 5:15 PM Louise C. Strong, MD (Abstract #9510) University of Texas M. D. Anderson Cancer Center SATURDAY 204 Saturday, June 4, 2011 3:00 PM - 6:00 PM ORAL ABSTRACT SESSION Gynecologic Cancer Location: E354a CME credit: 3 Track(s): Gynecologic Cancer 3:00 PM Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (Abstract #5003) J. A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. B. Vergote, G. J. Rustin, C. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, E. Macpherson, C. Watkins, J. Carmichael, U. Matulonis 3:15 PM A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. (Abstract #5004) R. T. Penson, C. Whalen, B. Lasonde, C. N. Krasner, P. Konstantinopoulos, T. E. Stallings, C. R. Bradley, M. J. Birrer, U. Matulonis 3:30 PM A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. (Abstract #5005) M. J. Birrer, P. Konstantinopoulos, R. T. Penson, M. Roche, A. Ambrosio, T. E. Stallings, U. Matulonis, C. R. Bradley Discussion 3:45 PM Stanley B. Kaye, MD (Abstracts #5003–5005) The Royal Marsden Hospital 4:00 PM Result of interim analysis of overall survival in the GCIG ICON7 phase III randomised trial of bevacizumab in women with newly diagnosed ovarian cancer. (Abstract #LBA5006) G. Kristensen, T. Perren, W. Qian, J. Pfisterer, J. A. Ledermann, F. Joly, M. S. Carey, P. J. Beale, A. Cervantes, A. M. Oza 4:15 PM OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinumsensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (Abstract #LBA5007) C. Aghajanian, N. J. Finkler, T. Rutherford, D. A. Smith, J. Yi, H. Parmar, L. R. Nycum, M. A. Sovak 4:30 PM Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). (Abstract #5008) R. J. Buckanovich, R. Berger, A. Sella, B. I. Sikic, X. Shen, D. A. Ramies, D. C. Smith, I. B. Vergote Discussion 4:45 PM Anil Sood, MD (Abstracts #LBA5006 –5008) University of Texas M. D. Anderson Cancer Center 5:00 PM A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. (Abstract #5009) A. M. Oza, A. Poveda, A. R. Clamp, S. Pignata, G. Scambia, J. Del Campo, M. McCormack, L. Sevcik, B. M. Schwartz, S. Guan, R. Lee, J. D. Cheng, F. G. Haluska 205 SATURDAY Ronald J. Buckanovich, MD—Co-Chair University of Michigan Gottfried E. Konecny, MD—Co-Chair University of California, Los Angeles Saturday, June 4, 2011 5:15 PM A comparative randomized, placebo-controlled, double-blind phase II study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment for advanced ovarian cancer. (Abstract #5010) I. B. Vergote, P. Harter, N. Kovalenko, T. Bauknecht, K. Mansouri, Y. Zhang, J. Sehouli 5:30 PM A phase II study of decitabine and carboplatin in recurrent platinum (Pt)resistant ovarian cancer (OC). (Abstract #5011) D. Matei, C. Shen, F. Fang, J. Schilder, M. Li, A. Arnold, Y. Zeng, J. M. Pilrose, C. Kulesavage, C. Balch, W. Berry, P. Wulfridge, T. H. Huang, K. P. Nephew Discussion 5:45 PM Helga B. Salvesen, MD, PhD (Abstracts #5009 –5011) Haukeland University Hospital, The University of Bergen SATURDAY 206 Saturday, June 4, 2011 4:30 PM - 6:00 PM CLINICAL SCIENCE SYMPOSIUM Finding the Targets, Restoring the Vision Location: Hall D1 CME credit: 1.5 Track(s): Gastrointestinal (Colorectal) Cancer 4:30 PM A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. (Abstract #3500) C. Eng, E. Van Cutsem, E. Nowara, A. Swieboda-Sadlej, N. C. Tebbutt, E. P. Mitchell, I. Davidenko, K. Oliner, L. Chen, J. Huang, I. McCaffery, E. Loh, D. Smethurst, J. Tabernero Discussion 4:45 PM Ravi Salgia, MD, PhD (Abstract #3500) The University of Chicago Colorectal Cancer: Exploiting the Targets 5:00 PM A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. (Abstract #3501) D. J. Watkins, J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe, H. M. Brown, J. Clark, K. Hsu, B. D. Lu, D. Cunningham Discussion 5:15 PM Margaret M. Mooney, MD, MBA (Abstract #3501) National Cancer Institute The Importance of Biomarker Codevelopment to Success 5:30 PM A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. (Abstract #3502) M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, K. Dorsch-Vogel, D. Kuda, T. McAndrew, L. M. Weiner, J. Marshall, J. R. Brody Discussion 5:45 PM Andrew Nicholas James Tutt, PhD, MBChB (Abstract #3502) Breakthrough Breast Cancer Research Unit, Guy’s Hospital 207 SATURDAY Ravi Salgia, MD, PhD—Chair The University of Chicago Saturday, June 4, 2011 4:45 PM - 6:00 PM SPECIAL SESSION ASCO/American Society of Hematology (ASH) Joint Session Location: Arie Crown Theater CME credit: 1.25 Track(s): Leukemia, Myelodysplasia, and Transplantation, Lymphoma and Plasma Cell Disorders, Special Session George W. Sledge Jr., MD—Co-Chair Indiana University Simon Cancer Center Welcome and Introduction SATURDAY Armand Keating, MD—Co-Chair Princess Margaret Hospital Welcome and Introduction Anna Jankowska, MSc Cleveland Clinic Impaired Hydroxylation of 5-Methylcytosine in TET2-mutated Patients with Myeloid Malignancies (ASH #33807) Menno Volkert Huisman, MD, PhD Leiden University Medical Center Outpatient Treatment in Patients with Acute Pulmonary Embolism: The Hestia Study (ASH #34998) Kaan Boztug, MD CeMM Research Center for Molecular Medicine Correction of Wiskott-Aldrich Syndrome by Hematopoietic Stem Cell Gene Therapy (ASH #33064) Kirit Ardeshna, MD University College London Hospitals An Intergroup Randomized Trial of Rituximab versus a Watch-and-Wait Strategy in Patients with Stage II, III, IV, Asymptomatic, Nonbulky Follicular Lymphoma (Grades 1, 2, and 3a). A Preliminary Analysis (ASH #27692) 208 Saturday, June 4, 2011 4:45 PM - 6:00 PM EDUCATION SESSIONS Design and Interpretation of Randomized Controlled Trials in Oncology to Achieve Meaningful Benefits for Patients and Society Location: S100a CME credit: 1.25 Track(s): Clinical Trials, Ethics SATURDAY Ralph M. Meyer, MD—Chair NCIC Clinical Trials Group, Queen’s University Explanatory versus Pragmatic Randomized Controlled Trials in Oncology: How and Why to Make This Distinction in the Design and Interpretation of Clinical Trials Antonio Tito Fojo, MD, PhD National Cancer Institute, National Institutes of Health How Much Is Life Worth: The Multibillion Dollar Question in Contemporary Oncology Alberto F. Sobrero, MD Ospedale San Martino Raising the Bar for Efficacy in Cancer Therapeutics New Developments in Lynch Syndrome and DNA Mismatch Repair: Screening, Genetics, Prognosis, and Treatment Location: E353 CME credit: 1.25 Track(s): Cancer Genetics, Gastrointestinal (Colorectal) Cancer Michael J. Hall, MD—Chair Fox Chase Cancer Center Controversies in Screening for Lynch Syndrome Noralane M. Lindor, MD Mayo Clinic Update on the Genetics of Lynch Syndrome: New Genes, New Mechanisms, New Insights Zsofia Kinga Stadler, MD Memorial Sloan-Kettering Cancer Center The Importance of DNA Mismatch Repair in the Prognosis and Treatment of Colorectal Cancer 209 Saturday, June 4, 2011 Nonphysician Providers in Oncology: Examining Collaborative Approaches and Next Steps Location: E354b CME credit: 1.25 Track(s): Practice Management and Information Technology, Patient and Survivor Care, Professional Development Dean F. Bajorin, MD—Chair Memorial Sloan-Kettering Cancer Center SATURDAY Elaine L. Towle, CMPE Oncology Metrics Partnering with Nonphysician Providers in the Community Setting: Results of the Study of Collaborative Practice Arrangements Funded by Susan G. Komen for the Cure® Shirley Shuster, APRN, BC, OCN Commonwealth Hematology Oncology Successful Implementation of the Nonphysician Provider in the Community Setting Michael Goldstein, MD Beth Israel Deaconess Medical Center/Harvard Medical School The Past Will Not Predict the Future of the Oncology Workforce 210 Saturday, June 4, 2011 4:45 PM - 6:00 PM MEET THE PROFESSOR SESSION Initial Management of Hepatocellular Carcinoma (M08)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Gastrointestinal (Noncolorectal) Cancer Jeff H. Geschwind, MD The Johns Hopkins University School of Medicine Nonsurgical Strategies for Hepatocellular Carcinoma SATURDAY Timothy M. Pawlik, MD, MPH The Johns Hopkins University School of Medicine What Are the Upfront Surgical Options for Hepatocellular Cancer? 4:45 PM - 6:00 PM CLINICAL PROBLEMS IN ONCOLOGY SESSION Multimodality Approach to Mucosal Melanoma (C05)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Melanoma/Skin Cancers Vernon Keith Sondak, MD—Chair H. Lee Moffitt Cancer Center & Research Institute Role of Surgery for Subtypes of Mucosal Melanoma Bryan Burmeister, MBBS Princess Alexandra Hospital Radiotherapy for Primary and Advanced Mucosal Melanoma Leslie Anne Fecher, MD University of Pennsylvania Abramson Cancer Center Systemic Therapy for Advanced Mucosal Melanoma 211 Sunday, June 5, 2011 7:30 AM - 9:00 AM HIGHLIGHTS OF THE DAY SESSION Highlights of the Day I Including Clinical Trials Participation Awards Location: Hall D1 CME credit: 1.5 Track(s): Special Session, General Oncology Douglas W. Blayney, MD—Co-Chair Stanford University Daniel F. Hayes, MD—Co-Chair University of Michigan Medical Center 7:30 AM Clinical Trials Participation Awards 7:45 AM Joel E. Tepper, MD University of North Carolina at Chapel Hill School of Medicine Gastrointestinal (Colorectal) Cancer SUNDAY 8:00 AM Gottfried E. Konecny, MD University of California, Los Angeles Gynecologic Cancer 8:15 AM Bruce D. Cheson, MD Georgetown University Medical Center Lymphoma 8:30 AM Antoni Ribas, MD Jonsson Comprehensive Cancer Center, University of California, Los Angeles Melanoma/Skin Cancers 212 Sunday, June 5, 2011 8:00 AM - 9:15 AM SPECIAL SESSION ASCO–American Cancer Society Award and Lecture Location: S100a CME credit: 1.25 Track(s): Special Session SUNDAY Jamie Von Roenn, MD Northwestern University Personalized Medicine: A Comprehensive Definition 213 Sunday, June 5, 2011 8:00 AM - 9:15 AM EDUCATION SESSIONS Diffuse Large B-cell Lymphoma: Present and Future Location: E354a CME credit: 1.25 Track(s): Lymphoma and Plasma Cell Disorders Jeremy S. Abramson, MD—Chair Massachusetts General Hospital Treatment of Diffuse Large B-cell Lymphoma in 2011 Ari Melnick, MD Weill Cornell Medical College Transcript Profiling and Novel Targets in Diffuse Large B-cell Lymphoma Christian Gisselbrecht, MD Hopital Saint Louis Novel Therapies for Diffuse Large B-cell Lymphoma Improving Drug Safety: From Toxicity Assessment to Post-marketing Surveillance Location: S504 CME credit: 1.25 Track(s): Health Services Research SUNDAY David Cella, PhD—Chair Robert H. Lurie Comprehensive Cancer Center of Northwestern University Using Patient-reported Outcomes to Measure Toxicities in Clinical Trials Richard Pazdur, MD U.S. Food and Drug Administration Improving Drug Safety: The U.S. Food and Drug Administration Past and Future Julia Bohlius, MD, MScPH Institute for Social and Preventive Medicine, University of Bern The Importance of Post-marketing Pharmacovigilance Molecular and Pathologic Controversies for Potentially Curative Lung Cancers Location: S406 CME credit: 1.25 Track(s): Lung Cancer Elisabeth Brambilla, MD—Chair CHU Grenoble The Histologic Reclassification of Adenocarcinoma of the Lung: Implications for Diagnosis and Therapy David Harpole Jr., MD Duke University Medical Center Genomic Prognostication in Early-stage Non-small Cell Lung Cancer: Past, Present, and Future Ethan Dmitrovsky, MD Dartmouth Medical School MicroRNA Profiling: Clinical Studies in Lung Cancer 214 Sunday, June 5, 2011 Oncology Practice Models: Strategies to Overcome Competitive Disadvantages Location: E353 CME credit: 1.25 Track(s): Practice Management and Information Technology, Professional Development Harvey D. Bichkoff, MPH—Chair California Cancer Care Practice Model for Success: Community-based/Single-specialty Denis Brin Hammond, MD New Hampshire Oncology-Hematology Practice Model for Success: Hospital/University-affiliated R. Steven Paulson, MD Texas Oncology Practice Model for Success: Regional/Multispecialty Standard Management of Stage IV Colorectal Cancer: Start and Stop, Maintenance, Bevacizumab beyond Progression? (eQuestions Session) Location: Hall D2 CME credit: 1.25 Track(s): Gastrointestinal (Colorectal) Cancer SUNDAY Axel Grothey, MD—Chair Mayo Clinic Bevacizumab beyond Progression Jeffrey A. Meyerhardt, MD, MPH Dana-Farber Cancer Institute Start and Stop, Maintenance, Chemotherapy Holiday Wells A. Messersmith, MD University of Colorado Cancer Center Toxicity of Chemotherapy The Molecular Biology, New Targets, and Pathways in Head and Neck Cancer Location: E354b CME credit: 1.25 Track(s): Head and Neck Cancer, Developmental Therapeutics, Tumor Biology David Sidransky, MD—Chair The Johns Hopkins University Genetic and Epigenetic Targets, High-throughput Technology Christine H. Chung, MD The Johns Hopkins University Targeted Pathways from Bench to Clinic Ezra E. W. Cohen, MD The University of Chicago Clinical Advances in Targeted Therapies 215 Sunday, June 5, 2011 8:00 AM - 9:15 AM MEET THE PROFESSOR SESSION Bone Protection in Prostate Cancer: Benefits and Pitfalls (M09)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Genitourinary Cancer, Geriatric Oncology Matthew Raymond Smith, MD, PhD Massachusetts General Hospital Cancer Center Bisphosphonates, RANK-ligand Inhibitors, and Other “Bone Protecting” Agents: The Standard of Care Ian Tannock, MD, PhD Princess Margaret Hospital and University of Toronto Bone-protective Agents: Do They Have Questionable Efficacy and Unacceptable Cost? SUNDAY 8:00 AM - 9:15 AM CLINICAL PROBLEMS IN ONCOLOGY SESSION Soft-tissue Sarcomas: A Continuing Clinical Conundrum for the Clinician? (C07)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Sarcoma Raphael E. Pollock, MD, PhD—Chair University of Texas M. D. Anderson Cancer Center Surgery for Soft-tissue Sarcomas Thomas F. DeLaney, MD Massachusetts General Hospital Radiation for Soft-tissue Sarcomas Rashmi Chugh, MD University of Michigan Chemotherapy for Soft-tissue Sarcomas 216 Sunday, June 5, 2011 8:00 AM - 10:00 AM SPECIAL SESSION Training Program Directors’ Breakfast (Training Program Directors Only) Location: S404 Track(s): Special Session, Professional Development Thomas H. Davis, MD—Chair Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center ACGME Open Discussion; MATCH Update; How Can ASCO Recognize Teachers? Michael P. Kosty, MD Scripps Clinic Informational Items: WAG, Classic References, QOPI for Fellows Frances A. Collichio, MD University of North Carolina at Chapel Hill School of Medicine ASCO MedOnc In-training Exam Statistics SUNDAY Howard R. Terebelo, DO Providence Hospital My Experience with Education Essentials for Oncology Fellows (EEOF) 217 Sunday, June 5, 2011 8:00 AM - 11:00 AM ORAL ABSTRACT SESSION Central Nervous System Tumors Location: S100bc CME credit: 3 Track(s): Central Nervous System Tumors Eric L. Chang, MD—Co-Chair University of Texas M. D. Anderson Cancer Center Martin Nicholas, MD, PhD—Co-Chair The University of Chicago SUNDAY 8:00 AM Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG1). (Abstract #2004) K. Jahnke, A. Korfel, P. Martus, S. Lokka, R. Moehle, F. Griesinger, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler, M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, A. Florschütz, L. Fischer, M. Weller, E. Thiel 8:15 AM Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: Results from a German phase III trial (G-PCNSL-SG-1). (Abstract #2005) P. Martus, K. Jahnke, A. Korfel, T. Rose, L. Fischer, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler, M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, J. Birkmann, M. Weller, E. Thiel Discussion 8:30 AM Lisa Marie DeAngelis, MD (Abstracts #2004 –2005) Memorial Sloan-Kettering Cancer Center 8:45 AM RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). (Abstract #2006) M. R. Gilbert, M. Wang, K. D. Aldape, R. Stupp, M. Hegi, K. A. Jaeckle, T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan, C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran Jr., M. P. Mehta 9:00 AM Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study. (Abstract #2007) W. Wick, J. Steinbach, S. E. Combs, M. Platten, C. Hartmann, F. K. Wenz, U. Boecker, C. Stoffregen Discussion 9:15 AM Jeffrey S. Abrams, MD (Abstracts #2006 –2007) National Cancer Institute 9:30 AM Correlation of treatment effects on progression-free survival at 6 months (PFS-6) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM). (Abstract #2008) X. Ye, S. A. Grossman, S. Desideri, S. Piantadosi, for the ABTC CNS Consortium Discussion 9:45 AM Martin J. Van Den Bent, MD (Abstract #2008) Daniel den Hoed Cancer Center 218 Sunday, June 5, 2011 10:00 AM Magnetic resonance (MR) perfusion imaging to differentiate early progression from pseudoprogression following chemoradiotherapy for glioblastoma (GBM). (Abstract #2009) J. J. Graber, R. J. Young, A. Gupta, A. D. Shah, T. A. Chan, Z. Zhang, W. Shi, K. Beal, A. M. Omuro 10:15 AM A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. (Abstract #2010) D. D. Eisenstat, L. B. Nabors, W. P. Mason, J. R. Perry, W. R. Shapiro, P. Kavan, S. Phuphanich, Y. Fu, X. J. Cong, M. Shahidi, D. A. Reardon 10:30 AM Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol. (Abstract #2011) G. Dhall, L. Ji, K. Haley, J. P. Grimm, F. H. Gilles, S. L. Gardner, J. C. Allen, A. Cornelius, K. R. Pradhan, J. H. Garvin, R. S. Olshefski, J. Hukin, M. Comito, S. Goldman, S. J. Thompson, A. Hirt, M. P. Atlas, A. W. Walter, R. Sposto, J. L. Finlay SUNDAY Discussion 10:45 AM Marc C. Chamberlain, MD (Abstracts #2009-2011) University of Washington 219 Sunday, June 5, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Genitourinary Cancer Location: Hall A Track(s): Genitourinary Cancer SUNDAY Brd. 1A Identification of mutations of the SWI/SNF complex gene PBRM1 by exome sequencing in renal carcinoma. (Abstract #4571) B. T. Teh, I. Varela, P. Tarpey, K. Raine, D. Huang, C. Ong, K. A. Furge, P. J. Campbell, M. R. Stratton, P. Futreal Brd. 1B The asociation between the number of nodes removed at retroperitoneal lymph node dissection and overall- and cancer-specific survival in patients with nonseminomatous germ cell tumor. (Abstract #4572) D. Lewinshtein, A. Schatz, C. R. Porter Brd. 1C CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer. (Abstract #4573) F. Lamoureux, M. Yin, A. Zoubeidi, M. E. Gleave Brd. 1D Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4574) X. Huang, Y. M. Ning, M. Mulquin, R. A. Madan, J. L. Gulley, P. G. Kluetz, D. Adelberg, P. M. Arlen, H. L. Parnes, B. Adesunloye, S. M. Steinberg, J. J. Wright, J. B. Trepel, C. Chen, C. Bassim, A. B. Apolo, W. D. Figg, W. L. Dahut Brd. 1E A phase II trial of dasatinib in subjects with hormone-refractory prostate cancer previously treated with chemotherapy. (Abstract #4575) P. Twardowski, C. Chen, A. S. Kraft, G. S. Chatta, E. Alexson, M. Mitsuhashi, W. Ye, M. Lilly Brd. 1F The association of PTEN loss on outcome in patients with early high-risk prostate cancer (CaP) treated with adjuvant docetaxel following radical prostatectomy (RP). (Abstract #4576) D. Keizman, Z. Zhang, V. J. Sinibaldi, A. DeMarzo, B. Gurel, T. Lotan, J. Hicks, E. Rosenbaum, E. S. Antonarakis, J. J. Kim, M. A. Carducci, M. A. Eisenberger Brd. 1G An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome. (Abstract #4577) D. Olmos, J. Clark, D. Brewer, L. Barwell, G. Attard, A. H. Reid, S. K. Sandhu, A. Zivi, D. Bianchini, N. Babu Oomen, E. Thompson, L. R. Molife, S. B. Kaye, C. Parker, C. Cooper, R. J. Jones, J. S. De Bono Brd. 2A The effect of tobacco exposure in renal cell carcinoma (RCC) overall and cancer-specific survival. (Abstract #4578) N. Kroeger, T. Klatte, F. D. Birkhaeuser, E. N. Rampersaud, D. B. Seligson, N. Zomorodian, F. F. Kabbinavar, A. S. Belldegrun, A. J. Pantuck Brd. 2B Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). (Abstract #4579) A. Jain, M. J. Brames, D. J. Vaughn, L. H. Einhorn Brd. 2C Phase III trial comparing long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: GICOR protocol DART01/05. (Abstract #4580) A. Zapatero, A. Guerrero, X. Maldonado, A. Alvarez, C. González San Segundo, A. Cabeza, V. Macı́as, F. Casas, A. Pedro-Olivé, S. Villa, A. Boladeras, M. Vazquez de La Torre, C. Martin de Vidales, F. A. Calvo, GICOR (Grupo Investigacion Clinica Oncologia Radioterapica) Brd. 2D Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). (Abstract #4581) S. J. Snedecor, J. A. Carter, S. Kaura, M. Botteman 220 Brd. 2E Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4582) G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, G. Sonpavde Brd. 2F Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC). (Abstract #4583) G. J. Chen, G. Sonpavde, C. L. Vale, D. Fisher, T. Powles, Advanced Bladder Cancer Meta-analysis Collaborators (ABCMAC) Brd. 2G The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score. (Abstract #4584) T. Powles, C. Mollevi, A. Kramar, A. Lorch, J. Beyer, for the International Prognostic Factors Study Group (IPFSG) Brd. 3A The interval to biochemical failure versus biochemical failure as predictors for cause-specific and overall survival following dose-escalated external beam radiation therapy for prostate cancer. (Abstract #4585) N. S. Kapadia, F. Y. Feng, K. B. Olson, H. M. Sandler, D. A. Hamstra Brd. 3B Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel: German Association of Urological Oncology (AUO) trial AB 20/99. (Abstract #4586) G. Niegisch, R. Fimmers, R. Siener, S. Park, P. Albers, German Association of Urological Oncology (AUO) Brd. 3D Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08). (Abstract #4588) A. Templeton, C. Rothermundt, R. Cathomas, D. Baertschi, C. Droege, O. Gautschi, M. M. Borner, E. Fechter, F. Stenner, R. C. Winterhalder, B. Mueller, V. Dutoit, P. Dietrich, R. Schiess, P. Wild, G. N. Thalmann, D. Klingbiel, S. Gillessen Brd. 3E Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma less than or equal to 2 cm. (Abstract #4589) M. Kates, G. M. Badalato, N. Sadeghi, M. S. Pitman, J. M. McKiernan Brd. 3F An analysis of STAT3 polymorphism on outcomes of interferon-alpha treatment in patients with metastatic renal cell carcinoma. (Abstract #4590) M. Eto, T. Kamba, H. Miyake, M. Fujisawa, K. Yoshida, H. Uemura, T. Tsukamoto, Y. Katsuoka, A. Matsubara, K. Nishimura, T. Nakamura, O. Ogawa, S. Naito Brd. 3G Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4591) C. Seidel, M. Fenner, C. W. Reuter, A. Ganser, V. Gruenwald Brd. 3H Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrateresistant prostate cancer (CRPC). (Abstract #4592) P. J. Wiechno, P. Chlosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry, D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies, V. Andre, K. Hurt, M. M. Lahn, M. Stöckle, C. Reuter, B. Heinrich Brd. 4A Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free testosterone levels. (Abstract #4593) C. W. Reuter, M. A. Morgan, M. Fenner, P. Ivanyi, V. Gruenwald, A. Ganser 221 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 SUNDAY Brd. 4B Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer. (Abstract #4594) J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. Sweeney Brd. 4C Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis. (Abstract #4595) S. Kapadia, S. Hapani, S. Wu Brd. 4D Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma. (Abstract #4596) M. S. Soper, J. R. Hastings, M. Tome, K. Lodin Brd. 4E LH-receptor polymorphisms and response to androgen deprivation therapy in prostate cancer. (Abstract #4597) S. V. Liu, T. B. Dorff, Q. Wang, S. Xiong, E. Thara, M. Keng, S. A. Ingles, J. K. Pinski Brd. 4F Cytokines’ profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC). (Abstract #4598) K. L. Mahon, M. D. Chatfield, M. Lee-Ng, S. N. Breit, D. A. Brown, M. P. Molloy, G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, R. Wykes, S. M. Henshall, R. L. Sutherland, L. Horvath Brd. 4G A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC) . (Abstract #4599) A. Reichle, M. Vogelhuber, S. Feyerabend, T. Suedhoff, M. Schulze, J. Hubner, R. Oberneder, M. Baier, A. Ruebel, K. Birkholz, A. Bakhshandeh-Bath, R. Andreesen Brd. 4H Sorafenib and sunitinib in renal cell cancer: A study based on register data. (Abstract #4600) A. E. Ambring, U. K. Stierner, A. S. Oden, I. N. Bjorholt Brd. 5A Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy. (Abstract #4601) V. Grünwald, P. I. Karakiewicz, S. E. Bavbek, K. Miller, J. H. Machiels, S. Lee, J. M. Larkin, P. Bono, S. Y. Rha, D. E. Castellano, C. U. Blank, J. J. Knox, R. Hawkins, R. R. Yuan, M. Rosamilia, J. L. Booth, I. Bodrogi, on behalf of the REACT Study Group Brd. 5B Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial. (Abstract #4602^) A. M. Stein, A. Carter, N. Hollaender, R. J. Motzer, C. Sarr Brd. 5C A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC). (Abstract #4603) L. Horvath, K. L. Mahon, W. Qu, J. Devaney, M. D. Chatfield, C. Paul, R. Wykes, M. J. Boyer, M. R. Stockler, G. M. Marx, R. L. Sutherland, S. J. Clark Brd. 5D A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4604) T. E. Hutson, R. M. Bukowski, B. I. Rini, M. E. Gore, J. M. Larkin, R. A. Figlin, C. H. Barrios, B. Escudier, X. Lin, K. D. Fly, B. Martell, E. Matczak, R. J. Motzer Brd. 5E Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC). (Abstract #4605) J. Medioni, J. Ferrero, G. Deplanque, T. Maurina, J. P. Rodier, E. Raymond, J. Allyon, S. Renaux, J. Dufour-Lamartinie, S. Oudard 222 Sunday, June 5, 2011 Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. (Abstract #4606) M. I. Milowsky, A. M. Regazzi, I. R. Garcia-Grossman, A. Trout, A. Flaherty, S. Gerst, H. Al-Ahmadie, I. Ostrovnaya, D. F. Bajorin Brd. 5G Does enrollment setting influence patient attributes and outcomes in RTOG prostate cancer trials? (Abstract #4607) W. Lee, J. Dignam, D. Bruner, J. A. Efstathiou, Y. Yan, G. E. Hanks, M. Roach III, M. V. Pilepich, H. M. Sandler Brd. 5H Late toxicity rates following definitive radiotherapy for prostate cancer: A meta-analysis revealing interactions between dose and technique. (Abstract #4608) N. Ohri, W. Shi, A. Dicker, T. N. Showalter Brd. 6A Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). (Abstract #4609^) M. E. Gore, R. J. Jones, A. Ravaud, M. Kuczyk, T. Demkow, A. Bearz, N. Laferriere, U. P. Strauss, C. Porta Brd. 6B Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC). (Abstract #4610) C. Porta, B. Escudier, T. E. Hutson, R. A. Figlin, E. Calvo, V. Grünwald, S. Osanto, A. Ravaud, A. Panneerselvam, J. J. Knox, R. J. Motzer Brd. 6C Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension. (Abstract #4611) A. A. van der Veldt, K. Eechoute, S. Oosting, M. H. Kappers, J. B. Haanen, A. K. Reyners, H. Gelderblom, H. Guchelaar, C. Van Herpen, E. Boven, R. Mathijssen Brd. 6D Tumor marker rise during second course high-dose chemotherapy in recurrent testicular cancer: Outcome analysis. (Abstract #4612) M. Pant-Purohit, M. J. Brames, R. Abonour, L. H. Einhorn Brd. 6E Final results of a risk-adapted policy of adjuvant chemotherapy (ACT) in patients with invasive bladder carcinoma (IBC). (Abstract #4613) J. Arranz Arija, Y. Jerez Gilarranz, A. Soria Lovelle, C. López López, P. Sabin Dominguez, M. Riesco, J. Adeva Alfonso, D. Urosa Velasco, E. López Juárez, R. González Beca, M. Martin Brd. 6F The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC). (Abstract #4614) P. Hadji, M. Ziller, T. Maurer, M. Muth, A. Ruebel, C. May, K. Birkholz, J. E. Gschwend Brd. 6G Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center. (Abstract #4615) A. M. Molina, X. Jia, M. S. Ginsberg, S. Velasco, D. R. Feldman, S. Patil, R. J. Motzer Brd. 6H Does absolute neutrophil count predict adverse tumor grade in African American men with prostate cancer? (Abstract #4616) N. Sadeghi, G. M. Badalato, G. W. Hruby, V. R. Grann, J. M. McKiernan Brd. 7A Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer. (Abstract #4617) Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, W. Song, J. W. Lee, M. B. Dabrow, M. Brody, H. Tuttle, G. R. Hudes Brd. 7B Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC). (Abstract #4618) A. Necchi, N. Nicolai, C. Ortega, T. Sava, C. Messina, C. Sacco, F. Crippa, C. Morosi, R. Lanocita, M. Colecchia, L. Mariani, N. Zaffaroni, R. Salvioni SUNDAY Brd. 5F 223 Sunday, June 5, 2011 SUNDAY Brd. 7C Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCa). (Abstract #4619) L. C. Pagliaro, A. J. Zurita, J. C. Araujo, J. F. Ward, J. W. Davis, C. A. Pettaway, S. Tu, J. Kim, P. Dieringer, C. Logothetis, L. L. Pisters Brd. 7D Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. (Abstract #4620^) S. Nilsson, C. G. O’Bryan-Tear, B. Bolstad, A. Lokna, C. C. Parker Brd. 7E The association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) with outcome of sunitinib tx in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4621) P. Huang, M. A. Carducci, M. A. Eisenberger, R. Pili, J. J. Kim, E. S. Antonarakis, H. J. Hammers, D. Keizman Brd. 7F Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers. . (Abstract #4622) E. Seront, B. Sautois, S. Rottey, L. A. D’Hondt, J. Canon, J. Vandenbulcke, N. Whenham, J. Goeminne, O. Feron, J. H. Machiels Brd. 7G Thioredoxin reductase RNA levels in expressed prostatic secretions as prognostic indicators of prostate cancer. (Abstract #4623) J. A. Linehan, R. Torrey, J. P. Clark, G. Babilonia, D. D. Smith, K. Chan, C. Lau, D. Y. Josephson, M. H. Kawachi, T. G. Wilson, S. S. Smith Brd. 7H A multicenter, randomized phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafururacil (UFT) for prostate cancer with relapse after initial hormonal therapy. (Abstract #4624) M. Takahashi, R. Kawabata, A. Kawano, Y. Murakami, Y. Sutou, T. Inai, S. Akazawa, T. Hamao, H. Hayashi, T. Fukawa, M. Takemura, Y. Yamamoto, K. Yamaguchi, H. Nakatsuji, T. Kishimoto, H. Izaki, T. Fukumori, H. Kanayama Brd. 8A Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. (Abstract #4625) C. Chevreau, A. Ravaud, B. Escudier, A. Caty, R. Delva, F. Rolland, S. Oudard, R. Herve, E. Blanc, C. Ferlay, N. Lignon, S. Negrier, French Group on Renal Cancer Brd. 8B Analysis of blood-derived circulating microvesicles for microRNA biomarkers of metastatic and nonmetastatic prostate cancer. (Abstract #4626) F. C. Hamdy, R. J. Bryant, T. L. Pawlowski, G. Marsden, S. Smith, R. Vessella, C. D. Kuslich Brd. 8C Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). (Abstract #4627) G. A. Bjarnason, R. Williams, J. M. Hudson, C. Bailey, C. R. Lee, B. A. Lloyd, S. Kandel, J. M. Ebos, A. Kiss, R. S. Kerbel, L. M. Milot, M. Atri, G. J. Stanisz, P. Burns Brd. 8D Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). (Abstract #4628) J. P. Bleuse, H. J. Meulenbeld, E. M. Vinci, E. Raymond, G. Vitali, A. Santoro, L. Dogliotti, R. Berardi, F. Cappuzzo, S. T. Tagawa, C. N. Sternberg, M. Jannuzzo, M. Mariani, A. Petroccione, R. De Wit Brd. 8E Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase I/II trial. (Abstract #4629) D. M. Waterhouse, W. C. Penley, C. D. Webb, F. A. Greco, H. A. Burris III, J. D. Hainsworth 224 Brd. 8F Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. (Abstract #4630) R. A. Fisher, A. Pender, K. Thillai, S. Chowdhury, L. M. Pickering, S. St. Rose, M. E. Gore, J. M. Larkin Brd. 8G Association of Raynaud’s phenomenon after bleomycin etoposide cisplatin (BEP) chemotherapy for testicular cancer (TC) with accelerated atherosclerosis. (Abstract #4631) R. Altena, H. Boer, C. Meijer, J. Nuver, A. M. van Roon, N. Zwart, E. De Vries, J. D. Lefrandt, A. J. Smit, J. A. Gietema Brd. 8H Relationship of T lymphocytes, T regulatory cells, and B lymphocytes to clinical outcome in prostate cancer. (Abstract #4632) M. Trepel, A. Flammiger, L. Weisbach, T. Schlomm, H. Huland, S. Minner, P. Tennstaedt, C. Bokemeyer, G. Sauter Brd. 9A Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials. (Abstract #4633) P. Wolter, L. McCann, C. N. Sternberg, T. E. Hutson, F. Mehmud, L. N. Pandite, P. Schoffski Brd. 9B Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN). (Abstract #4634) K. B. Blagoev, J. Wilkerson, W. D. Stein, R. J. Motzer, S. E. Bates, A. T. Fojo Brd. 9C The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload. (Abstract #4635) E. R. Dennis, J. J. Fox, S. M. Larson, J. S. Farrelly, L. H. Schwartz, H. Schöder, E. C. Haupt, L. S. Borwick, H. I. Scher, M. J. Morris Brd. 9D Quantifying the tradeoffs of active surveillance for low-risk prostate cancer: A clinical decision analysis. (Abstract #4636) D. Liu, H. P. Lehmann, K. D. Frick, B. Carter Brd. 9E Prevalence of prostate cancer (PC) clinical states (CS) in the United States: Estimates using a dynamic progression model. (Abstract #4637) K. Solo, M. Mehra, R. Dhawan, J. Valant, H. I. Scher Brd. 9F A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). (Abstract #4638) D. R. Feldman, L. H. Einhorn, D. I. Quinn, A. Horwich, Y. Loriot, J. K. Joffe, D. J. Vaughn, A. Flechon, J. Hajdenberg, A. U. Pande, K. Liu, I. Gorbatchevsky, R. J. Motzer Brd. 9G Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis. (Abstract #4639) R. Salvioni, N. Nicolai, L. Piva, M. Catanzaro, T. Torelli, D. Biasoni, S. Stagni, A. Milani, A. Necchi Brd. 9H Impact of 24 months of androgen deprivation therapy (ADT) on physical function in men with nonmetastatic prostate cancer. (Abstract #4640) S. M. Alibhai, H. Breunis, N. Timilshina, S. Duff Canning, N. Fleshner, M. Krahn, I. Tannock, G. A. Tomlinson, P. R. Warde, G. Naglie Brd. 10A The prognostic significance of prenephrectomy absolute lymphocyte count in clear cell renal cell carcinoma. (Abstract #4641) S. Saroha, R. Uzzo, G. R. Hudes, E. R. Plimack, K. Ruth, T. I. Al-Saleem Brd. 10B A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. (Abstract #4642) W. K. Oh, M. D. Galsky, M. Barry, F. Fennessey, J. P. Richie, J. H. Hayes, R. S. Bhatt, M. Taplin, P. G. Febbo, R. W. Ross Brd. 10C Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation. (Abstract #4643) J. M. Lang, J. C. Eickhoff, N. C. Binkley, M. J. Staab, G. Liu, G. Wilding, D. G. McNeel 225 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 SUNDAY Brd. 10D Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. (Abstract #4644) C. M. Booth, D. R. Siemens, I. Tannock, Y. Peng, G. Li, W. J. Mackillop Brd. 10E A case-control study examining associations of germ-line oxidative DNA repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer (PCa) risk. (Abstract #4645) N. M. Hahn, J. Jung, J. Dantzer, S. Philips, Y. R. Patel, K. A. Carr, Y. Mohammadi, D. Magjuka, C. Camp, M. Bolden, E. F. Dropcho, J. A. Knight II, M. L. Moore, A. D. Reed, M. J. Waddell, J. E. Klaunig, L. Li, C. Sweeney, T. C. Skaar Brd. 10F Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis. (Abstract #4646) J. Casper, D. Goebel, V. Gruenwald, A. Flörcken, D. Mueller, K. Toussaint, B. Metzner Brd. 10G Variation in sex steroid methyl transferases associated with androgen deprivation therapy (ADT) efficacy in advanced prostate cancer. (Abstract #4647) M. Kohli, D. W. Mahoney, H. S. Chai, D. W. Hillman, D. R. Rider, B. A. Costello, J. R. Cerhan Brd. 10H Quality-of-life assessment in a randomized, double-blind study of sipuleucelT in men with androgen-dependent prostate cancer. (Abstract #4648) T. M. Beer, P. F. Schellhammer, J. M. Corman, L. M. Glode, S. Hall, Y. Xu, M. W. Frohlich, D. F. Penson Brd. 11A A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer. (Abstract #4649) M. A. Bilen, D. Liu, P. Mathew, L. C. Pagliaro, C. Logothetis, J. C. Araujo, A. Aparicio, P. G. Corn, J. Hajdenberg, S. R. Dakhil, S. Tu Brd. 11B Prostate-specific membrane antigen antibody– drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. (Abstract #4650) D. P. Petrylak, P. W. Kantoff, R. C. Frank, N. D. Shore, Y. Rotshteyn, R. J. Israel, W. C. Olson, T. Ramakrishna, S. Morris Brd. 11C Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and intertissue heterogeneity and disease progression. (Abstract #4651) A. M. Joshua, A. Evans, J. Squire, M. Yoshimoto, O. Ludkovski, S. Tan, A. Dobi, B. Furusato, G. Petrovics, S. Srivastava, I. Sesterhenn Brd. 11D 9q32-q33.1 amplification as a prognostic factor for overall survival in metastatic germ cell tumors. (Abstract #4652) J. M. Piulats, A. Vidal, M. Nadal, A. Pisa, J. R. Germa-Lluch, E. Condom, A. Villanueva, X. Garcia del Muro Brd. 11E Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. (Abstract #4653) W. Choi, J. B. Shah, M. Tran, R. S. Svatek, L. Marquis, I. C. Lee, D. Yu, L. Adam, J. E. Bondaruk, S. Wen, Y. Shen, C. P. Dinney, B. Czerniak, D. J. McConkey, A. O. Siefker-Radtke Brd. 11F Lymphovascular invasion in clinical stage I testicular nonseminoma: Potential marker of more aggressive relapses and implications for active surveillance. (Abstract #4654) C. R. Nichols, S. Daneshmand, S. Tyldesley, K. N. Chi, N. Murray, A. I. So, P. C. Black, B. M. Hayes-Lattin, C. K. Kollmannsberger Brd. 11G Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC). (Abstract #4655) E. Y. Yu, F. E. Nathan, C. S. Higano 226 Brd. 11H Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease. (Abstract #4656) M. H. Voss, E. P. Jacobsen, S. Patil, S. Turkula, X. Jia, J. Sheinfeld, D. F. Bajorin, G. J. Bosl, R. J. Motzer, D. R. Feldman Brd. 12A Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (Abstract #4657) M. Nakabayashi, W. Xie, G. Buckle, G. Bubley, M. S. Ernstoff, W. V. Walsh, D. Morganstern, P. W. Kantoff, M. M. Regan, M. Taplin Brd. 12B Prostate-specific membrane antigen (PSMA)–targeted imaging of metastatic prostate cancer (PCa) via small molecule inhibitors: Comparison to bone scan, CT/MRI, and 111In capromab. (Abstract #4658) R. Coleman, J. A. Barrett, A. Hussain, K. M. Slawin, T. Armor, N. D. LaFrance, J. W. Babich Brd. 12C Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: A Sarah Cannon Research Institute phase II trial. (Abstract #4659) J. A. Reeves, D. R. Spigel, D. B. Daniel, E. K. Friedman, H. A. Burris III, J. D. Hainsworth Brd. 12D Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies. (Abstract #4660) M. Crepel, B. J. Escudier, J. H. Machiels, M. D. Staehler, A. Ravaud, G. Gravis, F. Joly, C. Chevreau, L. Zini, H. Lang, L. Salomon, P. Bigot Jr., J. Rigaud, J. Patard Sr. Brd. 12E Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. (Abstract #4661) E. J. Small, C. S. Higano, P. W. Kantoff, J. B. Whitmore, M. W. Frohlich, D. P. Petrylak Brd. 12F Phase I/II study of neoadjuvant docetaxel plus intensity-modulated radiotherapy (IMRT) prior to surgery for high-risk prostate cancer. (Abstract #4662) M. Garzotto, A. Hung, T. M. Beer, J. J. Alumkal, J. N. Graff, P. E. Farris, J. F. Flamiatos, S. Mongoue-Tchokote, S. N. Carter Brd. 12G Quantitative gene expression in primary and highest Gleason pattern cancer specimens identifies genes associated with clinical recurrence and prostate cancer–specific survival after radical prostatectomy. (Abstract #4663) E. A. Klein, S. M. Falzarano, T. Maddala, M. Lee, R. J. Pelham, W. F. Novotny, S. Shak, C. Magi-Galluzzi Brd. 12H Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. (Abstract #4664) D. J. George, S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, A. J. Armstrong, R. J. Varley, J. Madden, J. W. Moul Brd. 13A Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort study. (Abstract #4665) J. A. Talcott, A. L. Zietman, I. D. Kaplan, J. A. Clark, A. V. D’Amico Brd. 13B Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). (Abstract #4666) A. Aparicio, A. L. Harzstark, E. Lin, P. G. Corn, J. C. Araujo, S. Tu, L. C. Pagliaro, R. E. Millikan, W. Arap, J. Kim, C. J. Ryan, A. J. Zurita, N. M. Tannir, A. M. Lin, E. J. Small, P. Mathew, D. M. Jones, P. Troncoso, P. F. Thall, C. Logothetis, Prostate Cancer Clinical Trials Consortium 227 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 Brd. 13C Agent Orange as a risk factor for high-grade prostate cancer detected on initial prostate biopsy. (Abstract #4667) N. J. Ansbaugh, J. Shannon, M. Mori, P. E. Farris, L. Collins, M. Garzotto Brd. 13D Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC). (Abstract #4668) A. Finelli, A. M. Horgan, A. Evans, T. Kim, K. Durrant, S. Yap, C. A. Cassol, W. Dubinski, N. Fleshner, M. A. Jewett, A. M. Joshua, S. S. Sridhar, A. Zlotta, J. J. Knox Brd. 13E 11 C-choline-PET/CT (C-PET) versus transrectal ultrasound– guided prostate biopsies (TRUS-BP) to diagnose locally recurrent prostate cancer (PCA) following radiation therapy (RT). (Abstract #4669) A. Heidenreich, B. Brehmer, R. Epplen, D. J. Pfister, EURO Prostate Center Aachen Brd. 13F Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4670) K. M. Slawin, G. Sonpavde, J. D. McMannis, Y. Bai, M. Seethammagari, J. M. Bull, V. Hawkins, T. Dancsak, N. Lapteva, J. M. Levitt, D. M. Spencer SUNDAY 228 Sunday, June 5, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Gynecologic Cancer Brd. 14A A phase I/II study of cisplatin and radiation in combination with sorafenib in cervical cancer: Evaluation of biomarkers. (Abstract #5037) C. A. Townsley, M. Milosevic, M. A. Haider, H. Mackay, I. Yeung, S. Kim, W. Levin, L. Manchul, S. Bindra, K. MacAlpine, L. M. Tinker, L. Wang, J. Quintos, A. W. Fyles, A. M. Oza Brd. 14B Response rate and toxicity of primary concomitant radiochemotherapy in locally advanced cervical cancer: Results of an open prospective, multicenter phase II study of the NOGGO. (Abstract #5038) A. Mustea, A. Belau, J. Sehouli, K. Drzewiecki, M. H. Eichbaum, K. Bartz, E. Angelidou, S. Saegner, M. O. Langenbruch, P. Ledwon, M. Zygmunt, G. Koehler, D. Koensgen, North-Eastern Society of Gynaecological Oncology Brd. 14C Expression of embryonic stem cell factor SOX2 in serous ovarian carcinomas. (Abstract #5039) T. N. Fehm, D. Pham, V. Scheible, C. Lengerke, S. Perner, H. Neubauer, A. Staebler Brd. 14D Akt-mTOR pathway in uterine leiomyosarcoma. (Abstract #5040) G. Garg, A. Short, J. Liu, A. R. Munkarah, R. Morris, R. Ali-Fehmi Brd. 14E Treatment of cervical intraepithelial neoplasia with topical imiquimod. (Abstract #5041) S. Polterauer, C. Grimm, C. Natter, J. Rahhal, L. Hefler, A. Reinthaller, P. Speiser Brd. 14F MRI prior to systematic lymphadenectomy in patients with locally advanced cervical cancer. (Abstract #5042) M. Gold, Z. Zhang, H. Marques, J. Gorelick, L. M. Landrum, R. S. Mannel, L. T. Chuang, J. Q. Yu, C. K. McCourt, M. Harisinghani, A. Sohaib, D. Koh, S. Raman, M. S. Gee, H. Choi, M. Atri Brd. 14G Treatment and outcome of patients with invasive extramammary Paget’s disease. (Abstract #5043) A. Karam, O. Dorigo Brd. 14H Confirmatory factor analysis of the sexual adjustment and body image scale in women with a diagnosis of gynecologic cancer. (Abstract #5044) S. E. Ferguson, C. Massey, C. Classen, M. Wegener, N. Quartey, M. Pulandiran, D. Wiljer, S. Urowitz Brd. 15A PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. (Abstract #5045) R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale, E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann Brd. 15B Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. (Abstract #5046) B. J. Monk, T. J. Herzog, S. B. Kaye, C. N. Krasner, J. B. Vermorken, F. Muggia, E. Pujade-Lourraine, P. Zintl, T. V. Parekh, A. Poveda Brd. 15C The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD). (Abstract #5047) A. A. Garcia, I. B. Vergote, J. P. Micha, C. H. Pippitt Jr., G. G. Rao, D. L. Spitz, N. Reed, G. G. Dark, E. N. Ibrahim, V. A. Armenio, L. R. Duska, C. J. Poole, C. Gennigens, L. Y. Dirix, J. West, C. Zhao, A. C. Leung, L. K. Masuoka, G. J. Rustin 229 SUNDAY Location: Hall A Track(s): Gynecologic Cancer Sunday, June 5, 2011 Catumaxomab treatment of malignant ascites in patients with chemotherapyrefractory ovarian cancer: A phase II study. (Abstract #5048) J. S. Berek, R. P. Edwards, L. Parker, L. R. DeMars, T. J. Herzog, S. S. Lentz, R. Morris, W. L. Akerley, R. W. Holloway, M. Method, S. C. Plaxe, J. L. Walker, T. Schindler, E. Schulze, C. N. Krasner, Cooperative Ovarian Cancer Group (COGI) Brd. 15E Fibroblast growth factor receptor 4 (FGFR4) expression as a prognostic indicator in high-grade serous ovarian carcinoma (HGSC): Signaling pathway, mechanism, and implication for therapeutic targeting. (Abstract #5049) T. M. Zaid, M. Thompson, K. Wong, T. Yeung, Z. Yeung, D. M. Gershenson, M. J. Birrer, S. C. Mok Brd. 15F The relationship of polymorphism Mad1 1673 G>A on outcomes in patients with advanced ovarian cancer treated with carboplatine-paclitaxel. (Abstract #5050) M. Santibañez, D. Prada, C. Diaz, C. Castro, F. Morales-Vasquez, D. Gallardo Rincon, L. A. Herrera Brd. 15G Analysis of polymorphisms in sodium channel, voltage-gated, type I, alpha subunit (SCN1A) as predictors of clinical outcome and toxicity in advanced ovarian cancer patients enrolled in a phase III trial treated with patupilone. (Abstract #5051) Y. Ning, W. Zhang, D. Yang, D. Weber, F. Souami, P. O. Bohanes, A. Gerger, M. J. Labonte, L. Benhaim, H. Lenz Brd. 15H Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. (Abstract #5052) C. Marth, J. Alexandre, L. C. Hanker, C. Brown, J. Kaern, M. Heywood, A. Bonaventura, I. B. Vergote, S. Pignata, A. Ferrero, V. Gebski, M. Gropp, T. Skeie-Jensen, C. Giede, P. A. Vasey, C. Schauer, N. Reed, G. Ferrandina, R. Fossati, E. Pujade-Lauraine Brd. 16A A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: An evidence-based proposal for patient selection. (Abstract #5053) W. Tian, D. Chi, J. Sehouli, C. Trope, R. Jiang, A. Ayhan, G. Cormio, Y. Xing, G. Breitbach, E. I. Braicu, C. A. Rabbitt, H. Oksefjell, C. Fotopoulou, H. Meerpohl, A. Du Bois, J. S. Berek, R. Zang, P. Harter Brd. 16B Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibility study. (Abstract #5054) S. Nagao, T. Nishikawa, A. Kurosaki, R. Ohishi, N. Iwasa, K. Hasegawa, K. Fujiwara Brd. 16C Multimodality evaluation of excision repair cross-complementation 1 (ERCC1) expression as a predictive biomarker for platinum resistance in epithelial ovarian cancer (EOC). (Abstract #5055) C. O. Michie, L. Song, D. Faratian, J. Orr, T. Rye, J. Clark, J. M. Bartlett, D. J. Harrison, D. Melton, A. Williams, C. Gourley Brd. 16D Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC). (Abstract #5056) D. Jelovac, D. K. Armstrong, S. Weil, M. Phillips, B. M. Schwartz, J. M. Estes, R. D. Alvarez Brd. 16E Age-specific prognostic factors for survival in patients with advanced ovarian cancer (OC) treated with platinum/taxane-based primary chemotherapy: A combined explorative analysis of three prospective phase III trials from the AGO study group. (Abstract #5057) F. Hilpert, A. Hempel, J. Hedderich, O. Junge, P. Harter, A. Du Bois, J. Pfisterer, AGO Study Group SUNDAY Brd. 15D 230 Brd. 16F Expression profiles in matched primary and recurrent serous ovarian carcinomas. (Abstract #5058) D. A. Zajchowski, B. Y. Karlan, L. K. Shawver Brd. 16G Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. (Abstract #5059) S. Mahner, W. Meier, A. Du Bois, C. Brown, D. Lorusso, A. Ferrero, J. Cretin, H. Havsteen, P. Bessette, L. Angleitner-Boubenizek, I. B. Vergote, P. A. Vasey, V. Gebski, B. Slama, J. Herrstedt, L. Kaizer, A. Georgoulopoulos, N. Reed, U. Wagner Brd. 16H Phase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer (ROC) patients. (Abstract #5060) D. Lorusso, P. Malaguti, V. Masciullo, S. Mainenti, A. di Legge, M. Ludovisi, A. Pesce, F. Mascilini, E. Fusco, G. Scambia Brd. 17A Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study. (Abstract #5061) M. G. del Carmen, J. P. Micha, L. A. Small, D. G. Street, A. Londhe, T. McGowan Brd. 17B A North American population-based outcome for early-stage ovarian clear cell carcinoma (OCCC). (Abstract #5062) P. Hoskins, J. S. Albarrak, N. Le, A. Tinker, K. Swenerton, J. Santos, C. B. Gilks Brd. 17C Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer. (Abstract #5063) D. S. Tan, T. A. Yap, M. M. Hutka, P. Roxburgh, E. Grzybowska, C. Gourley, M. E. Gore, S. B. Kaye Brd. 17D Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer. (Abstract #5064) H. Gungor, A. Saleem, R. Agarwal, S. P. Blagden, A. Michael, E. A. Stronach, M. Chen, E. Pickford, N. R. Rama, Y. L. Lewis, S. C. Carme, C. Salinas, D. A. Smith, E. Krachey, A. Santiago-Walker, R. N. Gunn, M. El-Bahrawy, S. A. Babar, S. R. Morris, H. Gabra Brd. 17E Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study. (Abstract #5065) B. You, O. Colomban, M. Heywood, C. Lee, M. Davy, N. Reed, S. Pignata, R. Fossati, G. Emons, K. L. Rehman, K. D. Steffensen, E. Petru, V. Gebski, A. Burges, N. Tubiana-Matthieu, M. Hansen, P. A. Vasey, U. Denison, P. De Bruyne, A. M. Oza Brd. 17F Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921. (Abstract #5066) D. S. Dizon, M. Sill, N. S. Gould, S. C. Rubin, S. D. Yamada, R. DeBernardo, R. S. Mannel, E. L. Eisenhauer, L. R. Duska, P. M. Fracasso, Gynecologic Oncology Group Brd. 17G Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301. (Abstract #5067) A. Poveda, B. J. Monk, S. B. Kaye, J. B. Vermorken, I. B. Vergote, I. B. Runnebaum, E. Pujade-Lauraine, T. V. Parekh, A. Nieto, J. Gomez, Y. C. Park, N. Colombo Brd. 17H Acquired drug resistance in gynecologic cancer detected by drug response marker testing. (Abstract #5068) I. Benjamin, H. J. Dalton, B. J. Monk 231 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 SUNDAY Brd. 18A A novel plasma amino acid profile-based biomarker for early detection of ovarian cancer. (Abstract #5069) E. Miyagi, R. Numazaki, Y. Ihata, T. Muramatsu, A. Imaizumi, H. Yamamoto, M. Yamakado, N. Okamoto, M. Asai-Sato, F. Hirahara Brd. 18B Operative morbidity and mortality in octogenarians and nonagenarians with ovarian cancer. (Abstract #5070) C. L. Walters, K. E. Schneider, J. M. Whitworth, J. M. Fauci, J. M. Straughn, M. N. Barnes Brd. 18C First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology. (Abstract #5071) G. Oskay-Özcelik, R. Richter, K. Pietzner, H. Hindenburg, H. L. Sommer, R. Chekerov, O. Camara, E. Keil, J. Einenkel, W. Lichtenegger, J. Sehouli Brd. 18D Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. (Abstract #5072) K. M. Esselen, N. Rodriguez, N. S. Horowitz, S. M. Campos Brd. 18E Extended duration of response with second-line intraperitoneal platinumbased therapy for epithelial ovarian cancer. (Abstract #5073) M. E. Skaznik-Wikiel, J. L. Lesnock, W. C. McBee Jr., S. D. Richard, J. L. Kelley, K. K. Zorn, T. C. Krivak, R. P. Edwards Brd. 18F Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. (Abstract #5074) E. R. King, Y. T. Tsang, Z. Zu, D. M. Gershenson, S. C. Mok, K. Wong Brd. 18G Increased expression of C-terminal binding protein-2 in epithelial ovarian carcinoma modulates DNA repair pathways and decreases tumor response to histone deacetylase inhibitors. (Abstract #5075) T. May, L. M. Barroilhet, J. Yang, M. Singh, W. R. Welch, S. P. Sugrue, R. S. Berkowitz, S. Ng Brd. 18H Use of contrast-enhanced ultrasound imaging with microbubbles targeted to ␣v3 integrins to enhance detection of early-stage ovarian tumors. (Abstract #5076) A. Barua, A. Yellapa, P. Bitterman, J. M. Bahr, S. Sharma, D. B. Hales, J. L. Luborsky, J. S. Abramowicz Brd. 19A Surveillance for ovarian carcinoma patients after curative-intent treatment. (Abstract #5077) F. E. Johnson, K. S. Virgo, F. Gao, D. G. Mutch Brd. 19B Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC). (Abstract #5078) O. Smaletz, M. Diz, C. C. Carmo, J. Sabbaga, G. F. Cunha, S. J. Azevedo, F. C. Maluf, C. H. Barrios, R. L. Costa, A. G. Fontana, V. A. Alves, A. M. Moro, A. M. Scott, E. W. Hoffman, L. J. Old Brd. 19C Is there a place for neoadjuvant chemotherapy in the management of advanced malignant germ cell tumors of the ovary? (Abstract #5079) L. Kumar, S. Talukdar, R. Hariprasad, A. Gupta, A. Mookerjee, S. Kumar, N. Bhatla, S. Mathur Brd. 19D FDG-PET/CT imaging in gynecologic cancers: Is there an advance on patient management? (Abstract #5080) M. Dalla Palma, M. Gregianin, L. Evangelista, A. Cervino, G. Saladini, L. Borgato, M. O. Nicoletto, V. Zagonel Brd. 19E Prognostic significance of serum HE4 in epithelial ovarian cancer. (Abstract #5081) M. Marinaccio, E. Mele, V. Lorusso, A. Larocca, C. Pellegrino, R. Chiappetta, F. Sozzi 232 Brd. 19F Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: Two-year efficacy results from a multicenter, single-arm, phase II study. (Abstract #5082) J. Sehouli, A. Reinthaller, C. Marth, D. Reimer, T. Reimer, W. Stummvoll, L. Angleitner-Boubenizek, B. Lehnert, M. Marquardt, M. M. Essing, R. Chekerov Brd. 19G Assessing the value of weekly full blood counts (FBC) in patients with advanced serous gynecologic cancers receiving weekly carboplatin/paclitaxel (wCP) chemotherapy. (Abstract #5083) D. Ulahannan, G. J. Rustin, M. Hall Brd. 19H Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer. (Abstract #5084) L. J. Havrilesky, R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A. Secord, P. A. Gehrig, M. A. Lopez, A. Shafer, L. Van Le, D. C. Dale, J. Crawford, G. H. Lyman Brd. 20A Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer. (Abstract #5085) Y. Kikuchi, M. Takano, T. Goto, H. Kouta, R. Kikuchi, K. Kudoh, T. Kita, K. Furuya, K. Umayahara, K. Takizawa Brd. 20B Cyclin D1 and p57 expression in advanced ovarian epithelial carcinoma: A GOG study. (Abstract #5086) E. Hill, W. Brady, M. J. Birrer, K. M. Darcy, W. P. McGuire III, W. J. Hoskins, D. P. Warshal, R. D. Drake, P. Hanjani, J. Hurteau Brd. 20C The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC). (Abstract #5087) I. Pokataev, G. M. Manikhas, V. Borisov, M. Stenina, A. Tjulandina, S. Tjulandin Brd. 20D The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. (Abstract #5088) C. Kurzeder, L. Zhao, E. A. Eisenhauer, I. B. Vergote, A. Du Bois, D. Tai, Y. Wang, J. F. Gill, H. W. Hirte, B. Richter, L. C. Hanker, J. Bentley, U. A. Wagner, M. Plante, R. Kimmig, J. Pfisterer Brd. 20E Phase II trial of weekly irinotecan and carboplatin for relapsed ovarian cancer: A Kansai Clinical Oncology Group study. (Abstract #5089) H. Tsubamoto, K. Inoue, R. Kawaguchi, K. Ito, S. Takeuchi, T. Shiozaki, Y. Itani, A. Arakawa, T. Tabata, S. Toyoda Brd. 20F Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: A phase II study, CTEP #7431. (Abstract #5090) M. L. Hensley, S. J. Kravetz, X. Jia, W. P. Tew, L. Pereira, P. Sabbatini, C. Whalen, C. Aghajanian, C. Zarwan, S. T. Berlin Brd. 20G Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer. (Abstract #5091) A. G. Zeimet, S. Abdel-Azim, D. Reimer, E. Mueller-Holzner, B. Winterhoff, U. Puistola, A. Ben-Arie, L. vanKempen, F. Amant, E. Petru, S. Jahn, S. Polterauer, P. Oppelt, M. Weigert, P. Altevogt, M. Huszar, C. Marth, M. Fogel Brd. 20H Impact of the MDM2 promoter polymorphisms SNP285 and SNP309 on endometrial cancer risk among Caucasians. (Abstract #5092) S. Knappskog, J. Trovik, J. Marcickiewisz, S. Tingulstad, A. Staff, K. Hveem, L. Vatten, H. B. Salvesen, P. Lonning Brd. 21A Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group. (Abstract #5093) P. Harter, U. Canzler, H. Lueck, A. Reuss, W. Meier, T. N. Fehm, A. Staehle, A. Burges, C. Kurzeder, J. Sehouli, K. H. Baumann, L. C. Hanker, P. Wimberger, W. Schroeder, M. Gropp, S. Mahner, A. Du Bois 233 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 SUNDAY Brd. 21B The presence of racial disparities in histopathologic characteristics of uterine cancer in an equal-access environment. (Abstract #5094) K. E. Oliver, L. Enewold, K. Zhu, T. P. Conrads, G. S. Rose, G. L. Maxwell, J. H. Farley Brd. 21C Molecular analysis of endometrial pathogenesis in Lynch syndrome. (Abstract #5095) M. Huang, B. Djordjevic, D. Urbauer, S. N. Westin, C. C. Sun, J. K. Burzawa, L. Meyer, D. C. Bodurka, R. Broaddus, K. H. Lu Brd. 21D Recombinant adenovirus-p53 (rAd-p53) in combination with radiotherapy for treating cervical cancer. (Abstract #5096) S. Zhang Brd. 21E A phase II study of recombinant adeno-viral human p53 gene combined with radiotherapy in treatment of patients with locally advanced cervical carcinoma. (Abstract #5097) J. Pan Brd. 21F Gemcitabine for advanced endometrial carcinoma (EMC): A review of the MSKCC experience. (Abstract #5098) R. N. Grisham, C. H. Adaniel, D. M. Hyman, W. Ma, A. Iasonos, C. Aghajanian, J. A. Konner Brd. 21G Validation of the predictive value of modeled hCG decline profiles in low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX). (Abstract #5099) G. Freyer, B. You, R. Harvey, F. Golfier, H. Mitchell, P. Savage, M. Tod, C. Philip, T. Hajri, M. Seckl Brd. 21H Exploration of biomarkers for lymph node metastasis in patients with endometrial cancer using exon-expression microarray. (Abstract #5100) S. Sudo, Y. Konno, T. Odagiri, T. Kato, M. Hosaka, M. Takeda, H. Watari, M. Kaneuchi, N. Sakuragi Brd. 22A The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. (Abstract #5101) A. N. Viswanathan, J. Szymonifka, C. Tanaka, S. T. Berlin, S. M. Campos, N. S. Horowitz, J. Lee, C. Whalen, U. Matulonis Brd. 22B Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study. (Abstract #5102) M. Takekuma, Y. Hirashima, K. Ito, H. Tsubamoto, T. Tabata, A. Arakawa, Y. Itani, N. Furukawa, H. Murakoshi, S. Takeuchi Brd. 22C Paradigm shift in the management of high intermediate–risk stage I endometrial cancer. (Abstract #5103) J. O. Schorge, A. H. Russell, L. A. Garrett, A. Goodman, M. G. del Carmen, W. B. Growdon, D. M. Boruta II Brd. 22D Laparoscopic intraoperative sentinel lymph node detection by technetium-99 hysteroscopically injected in endometrial cancer patients. (Abstract #5104) G. Favero Brd. 22E Genome-wide single nucleotide polymorphism (SNP) arrays as a novel diagnostic tool in synchronous carcinomas. (Abstract #5105) Y. Ikeda, K. Oda, S. Nakagawa, S. Murayama-Hosokawa, K. Shoji, S. Yamamoto, S. Ishikawa, Y. Uehara, Y. Miyamoto, M. Tanikawa, T. Kashiyama, Y. Takazawa, D. Maeda, O. Hiraike-Wada, K. Miyagawa, F. McCormick, M. Fukayama, H. Aburatani, T. Yano, Y. Taketani Brd. 22F Ovarian preservation in premenopausal patients with early-stage endometrial cancer: A multicenter retrospective matched cohort study. (Abstract #5106) T. Lee, S. Seong, J. Kim, J. Lee, H. Ryu 234 Sunday, June 5, 2011 Factors associated with synchronous ovarian and endometrial cancer: A population-based case control study. (Abstract #5107) M. M. AlHilli, S. C. Dowdy, A. Weaver, J. St. Sauver, G. L. Keeney, A. Mariani, K. C. Podratz, J. N. Bakkum-Gamez Brd. 22H Endometrial cancer screening in patients with Lynch syndrome. (Abstract #5108) A. Bats, M. Le Frere-Belda, U. Metzger, P. Laurent-Puig, F. Lecuru Brd. 23A Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO. (Abstract #5109) D. Koensgen, A. Belau, J. Sehouli, H. L. Sommer, K. Bartz, S. Markmann, L. Schneidewind, J. P. Scharf, M. Ehmke, D. Stengel, P. Ledwon, H. Guba, M. Zygmunt, G. Koehler, A. Mustea, North-Eastern Society of Gynaecological Oncology Brd. 23B Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. (Abstract #5110) K. Oda, K. Shoji, S. Nakagawa, T. Kashiyama, Y. Ikeda, Y. Miyamoto, M. Tanikawa, H. Kuramoto, M. Nishida, O. Hiraike-Wada, T. Yano, S. Kozuma, Y. Taketani Brd. 23C Obesity, diabetes, and race in Type 1 and Type 2 endometrial cancers. (Abstract #5111) E. M. Ko, J. Franasiak, K. Sink, W. R. Brewster, P. A. Gehrig, V. L. Bae-Jump SUNDAY Brd. 22G 235 Sunday, June 5, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Melanoma/Skin Cancers Location: Hall A Track(s): Melanoma/Skin Cancers IL-6 as a prognostic biomarker in patients with metastatic melanoma. (Abstract #8538) L. Hoejberg, L. Bastholt, J. S. Johansen, K. Fode, H. Schmidt Brd. 24B Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF kinase in BRAF-mutant metastatic melanoma. (Abstract #8539) M. S. Carlino, C. A. Saunders, V. Gebski, A. M. Menzies, B. Ma, P. F. Lebowitz, R. Kefford, G. V. Long Brd. 24C Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations. (Abstract #8540) L. Poliseno, A. Haimovic, D. Hanniford, M. F. Segura, P. J. Christos, R. L. Shapiro, A. C. Pavlick, R. S. Berman, E. Hernando, J. Zavadil, I. Osman Brd. 24D An analysis of altered melanoma matrix metalloproteinase-23 (MMP-23) expression and response to immune biologic therapy. (Abstract #8541) M. Krogsgaard, M. W. Ma, E. B. Friedman, E. Vega-Saenz de Miera, F. Darvishian, A. Perez-Garcia, R. S. Berman, R. L. Shapiro, P. J. Christos, I. Osman, A. C. Pavlick Brd. 24E Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). (Abstract #8542) G. V. Long, J. S. Wilmott, J. R. Howle, M. D. Chatfield, V. Tembe, J. F. Thompson, P. Hersey, G. J. Mann, G. A. McArthur, H. Rizos, R. J. Young, L. L. Scurr, R. N. Sharma, R. F. Kefford, R. A. Scolyer Brd. 24F Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma. (Abstract #8543) P. Boasberg, R. W. Weber, S. Cruickshank, O. Hamid, S. O’Day, L. E. Spitler Brd. 24G A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients. (Abstract #8544) L. Si, L. L. Mao, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, B. X. Tang, J. Guo Brd. 24H Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). (Abstract #8545) J. L. Chang, P. A. Ott, C. Sorlie, C. Escano, E. Yepes, S. Mendoza, A. Gandhi, L. Liebes, A. C. Pavlick Brd. 25A A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma. (Abstract #8546) J. P. Fruehauf, Z. Eroglu, K. M. Kong, J. G. Jakowatz, W. L. Akerley, W. E. Samlowski Brd. 25B Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma. (Abstract #8547) J. Hansson, S. Aamdal, L. Bastholt, M. Hernberg, B. Nilsson, U. K. Stierner, H. von der Maase, Y. Brandberg, Nordic Melanoma Cooperative Group Brd. 25C An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. (Abstract #8548) R. Dummer, J. Rinderknecht, S. M. Goldinger, I. Wagner, L. Mitchell, M. Veronese, S. Nick, P. Hilfiker, S. Gobbi SUNDAY Brd. 24A 236 Brd. 26A MicroRNA oncogenes and tumor suppressors controlling malignant melanoma cell growth, apoptosis, migration, and invasion. (Abstract #8549) R. W. Georgantas, K. Streicher, W. Zhu, R. Carrasco, Z. Xiao, Z. Liu, P. Brohawn, C. Morehouse, D. Tice, B. W. Higgs, L. Richman, P. Kiener, B. Jallal, Y. Yao Brd. 26B Ultrasound (US)-guided fine-needle aspiration cytology (FNAC) for the prediction of sentinel node (SN) metastases and its effect on the nomogram for melanoma patients. (Abstract #8550) C. A. Voit, A. C. Van Akkooi, P. Siegel, W. Sterry, A. Schoengen, G. Schaefer-Hesterberg, A. M. Eggermont Brd. 26C A gene expression profile associated with clinical outcome in stage III melanoma. (Abstract #8551) J. Falkenius, J. Lindberg, H. Johansson, M. Frostvik-Stolt, J. Lundeberg, J. Hansson, S. Egyhazi Brd. 27A Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. (Abstract #8552) M. E. Valsecchi, D. Summers, C. M. Intenzo, S. Kim, M. J. Mastrangelo, T. Sato Brd. 27B Intratumoral neutrophils, plasmacytoid dendritic cells, and pSTAT3 in AJCC stage I/II melanoma prognosis. (Abstract #8553) T. O. Jensen, H. Schmidt, H. J. Moller, F. Donskov, M. Hoyer, P. Sjoegren, I. J. Christensen, T. Steiniche Brd. 27C Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. (Abstract #8554) S. O’Day, J. S. Weber, J. D. Wolchok, J. M. Richards, P. Lorigan, D. F. McDermott, W. J. Urba, V. DePril, K. N. Heller, R. A. Ibrahim, A. Hauschild Brd. 28A Two phase I studies of PTI-188, a radiolabeled murine antimelanin antibody, in patients with metastatic melanoma (MM). (Abstract #8555) M. Lotem, T. Peretz, S. Mizrachi, Y. Liberman, E. Dadachova, A. Casadevall, A. de Kater, N. Friedmann, G. B. Thornton, M. Klein Brd. 28B Association of CT antigen expression and survival in stage III melanoma. (Abstract #8556) N. H. Turner, T. John, S. Deb, A. M. Campbell, A. Azad, P. C. Boutros, Y. Chen, J. S. Cebon Brd. 28C A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma. (Abstract #8557) J. M. Mehnert, Y. Wen, J. H. Lee, L. Dudek, L. Pruski-Clark, W. Shih, S. Chen, J. S. Goydos Brd. 29A A germ-line polymorphism in the RET proto-oncogene predicts risk and recurrence in desmoplastic melanoma. (Abstract #8558) N. Kounalakis, C. M. Amato, J. Barr, W. Robinson Brd. 29B Exploratory analysis of technical factors that influence sentinel lymph node biopsy (SLNB) performance. (Abstract #8559) D. Silbermins, M. E. Valsecchi, N. de Rosa, S. L. Wong, G. H. Lyman Brd. 29C Primary melanoma features associated with increased risk of brain metastasis. (Abstract #8560) M. W. Ma, M. Qian, D. Lackaye, R. S. Berman, R. L. Shapiro, A. C. Pavlick, J. Golfinos, E. Parker, E. Hernando, Y. Shao, I. Osman Brd. 30A Impact of immune modulation on sentinel lymph node positivity and outcome in melanoma patients. (Abstract #8561) R. C. Medicherla, M. W. Ma, M. Qian, E. Vega-Saenz de Miera, R. S. Berman, R. L. Shapiro, A. C. Pavlick, N. Bhardwaj, Y. Shao, I. Osman, F. Darvishian Brd. 30B The prognostic relevance of altered antiglycan antibody profiles in the sera of primary melanoma patients. (Abstract #8562) A. Haimovic, M. W. Ma, M. I. Vuskovic, T. Miller, M. DiBenedetto, J. Grossman, R. L. Shapiro, A. C. Pavlick, R. S. Berman, H. I. Pass, M. Huflejt, I. Osman 237 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 SUNDAY Brd. 30C Melanoma pigmentation affects melanoma-specific survival and provides a potential target for radiopharmaceutical-based imaging and therapy. (Abstract #8563) D. Kee, W. Liu, B. A. Devitt, R. Wolfe, R. Ware, R. Salemi, A. Dobrovic, S. Brglevska, J. Kelly, J. Callahan, A. Katsifis, P. Roselt, O. C. Neels, T. Bourdier, R. J. Hicks, G. A. McArthur Brd. 31A Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials. (Abstract #8564) M. Blanco-Codesido, A. Brunetto, S. Frentzas, V. Moreno Garcia, D. Papadatos-Pastos, J. V. Pedersen, L. Trani, M. Puglisi, D. Sarker, L. R. Molife, U. Banerji Brd. 31B The burden of metastatic melanoma (mM): Treatment patterns, healthcare use, and costs. (Abstract #8565) C. Reyes, S. DaCosta Byfield, S. Satram-Hoang, A. H. Teitelbaum Brd. 31C The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma. (Abstract #8566) Y. Funahashi, J. Matsui, Y. Minoshima, A. Yokoi, T. Abe, K. Okamoto, K. Takahashi, T. Kadowaki, G. Kuznetsov, S. Agoulink Brd. 31D Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF inhibition. (Abstract #8567) J. Matsui, Y. Narita, T. Semba, Y. Adachi, T. Kadowaki, J. Oestreicher, M. Matijevic, M. Byrne, Y. Funahashi Brd. 31E Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese melanoma patients and their significance: Large-scale analysis of 644 patients. (Abstract #8568) Y. Kong, L. Si, J. Guo, Z. H. Chi, C. L. Cui, X. N. Sheng, B. X. Tang Brd. 31G Potency of new duplex drugs linking 3ⴕ-C-ethynylcytidine and 5-fluoro-2ⴕdeoxyuridine against human melanoma in vitro and in vivo. (Abstract #8570) S. Schott, H. Niessner, T. Sinnberg, S. Venturelli, A. Berger, S. Noor, D. Mailaender-Sanchez, C. Garbe, C. Busch Brd. 31H Phase I trial of temozolomide, thalidimide, and lomustine in patients with metastatic melanoma in the brain. (Abstract #8571) N. E. Papadopoulos, W. Hwu, S. Cain, L. Posada, K. B. Kim, J. Homsi, A. Y. Bedikian, M. A. Davies, P. Hwu Brd. 32A Association of response and survival in Allovectin melanoma trials. (Abstract #8572) D. D. Kharkevitch, A. Chu, L. G. Strause, L. R. Muenz, R. T. Kenney, A. Rolland Brd. 32B A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma. (Abstract #8573) D. Shafren, B. M. Smithers, M. Formby Brd. 32C Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients. (Abstract #8574) M. Colombino, M. Capone, M. Maio, V. De Giorgi, A. Cossu, A. Lissia, C. Rubino, B. Massidda, S. Staibano, O. Nappi, G. Botti, C. Caraco, N. Mozzillo, A. Manca, M. Sini, P. A. Ascierto, G. Palmieri, Italian Melanoma Intergroup (IMI) Brd. 32D Feasability and reliabity of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma. (Abstract #8575) M. D. Lozano, T. Labiano, J. I. Echeveste, M. Montana, N. Gomez, M. F. Sanmamed, A. Gurpide, M. A. Idoate, S. Martin-Algarra Brd. 32E Routine imaging to detect recurrences in high-risk melanoma patients. (Abstract #8576) T. S. Park, K. H. Lagisetty, R. M. Sherry, J. C. Yang, M. S. Hughes, K. Morton, D. E. White, Y. Klionsky, S. A. Rosenberg, G. Q. Phan 238 Sunday, June 5, 2011 The results of a randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in uveal melanoma patients with hepatic metastasis. (Abstract #8577) D. J. Eschelman, C. F. Gonsalves, M. Terai, M. Laudadio, K. L. Sullivan, M. J. Mastrangelo, T. Sato Brd. 32G Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma. (Abstract #8578) A. J. Eustace, S. Kennedy, A. Larkin, T. Mahgoub, D. Tryfonopoulos, L. O’Driscoll, M. Clynes, J. Crown, N. O’Donovan Brd. 32H Ipilimumab plus temozolomide in metastatic melanoma. (Abstract #8579) S. P. Patel, A. Y. Bedikian, N. E. Papadopoulos, W. Hwu, K. B. Kim, J. Homsi, M. A. Davies, S. E. Woodman, L. G. Radvanyi, K. Woodard, S. Mahoney, P. Hwu Brd. 33A Overall survival (OS) in the management of pretreated patients with unresectable stage III/IV melanoma: A systematic literature review and meta-analysis. (Abstract #8580) S. Kotapati, P. Dequen, M. Ouwens, M. van Baardewijk, R. A. Ibrahim, S. Wagner, J. P. Jansen Brd. 33B Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. (Abstract #8581) K. N. Heller, A. C. Pavlick, F. S. Hodi, J. A. Thompson, K. A. Margolin, D. P. Lawrence, D. F. McDermott, W. E. Samlowski, T. Michener, M. Karasarides Brd. 33C Plasma Tie-2 and its ligand Ang-2 in metastatic malignant melanoma: Relationships to clinicopathological parameters and tumor burden. (Abstract #8582) R. Mouawad, J. Thery, S. Vignot, R. Conforti, D. Khayat, J. Spano Brd. 33D Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. (Abstract #8583) R. A. Ibrahim, D. M. Berman, V. DePril, R. W. Humphrey, T. Chen, M. Messina, K. M. Chin, H. Y. Liu, M. Bielefield, A. Hoos Brd. 33E Multicohort model of prevalence estimation of advanced malignant melanoma in the United States: An increasing public health concern. (Abstract #8584) A. Y. Lin, P. F. Wang, J. Kolker Brd. 33F Correlation between lymphocyte counts and response to outpatient intravenous interleukin-2 preceded by famotidine in metastatic melanoma. (Abstract #8585) W. Quan, K. N. Donkor, F. M. Quan Brd. 33H Sentinel lymph node detection using laser-assisted indocyanine green dye lymphangiography in melanoma and breast cancer patients. (Abstract #8587) B. Phillips, V. Jain, N. Conkling, C. R. Pameijer Brd. 34A Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy. (Abstract #8588) P. Queirolo, A. Morabito, P. Piccioli, S. Lastraioli, S. Callegari, M. Camoriano, P. A. Ascierto, S. Laurent, B. Dozin, M. Pistillo Brd. 34B BRAF, NRAS, and KIT mutational analysis of spindle cell melanoma. (Abstract #8589) S. J. Dorkhom, J. Kim, A. J. Lazar, M. A. Davies, J. Homsi, N. E. Papadopoulos, W. Hwu, A. Y. Bedikian, S. E. Woodman, S. P. Patel, P. Hwu, K. B. Kim Brd. 34C The prognostic utility of LDH and disease-specific graded prognostic assessment for melanoma brain metastases. (Abstract #8590) M. Lowe, A. Cavitt, J. Shelton, N. Maynard, I. R. Crocker, G. W. Carlson, K. A. Delman, D. H. Lawson, M. Rizzo SUNDAY Brd. 32F 239 Sunday, June 5, 2011 SUNDAY Brd. 34D Use of microRNA signature to predict patient sensitivity to dendritic cell vaccination in metastatic melanoma. (Abstract #8591) L. Ridolfi, I. Vannini, F. Fanini, L. Fiammenghi, M. Petrini, V. Ancarani, A. Granato, M. Guidoboni, E. Pancisi, A. Riccobon, R. Ridolfi, C. Fernandez-Cymering, S. Volinia, C. Milandri, C. M. Croce, M. Fabbri Brd. 34E Acral lentiginous melanoma in Hawaii: Characterization of the mTOR pathway in the non-Caucasian population. (Abstract #8592) S. Y. Morita, S. Jim, C. A. Lum, D. E. Hemmings, J. Davis Brd. 34F A pilot study of endogenous heat shock protein vaccines for metastatic melanoma. (Abstract #8593) J. M. Heun, W. K. Nevala, J. B. Allred, V. Suman, M. R. Callstrom, T. D. Atwell, M. A. Farrell, E. Galanis, L. A. Erickson, W. J. Charboneau, S. Markovic Brd. 34G Antitumor activity of MLN4924, an investigational inhibitor of NEDD8activating enzyme (NAE), in preclinical models of melanoma. (Abstract #8594) T. Traore, M. Mihollen, J. Garnsey, A. Berger, M. Manfredi, K. Cosmopolous, J. Donelan, P. G. Smith Brd. 34H Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080. (Abstract #8595) J. J. Nemunaitis, D. S. Hong, R. Kurzrock, N. N. Senzer, N. C. Twine, T. Kadowaki, M. Ren, Y. Funahashi, J. P. O’Brien, J. S. Simon, A. Eisen Brd. 35A Adjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: A retrospective review of a single-center experience. (Abstract #8596) S. Markovic, P. A. Burch, B. LaPlant, J. M. Heun, R. Bradshaw Brd. 35B Frequency of mutations associated with targeted therapy in malignant melanoma patients. (Abstract #8597) S. Cheng, P. Chu, M. Hinshaw, K. Smith, J. Maize, A. Sferruzza 240 Sunday, June 5, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Pediatric Oncology Brd. 38A The impact of surveillance imaging on overall survival in patients with recurrent Wilms tumor: A report from the Children’s Oncology Group. (Abstract #9536) E. A. Mullen, J. R. Anderson, K. J. Steacy, J. I. Geller, D. M. Green, P. Norkool, C. V. Fernandez, G. Khanna, M. H. Malogolowkin, J. Dome Brd. 38B Association of GSTP1 hypermethylation with reduced protein expression and its correlation with clinical stage in neuroblastoma. (Abstract #9537) F. Gumy-Pause, B. Pardo, M. Khoshbeen-Boudal, M. Ansari, E. F. Attiyeh, H. Ozsahin Brd. 38C BMP signaling activity in pediatric germ cell tumors. (Abstract #9538) N. J. Fustino, D. Rakheja, J. F. Amatruda Brd. 38D Ewing sarcoma prognostic score (ESPS) at diagnosis, based on fever and metastatic status. (Abstract #9539) N. Gaspar, G. Le Teuff, A. Defachelles, C. Schmitt, D. Levy, M. Castex, O. Lejars, C. Verite, E. Plouvier, L. Claude, O. Oberlin Brd. 38E The effect of topotecan in advanced intraocular retinoblastoma with manageable toxicity. (Abstract #9540) I. A. Qaddoumi, C. Billups, C. F. Stewart, J. Wu, K. Helton, B. McCarville, T. E. Merchant, R. C. Brennan, B. Haik, C. Rodriguez-Galindo, M. W. Wilson Brd. 38F Pilot immunotherapy trial in high-risk pediatric sarcomas. (Abstract #9541) M. O. Amoako, M. S. Merchant, D. B. Bernstein, K. Baird, C. Mackall Brd. 38G Changes in incidence of infant cancer: Analysis of SEER data 1992–2007. (Abstract #9542) G. A. Pereira, K. B. Ribeiro, C. Rodriguez-Galindo, L. G. Spector, A. L. Frazier Brd. 38H A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. (Abstract #9543) K. M. Dorris, T. R. Hummel, A. M. Ingle, M. Kim, J. P. Perentesis, M. Fouladi Brd. 39A Incidence and outcomes of patients with late recurrence of Wilms tumor (WT): The international experience. (Abstract #9544) M. H. Malogolowkin, F. Spreafico, J. Dome, N. Breslow, H. van Tinteren, K. Pritchard-Jones, M. van den Heuvel, C. Bergeron, J. De Kraker, N. Graf, COG Renal Tumors Committee and SIOP Renal Tumors Study Group Brd. 39B A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. (Abstract #9545) L. M. McGregor, S. L. Spunt, D. Ward, J. Wu, C. Billups, S. P. Ivy, V. M. Santana, M. Fouladi, W. L. Furman Brd. 39C Cell cycle and apoptotic effects of PM00104 in pediatric cell lines and xenographs. (Abstract #9546) A. Beaugrand, C. Lanvers-Kaminsky, P. Aviles Marin, C. Cuevas Marchante, P. Opolon, L. Le Dret, A. Verschuur, G. Vassal, B. Geoerger, ITCC Biology and Preclinical Evaluation Committee Brd. 39D Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide equivalent dose—A report from the Childhood Cancer Survivor Study. (Abstract #9547) D. M. Green, V. G. Nolan, D. K. Srivastava, W. Leisenring, J. P. Neglia, C. A. Sklar, M. M. Hudson, L. Diller, M. Stovall, L. L. Robison Brd. 39F Toxicity of 131I-MIBG combined with high-dose chemotherapy in children with refractory neuroblastoma. (Abstract #9549) L. Amoroso, G. Villavecchia, M. Cabria, A. Piccardo, M. Conte, M. Nantron, A. Garaventa, B. De Bernardi 241 SUNDAY Location: Hall A Track(s): Pediatric Oncology Sunday, June 5, 2011 SUNDAY Brd. 39G Exposure-response analysis as evidence for antitumor activity of everolimus in the treatment of patients with subependymal giant-cell astrocytoma (SEGA) associated with tuberous sclerosis (TS). (Abstract #9550) N. Mehrotra, E. Pfuma, C. Garnett, Q. Liu, B. Booth, N. Rahman, A. H. Shahlaee, K. Liu Brd. 39H Changes in cardiovascular signaling proteins during doxorubicin treatment in children with high-risk ALL. (Abstract #9551) T. L. Miller, S. E. Lipshultz, R. E. Scully, D. Sawyer, S. R. Lipsitz, L. B. Silverman, H. Smith, J. M. Henkel, V. I. Franco, L. L. Cushman, S. E. Sallan Brd. 40A Allogeneic transplantation for patients with high-risk or refractory neuroblastoma. (Abstract #9552) T. A. Driscoll, P. L. Martin, J. Moffet, M. Daniel, K. Page, S. Parikh, V. Prasad, P. Szabolcs, J. Kurtzberg Brd. 40B Reversal of glucocorticoid resistance by the g-secretase inhibitor PF03084014 in T-cell acute lymphoblastic leukemia. (Abstract #9553) J. B. Samon, M. Castillo-Martin, J. L. Jakubczak, S. Randolph, C. Cordon-Cardo, A. A. Ferrando Brd. 40C Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB). (Abstract #9554) G. L. Saulnier Sholler, D. Eslin, W. D. Roberts, J. Kaplan, G. Bergendahl, T. Ashikaga, T. Higgins, S. Lenox, S. Silberman, W. Ferguson Brd. 40D NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric glial tumors. (Abstract #9555) G. Berghtold, C. Dantas Barbosa, G. Dieffenbach, E. Daudigeos-Dubus, H. Blokus, C. Ferreira, J. Boylan, M. Abely, G. Vassal, J. Grill, B. Geoerger Brd. 40E INI1 and mib-1 expression in childhood chordomas. (Abstract #9556) H. Yin, K. M. Dorris, L. M. Wagner, M. H. Collins, A. Towbin, R. Nagarajan Brd. 40F Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: Results from a series of 12 patients. (Abstract #9557) M. Massimino, V. Biassoni, L. Gandola, E. Schiavello, E. Pecori, F. Bach Brd. 40G Survivin expression in Ewing sarcoma family of tumors. (Abstract #9558) P. Hingorani, D. Azorsa, A. white-Collins, P. Dickman, M. Seidel Brd. 40H PARP-1 inhibitor MK-4827 in combination with radiation as a treatment strategy for metastatic neuroblastoma. (Abstract #9559) S. Bhargava, S. Mueller, L. Wehmeijer, X. Yang, A. Gragg, K. K. Matthay, W. A. Weiss, D. A. Haas-Kogan Brd. 41A Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents: Analysis of growth signaling pathways expression and clinical outcome. (Abstract #9560) J. Mora, C. de Torres, E. Rodriguez, T. M. Cardesa, E. de Alava, O. Cruz Brd. 41B Oncologic outcomes of partial versus radical nephrectomy for unilateral Wilms tumor. (Abstract #9561) N. G. Cost, J. D. Lubahn, H. A. Penn, C. F. Granberg, B. J. Schlomer, J. E. Wickiser, D. Rakheja, P. C. Gargollo, D. Leonard, L. A. Baker, G. Raj, V. Margulis Brd. 41C Back pain and hip pain among survivors of childhood acute lymphoblastic leukemia. (Abstract #9562) D. C. Bowers, T. Griffith, L. Gargan, C. Cochran, B. Kleiber, A. Foxwell, A. Farrow-Gillespie, A. Orlino, J. N. Germann Brd. 41D A phase I study of temsirolimus and valproic acid for refractory solid tumors in children. (Abstract #9563) D. W. Coulter, S. H. Gold, B. Weston, I. Davis, J. Blatt 242 Brd. 41E Feasibility and pharmacokinetic study of potential ABCG2 inihibitor, gefitinib (GB), in combination with irinotecan (IRN) for adolescents and young adults (AYA). (Abstract #9564) H. Kawamoto, Y. Tabei, T. Kimura, K. Hishima, A. Makimoto Brd. 41F Randomized double-blind controlled trial (RCT) of pegfilgrastim as prophylactic therapy in pediatric patients with solid tumors during myelosuppressive chemotherapy. (Abstract #9565) S. Anaya Aguirre, V. Wanzke Del Angel, H. Rivera Marquez, M. Villasis Keever, E. Lopez Aguilar, F. Cerecedo Diaz Brd. 41G Characteristics of childhood cancer survivors who attend long-term followup (LTFU) clinic. (Abstract #9566) K. Devine, J. R. Andolina, N. Murray, G. R. Morrow, O. J. Sahler Brd. 41H Central nervous system relapse in pediatric acute lymphoblastic leukemia: Should we be making the diagnosis sooner? (Abstract #9567) A. E. Aguilar, A. K. Agrawal, J. H. Feusner Brd. 42A A survey of insurance retention in pediatric patients diagnosed with malignancies in a vertically integrated health care system. (Abstract #9568) R. M. Cooper, V. Y. Chiu Brd. 42B B-cell non-Hodgkin lymphomas in childhood: Twenty years experience in a single institution. (Abstract #9569) A. Pourtsidis, M. Servitzoglou, M. Baka, D. Bouhoutsou, M. Varvoutsi, D. Doganis, C. Strantzia-Michail, H. Kosmidis Brd. 42C Effect of selenium supplemantation on anthracycline-induced cardiac toxicity in children treated for cancer: Correlation with pro-brain natriuretic peptide levels. (Abstract #9570) N. Tacyildiz, D. Ozyoruk, G. Ozelci Kavas, H. Dincaslan, G. Yavuz, E. Unal, S. Atalay, A. Ikinciogullari, T. Ucar, B. Doganay, G. Oktay, A. Cavdar, O. Kucuk Brd. 42D Surviving childhood cancer: What next? Challenges in developing countries. (Abstract #9571) P. Kurkure, V. Dhamankar, S. Goswami, N. Dalvi, E. Rawat-Pawar Brd. 42E Influence of prognostic factors in pediatric high-grade osteosarcoma survival. (Abstract #9572) A. Castellanos-Toledo, R. Rivera-Luna, R. Cardenas-Cardos, J. Figueroa Carbajal, C. Leal-Cavazos Brd. 42F Second malignant tumors in childhood cancer survivors. (Abstract #9573) R. Kebudi, I. Ayan, O. Gorgun, F. Y. Agaoglu, G. N. Ozdemir, Y. Dizdar, B. Zulfikar, E. Darendeliler Brd. 42H Sorafenib (Soraf) and bevacizumab (Beva) for recurrent metastatic hepatoblastoma (HB). (Abstract #9575) A. Marsh, L. Lo, J. H. Feusner Brd. 43A Long-term echocardiogram monitoring and cardiac outcomes of childhood cancer survivors with exposure to high doses of anthracyclines. (Abstract #9576) R. Nagarajan, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, K. C. Burns Brd. 43B Secondary leukemia 15 years or more after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9577) K. Nottage, J. Lanctot, Z. Li, J. P. Neglia, S. Bhatia, S. Hammond, W. Leisenring, A. T. Meadows, D. K. Srivastava, L. L. Robison, G. T. Armstrong Brd. 43C Cardiopulmonary outcomes in pediatric surivors of Hodgkin’s lymphoma. (Abstract #9578) K. C. Burns, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, R. Nagarajan 243 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 Brd. 43D A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study. (Abstract #9579) T. R. Hummel, L. M. Wagner, C. H. Ahern, R. M. McGovern, M. M. Ames, R. J. Gilbertson, T. M. Horton, A. M. Ingle, B. Weigel, S. Blaney, Children’s Oncology Group Brd. 43E Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. (Abstract #9580) A. C. Dietz, S. Sivanandam, C. Kaufman, A. Kelly, J. P. Neglia, P. R. Gaillard, D. A. Mulrooney Brd. 43F School attendance in childhood cancer survivors. (Abstract #9581) A. E. French, E. Tsangaris, S. Guger, M. Barrera, R. Brown, S. Urbach, D. Stephens, P. C. Nathan SUNDAY 244 Sunday, June 5, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Sarcoma Brd. 44A Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study. (Abstract #10034) J. Blay, S. P. Chawla, J. Martin Broto, E. Choy, M. Dominkus, J. Engellau, R. Grimer, R. M. Henshaw, E. Palmerini, P. Reichardt, P. Rutkowski, K. M. Skubitz, D. M. Thomas, Y. Zhao, Y. Qian, I. A. Jacobs Brd. 44B A novel combined radiologic method for evaluation of the response to chemotherapy for primary bone sarcoma. (Abstract #10035) S. Miwa, T. Shirai, J. Taki, N. Yamamoto, H. Nishida, K. Hayashi, H. Kimura, A. Takeuchi, K. Igarashi, H. Tsuchiya Brd. 44C Primary osteosarcomas of the mandible: Joint study of the Groupe Sarcome Francais (GSF), Rare Cancer Network, and Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). (Abstract #10036) J. Thariat, I. Ray-Coquard, A. Thyss, A. Italiano, J. Sarini, R. C. Miller, E. Bompas, A. Brouchet, O. Dassonville, S. Salas, P. Maingon, J. Kurtz, H. Reychler, T. de La Motte Rouge, K. Aldabbagh, J. Usseglio, P. Kerbrat, J. Lotz, L. Chaigneau, M. Julieron, Groupe Sarcome Francais-Groupe d’Etude des Tumeurs Ossseuses (GSF-GETO), Rare Cancer Network, Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC) Brd. 44D Effects of denosumab on pain reduction in giant cell tumor of bone (GCTB): Interim phase II study results. (Abstract #10037) C. S. Cleeland, A. P. Staddon, S. Schuetze, A. Powell, A. Lopez Pousa, A. Cioffi, J. R. Kroep, S. Stacchiotti, K. Chung, C. Atchison, Y. Qian, Y. Zhao, I. A. Jacobs Brd. 44E Functional characterization of IGFBP5 in the inhibition of osteosarcoma tumorgenicity. (Abstract #10038) G. Luther, E. Wagner, H. Luu, R. Haydon, T. He Brd. 44F Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 patients. (Abstract #10039) E. Palmerini, N. Fabbri, E. L. Staals, E. Marchesi, M. Alberghini, A. Tienghi, F. Fagioli, P. Picci, M. Mercuri, S. Ferrari Brd. 44G Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cell for patients with osteosarcoma with bone metastasis. (Abstract #10040) B. Massimo, G. Grignani, A. Giostra, M. Pagano, S. Ferrari, B. Elia, F. Carnevale-Scianca, M. Aglietta, R. Pellerito, F. Fagioli Brd. 44H Clinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-year single institution experience. (Abstract #10041) S. I. Robinson, S. K. Ahmed, N. N. Laack, P. S. Rose, S. H. Okuno Brd. 45A High-dose chemotherapy plus autologous stem cell transplation (HDCT/ SCT) in patients with sarcoma: A single institution experience. (Abstract #10042) A. Stradella, A. Lopez-Pousa, M. Quintana, P. Murata, M. Ortin, O. Gallego, I. Sullivan, L. Robert, A. Sebio, I. Gracia, J. De Vega, A. Barnadas Brd. 45B Prevalence of hereditary GIST susceptibility in adults with GIST. (Abstract #10043) I. R. Rainville, E. J. Root, M. Salerno, L. DiGianni, D. A. Nelson, C. L. Corless, M. C. Heinrich, M. E. Robson, J. E. Garber 245 SUNDAY Location: Hall A Track(s): Sarcoma Sunday, June 5, 2011 SUNDAY Brd. 45C Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. (Abstract #10044) A. Italiano, A. Cioffi, R. G. Maki, P. Schoffski, P. Rutkowski, A. Le Cesne, F. Duffaud, A. Adenis, N. Isambert, E. Bompas, J. Blay, P. G. Casali, P. Coco, D. R. D’Adamo, M. Keohan, M. Toulmonde, C. Antonescu, M. Debiec-Rychter, J. Coindre, B. Bui Nguyen Brd. 45D Identification of SDHA (subunit A of the succinate dehydrogenase) mutations in KIT/PDGFRA WT gastrointestinal stromal tumors (GISTs). (Abstract #10045) M. A. Pantaleo, A. Astolfi, V. Indio, P. Paterini, S. Formica, R. Casadio, P. Martelli, A. Maleddu, M. Nannini, A. P. Dei Tos, M. C. Heinrich, D. Santini, F. Catena, C. Ceccarelli, M. Fiorentino, M. di Battista, R. Moore, N. Thiessen, C. Gnocchi, G. Biasco Brd. 45E Identification of single nucleotide variants in gastrointestinal stromal tumor KIT/PDGFRA wild-type (WT GISTs) by massively parallel sequencing. (Abstract #10046) V. Indio, M. A. Pantaleo, A. Astolfi, R. Casadio, P. Paterini, S. Formica, P. Martelli, R. Moore, N. Thiessen, M. di Battista, F. Catena, D. Santini, M. C. Heinrich, C. Gnocchi, A. P. Dei Tos, G. Biasco Brd. 45F KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. (Abstract #10047) J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero, Spanish Group for Sarcoma Research (GEIS) Brd. 45G Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (Abstract #10048) A. Blesius, P. A. Cassier, I. Ray-Coquard, A. Italiano, A. Adenis, M. Rios, F. Bertucci, T. Huynh, D. Cupissol, Y. Berge, E. Bompas, J. Emile, S. Chabaud, D. Perol, A. Le Cesne Brd. 45H Mechanism of early radiographic response to imatinib in GIST. (Abstract #10049) J. Gao, J. C. McAuliffe, A. J. Lazar, W. Wang, H. Choi, K. Hunt, D. M. Araujo, R. E. Pollock, R. S. Benjamin, J. C. Trent Brd. 46A Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). (Abstract #10050) A. D. Van Den Abbeele, Y. Tanaka, T. Locascio, C. Sakellis, M. C. Heinrich, M. von Mehren, E. Choy, W. D. Tap, J. Manola, G. D. Demetri, S. George, J. T. Yap Brd. 46B FDG-PET as a predicitve marker for primary resistance to imatinib (IM) in patients with gastrointestinal stromal tumors (GIST) (Abstract #10051) S. Oosting, M. W. Den Hollander, B. Rikhof, D. B. Rouw, J. R. De Jong, P. L. Jager, A. H. Brouwers, W. Van Der Graaf, E. De Vries, J. A. Gietema, A. K. Reyners Brd. 46C Outcome of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched cohort study. (Abstract #10052) H. T. Hatoum, J. C. Trent, A. Guo, S. Lin, L. A. Sirulnik, M. Sasane Brd. 46D Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts). (Abstract #10053) F. Duffaud, I. Ray-Coquard, A. Blesius, T. Huynh, E. Boucher, O. Bouche, J. Bay, F. Marchal, J. Spano, F. Bertucci, B. Bui Nguyen, O. Collard, L. Chaigneau, N. Isambert, A. Adenis, J. Mancini, A. Le Cesne, J. Blay, French Sarcoma Group (GSF-GETO) 246 Brd. 46E Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (Abstract #10054) J. Domont, J. Blay, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci, F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, V. Bourne-Branchu, S. Chabaud, A. Le Cesne Brd. 46F Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. (Abstract #10055) J. Rubió, J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra, A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan, I. Sevilla, R. Andres, J. Cruz, M. Safont, J. Martin Broto, X. Garcia-Albeniz, J. Maurel Brd. 46G MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype. (Abstract #10056) S. Formica, A. Astolfi, M. Nannini, M. A. Pantaleo, M. Ferracin, B. Zagatti, M. Negrini, D. Santini, P. Paterini, M. di Battista, A. Maleddu, M. Saponara, M. Pallotti, A. Mandrioli, C. Lolli, F. Catena, A. P. Dei Tos, G. Biasco Brd. 46H Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132. (Abstract #10057) D. Wang, Q. Zhang, C. D. Blanke, G. D. Demetri, M. C. Heinrich, J. C. Watson, J. P. Hoffman, S. H. Okuno, J. M. Kane, M. vonMehren, B. L. Eisenberg Brd. 47A Exploring the relation between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) via meta-analysis. (Abstract #10058) R. L. Keyser, K. E. Tranbarger Freier, D. C. Hoaglin, S. Tzivelekis, D. Muston, I. Ozer-Stillman Brd. 47B Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM). (Abstract #10059) G. Schiavon, A. Ruggiero, S. Sleijfer, K. Eechoute, G. P. Krestin, J. Verweij, R. Mathijssen Brd. 47C Validating innovation: A population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib. (Abstract #10060) D. Goldstein, C. Lee, E. Tracey, C. Cook-Yarborough, S. Lord Brd. 47D Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC). (Abstract #10061) D. Galizia, C. Ortega, E. Palesandro, V. Prati, S. Gallo, L. D’Ambrosio, A. Bonzano, D. Rota Scalabrini, S. Aliberti, G. Grignani, M. Aglietta Brd. 47E Study of dynamic contrast-enhanced ultrasound (DCE-US) for the early evaluation of imatinib. (Abstract #10062) G. Abboud, N. Lassau, S. Koscielny, B. Benatsou, F. Tabarout, L. Chami, E. Girard, S. Bidault, J. Domont, A. Cioffi, S. Bonvalot, A. Le Cesne Brd. 47F Imatinib efficacy by tumor genotype in Asian patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs): A retrospective study of Korean GIST Study Group (KGSG). (Abstract #10063) H. Kang, M. Ryu, K. Kim, Y. Park, W. Kim, S. Im, S. Park, K. Lee, H. Song, Y. Kang Brd. 47G A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas. (Abstract #10064) S. N. Dumont, J. C. Trent, S. Patel, D. M. Araujo, A. G. Dumont, R. S. Benjamin 247 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 SUNDAY Brd. 47H High rates of histopathologic discordance in sarcoma with implications for clinical care. (Abstract #10065) C. P. Raut, S. George, J. L. Hornick, J. E. Butrynski, J. A. Morgan, J. Ready, A. F. Nascimento, C. D. Fletcher, G. D. Demetri, E. H. Baldini Brd. 48A Differences between neurofibromatosis-1-associated malignant peripheral nerve sheath tumors (MPNST) and sporadic MPNST: The Mayo Clinic experience. (Abstract #10066) K. N. Johnson, C. H. Stucky, B. A. Pockaj, R. J. Gray, P. S. Rose, N. Wasif Brd. 48B Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) in endemic or classic Kaposi’s sarcoma (C06 – 46). (Abstract #10067) R. Porcher, D. Kerob, N. Dupin, B. Guillot, T. Jouary, A. Mathieu-Boue, K. Slimane, V. Furlan, M. Battistella, F. Agbalika, S. Mourah, C. Lebbé Brd. 48C Effect of Notch3 to regulate rhabdomyosarcoma growth in vitro and in vivo. (Abstract #10068) R. Rota, L. Raimondi, R. Ciarapica, F. Verginelli, M. Gueguen, R. Boldrini, L. De Sio, A. Inserra, M. Locatelli, T. Dang, L. Miele, S. Stifani, I. Limon, F. Locatelli Brd. 48D Quantitative analysis of IGF-1R expression in FFPE human rhabdomyosarcoma tumor tissue by mass spectrometry. (Abstract #10069) S. Malempati, T. A. Hembrough, S. Thyparambil, L. Cao, M. Darfler, D. Krizman, D. S. Hawkins, S. Skapek, L. J. Helman, J. Burrows Brd. 48E Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO). (Abstract #10070) E. Bompas, L. Campion, A. Italiano, A. l. Cesne, M. Giaj Levra, C. Chevreau, S. Piperno-Neumann, N. Isambert, A. Thyss, M. Rios, J. Kurtz, C. Delcambre, J. Bay, F. Duffaud, M. Trassard, P. Soulie, J. Blay Brd. 48F Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. (Abstract #10071) M. Toulmonde, A. Italiano, N. Penel, A. Cioffi, A. Le Cesne, N. Isambert, E. Bompas, F. Duffaud, A. Patrikidou, R. G. Maki, J. Coindre, J. Blay, B. Bui Nguyen Brd. 48G A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial. (Abstract #10072) A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. Blay Brd. 48H A phase I dose-escalation study of azacitidine in combination with temozolomide in patients with soft tissue sarcomas. (Abstract #10073) I. Matushansky, K. E. Coakley, T. S. Uldrick, R. N. Taub Brd. 49A Expression of MGMT and response to treatment with temozolomide in patients with leiomyosarcoma. (Abstract #10074) A. Marrari, J. L. Hornick, N. H. Ramaiya, J. Manola, A. J. Wagner Brd. 49B A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. (Abstract #10075) S. Attia, M. R. Mahoney, S. H. Okuno, D. Adkins, H. G. Ahuja, T. P. Ducker, W. J. Maples, L. Ochs, N. L. Wentworth-Hartung, C. Erlichman, H. H. Bailey Brd. 49C A phase II trial evaluating efficacy of neo-/adjuvant EIA CTX, surgery, and radiation therapy in high-risk soft tissue sarcoma. (Abstract #10076) T. Schmitt, B. Kasper, M. Bischof, B. Lehner, S. Dietrich, A. DimitrakopoulouStrauss, L. G. Strauss, G. Mechtersheimer, P. Wuchter, A. D. Ho, G. Egerer Brd. 49D Growth factor receptors and cell cycle proteins as new molecular prognosis markers in high-grade undifferentiated pleomorphic sarcoma (HGUPS). (Abstract #10077) C. Serrano, S. Simonetti, C. M. Valverde, R. Morales, C. Suarez, T. Moline, J. Carles, S. Ramon y Cajal, C. Romagosa 248 Brd. 49E Adjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) and doxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG030404. (Abstract #10078) K. Tanaka, J. Mizusawa, H. Fukuda, N. Araki, H. Chuuman, M. Takahashi, T. Ozaki, T. Hiruma, H. Tsuchiya, H. Morioka, T. Morita, T. Wada, M. Hatori, Y. Yoshida, J. Toguchida, S. Abe, A. Matsumine, R. Yokoyama, Y. Iwamoto Brd. 49F Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. (Abstract #10079) A. Cioffi, A. Italiano, N. Penel, Y. Berge, M. Toulmonde, S. Salas, C. Chevreau, A. Le Cesne, F. Duffaud, D. R. D’Adamo, M. Keohan, C. Genebes, C. Antonescu, J. Coindre, B. Bui Nguyen, R. G. Maki Brd. 49G Effect of the combination of mTOR inhibitor ridaforolimus and HDAC inhibitor vorinostat on in vitro synergism in synovial sarcoma, osteosarcoma, and a range of other tumor subtypes. (Abstract #10080) S. S. Morgan, L. D. Cranmer Brd. 49H Identification of potential molecular candidate lesions by molecular analysis of desmoid tumors with QRT-PCR and high-density SNP arrays. (Abstract #10081) P. Erben, D. Nowak, W. Hofmann, R. Hofheinz, P. Hohenberger, B. Kasper Brd. 50A Heterogeneity of metastatic behavior among high-grade pleomorphic soft tissue sarcomas identified by gene expression analysis. (Abstract #10082) K. M. Skubitz, P. Francis, A. Skubitz, X. Luo, M. Nilbert Brd. 50B Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI). (Abstract #10083) Y. Kojima, K. Hashimoto, M. Ando, K. Yonemori, H. Yamamoto, M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. Fujiwara Brd. 50C Topoisomerase-based chemotherapy in adults with relapsed or refractory pediatric-type sarcoma: A retrospective analysis of the German AIO Sarcoma Group/BMBF SAREZ registry. (Abstract #10084) J. T. Hartmann, I. Sturm, R. D. Issels, S. W. Krause, V. Gruenwald, A. Kunitz, L. Lindner, K. San Nicolo, F. Mayer, B. Hertenstein, L. Mueller, U. Kontny, J. Topaly, R. U. Trappe, W. Grothe Brd. 50D Metastatic angiosarcomas (mAS): Identification of treatments that significantly improve the outcome. (Abstract #10085) E. Amela, A. Italiano, I. Ray-Coquard, L. Chaigneau, C. Delcambre, B. Bui Nguyen, F. Bertucci, N. Isambert, D. Cupissol, E. Bompas, J. Bay, F. Duffaud, C. Guillemet, N. Corradini, P. A. Cassier, C. Chevreau, J. Blay, N. Penel, French Sarcoma Group (GSF/GETO) Brd. 50E Predictive role of topoisomerase II␣, gp170, Bcl-2, tumor burden, and histology in neoadjuvant chemotherapy for soft tissue sarcomas of the extremities. (Abstract #10086) A. Comandone, P. Porrino, E. Berardengo, A. Linari, A. Boglione, C. Oliva, G. Gino, C. Faletti, P. Bergnolo, P. Pochettino, A. Bernardi, E. M. Brach del Prever, R. Piana Brd. 50F Creatinine clearance and serum albumin as factors for encephalopathy with ambulatory 14-day infusional ifosfamide for advanced liposarcomas. (Abstract #10087) S. M. Alam, C. Benson, R. L. Jones, E. Thanopoulou, S. Mitchell, O. Al-Muderis, A. Dunlop, C. Propert-Lewis, I. R. Judson, M. R. Scurr Brd. 50G Pulmonary metastasectomy in soft tissue sarcomas (STS): A singleinstitution experience. (Abstract #10088) M. Glogowski, L. Talarek, I. A. Lugowska, S. Falkowski, T. Switaj, M. Zmijewski, R. Wlodarczyk, H. Kosela, M. Turski, M. J. Krzakowski, P. Rutkowski 249 SUNDAY Sunday, June 5, 2011 Sunday, June 5, 2011 Histology and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). (Abstract #10089) P. G. Casali, S. Stacchiotti, P. Verderio, P. Collini, A. P. Dei Tos, M. Alberghini, A. Llombart-Bosch, C. Morosi, A. Messina, M. Mercuri, A. Gronchi Brd. 51A Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. (Abstract #10090) N. Penel, M. M. Van Glabbeke, B. Bui Nguyen, M. Ouali, S. Mathoulin-Pelissier, S. Marreaud, A. Italiano, V. Brouste, P. C. Hogendoorn, J. Coindre, J. Blay, P. Hohenberger Brd. 51B Mucocutaneous angiosarcoma (MC-AS) versus non-MC-AS: Clinicopathologic features and treatment outcomes in 44 patients (pts). (Abstract #10091) R. H. Quek, M. R. Harunal Rashid, W. Ong, M. J. Lee, R. Jeevan, Z. Ho, F. Chin, L. Soh, D. Poon, M. Teo Brd. 51C Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy. (Abstract #10092) K. Harano, Y. Kojima, K. Hashimoto, M. Ando, A. Hirakawa, K. Yonemori, M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. Fujiwara Brd. 51D Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG). (Abstract #10093) N. Isambert, I. Ray-Coquard, B. Bui Nguyen, M. Rios, P. Kerbrat, A. Blouet, L. Chaigneau, F. Duffaud, S. Piperno-Neumann, J. Kurtz, J. Thariat, N. Girard, O. Collard, E. Bompas, N. Penel, J. Bay, C. Guillemet, F. Collin, J. Blay, A. Le Cesne Brd. 51E Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). (Abstract #10094) U. Bitz, D. Pink, C. Busemann, P. Reichardt Brd. 51F Prognostic factors in leiomyosarcoma (LMS): Does primary site influence outcome? (Abstract #10095) M. R. Harunal Rashid, W. Ong, M. Teo, M. Tan, L. Foo, Y. Lim, F. Chin, M. J. Lee, Z. Ho, R. Jeevan, J. W. Chia, L. Soh, D. Poon, R. H. Quek Brd. 51G The role of E-cadherin expression in response and outcome in patients with leiomyosarcoma treated with chemotherapy. (Abstract #10096) V. Ravi, J. Yang, D. M. Araujo, M. S. Park, R. S. Benjamin, W. Zhang, J. C. Trent, S. Patel Brd. 51H The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous tumor. (Abstract #10097) M. S. Park, S. Patel, V. Ravi, A. P. Conley, J. C. Trent, A. J. Lazar, D. Lev, X. Wang, R. S. Benjamin, D. M. Araujo Brd. 52A Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation of preoperative therapy for extremity soft tissue sarcomas (STS). (Abstract #10098) J. M. Meyer, K. S. Perlewitz, S. L. Hemmingson, J. B. Hayden, A. Hung, A. Mansoor, M. L. Holtorf, W. J. Woodward, C. S. Springer, W. Huang, C. W. Ryan SUNDAY Brd. 50H 250 Sunday, June 5, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Patient and Survivor Care Display Time: 8:00 AM - 12:00 PM Display Location: S102 Discussion Time: 11:30 AM - 12:30 PM Discussion Location: S100bc CME credit: 1 Track(s): Patient and Survivor Care Thomas J. Smith, MD—Chair Massey Cancer Center of Virginia Commonwealth University Discussion 11:30 AM James Lloyd Wade, MD (Abstracts #9017–9022) Cancer Care Specialists of Central Illinois Discussion 11:45 AM Pamela Jean Goodwin, MD (Abstracts #9023–9029) Mount Sinai Hospital Discussion 12:00 PM Patricia A. Ganz, MD (Abstracts #9030 –9035) University of California, Los Angeles Schools of Medicine and Public Health SUNDAY Discussion 12:15 PM Teresa Gilewski, MD (Abstracts #9036 –9041) Memorial Sloan-Kettering Cancer Center Brd. 1 Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: A pilot study. (Abstract #9017) F. M. Cruz, A. Del Giglio, D. d. Cubero, P. Taranto, T. Lerner, A. T. Lera, M. C. Miranda, M. C. Vieira, A. B. Fede, F. Schindler, S. O. Afonseca, H. Pinczowski Brd. 2 Antiemetic choice based on economic advantage. (Abstract #9018) E. Z. Touloukian, A. Yakan, R. E. Bloom Brd. 3 Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting. (Abstract #9019) P. J. Hesketh, V. Moiseyenko, G. Rosati, A. Makhson, J. Levin, M. W. Russo Brd. 4 A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. (Abstract #9020) J. L. Vardy, G. R. Pond, A. Dodd, D. Warr, B. Seruga, M. J. Clemons, L. Bordeleau, I. Tannock Brd. 5 Testing the cutaneous absorption of lorazepam, diphenhydramine, and haloperidol gel (ABH gel) used for cancer-related nausea. (Abstract #9021) T. J. Smith, J. K. Ritter, P. J. Coyne, G. L. Parker, P. Dodson, D. S. Fletcher Brd. 6 Effect of GTx-024, a selective androgen receptor modulator (SARM), on physical function in patients with non-small cell lung cancer (NSCLC) with cancer cachexia. (Abstract #9022) M. S. Steiner, A. Dobs, M. L. Hancock, M. A. Johnston, G. Barnette, S. Dodson Brd. 7 Buspirone treatment of dyspnea in outpatients receiving chemotherapy: A University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP) study. (Abstract #9023) P. W. Bushunow, J. A. Roscoe, D. J. Dudgeon, J. J. Kirshner, C. E. Heckler, G. R. Morrow, S. R. Dakhil, T. S. Collins, D. A. Churchill, University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP) 251 Sunday, June 5, 2011 SUNDAY Brd. 8 Mortality reduction by talactoferrin alfa (TLF) in severe sepsis with different types of infections. (Abstract #9024) J. Crawford, K. K. Guntupalli, N. C. Dean, P. E. Morris, R. K. Malik, J. P. Schaumberg Brd. 9 Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). (Abstract #9025) J. A. Carter, S. J. Snedecor, S. Kaura, M. Botteman Brd. 10 Vitamin D repletion and prevention of bone loss in nonosteoporotic women with breast cancer. (Abstract #9026) S. Servitja, D. Prieto-Alhambra, M. Martinez-Garcia, L. Garrigos, M. J. Pena, A. Diez-Perez, J. Albanell, X. Nogues, I. Tusquets Brd. 11 Phase III randomized, double-blind, placebo-controlled trial of soy protein and venlafaxine for treatment of hot flashes in men with prostate cancer. (Abstract #9027) M. Vitolins, L. Griffin, W. V. Tomlinson, J. Vuky, D. B. Fried, P. T. Adams, D. Moose, B. Frizzell, J. E. Radford, T. Shah, E. G. Shaw Brd. 12 Final results of a randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed-dose pregabalin for the treatment of oncologic neuropathic pain (NEUROPAIN-01). (Abstract #9028) M. C. Garassino, A. Bianchi, A. Febbraro, I. Spagnoletti, V. Iorno, A. Bramati, C. Carbone, L. Isa, E. Breda, R. Magarotto, V. Torri, G. Farina Brd. 13 Acupuncture for chemotherapy-induced fatigue: A randomized controlled trial. (Abstract #9029) G. E. Deng, Y. Chan, K. Yeung, A. J. Vickers, B. R. Cassileth Brd. 14 Long-term protective effects of the angiotensin-receptor blocker telmisartan on epirubucin-induced inflammation, oxidative stress, and myocardial dysfunction. (Abstract #9030) G. Mantovani, C. Madeddu, M. Dessı̀, E. Massa, G. Antoni, A. Piras, C. Cadeddu, M. Deidda, G. Mercuro Brd. 15 The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. (Abstract #9031) D. P. Steensma, B. J. Sasu, J. A. Sloan, D. Tomita, C. L. Loprinzi Brd. 16 Role of hypoalbuminemia in the development of venous thromboembolism in cancer chemotherapy patients. (Abstract #9032) Z. Li, W. B. Webb III, J. Mao, S. Gautam, S. Singh, G. H. Lyman Brd. 17 Molecular diagnosis of bacteriemia in patients with neutropenic febrile oncohematologic. (Abstract #9033) E. Gimeno, L. Sorli, E. Abella, A. Alvarez-Larran, J. Horcajada, L. Garrigos, A. Taus, A. Salar, B. Sanchez, C. Pedro, C. Besses, M. Salvado Brd. 18 Effect of YOCAS yoga on circadian rhythm, anxiety, and mood: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors. (Abstract #9034) K. M. Mustian, L. Sprod, L. J. Peppone, S. G. Mohile, M. C. Janelsins, O. Palesh, K. Devine, P. S. Reddy, M. Melnik, J. K. Giguere, G. R. Morrow Brd. 19 Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in patients with cancer: A randomized controlled trial. (Abstract #9035) B. Oh, P. Butow, N. Pavlakis, P. J. Beale, S. J. Clarke, D. S. Rosenthal, L. Larkey, J. L. Vardy Brd. 20 Exercise and side effects among 417 older patients with cancer during and after cancer treatment: A URCC CCOP study. (Abstract #9036) L. Sprod, S. G. Mohile, K. Devine, M. C. Janelsins, L. J. Peppone, G. R. Morrow, R. S. Lord, H. M. Gross, K. M. Mustian 252 Sunday, June 5, 2011 Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes. (Abstract #9037) A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, H. D. Klepin, C. P. Gross, S. M. Lichtman, R. Ramani, J. Brown, V. Katheria, R. Jayani, K. Hansen, K. Togawa, S. Klapper, A. Hurria, Cancer and Aging Research Group Brd. 22 Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9038) K. E. Kinahan, L. K. Sharp, A. Didwania, K. Seidel, W. Leisenring, M. E. Lacouture, M. Stovall, L. L. Robison, K. R. Krull Brd. 23 Disability pension among patients with breast cancer: A Norwegian population-based controlled study. (Abstract #9039) B. Hauglann, J. Šaltytë Benth, S. D. Fossa, A. A. Dahl Brd. 24 What leads to better quality of life at the end of life? (Abstract #9040) M. E. Nilsson, B. Zhang, E. Reitschuler-Cross, A. A. Wright, X. Gao, J. S. Temel, T. A. Balboni, H. G. Prigerson Brd. 25 Do the preferences of patients with terminal cancer or their family caregivers and end-of-life care discussions influence utilization of hospice-palliative care? (Abstract #9041) A. An, Y. Yun, W. Lee, K. Jung, Y. Do, S. Kim, D. S. Heo, J. Choi, S. Park, H. Jeong, J. Kang, J. Ro SUNDAY Brd. 21 253 Sunday, June 5, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Pediatric Oncology Display Time: 8:00 AM - 12:00 PM Display Location: Hall A Discussion Time: 11:30 AM - 12:30 PM Discussion Location: S504 CME credit: 1 Track(s): Pediatric Oncology Birgit Geoerger, MD, PhD—Chair Institut Gustave Roussy Discussion 11:30 AM Julia Lynne Glade Bender, MD (Abstracts #9520 –9523) Columbia University Discussion 11:45 AM Paul Graham Fisher, MD (Abstract #9524) Stanford Cancer Center Discussion 12:00 PM William D. Tap, MD (Abstracts #9526 –9531) University of California, Los Angeles SUNDAY Discussion 12:15 PM Lillian Sung, MD, PhD (Abstracts #9532–9535) The Hospital for Sick Children Brd. 36A A phase I trial of IMC-A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group Study. (Abstract #9520) M. Fouladi, J. P. Perentesis, L. M. Wagner, A. M. Ingle, J. Gammon, G. Thomas, D. A. Krueger, P. Houghton, S. Vinks, B. Weigel, S. Blaney Brd. 36B Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia. (Abstract #9521) P. Kearns, N. J. Graham, M. Cummins, B. Gibson, J. D. Grainger, R. Keenan, D. Lancaster, G. Shenton, J. Vormoor, D. Webb, I. Hawley, P. J. Johnson Brd. 36C A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children’s Oncology Group study. (Abstract #9522) J. A. Muscal, P. A. Thompson, T. M. Horton, A. M. Ingle, C. H. Ahern, R. M. McGovern, J. M. Reid, M. M. Ames, B. Weigel, S. Blaney Brd. 36D A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: Early-phase evaluation. (Abstract #9523) F. Navid, R. C. Barfield, R. Handgretinger, P. M. Sondel, B. L. Shulkin, R. Kaufman, C. Billups, J. Wu, W. L. Furman, L. M. McGregor, M. Otto, S. Gillies, V. M. Santana Brd. 36E Vinorelbine in progressive unresectable low-grade glioma in children. (Abstract #9524) A. M. Cappellano, E. Bouffet, F. Silva, P. Paiva, M. d. Alves, S. Cavalheiro, N. S. Silva Brd. 36G Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma family of tumors: A Children’s Oncology Group trial. (Abstract #9526) L. Mascarenhas, J. L. Felgenhauer, M. C. Bond, J. D. Femino, N. N. Laack, S. Ranganathan, M. D. Krailo, N. Marina, Children’s Oncology Group Brd. 36H The management of pulmonary nodules at diagnosis in patients with Ewing sarcoma (ES). (Abstract #9527) C. Owens, M. Le Deley, J. M. Michon, I. Marzouk, E. Thebault, P. Marec Bérard, O. Oberlin 254 Sunday, June 5, 2011 Proposal of a prognostic score system for the Brazilian Osteosarcoma Treatment Group (BOTG) patients. (Abstract #9528) M. Cypriano, A. Ferraro, C. M. Costa, V. Odone, D. Lustosa, M. Borsato, A. L. Brunetto, L. Calheiros, J. Barreto, S. Epelman, E. Carvalho, W. V. Pereira, E. M. Pontes, R. J. Garcia Filho, M. d. Alves, C. R. Macedo, O. P. de Camargo, P. Pericles, V. Penna, A. S. Petrilli, Sociedade Brasileira de Oncologia Pediatrica (SOBOPE) Brd. 37B Parameningeal rhabdomyosarcoma: Results of a pooled analysis from U.S. and European Cooperative Groups. (Abstract #9529) J. H. Merks, G. De Salvo, C. Bergeron, G. Bisogno, A. Rey, O. Oberlin, A. Kelsey, I. Zanetti, J. M. Michalski, D. S. Hawkins, J. R. Anderson Brd. 37C Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma. (Abstract #9530) J. C. van Gaal, U. E. Flucke, M. H. Roeffen, E. S. de Bont, A. J. Suurmeijer, W. Van Der Graaf, Y. M. Versleijen-Jonkers Brd. 37D Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited for T-cell-based immunotherapy of pediatric sarcomas? (Abstract #9531) S. Ramakrishna, S. Gottschalk, R. Morgan, G. Dotti, M. K. Brenner, R. Orentas, C. Mackall Brd. 37E Performance-based physical function in long-term survivors of Hodgkin lymphoma. (Abstract #9532) K. K. Ness, M. Metzger, T. T. Huang, G. T. Armstrong, L. L. Robison, M. M. Hudson Brd. 37F Risk factors for clostridium difficile infection in children with malignancy. (Abstract #9533) P. M. De Blank, T. Zaoutis, B. Fisher, A. B. Troxel, J. Kim, R. Aplenc Brd. 37G L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol. (Abstract #9534) P. V. Plourde, S. Jeha, L. B. Silverman, J. B. Nachman, S. R. Rheingold, G. V. Dahl, E. A. Raetz, T. Mercedes, T. Corn Brd. 37H Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. (Abstract #9535) H. Schroeder, S. Nadaraja, S. Rosthoej, P. S. Wehner, H. Thomassen SUNDAY Brd. 37A 255 Sunday, June 5, 2011 9:00 AM - 12:00 PM ORAL ABSTRACT SESSION Breast Cancer—HER2/ER Location: Hall B1 CME credit: 3 Track(s): Breast Cancer Harold J. Burstein, MD, PhD—Co-Chair Dana-Farber Cancer Institute Rebecca Alexandra Dent, MD—Co-Chair Sunnybrook Health Sciences Centre 9:00 AM Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized placebo-controlled clinical trial. (Abstract #LBA504) P. E. Goss, J. N. Ingle, J. Ales-Martinez, A. Cheung, R. T. Chlebowski, J. Wactawski-Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, E. Winquist, G. Sarto, J. E. Garber, C. J. Fabian, P. Pujol, E. Maunsell, P. Farmer, K. A. Gelmon, D. Tu, H. Richardson Discussion 9:15 AM Andrea Decensi, MD (Abstract #LBA504) Ente Ospedaliero Ospedali Galliera SUNDAY 9:30 AM TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. (Abstract #505) J. C. Chang, I. A. Mayer, A. Forero-Torres, R. Nanda, M. P. Goetz, A. A. Rodriguez, A. C. Pavlick, T. Wang, S. G. Hilsenbeck, C. Gutierrez, R. Schiff, C. K. Osborne, M. F. Rimawi, on behalf of the Translational Breast Cancer Research Consortium 9:45 AM Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined, prior to neoadjuvant breast cancer chemotherapy. (Abstract #506) F. A. Holmes, Y. M. Nagarwala, V. A. Espina, L. A. Liotta, M. A. Danso, R. I. Gallagher, K. McIntyre, C. R. Osborne, J. M. Mahoney, A. M. Florance, T. C. Anderson, J. O’Shaughnessy 10:00 AM Final results of a phase II randomized trial of neoadjuvant anthracyclinetaxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). (Abstract #507) V. Guarneri, A. Frassoldati, A. Bottini, D. G. Generali, K. Cagossi, F. Artioli, G. Bisagni, C. Boni, A. Ravaioli, D. Amadori, A. Musolino, L. Cavanna, M. Untch, L. Orlando, G. Giardina, F. Piacentini, E. Tagliafico, M. Bagnalasta, R. D’Amico, P. F. Conte Discussion 10:15 AM Gunter Von Minckwitz, MD, PhD (Abstracts #505–507) German Breast Group 10:30 AM A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and nonamplified metastatic breast cancer. (Abstract #508) F. Andre, T. D. Bachelot, M. Campone, F. Dalenc, J. M. Perez-Garcia, S. A. Hurvitz, N. C. Turner, H. S. Rugo, M. M. Shi, Y. Zhang, A. C. Kay, A. J. Yovine, J. Baselga 10:45 AM LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (ⴙ) metastatic breast cancer (MBC) before whole brain radiotherapy (WBR). (Abstract #509) T. D. Bachelot, G. Romieu, M. Campone, V. Dieras, C. Cropet, H. H. Roche, M. Jimenez, E. Le Rhun, J. Pierga, A. Gonçalves, M. Leheurteur, J. Domont, M. Gutierrez, H. Cure, J. Ferrero, C. Labbe 256 Sunday, June 5, 2011 Discussion 11:00 AM Nancy U. Lin, MD (Abstract #509) Dana-Farber Cancer Institute 11:15 AM Patterns and correlates of adjuvant breast cancer endocrine therapy use. (Abstract #510) T. M. Pini, J. J. Griggs, A. S. Hamilton, S. J. Katz 11:30 AM When to intervene to increase use of adjuvant hormone therapy among women with hormone-sensitive breast cancer. (Abstract #511) V. P. Quinn, J. A. Strauss, J. E. Schottinger, C. T. Cheetham, R. Haque SUNDAY Discussion 11:45 AM Dawn L. Hershman, MD, MS (Abstracts #510 –511) Columbia University Medical Center 257 Sunday, June 5, 2011 9:30 AM - 12:30 PM ORAL ABSTRACT SESSION Developmental Therapeutics—Experimental Therapeutics Location: Arie Crown Theater CME credit: 3 Track(s): Developmental Therapeutics Patricia LoRusso, DO—Co-Chair Karmanos Cancer Institute E. Gabriela Chiorean, MD—Co-Chair Indiana University Melvin and Bren Simon Cancer Center Discussion 9:30 AM Sarat Chandarlapaty, MD, PhD Memorial Sloan-Kettering Cancer Center SUNDAY 9:45 AM Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. (Abstract #3003) H. A. Burris, L. L. Siu, J. R. Infante, J. J. Wheler, C. Kurkjian, J. Opalinska, D. A. Smith, J. M. Antal, J. L. Gauvin, T. Gonzalez, L. M. Adams, P. Bedard, J. F. Gerecitano, R. Kurzrock, K. N. Moore, S. R. Morris, C. Aghajanian 10:00 AM A phase I dose escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. (Abstract #3004) A. W. Tolcher, R. D. Baird, A. Patnaik, V. Moreno Garcia, K. P. Papadopoulos, C. R. Garrett, D. Olmos, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith, J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono 10:15 AM Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. (Abstract #3005^) G. Shapiro, P. LoRusso, E. L. Kwak, J. M. Cleary, L. Musib, C. Jones, A. de Crespigny, M. Belvin, M. McKenzie, M. R. Gates, I. T. Chan, J. C. Bendell Discussion 10:30 AM Pasi A. Janne, MD, PhD (Abstracts #3003–3005∧) Dana-Farber Cancer Institute 10:45 AM First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors. (Abstract #3006^) S. O. Dolly, J. Albanell, F. Kraeber-Bodere, U. Banerji, R. Bahleda, M. Martinez Garcia, Z. X. Xu, E. Guarin, J. Tessier, E. Shochat, J. Deutsch, S. Blotner, V. Meresse, J. Soria 11:00 AM Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86 –9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. (Abstract #3007) L. Gore, K. Lewis, D. D. Von Hoff, G. J. Weiss, R. K. Ramanathan, A. A. Adjei, G. K. Dy, W. Ma, N. J. Clendeninn, D. P. Leffingwell, B. Sheedy, C. Iverson, J. N. Miner, Z. Shen, L. Yeh, R. L. Dubowy, M. Jeffers, P. Rajagopalan, C. D. Weekes Discussion 11:15 AM Patrick G. Johnston, MD, PhD (Abstracts #3006∧–3007) Queen’s University Belfast 11:30 AM 258 Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. (Abstract #3008) B. I. Sikic, S. G. Eckhardt, G. Gallant, H. A. Burris III, D. R. Camidge, A. D. Colevas, S. F. Jones, W. A. Messersmith, H. A. Wakelee, H. Li, P. G. Kaminker, S. Morris, J. R. Infante Sunday, June 5, 2011 11:45 AM Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF receptor involved in tumor angiogenesis. (Abstract #3009) L. W. Goff, R. B. Cohen, J. Berlin, C. Noberasco, H. Borghaei, C. Gallo-Stampino, E. Wang, D. Hu Lowe, W. J. Levin, F. G. De Braud 12:00 PM Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. (Abstract #3010) M. S. Gordon, N. J. Vogelzang, P. Schoffski, A. Daud, A. I. Spira, B. A. O’Keeffe, T. Rafferty, Y. Lee, R. Berger, G. Shapiro SUNDAY Discussion 12:15 PM Jaap Verweij, MD, PhD (Abstracts #3008 –3010) Erasmus University Medical Center 259 Sunday, June 5, 2011 9:30 AM - 12:30 PM ORAL ABSTRACT SESSION Lung Cancer—Metastatic/Non-small Cell Location: Hall D1 CME credit: 3 Track(s): Lung Cancer D. Ross Camidge, MD, PhD—Co-Chair University of Colorado Denver Scott Arthur Kono, DO—Co-Chair Winship Cancer Institute at Emory University SUNDAY 9:30 AM Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. (Abstract #7503) R. Rosell, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, F. Cardenal, R. Garcia Gomez, C. Pallares, J. Sanchez, R. Porta, M. Cobo, M. Di Seri, P. Garrido Lopez, A. Insa, F. De Marinis, R. Corre, M. Carreras, E. Carcereny, M. Taron, L. G. Paz-Ares, Spanish Lung Cancer Group 9:45 AM Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (Abstract #7504) M. Thomas, A. Reuss, J. R. Fischer, S. Andreas, C. Kortsik, C. Grah, M. H. Serke, M. von Eiff, C. Witt, J. Kollmeier, E. Müller, L. Müller, M. Schenk, R. Heine, D. M. Behringer, M. Schroeder, N. Reinmuth, P. Schnabel, T. Acker, M. Wolf 10:00 AM Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. (Abstract #7505) D. R. Spigel, T. J. Ervin, R. Ramlau, D. B. Daniel, J. H. Goldschmidt Jr., G. R. Blumenschein Jr., M. J. Krzakowski, G. Robinet, C. Clement-Duchene, F. Barlesi, R. Govindan, T. Patel, S. V. Orlov, M. S. Wertheim, J. Zha, A. Pandita, W. Yu, R. L. Yauch, P. H. Patel, A. C. Peterson Discussion 10:15 AM Tony Mok, MD (Abstracts #7503–7505) Prince of Wales Hospital 10:30 AM Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). (Abstract #CRA7506) M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn 10:45 AM Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. (Abstract #7507) A. T. Shaw, B. Y. Yeap, B. J. Solomon, G. J. Riely, A. J. Iafrate, G. Shapiro, D. B. Costa, M. Butaney, S. I. Ou, R. G. Maki, Y. Bang, M. Varella-Garcia, R. Salgia, K. D. Wilner, K. Kulig, P. Selaru, Y. Tang, E. L. Kwak, J. W. Clark, D. R. Camidge Discussion 11:00 AM Ramaswamy Govindan, MD (Abstracts #CRA7506 –7507) Washington University School of Medicine 260 Sunday, June 5, 2011 11:15 AM Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L. (Abstract #7509) T. Abe, A. Yokoyama, K. Takeda, Y. Ohe, S. Kudoh, Y. Ichinose, H. Okamoto, N. Yamamoto, H. Yoshioka, K. Minato, T. Sawa, Y. Iwamoto, H. Saka, J. Mizusawa, T. Shibata, S. Nakamura, M. Ando, K. Nakagawa, N. Saijo, T. Tamura 11:30 AM PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #CRA7510) L. G. Paz-Ares, F. De Marinis, M. Dediu, M. Thomas, J. Pujol, P. Bidoli, O. Molinier, T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki, A. Zimmerman, C. M. Visseren Grul, C. Gridelli 11:45 AM Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). (Abstract #LBA7511) L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu, L. Yun-Peng, M. Wang, and X. Zhang SUNDAY Discussion 12:00 PM Martin J. Edelman, MD (Abstracts #7509 –LBA7511) University of Maryland Greenebaum Cancer Center 261 Sunday, June 5, 2011 9:30 AM - 12:30 PM ORAL ABSTRACT SESSION Myeloma Location: E354a CME credit: 3 Track(s): Lymphoma and Plasma Cell Disorders Andrzej J. Jakubowiak, MD, PhD—Co-Chair University of Michigan Taimur Sher, MBBS—Co-Chair Roswell Park Cancer Institute SUNDAY 9:30 AM Incidence of second primary malignancy (SPM) in melphalan-prednisonelenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. (Abstract #8007) A. P. Palumbo, M. Delforge, J. Catalano, R. Hajek, M. Kropff, M. Petrucci, Z. Yu, J. M. Mei, M. A. Dimopoulos 9:45 AM Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). (Abstract #8008) A. C. Rossi, T. M. Mark, D. Jayabalan, P. J. Christos, F. Zafar, K. Pekle, T. Shore, R. N. Pearse, J. Leonard, S. Chen-Kiang, M. Coleman, R. Niesvizky 10:00 AM Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. (Abstract #8009) M. A. Dimopoulos, R. Z. Orlowski, R. Niesvizky, S. Lonial, N. A. Brandenburg, D. M. Weber Discussion 10:15 AM Ola Landgren, MD, PhD (Abstracts #8007– 8009) National Cancer Institute 10:30 AM Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results. (Abstract #8010) K. Boyd, G. Morgan, F. Davies, P. Wu, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G. H. Jackson, J. A. Child 10:45 AM Are there temporal benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. (Abstract #8011) F. Davies, G. Morgan, P. Wu, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child Discussion 11:00 AM G. David Roodman, MD, PhD (Abstracts #8010 – 8011) University of Pittsburgh Medical Center 11:15 AM 262 Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. (Abstract #8012) N. S. Raje, R. J. Hohl, E. A. Faber, P. G. Richardson, A. Forero-Torres, G. J. Schiller, A. D. Cohen, S. P. Carpenter, D. Cronier, M. Pashkevich, J. Wooldridge, K. C. Anderson Sunday, June 5, 2011 11:30 AM Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56positive relapsed or relapsed/refractory multiple myeloma (MM). (Abstract #8013) J. G. Berdeja, S. Ailawadhi, S. D. Weitman, S. Zildjian, J. J. O’Leary, J. O’Keeffe, R. Guild, K. Whiteman, A. A. Chanan-Khan 11:45 AM Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study. (Abstract #8014) P. G. Richardson, P. Moreau, A. J. Jakubowiak, T. Facon, S. Jagannath, R. Vij, D. E. Reece, D. White, M. Raab, L. Benboubker, J. Rossi, C. Tsao, T. Parli, D. M. Berman, A. K. Singhal, S. Lonial SUNDAY Discussion 12:00 PM Asher Alban Akmal Chanan-Khan, MD (Abstracts #8012– 8014) Roswell Park Cancer Institute 263 Sunday, June 5, 2011 9:45 AM - 11:00 AM SPECIAL SESSION Innovation in Delivering Quality Care in Low-resource Scenarios Location: S504 CME credit: 1.25 Track(s): Health Services Research, International, Special Session Clement Adebayo Adebamowo, MD, ScD—Chair Institute of Human Virology, University of Maryland School of Medicine Challenges for Improving the Quality of Care in Low-resource Scenarios Benjamin O. Anderson, MD University of Washington Lessons from the Breast Health Global Initiative William Tierney, MD Indiana University School of Medicine Solutions for Improving Quality in Low-resource Areas: Lessons Learned from HIV SUNDAY 264 Sunday, June 5, 2011 9:45 AM - 11:00 AM EDUCATION SESSIONS Dutasteride, Fenasteride, Micronutrients, and Vitamins for Prostate Cancer Prevention: How Do We Apply What We Have Learned to the Community? Location: S100a CME credit: 1.25 Track(s): Cancer Prevention/Epidemiology, Genitourinary Cancer Ian Thompson, MD—Chair University of Texas Health Science Center at San Antonio PCPT and SELECT: The Southwest Oncology Group Experience Gerald L. Andriole, MD Washington University School of Medicine Dutasteride and Prostate Cancer Prevention Otis W. Brawley, MD American Cancer Society Translating Prostate Cancer Prevention Research to the Community: Barriers to Uptake Integration of Molecularly Targeted Therapy and Chemotherapy in the Treatment of Advanced Head and Neck Cancers SUNDAY Location: E354b CME credit: 1.25 Track(s): Head and Neck Cancer David G. Pfister, MD—Chair Memorial Sloan-Kettering Cancer Center Updates on Concomitant Chemoradiation David Raben, MD University of Colorado Denver Integration of Targeted Therapy with Radiation Athanassios Argiris, MD, PhD University of Pittsburgh Molecularly Targeted Therapy and Combinations with Chemotherapy for Recurrent/Metastatic Head and Neck Cancer Moving the Bar in Upper Gastrointestinal Malignancies: A Review of Recent Upper Gastrointestinal Phase III Studies—Clinically Meaningful or Just Statistically Positive? (eQuestions Session) Location: Hall D2 CME credit: 1.25 Track(s): Gastrointestinal (Noncolorectal) Cancer Eileen Mary O’Reilly, MD—Chair Memorial Sloan-Kettering Cancer Center Review of Recent Phase III Studies in Upper Gastrointestinal Malignancies Neal J. Meropol, MD Case Western Reserve University Health Care Economics in Relation to Upper Gastrointestinal Cancers Donna Niedzwiecki, PhD Duke University Statistical Review of the Benefit: Is It Meaningful? 265 Sunday, June 5, 2011 Weight of Evidence: Associations between Body Weight and Health Outcomes (Including Survival) in Cancer Populations Location: S406 CME credit: 1.25 Track(s): Patient and Survivor Care, Cancer Prevention/Epidemiology, General Oncology Jennifer A. Ligibel, MD—Chair Dana-Farber Cancer Institute Overview of the Current Evidence Supporting Body Weight Status, Adiposity, and Weight Loss on Cancer Outcomes Rudolf Kaaks, PhD German Cancer Research Center DKFZ Biological Mechanisms whereby Weight Status and Weight Loss Affects Cancer Progression Cheryl L. Rock, PhD University of California, San Diego Presentation of the ENERGY Trial in Terms of Rationale, Design, Methods, and Outcomes SUNDAY 266 Sunday, June 5, 2011 9:45 AM - 11:00 AM MEET THE PROFESSOR SESSION CA-125 Use in Practice: The Promise and Pitfalls (M10)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Gynecologic Cancer Robert C. Bast, MD University of Texas M. D. Anderson Cancer Center Current State and Future Use of CA-125 in the Management of Ovarian Cancer SUNDAY M. E. L. Van Der Burg, MD, PhD Erasmus University Medical Center Breaking the Addiction to CA-125 9:45 AM - 11:00 AM CLINICAL PROBLEMS IN ONCOLOGY SESSION Treatment of HIV-related Lymphomas: Integration of New Strategies to Control and Monitor HIV while Treating High-risk Lymphomas (C08)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Lymphoma and Plasma Cell Disorders Amrita Y. Krishnan, MD—Chair City of Hope Stem Cell Transplantation for Treatment of HIV-related Malignancies Steven G. Deeks, MD University of California, San Francisco School of Medicine Therapy of HIV Infection: New Antiretrovirals and Monitoring Strategies Wyndham Hopkins Wilson, MD, PhD National Cancer Institute Overview of HIV-related Lymphoma 267 Sunday, June 5, 2011 10:30 AM - 12:30 PM SPECIAL SESSION Training Program Directors Session: Talking Business—The Finances of Your Program and Teaching Interprofessional Communication Skills (Training Program Directors Only) Location: S404 CME credit: 2 Track(s): Special Session, Professional Development Thomas H. Davis, MD—Chair Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center Welcome and Introduction Walter F. Baile, MD University of Texas M. D. Anderson Cancer Center The Principles of Communication Mentoring Daniel E. Epner, MD University of Texas M. D. Anderson Cancer Center Measuring Competency in Communication Lori K. Mihalich-Levin, JD Association of American Medical Colleges Medicare Funding of Graduate Medical Education: Fundamentals and the Future SUNDAY Robert A. Wolff, MD University of Texas M. D. Anderson Cancer Center The Business of Running a Training Program: Microeconomics 268 Sunday, June 5, 2011 11:30 AM - 12:45 PM EDUCATION SESSIONS Advanced Renal Cell Cancer: Which Drug to Use and in What Way? (eQuestions Session) Location: Hall D2 CME credit: 1.25 Track(s): Genitourinary Cancer Sandy Srinivas, MD—Chair Stanford Medical Center Today’s Renal Cell Cancer Therapeutic Landscape Thomas E. Hutson, DO, PharmD Baylor Sammons Cancer Center-Texas Oncology PA Management of Unique Subsets of Patients with Renal Cell Cancer Eric Jonasch, MD University of Texas M. D. Anderson Cancer Center Sequential versus Combination Therapy: Which One Wins? Diabetes and Antidiabetic Drugs: Association with Cancer Risk and Potential for Primary and Secondary Prevention SUNDAY Location: S100a CME credit: 1.25 Track(s): Cancer Prevention/Epidemiology Pamela Jean Goodwin, MD—Chair Mount Sinai Hospital Metformin and Cancer Prevention Lorraine Lipscombe, MD University of Toronto Association of Diabetes and Cancer: Epidemiology Data Ann D. Thor, MD University of Colorado Denver Metformin: In Vivo and in Vitro Studies Is Patient and Physician Acceptance of Palliative and End-of-Life Care Socially and Culturally Determined? Location: E353 CME credit: 1.25 Track(s): Ethics, Patient and Survivor Care, Professional Development Antonella Surbone, MD, PhD—Chair New York University Variables in Patients’ and Caregivers’ Acceptance of Palliative and End-of-Life Care Guido Biasco, MD University of Bologna Cultural Dynamics in Providing Palliative Care Marjorie Kagawa-Singer, PhD, MA, MN, RN University of California, Los Angeles School of Public Health Overcoming Patients, Caregivers, and Health Professionals Cross-cultural Differences at the End of Life 269 Sunday, June 5, 2011 Melanoma: Therapeutic Decisions for the Practicing Oncologist in 2011 Location: E354b CME credit: 1.25 Track(s): Melanoma/Skin Cancers, General Oncology Antoni Ribas, MD—Chair Jonsson Comprehensive Cancer Center, University of California, Los Angeles Immunotherapeutic Options in Advanced Melanoma (IL-2, Ipilimumab, Adoptive Cell Therapy, GM-CSF) Jeffrey Alan Sosman, MD Vanderbilt University Medical Center State of Targeted Therapy and How Testing and Treatment Can Be Incorporated into the Care of Patients with Melanoma in 2011 Christopher D. Lao, MD University of Michigan When Is Cytotoxic Therapy or Palliative Therapy Indicated in the Era of Increasing Therapeutic and Clinical Trial Options SUNDAY 270 Sunday, June 5, 2011 11:30 AM - 12:45 PM MEET THE PROFESSOR SESSION Prognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid Cancer (M11)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Head and Neck Cancer SUNDAY Michael Xing, MD, PhD The Johns Hopkins University Prognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid Cancer 11:30 AM - 12:45 PM CLINICAL PROBLEMS IN ONCOLOGY SESSION Doctor, Is There Any Hope? Communicating Prognosis while Maintaining Hope at the End of Life (C09)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Professional Development, Ethics, Patient and Survivor Care Ross C. Donehower, MD—Chair Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Developing Effective Communication Strategies to Discuss Poor Prognosis Philip C. Hoffman, MD University of Chicago Medical Center Managing End-of-Life Decisions 271 Sunday, June 5, 2011 1:00 PM - 4:00 PM PLENARY SESSION Plenary Session Including Science of Oncology Award and Lecture Location: Hall B1 CME credit: 3 Track(s): Special Session, General Oncology Kathy Miller, MD—Co-Chair Indiana University Simon Cancer Center George W. Sledge Jr., MD—Co-Chair Indiana University of Simon Cancer Center 1:00 PM Robert Weinberg, PhD—Science of Oncology Award Recipient Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology The EMT and the Pathogenesis of High-grade Carcinomas 1:45 PM Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). (Abstract #LBA1) H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. E. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt SUNDAY Discussion 2:00 PM Charles D. Blanke, MD (Abstract #LBA1) University of British Columbia/British Columbia Cancer Agency 2:15 PM Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. (Abstract #2) R. L. Ladenstein, U. Poetschger, R. Luksch, P. Brock, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W. Balwierz, E. Ruud, P. Kogner, H. Schroeder, A. Forjaz De Lacerda, M. Beck Popovic, P. Bician, M. Garami, T. Trahair, A. D. Pearson, D. Valteau Couanet Discussion 2:30 PM Julie R. Park, MD (Abstract #2) Seattle Children’s Hospital 2:45 PM Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group Study AALL0232. (Abstract #3) E. C. Larsen, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh, N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood, C. L. Willman, N. J. Winick, S. Hunger, W. L. Carroll Discussion 3:00 PM Martin S. Tallman, MD (Abstract #3) Memorial Sloan-Kettering Cancer Center 3:15 PM 272 Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAFmutated melanoma. (Abstract #LBA4) P. B. Chapman, A. Hauschild, C. Robert, J. M. G. Larkin, J. B. A. G. Haanen, A. Ribas, D. Hogg, S. O’Day, P. A. Ascierto, A. Testori, P. Lorigan, R. Dummer, J. A. Sosman, C. Garbe, R. J. Lee, K. B. Nolop, B. Nelson, J. Hou, K. T. Flaherty, and G. A. McArthur Sunday, June 5, 2011 3:30 PM Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. (Abstract #LBA5) J. D. Wolchok, L. Thomas, I. N. Bondarenko, S. O’Day, J. S. Weber, C. Garbe, S. Francis, R. A. Ibrahim, A. Hoos, and C. Robert SUNDAY Discussion 3:45 PM Kim Allyson Margolin, MD (Abstracts #LBA4 –LBA5) University of Washington 273 Sunday, June 5, 2011 4:30 PM - 5:30 PM CLINICAL SCIENCE SYMPOSIUM Antiangiogenic Therapies and Biomarkers in Pediatric Cancer Location: S504 CME credit: 1 Track(s): Pediatric Oncology Steven G. DuBois, MD—Chair University of California, San Francisco SUNDAY 4:30 PM Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors. (Abstract #9500) V. M. Santana, S. D. Baker, B. McCarville, C. F. Stewart, J. Wu, C. Billups, S. L. Spunt, W. L. Furman, L. M. McGregor, S. Hu, J. C. Panetta, W. E. Reddick, A. Davidoff, W. H. Leung, F. Navid 4:45 PM Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children’s Oncology Group Phase I Consortium Trial. (Abstract #9501) J. L. Glade Bender, A. Lee, P. C. Adamson, A. M. Ingle, C. H. Ahern, B. Wu, S. Baruchel, P. J. Harris, M. M. Ames, B. Weigel, S. Blaney, Children’s Oncology Group 5:00 PM Surrogate biomarkers of antiangiogenesis in Children’s Oncology Group (COG) phase I trials. (Abstract #9502) S. Baruchel, B. Wu, R. B. Mokhtari, J. L. Glade Bender, S. G. DuBois, B. C. Widemann, J. R. Park, D. Stempak, C. H. Ahern, B. Weigel Discussion 5:15 PM Michael L. Maitland, MD, PhD (Abstracts #9500–9502) The University of Chicago 274 Sunday, June 5, 2011 4:30 PM - 6:00 PM CLINICAL SCIENCE SYMPOSIUM Geriatric Biology, Screening Tools, Dose Intensity, and Impact on Survival Location: S406 CME credit: 1.5 Track(s): Patient and Survivor Care, Geriatric Oncology Gretchen Genevieve Kimmick, MD, MS—Co-Chair Duke University Medical Center Christine Ritchie, MD, MSPH—Co-Chair University of Alabama at Birmingham 4:30 PM Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older. (Abstract #9000) E. E. Ramsdale, B. N. Polite, K. A. Bylow, H. L. Kindler, W. Dale 4:45 PM Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project. (Abstract #9001) P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Cure, H. Rousselot, G. Albrand, V. Servent, O. Saint Jean, C. Roy, S. Mathoulin-Pelissier, M. Rainfray 5:15 PM P16INK4a expression after chemotherapy in older women with early-stage breast cancer. (Abstract #9002) H. B. Muss, J. Krishnamurthy, S. M. Alston, A. C. Lacy, T. A. Jolly, G. Williams, L. A. Carey, E. C. Dees, C. K. Anders, W. J. Irvin Jr., N. E. Sharpless 5:30 PM Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo). (Abstract #9003) H. D. Klepin, A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, C. P. Gross, S. M. Lichtman, R. Ramani, V. Katheria, J. Brown, R. Jayani, K. Hansen, K. Togawa, S. Klapper, F. L. Wong, A. Hurria, on behalf of the Cancer and Aging Research Group Discussion 5:45 PM Matti S. Aapro, MD (Abstracts #9002–9003) Clinique De Genolier 275 SUNDAY Discussion 5:00 PM Gretchen Genevieve Kimmick, MD, MS (Abstract #9001) Duke University Medical Center Sunday, June 5, 2011 4:30 PM - 6:00 PM CLINICAL SCIENCE SYMPOSIUM PK/PD According to Dr. Merrill Egorin: A Tribute to a Great Translational Scientist Location: Arie Crown Theater CME credit: 1.5 Track(s): Developmental Therapeutics Duncan Ian Jodrell, MSc, DM, MRCP—Co-Chair NIHR Cambridge Biomedical Research Centre S. Percy Ivy, MD—Co-Chair National Cancer Institute 4:30 PM Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. (Abstract #3000) P. LoRusso, J. J. Ji, J. Li, L. K. Heilbrun, G. Shapiro, E. A. Sausville, S. A. Boerner, D. W. Smith, M. Pilat, J. Zhang, A. P. Chen, N. Nechiporchik, R. E. Parchment Discussion 4:45 PM James H. Doroshow, MD (Abstract #3000) National Cancer Institute 5:00 PM SUNDAY Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. (Abstract #3001^) T. A. Yap, L. Yan, A. Patnaik, D. Olmos, I. Fearen, R. D. Baird, K. P. Papadopoulos, N. Tunariu, A. Biondo, H. Keilhack, L. M. Delgado, A. Taylor, S. C. Blackman, C. L. Carpenter, S. Decordova, S. Heaton, M. D. Garrett, D. Sullivan, J. S. De Bono, A. W. Tolcher Discussion 5:15 PM Jerry M. Collins, PhD (Abstract #3001∧) National Cancer Institute 5:30 PM Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. (Abstract #3002) S. F. Jones, G. Shapiro, J. C. Bendell, E. X. Chen, P. Bedard, J. M. Cleary, S. Pandya, K. J. Pierce, B. Houk, N. Hosea, K. S. Zandi, W. G. Roberts, S. M. Shreeve, L. L. Siu Discussion 5:45 PM Alan Hilary Calvert, MD (Abstract #3002) University College London 276 Sunday, June 5, 2011 4:30 PM - 6:00 PM CLINICAL SCIENCE SYMPOSIUM Predictive Markers in Breast Cancer: How Many Tests Do We Need, and What Do They Tell Us? Location: Hall B1 CME credit: 1.5 Track(s): Breast Cancer Harold J. Burstein, MD, PhD—Chair Dana-Farber Cancer Institute 4:30 PM Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) 3 docetaxel (T) with or without capecitabine (X), in high-risk EBC: Exploratory Ki-67 analyses. (Abstract #500) J. E. Pippen, D. Paul, C. T. Stokoe, J. L. Blum, L. Krekow, F. A. Holmes, D. L. Lindquist, S. M. Sedlacek, R. R. Rivera, R. J. Brooks, S. J. Vukelja, K. McIntyre, C. Lopez-Diaz, J. O’Shaughnessy 4:45 PM Neoadjuvant anastrozole or tamoxifen for premenopausal breast cancer: Ki67 expression data from the STAGE study. (Abstract #501^) T. Kinoshita, N. Masuda, Y. Sagara, H. Iwata, S. Nakamura, Y. Yanagita, R. Nishimura, H. Iwase, S. Kamigaki, H. Takei, H. Tsuda, S. Noguchi 5:15 PM Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. (Abstract #502) A. Prat, J. S. Parker, C. Fan, M. Cheang, L. D. Miller, J. Bergh, S. K. Chia, P. S. Bernard, T. O. Nielsen, M. J. Ellis, L. A. Carey, C. M. Perou 5:30 PM Using the PAM50 breast cancer intrinsic classifier to assess risk in ERⴙ breast cancers: A direct comparison to Oncotype DX. (Abstract #503) R. R. Bastien, M. T. Ebbert, K. M. Boucher, C. M. Kelly, B. Wang, T. Iwamoto, S. Krishnamurthy, L. Pusztai, P. S. Bernard SUNDAY Discussion 5:00 PM Mitchell Dowsett, PhD (Abstracts #500 –501∧) The Royal Marsden Hospital Discussion 5:45 PM Daniel F. Hayes, MD (Abstracts #502–503) University of Michigan Medical Center 277 Sunday, June 5, 2011 4:45 PM - 6:00 PM SPECIAL SESSION B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology Location: S100bc CME credit: 1.25 Track(s): Special Session, Geriatric Oncology John M. Bennett, MD University of Rochester Medical Center Enhancing Geriatric Oncology Training to Care for Elders with Malignancies SUNDAY 278 Sunday, June 5, 2011 4:45 PM - 6:00 PM EDUCATION SESSIONS Chronic Lymphocytic Leukemia Therapy: An Update on Frontline and Novel Therapies Location: E354b CME credit: 1.25 Track(s): Leukemia, Myelodysplasia, and Transplantation Susan Mary O’Brien, MD—Chair University of Texas M. D. Anderson Cancer Center Novel Therapies in Chronic Lymphocytic Leukemia Michael J. Hallek, MD University of Cologne Update on Frontline Therapy for Chronic Lymphocytic Leukemia: Is Fludarabine, Cyclophosphamide, and Rituximab (FCR Regimen) the Treatment of Choice? John C. Byrd, MD The Ohio State University Comprehensive Cancer Center and Arthur G. James Cancer Hospital and Solove Research Institute Molecular, Biochemical, and Clinical Predictive Factors in Chronic Lymphocytic Leukemia: An Update Clinical Problems in Management of Multiple Myeloma (eQuestions Session) SUNDAY Location: Hall D2 CME credit: 1.25 Track(s): Lymphoma and Plasma Cell Disorders, General Oncology Asher Alban Akmal Chanan-Khan, MD—Chair Roswell Park Cancer Institute Complications of Antimyeloma Therapies Ivan Borrello, MD The Johns Hopkins University School of Medicine Smoldering and Asymptomatic Myeloma G. David Roodman, MD, PhD University of Pittsburgh Medical Center Bone Disease and Its Management in Multiple Myeloma Early-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific? Location: E353 CME credit: 1.25 Track(s): Ethics, Clinical Trials, Developmental Therapeutics Steven Joffe, MD, MPH—Chair Dana-Farber Cancer Institute Introduction to the Ethics of Early-phase Clinical Trials Nancy King, JD Wake Forest University School of Medicine The Need to Emphasize the Research Orientation of Early-phase Clinical Trials Razelle Kurzrock, MD University of Texas M. D. Anderson Cancer Center Early-phase Trials as Optimal Therapy in Some Settings 279 Sunday, June 5, 2011 Genetic Syndromes in Upper Gastrointestinal Cancer for the Clinical Oncologist: Syndromes, Testing, and Screening Location: Hall D1 CME credit: 1.25 Track(s): Gastrointestinal (Noncolorectal) Cancer, Cancer Genetics Manish A. Shah, MD—Chair Memorial Sloan-Kettering Cancer Center Incidence of Hereditable Upper Gastrointestinal Cancers: How Common Are They and What Are the Genetic Considerations? Zsofia Kinga Stadler, MD Memorial Sloan-Kettering Cancer Center Genetic Testing: Indications, Insurance/Legal Ramifications, and What Tests Should Be Done Marcia Canto, M.D. The Johns Hopkins University Indications for Screening: Pancreatic, Esophageal, and Stomach Cancers Inclusion of Patients with Brain Metastases in Clinical Trials Location: E354a CME credit: 1.25 Track(s): Clinical Trials, Central Nervous System Tumors, Developmental Therapeutics Lauren E. Abrey, MD—Chair Memorial Sloan-Kettering Cancer Center Overview of the Treatment of Brain Metastases in Patients with Solid Tumors SUNDAY Karen Kelly, MD University of California, Davis Cancer Center Pharmacokinetic/Pharmacodynamic Issues in the Treatment of Brain Metastases Minesh P. Mehta, MD Northwestern University Radiation Therapy for Brain Metastases: Techniques, Trials, and Outcomes Next-generation Therapeutic Targets and Drugs Location: S404 CME credit: 1.25 Track(s): Tumor Biology, Developmental Therapeutics Kapil N. Bhalla, MD—Chair University of Kansas Cancer Center Molecular Chaperones in Tumor Biology and Therapy Jean-Pierre J. Issa, MD University of Texas M. D. Anderson Cancer Center Deregulated Epigenetic Mechanisms: Developing Therepeutic Opportunities Anil Sood, MD University of Texas M. D. Anderson Cancer Center siRNA and miRNA Therapeutics: Rapid Translation from Bench to Bedside 280 Sunday, June 5, 2011 You Can Write an Outstanding Manuscript Location: S100a CME credit: 1.25 Track(s): Professional Development Daniel G. Haller, MD—Chair University of Pennsylvania An Editor’s Perspective Stephen A. Cannistra, MD Beth Israel Deaconess Medical Center How to Reach Meaningful Conclusions SUNDAY Cynthia Dunbar, MD National Heart, Lung, and Blood Institute How to Present Data Effectively 281 Sunday, June 5, 2011 4:45 PM - 6:00 PM MEET THE PROFESSOR SESSION Therapy of the Elderly Patient with Acute Myeloid Leukemia (M12)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric Oncology Charles Alan Schiffer, MD Wayne State University Therapy of the Elderly Patient with Acute Myeloid Leukemia Harry Paul Erba, MD, PhD University of Michigan Medical Center Controversies in Treating the Elderly Patient with Acute Myeloid Leukemia SUNDAY 4:45 PM - 6:00 PM CLINICAL PROBLEMS IN ONCOLOGY SESSION Current State of Neuro-oncology: Successes, Failures, and the Future (C10)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Central Nervous System Tumors John L. Villano, MD, PhD—Chair University of Illinois Henry S. Friedman, MD Duke University Medical Center Jan C. Buckner, MD Mayo Clinic 282 Monday, June 6, 2011 7:30 AM - 9:00 AM HIGHLIGHTS OF THE DAY SESSION Highlights of the Day II Including Partners in Progress Award Location: Hall D1 CME credit: 1.5 Track(s): Special Session, General Oncology Charles D. Blanke, MD—Chair University of British Columbia/British Columbia Cancer Agency 7:30 AM Benjamin O. Anderson, MD—Partners in Progress Award Recipient University of Washington 7:40 AM Stepen R. D. Johnston, MA, MD, PhD Royal Marsden Hospital Breast Cancer—HER2/ER 7:55 AM Jyoti D. Patel, MD Northwestern University Lung Cancer—Metastatic/Non-small Cell 8:10 AM Ivan Borrello, MD The Johns Hopkins University School of Medicine Myeloma MONDAY 8:25 AM Gregory T. Armstrong, MD, MSCE St. Jude Children’s Research Hospital Pediatric Oncology 283 Monday, June 6, 2011 8:00 AM - 9:15 AM SPECIAL SESSION ASCO/European Society for Medical Oncology (ESMO) Joint Session: Cancer in Low- and Middle-income Countries Location: S406 CME credit: 1.25 Track(s): Developmental Therapeutics, Clinical Trials, International, Special Session David J. Kerr, MD, PhD—Co-Chair University of Oxford George W. Sledge Jr., MD—Co-Chair Indiana University Simon Cancer Center Peter Boyle, PhD International Prevention Research Institute Epidemiologic Overview of Cancer in Low- and Middle-income Countries Jan Agosti, MD Bill and Melinda Gates Foundation Cervical Cancer and HPV Vaccines in Low- and Middle-income Countries Henry L. Y. Chan, MD Chinese University of Hong Kong Hepatocellular Carcinoma: Prevention and Control in Low- and Middle-income Countries MONDAY 284 Monday, June 6, 2011 8:00 AM - 9:15 AM EDUCATION SESSIONS Breast Cancer in Older Women: The Whole Picture Location: Hall B1 CME credit: 1.25 Track(s): Breast Cancer, Geriatric Oncology, International Richard C. Zellars, MD—Chair The Johns Hopkins University School of Medicine Locoregional Implications for Therapy in Older Women Arti Hurria, MD City of Hope Patterns of Care and Outcomes Disparities in Older Patients inside and outside of the United States Hyman Bernard Muss, MD University of North Carolina Lineberger Comprehensive Cancer Center Overview and Medical Therapeutic Implications of Breast Cancer in Elderly Patients Communicating Effectively across the Trajectory of Cancer Care and Survivorship (eQuestions Session) Location: E353 CME credit: 1.25 Track(s): Patient and Survivor Care, Health Services Research Edward G. Shaw, MD—Chair Wake Forest University School of Medicine Communication from the Perspective of the Physician Jessie Gruman, PhD Center for Advancing Health Communication on Both the Giving and Receiving End: Perspectives from a Physician and a Patient Intraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer: A Debate Location: Arie Crown Theater CME credit: 1.25 Track(s): Gastrointestinal (Colorectal) Cancer David P. Ryan, MD—Chair Massachusetts General Hospital and Harvard Medical School Surgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: Stop Selecting Patients and Start Proving Efficacy Paul H. Sugarbaker, MD Washington Hospital Center Surgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: If You Select the Right Patients, Long-term Survival Can Be Achieved 285 MONDAY Neeraj Arora, PhD National Cancer Institute Enhancing the “Patient Centeredness” of Communication between the Care Team and Patients and Their Family Members: Understanding Patient Perspectives Monday, June 6, 2011 Optimizing the Use of Alkylators in Neuro-oncology Location: S100a CME credit: 1.25 Track(s): Central Nervous System Tumors James R. Perry, MD—Chair Sunnybrook Health Sciences Centre Temozolomide in Upfront Therapy for Low- and High-grade Gliomas Wolfgang Wick, MD University Hospital Heidelberg Temozolomide in Refractory Disease-alternative Schedules Michael Weller, MD University Hospital Zurich What about the Older Generation Alkylators? Revisiting the Role of Nitrosoureas in Neurooncology The Patient Protection and Affordable Care Act of 2010: Reform Initiatives and Their Implications Location: E354b CME credit: 1.25 Track(s): Health Services Research, Practice Management and Information Technology David Christopher Miller, MD, MPH—Chair University of Michigan ACOs and Their Implications for Cancer-related Quality and Spending Lee Nisley Newcomer, MD United Health Group Payment Bundling and Its Implications for Improving Cancer-related Quality Scott Gottlieb, MD American Enterprise Institute for Public Policy Research The IPAB and Implications for Cancer-related Medicare Spending Transition from Therapy Improvement to Potential Cure for Chronic Myelogenous Leukemia: Roadblocks and Opportunities MONDAY Location: E354a CME credit: 1.25 Track(s): Leukemia, Myelodysplasia, and Transplantation Moshe Talpaz, MD—Chair University of Michigan Comprehensive Cancer Center The Frontline Therapy of Chronic Myelogenous Leukemia: Nilotinib or Imatinib? Jorge E. Cortes, MD University of Texas M. D. Anderson Cancer Center Resistant Disease: Assessment, Monitoring, and Therapy Ravi Bhatia, MD City of Hope The Chronic Myelogenous Leukemia Stem Cell: The Roadblock to Cure? 286 Monday, June 6, 2011 8:00 AM - 9:15 AM MEET THE PROFESSOR SESSIONS Management of Neuroendocrine Tumors of the Lung Exclusive of Small Cell Lung Cancer (M13)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Lung Cancer William D. Travis, MD Memorial Sloan-Kettering Cancer Center Neuroendocrine Tumors of the Lung: Update on Histology Update in Hereditary Renal Cancer (M20)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Cancer Genetics, Genitourinary Cancer MONDAY W. Marston Linehan, MD National Institutes of Health 287 Monday, June 6, 2011 8:00 AM - 11:00 AM ORAL ABSTRACT SESSION Genitourinary (Nonprostate) Cancer Location: Hall D2 CME credit: 3 Track(s): Genitourinary Cancer Evan Y. Yu, MD—Co-Chair Fred Hutchinson Cancer Research Center Carsten Bokemeyer, MD—Co-Chair University Medical Center Hamburg-Eppendorf 8:00 AM Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. (Abstract #4503) B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, T. E. Hutson, C. Szczylik, J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer 8:15 AM Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). (Abstract #4504) D. Cella, B. Escudier, B. I. Rini, C. Chen, H. Bhattacharyya, J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer 8:30 AM Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). (Abstract #4505) M. Aitchison, C. A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon, P. A. Vasey 8:45 AM Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. (Abstract #4506) F. A. Schutz, K. P. Gray, M. Pomerantz, M. B. Atkins, J. E. Rosenberg, M. S. Hirsch, D. F. McDermott, G. M. Lee, S. Signoretti, P. W. Kantoff, M. L. Freedman, T. K. Choueiri Discussion 9:00 AM Bruce G. Redman, DO (Abstracts #4503– 4506) University of Michigan MONDAY 9:15 AM Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial. (Abstract #4507) A. Lorch, A. Kleinhans, A. Kramar, J. T. Hartmann, C. Bokemeyer, O. Rick, J. Beyer, for the German Testicular Cancer Study Group 9:30 AM A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604). (Abstract #4508) R. A. Huddart, R. Gabe, F. Cafferty, P. Pollock, J. D. White, J. Shamash, S. P. Stenning, TE23 Trial Management Group and Collaborators, NCRI Testis Cancer Clinical Studies Group 9:45 AM A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). (Abstract #4509) R. De Wit, I. A. Skoneczna, K. Gedske Daugaard, M. de Santis, A. Garin, N. Aass, J. A. Witjes, P. Albers, J. White, J. Germa-Lluch, S. Osanto, S. Marreaud, L. Collette Discussion 10:00 AM Christopher Sweeney, MBBS (Abstracts #4507– 4509) Dana-Farber Cancer Institute 288 Monday, June 6, 2011 10:15 AM Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. (Abstract #4510) A. Bamias, A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis, C. Papandreou, G. Lainakis, F. Zagouri, N. Soupos, E. Kostouros, E. Samantas, C. Hatzimouratidis, C. Konstantinidis, C. Deliveliotis, D. G. Pectasides, G. Fountzilas, M. A. Dimopoulos, Hellenic Cooperative Oncology Group 10:30 AM Association of germ-line variation with platinum-based chemotherapy response in patients (pts) with urothelial carcinoma (UC). (Abstract #4511) D. J. Gallagher, V. Joseph, R. J. Hamilton, I. Ostrovnaya, I. R. Garcia-Grossman, J. C. Riches, A. M. Regazzi, J. A. Przybylo, M. Gaudet, M. I. Milowsky, K. Offit, D. F. Bajorin MONDAY Discussion 10:45 AM Maria De Santis, MD (Abstracts #4510 – 4511) KFJ Spital Austria 289 Monday, June 6, 2011 8:00 AM - 11:00 AM ORAL ABSTRACT SESSION Pediatric Oncology II Location: S504 CME credit: 3 Track(s): Pediatric Oncology Edward F. Attiyeh, MD—Co-Chair Children’s Hospital of Philadelphia Alejandro Gutierrez, MD—Co-Chair Dana-Farber Cancer Center 8:00 AM The prognostic value of semi-quantitative 123I mIBG scintigraphy at diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score method. (Abstract #9511) V. Lewington, U. Poetschger, A. Boubaker, Z. Bar-Sever, B. Drake, A. Staudenherz, M. Castellani, B. Lambert, K. Grange, P. Brock, A. Garaventa Sr., I. Yaniv, D. Valteau Couanet, V. Castel, A. Forjaz De Lacerda, J. Malis, H. Schroeder, R. Luksch, K. Beiske, R. L. Ladenstein 8:15 AM Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. (Abstract #9512) K. K. Matthay, B. D. Weiss, J. Villablanca, J. M. Maris, G. A. Yanik, S. G. Groshen, H. Jackson, R. Hawkins, F. Goodarzian, A. Panigrahy, S. G. DuBois, J. Stubbs, A. Towbin, J. A. Barrett, N. D. LaFrance, J. W. Babich 8:30 AM Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. (Abstract #9513) S. G. DuBois, L. Chesler, S. G. Groshen, R. Hawkins, F. Goodarzian, G. A. Yanik, C. F. Stewart, Y. P. Mosse, J. M. Maris, J. Villablanca, K. K. Matthay Discussion 8:45 AM Mark Gaze, MD (Abstracts #9511–9513) University College London MONDAY 9:00 AM Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. (Abstract #9514) D. Weiser, M. Laudenslager, E. Rappaport, E. Carpenter, E. F. Attiyeh, S. Diskin, W. B. London, J. M. Maris, Y. P. Mosse 9:15 AM Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales—A report from the Children’s Oncology Group (COG). (Abstract #9515) W. Landier, K. R. Knight, F. L. Wong, J. K. Lee, O. Thomas, H. Kim, S. G. Kreissman, M. L. Schmidt, L. Chen, W. B. London, S. Bhatia, J. G. Gurney, Children’s Oncology Group 9:30 AM Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children’s Oncology Group (COG). (Abstract #9516) D. Walterhouse, A. S. Pappo, J. L. Meza, J. C. Breneman, A. A. Hayes-Jordan, D. Parham, T. P. Cripe, W. H. Meyer, D. S. Hawkins 9:45 AM Randomized comparison of VAC versus VAI chemotherapy (CT) as consolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results of the Euro-EWING.99-R1 trial. (Abstract #9517) O. Oberlin, M. Le Deley, U. Dirksen, I. J. Lewis, A. Ranft, J. M. Michon, M. Paulussen, J. Whelan, R. L. Ladenstein, B. Brennan, P. Marec Bérard, V. Laurence, H. Van Den Berg, L. Hjorth, C. Douglas, K. Wheatley, M. M. Van Glabbeke, I. R. Judson, A. W. Craft, H. Juergens, European Ewing Tumour Working Initiative of National Groups 290 Monday, June 6, 2011 10:00 AM Outcome of Head Start III multinational protocol for newly diagnosed central nervous system (CNS) primitive neuroectodermal tumors (pnet) of young children. (Abstract #9519) T. B. Davidson, L. Ji, K. Haley, G. Dhall, J. P. Grimm, F. H. Gilles, S. L. Gardner, J. C. Allen, A. A. Bedros, M. M. Etzl, R. S. Olshefski, A. Cornelius, J. Torkildson, G. A. Kennedy, J. R. Fangusaro, S. R. Rassekh, M. J. Joyce, S. J. Bertolone, R. Sposto, J. L. Finlay Discussion 10:15 AM Roger Packer, MD (Abstract #9519) Children’s National Medical Center Relevance of germ-line genetic variations for treatment response in pediatric osteosarcoma patients. (Abstract #9518) M. Hagleitner, P. Hoogerbrugge, B. W. Schreuder, U. E. Flucke, M. J. Coenen, D. M. Te Loo MONDAY 10:30 AM 291 Monday, June 6, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Developmental Therapeutics—Clinical Pharmacology and Immunotherapy Location: Hall A Track(s): Developmental Therapeutics MONDAY Brd. 1A Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand. (Abstract #2540) D. J. Schwartzentruber, J. M. Kirkwood, M. J. Guarino, J. M. Richards, O. Hamid, S. O’Day, J. J. Nemunaitis, J. E. Talmadge, S. Chada, K. B. Menander, K. Shafer-Weaver, J. H. Senesac, M. O. Thornton, J. J. Lewis, R. B. Herberman Brd. 1B Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies (Abstract #2541) C. A. Ramos, B. Savoldo, E. Liu, C. M. Bollard, M. P. Mims, M. J. Keating, A. P. Gee, Z. Mei, C. M. Rooney, H. E. Heslop, M. K. Brenner, G. Dotti Brd. 1C Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a phase III study. (Abstract #2542) R. Harrop, W. H. Shingler, M. McDonald, P. Treasure, R. J. Amato, R. E. Hawkins, H. Kaufman, J. de Belin, M. Goonewardena, S. Naylor Brd. 1D Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. (Abstract #2543) E. M. Posadas, N. M. Tannir, Y. Wong, M. S. Ernstoff, C. K. Kollmannsberger, J. Qian, P. J. Ansell, E. M. McKeegan, M. D. McKee, J. L. Ricker, D. M. Carlson, D. Michaelson Brd. 1E Eribulin dosing in patients with advanced solid tumors and hepatic impairment. (Abstract #2544) L. A. Devriese, P. Witteveen, E. E. Voest, E. N. Overkleeft, M. Langenberg, J. H. Beijnen, L. Reyderman, J. Wanders, D. R. Mould, A. Gupta, Z. Hussein, J. H. Schellens Brd. 1F The role of the electrocardiogram (ECG) in phase I drug development in patients with cancer: The University of Texas M. D. Anderson Cancer Center experience with 8,966 ECGs. (Abstract #2545) H. Veasey Rodrigues, A. Naing, D. S. Hong, G. S. Falchook, S. Fu, J. J. Wheler, A. M. Tsimberidou, S. L. Moulder, F. Janku, S. Wen, S. N. Fessahaye, E. C. Golden, D. I. Westerhold, M. Ewer, R. Kurzrock Brd. 1G A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid tumor patients. (Abstract #2546) M. P. Goetz, J. M. Reid, Y. Qi, A. Chen, R. M. McGovern, M. J. Kuffel, P. D. Scanlon, C. Erlichman, M. M. Ames Brd. 2A The effect of enoxaparin on inflammatory and thrombotic mediators in cancer patients as studied using protein and biochip array approaches. (Abstract #2547) D. Hoppensteadt, E. Litinas, H. Khan, J. Cunanan, I. Thethi, J. Fareed Brd. 2B T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results. (Abstract #2548) L. G. Lum, R. Rathore, Z. Al-Kadhimi, P. Davol, A. Thakur, C. Pray, Q. Liu, E. Tomaszewski, F. Cummings, P. Steele, J. Wedge, N. Kouttab, A. Maizel, W. Colaiace, R. Joyrich, V. Ratanatharathorn, J. P. Uberti Brd. 2C Population pharmacokinetics and pharmacogenomics of erlotinib: Effect of drug exposure on treatment outcomes in Japanese patients with non-small cell lung cancer. (Abstract #2549) M. Fukudo, Y. Ikemi, Y. Togashi, K. Masago, Y. Kim, T. Mio, M. Mishima, K. Inui, T. Katsura 292 Brd. 2D Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer. (Abstract #2550) W. P. Caron, J. C. Lay, A. M. Fong, N. M. La-Beck, S. E. Newman, D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. Zamboni Brd. 2E Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in adults with solid tumor malignancy (STM). (Abstract #2551) K. M. Mullane, M. R. Mullane, B. M. Wong, Y. Zhao, T. Sterling, S. Manoff, P. W. Annunziato Brd. 2F Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC). (Abstract #2552) J. Liu, K. S. Albain, S. Chan, A. D. Seidman, D. Tai, Y. Wang, L. Zhao Brd. 2G Procoagulant and inflammatory mediators in small cell lung carcinoma: Potential role in thromboembolic complications. (Abstract #2553) I. Thethi, D. Hoppensteadt, H. Khan, M. Demir, C. Adiguzel, E. Litinas, J. Fareed Brd. 3A Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers. (Abstract #2554) J. J. Wheler, F. Janku, T. Jackson, S. Fu, M. Sun, H. Yang, A. Naing, S. L. Moulder, A. M. Tsimberidou, D. S. Hong, G. S. Falchook, S. A. Piha-Paul, G. Garcia-Manero, R. Kurzrock Brd. 3B Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit. (Abstract #2555) J. Ang, D. Olmos, V. Moreno Garcia, A. Brunetto, D. Papadatos-Pastos, H. Arkenau, M. Blanco, R. D. Baird, P. A. Cassier, D. S. Tan, R. S. Kristeleit, S. Dolly, K. J. Shah, B. Amin, B. G. Anghan, L. R. Molife, U. Banerji, J. S. De Bono, S. B. Kaye Brd. 3C Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. (Abstract #2556) J. P. Connor, R. Stupp, M. C. Cristea, N. Lewis, L. D. Lewis, M. R. Mattiacci, M. Felder, S. Stewart, J. Henslee-Downey, R. Neugebauer, P. B. Komarnitsky Brd. 3D Adoptive immunotherapy with autologous CD3/CD28-costimulated T-cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. (Abstract #2557) S. J. Schuster, C. Hosing, E. J. Shpall, B. Levine, N. Aqui, E. A. Chong, J. Svoboda, A. Gordon, J. D. McMannis, D. Bosque, J. Cotte, A. Brennan, Z. Zheng, L. Leinbach, Y. Xu, E. A. Veloso, W. Decker, C. M. Bollard, M. J. Keating, C. H. June Brd. 3E Effect of cellular vaccination of prostate cancer patients on IgG responses to peptide epitopes predicted from prostate tumor–associated autoantigens. (Abstract #2558) G. P. Hemstreet, V. M. Pisarev, C. A. Enke, R. J. Hauke, G. R. Rossi, L. Tennant, W. J. Ramsey, N. N. Vahanian, C. J. Link Brd. 3F Blinded independent radiologic review (BIRR) versus investigator radiologic evaluation (IRE) for response assessment in metastatic colorectal cancer (mCRC): Systematic review and meta-analysis. (Abstract #2559) J. S. Lima, F. M. Carcano, F. H. Souza, L. V. dos Santos Brd. 3G Clinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1-expressing solid tumors as compared to patients with AML/MDS. (Abstract #2560) A. Letsch, C. Scheibenbogen, A. Asemissen, K. Zimmermann, S. Bauer, M. Voelker-Call, D. Stather, E. Thiel, U. Keilholz 293 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 3H Posterior reversible encephalopathy syndrome in patients with cancer. (Abstract #2561) A. M. Paker, L. Chi, M. C. Ruiz, M. E. Loghin Brd. 4A Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs). (Abstract #2562) H. K. Gan, B. You, G. R. Pond, E. X. Chen Brd. 4B RECIST 1.0 versus 1.1: Implications for trial interpretation and design in advanced prostate cancer. (Abstract #2563) C. I. Piatek, B. B. Desai, D. Wei-Tsao, R. Tang, F. Acosta, J. K. Pinski, T. B. Dorff, A. Goldkorn, H. Jadvar, D. I. Quinn Brd. 4C A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa) . (Abstract #2564) A. K. Patel, L. J. Appleman, W. E. Gooding, D. Friedland, J. McKolanis, A. M. Salazar, O. J. Finn, G. S. Chatta Brd. 4D Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial with immunological assessments. (Abstract #2565) A. Parsa, C. Crane, S. Han, V. Kivett, A. Fedoroff, N. A. Butowski, S. M. Chang, J. L. Clarke, M. S. Berger, M. McDermott, M. Aghi, C. Yanes, M. Prados, A. E. Sloan, J. N. Bruce Brd. 4E Incidence of hypersensitivity reactions (HSRs) to albumin-bound paclitaxel (ABI) in patients (pts) with a history of HSR to cremophor-based paclitaxel (P). (Abstract #2566) J. P. Timoney, D. McGuffy, D. DeRitis, E. Tyler, J. Sumka, M. Pozotrigo, V. Bhatt, A. Chan, N. T. Sklarin Brd. 4F Comparison of 12 current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. (Abstract #2567) X. Li, Q. Lin, M. Dong, X. Wu, L. Wei, J. Wen, X. Ma, Z. Chen Brd. 4G First-in-human phase I study of the antiangiogenic vaccine (OTS11101) targeting VEGFR-1 in patients with solid tumors. (Abstract #2568) H. Hayashi, T. Kurata, Y. Fujisaka, T. Satoh, M. Takeda, M. Miyazaki, T. Okabe, H. Kiyota, K. Tanaka, T. Tsunoda, K. Nakagawa Brd. 4H Pro- versus antitumor effects of bisphosphonate-activated ␥␦ T cells in cancer immunotherapy. (Abstract #2569) V. Kunzmann, M. Smetak, B. Kimmel, K. Weigang-Koehler, M. Goebeler, J. Birkmann, J. Becker, I. Schmidt-Wolf, H. Einsele, M. Wilhelm Brd. 5A Influence of renal dysfunction on the pharmacokinetic of intravenous vinflunine: Results of a phase I trial in patients with cancer. (Abstract #2570) J. Delord, N. Isambert, P. Fumoleau, A. Ravaud, T. Nguyen, P. Ferre, S. Favrel, M. Pinel, J. Tourani Brd. 5B Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, MetMAb, in patients with advanced solid tumors. (Abstract #2571) S. Bai, Y. Xin, D. Jin, S. Kaur, I. Nijem, J. G. Bothos, A. C. Peterson, P. H. Patel Brd. 5C The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM). (Abstract #2572) S. M. Collins, C. E. Bakan, Y. Alghothani, H. Kwon, B. Balasa, G. Starling, A. Rice, D. M. Benson Jr. Brd. 5D Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study. (Abstract #2573) J. Shamash, J. Jacob, T. Powles, S. Agrawal, K. Mutsvangwa, N. Saunders, P. Wilson, J. Stebbing 294 Brd. 5E Systemic immune responses induced by intratumoral plasmid IL-12 electroporation in patients with melanoma. (Abstract #2574) E. Cha, A. Daud, D. G. McNeel, R. Heller, L. Fong Brd. 5F Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. (Abstract #2575) P. Ruf, M. Jäger, B. Foerster, H. Martinius, D. Seimetz, H. Lindhofer Brd. 5G Reduction of toxicity by reversing the order of infusion in docetaxel and cyclophosphamide (TC). (Abstract #2576) D. Miura, M. Fujii, T. Iwatani, T. Takano, H. Kawabata Brd. 5H A phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging. (Abstract #2577) J. V. Pedersen, E. M. Karapanagiotou, A. Biondo, N. Tunariu, M. Puglisi, K. A. Denholm, S. Sassi, D. Mansfield, T. A. Yap, J. S. De Bono, K. J. Harrington Brd. 6A A phase 0 microdosing trial of an in vivo assay for predicting chemoresistance to platinum. (Abstract #2578^) C. Pan, S. Wang, R. deVere White, D. R. Gandara, P. Lara Jr., T. Li, P. Mack, A. Rodriguez-Fahrni, J. S. Lee, M. Malfatti, K. Turteltaub, P. T. Henderson Brd. 6B New lesions versus growth of existing disease: Does it impact prognosis? (Abstract #2579) A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. Sargent Brd. 6C Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial. (Abstract #2580) J. T. Lettieri, A. L. Mazzu, L. Huang, C. D. Lathia Brd. 6D Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult patients with cancer with advanced solid tumors. (Abstract #2581) A. Thomas-Schoemann, M. Tod, O. Mir, N. Bancelin, R. Coriat, F. Taieb, P. Boudou-Rouquette, H. Abbas, S. Ropert, J. Durand, A. Dauphin, F. Goldwasser, B. Blanchet Brd. 6E Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). (Abstract #2582) M. D. Walsh, H. Giovinazzo, A. Sheikh, M. Ivanovic, A. B. Whitlow, S. E. Newman, N. M. La-Beck, R. J. Kowalsky, B. A. Zamboni, D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. Zamboni Brd. 6F Meta-analysis of the pharmacokinetic variability of liposomal anticancer agents compared with nonliposomal anticancer agents. (Abstract #2583) B. Sidone, B. A. Zamboni, W. Zamboni Brd. 6G Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. (Abstract #2584) M. Sebastian, L. von Boehmer, A. Zippelius, F. Mayer, M. Reck, D. Atanackovic, M. Thomas, F. Schneller, J. Stoehlmacher, E. Goekkurt, H. Bernhard, A. Groeschel, R. Bals, S. Schmidt, B. Scheel, S. D. Koch, T. Lander, K. Kallen, A. Knuth Brd. 6H Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. (Abstract #2585) R. Bahleda, J. Soria, Y. Berge, C. Massard, S. Wind, M. M. Uttenreuther-Fischer, F. Fleischer, H. De-Montserrat, F. Solca, I. Tschoepe, J. Delord Brd. 7A Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. (Abstract #2586) Y. Xin, M. S. Gordon, D. Jin, E. Wakshull, D. S. Chen, L. S. Rosen, P. N. Munster, L. Naumovski, S. Bai 295 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 7B Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. (Abstract #2587) J. Jackson, G. Whitney, O. Hamid, H. Schmidt, S. D. Chasalow, S. Alaparthy, Y. Bao, V. Shahabi Brd. 7C Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC). (Abstract #2588) R. F. Gabitass, N. E. Annels, J. Crawshaw, H. S. Pandha, G. W. Middleton Brd. 7D Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study of intravenous Rexin-G and Reximmune-C for chemotherapy-resistant cancers. (Abstract #2589) J. G. Ignacio, H. Bruckner, R. E. Manalo, F. S. San Juan, L. Baniqued, A. Madamba, E. M. Gordon, F. L. Hall Brd. 7E Outcomes in phase II trials of metastatic breast cancer: Where is the bar? (Abstract #2590) A. Kamal, T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, J. M. Peppercorn Brd. 7F AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIVⴙ patients with solid tumors. (Abstract #2591) J. F. Deeken, M. A. Rudek, D. M. Aboulafia, R. J. Sullivan, J. F. Gerecitano, M. E. Cianfrocca, D. H. Henry, L. Ratner, B. J. Dezube, K. Mosby, M. Tibbals, R. F. Little, S. P. Ivy, P. C. Moore, R. T. Mitsuyasu Brd. 7G A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens. (Abstract #2592) E. P. Hui, G. S. Taylor, B. Ma, S. L. Chan, R. Ho, W. Wong, H. Jia, C. Edwards, A. B. Rickinson, A. T. Chan, N. M. Steven Brd. 7H Metabolic profiles as predictive biomarkers of erlotinib-induced adverse effects in patients with non-small cell lung cancer. (Abstract #2593) A. Hamada, J. Sasaki, S. Saeki, N. Iwamoto, M. Inaba, S. Ushijima, H. Kishi, S. Fujii, H. Semba, K. Kashiwabara, Y. Tsubata, Y. Kai, T. Isobe, H. Kohrogi, H. Saito Brd. 8A An evaluation of plasma homocysteine levels and the hematological toxicity of pemetrexed even with folate supplementation. (Abstract #2594) A. Horiike, H. Tanaka, T. Sakatani, R. Saito, K. Kaburaki, N. Yanagitani, K. Kudo, F. Ohyanagi, S. Hagiwara, T. Horai, M. Nishio Brd. 8B Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. (Abstract #2595) F. G. De Braud, C. Catania, A. Onofri, C. Pierantoni, S. Cascinu, M. Maur, C. Masini, P. F. Conte, L. Giovannoni, A. Tasciotti, V. Lovato, D. Neri, H. D. Menssen Brd. 8C NAD(P)H oxidase genetic polymorphisms and anthracyclines-induced cardiac lesions in patients with cancer. (Abstract #2596) A. Cascales, F. Pastor, B. Sanchez-Vega, J. Corral, A. Vicente, T. Garcia, V. Vicente, F. Ayala Brd. 8D Key drug development features in the design of early-phase oncology trials: An FDA perspective. (Abstract #2597) R. Charlab Orbach, G. M. Blumenthal, P. Cortazar, K. K. Filipski, C. Grimstein, L. Zhang, P. Mummaneni, B. Booth, I. Zineh Brd. 8E Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitorpolymer conjugate, in patients with advanced solid tumors. (Abstract #2598) M. A. Eldon, U. Hoch Brd. 8F A pilot study of vaccination with sialyl Lewisa (sLea)– keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in metastatic breast cancer patients (pts). (Abstract #2599) A. Diab, G. Ragupathi, W. W. Scholz, K. Panageas, C. Hudis, P. O. Livingston, T. Gilewski 296 Brd. 8G A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642). (Abstract #2600) K. C. Shih, J. R. Infante, K. P. Papadopoulos, J. C. Bendell, A. W. Tolcher, H. A. Burris III, M. Beeram, L. Jackson, R. Arcos, E. H. Westin, D. Farrington, A. McGlothlin, S. Hynes, J. Leohr, J. T. Brandt, A. Nasir, A. Patnaik Brd. 8H The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer. (Abstract #2601) H. Reinhard, S. K. Meyer, K. Bartels, R. Fischer, D. Seimetz, C. Bokemeyer, D. Atanackovic Brd. 9A Correlation between adverse event reports of hypothyroidism and clinical response in patients treated with vascular endothelial growth factor receptor inhibitors (VEGFR-I). (Abstract #2602) G. Speranza, L. Rubinstein, S. P. Ivy, P. J. Harris Brd. 9B Added value of pre- and on-treatment tumor growth kinetics assessment to RECIST in patients (pts) treated with molecularly targeted agents (MTAs). (Abstract #2603) C. Le Tourneau, V. Servois, L. Ollivier, X. Paoletti Brd. 9C A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. (Abstract #2604) R. A. Madan, M. Bilusic, J. W. Hodge, K. Y. Tsang, P. M. Arlen, C. R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian, A. Franzusoff, Z. Guo, J. Schlom, J. L. Gulley Brd. 9D Development and validation of a prediction tool for hand-foot skin reaction (HFSR) in patients receiving sorafenib. (Abstract #2605) J. Yu, G. Dranitsaris, M. D. Vincent, L. Huang, F. Fang, M. E. Lacouture Brd. 9E Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK). (Abstract #2606) G. J. Fetterly, K. E. Thudium, J. Kalabus, M. Murphy, P. D. Zagst, J. Prey, E. Kittleman, A. A. Adjei, T. L. O’Connor, J. G. Blanco Brd. 9F A phase I dose escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment. (Abstract #2607) N. R. Dickson, S. F. Jones, H. A. Burris III, R. K. Ramanathan, G. J. Weiss, J. R. Infante, J. C. Bendell, W. McCulloch, D. D. Von Hoff Brd. 9G The effect of metformin (M) on overall survival (OS) of patients (Pts) with colorectal cancer (CRC) treated with chemotherapy (CTX). (Abstract #2608) M. Bansal, E. Siegel, R. Govindarajan Brd. 9H Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies. (Abstract #2609) S. Vemulapalli, A. C. Mita, N. S. Gallegos, G. Anderson, J. Charles, J. M. Rogers, A. Kousba, K. K. Sankhala, J. J. Nemunaitis Brd. 10A Enrichment of allogeneic tumor antigen-specific T-cells from bone marrow (BM) of patients treated with high-dose post-transplant cyclophoshamide (Cy): A novel approach to adoptive immunotherapy. (Abstract #2610) K. Noonan, L. Luznik, I. Borrello Brd. 10B Returning research results to clinical trial participants: A survey of patients with cancer. (Abstract #2611) K. Elzinga, C. V. Fernandez, D. Y. Heng, P. A. Tang Brd. 10C Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function. (Abstract #2612) D. Mahalingam, J. Sarantopoulos, M. S. Gordon, N. B. Pandya, B. R. Tan, A. C. Mita, C. Zergebel, K. Saito, C. H. Takimoto, M. Saif 297 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 Brd. 10D Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy. (Abstract #2613^) H. Kristeleit, M. Puglisi, G. W. Middleton, D. Propper, M. T. Kelleher, L. Trani, K. A. Denholm, G. Wallenstein, P. Stopfer, S. Buschke, M. M. UttenreutherFischer, E. Bent, D. O’Brien, J. F. Spicer, L. R. Molife Brd. 10E A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. (Abstract #2614) L. S. Rosen, M. S. Gordon, S. Bai, P. Hegde, J. Fredrickson, D. S. Chen, I. Chang, R. P. Funke, G. S. Chandler, L. Naumovski, P. N. Munster MONDAY 298 Monday, June 6, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Developmental Therapeutics—Experimental Therapeutics Brd. 10F Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. (Abstract #3033) A. L. Ho, J. C. Bendell, J. M. Cleary, G. K. Schwartz, H. A. Burris III, P. Oakes, F. Agbo, P. N. Barker, A. M. Senderowicz, G. Shapiro Brd. 10G Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. (Abstract #3034) A. A. Adjei, J. A. Sosman, R. E. Martell, G. K. Dy, L. W. Goff, W. Ma, L. Horn, G. J. Fetterly, S. A. Michael, J. A. Means, F. Chai, M. Lamar, G. M. Strauss, W. Chiang, J. Jarboe, B. E. Schwartz, I. Puzanov Brd. 10H A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. (Abstract #3035) A. Patnaik, L. J. Appleman, J. M. Mountz, R. K. Ramanathan, M. Beeram, A. W. Tolcher, K. P. Papadopoulos, M. T. Lotze, D. P. Petro, C. Laymon, L. Paige, P. Rajagopalan, M. Jeffers, D. Roth, R. L. Dubowy Brd. 11A A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies. (Abstract #3036) A. P. Moore, S. Thomas, C. J. Ryan, T. M. Jahan, S. G. DuBois, J. K. Chan, K. T. Thurn, E. A. Collisson, A. Reinert, A. Daud, P. N. Munster Brd. 11B Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. (Abstract #3037^) A. Biondo, T. A. Yap, L. Yan, A. Patnaik, I. Fearen, R. D. Baird, K. P. Papadopoulos, L. M. Delgado, A. Taylor, L. Lupinacci, S. C. Blackman, S. Decordova, M. Tall, S. Heaton, M. D. Garrett, D. Sullivan, J. S. De Bono, A. W. Tolcher Brd. 11C A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer. (Abstract #3038) A. J. Brenner, Y. Cohen, F. J. Giles, E. C. Borden, E. Breitbart, L. Bangio, N. Sher, P. L. Triozzi Brd. 11D Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. (Abstract #3039) A. Beryozkina, G. L. Nichols, M. Reckner, L. T. Vassilev, R. Rueger, L. Jukofsky, S. Middleton, M. Andreeff, S. Padmanabhan, R. Strair, M. L. Delioukina, P. G. Maslak, P. Hillmen, R. Kurzrock, L. Gore, A. Patnaik, R. G. Maki, G. K. Schwartz, A. J. Wagner, J. Zhi Brd. 11E A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensivestage small cell lung cancer (ES-SCLC). (Abstract #3040) A. M. Traynor, J. Kolesar, R. M. Marnocha, J. C. Eikhoff, D. B. Alberti, N. Takebe, G. Wilding, G. Liu, W. R. Schelman Brd. 11F Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. (Abstract #3041) A. R. Tan, D. Toppmeyer, M. N. Stein, R. A. Moss, M. Gounder, D. C. Lindquist, J. J. Ji, A. P. Chen, M. J. Egorin, B. Kiesel, J. H. Beumer, R. S. DiPaola 299 MONDAY Location: Hall A Track(s): Developmental Therapeutics Monday, June 6, 2011 MONDAY Brd. 11G Development and validation of biomarker assays to assess pharmacodynamic modulation of MET. (Abstract #3042) A. K. Srivastava, M. G. Hollingshead, J. Weiner, S. Khin, S. Borgel, P. Risbood, T. D. Pfister, S. M. Lawrence, R. J. Kinders, D. P. Bottaro, J. E. Tomaszewski, R. E. Parchment, J. H. Doroshow Brd. 11H Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. (Abstract #3043) B. Grana, H. A. Burris III, J. Rodon Ahnert, A. R. Abdul Razak, M. J. De Jonge, F. Eskens, L. L. Siu, Q. C. Ru, N. F. Homji, D. Demanse, E. Di Tomaso, J. G. Cosaert, C. Quadt, J. Baselga, J. C. Bendell Brd. 12A A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #3044) B. Besse, J. Soria, C. Gomez-Roca, J. A. Ware, A. A. Adjei, G. K. Dy, G. Shankar, R. K. Brachmann, H. J. Groen Brd. 12B Genetic correlations with chemotherapy-induced hepatic injury. (Abstract #3045) C. H. Pilgrim, K. Brettingham-Moore, A. Pham, W. Murray, E. Link, M. Smith, V. Usatoff, P. M. Evans, S. Banting, B. N. Thomson, M. Michael, W. A. Phillips Brd. 12C A phase I dose escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies. (Abstract #3046) C. Lin, W. Su, C. Yen, A. Cheng, Y. Lu, C. Hsu, D. C. Huang, H. Fritsch, F. Voss, R. Schreck, T. Taube, C. Yang Brd. 12D Angiogenic factors and soluble receptors in NCIC CTG BR.24. (Abstract #3047) C. L. Addison, K. Ding, H. Zhao, A. Le Maitre, S. A. Laurie, G. D. Goss, F. A. Shepherd, P. A. Bradbury, L. Seymour Brd. 12E Imaging with [18f]-fluorodeoxyglucose positron emission tomography (FDG-PET) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as markers of drug effect in a phase I dose-escalation study of combined RAD 001 and cetuximab. (Abstract #3048) C. A. Martin, R. F. Perini, A. N. Avadhani, M. Redlinger, K. Harlacker, K. T. Flaherty, M. A. Rosen, C. R. Divgi, P. J. O’Dwyer Brd. 12F A phase I schedule optimization study of pegylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-l-norleucine (DON) in patients (pts) with advanced solid tumors. (Abstract #3049) C. Unger, C. Mueller, M. P. Bausch, K. Krzemieniecki, S. Ochenduszko, B. Wilk, E. Jaeger, S. Al-Batran Brd. 12G A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors. (Abstract #3050^) C. D. Weekes, P. LoRusso, V. Ramakrishnan, L. M. Shih, W. C. Darbonne, P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, A. Patnaik Brd. 12H A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA9090) administered twice weekly in patients with solid tumors: Updated report. (Abstract #3051) D. C. Cho, E. I. Heath, J. M. Cleary, E. L. Kwak, L. Gandhi, D. P. Lawrence, C. Zack, F. Teofilovici, R. Bradley, M. D. Karol, G. Shapiro, P. LoRusso Brd. 13A A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. (Abstract #3052^) D. D. Von Hoff, P. LoRusso, G. D. Demetri, G. J. Weiss, G. Shapiro, R. K. Ramanathan, J. A. Ware, R. Raja, J. Jin, G. G. Levy, K. E. Mazina, A. J. Wagner 300 Brd. 13B Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy: Pilot study results. (Abstract #3053) D. R. Gandara, T. A. Van Dyke, Z. Weaver Ohler, T. Li, P. Lara Jr., P. C. Mack, R. F. Calhoun, R. Gandour-Edwards, K. D. Danenberg, R. de Vere White, N. Goodwin Brd. 13C Poly (ADP ribose) polymerase (PARP) inhibition in peripheral blood lymphocytes (PBLs): Does it reflect PARP inhibition in tumor? (Abstract #3054) D. R. Shalinsky, D. D. Wang, K. A. Kern, P. English, N. J. Curtin, R. Plummer Brd. 13D First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor. (Abstract #3055) D. S. Mendelson, L. S. Rosen, M. S. Gordon, J. W. Goldman, A. J. Olszanski, H. Dai, R. Perea, A. Gollerkeri Brd. 13E Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235. (Abstract #3056) D. Bottino, J. Tabernero, H. A. Burris III, C. Britten, L. Chen, J. C. Bendell, O. Chiparus, V. Duval, E. Di Tomaso, C. Sarr, W. Hackl, J. Baselga, J. Rodon Ahnert Brd. 13F First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors. (Abstract #3057) D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese, J. Kaufmann, J. Drevs Brd. 13G Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. (Abstract #3058) E. A. Sausville, P. LoRusso, M. A. Carducci, P. N. Barker, F. Agbo, P. Oakes, A. M. Senderowicz Brd. 13H Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents. (Abstract #3059) E. F. Smit, M. Lubberink, I. Bahce, M. Walraven, M. P. de Boer, H. N. Greuter, N. Hendrikse, J. Eriksson, A. D. Windhorst, P. E. Postmus, H. M. Verheul, E. H. Serne, A. A. Lammertsma, A. A. van der Veldt Brd. 14A Early targeted drug development: Pilot FDA review of PI3K inhibitor phase I studies using a knowledge management database. (Abstract #3060) G. M. Blumenthal, R. Charlab Orbach, I. Zineh, P. Cortazar, R. L. Justice, R. Pazdur Brd. 14B Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated patients (pts) with renal cell carcinoma (RCC). (Abstract #3061) H. A. Ball, Y. Lin, Z. Xue, B. Suttle, C. Xu, L. Huang, L. McCann, T. E. Hutson, C. N. Sternberg, L. N. Pandite Brd. 14C Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. (Abstract #3062) H. A. Tawbi, J. Rodon Ahnert, R. Dummer, A. L. Thomas, C. Granvil, Y. Shou, J. Dey, M. M. Mita, D. D. Amakye, A. C. Mita Brd. 14D A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer. (Abstract #3063) I. R. MacPherson, D. Bissett, R. D. Petty, B. Tait, L. M. Samuel, J. MacDonald, M. Smith, J. A. Birse-Archbold, A. L. Barnett, C. R. Wolf, C. R. Elcombe, A. Jeynes-Ellis, T. Evans 301 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 14E A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110␦, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. (Abstract #3064) I. W. Flinn, M. T. Schreeder, S. E. Coutre, J. Leonard, N. D. Wagner-Johnston, S. De Vos, R. V. Boccia, L. Holes, S. Peterman, L. L. Miller, A. S. Yu Brd. 14F Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. (Abstract #3065) I. Garrido-Laguna, R. Kurzrock, J. J. Wheler, G. S. Falchook, S. A. Piha-Paul, S. Fu, A. Naing, C. Hinojosa, R. Mistry, A. Scamardo, K. S. Culotta, S. Ekmekcioglu, S. Wen, L. H. Camacho, S. P. Ivy, D. S. Hong Brd. 14G A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. (Abstract #3066) J. D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L. Chen, J. Tabernero, V. Duval, N. Rouyrre, A. P. Silva, C. Quadt, J. Baselga Brd. 14H Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors. (Abstract #3067) J. M. Cleary, C. S. Rocha Lima, H. Hurwitz, A. J. Montero, G. Shapiro, C. Franklin, J. Yang, A. M. Graham, T. Busman, M. Mabry, K. D. Holen, A. Krivoshik, R. Humerickhouse, H. Uronis Brd. 15A Update on a phase I pharmacologic and pharmacodynamic study of MK1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. (Abstract #3068) J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, S. Leijen, S. M. Tolaney, I. Diaz-Padilla, R. K. Ramanathan, T. Demuth, J. Viscusi, J. D. Cheng, R. Lam, Y. Xu, A. M. Oza Brd. 15B Results of a study of the oral inhibitor PTC299 on tumor VEGF synthesis. (Abstract #3069) J. J. Luke, L. A. Callahan, C. H. Darby, E. Moss, J. Winkelman, J. Barth, G. L. Elfring, A. Ogden, G. K. Schwartz, M. M. Gounder Brd. 15C Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors. (Abstract #3070) J. C. Bendell, M. S. Gordon, H. Hurwitz, C. H. Condon, Y. Yang, D. Wilson, K. M. Attie, M. L. Sherman, S. Sharma Brd. 15D The effect of SGN-75, a novel antibody– drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study. (Abstract #3071) J. A. Thompson, A. Forero-Torres, E. I. Heath, S. M. Ansell, S. K. Pal, J. R. Infante, S. De Vos, P. A. Hamlin, B. Zhao, K. Klussman, N. C. Whiting Brd. 15E Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. (Abstract #3072) J. Sarantopoulos, H. Lenz, P. LoRusso, S. Shibata, S. Kummar, D. Mulkerin, R. K. Ramanathan, M. M. Mita, P. O’Rourke, S. C. Remick, S. Goel, M. Gutierrez, S. S. Ramalingam, A. Murgo, A. M. Davies, S. Mani, J. Boni, M. Shapiro, S. P. Ivy, C. H. Takimoto, National Cancer Institute Organ Dysfunction Working Group Brd. 15F A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors. (Abstract #3073) J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams, D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh, L. S. Rosen Brd. 15G Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens. (Abstract #3074) K. K. Sankhala, A. W. Tolcher, M. M. Mita, M. S. Gordon, L. S. Rosen, K. P. Papadopoulos, A. Patnaik, R. L. Drengler, A. C. Mita, J. Sarantopoulos, R. G. Bristow, G. Fine, G. S. Choy, M. Azab 302 Brd. 15H A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. (Abstract #3075) K. P. Papadopoulos, D. S. Mendelson, A. W. Tolcher, A. Patnaik, H. A. Burris III, D. W. Rasco, J. C. Bendell, M. S. Gordon, G. Kato, H. Wong, D. Bomba, S. Lee, H. H. Gillenwater, T. Woo, J. R. Infante Brd. 16A First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort. (Abstract #3076) L. Chen, L. S. Rosen, T. Iyengar, J. W. Goldman, R. Savage, J. Kazakin, T. C. Chan, B. E. Schwartz, G. Abbadessa, D. D. Von Hoff Brd. 16B Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors. (Abstract #3077) L. H. Camacho, S. Pant, M. N. Saleh, G. Abbadessa, J. Kazakin, B. E. Schwartz, J. C. Bendell Brd. 16C Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. (Abstract #3078) M. A. Dickson, P. LoRusso, E. A. Sausville, N. Rao, E. Kobayashi, M. R. Kurman, S. Akinaga, G. K. Schwartz Brd. 16D Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). (Abstract #3079) M. J. Ratain, G. K. Schwartz, A. M. Oza, C. M. Rudin, S. B. Kaye, M. J. De Jonge, D. Khayat, A. Awada, M. B. Sawyer, J. C. Obel, J. Medioni, T. Evans, J. De Greve, P. M. Soetekouw, J. Baurain, P. J. O’Dwyer, C. Hartman, V. Poulart, I. B. Walters Brd. 16E A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. (Abstract #3080) M. M. Mita, A. C. Mita, J. Moseley, J. Poon, K. A. Small, Y. Jou, P. Kirschmeier, D. Zhang, P. Statkevich, K. K. Sankhala, J. Sarantopoulos, J. M. Cleary, L. R. Chirieac, S. Rodig, R. Bannerji, G. Shapiro Brd. 16F Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs). (Abstract #3081) M. Kittaneh, A. J. Montero, K. Kovacs, V. D. Guardiola Amado, A. M. Flores, A. Ferrell, M. Vulfovich, M. D. Pegram, P. W. Benedetto, C. S. Rocha Lima, J. R. Merchan Brd. 16G Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer. (Abstract #3082) N. M. Kuderer, E. Culakova, M. Huang, M. S. Poniewierski, G. S. Ginsburg, W. T. Barry, P. K. Marcom, N. Ready, A. P. Abernethy, G. H. Lyman Brd. 16H MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience. (Abstract #3083) P. J. O’Dwyer, K. P. Papadopoulos, A. W. Tolcher, U. R. Teitelbaum, K. Harlacker, M. Beeram, D. Sohal, M. Mehran, M. Tawashi, M. A. Drouin, C. R. Maroun, J. Wang, M. Fournel, A. Karam, J. M. Besterman, A. Patnaik Brd. 17A Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. (Abstract #3084) P. A. Cassier, V. Moreno Garcia, C. Gomez-Roca, D. Olmos, R. Morales, G. Del Conte, E. Gallerani, A. Brunetto, P. Schoffski, S. Marsoni, J. H. Schellens, N. Penel, E. E. Voest, T. Evans, R. Plummer, R. H. Wilson, J. Soria, J. Tabernero, J. Verweij, S. B. Kaye, European Drug Development Network 303 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 17B Phase I dose escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). (Abstract #3085) R. Kurzrock, A. Patnaik, L. Rosenstein, S. Fu, K. P. Papadopoulos, D. A. Smith, G. S. Falchook, G. Chambers, J. L. Gauvin, A. Naing, L. S. Smith, T. Gonzalez, A. M. Tsimberidou, T. A. Mays, D. S. Cox, D. S. Hong, D. J. DeMarini, N. T. Le, S. R. Morris, A. W. Tolcher Brd. 17C A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. (Abstract #3086) R. D. Carvajal, M. M. Gounder, C. M. Coughlin, J. Fishel, J. Heyburn, D. O’Shannessy, L. Grasso, C. Schweizer, J. Parno, L. J. Old, N. S. Azad, L. A. Diaz Jr. Brd. 17D Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. (Abstract #3087) R. F. Marschke, M. J. Borad, R. W. McFarland, R. H. Alvarez, J. K. Lim, C. S. Padgett, D. D. Von Hoff, S. E. O’Brien, D. W. Northfelt Brd. 17E Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1. (Abstract #3088) R. F. Perini, A. DeMichele, D. J. Vaughn, M. Gallagher, W. Sun, B. J. Giantonio, U. R. Teitelbaum, S. Randolph, J. G. Christensen, R. D. Courtney, D. A. Pryma, C. R. Divgi, P. J. O’Dwyer Brd. 17F Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. (Abstract #3089) R. Dienstmann, A. W. Tolcher, K. P. Papadopoulos, D. W. Rasco, J. Tabernero, I. Brana, A. Piera, N. Skartved, H. Aladdin, J. Petersen, A. Patnaik Brd. 17G A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors. (Abstract #3090) R. J. Kelly, A. Rajan, G. Chun, A. Lopez-Chavez, G. Giaccone Brd. 17H A phase I dose escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors. (Abstract #3091) R. C. Donehower, A. Scardina, M. Hill, J. Bowman, R. C. Newton, X. Liu, P. Scherle, Q. Wang, S. Diamond, J. Boer, F. Lee, T. Gau, H. A. Burris III, J. C. Bendell, S. F. Jones, J. R. Infante Brd. 18A Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. (Abstract #3092) S. R. Palmer, C. Erlichman, M. Fernandez-Zapico, Y. Qi, L. Almada, A. McCleary-Wheeler, M. J. Borad, J. R. Molina, A. Grothey, H. C. Pitot, A. Jatoi, D. W. Northfelt, R. R. McWilliams, S. H. Okuno, P. Haluska, G. P. Kim, G. Colon-Otero Brd. 18B Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit. (Abstract #3093) S. P. Anthony, I. Puzanov, P. S. Lin, K. B. Nolop, B. West, D. D. Von Hoff Brd. 18C Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. (Abstract #3094) S. Sharma, R. Kurzrock, L. Gouw, D. S. Hong, K. Jones, X. Zhou, H. Shi, H. Fingert, G. S. Falchook Brd. 18D A phase I/II study of the hypomethylating agent azacitadine with the nanoparticle albumin bound paclitaxel in the treatment of patients with advanced or metastatic solid tumors. (Abstract #3095^) T. L. Dumlao, T. W. Butler, D. L. Dyess, H. T. Khong 304 Brd. 18E First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. (Abstract #3096) U. Banerji, C. Aghajanian, E. Raymond, R. Kurzrock, M. Blanco-Codesido, E. Oelmann, L. Grinsted, W. Burke, S. B. Kaye, A. Naing Brd. 18F Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors. (Abstract #3097) U. Keilholz, V. Moiseyenko, A. Makhson, V. Semiglazov, M. Learoyd, A. Saunders, M. Stuart, S. Tjulandin Brd. 18G Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. (Abstract #3098^) V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, C. M. Rudin, A. Manukyants, S. Gogov, S. Poondru, R. Gedrich, S. M. Gadgeel Brd. 18H A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. (Abstract #3099) W. A. Harb, C. Sessa, H. W. Hirte, S. B. Kaye, R. Simantov, S. N. Banerjee, A. Christinat, D. W. Sternberg, M. Singh, R. Light, S. Poondru Brd. 19A A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. (Abstract #3100) W. A. Messersmith, P. LoRusso, J. M. Cleary, A. Dasari, X. Zhang, M. N. Shaik, R. D. Courtney, S. Randolph, G. Shapiro Brd. 19B Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. (Abstract #3101) W. Ma, W. A. Messersmith, G. K. Dy, E. Freas, A. Whitworth, F. Wilhelm, S. G. Eckhardt, A. A. Adjei, A. Jimeno Brd. 19C First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCAdeficient tumors and sporadic ovarian cancers (soc). (Abstract #3102) W. R. Schelman, S. K. Sandhu, V. Moreno Garcia, G. Wilding, L. Sun, C. Toniatti, M. Stroh, N. Kreischer, C. L. Carpenter, L. R. Molife, S. B. Kaye, J. S. De Bono, R. M. Wenham Brd. 19D Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies. (Abstract #3103) Y. Pan, V. Haddad, T. Sabin, N. Baker, Y. Hei, F. Galimi, J. Graves, C. Huang, S. Cottrell Brd. 19E Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. (Abstract #3104) Y. Drew, J. A. Ledermann, A. Jones, G. Hall, G. C. Jayson, M. Highley, D. Rea, R. M. Glasspool, S. E. Halford, G. Crosswell, S. Colebrook, A. V. Boddy, N. J. Curtin, E. R. Plummer Brd. 19F Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P). (Abstract #3105) J. A. Lopez-Martin, M. Vidal Losada, J. Cortes, B. Bermejo, A. Lluch Fernandez, M. Learoyd, A. Saunders, M. Stuart, J. Baselga Brd. 19G FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors. (Abstract #3106) J. Chang, M. Rand, G. M. Blumenthal, P. Cortazar, C. Kulick, E. Hausman, S. Chang, R. Pratt, B. Habtemarium, Y. Chen, J. Bullock, R. Charlab Orbach, I. Zineh, R. L. Justice, R. Pazdur 305 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 8:00 AM - 12:00 PM GENERAL POSTER SESSION Tumor Biology Location: Hall A Track(s): Tumor Biology MONDAY Brd. 20A Evaluation of the prognostic significance of human mammaglobin expression in pleural effusion from patients with negative thoracoscopy. (Abstract #10534) A. Vigani, P. A. Canessa, C. Manta, P. Ferro, M. C. Franceschini, A. Morabito, M. Sivori, V. Fontana, F. Fedeli, M. Pistillo, S. Roncella Brd. 20B Clinical characterstics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. (Abstract #10535) H. E. El-Osta, G. S. Falchook, A. M. Tsimberidou, D. S. Hong, A. Naing, K. B. Kim, S. Wen, F. Janku, R. Kurzrock Brd. 20C The association of long pentraxin 3 on prognosis in pancreatic carcinoma patients on gemcitabine-based chemotherapy. (Abstract #10536) S. Kondo, H. Ueno, C. Morizane, F. Koizumi, K. Tamura, T. Okusaka Brd. 20D The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. (Abstract #10537) M. Maitah, S. Ali, P. LoRusso, F. H. Sarkar, S. M. Gadgeel Brd. 20E Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III nonsmall cell lung cancer. (Abstract #10538) B. C. Creelan, G. Bepler, S. Antonia, T. Garrett, H. H. Soliman Brd. 20F The predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2 alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. (Abstract #10539) S. Keskin, Y. Eralp, E. Akisik, A. Igci, M. Muslumanoglu, S. Yilmaz, M. Tunaci, H. Camlica, S. Tuzlali, P. Saip, N. Dalay, V. Ozmen, E. Topuz Brd. 20G Role of the type III TGF- receptor in modulating antitumor immunity during breast cancer progression. (Abstract #10540) B. A. Hanks, O. M. Campbell, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, G. C. Blobe Brd. 20H Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #10541) S. Viteri, R. Rosell, C. Costa, M. Taron, J. Sanchez, S. Benlloch, T. Moran, B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco, N. Mederos, I. Magri, C. D. Rolfo, M. Garcia-Campelo, A. Gimenez Capitan, I. de Aguirre, C. Queralt Brd. 21A The relationship between the number of aberrantly methylated regions and the methylation status of p73 and RARB genes and prognosis in patients with breast cancer. (Abstract #10542) D. M. Marzese, F. Gago, J. I. Orozco, O. M. Tello, L. M. Vargas-Roig, M. Roqué Brd. 21B An evaluation of molecular imaging with 11c-PD153035 PET/CT and its association in predicting outcomes in non-small cell lung cancer treated with EGFR-TKI. (Abstract #10543) X. Meng, J. Yu, B. W. Loo, L. Ma, X. Sun, J. D. Murphy, S. Q. Zhao, L. Kong, G. R. Yang, W. L. Li, X. G. Zhao 306 Brd. 21C A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumor responses to chemotherapy. (Abstract #10544) J. Stebbing, A. Sharma, B. North, T. J. Athersuch, A. Zebrowski, D. Pchejetski, R. C. Coombes, J. K. Nicholson, H. C. Keun Brd. 21D The prognostic role of calretinin expression and neutrophil-to-lymphocyte ratio (NLR) in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). (Abstract #10545) S. C. Kao, S. Klebe, D. Henderson, G. Reid, M. D. Chatfield, N. Armstrong, T. Yan, J. L. Vardy, S. J. Clarke, N. Van Zandwijk, B. McCaughan Brd. 21E The relationship of HOXB9 expression promoting tumor cell proliferation and angiogenesis to clinical outcomes of patients with breast cancer. (Abstract #10546) T. Hayashida, H. Jinno, H. Seki, M. Takahashi, M. Sakata, S. Hirose, M. Mukai, Y. Kitagawa Brd. 21F Correlation of 18F-FDG uptake and EGFR/KRAS mutations in surgically resected lung cancer. (Abstract #10547) K. Takamochi, S. Oh, M. Fukui, K. Suzuki Brd. 21G The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P)-carboplatin (C). (Abstract #10548) D. S. Tan, S. Aamdal, G. Freyer, R. J. Jones, S. B. Kaye, E. Pujade-Lauraine, J. Fog, M. Wrang Teilum, C. Glue, A. Baker, U. A. Emeribe, P. Elvin, C. Stephens, M. Stuart, J. Walker, E. Boven Brd. 21H Molecular characterization of primary breast cancer in older women using partitional clustering and correlation with long-term clinical outcome. (Abstract #10549) B. M. Syed, A. R. Green, D. Soria, E. C. Paish, J. Garibaldi, D. A. Morgan, I. O. Ellis, K. Cheung Brd. 22A Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissue derived from lung cancer patients. (Abstract #10550) A. J. Yee, T. Raz, A. Amzallag, D. Lipson, E. Giladi, H. Lopez, D. R. Borger, M. Mino-Kenudson, J. F. Thompson, A. J. Iafrate, P. Milos, D. A. Haber, S. Ramaswamy Brd. 22B MicroRNA expression patterns in lobular neoplasia. (Abstract #10551) L. A. Stead, A. Ramnauth, S. Fineberg, O. Loudig Brd. 22C Identification of LASEP3 as a new serological and prognostic biomarker for lung cancer. (Abstract #10552) A. Takano, Y. Nakamura, Y. Daigo Brd. 22D Clinical relevance of circulating CK-19mRNA-positive tumor cells at first diagnosis in patients with metastatic breast cancer. (Abstract #10553) N. E. Androulakis, M. Perraki, S. Apostolaki, V. Bozionelou, A. G. Pallis, K. Kalbakis, S. Agelaki, A. Xyrafas, D. Mavroudis, V. Georgoulias Brd. 22E Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumor cells in patients with early breast cancer. (Abstract #10554) N. Xenidis, M. Perraki, S. Apostolaki, S. Agelaki, K. Kalbakis, N. K. Vardakis, A. Kalykaki, A. Xyrafas, S. Kakolyris, D. Mavroudis, V. Georgoulias Brd. 22F Microarray-based gene expression profiles reliably predict ELISA-derived uPA and PAI-1 levels in breast cancer biopsies, a comparison between fresh frozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples. (Abstract #10555) C. Matuschek, H. Prisack, E. Boelke, W. Budach, M. Peiper, M. Rezai, W. Janni, H. Bojar 307 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 22G The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA technology. (Abstract #10556) Y. Kato, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, C. Tran, K. Yoshida, J. Matsubayashi, E. Nakajima, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, F. R. Hirsch Brd. 22H Clinical relevance of mesenchymal stem cell–induced resistance to chemotherapy. (Abstract #10557) J. M. Roodhart, L. G. Daenen, E. C. Stigter, R. H. Medema, A. C. Martens, A. B. Brenkman, E. E. Voest Brd. 23A A polymorphism in the coding sequence of WT1 is an independent prognostic marker in 1,101 patients with lobular breast cancer. (Abstract #10558) M. Heuser, F. Damm, P. Schuermann, M. Zucknick, M. Shah, P. Harrington, P. Pharoah, M. Schmidt, A. Broeks, R. van Hien, R. A. Tollenaar, H. Nevanlinna, T. Heikkinen, K. Aittomaki, C. Blomqvist, J. Krauter, P. Hillemanns, A. Ganser, T. Park-Simon, T. Dork Brd. 23B The prognosic value of the downregulation of leukocyte cell– derived chemotaxin 2 gene of hepatocellular carcinoma. (Abstract #10559) C. Yang, M. Ho, C. Chen, H. Hsu, P. Lee, M. Kuo Brd. 23C Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis. (Abstract #10560) D. S. Thompson, J. D. Hainsworth, C. M. Lane, W. J. Lennington, D. R. Spigel, F. A. Greco Brd. 23D Non-small cell lung cancer biomarkers: Discovery using mab proteomics. (Abstract #10561) L. Takacs, M. Guergova-Kuras, I. Kurucz, N. Tardieu, J. Kadas, C. Malderez-Bloes, A. Jullien, Y. Kieffer, B. Dezso, B. Karger Brd. 23E Performance characteristics and validation of automated tumor-infiltrating lymphocyte counting. (Abstract #10562) C. C. Hoyt, I. S. Hagemann, A. R. Hagemann, L. Wang, E. Hung, K. Lane, G. Coukos, M. D. Feldman Brd. 23F Thymidylate synthase expression in adenosquamous carcinoma of lung. (Abstract #10563) C. Shu, H. Cheng, A. Wang, M. Mansukhani, C. A. Powell, B. Halmos, A. C. Borczuk Brd. 23G Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues. (Abstract #10564) J. S. Ross, D. Lipson, R. Yelensky, M. Jarosz, A. Parker, C. E. Sheehan, F. Juhn, Z. Zwirko, K. Brennan, T. Bloom, S. Downing, J. Curran, M. T. Cronin Brd. 23H Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors. (Abstract #10565) Y. Liu, M. Starr, H. Pang, J. Marcello, B. R. Leigh, C. P. Theuer, H. Hurwitz, A. B. Nixon Brd. 24A Disparities in the prognostic significance of proliferation amongst different molecular subtypes in node-negative breast cancer. (Abstract #10566) M. Schmidt, I. Petry, D. Boehm, A. Lebrecht, S. Gebhard, H. Koelbl, M. Gehrmann, J. G. Hengstler Brd. 24B SmgGDS splice variants: Potential novel targets for breast cancer therapeutics. (Abstract #10567) C. Bergom, A. Hauser, E. L. Lorimer, R. Li, A. C. Mackinnon, C. L. Williams Brd. 24C Discovery of oncoproteins as cancer biomarkers and molecular targets for antibody-based immunotherapy. (Abstract #10568) Y. Daigo, A. Takano, Y. Nakamura 308 Brd. 24E Exonic expression variations of EGFR and KRAS in small bronchoscopic biopsies from patients with advanced non-small cell lung cancer treated by combined bevacizumab/erlotinib therapy followed by platinum-based chemotherapy at disease progression: A multicenter phase II trial SAKK19/05. (Abstract #10570) M. H. Brutsche, M. Frueh, S. Crowe, K. Na, C. Droege, D. C. Betticher, R. von Moos, F. Zappa, M. Pless, L. Bubendorf, F. Baty, on behalf of the Swiss Group for Clinical Cancer Research (SAKK) Brd. 24F An integrated analysis of three distinct IBC/non-IBC affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC. (Abstract #10571) S. J. Van Laere, N. T. Ueno, P. Finetti, P. B. Vermeulen, A. Lucci Jr., D. Birnbaum, F. Robertson, T. Iwamoto, P. A. van Dam, W. A. Woodward, P. Viens, L. Y. Dirix, J. M. Reuben, F. Bertucci Brd. 24G Circulating tumor cell (CTC) as a clinical marker in malignant pleural mesothelioma (MPM). (Abstract #10572) F. Tanaka, K. Yoneda, N. Kondo, M. Hashimoto, T. Takuwa, S. Matsumoto, S. Hasegawa, Y. Okumura, T. Tsujimura, K. Fukuoka, T. Nakano Brd. 24H Pathway analysis of primary human non-small cell lung cancer (NSCLC). (Abstract #10573) N. Daraselia, Y. Wang, A. Budoff, A. Lituev, O. Potapova, J. Monforte, V. Ossovskaya Brd. 25B A second generation microRNA-based assay for diagnosing tumor tissue origin. (Abstract #10575) R. T. Aharonov, S. Rosenwald, T. B. Edmonston, I. Barshack, M. Feinmesser, M. Huszar, W. C. Mueller, F. Fogt, H. Shomin, L. Cohen, I. Burnstein, E. Goren, B. St. Cyr, Y. Spector, N. Dromi, E. Meiri Brd. 25C NY-ESO-1 as a predictive marker for neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer (NSCLC). (Abstract #10576) T. John, Y. Chen, M. H. Starmans, M. Walkiewicz, P. Russell, A. Azad, S. Deb, N. K. Altorki, P. C. Boutros, P. Mitchell, J. S. Cebon Brd. 26A Circulating endothelial cell (CEC), a surrogate of tumor angiogenesis, as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM). (Abstract #10577) K. Yoneda, F. Tanaka, N. Kondo, H. Orui, M. Hashimoto, T. Takuwa, S. Matsumoto, Y. Okumura, A. Sato, T. Tsujimura, N. Tsubota, K. Kuribayashi, K. Fukuoka, T. Nakano, S. Hasegawa Brd. 26B A microRNA-based diagnostic test for kidney tumor classification. (Abstract #10578) A. Chajut, E. Fridman, I. Barshack, Z. A. Dotan, M. Zepeniuk, S. Tabak, D. Lebanony, E. Klinke, S. Rosenwald, O. Zion, A. Faerman, M. Ben-David, A. Bokish, Y. Spector Brd. 26C Use of immunohistochemical evaluation of DNA repair proteins to demonstrate cisplatin response prediction in resected NSCLC squamous cell carcinoma. (Abstract #10579) W. E. Pierceall, K. M. Sprott, E. Brambilla, R. Pirker, H. H. Popper, X. Wang, Y. Chen, S. Quan, M. Filipits, L. Alaparthi, J. Kutok, D. T. Weaver, M. Al-Adhami, F. Andre, T. Le Chevalier, B. E. Ward, J. Soria Brd. 27A MYC and human telomerase gene (TERC) gene copy number gain in resected in non-small cell lung cancer (NSCLC). (Abstract #10580) A. Flacco, V. Ludovini, F. R. Tofanetti, F. Bianconi, G. Bellezza, M. G. Mameli, G. Metro, C. Bennati, L. Cagini, N. Daddi, L. Pistola, A. Siggillino, E. Baldelli, A. Sidoni, F. Puma, M. Varella-Garcia, L. Crinò Brd. 27B A novel inflammatory-based prognostic score in hepatocellular carcinoma. (Abstract #10581) D. J. Pinato, H. S. Wasan, L. Maslen, B. North, R. Sharma 309 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 27C Disseminated tumor cells in the bone marrow of ductal carcinoma in situ patients. (Abstract #10582) N. Sänger, K. E. Effenberger, S. Riethdorf, E. Ruckhäberle, L. C. Hanker, I. Wiegratz, K. Strebhardt, K. Pantel, M. Kaufmann Brd. 28A SOX2-related micrornas, miR-145 and miR-367, as prognostic markers of time to recurrence (TTR) in surgically resected non-small cell lung cancer (NSCLC) patients (p). (Abstract #10583) A. Navarro, M. Campayo, N. Vinolas, V. Ciria, T. Diaz, R. M. Marrades, L. Molins, J. Ramirez, M. Monzo Brd. 28B Evaluation of anti-CTLA4 treatment in a murine model of intestinal polyposis. (Abstract #10584) J. D. Phillips, N. R. Blatner, M. F. Mulcahy, P. Beckhove, D. J. Bentrem, K. Khazaie Brd. 28C ALK chromosomal alterations in neuroendocrine tumors. (Abstract #10585) C. Montagut, E. Arriola, A. B. Galvan, F. G. Rojo, M. Salido, M. Gallen, M. Garcia, A. Martinez, F. Pons, S. Servitja, M. Iglesias, S. Menendez, S. Serrano, F. Sole, A. Rovira, J. Albanell, J. Bellmunt Brd. 29A Correlation of high levels of immature blood vessels in colorectal tumors with longer survival following bevacizumab treatment. (Abstract #10586) S. Noonan, P. Martin, M. Biniecka, A. Maguire, M. Tosetto, J. Hyland, K. Sheahan, D. O’Donoghue, H. Mulcahy, D. Fennelly, J. O’Sullivan Brd. 29B A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site of KRT81 and time to recurrence (TTR) in patients (p) with surgically resected non-small cell lung cancer (NSCLC). (Abstract #10587) M. Campayo, A. Navarro, N. Vinolas, R. Tejero, C. Munoz, T. Diaz, R. M. Marrades, M. L. Cabanas, J. M. Gimferrer, J. Ramirez, P. Gascon, M. Monzo Brd. 29C Gastrin-releasing peptide receptor expression in Brazilian and Japanese patients with lung cancer and normal lung tissue samples from healthy individuals. (Abstract #10588) J. Mattei, Y. Kato, M. W. Wynes, C. Cano, R. D. Achcar, B. Reyna Asuncion, B. R. de Macedo, L. Meurer, J. Kulczynski, R. Roesler, K. Yoshida, J. Matsubayashi, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, A. Brunetto, G. Schwartsmann Brd. 30A Prognostic value of CA27.29 trend during adjuvant chemotherapy and until 2 years thereafter in patients with primary breast cancer. (Abstract #10589) B. K. Rack, P. G. Hepp, U. Andergassen, J. K. Neugebauer, J. Salmen, G. Heinrich, J. Schreier, A. Hoenig, D. Finas, T. Zwingers, R. Kreienberg, M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Friese, W. Janni, SUCCESS Study Group Brd. 30B Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. (Abstract #10590) N. R. Foster, F. Sinicrope, G. A. Yothers, C. J. Allegra, D. J. Sargent Brd. 30C Reactivation of oncogene-induced senescence in KRAS mutant non-small cell lung cancer by inhibition of TWIST1. (Abstract #10591) T. F. Burns, I. Dobromilskaya, S. Murphy, S. Thiyagarajan, S. Das, P. T. Tran, C. M. Rudin Brd. 31A Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). (Abstract #10592) M. C. Liu, M. Mego, S. Nakamura, F. Nole, J. Pierga, M. Toi, E. Munzone, H. Yagata, M. T. Sandri, F. Bidard, H. Wang, D. F. Hayes, M. Cristofanilli Brd. 31B Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria. (Abstract #10593) L. Ding, R. L. Bliss, M. Ingebrand, T. Allen, P. Ives, A. Dudek, R. A. Kratzke 310 Monday, June 6, 2011 Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial. (Abstract #10594) T. Degenhardt, O. Gluz, H. H. Kreipe, R. E. Kates, C. Liedtke, S. Shak, M. R. Clemens, D. Augustin, U. Nitz, N. Harbeck, on behalf of the Plan B investigators Brd. 31D Association of the MDM2 T309G polymorphism and gastroesophageal reflux disease (GERD) with overall survival (OS) in esophageal adenocarcinoma (EAC). (Abstract #10595) D. J. Renouf, B. Sun, R. Zhai, W. Xu, R. S. Heist, M. Kulke, L. Su, D. C. Christiani, G. Liu Brd. 31E Molecular and clinicopathologic characteristics of HER2-mutant lung adenocarcinoma (ADC). (Abstract #10596) M. E. Arcila, J. E. Chaft, K. Nafa, M. G. Kris, M. F. Zakowski, M. Ladanyi Brd. 31F PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte laboratory developed test. (Abstract #10597) M. T. Ebbert, R. R. Bastien, L. R. Rowe, P. A. Miller, D. Anderson, K. M. Boucher, L. M. Pappas, C. Fauron, B. W. Lyons, T. Dowell, D. E. Wall, L. Barley, P. S. Bernard Brd. 31G Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. (Abstract #10598) A. Tamburrino, A. A. Molinolo, P. Salerno, R. Chernock, M. Raffeld, L. Xi, J. S. Gutkind, J. F. Moley, S. A. Wells, M. Santoro Brd. 31H Molecular predictors of metastases and stage of thymoma. (Abstract #10599) S. S. Badve, C. Goswami, Y. Gokmen-Polar, R. P. Nelson Jr., J. Henley, N. Miller, R. K. Jain, R. J. Mehta, N. A. Zaheer, G. W. Sledge Jr., L. Li, K. Kesler, P. J. Loehrer Brd. 32A Expression of Adam28 as a prognostic biomarker of survival in patients with early-stage non-small cell lung cancer. (Abstract #10600) Y. Zhang, X. Zhang, Y. Wu, G. Zhang, H. Cheng, S. Dong Brd. 32B An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma. (Abstract #10601) M. Nishio, T. Yamanaka, K. Matsumoto, H. Kimura, K. Sakai, A. Sakai, T. Sone, A. Horiike, F. Koizumi, K. Kasahara, T. Ohira, N. Ikeda, N. Saijo, T. Arao, K. Nishio Brd. 32C Signatures of drug sensitivity in non-small cell lung cancer. (Abstract #10602) H. Gong, D. G. Beer, S. Singh Brd. 32D Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling. (Abstract #10603) H. A. Azim, S. Michels, P. Bedard, D. Fumagalli, S. K. Singhal, B. Haibe-Kains, M. Piccart, C. Sotiriou, S. Loi Brd. 32E A mouse model of rectal cancer that mimics the clinical disease. (Abstract #10604) H. Kishimoto, M. Momiyama, R. Aki, H. Kimura, A. Suetsugu, M. Bouvet, T. Fujiwara, R. M. Hoffman Brd. 32F MicroRNA analysis as a potential diagnostic tool in the cytological diagnosis of non-small cell lung cancer. (Abstract #10605) A. Fassina, R. Cappellesso, A. Olivotto, M. Fassan Brd. 32G TGF1 gene polymorphisms with the risk of radiation pneumonitis in nonsmall cell lung cancer in different ethnic study. (Abstract #10606) X. Niu, S. Lu, H. Li, Y. Liu, Z. Chen, D. Zhou, M. Kan, Z. Li, Y. Yu, C. LV Brd. 32H Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. (Abstract #10607) S. Carp, C. Wanyo, M. Specht, L. Schapira, B. Moy, D. Finkelstein, D. Boas, S. J. Isakoff MONDAY Brd. 31C 311 Monday, June 6, 2011 MONDAY Brd. 33A Diagnostic and therapeutic significance of the cerebrospinal fluid (CSF) EGFR mutation analysis for the patients with NSCLC suffering meningitis carcinomatosa harboring active EGFR mutation, after gefitinib therapy failure. (Abstract #10608) S. Sasaki, Y. Yoshioka, R. Ko, Y. Katsura, Y. Namba, K. Koike, M. Yoshioka, S. Tominaga Brd. 33B KRAS and BRAF mutation analysis on paired biopsy and resection specimens of patients with colorectal cancer: Molecular analysis using high-resolution melting, direct sequencing, KRAS ARMS-scorpion PCR and BRAF pyrosequencing. (Abstract #10609) L. C. Krol, N. A. Hart, N. Methorst, A. J. Knol, C. Prinsen, J. E. Boers Brd. 33C An evaluation of bone marrow stromal-derived growth factor-1 and interleukin-8 levels in stage I-III breast cancer patients with disseminated tumor cells. (Abstract #10610) C. Hall, S. Krishnamurthy, A. Lodhi, A. Bhattacharyya, A. Anderson, H. M. Kuerer, I. Bedrosian, A. Lucci Jr. Brd. 33D Circulating levels of RANK/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: A prospective study. (Abstract #10611) T. Ibrahim, L. Mercatali, E. Sacanna, R. Ricci, E. Scarpi, P. Serra, F. Fabbri, C. Tison, D. Amadori Brd. 33E Differential efficacy of pemetrexed in non-squamous NSCLC based on human cytokeratin fragment antigen 21-1 (CYFRA21–1) serum levels. (Abstract #10612) K. Kaburaki, A. Horiike, T. Sakatani, R. Saito, H. Tanaka, N. Yanagitani, K. Kudo, F. Ohyanagi, S. Hagiwara, T. Horai, M. Nishio Brd. 33F Combined use of MammaPrint and molecular subtyping profile (BluePrint) to identify subgroups with marked differences in response to neoadjuvant treatment. (Abstract #10613) F. De Snoo, P. Roepman, O. Krijgsman, R. A. Bender, R. Bernards, A. Glas Brd. 33G A miRNA assay for the classification of benign and neoplastic lesions in pancreatic fine needle aspirates. (Abstract #10614) A. E. Schwarzbach, A. Adai, M. Lloyd, B. F. Andruss Brd. 33H Collecting tissue for research purposes: A survey of 16 institutions in the Translational Breast Cancer Research Consortium (TBCRC). (Abstract #10615) E. S. Frank, R. T. Burns, N. E. Carbine, L. Cargen, C. Chauhan, D. K. Cline, R. Kleban, S. A. Mertz, A. H. Meyn, J. Perlmutter, C. A. Rufenbarger, M. Smith, P. A. Spears, L. V. Vincent, A. C. Wolff Brd. 34A Use of the DEPArray platform to detect, isolate, and molecularly characterize pure tumor cells from peripheral blood samples enriched using the CellSearch system. (Abstract #10616) G. Medoro, S. Gross, N. Manaresi, M. Sergio, F. Fontana, S. Gianni, A. Calanca, E. Peruzzi, M. Banzi, G. Signorini, C. Rao, J. Patel, J. Karkera, G. Giorgini, M. Mata, M. C. Connelly Brd. 34B The prognostic impact of circulating tumor cells in patients with small cell lung cancer. (Abstract #10617) T. Naito, F. Tanaka, K. Yoneda, T. Takahashi, H. Murakami, Y. Nakamura, A. Tsuya, M. Endo, H. Kenmotsu, K. Kaira, T. Shukuya, A. Ono, H. Akamatsu, S. Miura, M. Kimura, N. Yamamoto Brd. 34C Significance of FANCJ expression as a predictive marker of sensitivity to 5-fluorouracil in colorectal cancer. (Abstract #10618) R. Nakanishi, H. Kitao, N. Yamashita, N. Kubo, Y. Fujinaka, M. Iimori, E. Oki, M. Morita, Y. Kakeji, Y. Maehara 312 Brd. 34D Implications of specific T-cell responses by different novel and known immunogenic tumor-associated antigens (TAA) in patients with metastatic lung cancer. (Abstract #10619) A. M. Babiak, M. Steinhauser, S. Hofmann, J. Conzelmann, V. Schneider, M. Goetz, L. Zhang, H. Dohner, J. Greiner Brd. 34E Influence of KRAS status of colorectal cancer liver metastases in patients receiving neoadjuvant chemotherapy including bevacizumab prior liver resection. (Abstract #10620) S. Stremitzer, J. Maresch, T. Aschacher, B. Wolf, F. Wrba, T. Gruenberger, B. Gruenberger Brd. 34F Intravital evaluation of time-course efficacy of anticancer drugs on colorectal liver metastases in the same living mice using two-photon laser scanning microscopy. (Abstract #10621) K. Tanaka, Y. Morimoto, Y. Toiyama, S. Saigusa, Y. Okugawa, Y. Inoue, K. Uchida, K. Matsushita, M. Kawamura, A. Mizoguchi, M. Kusunoki Brd. 34G Clinical, biological, and pathological features predicting non-sentinel lymph node (NSLN) status in breast cancer (BC). (Abstract #10622) J. Furlanetto, E. Fiorio, G. Pollini, Z. Franchini, P. Pietrarota, Q. Piubello, F. Bonetti, R. Micciolo, E. Manfrin, G. L. Cetto, A. Molino Brd. 34H Prognostic role of interleukin-1B and interleukin-1-receptor antagonist polymorphisms in localized gastric cancer. (Abstract #10623) E. Goekkurt, G. Folprecht, S. Lehmann, L. Obermann, M. Kramer, A. Rentsch, S. Wilop, G. Ehninger, T. H. Brummendorf, J. Stoehlmacher-Williams Brd. 35A Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. (Abstract #10624) E. De Vries, L. B. Anthony, L. Sideris, L. Chen, J. Lebrec, Z. Tsuchihashi, R. E. Winkler, J. C. Yao, K. E. Oberg Brd. 35B Comparison of predictive and prognostic impact of molecular subtypes and central grade regarding taxane-based therapy in intermediate-risk breast cancer: Results from the EC-Doc trial. (Abstract #10625) U. Nitz, O. Gluz, C. Liedtke, J. B. Huober, A. Hartmann, R. E. Kates, H. H. Kreipe, E. Pelz, W. Kuhn, N. Harbeck, on behalf of the EC-Doc investigators (West German Study Group/AGO-B) Brd. 35C Correlation of CA 27.29 and circulating tumor cells before, at the end, and 2 years after adjuvant chemotherapy in patients with primary breast cancer: The SUCCESS trial. (Abstract #10626) P. G. Hepp, B. K. Rack, H. Tesch, M. Rezai, T. Beck, J. Salmen, U. Andergassen, U. Ortmann, T. Zwingers, M. W. Beckmann, W. Lichtenegger, J. W. Janni, SUCCESS Study Group Brd. 35D Determining argininosuccinate synthetase (ASS) expression in melanoma patients treated with arginine depleting therapy. (Abstract #10627) V. Dinh, M. You, N. Savaraj, C. Wu, M. T. Kuo, M. Wangpaichitr, L. G. Feun Brd. 35E Pathoepidemiological patterns of contralateral breast cancers in Black and White women. (Abstract #10628) H. Nsouli-Maktabi, A. M. Schwartz, S. D. Cleary, N. Younes, H. A. Young, D. E. Henson Brd. 35F Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. (Abstract #10629) R. Audet, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. M. Litwiniuk, S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. Chang, K. Miller, J. Jassem, G. W. Sledge Jr., B. Leyland-Jones Brd. 35G Biomarkers affecting metastasis and survival in paired tissues of 107 patients with metastatic breast cancer. (Abstract #10630) E. Kim, H. Lee, G. Gong, K. Jung, J. Ahn, B. Son, S. Ahn, H. Kim, S. Kim 313 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 Brd. 35H Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH. (Abstract #10631) F. Z. Bischoff, T. J. Pircher, T. Pham, K. Wong, S. Mikolajczyk, P. Cotter, J. A. Mayer Brd. 36A Proof of concept of immuno-PET molecular imaging of met using 76Br- and Zr-labeled MetMAb. (Abstract #10632) M. Merchant, J. Marik, J. Peng, S. P. Williams, A. Ogasawara, J. N. Tinianow, V. Bhadrasetty, L. Lang, S. M. Lee, I. Kim, M. Williams, L. Szajek, K. E. Raffensperger, F. Cecchi, E. Jagoda, P. L. Choyke, C. Paik, D. P. Bottaro 89 MONDAY 314 Monday, June 6, 2011 8:00 AM - 12:00 PM TRIALS IN PROGRESS POSTER SESSION Trials in Progress Poster Session Brd. 36B A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. (Abstract #TPS100) R. S. Finn, K. Boer, I. Lang, R. J. Parikh, R. Patel, M. Schmidt, C. T. Hagenstad, H. J. Lim, T. Pinter, D. Amadori, D. Chan, R. Dichmann, S. T. Kim, S. Randolph, D. J. Slamon, J. P. Crown Brd. 36C Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. (Abstract #TPS101) S. D. Ramsey, W. E. Barlow, C. Moinpour, A. M. Gonzalez-Angulo, G. N. Hortobagyi, D. L. Veenstra, L. P. Garrison, S. R. Tunis, L. H. Baker Brd. 36D MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). (Abstract #TPS102) P. A. Ellis, C. H. Barrios, Y. Im, M. Patre, F. Branle, E. A. Perez Brd. 36E A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC; NCIC Clinical Trials Group MA.32). (Abstract #TPS103) W. Parulekar, B. E. Chen, C. Elliott, L. E. Shepherd, K. A. Gelmon, K. I. Pritchard, T. J. Whelan, J. A. Ligibel, D. L. Hershman, I. A. Mayer, T. J. Hobday, P. Rastogi, J. Lemieux, P. A. Ganz, V. Stambolic, P. J. Goodwin Brd. 36F SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. (Abstract #TPS104) A. M. Gonzalez-Angulo, W. E. Barlow, J. Gralow, F. Meric-Bernstam, D. F. Hayes, C. Moinpour, S. D. Ramsey, A. F. Schott, D. B. Sparks, K. S. Albain, G. N. Hortobagyi Brd. 36G Ongoing clinical development of lapatinib in HER2-positive (HER2ⴙ) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. (Abstract #TPS105) S. R. Johnston, K. A. Gelmon, X. B. Pivot, W. J. Gradishar, A. Conner, D. Kothari, P. Legenne, M. Leigh, L. O’Rourke, R. Parikh Brd. 36H A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). (Abstract #TPS106) S. Viswanathan, R. Wesolowski, R. M. Layman, G. Alejandra, B. Miller, J. J. Chalmers, S. Bejastani, W. Zhao, G. Pierluigu, J. Cotrill, M. A. Phelps, L. J. Schaaf, S. M. Geyer, N. Hall, M. V. Knopp, C. L. Shapiro, M. A. Villalona-Calero, A. Chen, M. R. Grever, B. Ramaswamy Brd. 37A An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2ⴙ) advanced or metastatic breast cancer (MBC). (Abstract #TPS107) R. C. Coombes, J. A. Reise, M. Lau, S. C. Carme, G. E. Searle, M. Huiban, P. Burgess, K. Koch, A. Das-Gupta, A. Saleem 315 MONDAY Location: Hall A Track(s): Clinical Trials; Special Session Monday, June 6, 2011 MONDAY Brd. 37B Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919). (Abstract #TPS108) W. Parulekar, J. W. Chapman, S. Aparicio, Y. Murray, F. M. Boyle, A. Di Leo, B. Kaufman, C. Levy, A. Manikhas, M. Martin, K. I. Pritchard, L. S. Schwartzberg, M. J. Burnell, S. Dent, S. Ellard, K. S. Tonkin, T. J. Whelan, J. Lemieux, L. Bordeleau, K. A. Gelmon Brd. 37C Safety and efficacy of single-agent adjuvant trastzumab in older women with breast cancer. (Abstract #TPS109) C. Owusu, H. D. Klepin, G. G. Kimmick, L. Sutton, A. Brufsky Brd. 37D A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ERⴙ) breast cancer. (Abstract #TPS110) S. Ebbinghaus, J. L. Blum, J. Cortes, H. S. Rugo, C. Swanton, L. Eaton, Y. Song, T. Zhang, J. Baselga Brd. 37E Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. (Abstract #TPS111) P. Haluska, A. Dhar, X. Hou, F. Huang, D. S. Nuyten, J. Park, A. H. Brodie, J. N. Ingle, J. M. Carboni, M. M. Gottardis, A. C. Wolff, F. G. Finckenstein Brd. 37F A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ERⴙ) and/or progesterone receptor-positive (PRⴙ), HER2-negative breast cancer. (Abstract #TPS112) V. M. Moyo, M. J. Higgins, R. Aravelo-Araujo, N. Iannotti, V. Charu, N. Dhindsa, P. E. Goss Brd. 37G HER2 suppression with the addition of lapatinib to trastuzumab in HER2positive metastatic breast cancer (LPT112515). (Abstract #TPS113) N. U. Lin, M. A. Danso, A. K. David, J. J. Muscato, C. E. Ellis, S. Lahiri, T. Sessa, Y. M. Nagarwala, E. Winer Brd. 37H Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neunegative metastatic breast cancer: New York Cancer Consortium trial P8853. (Abstract #TPS114) E. Andreopoulou, A. P. Chen, J. Zujewski, M. Kim, D. L. Hershman, K. Kalinsky, T. Cigler, L. T. Vahdat, G. Raptis, B. Ramaswamy, Y. Novik, F. Muggia, J. A. Sparano Brd. 38A A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). (Abstract #TPS115) R. C. Coombes, G. Von Minckwitz, J. Hicks, P. Klare, A. A. Evans, M. Schmidt, A. Makris, R. Grieve, S. Loibl, L. Maher, K. Mousa, K. Buchsenscuhtz, R. A’Hern, J. M. Bliss Brd. 38B EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. (Abstract #TPS116) S. Verma, V. Dieras, L. Gianni, D. Miles, M. Welslau, M. D. Pegram, J. Baselga, E. Guardino, L. Fang, C. M. Linehan, K. L. Blackwell Brd. 38C Trial of perioperative endocrine therapy: Individualizing care (POETIC). (Abstract #TPS117) I. E. Smith, L. Johnson, M. Dowsett, J. F. Robertson, L. E. Robison, J. S. Kokan, A. A. Evans, C. Holcombe, K. Horgan, A. Skene, R. Prasad, M. S. Absar, R. Vidya, N. J. Bundred, C. Harding-Mackean, D. A. Wheatley, M. W. Kissin, I. F. Pinhel, L. S. Kilburn, J. M. Bliss, on behalf of the POETIC Trialists 316 Brd. 38D Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA). (Abstract #TPS118) M. Munoz-Mateu, A. Urruticoechea, R. Separovic, J. Erfán, T. D. Bachelot, J. Canon, N. Kovalenko, E. Staroslawska, B. Pikó, C. Veyret, O. Pribylova, D. L. Ciule, J. Ratnayake, S. Das, K. Mayne, G. Ross Brd. 38E A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer. (Abstract #TPS119) M. J. Higgins, N. Y. Gabrail, K. Miller, S. V. Agresta, S. Sharma, C. McDonagh, J. Murray, K. Andreas, S. Frye, V. M. Moyo, C. Niyikiza, P. D. Ryan Brd. 38F A randomized trial assessing the use of electro-acupuncture for aromatase inhibitor-induced arthralgia. (Abstract #TPS120) J. M. Beith, E. Segelov, K. Orme, A. McLean, B. Oh Brd. 38G Serum NT pro-BNP and individual genetic polymorphisms as predictors of trastuzumab-related cardiotoxicity. (Abstract #TPS121) S. Goel, J. Lynch, L. A. Chantrill, J. J. Rutovitz, B. Murray, E. A. Abdi, R. Bell, A. L. Sullivan, A. Goldrick, T. M. Hayes, G. Asghari, N. Wilcken, N. J. McCarthy, J. M. Beith Brd. 38H TBCRC 011: Targeting the androgen receptor (AR) for the treatment of ARⴙ/ER-/PR- metastatic breast cancer (MBC). (Abstract #TPS122) A. Gucalp, S. M. Tolaney, S. J. Isakoff, J. N. Ingle, M. C. Liu, L. A. Carey, K. L. Blackwell, H. S. Rugo, L. Nabell, A. Abbruzzi, J. Gonzalez, D. D. Giri, S. Patil, K. Feigin, G. D’Andrea, M. Theodoulou, P. Drullinsky, N. T. Sklarin, C. Hudis, T. A. Traina, Translational Breast Cancer Research Consortium Brd. 39A Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer. (Abstract #TPS123) L. S. Schwartzberg, M. Beeram, A. Patnaik, A. W. Tolcher, L. Itri, A. L. Olson, A. D. Seidman Brd. 39B Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). (Abstract #TPS124) J. Baselga, L. S. Schwartzberg, O. Petrenciuc, M. Shan, W. J. Gradishar Brd. 39C ACRIN 6688 phase II study of fluorine-18 3-deoxy-3 fluorothymidine (FLT) in invasive breast cancer. (Abstract #TPS125) P. R. Jolles, L. Kostakoglu, H. D. Bear, M. O. Idowu, K. A. Kurdziel, L. Shankar, D. A. Mankoff, F. Duan, D. L’Heureux Brd. 39D ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen—A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but oestrogen receptor beta-positive metastatic breast cancer. (Abstract #TPS126) B. E. Kiely, K. Phillips, P. A. Francis, F. M. Boyle, J. F. Forbes, S. B. Fox, L. Murphy, V. Gebski, D. F. Lindsay, R. L. Sutherland, H. Badger Brd. 39E TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triplenegative breast cancer (TNBC) brain metastases (BM). (Abstract #TPS127) C. K. Anders, R. Nanda, M. C. Liu, K. L. Blackwell, C. H. Van Poznak, V. G. Abramson, A. M. Storniolo, N. U. Lin, V. Stearns, A. Melhem, S. Puhalla, J. T. Carpenter, M. E. Melisko, A. M. Deal, C. Hudis, E. P. Winer, C. M. Perou, C. R. Bradley, A. C. Wolff, L. A. Carey, Translational Breast Cancer Research Consortium 317 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 39F TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer. (Abstract #TPS128) A. Forero-Torres, N. U. Lin, M. C. Liu, H. S. Rugo, S. Puhalla, R. Nanda, I. A. Mayer, A. M. Storniolo, T. A. Traina, D. F. Hayes, M. F. Rimawi, M. P. Goetz, F. J. Esteva, W. J. Irvin Jr., A. C. Wolff, on behalf of the Translational Breast Cancer Research Consortium Brd. 39G An observational study using ␥-H2AX foci to investigate cardiac doses of radiation following adjuvant radiotherapy for breast cancer: Standard external beam radiotherapy to the breast versus intraoperative radiotherapy. (Abstract #TPS129) D. Woolf, R. Bakhshi, S. Fawcitt, M. Worku, D. B. Ghosh, S. Sivabalasingham, N. R. Williams, S. Short, K. Pigott, M. R. Keshtgar Brd. 39H PARP inhibition after preoperative chemotherapy in patients with triplenegative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. (Abstract #TPS130) S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge Jr., K. Miller Brd. 40A Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial). (Abstract #TPS131) D. Azria, D. Cowen, C. Bourgier, B. de la Lande, S. Gourgou-Bourgade, Z. Douadi Gaci, M. Leblanc-Onfroy, I. Latorzeff, O. Pradier, P. Maingon, I. Lecouillard, P. Bontemps, S. Ellis, C. Levy, A. Benyoucef, S. Racadot, H. Laharie-Mineur, P. Lagarde, C. Marchal, C. Lemanski Brd. 40B A phase IIa clinical biomarker trial of aspirin and dietary arginine restriction in colorectal cancer patients. (Abstract #TPS132) J. A. Zell, C. E. McLaren, C. G. Albers, E. W. Gerner, L. B. Wenzel, F. L. Meyskens Brd. 40C Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB) and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). (Abstract #TPS133^) M. Khasraw, S. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, H. Wheeler Brd. 40D CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma. (Abstract #TPS134) V. Verschaeve, L. A. D’Hondt, L. M. Verbeke, F. Van Fraeyenhove, S. Du Four, J. Duerinck, B. Neyns Brd. 40E A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma. (Abstract #TPS135) D. M. Peereboom, J. N. Rich, J. G. Supko, K. Lamborn, X. Ye, A. E. Sloan, M. Prados, S. A. Grossman, Adult Brain Tumor Consortium (ABTC) Brd. 40F AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. (Abstract #TPS136) O. L. Chinot, W. Wick, F. Saran, W. P. Mason, R. Henriksson, R. Nishikawa, A. H. Zeaiter, N. Moore, A. Das, T. F. Cloughesy Brd. 40G A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2ⴙ breast cancer (BC). (Abstract #TPS137) P. E. Goss, C. H. Barrios, A. Chan, S. K. Chia, S. Delaloge, B. Ejlertsen, J. N. Ingle, B. Moy, H. Iwata, F. A. Holmes, J. Mansi, G. Von Minckwitz, L. Han, A. Thiele, V. Agrapart, A. Freyman, J. Truscello, A. Berkenblit, D. Finkelstein 318 Brd. 40H A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. (Abstract #TPS138) N. M. Reddy, R. Simmons, M. Caldwell, M. H. Jagasia, D. S. Morgan, S. I. Park, J. P. Greer, K. L. Richards Brd. 41A Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). (Abstract #TPS139) L. M. Krug, A. S. Tsao, S. Kass, V. W. Rusch, W. D. Travis, K. Panageas, P. S. Adusumili, M. G. Kris, P. G. Maslak, D. A. Scheinberg Brd. 41B CYPTAM-BRUT 2: A prospective multicenter observational study in the neoadjuvant and metastatic setting investigating tamoxifen response between women with a favorable versus unfavorable endoxifen profile. (Abstract #TPS140) A. Dieudonné, H. Wildiers, D. Lambrechts, H. Guchelaar, V. O. Dezentje, M. Joerger, K. Zaman, I. B. Vergote, P. Neven Brd. 41C A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. (Abstract #TPS141) N. S. Azad, L. A. Diaz Jr., C. E. Devoe, D. Laheru, D. T. Le, D. Cosgrove, L. Zheng, A. De Jesus-Acosta, R. C. Donehower, P. M. Arlen, J. A. Bristol Brd. 41D A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC). (Abstract #TPS142) M. Ciprotti, I. D. Davis, D. W. Pook, F. T. Lee, T. Cavicchiolo, S. Lee, B. Chappell, G. J. O’Keefe, H. Tochon-Danguy, F. E. Smyth, W. Hopkins, A. M. Scott Brd. 41E Validation of the phase 0 concept. (Abstract #TPS143) J. R. Westin, S. Fu, D. S. Hong, T. Helgason, F. Ouyang, L. S. Angelo, K. S. Culotta, S. N. Westin, R. Kurzrock Brd. 41F A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy. (Abstract #TPS144) T. Ikdahl, I. Davidenko, C. Bassi, E. Tomasetto, L. Smith, S. McLachlan, S. Jones, M. Raponi, J. Isaacson, C. Voong, L. Rolfe, A. R. Allen, E. Poplin Brd. 41G First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. (Abstract #TPS145) J. A. Sosman, A. A. Adjei, P. LoRusso, S. A. Michael, G. K. Dy, A. Bowditch, B. Chmielowski, S. Lee, R. M. Walker, S. Faucette, E. S. Izmailova, V. Bozon, A. Ribas Brd. 41H A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors. (Abstract #TPS146) L. E. Strong, J. A. Kink, B. Mei, M. N. Shahan, R. T. Raines Brd. 42A Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. (Abstract #TPS147) K. Kalinsky, J. A. Sparano, M. Kim, K. D. Crew, M. A. Maurer, B. Taback, S. M. Feldman, H. Hibshoosh, L. Wiechmann, K. B. Adelson, D. L. Hershman Brd. 42B Valproic Acid Signature Trial (VAST): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer. (Abstract #TPS148) A. L. Cohen, M. Schabel, A. Bild, T. L. Werner Brd. 42C First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. (Abstract #TPS149) J. Soria, F. G. De Braud, R. Cereda, R. Bahleda, A. Delmonte, E. Angevin, A. Varga, C. Noberasco, E. Dall’O’, N. Lassau, C. Dromain, M. Bellomi, F. Farace, F. Bertolini, M. Zucchetti, S. Marsoni, M. G. Camboni 319 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 42D Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available. (Abstract #TPS150) R. E. Martell, E. G. Chiorean, H. Youssoufian, M. D. Rutstein, B. Pytowski, L. Benjamin, L. Abad, J. Patel, T. Steele, M. Dowd, A. Qin, C. F. Kukel, F. E. Fox, A. Dontabhaktuni, A. Morozov Brd. 42E Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20 – 0903/NCT01234402). (Abstract #TPS151) L. T. Vahdat, K. Miller, J. A. Sparano, H. Youssoufian, J. D. Schwartz, S. Nanda, W. Wang, L. Abad, A. Dontabhaktuni, M. D. Rutstein Brd. 42F A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (DCARE). (Abstract #TPS152) P. E. Goss, C. H. Barrios, R. Bell, D. Finkelstein, H. Iwata, M. Martin, A. H. Braun, R. D. Dansey, R. E. Coleman Brd. 42G Integrative and multidisciplinary clinical trial using imaging, molecular, and dynamic biomarkers to predict bevacizumab plus chemotherapy response in breast cancer. (Abstract #TPS153) J. Lopez Vega, E. G. Calvo, A. Plazaola, B. Hernando, S. Morales Murillo, A. Anton, R. S. Gomez, I. Alvarez, J. J. Illarramendi, A. De Juan, P. Martinez, A. Llombart, S. J. Scherer, L. Sabariz, A. la Huerta, L. J. Pina, I. Dominguez, M. J. Garcia Velloso, V. Boni, J. Garcia-Foncillas Brd. 42H Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. (Abstract #TPS154) A. Leary, L. M. Pickering, J. M. Larkin, M. O. Leach, M. E. Gore, A. Sohaib, D. J. Collins, D. Koh Brd. 43A Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma. (Abstract #TPS155) G. Anandappa, E. Sala, H. K. Cheow, N. J. Bird, A. Shaw, A. N. Priest, A. Gill, T. Fryer, Y. T. Hong, R. Smith, A. Backen, B. Whitcher, A. Jonson, D. Richards, L. Cookson, W. M. Lee, C. Dive, K. M. Fife, D. I. Jodrell, T. Eisen Brd. 43B A phase I, single-institution open label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. (Abstract #TPS156) S. R. Ahmed, D. Cosgrove, D. Ball, R. C. Donehower, B. Nelkin, E. Petito, M. Downs, H. X. Chen, A. Doyle, A. Scardina, M. A. Carducci, N. S. Azad Brd. 43C Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC). (Abstract #TPS157) M. R. Khawaja, A. Younger, J. M. Funke, M. J. Waddell, D. R. Jones, K. Pollok, N. K. Prasad, W. Berry, G. Sandusky, E. G. Chiorean Brd. 43D A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor olaparib with carboplatin in refractory/recurrent women’s cancers: NCT01237067. (Abstract #TPS158) J. Lee, J. Squires, J. L. Hays, H. L. Kotz, D. Nielsen, N. D. Houston, E. C. Kohn Brd. 43E A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. (Abstract #TPS159) K. P. Papadopoulos, N. G. Chau, A. Patnaik, L. Adriaens, A. S. Lalani, C. Daly, L. L. Siu 320 Brd. 43F A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment. (Abstract #TPS160) L. A. Fecher, Y. McGrath, D. D. Williams, N. J. Hassan, M. Kalos, L. M. Schuchter, R. K. Amaravadi, A. Chew, E. A. Veloso, B. J. Czerniecki, G. Karakousis, G. P. Linette, B. K. Jakobsen, C. H. June Brd. 43G A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy. (Abstract #TPS161) A. L. Thomas, R. H. Wilson, W. P. Steward, R. A. Adams, S. E. Bridges, A. C. Casbard, T. S. Maughan, G. Griffiths, NCRI Colorectal Clinical Studies Group Brd. 43H A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT). (Abstract #TPS162) A. R. Townsend, L. Pirc, J. Hardingham, C. S. Karapetis, N. C. Tebbutt, N. Singhal, T. J. Price Brd. 44A A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial. (Abstract #TPS163) J. D. Shapiro, L. L. Siu, J. R. Zalcberg, M. J. Moore, J. Ringash, N. Mittmann, J. Simes, C. J. O’Callaghan, D. Tu, I. B. Walters, N. Magoski, P. Smith, D. Nomikos, L. Zhu, M. Savoie, S. Virk, F. El-Tahche, R. Gill, T. J. Price, D. J. Jonker Brd. 44B PULSE: An open-label, phase II study assessing double positivity (phosphoinsulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6 —A GEMCAD study. (Abstract #TPS164) J. Maurel, X. Garcia-Albeniz, C. Méndez Méndez, M. Martin-Richard, C. Pericay, R. Vera, J. Aparicio, M. Rubini, M. Cuatrecasas, on behalf of the GEMCAD Cooperative Group Brd. 44C Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study. (Abstract #TPS165) T. S. Maughan, R. H. Wilson, G. T. Williams, M. T. Seymour, S. Richman, P. Quirke, M. Pope, J. Pope, M. Parmar, A. Nelson, A. M. Meade, S. L. Kenny, B. Jasani, E. Hodgkinson, D. Fisher, R. Butler, J. A. Bridgewater, R. A. Adams, R. S. Kaplan Brd. 44D LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial. (Abstract #TPS166) C. C. Schimanski, P. R. Galle, H. Lang, M. Schoen, M. H. Moehler Brd. 44E The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS167) R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, J. J. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots, R. A. Bender, J. Capdevila Brd. 44F A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome. (Abstract #TPS168) M. Kulke, T. M. O’Dorisio, A. T. Phan, R. M. Langdon Jr., B. J. Marek, N. Iklaque, E. K. Bergsland, J. Freiman, K. Frazier, J. Jackson, B. Zambrowicz Brd. 44G IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer. (Abstract #TPS169) S. A. Szyldergemajn, A. Gonçalves, J. Metges, K. Gunzer, C. Montagut, R. Salazar, M. Alsina, T. Evans, D. Swinson, R. D. Petty, H. Singer, C. M. Kahatt 321 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 44H A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer. (Abstract #TPS170) M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, L. Ley, S. K. Apte, S. J. Littman, L. M. Weiner, J. Marshall, J. R. Brody Brd. 45A PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment. (Abstract #TPS171) J. Capdevila, A. Teule, D. E. Castellano, J. Sastre, R. Garcia-Carbonero, I. Sevilla, I. Duran, P. Escudero, J. Fuster, E. Grande Pulido Brd. 45B Phase I trial of sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation (LT). (Abstract #TPS172) A. B. Siegel, R. Hidalgo, D. Tsushima, J. Zaretsky, J. Emond, T. Kato, R. S. Brown Jr. Brd. 45C A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376). (Abstract #TPS173) D. J. Cohen, L. Liebes, R. Xu, N. Takebe, J. A. Sparano, New York Cancer Consortium Brd. 45D A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer. (Abstract #TPS174) W. M. D. Tai, W. S. Ooi, J. Y. Ngeow, N. Deng, H. Wang, C. K. Tham, H. Y. Lim, S. P. Choo, P. Tan, H. C. Toh, I. B. Tan Brd. 45E Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma. (Abstract #TPS175) J. Ricke, K. Schuette, I. W. Graziadei, A. Jakob, C. Verslype, B. Sangro, J. Walecki, H. Klümpen, B. Peynircioglu, S. Yalcin, C. Bartolozzi, H. Amthauer, P. Malfertheiner Brd. 45F Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. (Abstract #TPS176) M. J. Borad, D. Sigal, H. Uronis, J. Stephenson Jr., N. Bahary, M. U. Rarick, L. C. DeMarco, T. J. Finnegan, E. G. Chiorean, D. P. Ryan, A. L. Cohn, B. K. Ulrich, V. C. Harish, E. N. Anderes, W. Ma, P. P. Yu, F. Sinicrope, C. Eng, U. K. Sunkara, S. G. Reddy Brd. 45G ACRIN 6690: Can contemporary imaging reduce false-positive rate in liver transplant (LT) allocation? A multicenter comparison of CT and MRI for diagnosis of hepatocellular carcinoma (HCC). (Abstract #TPS177) C. Wald, M. Nalesnik, E. A. Pomfret, M. Russo, M. A. Rosen, D. M. Hartfeil, P. Fox, M. L. Heckel, C. Gatsonis Brd. 45H Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial. (Abstract #TPS178) D. Malka, S. Gourgou-Bourgade, J. Emile, P. Laurent-Puig, J. Taı̈eb Brd. 46A The Personalized RNA Interference to Enhance the Delivery of Individualized Cytotoxic and Targeted Therapeutics (PREDICT) approach to biomarker discovery in renal cell carcinoma. (Abstract #TPS179) M. Gerlinger, L. Albiges, on behalf of the PREDICT Consortium (www.predictconsortium.eu) Brd. 46B SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). (Abstract #TPS180) K. N. Chi, J. S. De Bono, C. S. Higano 322 Brd. 46C A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). (Abstract #TPS181) C. G. Drake, H. I. Scher, W. R. Gerritsen, R. Ezzeddine, T. F. Fitzmaurice, J. Cuillerot, K. M. Chin, P. Gagnier Brd. 46D Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naı̈ve castration-resistant prostate cancer (CRPC). (Abstract #TPS182) T. M. Beer, C. Logothetis, P. Sharma, W. R. Gerritsen, R. Ezzeddine, J. P. Fairchild, P. Gagnier, K. M. Chin, J. Cuillerot Brd. 46E IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (Abstract #TPS183) B. I. Rini, T. Eisen, A. Stenzl, W. Brugger, T. Weinschenk, A. Mahr, J. Fritsche, N. Hilf, R. Mendrzyk, J. Lindner, A. Schmid, A. Kirner, S. Walter, H. Singh, C. Reinhardt Brd. 46F A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naive metastatic castrationresistant prostate cancer (mCRPC). (Abstract #TPS184) F. Saad, H. Akaza, M. A. Eisenberger, J. Nelson, H. I. Scher, K. Suzuki, M. Wirth, I. J. Webb, J. Wang, D. MacLean, R. De Wit Brd. 46G Phase I/II trial to establish the safety and preliminary efficacy of the combination of docetaxel, prednisone, and SOM 230 in metastatic castrateresistant prostate cancer (CRPC). (Abstract #TPS185) H. M. Vankayala, L. K. Heilbrun, J. A. Fontana, U. N. Vaishampayan Brd. 46H A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. (Abstract #TPS186) M. I. Milowsky, G. L. Carlson, M. M. Shi, G. Urbanowitz, Y. Zhang, C. N. Sternberg Brd. 47A Design of a phase II randomized, open-label trial of DN24 – 02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. (Abstract #TPS187) D. F. Bajorin, P. Sharma, R. B. Sims, A. Sandler, S. P. Lerner Brd. 47B A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. (Abstract #TPS188) K. Fizazi, T. Powles, D. J. George, C. H. Poehlein Brd. 47C Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate-specific antigen (PSA) after primary therapy. (Abstract #TPS189) E. S. Antonarakis, A. S. Kibel, D. W. Lin, R. C. Tyler, M. Tabesh, C. G. Drake Brd. 47D A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-ofconcept study of ARN-509 in patients with progressive advanced castrationresistant prostate cancer (CRPC). (Abstract #TPS190) D. E. Rathkopf, D. C. Danila, S. F. Slovin, M. J. Morris, J. E. Steinbrecher, Y. Chen, M. Fleisher, S. M. Larson, C. L. Sawyers, H. I. Scher Brd. 47E Predicting response to platinum chemotherapy in metastatic castrationresistant prostate cancer (mCRPC) using a genomic signature for “BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel. (Abstract #TPS191) S. M. Seng, M. D. Galsky, C. Tsao, J. Li, P. G. Febbo, W. K. Oh 323 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 47F A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma (NCI 8727). (Abstract #TPS192) E. Jonasch, P. Lara Jr., N. M. Tannir Brd. 47G Radiolabeled antiprostate specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial. (Abstract #TPS193) S. T. Tagawa, N. M. Hahn, D. A. Vaena, D. I. Quinn, W. K. Kelly, P. J. Christos, J. Osborne, S. Vallabhajosula, K. Nadeau, G. Mileo, L. Tyrell, A. Saran, C. Ecker, H. Beltran, S. J. Goldsmith, D. M. Nanus Brd. 47H Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors. (Abstract #TPS194) T. E. Hutson, J. Sarantopoulos, T. Logan, G. Sonpavde, M. D. Galsky, C. Sweeney, D. C. Bibby, G. Kremmidiotis, E. E. Doolin, N. M. Hahn, Hoosier Oncology Group Brd. 48A A phase II study to evaluate the efficacy and safety of catumaxomab as consolidation treatment in patients with epithelial ovarian cancer in second or third complete remission. (Abstract #TPS195) A. M. Oaknin, L. Chiva, I. Romero, A. Romero, M. M. Essing, A. González-Martı́n, GEICO Brd. 48B Concomitant chemoradiation or RT/cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: A randomized phase III factorial study. (Abstract #TPS196) A. Paccagnella, M. G. Ghi, I. Floriani, A. Gava, A. Buffoli, on behalf of the GSTTC Italian Collaborative Group Brd. 48C EORTC 22071–24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence. (Abstract #TPS197) C. Liberatoscioli, J. A. Langendijk, C. Van Herpen, L. Collette, E. M. Ozsahin, R. Karra Gurunath, D. A. Lacombe, A. Gulyban, N. Gosselin, W. Budach Brd. 48D PAPILLOPHAR: Impact of the human papillomavirus (HPV) status in the prognosis of oropharynx squamous cell carcinoma (OSCC). (Abstract #TPS198) J. Lacau Saint Guily, J. Pretet, G. Agius, A. Rousseau, B. Barry, X. Dufour, S. Perie, M. Lefevre, P. Birembaut, C. Mougin, T. Simon, C. Clavel, PAPILLOPHAR Group Brd. 48E CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naı̈ve patients with FLT3 mutated AML. (Abstract #TPS199) R. M. Stone, H. Dohner, G. Ehninger, M. Villeneuve, T. Teasdale, J. D. Virkus, L. R. Bressler, M. M. Seiler, G. Marcucci, R. A. Larson, on behalf of all study investigators Brd. 48F A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). (Abstract #TPS200) J. R. Gotlib, H. Kluin-Nelemans, M. J. Mauro, O. Hermine, E. O. Hexner, J. H. Lipton, F. T. Awan, Z. G. Nikolova, S. H. Gross, C. Dutreix, B. Dharan, T. George, P. Horny, C. Akin, K. Hartmann, P. Valent, A. Reiter, on behalf of all PKC412 D2201 study investigators 324 Brd. 48G Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. (Abstract #TPS201) C. R. Mehta, G. Michelson, M. Salganik, J. Feaster, R. Allen, A. L. Cahill, J. A. Fox, S. B. Ketchum, F. Ravandi, H. P. Erba, G. J. Schiller, R. K. Stuart, N. Vey, E. J. Feldman Brd. 48H Multicenter, single-arm phase II study of nilotinib in Philadelphia chromosome-positive (Phⴙ) chronic myeloid leukemia in chronic-phase (CML-CP) patients with low imatinib trough plasma concentrations. (Abstract #TPS202) S. Lim, R. C. Holdridge, M. Talpaz, C. N. Abboud, S. Yi, E. Noon, S. Ericson, M. Jones Brd. 49A RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU). (Abstract #TPS203) S. Verstovsek, J. Kiladjian, R. J. Waltzman, V. Sandor, J. Lukawy, W. M. Garrett, K. Malek, R. M. Huber, A. M. Vannucchi Brd. 49B A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia-chromosome positive (Phⴙ) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #TPS204) I. W. Flinn, S. Goldberg, R. L. Robles, D. Rizzieri, J. P. Radich, M. J. Mauro, S. Ericson, J. E. Cortes Brd. 49C Prospective, observational registry of branded imatinib and nilotinib exposure in pregnant women: Voluntary postauthorization safety study. (Abstract #TPS205) M. Juma, S. Ericson, D. Eng, A. Adeoye Brd. 49D A randomized phase III study of elacytarabine versus limited investigator’s choice in patients with refractory acute myeloid leukemia (AML). (Abstract #TPS206) D. Rizzieri, N. Vey, M. Gobbi, D. L. Selleslag, M. W. Dennis, K. Kuliczkowski, U. Krug, F. Moscardo, D. Bron, A. D. Moicean, A. Venditti, T. F. Jacobsen, O. Foss, F. J. Giles Brd. 49E A phase II study of elacytarabine plus idarubicin as second-course remission-induction therapy in patients with acute myeloid leukemia. (Abstract #TPS207) D. Rizzieri, U. Krug, R. F. Schlenk, N. Vey, X. G. Thomas, F. Huguet, M. Johansen, T. F. Jacobsen Brd. 49F SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. (Abstract #TPS208) B. Massuti, U. Jimenez, J. M. Rodriguez Paniagua, Y. W. Pun, M. Cobo, E. Carcereny Costa, R. Arrabal, J. Astudillo, I. Barneto, R. De Las Penas, C. Baamonde, G. Sales, J. Gonzalez-Larriba, G. Lopez-Vivanco, F. Hernando-Trancho, J. Pac, A. Artal-Cortes, J. Rivas, R. Rosell, J. Sanchez, Spanish Lung Cancer Group / SLCG-GECP Brd. 49G The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). (Abstract #TPS209) N. A. Pennell, J. W. Neal, R. Govindan, P. A. Janne, T. L. Evans, D. B. Costa, R. P. Rosovsky, M. Lanuti, C. G. Azzoli, L. V. Sequist 325 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 49H MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC. (Abstract #TPS210) P. Therasse, J. F. Vansteenkiste, M. Zielinski, T. M. De Pas, D. Atanackovic, L. V. Sequist, E. Vallieres, S. Swisher, S. Adams, B. Passlick, W. E. Eberhardt, D. Grunenwald, T. Mok, M. Boyer, A. Katz, J. Douillard, M. Debois, V. G. Brichard, N. K. Altorki Brd. 50A Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. (Abstract #TPS211) B. Halmos, P. Fu, N. A. Pennell, G. A. Otterson, T. Mekhail, M. R. Snell, J. P. Kuebler, S. M. Gadgeel, A. Conrad, A. T. Stefanski, A. Dowlati Brd. 50B A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab. (Abstract #TPS212) B. T. McLaughlin, S. Land, A. A. Tarhini, J. Siegfried, A. Argiris Brd. 50C Randomized phase II study of ficlatuzumab (formerly AV-299), an antihepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. (Abstract #TPS213) T. Mok, E. Tan, K. Park, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava, W. Slichenmyer Brd. 50D PROSE: Randomized proteomic stratified phase III study of second-line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). (Abstract #TPS214) C. Sorlini, S. Barni, F. Petrelli, S. Novello, F. De Marinis, T. M. De Pas, F. Grossi, A. Bearz, M. Mencoboni, M. Aieta, A. Caprioli, P. Antonelli, N. Zilembo, A. Bachi, I. Floriani, H. Roder, J. Roder, J. Grigorieva, C. Lazzari, V. Gregorc Brd. 50E A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #TPS215) L. V. Sequist, W. A. Harb, M. Modiano, D. M. Jackman, K. Wong, J. A. Engelman, R. Nering, M. Onsum, V. M. Moyo Brd. 50F Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). (Abstract #TPS216) E. B. Garon, S. M. Dubinett, F. F. Kabbinavar, K. L. Reckamp, D. C. Marquez-Garban, L. Goodglick, S. Sharma, L. P. Stabile, J. Siegfried, R. J. Pietras Brd. 50G A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) . (Abstract #TPS217) A. Sandler, J. H. Schiller, V. Hirsh, L. V. Sequist, J. Soria, J. Von Pawel, Q. Wang, A. U. Pande, B. E. Schwartz, E. G. Garmey, I. Gorbatchevsky, G. Scagliotti Brd. 50H A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel, and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). (Abstract #TPS218) S. E. Dahlberg, S. S. Ramalingam, C. P. Belani, J. H. Schiller 326 Brd. 51A Study ESOGIA-GFPC 08 – 02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an “optimized” strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary. (Abstract #TPS219) R. Corre, C. Chouaid, F. Barlesi, H. Le Caer, E. Dansin, A. Vergnenegre, P. Fournel, GFPC Brd. 51B Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). (Abstract #TPS220) D. R. Spigel, P. G. Harper, J. D. Hainsworth, F. De Marinis, F. F. Kabbinavar, E. S. Kim, T. J. Lynch, R. Rosell, F. A. Shepherd, M. A. Socinski, A. Vergnenegre Brd. 51C E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). (Abstract #TPS221) A. Argiris, J. Lee, J. H. Schiller, Eastern Cooperative Oncology Group Brd. 51D Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma. (Abstract #TPS222) A. Bair, G. Hess, J. Boni, F. Offner Brd. 51E A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). (Abstract #TPS223) V. A. Morrison, S. Jung, J. L. Johnson, J. Leonard, B. D. Cheson, Cancer and Leukemia Group B Brd. 51F An open-label phase II study of intravenous bortezomib and oral panobinostat (LBH589) in adult patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL) after failure of conventional chemotherapy. (Abstract #TPS224) D. C. Tan, P. Chan, B. L. Ng, B. K. Yap, Y. H. Chan, L. P. Koh, F. A. Wahid, S. Lim, N. S. Chin, W. Kim, S. Y. Tan, Y. T. Goh Brd. 51G A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). (Abstract #TPS225) P. Moreau, A. P. Palumbo, A. K. Stewart, V. Rajkumar, A. J. Jakubowiak, K. Halka, S. Goranov, H. Bumbea, K. B. Pendergrass, A. Lupu, A. Dimopoulos, A. O. Rocafiguera, J. G. Gandhi, G. Mihaylov, T. Masszi, J. Matous, G. Fonseca, R. Bryce, D. S. Siegel Brd. 51H PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification. (Abstract #TPS226) J. Leonard, J. Reeves, B. Ferhanoglu, K. T. Doner, H. Eom, I. W. Flinn, J. Raposo, N. M. Chowhan, C. Suh, S. Noga, G. Tumyan, S. Aung, J. Hajdenberg, B. K. Ulrich, K. B. Pendergrass, G. Mulligan, A. Rizo, S. Kussick, F. Offner Brd. 52A PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. (Abstract #TPS227) J. F. San-Miguel, S. Lonial, V. Hungria, P. Moreau, H. Einsele, J. Lee, S. Yoon, P. Corradini, W. W. Jedrzejczak, D. C. Tan, K. Yong, A. Guenther, M. M. Wroclawska-Swacha, H. J. Weber, P. M. Bourquelot, P. G. Richardson 327 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 52C A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). (Abstract #TPS229) J. M. Larkin, S. Turajlic, P. D. Nathan, P. Lorigan, G. Stamp, D. Gonzalez de Castro, N. Martin, J. Griffiths, K. Edmonds, S. Sarker, M. G. James, R. A’Hern, G. Coombes, C. Snowdon, J. M. Bliss, M. E. Gore, R. Marais Brd. 52D A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. (Abstract #TPS230) A. Di Giacomo, P. A. Ascierto, E. Fonsatti, E. Pittiglio, P. Queirolo, L. Pilla, R. Ridolfi, M. Santinami, A. Testori, G. Parmiani, M. Maio Brd. 52E PREDICT phase II: A trial to prospectively validate a gene signature associated with clinical benefit from MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) in patients with unresected metastatic cutaneous melanoma. (Abstract #TPS231) P. Saiag, J. S. Weber, B. Dreno, A. Hauschild, C. Jamoul, O. Peeters, P. Therasse Brd. 52F DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3positive resected stage III melanoma. (Abstract #TPS232) J. M. Kirkwood, B. Dreno, A. Hauschild, D. Schadendorf, A. Testori, P. Hersey, C. Jamoul, O. Peeters, P. Therasse Brd. 52G A randomized multicenter phase II trial on efficacy of high-slip skin care pad for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. (Abstract #TPS233) N. Shinohara, N. Nonomura, G. Kimura, M. Eto, H. Minami, N. Yamazaki, S. Naito, Japanese Society of Renal Cancer Brd. 52H The use of subcutaneous natural ghrelin to treat cachexia (CC) related symptom distress, nutritional intake (NI), and physical functioning: A two-step phase I/II study with an intrapatient dose escalation followed by maintenance treatment. (Abstract #TPS234) F. Strasser, D. Blum, R. Oberholzer, S. deWolf-Linder, C. Driessen, T. Cerny Brd. 53A A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy. (Abstract #TPS235) H. Raftopoulos, A. Laadem, M. Puccio, R. D. Knight Brd. 53B Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation in cancer patients. (Abstract #TPS236) M. Mori, T. Ashikaga, S. M. Grunberg Brd. 53C Randomized clinical trial to evaluate an e-health intervention for fear of cancer recurrence, anxiety, and depression among cancer survivors. (Abstract #TPS237) L. I. Wagner, J. Duffecy, K. A. Lehman, S. D. Sanford, M. Begale, E. Nawacki, D. C. Mohr Brd. 53D A randomized placebo-controlled trial of testosterone replacement for fatigue in male hypogonadic patients with advanced cancer. (Abstract #TPS238) E. Del Fabbro, J. Garcia, R. Dev, J. L. Palmer, C. Klingner-Winton, L. E. Roberts, J. Allo, G. Cardwell, E. Bruera Brd. 53E Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A multicenter, randomized, double-blind, proof-of-concept study of fixed dose or CRP-response-guided dose or placebo. (Abstract #TPS239) F. Strasser, R. Oberholzer, D. Blum, M. Joerger, C. Driessen, S. deWolf-Linder, S. R. Haile, R. von Moos, N. Zerkiebel, A. Jatoi, R. Woelky, K. Fearon, T. Cerny, Swiss Group for Clinical Cancer Research (SAKK 96/10) 328 Brd. 53F A longitudinal study of alterations in cognitive function and brain metabolites among women receiving chemotherapy for primary breast cancer. (Abstract #TPS240) S. Kohli, J. C. Buckner, J. H. Cerhan, K. Kantarci, D. L. Barton, J. A. Sloan, P. J. Novotny Brd. 53G Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ GCIG/PoCoG). (Abstract #TPS241) M. Friedlander, M. R. Stockler, M. King, A. M. Oza, M. Voysey, J. Martyn, K. Gillies, K. M. Sjoquist, P. Butow, Australia New Zealand Gynaecological Oncology Group (ANZGOG), Psycho-Oncology Group (PoCoG), Gynecologic Cancer Intergroup (GCIG) Brd. 53H A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial. (Abstract #TPS242) N. Bouganim, J. F. Hilton, L. Vandermeer, S. Hopkins, D. Robbins, E. Amir, S. Dent, C. Milano, O. C. Freedman, R. A. Dent, G. Dranitsaris, M. J. Clemons Brd. 54A Effect of Chinese herbal medicine JDXZO on epidermal growth factor receptor inhibitor (EGFRIs)–related skin toxicity. (Abstract #TPS243) H. Lin, J. Li Brd. 54B Clinical performance, efficacy, and safety of the DigniCap system, a scalphypothermia system, in preventing chemotherapy (CTX)-induced alopecia in patients (pts) with early-stage breast cancer (BC). (Abstract #TPS244) A. Glencer, M. E. Melisko, L. Esserman, S. A. Melin, H. S. Rugo Brd. 54C A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. (Abstract #TPS245) M. I. Hu, R. Gucalp, K. L. Insogna, I. Glezerman, H. G. Bone, A. Jaccard, W. Misiorowski, B. W. Yu, H. Yeh Brd. 54D AMC 070: A phase I/II study of lenalidomide in patients with AIDS-associated Kaposi sarcoma (Abstract #TPS246) K. A. Shimabukuro, E. G. Reid, AMC 070 Study Team Brd. 54E Cancer Research UK Stratified Medicine Programme. (Abstract #TPS247) J. Peach, A. Tuff, J. Bull, F. Hemsley, L. Jones, M. Jones, C. Westwood, P. W. Johnson Brd. 54F A pilot study of tumor-derived exosomes as diagnostic and prognostic markers in breast cancer patients receiving neoadjuvant chemotherapy. (Abstract #TPS248) R. E. Raab, T. L. Pawlowski, D. Spetzler, M. R. Klass, C. D. Kuslich, L. S. Bellin, J. H. Wong, A. S. Asch Brd. 54G ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). (Abstract #TPS249) B. J. Tromberg, J. A. Butler, D. A. Mankoff, S. J. Isakoff, N. M. Hylton, A. G. Yodh, D. Boas, K. Paulsen, B. W. Pogue, P. A. Kaufman, R. S. Mehta, P. M. Carpenter, A. Cerussi, Z. Zhang, D. M. Hartfeil, D. L’Heureux 329 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Cancer Prevention/Epidemiology Display Time: 8:00 AM - 12:00 PM Display Location: S102 Discussion Time: 11:30 AM - 12:30 PM Discussion Location: S100a CME credit: 1 Track(s): Cancer Prevention/Epidemiology Gary E. Goodman, MD—Co-Chair Swedish Cancer Institute Marie Wood, MD—Co-Chair University of Vermont Discussion 11:30 AM Claudine Isaacs, MD (Abstracts #1509 –1513) Lombardi Comprehensive Cancer Center Discussion 11:45 AM Susan M. Domchek, MD (Abstracts #1514 –1518) Abramson Cancer Center, University of Pennsylvania Discussion 12:00 PM Stephen B. Gruber, MD, PhD, MPH (Abstracts #1519 –1524) University of Michigan Discussion 12:15 PM Kala Visvanathan, MD, MHS (Abstracts #1525–1529) The Johns Hopkins University Bloomberg School of Public Health MONDAY Brd. 1 Feasibility and yield of offering genetic counseling to all patients with newly diagnosed high-grade epithelial ovarian cancer. (Abstract #1509) A. G. Arnold, J. Bhatia, M. F. Phillips, G. J. Gardner, K. M. Bell-McGuinn, C. Aghajanian, R. R. Barakat, K. Offit, N. D. Kauff Brd. 2 Does maternal or paternal inheritance of BRCA mutation affect the age of cancer diagnosis? (Abstract #1510) I. Shapira, R. J. Gralla, M. Akerman, L. R. Weiselberg, V. S. John, H. Raftopoulos, V. Vinciguerra, J. L. Lovecchio, A. Menzin, S. Cohen Brd. 3 Effect of rapid genetic testings on the rate of bilateral prophylactic mastectomy in BRCA1/2 mutation carriers. (Abstract #1511) L. Cortesi, E. De Matteis, E. Razzaboni, V. Medici, G. Tazzioli, A. Andreotti, M. Federico Brd. 4 Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. (Abstract #1512) N. Elsayegh, S. Bayraktar, A. M. Gutierrez-Barrera, H. Lin, H. M. Kuerer, K. I. Muse, K. Ready, J. K. Litton, F. Meric-Bernstam, G. N. Hortobagyi, B. Arun Brd. 5 Identification of BRCA1/BRCA2 carriers by screening in the healthy population and its implications. (Abstract #1513) E. Levy-Lahad, E. Gabai-Kapara, B. Kaufman, R. Catane, S. Segev, P. Renbaum, U. Beller, M. King, A. Lahad Brd. 6 Prevalence and ancestral origin of hispanic BRCA mutations: Insights for ancestry-informed genetic cancer risk assessment. (Abstract #1514) J. N. Weitzel, J. N. DeHart, R. M. Ogaz, A. E. Martir-Negron, J. Herzog, C. Ricker, J. Congleton, C. Cina, P. R. Duncan, G. W. Unzeitig, J. Saldivar, M. Beattie, N. R. Feldman, S. Sand, D. Port, E. M. John, C. Haiman, R. Varma, S. L. Neuhausen, G. P. Larson, Cancer Genetics Community Research Network Brd. 7 Analysis of genomic ancestry in a sample of hereditary breast cancer high risk patients from Bahia, Brazil. (Abstract #1515) I. O. Nascimento, T. B. Machado, B. Toralles, L. A. Ferreira, M. Romeo, C. A. Sandes, L. Meyer, B. Garicochea, R. Meyer, S. Freire, K. Abe-Sandes 330 Brd. 8 Prospective study of breast cancer risk in mutation-negative women from BRCA1 or BRCA2 mutation-positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). (Abstract #1516) S. Harvey, R. L. Milne, K. E. Birch, P. Weideman, S. McLachlan, M. Friedlander, D. Goldgar, J. L. Hopper, K. Phillips Brd. 9 Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome. (Abstract #1517) E. Castro, C. L. Goh, D. Olmos, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, L. OBrien, E. Sawyer, A. Hall, R. Wilkinson, Z. Kote-Jarai, R. A. Eeles, The UKGPCS collaborators Brd. 10 Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. (Abstract #1518) K. L. Jhaveri, S. Patil, M. Khasraw, J. Bhatia, Z. K. Stadler, N. D. Kauff, C. Hudis, K. Offit, M. E. Robson Brd. 11 Breast cancer phenotype in women with TP53 germ-line mutations: An LFS consortium effort. (Abstract #1519) S. Masciari, D. Dillon, M. G. Dick, M. E. Robson, J. N. Weitzel, J. M. Ford, J. Balmaña, S. B. Gruber, D. Euhus, J. E. Garber Brd. 12 Li-Fraumeni syndrome: Retesting archival DNA samples identifies previously unrecognized germline p53 mutations. (Abstract #1520) A. Novokmet, B. Baskin, D. Malkin Brd. 13 Factors associated with type I and type II endometrial cancers in women with a germline mutation in a mismatch repair gene. (Abstract #1521) Y. C. Antill, A. Win, P. Webb, J. L. Hopper, S. Gallinger, N. M. Lindor, P. A. Newcomb, R. W. Haile, J. Church, L. Le Marchand, I. Winship, A. B. Spurdle, M. A. Jenkins, Colon Cancer Family Registry Brd. 14 Incremental impact of breast cancer SNP panel on risk classification and screening. (Abstract #1522) K. Armstrong, E. Conant, J. Chen, E. Handorf, M. Jones, L. Boghossian, S. M. Domchek Brd. 15 Single nucleotide polymorphisms and expression/amplification of HER2 in patients with breast cancer. (Abstract #1523) A. V. Boddy, N. Cresti, D. Jamieson, M. Pinkilgton, M. W. Verrill Brd. 16 Prognostic value of single nucleotide polymorphisms (SNPs) of candidate genes associated with inflammation in early-stage breast cancer. (Abstract #1524) J. L. Murray, P. Thompson, R. Zhou, S. Y. Yoo, Y. Liu, K. Do, A. A. Sahin, M. Bondy, A. M. Brewster Brd. 17 Performance of the Gail model in individual women with benign breast disease. (Abstract #1525) Y. Tarabishy, L. C. Hartmann, M. H. Frost, S. D. Maloney, R. A. Vierkant, V. S. Pankratz Brd. 18 Presentation of breast cancer (BC) diagnosed at or before age 30: Implications for screening women at hereditary risk. (Abstract #1526) P. de Alcantara Filho, T. A. King, E. A. Morris, C. Hudis, M. E. Robson Brd. 19 Safety and efficacy of HRT and low dose tamoxifen in a phase II trial (HOT): Analysis of mammographic density and endometrial thickness. (Abstract #1527) B. Bonanni, P. Maisonneuve, D. Serrano, C. Varricchio, M. Cazzaniga, M. Lazzeroni, B. Santillo, R. Di Pace, L. Meneghetti, A. Tagliafico, U. Veronesi, A. De Censi 331 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 Brd. 20 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1. (Abstract #1528) E. Amir, R. S. Cecchini, P. A. Ganz, J. P. Costantino, S. Beddows, N. Hood, P. J. Goodwin Brd. 21 Relationship of body mass index to the intrinsic subtypes of breast cancer. (Abstract #1529) C. A. Santa-Maria, Y. Zhao, N. Ketring, I. Rodriguez, A. Condren, D. Euhus MONDAY 332 Monday, June 6, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Gastrointestinal (Colorectal) Cancer Display Time: 8:00 AM - 12:00 PM Display Location: E450b Discussion Time: 11:30 AM - 12:30 PM Discussion Location: Hall D1 CME credit: 1 Track(s): Gastrointestinal (Colorectal) Cancer Blase N. Polite, MD, MPH—Co-Chair The University of Chicago Sharlene Gill, MD—Co-Chair British Columbia Cancer Agency Discussion 11:30 AM John S. Kauh, MD (Abstracts #3512–3517) Winship Cancer Institute of Emory University Discussion 11:45 AM Chris R. Garrett, MD (Abstracts #3518 –3522) University of Texas M. D. Anderson Cancer Center Discussion 12:00 PM Josep Tabernero, MD (Abstracts #3523–3528) Vall d’Hebron University Hospital Brd. 1 The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: Preliminary results of a phase III trial. (Abstract #3512) A. K. Jakobsen, A. L. Appelt, J. Lindebjerg, J. Ploeen, S. R. Rafaelsen, T. Vuong Brd. 2 EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. (Abstract #3513) A. Dewdney, J. Capdevila, B. Glimelius, A. Cervantes, D. M. Tait, G. Brown, A. Wotherspoon, D. Gonzalez de Castro, Y. Chua, R. Wong, Y. Barbachano, J. R. Oates, I. Chau, D. Cunningham Brd. 3 Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME. (Abstract #3514) J. Garcia-Aguilar, J. Marcet, T. Coutsoftides, P. Cataldo, A. Fichera, L. E. Smith, S. Oommen, S. R. Hunt, D. Herzig, D. Dietz, M. G. Varma, C. A. Ternent, M. J. Stamos, K. Avila, D. D. Smith Brd. 4 Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stage II/III rectal treated with neoadjuvant therapy: A National Comprehensive Cancer Network (NCCN) analysis. (Abstract #3515) P. Khrizman, J. C. Niland, A. ter Veer, D. Milne, K. Bullard Dunn, W. E. Carson III, P. F. Engstrom, S. Shibata, J. M. Skibber, M. R. Weiser, D. Schrag, A. B. Benson Brd. 5 Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. (Abstract #3516) R. Sauer, T. Liersch, S. Merkel, H. Becker, W. Hohenberger, H. Witzigmann, C. F. Hess, R. Fietkau, C. Wittekind, C. Roedel, German Rectal Cancer Study Group 333 MONDAY Discussion 12:15 PM Sabine Tejpar, MD, PhD (Abstracts #3529 –3536) University Hospital Gasthuisberg Monday, June 6, 2011 MONDAY Brd. 6 Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer. (Abstract #3517) S. J. Wong, J. Moughan, N. J. Meropol, P. R. Anne, L. A. Kachnic, A. Rashid, J. C. Watson, E. P. Mitchell, J. Pollock, M. G. Haddock, B. Erickson, C. G. Willett Brd. 7 Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. (Abstract #3518) A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel, K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group B Brd. 8 Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. (Abstract #3519) R. Adam, E. Barroso, C. Laurent, G. Nuzzo, C. Hubert, G. Mentha, J. Ijzermans, L. Capussotti, S. Lopezben, D. Mirza, G. Kaiser, E. Oussoultzoglou, T. Gruenberger, G. J. Poston, O. Skipenko, The LiverMetSurvey Centers Brd. 9 An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). (Abstract #3520) C. Moulton, M. N. Levine, C. Law, R. Hart, L. Ruo, C. Gu, A. Hendler, K. Y. Gulenchyn, M. A. Haider, M. Marcaccio, V. Tandan, D. Quan, D. Jalink, R. Fairfull Smith, S. Hanna, P. D. Greig, M. Husien, T. Finch, J. A. Julian, S. Gallinger Brd. 10 Follow-up after colorectal cancer surgery: Preliminary observational findings from the UK FACS trial. (Abstract #3521) J. N. Primrose, A. Fuller, P. Rose, R. Perera-Salazar, J. Mellor, A. Corkhill, S. George, D. Mant Brd. 11 Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. (Abstract #3522) J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope, S. G. Nair, S. R. Alberts Brd. 12 Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (Abstract #3523) M. T. Seymour, S. R. Brown, S. Richman, G. W. Middleton, T. S. Maughan, C. Olivier, S. J. Gwyther, J. Wadsley, I. Chau, T. Hickish, L. K. Dawson, S. Falk, A. O’Callaghan, K. Benstead, N. Wadd, A. Oliver, P. Chambers, H. Marshall, V. Napp, P. Quirke, UK NCRI Colorectal Clinical Studies Group Brd. 13 A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer. (Abstract #3524) Y. Park, H. Lim, J. Lee, T. Kim, Y. Hong, S. Kim, J. Baek, J. Kim, K. Lee, I. Chung, S. Cho, S. J. Shin, H. Kang, D. Shin, S. Jo Brd. 14 Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). (Abstract #3525) C. Becerra, R. Salazar, R. Garcia-Carbonero, A. L. Thomas, F. VázquezMazón, J. Cassidy, T. Maughan, M. Gallén, T. Iveson, M. Hixon, A. Gualberto, D. Yin, D. Li, E. K. Bergsland Brd. 15 A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). (Abstract #3526) A. Johnsson, J. Frodin, A. Berglund, H. Hagman, J. Sundberg, D. Bergstrom, R. D. Christensen, N. Keldsen, K. G. Spindler, A. K. Jakobsen 334 Monday, June 6, 2011 A double-blind, randomized, placebo-controlled, phase II study of maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following first-line therapy for metastatic colorectal cancer (mCRC). (Abstract #3527) R. A. Wolff, W. Schepp, M. Di Bartolomeo, A. Hossain, C. Stoffregen, S. Nicol, V. Heinemann Brd. 17 An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. (Abstract #3528) R. Geva, B. V. Jensen, G. Fountzilas, T. Yoshino, D. Paez, C. Montagut, I. Sougklakos, F. Cappuzzo, A. Cervantes-Ruiperez, D. Papamichael, M. Frattini, B. Vincenzi, T. Macarulla, F. Loupakis, K. G. Spindler, C. Qvortrup, F. Ciardiello, S. Tejpar Brd. 18 Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). (Abstract #3529) M. Lin, E. Hawk, M. Huang, J. Lin, J. Gu, L. M. Ellis, X. Wu, C. Eng Brd. 19 Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC). (Abstract #3530) K. Oliner, M. Peeters, S. Siena, E. Van Cutsem, J. Huang, Y. Humblet, J. Van Laethem, T. Andre, J. S. Wiezorek, S. D. Patterson Brd. 20 Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. (Abstract #3531) A. J. Weickhardt, D. Williams, C. Lee, J. Simes, C. Murone, K. Wilson, M. Cummins, K. Asadi, T. J. Price, J. Mariadason, N. C. Tebbutt, Australasian GI Trials Group Brd. 21 Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment (Abstract #3532) J. V. Schou, K. K. Andersen, B. V. Jensen, D. L. Nielsen, P. Pfeiffer, E. V. Høgdall, M. Yilmaz, M. Kruhoffer, J. S. Johansen Brd. 22 The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. (Abstract #3533) C. H. Lieu, H. T. Tran, Z. Jiang, M. Mao, M. J. Overman, C. Eng, J. Morris, L. M. Ellis, J. Heymach, S. Kopetz Brd. 23 The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer. (Abstract #3534) I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla, L. van’t Veer, R. Bernards, G. Capella Brd. 24 Primary colorectal tumors and their metastasis are genetically not the same: Implications for choice of targeted treatment? (Abstract #3535) J. S. Vermaat, I. J. Nijman, M. J. Koudijs, W. M. Roessingh, F. L. Gerritse, M. Mokry, R. H. Giles, P. J. van Diest, E. Cuppen, E. E. Voest Brd. 25 Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients. (Abstract #3536) A. L. Russo, D. R. Borger, D. P. Ryan, K. C. Fan, H. Lopez, V. Scialabba, L. S. Blaszkowsky, E. L. Kwak, J. W. Clark, J. N. Allen, R. C. Wadlow, A. X. Zhu, R. Wang, D. Dias-Santagata, T. S. Hong, A. J. Iafrate MONDAY Brd. 16 335 Monday, June 6, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell Display Time: 8:00 AM - 12:00 PM Display Location: E450a Discussion Time: 11:30 AM - 12:30 PM Discussion Location: Hall D2 CME credit: 1 Track(s): Lung Cancer Katherine Pisters, MD—Co-Chair University of Texas M. D. Anderson Cancer Center William J. Petty, MD—Co-Chair Wake Forest University Discussion 11:30 AM Tetsuya Mitsudomi, MD, PhD (Abstracts #7007–7010) Aichi Cancer Center Hospital Discussion 11:40 AM Enriqueta Felip, MD (Abstracts #7011–7015) Vall d’Hebron University Hospital Discussion 11:55 AM Joseph Kamel Salama, MD (Abstracts #7016 –7020) Duke University Medical Center Discussion 12:05 PM Kaoru Kubota, MD (Abstracts #7021–7023) National Cancer Center Discussion 12:20 PM Nasser H. Hanna, MD (Abstracts #7024 –7028) Indiana University MONDAY Brd. 1 Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial. (Abstract #7007) C. Mascaux, G. Levallet, E. Bergot, L. Baudrin, M. Antoine, G. Anthoine, V. Westeel, A. Lavole, E. A. Quoix, D. Debieuvre, J. Mazieres, J. Pujol, D. Moro-Sibilot, F. Morin, B. Milleron, G. Zalcman, on behalf of the Intergroupe Francophone de Cancerologie Thoracique (IFCT) Brd. 2 Association between DNA-repair gene and glutathione S-transferase gene polymorphisms and clinical outcome in patients (pt) with localized nonsmall-cell lung cancer (NSCLC) treated with sequential radiochemotherapy. (Abstract #7008) J. Stoehlmacher-Williams, B. Krassler, M. Kramer, G. Ehninger, G. Hoeffken, E. Goekkurt Brd. 3 Genetic variations in multiple drug action pathways and survival in advanced-stage non-small cell lung cancer treated with chemotherapy. (Abstract #7009) P. Yang, Y. Li, Z. Sun, J. M. Cunningham, M. Aubry, J. A. Wampfler, G. Croghan, C. Johnson, D. Wu, J. Aakre, J. R. Molina, L. Wang, V. S. Pankratz Brd. 4 Use of a gene expression signature related to epithelial-to-mesenchymal transition (EMT) to predict for overall survival (OS) in cohorts of lung and head and neck cancer (HNSCC) patients. (Abstract #7010) J. S. Yordy, L. Shen, L. Diao, J. Wang, K. Coombes, U. Giri, Y. Xie, J. D. Minna, L. Girard, J. Weinstein, J. Heymach, K. Ang, M. D. Story, R. Meyn Brd. 5 Oncologists’, physicians’, and surgeons’ opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. (Abstract #7011) K. Khor, D. Tai, S. Popat, M. Beckles, M. Leung, M. Al Sahaf, E. K. Lim 336 Brd. 6 Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. (Abstract #7012) S. Cuffe, C. M. Booth, Y. Peng, G. E. Darling, G. Li, W. Kong, W. J. Mackillop, F. A. Shepherd Brd. 7 Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early stage non-small cell lung cancer (NSCLC). (Abstract #7013) H. A. Wakelee, S. E. Dahlberg, S. M. Keller, D. R. Gandara, S. L. Graziano, N. B. Leighl, A. A. Adjei, J. H. Schiller, Eastern Cooperative Oncology Group Brd. 8 Platinum-based adjuvant chemotherapy (ACT) in elderly patients with non-small cell lung cancer (NSCLC) in the SEER-Medicare database: Comparison between carboplatin- and cisplatin-based regimens. (Abstract #7014) F. Gu, G. M. Strauss, J. P. Wisnivesky Brd. 9 Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. (Abstract #7015) G. M. Strauss, X. F. Wang, M. Maddaus, D. Johnstone, E. Johnson, D. Harpole, H. H. Gillenwater, L. Gu, D. Sugarbaker, M. R. Green, S. L. Graziano, R. A. Kratzke, R. L. Schilsky, J. Crawford, E. E. Vokes Brd. 10 Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). (Abstract #7016) T. Stinchcombe, M. A. Socinski, D. T. Moore, S. N. Gettinger, R. H. Decker, W. J. Petty, A. W. Blackstock, G. Schwartz, S. Lankford, D. E. Morris Brd. 11 Phase II study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. (Abstract #7017) J. Y. Chang, R. Komaki, C. Lu, H. Y. When, P. Allen, A. S. Tsao, M. Gillin, R. Mohan, J. D. Cox Brd. 12 An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. (Abstract #7018) Y. Ung, C. Gu, K. Cline, A. Sun, R. M. MacRae, J. R. Wright, E. Yu, L. Ehrlich, K. Y. Gulenchyn, H. Shulman, I. S. Dayes, S. K. Dhesy-Thind, G. E. Darling, N. B. Leighl, W. K. Evans, J. A. Julian, M. N. Levine Brd. 13 Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC). (Abstract #7019) A. P. Kotsakis, S. S. Ramalingam, A. A. Tarhini, D. E. Heron, R. Smith, D. Friedland, D. P. Petro, L. E. Raez, J. R. Brahmer, J. S. Greenberger, S. Dacic, P. Hershberger, R. J. Landreneau, C. P. Belani, J. D. Luketich, A. Argiris Brd. 14 Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. (Abstract #7020) R. Komaki, G. R. Blumenschein Jr., I. I. Wistuba, J. Lee, P. Allen, X. Wei, J. Welsh, M. O’Reilly, R. S. Herbst, X. Tang, R. Meyn, D. Liu, W. K. Hong Brd. 15 Surgical resection in early limited stage small cell lung cancer: Time to rethink? A retrospective analysis of the VA Central Cancer Registry. (Abstract #7021) T. Tashi, I. T. Aldoss, W. Gonsalves, A. Ganti, P. T. Silberstein, P. Townley, S. Subbiah 337 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 Brd. 16 COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatinbased chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC). (Abstract #7022) A. Rossi, M. Di Maio, P. Chiodini, R. Rudd, H. Okamoto, D. Skarlos, M. Frueh, W. Qian, T. Tamura, E. Samantas, T. Shibata, F. Perrone, C. Gallo, C. Gridelli, O. Martelli, S. M. Lee Brd. 17 Thymoma: A population-based study of the management and outcomes for the province of British Columbia. (Abstract #7023) C. J. Mariano, D. Ionescu, W. Y. Cheung, R. Ali, J. J. Laskin, H. Carolan, K. Evans, N. Murray Brd. 18 Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. (Abstract #7024) D. C. Christoph, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, J. Wohlschlaeger, D. Theegarten, T. C. Gauler, M. H. Schuler, W. E. Eberhardt, F. R. Hirsch Brd. 19 Does disease control rate (DCR) at 9 and 18 weeks predict overall survival (OS) in patients with malignant pleural mesothelioma (MPM)? An individual patient data combined analysis of 10 European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG) studies. (Abstract #7025) L. Greillier, B. Hasan, P. Baas, J. J. Welch, J. P. Van Meerbeeck, R. M. Gaafar, R. Sylvester, D. A. Lacombe, M. O’Brien Brd. 20 Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. (Abstract #7026) R. Hassan, E. Sharon, B. Schuler, Y. Mallory, J. Zhang, A. Ling, I. Pastan Brd. 21 Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago phase II consortium. (Abstract #7027) N. P. Campbell, R. Kunnavakkam, N. B. Leighl, M. D. Vincent, D. R. Gandara, M. Koczywas, B. J. Gitlitz, E. S. Agamah, S. P. Thomas, W. M. Stadler, E. E. Vokes, H. L. Kindler Brd. 22 Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM). (Abstract #7028) L. M. Krug, J. Arduino, X. Sun, H. L. Kindler, C. Manegold, D. Fennell, G. M. Lubiniecki, P. Baas MONDAY 338 Monday, June 6, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Melanoma/Skin Cancers Display Time: 8:00 AM - 12:00 PM Display Location: S403 Discussion Time: 11:30 AM - 12:30 PM Discussion Location: S406 CME credit: 1 Track(s): Melanoma/Skin Cancers Bartosz Chmielowski, MD, PhD—Co-Chair University of California, Los Angeles Georgina V. Long, MBBS, PhD—Co-Chair Royal Prince Alfred Hospital Discussion 11:30 AM David Fisher, MD, PhD (Abstracts #8513– 8520) Massachusetts General Hospital Discussion 11:45 AM Michael S. Sabel, MD (Abstracts #8521–LBA8526∧) University of Michigan Discussion 12:00 PM Christopher D. Lao, MD (Abstracts #8527– 8532) University of Michigan Brd. 1 An analysis of sera-based microRNAs as biomarkers of recurrence in melanoma. (Abstract #8513) E. B. Friedman, S. Shang, E. Vega-Saenz de Miera, M. W. Ma, R. S. Berman, R. L. Shapiro, A. C. Pavlick, E. Hernando, Y. Shao, I. Osman Brd. 2 Functional characterization of an oncogenic role for the miRNA-506 –514 cluster in initiating melanocyte transformation and promoting melanoma growth. (Abstract #8514) K. Streicher, W. Zhu, K. Lehmann, R. W. Georgantas III, C. Morehouse, P. Brohawn, R. Carrasco, Z. Xiao, D. Tice, B. W. Higgs, L. Richman, B. Jallal, Y. Yao Brd. 3 Whole-genome expression profiling of brain metastases from melanoma (BrMM) provides preliminary insights into its biology and mechanisms of development. (Abstract #8515) M. T. Krauze, R. H. Hamilton, S. Bortoluzzi, S. C. Buch, M. Romkes, A. H. Mintz, D. Kondziolka, J. M. Kirkwood, S. J. Moschos Brd. 4 Targeting histone deacetylase to overcome resistance of B-RAFV600E melanoma cells to apoptosis. (Abstract #8516) P. Hersey, Chen Chen Jiang, Fritz Lai, Xu Dong Zhang Brd. 5 Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (RG7204, PLX4032). (Abstract #8517) F. Su, H. Yang, B. Higgins, K. D. Kolinsky, K. Packman, M. Kim, B. J. Lestini, G. Bollag, D. C. Heimbrook Brd. 6 Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. (Abstract #8518) F. E. Meier, D. Beck, H. Niessner, K. T. Flaherty, J. Iovanna, D. Kulms, D. Schadendorf, C. Garbe 339 MONDAY Discussion 12:15 PM F. Stephen Hodi, MD (Abstracts #8533– 8537) Dana-Farber Cancer Institute Monday, June 6, 2011 MONDAY Brd. 7 Pattern and outcome of disease progression in phase I study of vemurafenib (RG7204) in patients with metastatic melanoma (MM). (Abstract #8519) K. B. Kim, K. T. Flaherty, P. B. Chapman, J. A. Sosman, A. Ribas, G. A. McArthur, R. K. Amaravadi, R. J. Lee, K. B. Nolop, I. Puzanov Brd. 8 Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (Abstract #8520) M. E. Lacouture, P. B. Chapman, A. Ribas, J. A. Sosman, G. A. McArthur, K. T. Flaherty, K. B. Kim, I. Puzanov, K. B. Nolop, A. K. Joe, O. Spleiss, A. Koehler, W. Wu, C. Robert, A. Hauschild, D. Schadendorf, J. L. Troy, M. Duvic, K. Trunzer Brd. 9 Impact of population genetic substructure on association studies and risk assessment for melanoma. (Abstract #8521) I. Lobach, I. Belitskaya-Levy, J. D. Goldberg, H. Ostrer, R. S. Berman, A. C. Pavlick, R. L. Shapiro, I. Osman, P. Manga Brd. 10 Disparities in the management of melanoma in elderly patients: An analysis of patients from the National Cancer Database. (Abstract #8522) S. Tsai, S. Soong, C. M. Balch, J. R. Lange Brd. 11 The impact of gender on the outcome of malignant melanoma: Overview of seven EORTC phase III trials. (Abstract #8523) A. Joosse, S. Collette, S. Suciu, E. de Vries, T. Nijsten, P. Patel, U. R. Kleeberg, U. Keilholz, A. M. Eggermont, J. W. Coebergh, EORTC Melanoma Group Brd. 12 The effect of beta-blocker treatment in patients with cutaneous melanoma. (Abstract #8524) V. De Giorgi, M. Grazzini, S. Gandini, S. Benemei, T. Lotti, N. Marchionni, S. Rossari, A. Gori, P. Geppetti Brd. 14 A phase III study of receptor-targeted 99mTc-tilmanocept versus blue dye in evaluation of SLNs in breast cancer and melanoma. (Abstract #LBA8526^) F. O. Cope, V. K. Sondak, A. M. Wallace Brd. 15 Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials. (Abstract #8527) D. S. Hong, D. S. Boss, H. Glen, J. Mink, M. Ren, C. Andresen, J. P. O’Brien, R. Kurzrock, J. H. Schellens, J. J. Nemunaitis, T. Evans Brd. 16 A phase II clinical/translational trial of sequential axitinib/carboplatin/ paclitaxel in melanoma. (Abstract #8528) A. P. Algazi, E. Cha, C. Soon, S. Ortiz-Urda, B. Cortez, L. Ziani, F. V. Coakley, A. Daud Brd. 17 MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study. (Abstract #8529) S. Bhatia, O. Hamid, A. C. Pavlick, G. Mulligan, P. G. Smith, M. D. Pickard, M. Shultz, R. M. Walker, B. Dezube, S. O’Day Brd. 18 Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM). (Abstract #8530) J. H. Beumer, H. A. Tawbi, A. A. Tarhini, S. J. Moschos, M. J. Egorin, S. C. Buch, Y. Lin, J. M. Kirkwood Brd. 19 Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). (Abstract #8531) A. Y. Bedikian, C. Lebbé, C. Robert, S. S. Agarwala, T. Cousin, J. Wu, C. Garbe, J. J. Grob 340 Monday, June 6, 2011 A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775). (Abstract #8532) L. A. Kottschade, V. Suman, D. G. Perez, R. R. McWilliams, J. S. Kaur, T. Amatruda, F. J. Geoffroy, H. M. Gross, P. A. Cohen, A. J. Jaslowski, M. L. Kosel, S. Markovic Brd. 21 Phase II study of recombinant adeno-viral human p53 (rAd-p53) gene therapy combined with surgery in treatment of melanomas of oral mucosa. (Abstract #8533) L. Li Brd. 22 Combination immunotherapy for high-risk and advanced melanoma patients. (Abstract #8534) A. I. Riker, N. N. Vahanian, C. J. Link, L. Tennant, W. J. Ramsey, G. R. Rossi, L. C. Alsfeld, E. Davila, M. Harrison Brd. 23 Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). (Abstract #8535) W. Kruit, S. Suciu, B. Dreno, V. Chiarion-Sileni, L. Mortier, C. Robert, M. Maio, F. Lehmann, V. G. Brichard, A. Spatz, A. M. Eggermont, U. Keilholz Brd. 24 Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: Immunogenicity and biomarker analysis. (Abstract #8536) A. A. Tarhini, H. Edington, L. H. Butterfield, M. Sinha, S. J. Moschos, H. Tawbi, Y. Shuai, J. Shipe-Spotloe, M. Simonettta, C. Milburn, M. Horak, C. Sander, J. M. Kirkwood Brd. 25 Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2. (Abstract #8537) R. W. Joseph, P. Hwu, M. A. Davies, M. B. Atkins, R. J. Sullivan MONDAY Brd. 20 341 Monday, June 6, 2011 9:30 AM - 12:30 PM ORAL ABSRACT SESSION Breast Cancer—Triple-negative/Cytotoxics/Local Therapy Location: Hall B1 CME credit: 3 Track(s): Breast Cancer Lisa Yee, MD—Chair The Ohio State University 9:30 AM NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer (Abstract #LBA1003) T. J. Whelan, I. Olivotto, I. Ackerman, J. A. W. Chapman, B. Chua, A. Nabid, K. A. Vallis, J. R. White, P. Rousseau, A. Fortin, L. J. Pierce, L. Manchul, P. Craighead, M. C. Nolan, J. Bowen, D. R. McCready, K. I. Pritchard, M. N. Levine, and W. Parulekar Discussion 9:45 AM Thomas A. Buchholz, MD (Abstract #LBA1003) University of Texas M. D. Anderson Cancer Center MONDAY 10:00 AM First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. (Abstract #1004) G. T. Budd, W. E. Barlow, H. C. Moore, T. J. Hobday, J. A. Stewart, C. Isaacs, M. Salim, J. K. Cho, K. Rinn, K. S. Albain, H. K. Chew, G. V. Burton, T. D. Moore, G. Srkalovic, B. A. McGregor, L. E. Flaherty, R. B. Livingston, D. Lew, J. Gralow, G. N. Hortobagyi, SWOG 10:15 AM The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (Abstract #LBA1005) H. D. Bear, G. Tang, P. Rastogi, C. E. Geyer, A. Robidoux, J. N. Atkins, L. Baez, A. Brufsky, R. S. Mehta, L. Fehrenbacher, E. R. Pajon, F. M. Senecal, R. Gaur, R. G. Margolese, P. T. Adams, H. M. Gross, S. M. Swain, E. P. Mamounas, J. P. Costantino, N. Wolmark 10:30 AM Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GEPARQUINTO study (GBG 44). (Abstract #1006) B. Gerber, H. Eidtmann, M. Rezai, P. A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. A. Hanusch, R. Kreienberg, C. Solbach, C. Jackisch, G. Kunz, J. U. Blohmer, J. B. Huober, M. Hauschild, S. Loibl, V. Nekljudova, M. Untch, G. Von Minckwitz, GBG/AGO Study Groups Discussion 10:45 AM Hope S. Rugo, MD (Abstracts #1004 –1006) University of California, San Francisco 11:00 AM A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (Abstract #1007) J. O’Shaughnessy, L. S. Schwartzberg, M. A. Danso, H. S. Rugo, K. Miller, D. A. Yardley, R. W. Carlson, R. S. Finn, E. Charpentier, M. Freese, S. Gupta, A. Blackwood-Chirchir, E. P. Winer Discussion 11:15 AM Lisa A. Carey, MD (Abstract #1007) University of North Carolina at Chapel Hill 11:30 AM 342 Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009 – 05 study. (Abstract #1008) M. Martin, N. Martinez, M. Ramos, L. Calvo, A. Lluch, P. Zamora, M. Munoz-Mateu, D. Caronia, E. M. Carrasco, J. Garcia Saenz, A. Casado, I. Chacón, B. Hernando, M. Ruiz-Borrego, A. Gonzalez-Neira Monday, June 6, 2011 11:45 AM Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). (Abstract #1009) C. Hudis, K. W. Tauer, R. C. Hermann, G. Makari-Judson, C. Isaacs, J. T. Beck, V. G. Kaklamani, E. J. Stepanski, H. S. Rugo, W. Wang, K. M. Bell-McGuinn, H. Chera, B. Zaugg, S. Ro, S. Li, L. S. Schwartzberg 12:00 PM Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (Abstract #1010) A. Brufsky, V. Valero, B. Tiangco, S. R. Dakhil, A. Brize, N. Bousfoul, H. S. Rugo, D. A. Yardley MONDAY Discussion 12:15 PM Stephen R. D. Johnston, MA, MD, PhD (Abstracts #1008 –1010) Royal Marsden Hospital 343 Monday, June 6, 2011 9:30 AM - 12:30 PM ORAL ABSTRACT SESSION Health Services Research Location: S404 CME credit: 3 Track(s): Health Services Research Monika K. Krzyzanowska, MD—Co-Chair Princess Margaret Hospital Christopher Ryan Friese, RN, PhD—Co-Chair University of Michigan 9:30 AM Identification of barriers to clinical trials: The impact of education level. (Abstract #CRA6003) J. R. Eads, T. L. Albrecht, B. Egleston, J. S. Buzaglo, R. B. Cohen, L. Fleisher, T. Foster, M. Katz, T. Kinzy, S. Manne, D. M. Miller, S. M. Miller, S. Raivitch, N. Roach, A. Silver, N. J. Meropol 9:45 AM The impact of socioeconomic status on cancer care and survival. (Abstract #6004) S. L. Wong, N. Gu, M. Banerjee, J. D. Birkmeyer, N. J. Birkmeyer 10:00 AM The impact of economic recession on the incidence and treatment of cancer. (Abstract #6005) K. Y. Ennis, M. Chen, G. C. Smith, A. V. D’Amico, Y. Zhang, L. B. Harrison, R. D. Ennis 10:15 AM Impact of out-of-pocket expenses on cancer care. (Abstract #6006) Y. Zafar, A. M. Goetzinger, R. Fowler, A. Gblokpor, D. Warhadpande, D. H. Taylor, D. Schrag, J. M. Peppercorn, A. P. Abernethy 10:30 AM Cancer diagnosis as a risk factor for personal bankruptcy. (Abstract #6007) S. D. Ramsey, C. R. Fedorenko, K. S. Snell, A. C. Kirchhoff, W. Hollingworth, D. K. Blough Discussion 10:45 AM Neal J. Meropol, MD (Abstracts #CRA6003– 6007) Case Western Reserve University MONDAY 11:00 AM Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. (Abstract #CRA6008) M. Fisch, J. Lee, M. Weiss, L. I. Wagner, V. T. Chang, D. Cella, J. Manola, L. M. Minasian, W. J. McCaskill-Stevens, T. R. Mendoza, C. S. Cleeland 11:15 AM Effect of early palliative care on chemotherapy utilization and end-of-life care in patients with metastatic non-small cell lung cancer (NSCLC). (Abstract #6009) J. A. Greer, W. F. Pirl, V. A. Jackson, I. T. Lennes, R. S. Heist, E. R. Gallagher, J. S. Temel Discussion 11:30 AM Susan Yount, PhD (Abstracts #CRA6008 – 6009) Northwestern University, Feinberg School of Medicine 11:45 AM Correlates of contralateral prophylactic mastectomy in a population-based sample. (Abstract #6010) S. T. Hawley, R. Jagsi, M. Morrow, S. J. Katz 12:00 PM Quality of non-small cell lung cancer (NSCLC) care in the Veterans Health Administration (VHA): Impact of patient preference and clinical judgment. (Abstract #6011) J. J. Ryoo, B. Kim, D. L. Ordin, S. M. Oishi, S. M. Asch, A. M. Antonio, R. He, M. K. Gould, J. Malin 344 Monday, June 6, 2011 MONDAY Discussion 12:15 PM David J. Bentrem, MD (Abstracts #6010 – 6011) Northwestern University, Feinberg School of Medicine 345 Monday, June 6, 2011 9:30 AM - 12:30 PM ORAL ABSTRACT SESSION Leukemia, Myelodysplasia, and Transplantation Location: Arie Crown Theater CME credit: 3 Track(s): Leukemia, Myelodysplasia, and Transplantation Attaya Suvannasankha, MD—Co-Chair Indiana University Guido Marcucci, MD—Co-Chair The Ohio State University Comprehensive Cancer Center 9:30 AM Results of COMFORT- I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). (Abstract #6500) S. Verstovsek, R. A. Mesa, J. R. Gotlib, R. S. Levy, V. Gupta, J. F. DiPersio, J. Catalano, M. Deininger, C. B. Miller, R. T. Silver, M. Talpaz, E. F. Winton, J. H. Harvey, K. Vaddi, S. K. Erickson-Viitanen, I. Koumenis, W. Sun, V. Sandor, H. Kantarjian, on behalf of all COMFORT-I investigators 9:45 AM Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), postpolycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) (Abstract #LBA6501) C. N. Harrison, J. J. Kiladjian, H. K. Al-Ali, H. Gisslinger, R. J. Waltzman, V. Stalbovskaya, M. McQuitty, D. S. Hunter, R. S. Levy, F. Cervantes, A. M. Vannucchi, T. Barbui, G. Barosi 10:00 AM The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: Twenty-four-month follow-up. (Abstract #6502) G. Saglio, H. Kantarjian, J. Reiffers, S. Jootar, M. E. Kalaycio, H. Shibayama, X. Fan, N. J. Gallagher, Y. Shou, R. A. Larson, T. P. Hughes, A. Hochhaus Discussion 10:15 AM Ross L. Levine, MD (Abstracts #6500 – 6502) Memorial Sloan-Kettering Cancer Center MONDAY 10:30 AM Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. (Abstract #6503^) S. Faderl, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacsovics, S. Goldberg, K. Seiter, P. Hari, F. Ravandi, E. S. Wang, S. Eckert, D. Huebner, H. Kantarjian 10:45 AM Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. (Abstract #6504) X. G. Thomas, A. Dmoszynska, A. Wierzbowska, K. Kuliczkowski, J. Mayer, T. Shelekhova, J. Gau, W. Chou, R. Buckstein, J. Cermak, C. Kuo, A. O. Rocafiguera, V. Koza, F. Ravandi, H. Kantarjian 11:00 AM Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study. (Abstract #6505) D. A. Pollyea, H. E. Kohrt, L. Gallegos, B. Zhang, M. Figueroa, A. Melnick, C. Berube, S. E. Coutre, J. R. Gotlib, J. L. Zehnder, M. Liedtke, B. S. Mitchell, B. C. Medeiros 346 Monday, June 6, 2011 11:15 AM Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. (Abstract #6506) G. Borthakur, L. Popplewell, M. H. Kirschbaum, J. M. Foran, T. M. Kadia, E. Jabbour, M. Boyiadzis, A. Verma, R. B. Walter, P. S. Wissel, L. Xu, J. W. Bauman, J. Z. Zhu, J. Mazumdar, M. Baccus, J. M. Connor, J. E. Cortes, H. Kantarjian Discussion 11:30 AM Gail J. Roboz, MD (Abstracts #6503∧– 6506) Weill Medical College of Cornell University 11:45 AM Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). (Abstract #6507) E. Jabbour, S. M. O’Brien, D. A. Thomas, F. Ravandi, S. York, M. Kwari, S. Faderl, T. M. Kadia, C. Wilson, R. Tarnai, A. S. Advani, G. Garcia-Manero, J. E. Cortes, H. Kantarjian 12:00 PM The Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 is highly active and tolerable in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. (Abstract #6508) J. C. Byrd, K. A. Blum, J. A. Burger, S. E. Coutre, J. P. Sharman, R. R. Furman, I. W. Flinn, B. W. Grant, D. A. Richards, W. Zhao, N. A. Heerema, A. J. Johnson, R. Izumi, A. Hamdy, S. M. O’Brien MONDAY Discussion 12:15 PM Ross L. Levine, MD (Abstracts #6507– 6508) Memorial Sloan-Kettering Cancer Center 347 Monday, June 6, 2011 9:45 AM - 11:00 AM SPECIAL SESSION AIDS-associated Malignancies in Low- and Middle-income Countries Location: E354b CME credit: 1.25 Track(s): Special Session, Cancer Prevention/Epidemiology, International Clement Adebayo Adebamowo, MD, ScD—Chair Institute of Human Virology, University of Maryland School of Medicine AIDS-associated Malignancies: An Epidemic Foretold Ronald T. Mitsuyasu, MD University of California, Los Angeles Care Center Conducting Clinical Trials in Resource Low-income Countries: Challenges and Opportunities William A. Blattner, MD University of Maryland Baltimore Patterns and Trends in HIV-associated Malignancy E. Akin Abayomi, MBBS, MRCP, MPhil Stellenbosch University Effect of Antiretroviral Therapy on the Evolving Pattern and Incidence of HIV-related Lymphoma in South Africa MONDAY 348 Monday, June 6, 2011 9:45 AM - 11:00 AM EDUCATION SESSIONS Assessing Patients’ Psychosocial Needs: How to Do This in (Your Busy) Practice Location: S100a CME credit: 1.25 Track(s): Patient and Survivor Care, Breast Cancer Michelle Joy Naughton, PhD—Chair Wake Forest University School of Medicine Overview of Psychosocial Problems and Risk Factors among Cancer Survivors Paul B. Jacobsen, PhD H. Lee Moffitt Cancer Center & Research Institute Psychosocial Screening for Patients with Cancer: Opportunities and Challenges David Goldstein, MD Prince of Wales Hospital Translating Research into Everyday Patient Care: Applying the Outcomes of Psychosocial Screening and Intervention Trials into Clinical Practice Immunotherapy for Advanced and High-risk Melanoma: Lessons Learned and Future Directions Location: E354a CME credit: 1.25 Track(s): Melanoma/Skin Cancers John M. Kirkwood, MD—Chair University of Pittsburgh Medical Center Historical Perspective of Immunotherapy for Advanced or Metastatic Melanoma Thomas Gajewski, MD, PhD The University of Chicago Limitations of Immunotherapy, Mechanisms of Resistance, Immune Escape, Effect of Tumor Microenvironment, and Why Immunotherapy Strategies May Have Been Ineffective MONDAY Suzanne Louise Topalian, MD The Johns Hopkins University School of Medicine Overview of the Future of Immunotherapy Strategies for Advanced Melanoma New Targeted Therapies in Neuroendocrine Cancers: What Should Be the Sequence of Therapy? Location: Hall D1 CME credit: 1.25 Track(s): Gastrointestinal (Noncolorectal) Cancer, Developmental Therapeutics Matthew Kulke, MD, MMSc—Chair Dana-Farber Cancer Institute What Is the Best Sequence of Therapy for Pancreatic Neuroendocrine Tumors? Emily K. Bergsland, MD University of California, San Francisco Cancer Center What Is the Best Sequence of Treatment for Carcinoid Tumors? Martyn Caplin, MD Royal Free Hampstead NHS Trust The Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors: When Should They Be Started and When Do We Add Other Agents? 349 Monday, June 6, 2011 What Is Going on with Mesothelioma? Location: S406 CME credit: 1.25 Track(s): Lung Cancer, Sarcoma Harvey I. Pass, MD—Chair New York University School of Medicine Surgery for Pleural Mesothelioma: Are We Closer to Personalized Selection? Michele Carbone, MD, PhD University of Hawaii Cancer Center New Concepts in Mesothelial Carcinogenesis: Fibers, Inflammation, and Hotspots Anna K. Nowak, MBBS, PhD Sir Charles Gairdner Hospital Mesothelioma Chemotherapy, Biologic Therapy, and Immunotherapy: Pathways, Personalized Prediction, and Results to Date MONDAY 350 Monday, June 6, 2011 9:45 AM - 11:00 AM MEET THE PROFESSOR SESSIONS Follicular Lymphoma Case Studies: Blending the Art and Science of Medicine Together (M14)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Lymphoma and Plasma Cell Disorders Myron Stefan Czuczman, MD Roswell Park Cancer Institute Preparing for New Cultural Competence Requirements for Oncology Professionals (M21)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Ethics, Patient and Survivor Care, Professional Development Marjorie Kagawa-Singer, PhD, MA, MN, RN University of California, Los Angeles School of Public Health Understanding the Notion of Culture and Its Influence on Health-related Matters and Oncology Practice MONDAY Antonella Surbone, MD, PhD New York University Meeting Oncologists’ Educational Needs in Preparation for the Joint Commission 2012 Standards in Cultural Competence 351 Monday, June 6, 2011 9:45 AM - 11:15 AM SPECIAL SESSION ASCO/American Association for Cancer Research (AACR) Joint Session: Telomeres and Telomerase in Cancer Location: S100bc CME credit: 1.5 Track(s): Tumor Biology, Special Session George W. Sledge Jr., MD—Co-Chair Indiana University Simon Cancer Center Welcome and Introduction Elizabeth H. Blackburn, PhD—Co-Chair University of California, San Francisco Telomeres and Telomerase in Human Cancer and in the Aging Population Steven Artandi, MD, PhD Stanford School of Medicine Functional Involvement of Telomerase in New Cellular Functions Kathy Miller, MD Indiana University Simon Cancer Center The Clinical Perspective: Where We Are Going with Telomeres and Telomerase MONDAY 352 Monday, June 6, 2011 11:30 AM - 12:45 PM EDUCATION SESSIONS Advances in Risk Stratification, Biology, and Treatment of Neuroblastoma Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology Susan Lerner Cohn, MD—Chair University of Chicago Pritzker School of Medicine Refining Risk Classification for Children with Neuroblastoma Meredith Irwin, MD The Hospital for Sick Children What Role Do “Stem Cells” Play in Neuroblastoma? Rochelle Bagatell, MD The Children’s Hospital of Philadelphia Advances in the Treatment of Patients with High-risk Neuroblastoma Considerations When Standard of Care Fails (eQuestions Session) Location: E353 CME credit: 1.25 Track(s): Ethics, Clinical Trials, Practice Management and Information Technology Jeffrey M. Peppercorn, MD, MPH—Chair Duke University Medical Center Options to Consider in Developing an Individualized Approach to Advanced Cancer Care Robert L. Erwin, MS Marti Nelson Cancer Foundation A Patient’s Perspective on Options to Consider When Standard Interventions Are Exhausted Thomas J. Smith, MD Massey Cancer Center of Virginia Commonwealth University How and Why to Discuss Palliative Care with Patients with Advanced Cancer after Standard Care Has Failed MONDAY Management of Complications and Palliative Care for Patients with Brain Tumors Location: E354b CME credit: 1.25 Track(s): Central Nervous System Tumors, Patient and Survivor Care Denise Correa, PhD—Chair Memorial Sloan-Kettering Cancer Center An Overview of Cognitive Functions in Patients with Brain Tumors Nigel Key, MD University of North Carolina at Chapel Hill Approach to Thromboembolic Disease in Patients with Brain Tumors Alan D. Valentine, MD University of Texas M. D. Anderson Cancer Center Pharmacologic Stimulant Therapies, Such As Methylphenidate and Modafinil 353 Monday, June 6, 2011 The Art and Business of a Successful Early Clinical Trials Program: Academic, Private, and Industry Perspectives Location: E354a CME credit: 1.25 Track(s): Developmental Therapeutics, Clinical Trials Chris H. M. Takimoto, MD, PhD—Chair University of Texas Health Science Center at San Antonio Industry Considerations for Phase I Partnerships Patricia LoRusso, DO Karmanos Cancer Institute Academic Phase I Program: If You Build It, Will They Come? Lee S. Rosen, MD Premiere Oncology A Private Model for a Successful Phase I Clinical Trials Program MONDAY 354 Monday, June 6, 2011 11:30 AM - 12:45 PM MEET THE PROFESSOR SESSIONS Melanoma FISH ’n’ Chips (M15)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Melanoma/Skin Cancers Hensin Tsao, MD Massachusetts General Hospital Multidisciplinary Treatment of Skull Base Tumors (M22)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Head and Neck Cancer Francis P. Worden, MD University of Michigan Cancer Center Chemotherapy for Skull Base Maligancies MONDAY Ehab Y. Hanna, MD University of Texas M. D. Anderson Cancer Center Surgical Management of Base of Skull Tumors 355 Monday, June 6, 2011 1:00 PM - 4:00 PM ORAL ABSTRACT SESSION Developmental Therapeutics—Clinical Pharmacology and Immunotherapy Location: Arie Crown Theater CME credit: 3 Track(s): Developmental Therapeutics Tyler J. Curiel, MD—Chair University of Texas Health Science Center at San Antonio 1:00 PM Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. (Abstract #2506) H. Okada, P. Kalinski, A. H. Mintz, J. A. Engh, L. H. Butterfield, R. H. Hamilton, D. M. Potter, A. M. Salazar, F. S. Lieberman 1:15 PM Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. (Abstract #2507) J. Chesney, M. Rasku, A. C. Klarer, D. M. Miller, S. Telang 1:30 PM Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus. (Abstract #2508) J. Nesselhut, D. Marx, D. Lorenzen, N. Cillien, W. Goebel, R. Y. Chang, W. Brockmann, J. Peters, K. Nesselhut, F. Fändrich, T. Nesselhut Discussion 1:45 PM Tyler J. Curiel, MD (Abstract #2506 –2508) University of Texas Health Science Center at San Antonio MONDAY 2:00 PM Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. (Abstract #2509) J. Brody, R. Advani, W. Weng, D. Czerwinski, A. A. Alizadeh, H. E. Kohrt, R. Negrin, R. Levy 2:15 PM Phase I clinical trial of cancer vaccine with five novel epitope peptides for patients with metastatic colorectal cancer (mCRC). (Abstract #2510) S. Hazama, M. Oka, K. Yoshida, T. Tsunoda, S. Yoshino, Y. Hinoda, Y. Nakamura 2:30 PM The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Followup results from a phase ll/lll study. (Abstract #2512) M. M. Heiss, M. A. Ströhlein, C. Bokemeyer, D. Arnold, S. L. Parsons, M. G. Ott, E. Schulze, H. Lindhofer, D. Seimetz, M. Hennig Discussion 2:45 PM Eduardo M. Sotomayor, MD (Abstracts #2509 –2510, 2512) H. Lee Moffitt Cancer Center & Research Institute 3:00 PM A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. (Abstract #2511) J. M. Richards, M. A. Warso, D. Mehta, K. Christov, C. M. Schaeffer, T. Yamada, C. W. Beattie, L. R. Bressler, T. K. Das Gupta 3:15 PM Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. (Abstract #2513) H. Oettle, A. Hilbig, T. Seufferlein, A. Tsianakas, T. Luger, R. M. Schmid, G. von Wichert, E. Endlicher, C. Garbe, K. K. Kaehler, A. Hauschild, A. Enk, P. Kiessling, S. Schmaus, H. Heinrichs, K. Schlingensiepen 356 Monday, June 6, 2011 3:30 PM A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. (Abstract #2514) L. Naumovski, M. S. Gordon, P. N. Munster, P. Hegde, J. Fredrickson, S. Bai, R. P. Funke, I. Chang, G. S. Chandler, D. S. Chen, L. S. Rosen MONDAY Discussion 3:45 PM Padmanee Sharma, MD, PhD (Abstracts #2511–2514) University of Texas M. D. Anderson Cancer Center 357 Monday, June 6, 2011 1:00 PM - 4:00 PM ORAL ABSTRACT SESSION Genitourinary (Prostate) Cancer Location: Hall D1 CME credit: 3 Track(s): Genitourinary Cancer Joshi J. Alumkal, MD—Co-Chair Oregon Health & Science University Ajjai Shivaram Alva, MBBS, MS—Co-Chair University of Michigan 1:00 PM Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SUⴙP) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4515) M. D. Michaelson, Y. Ou, L. Sengeløv, F. Saad, N. Houede, P. J. Ostler, A. Stenzl, G. Daugaard, R. J. Jones, F. Laestadius, A. Bahl, D. E. Castellano, J. Gschwend, T. Maurina, D. Ye, I. Chen, S. Wang, E. C. Maneval, S. Oudard 1:15 PM Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. (Abstract #4516) M. Hussain, M. R. Smith, C. Sweeney, P. G. Corn, A. Elfiky, M. S. Gordon, N. B. Haas, A. L. Harzstark, R. Kurzrock, P. Lara Jr., C. Lin, A. Sella, E. J. Small, A. I. Spira, U. N. Vaishampayan, N. J. Vogelzang, C. Scheffold, M. D. Ballinger, F. Schimmoller, D. C. Smith 1:30 PM Evaluation of circulating tumor cell (CTCs) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. (Abstract #LBA4517) H. I. Scher, G. Heller, A. Molina, T. S. Kheoh, G. Attard, J. Moreira, S. K. Sandhu, C. Parker, C. Logothetis, R. T. McCormack, K. Fizazi, A. Anand, D. C. Danila, M. Fleisher, D. Olmos, C. M. Haqq, J. S. De Bono MONDAY Discussion 1:45 PM Daniel J. George, MD (Abstracts #4515–LBA4517) Duke Cancer Institute 2:00 PM Toward a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years. (Abstract #4512) H. Lilja, C. Savage, A. Gerdtsson, T. Bjork, J. Manjer, P. Nilsson, A. Dahlin, A. Bjartell, P. T. Scardino, D. Ulmert, A. J. Vickers 2:15 PM Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12). (Abstract #4513) K. Fizazi, F. Lesaunier, R. Delva, G. Gravis, F. Rolland, F. Priou, J. Ferrero, N. Houede, L. Mourey, C. Theodore, I. Krakowski, J. Berdah, M. Baciuchka, P. Kerbrat, J. Davin, J. Berille, M. Habibian, J. Ichante, A. Laplanche, S. Culine 2:30 PM A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). (Abstract #4514) J. M. Crook, C. J. O’Callaghan, K. Ding, G. Duncan, D. P. Dearnaley, C. S. Higano, E. M. Horwitz, E. Frymire, S. Malone, J. Chin, A. Nabid, P. R. Warde, T. B. Corbett, S. Angyalfi, S. L. Goldenberg, M. K. Gospodarowicz, F. Saad, J. P. Logue, P. F. Schellhammer, L. Klotz 358 Monday, June 6, 2011 Discussion 2:45 PM Joel B. Nelson, MD (Abstracts #4512– 4514) University of Pittsburgh 3:00 PM Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): The Netherlands Prostate Study (NePro). (Abstract #4518) H. J. Meulenbeld, E. D. van Werkhoven, J. L. Coenen, G. Creemers, O. J. Loosveld, P. C. De Jong, A. J. Ten Tije, S. D. Fossa, M. Polee, W. R. Gerritsen, O. Dalesio, R. De Wit 3:15 PM Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. (Abstract #4520) C. Logothetis, J. S. De Bono, A. Molina, E. M. Basch, K. Fizazi, S. A. North, K. N. Chi, R. J. Jones, O. B. Goodman, P. N. Mainwaring, C. N. Sternberg, D. D. Gagnon, R. Dhawan, M. Rothman, Y. Hao, C. S. Liu, T. S. Kheoh, H. I. Scher, C. M. Haqq MONDAY Discussion 3:30 PM Michael J. Morris, MD (Abstracts #4518 and 4520) Memorial Sloan-Kettering Cancer Center 359 Monday, June 6, 2011 1:00 PM - 4:00 PM ORAL ABSTRACT SESSION Patient and Survivor Care Location: S404 CME credit: 3 Track(s): Patient and Survivor Care Teresa Gilewski, MD—Chair Memorial Sloan-Kettering Cancer Center 1:00 PM Does circulating tumor necrosis factor (TNF) play a role in post-chemotherapy cerebral dysfunction in breast cancer survivors (BCS)? (Abstract #9008) P. A. Ganz, S. A. Castellon, D. H. Silverman, L. Kwan, J. E. Bower, M. R. Irwin, S. W. Cole 1:15 PM Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast cancer undergoing radiotherapy. (Abstract #9009) L. Cohen, K. Chandwani, N. Raghuram, R. Haddad, G. H. Perkins, A. Spelman, R. Nagarathna, K. Johnson, A. Fortier, B. Arun, Q. Wei, C. Kirschbaum, H. Nagendra Discussion 1:30 PM Karen Michelle Mustian, PhD, MPH (Abstracts #9008 –9009) University of Rochester Medical Center MONDAY 1:45 PM A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy. (Abstract #9010) Y. Guo, J. L. Palmer, A. Forman, S. R. Dakhil, M. R. Velasco, M. Weiss, P. Gilman, G. M. Mills, S. J. Noga, C. Eng, M. J. Overman, M. Fisch 2:00 PM A phase III study for prevention of delayed nausea: A University of Rochester CCOP study of 1,021 patients receiving chemotherapy. (Abstract #9012) G. R. Morrow, J. A. Roscoe, C. Heckler, S. R. Dakhil, J. L. Wade, J. P. Kuebler, S. G. Mohile, L. J. Peppone, M. C. Janelsins 2:15 PM Phase III, double-blind, placebo-controlled, crossover study evaluating a 5HT3 antagonist with dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A Hoosier Oncology Group (HOG) study. (Abstract #9013) M. J. Brames, J. Picus, M. Yu, E. L. Johnston, B. Bottema, C. E. Williams, L. H. Einhorn Discussion 2:30 PM Debra L. Barton, PhD, AOCN, RN (Abstracts #9010 –9013) Mayo Clinic 2:45 PM The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: SAVE ONCO study. (Abstract #LBA9014) G. Agnelli, D. J. George, W. Fisher, A. K. Kakkar, M. R. Lassen, P. Mismetti, P. Mouret, U. Chaudhari, A. G. G. Turpie 3:00 PM The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. (Abstract #CRA9015) S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. Shah, K. F. Tucker, S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton 360 Monday, June 6, 2011 3:15 PM Does L-arginine/Korean ginseng/gingko biloba/damiana-based supplement improve the sexual function and quality of life of female cancer survivors? A randomized trial. (Abstract #9016) K. Greven, L. D. Case, L. R. Nycum, P. J. Zekan, D. D. Hurd, E. P. Balcueva, G. M. Mills, R. Zon, P. J. Flynn, D. Biggs, E. G. Shaw, Comprehensive Cancer Center of Wake Forest University CCOP Research Base MONDAY Discussion 3:30 PM Vered Stearns, MD (Abstracts #LBA9014 –9016) The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University 361 Monday, June 6, 2011 1:00 PM - 5:00 PM GENERAL POSTER SESSION Breast Cancer—HER2/ER Location: Hall A Track(s): Breast Cancer MONDAY Brd. 1A Use of a gene profile to identify molecular subtypes of breast cancer. (Abstract #537) W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S. Tian, A. Glas, R. A. Bender, J. Carroll, R. Bernards Brd. 1B Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients. (Abstract #538) T. Winder, G. Giamas, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, A. Gerger, M. J. Labonte, J. Stebbing, H. Lenz Brd. 1C Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positive grading groups of early breast cancer (EBC) in distinct biologic entities. (Abstract #539) A. Ferro, M. Barbareschi, C. Eccher, A. Caldara, D. Aldovini, R. Triolo, L. Cuorvo, F. Berloffa, S. Brugnara, O. Caffo, M. di Pasquale, M. Frisinghelli, V. Murgia, B. Soini, F. Valduga, A. Veccia, E. Galligioni Brd. 1D Estrogen and vascular endothelial growth factor (VEGF): Their role in breast cancer (BC) carcinogenesis and disease progression in premenopause. (Abstract #540) F. Recchia, G. Candeloro, G. Desideri, S. Necozione, S. Rea Brd. 1E An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib. (Abstract #541) X. Hu, L. Wang, Q. Zhang, J. Zhang, H. Guo, S. Sun, B. Y. Wang, Z. Jia, Z. Shao, Z. Wang Brd. 1F Long-term results of the Toronto magnetic resonance imaging (MRI) breast surveillance study of women with BRCA1 or BRCA2 mutations. (Abstract #542) K. Passaperuma, D. B. Plewes, P. Causer, K. A. Hill, S. J. Messner, J. Wong, R. A. Jong, F. Wright, M. Yaffe, E. Ramsay, S. Balasingham, L. Verity, A. Eisen, B. Curpen, R. Shumak, S. Narod, E. Warner Brd. 1G Survival after brain metastases in Asian patients with HER2ⴙ breast cancer. (Abstract #543) Y. Yap, B. C. Devi, C. Khorprasert, G. H. Cornelio, N. Sutandyo, E. Yeoh, S. Landis, M. Kobayashi, H. Moon, J. Ro Brd. 2A A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). (Abstract #544) V. Dieras, J. Jassem, L. Y. Dirix, J. P. Guastalla, P. Bono, S. A. Hurvitz, A. Gonçalves, G. Romieu, S. A. Limentani, G. H. Jerusalem, K. Lakshmaiah, H. H. Roche, P. Sánchez-Rovira, T. Pienkowski, M. Seguı́-Palmer, A. Li, Y. Sun, C. A. Pickett-Gies, H. Wildiers Brd. 2B Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer. (Abstract #545) N. Niikura, J. Liu, N. Hayashi, E. A. Mittendorf, Y. Gong, S. L. Palla, Y. Tokuda, A. M. Gonzalez-Angulo, G. N. Hortobagyi, N. T. Ueno Brd. 2C Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. (Abstract #546) G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G. Pruneri, E. Montagna, S. Dellapasqua, M. Iorfida, A. Cardillo, P. Veronesi, A. Luini, M. Intra, O. D. Gentilini, E. Scarano, D. Pastrello, A. Goldhirsch, M. Colleoni 362 Brd. 2D HLA-DRB1*07:01-DQA1*02:01 and UGT1A1*28 allele carriage in hepatic serious adverse event cases identified during lapatinib clinical trials. (Abstract #547) C. F. Spraggs, L. R. Budde, L. P. Briley, C. Cox, E. Rappold, G. Aktan, L. S. Williams, V. E. Mooser, L. R. Cardon Brd. 2E Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer. (Abstract #548) G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun, J. H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I. B. Paz, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van’t Veer, R. A. Bender Brd. 2F Results of a Belgian multicenter retrospective study to determine the incidence of HER2 gene amplification in patients scored as immunohistochemistry 0 or 1ⴙ. (Abstract #549) D. Larsimont, C. Colpaert, R. Salgado, N. Vermeesen, V. D’hondt, T. De Celle Brd. 2G Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer. (Abstract #550) P. F. Conte, V. Guarneri, D. G. Generali, A. Bottini, L. Bazzola, F. Piacentini, F. Artioli, K. Cagossi, G. Bisagni, M. Bagnalasta, E. Tagliafico, E. Barbieri, L. Cavanna, A. Ravaioli, R. D’Amico, R. Vicini, A. Frassoldati Brd. 3A T1abN0M0 HER2ⴙ invasive breast cancer recurrence: Population-based cohort of 17,000ⴙ consecutive breast cancers 2000 –2006 at Kaiser Permanente, Northern California (KPNC). (Abstract #551) L. Fehrenbacher, P. Shiraz, M. Sattavat, A. Capra, C. Quesenberry, R. Fulton, L. A. Habel Brd. 3B Pharmacogenetic investigation of lapatinib-associated diarrhea in metastatic breast cancer clinical trials. (Abstract #552) L. P. Briley, M. Chiano, K. King, M. Casey, A. J. Preston, F. Sapunar, V. E. Mooser, L. R. Cardon, C. F. Spraggs Brd. 3C Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH). (Abstract #553) V. Valero, D. J. Slamon, W. Eiermann, N. J. Robert, T. Pienkowski, M. Martin, J. R. Mackey, M. Lindsay, V. Bee-Munteanu, M. F. Press, G. Sauter, J. Crown Brd. 3D PAM50 intrinsic subtyping and pathological responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. (Abstract #554) P. Gomez Pardo, A. Prat, G. Bianchini, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. Vázquez-Mazón, L. Gianni, J. Baselga Brd. 3E A molecular portrait of circulating free DNA of patients with breast cancer: High resolution analysis using SNP 6.0 arrays. (Abstract #555) J. A. Shaw, K. Page, K. Blighe, N. Hava, D. Guttery, B. Ward, J. Brown, C. Ruangpratheep, R. Payne, C. Palmieri, S. Cleator, R. Walker, C. Coombes Brd. 3F Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2–98) of node-positive (Nⴙ) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (Abstract #556) S. Loi, R. Salgado, F. Piette, N. Sirtaine, F. Van Eenoo, R. Kammler, G. Rouas, P. A. Francis, J. Crown, B. Nordenskjold, J. Gutierrez, M. Andersson, M. M. Vila, R. Jakesz, G. Viale, E. M. Quinaux, A. Di Leo, S. Michiels, C. Sotiriou, M. J. Piccart-Gebhart 363 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 3G Treatment of small node-negative HER2ⴙ invasive breast carcinomas: Forty-month update of the joint Aerio/Remagus study. (Abstract #557) J. Wassermann, L. Albiges, M. J. Rodrigues, E. Brain, S. Delaloge, J. Guinebretiere, M. Mathieu, E. Guillot, A. Vincent-Salomon, P. H. Cottu, AERIO/REMAGUS Brd. 3H A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen receptor–positive breast cancer. (Abstract #558) N. Masuda, M. Toi, T. Ueno, T. Yamanaka, S. Saji, K. Kuroi, N. Sato, H. Takei, Y. Yamamoto, S. Ohno, H. Yamashita, K. Hisamatsu, K. Aogi, H. Iwata, H. Sasano Brd. 4A A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy. (Abstract #559) T. Cigler, M. J. Higgins, J. Szymonifka, A. H. Partridge, J. A. Ligibel, D. Finkelstein, S. E. Come, P. D. Ryan, P. E. Goss Brd. 4B Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer. (Abstract #560) M. Basik, D. Keilty, O. Aleynikova, D. Tu, X. Li, L. E. Shepherd, V. Bramwell Brd. 4C A functional assay for the identification of DNA double strand break repair deficiency in heterozygous carriers of BRCA1/2 and RAD51C mutations. (Abstract #561) A. Becker, M. Graeser, C. Landwehr, T. Hilger, W. Baus, R. Weber, B. Wappenschmidt, R. Schmutzler Brd. 4D Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer. (Abstract #562) V. O. Dezentje, J. den Hartigh, H. Guchelaar, T. Hessing, T. van der Straaten, J. M. Vletter - Bogaartz, R. Vree, E. Maartense, C. H. Smorenburg, H. Putter, A. Dieudonné, P. Neven, J. W. Nortier, H. Gelderblom Brd. 4E Elevated pretreatment serum CA9 (carbonic anhydrase 9) and correlation with progression-free and overall survival in trastuzumab-treated metastatic breast cancer. (Abstract #563) K. Leitzel, H. Hou, U. Anyanwu, V. Shrivastava, M. S. Evans, S. M. Ali, W. Koestler, E. Fuchs, F. J. Esteva, W. P. Carney, A. Lipton Brd. 4F Sequential administration of trastuzumab and a CD8 T cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone. (Abstract #564) A. K. Sears, G. T. Clifton, R. Patil, N. M. Shumway, M. G. Carmichael, D. C. Van Echo, J. P. Holmes, S. Ponniah, E. A. Mittendorf, G. E. Peoples Brd. 4G Fc␥-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab. (Abstract #565) N. Cresti, D. Jamieson, M. W. Verrill, M. Pinkilgton, A. V. Boddy Brd. 4H Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC). (Abstract #566) A. Gennari, M. Puntoni, O. Nanni, P. F. Conte, D. Amadori, V. Lorusso, A. De Censi, M. Sormani, V. Guarneri, M. D’Amico, A. Gozza, P. Bruzzi Brd. 5A Standardized uptake value (SUV) by positron emission tomography/ computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC). (Abstract #567) P. G. Morris, M. Fazio, K. L. Jhaveri, C. Serna-Tamayo, A. Eaton, S. Patil, G. Ulaner, J. Howard, S. M. Larson, C. Hudis, M. S. Jochelson, H. L. McArthur 364 Monday, June 6, 2011 Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2ⴙ) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy. (Abstract #568) S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi, R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrisi, D. Crivellari Brd. 5C Post-operative complications in neoadjuvant treatment including bevacizumab for HER2 positive inflammatory breast cancer (IBC): Results from a phase II prospective trial. (Abstract #569^) R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roche, D. Pau, P. Viens, R. J. Salmon Brd. 5D Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). (Abstract #570) E. De Azambuja, M. Lemort, J. R. Rossari, C. Moulin, A. Buttice, V. D’hondt, F. Lebrun, Y. Lalami, F. Cardoso, C. Sotiriou, T. Gil, D. Devriendt, W. Marinus, M. Paesmans, M. Piccart, A. Awada Brd. 5E First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2ⴙ LA/MBC. (Abstract #571) S. Tjulandin, A. Makhson, J. Gligorov, M. Lichinitser, A. Lluch, V. Semiglazov, N. Scotto, L. Mitchell, M. Martin Brd. 5F Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2ⴙ) metastatic breast cancer (MBC). (Abstract #572) A. Berghoff, R. Bartsch, Z. Bago-Horvath, P. C. Dubsky, M. Rudas, U. Pluschnig, C. Wiltschke, M. Gnant, G. G. Steger, C. Zielinski Brd. 5G The role of the genomic breast cancer index in predicting pathological complete response in breast cancer patients treated with neoadjuvant anthracycline plus taxane. (Abstract #573) M. Mathieu, N. C. Kesty, H. Li, V. Scott, V. Marty, P. Viehl, J. Delacruz, S. Delaloge, C. Schnabel, M. G. Erlander, F. Andre Brd. 5H Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer. (Abstract #574) D. Gajria, T. A. King, H. Pannu, R. Sakr, A. D. Seidman, A. Syldor, S. Patil, M. Maybody, L. Norton, N. Rosen, C. Hudis, S. Chandarlapaty Brd. 6A Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2positive breast cancer. (Abstract #575) I. Lang, R. Bell, F. Feng, R. I. Lopez, J. Jassem, V. Semiglazov, N. Al-Sakaff, E. Carreras, J. Chang Brd. 6B Are St. Gallen endocrine response classes predictive for recurrence rates over time? (Abstract #576) R. H. Koornstra, K. J. Beelen, A. Vincent, P. J. van Diest, S. C. Linn Brd. 6C Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (Abstract #577) A. Aguilar-Mahecha, M. Basik, J. W. Chapman, K. Jahan, S. Hassan, L. Zhu, C. F. Wilson, K. I. Pritchard, L. E. Shepherd, M. N. Pollak Brd. 6D Discordance in estrogen receptor status between primary, metastatic, and second primary breast cancers: Impact of misclassification. (Abstract #578) D. Huo, J. Liu, O. I. Olopade Brd. 6E Long-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). (Abstract #579) C. T. Dang, P. G. Morris, S. Patil, C. Chen, A. Abbruzzi, R. Lehman, R. Steingart, L. Norton, C. Hudis MONDAY Brd. 5B 365 Monday, June 6, 2011 MONDAY Brd. 6F Predicting invasive disease at excision of ductal carcinoma in situ in core biopsies: A predictive model. (Abstract #580) C. McGathey, A. Fought, D. Scholtens, S. A. Khan Brd. 6G Salvage stereotactic radiosurgery (SRS) after previous whole brain radiation therapy (WBRT) for breast cancer brain metastases: Outcomes and prognostic factors including tumor phenotype. (Abstract #581) P. J. Kelly, N. U. Lin, E. B. Claus, S. E. Weiss, B. M. Alexander Brd. 6H Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC). (Abstract #582) J. W. Cook, E. Paxinos, L. J. Goodman, S. M. Ali, K. Leitzel, W. Koestler, A. Rivera, J. M. Weidler, W. Huang, J. Sperinde, S. J. Williams, M. Bates, A. Lipton Brd. 7A Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells. (Abstract #583) M. McDermott, B. Browne, J. Crown, N. O’Brien, D. J. Slamon, N. O’Donovan Brd. 7B The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with at least one inactive CYP2D6 variant allele and/or concomitant use of a CYP2D6 inhibitor. (Abstract #584) M. E. Welzen, V. O. Dezentje, R. H. van Schaik, E. P. Colbers, H. Guchelaar, J. den Hartigh, D. M. Burger, H. Van Laarhoven Brd. 7C Discordance in pathology report after central pathology review in early breast cancer and its impact on treatment choice. (Abstract #585) L. Orlando, G. Viale, P. Schiavone, P. Fedele, A. Nacci, P. Rizzo, N. Calvani, F. Sponziello, C. Chetri, E. Mazzoni, M. D’ Amico, A. Marino, M. Cinefra, S. Cinieri Brd. 7D Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein expression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation of clinical cutoffs. (Abstract #586) W. Biernat, R. Duchnowska, B. Szostakiewicz, J. Sperinde, M. Haddad, A. Paquet, Y. Lie, J. Weidler, W. Huang, J. Winslow, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wysocki, M. Foszczynska-Kloda, B. Radecka, M. M. Litwiniuk, S. Debska, M. Bates, J. Jassem Brd. 7E IGF1R and phosphorylated IGF1R in HER2-positive breast cancer. (Abstract #587) B. Browne, J. Crown, A. J. Eustace, S. Kennedy, N. O’Brien, A. Larkin, J. Ballot, T. Mahgoub, Z. Qadir, F. Sclafani, S. F. Madden, M. J. Kennedy, M. J. Duffy, N. O’Donovan Brd. 7F Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43. (Abstract #588) K. P. Siziopikou, M. A. Cobleigh, S. J. Anderson, T. B. Julian, D. W. Arthur, P. Zheng, E. P. Mamounas, E. R. Pajon, R. J. Behrens, L. Chu, N. C. Leasure, J. N. Atkins, J. Polikoff, T. E. Seay, W. J. McCaskill-Stevens, R. Rabinovitch, N. Wolmark Brd. 7G Bcl2 expression and prediction of outcomes to anthracycline-based neoadjuvant chemotherapy in ER-positive breast cancer and to nonanthracycline adjuvant therapy. (Abstract #589) P. D. Dickinson, T. M. Abdel-Fatah, A. R. Green, P. Moseley, J. S. Reis-Filho, I. O. Ellis, S. Chan Brd. 7H Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. (Abstract #590) S. Modi, C. Saura, C. A. Henderson, N. U. Lin, R. L. Mahtani, J. Goddard, E. Rodenas, J. O’Shaughnessy, J. Baselga Brd. 8A Strategies for protecting patients from anthracyline-induced cardiac dysfunction. (Abstract #591) A. K. Dickey, C. Geisberg, Y. R. Su, I. A. Mayer, J. A. Means-Powell, C. Silverstein, X. Peng, D. Freehardt, B. White, D. J. Lenihan, D. Sawyer 366 Brd. 8B Using the 21-gene recurrence score and the recently developed recurrence score clinical pathologic to assess recurrence risk in patients with nodenegative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone. (Abstract #592) M. Crager, G. Tang, S. Shak Brd. 8C Population-based comparison of breast cancer screening and treatment utilization by remoteness of residence in British Columbia. (Abstract #593) R. A. Olson, N. R. Caron, I. Olivotto, C. Speers, A. Davidson, S. K. Chia, A. Coldman, A. Nichol, C. Bajdik, S. Tyldesley Brd. 8D Association between bone turnover markers and skeletal-related events in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study results at 9 months of follow-up). (Abstract #594) A. Barnadas, C. De la Piedra, C. Crespo, P. Gomez Pardo, L. Calvo, E. G. Calvo, M. Ruiz-Borrego, J. Rifa, L. Manso, A. Anton, M. Codes, M. Margeli, A. Murias, J. Salvador, M. Seguı́-Palmer, A. De Juan, J. Gavila, D. Perez, M. Luque, I. Tusquets Brd. 8E Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. (Abstract #595) A. Wenners, K. Mehta, S. Loibl, H. Park, N. Arnold, S. Hamann, J. Weimer, B. Ataseven, C. Schem, F. Khandan, C. Thomssen, W. Jonat, H. Holzhausen, G. Von Minckwitz, C. Denkert, M. Bauer Brd. 8F An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs). (Abstract #596) D. W. Cescon, M. Ennis, P. A. Ganz, S. Beddows, F. Z. Stanczyk, S. S. Sridhar, P. J. Goodwin Brd. 8G Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2ⴙ) metastatic breast cancer (MBC). (Abstract #597) R. Bartsch, A. Berghoff, U. Pluschnig, Z. Bago-Horvath, P. C. Dubsky, A. Rottenfusser, C. Wenzel, M. Rudas, F. Fitzal, K. Dieckmann, M. Gnant, C. Zielinski, G. G. Steger Brd. 8H A phase II study of lonafarnib (LF) in patients with locally advanced and metastatic breast cancer (MBC): Hoosier Oncology Group BRE07–126. (Abstract #598) B. Leyland-Jones, K. Miller, P. Silverman, C. Shen, C. E. Williams, T. Breen, G. W. Sledge Jr. Brd. 9A The expression of GATA-3 and FOXA1 in breast cancer: The biomarkers of hormonal sensitivity in luminal type tumors. (Abstract #599) Y. Hisamatsu, E. Tokunaga, S. Akiyoshi, S. Okada, N. Yamashita, E. Oki, M. Morita, Y. Kakeji, Y. Maehara Brd. 9B Does metformin use influence outcome in diabetic women with invasive breast cancer? (Abstract #600) B. Oppong, S. Oskar, M. Stempel, A. Eaton, S. Patil, T. A. King Brd. 9C The prognostic value of the cocaine and amphetamine-regulated transcript (CART) in breast cancer (BC). (Abstract #601) D. P. O’Connor, D. J. Brennan, H. Laursen, S. F. McGee, S. McCarthy, R. Zagozdzon, E. Rexhepaj, A. Culhane, F. M. Martin, M. J. Duffy, G. Landberg, L. Ryden, S. M. Hewitt, M. J. Kuhar, R. Bernards, R. C. Millikan, J. Crown, K. Jirstrom, W. M. Gallagher Brd. 9D Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting. (Abstract #602) A. Guerin, D. Lalla, D. Latremouille-Viau, A. P. Yu, E. Q. Wu, M. Brammer, S. A. Hurvitz 367 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 9E High false-negative rate of HER2 qRT-PCR of the Oncotype DX test: An independent quality assurance study. (Abstract #603) D. J. Dabbs, M. Klein, S. Mohsin, R. R. Tubbs, R. Bhargava Brd. 9F Association of GP88 (progranulin) tumor expression with decreased diseasefree and overall survivals in patients with breast cancer with estrogen receptor-positive invasive ductal carcinoma. (Abstract #604) G. Serrero, D. M. Hawkins, B. Yue, O. B. Ioffe, P. Bejarano, J. T. Phillips, J. F. Head, R. L. Elliott, A. K. Godwin, J. Weaver, W. Kim, S. Kamimura Brd. 9G A semiphysiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumabDM1 (T-DM1) on platelet counts in patients with HER2-positive MBC. (Abstract #605) B. C. Bender, F. Schaedeli Stark, A. Joshi, Y. Chu, H. S. Rugo, I. E. Krop, S. Girish, M. Gupta Brd. 9H Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer. (Abstract #606) O. Metzger, A. Catteau, S. Michiels, M. E. Buyse, K. V. Saini, V. Fasolo, J. Canon, P. Delrée, M. Coibion, V. Jossa, J. Kains, D. Larsimont, V. Richard, D. Faverly, N. Cornez, P. Vuylsteke, B. Vanderschueren, H. P. Peyro Saint Paul, M. J. Piccart-Gebhart, C. Sotiriou Brd. 10A Adjuvant treatment strategy and results in small breast cancer tumors (pT1) with HER2 overexpression. (Abstract #607) A. Hinke, P. Dall, G. Lenzen, C. Schumacher, D. Rezek, N. Gazawi, A. Ammon, F. G. Foerster, F. Beldermann, U. Cirrincione, J. Wilke Brd. 10B Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients. (Abstract #608) M. Arnedos, R. Ferraldeschi, R. A’Hern, K. Hadfield, S. Roberts, S. Drury, A. Howell, D. G. Evans, A. M. Wardley, I. E. Smith, W. G. Newman, M. Dowsett Brd. 10C High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients. (Abstract #609) A. Vaccaro, F. Ciancola, L. Pizzuti, I. Sperduti, L. Moscetti, P. Vici, F. Longo, E. Ruggeri, M. Di Seri, M. Giampaolo, T. Gamucci Brd. 10D Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients. (Abstract #610) M. Giuliano, A. Giordano, A. Patt, L. Hsu, R. H. Alvarez, N. T. Ueno, V. Valero, G. N. Hortobagyi, M. Cristofanilli, J. M. Reuben Brd. 10E Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial. (Abstract #611) P. S. Bernard, C. Davis, B. Munarriz, I. J. Stijleman, M. Ruiz-Borrego, M. T. Ebbert, A. Rodriguez-Lescure, R. R. Bastien, C. Crespo, C. M. Perou, C. Rodriguez, F. I. Aranda, V. Furió, I. Alvarez, M. Seguı́, E. Alba, A. Anton, E. M. Carrasco, R. Caballero, M. Martin Brd. 10F Evaluation of HER2 gene status by qPCR in breast cancer samples with nonconclusive FISH. (Abstract #612) V. Koudelakova, J. Berkovcova, R. Trojanec, L. Radova, J. Ehrmann, Z. Kolar, B. Melichar, M. Hajduch Brd. 10G Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology, CEE). (Abstract #613) S. Krishnamurthy, F. Z. Bischoff, J. A. Mayer, K. Wong, S. Mikolajczyk, T. Pham, H. M. Kuerer, A. Lodhi, A. Bhattacharyya, C. Hall, A. Lucci Jr. Brd. 10H Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC). (Abstract #614) L. Chow, B. Xu, L. Y. Dirix, B. Moy, E. Leip, N. Bardy-Bouxin, L. Duvillie, T. Sarosiek 368 Brd. 11A Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. (Abstract #615) E. Ruckhäberle, T. Karn, C. Denkert, S. Loibl, B. Ataseven, T. Reimer, L. C. Hanker, N. Sänger, U. Holtrich, M. Kaufmann, S. Darb-Esfahani, V. Nekljudova, G. Von Minckwitz Brd. 11B Prognostic impact of phosphorylated HER2 in HER2-positive primary breast cancer using reverse-phase protein array. (Abstract #616) N. Hayashi, T. Iwamoto, A. M. Gonzalez-Angulo, J. Ferrer-Lozano, A. Lluch, N. Niikura, C. Bartholomeusz, S. Nakamura, G. N. Hortobagyi, N. T. Ueno Brd. 11C Long-term survival in patients with HER2-positive metastatic breast cancer treated with trastuzumab as first-line therapy: Seven-year follow-up of the French observational hermine study. (Abstract #617) E. Antoine, F. Dalenc, C. Hebert, P. Rivera, G. Romieu, N. Varoqueaux, J. P. Guastalla, M. Namer Brd. 11D A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptorpositive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells. (Abstract #618) T. Ueno, N. Masuda, S. Kamigaki, T. Morimoto, S. Nakamura, K. Kuroi, H. Iwata, S. Ohno, S. Tanaka, M. Toi Brd. 11E Protection of adjuvant trastuzumab in sites of early relapses. (Abstract #619) M. Campiglio, E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, L. Gianni, S. Ménard, on the behalf of GHEA group Brd. 11F Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HRⴙ), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC). (Abstract #620) K. B. Kabaker, J. Canar, R. D. Rao, M. A. Cobleigh Brd. 11G Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial. (Abstract #621) J. D. Zubkus, D. B. Daniel, J. F. Eakle, R. G. Bechhold, M. Shastry, P. S. Tucker, H. A. Burris III, J. D. Hainsworth, D. A. Yardley Brd. 11H Hormonal therapy versus chemotherapy as first-line line treatment for estrogen receptor–positive metastatic breast cancer (MBC) patients. (Abstract #622) T. Y. Chang, C. Lin, Y. Lu, S. H. Kuo, S. Huang, C. Huang, A. Cheng Brd. 12A Epithelial-mesenchymal transition in patients with HER2ⴙ metastatic breast cancer. (Abstract #623) A. Giordano, M. Mego, B. Lee, S. Anfossi, C. A. Parker, R. H. Alvarez, N. T. Ueno, V. Valero, M. Cristofanilli, J. M. Reuben Brd. 12B Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab containing regimen. (Abstract #624) K. Sail, D. Lalla, M. Brammer, M. Halm, D. A. Patt Brd. 12C Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. (Abstract #625) C. Chen, D. A. Patt, D. R. Kazzaz, J. Shankleton, M. T. Forsyth, R. Ganesh Brd. 12D BRCAⴙ test result impact and timing on surgical treatment decisions for patients with breast cancer. (Abstract #626) K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, T. J. Fallen, W. J. Gradishar, J. C. Schink Brd. 12E Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. (Abstract #627) I. I. Abdel Halim, M.El Ashri, W. El Sadda, Clinical Oncology and Nuclear Medicine Department 369 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 12F Proteomics-based characterization of potential biomarkers in tamoxifen resistance in breast cancer. (Abstract #628) B. C. Sanchez, H. Johansson, J. Forshed, O. Stål, J. Lehtio, B. K. Linderholm Brd. 12G Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of Turkish Oncology Group. (Abstract #629) F. Icli, K. Altundag, U. Coskun, S. Paydas, G. Basaran, P. Saip, G. G. Dogu, Y. Eralp, R. Uslu, A. Sevinc, H. Onur, N. M. Mandel, C. Sezgin, M. Altinbas, N. Guler, A. Isikdogan, E. Gokmen, K. Uygun, Z. Ustuner, A. Yaren, Turkish Oncology Group Brd. 12H Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study. (Abstract #630) J. De la Haba, A. Rodriguez-Lescure, J. Baena, J. Martin Liberal, S. Morales, J. Chacon, J. Lopez, I. Fernandez, D. Aguiar, A. Garcia-Palomo, R. Llorente, J. Barea, E. Alvarez, I. Blancas, Y. Fernandez, P. Sanchez Rovira, G. Vinyes Brd. 13A Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HRⴙ) HER2-negative (HER2–) advanced breast cancer (ABC). (Abstract #631) B. Moy, F. Lebrun, M. Bellet, L. Chow, I. Lang, B. Xu, R. A. Badwe, D. L. Hershman, E. Leip, N. Bardy-Bouxin, L. Duvillie, P. Neven Brd. 13B Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort. (Abstract #632) N. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, C. Yoshizawa, S. Shak, N. Siegelmann-Danieli Brd. 13C Pharmacokinetic and pathophysiological covariates influencing treatment outcomes with t-DM1 in patients with HER2-positive metastatic breast cancer (MBC). (Abstract #633) M. Gupta, P. LoRusso, H. A. Burris III, B. Wang, A. Joshi, Y. B. Tong, Y. Chu, S. Girish Brd. 13D RAD51 and brain metastases (BM) in patients (pts) with HER2ⴙ breast cancer. (Abstract #634) R. Duchnowska, J. Jassem, E. Szutowicz, W. Biernat, T. Jankowski, W. Och, R. Staszkiewicz, M. Chudzik, W. Rogowski, N. Flores, S. Woditschka, L. Li, C. Goswami, M. A. Thorat, Y. Gokmen-Polar, G. W. Sledge Jr., P. S. Steeg, D. Palmieri, S. S. Badve Brd. 13E Effect of a soy isoflavone intervention on estrogen-related gene expression in the healthy high risk breast. (Abstract #635) S. A. Khan, O. Lee, I. B. Helenowski, D. Ivancic, B. Jovanovic, R. C. Bergan Brd. 13F A randomized trial of exercise versus control for musculoskeletal symptoms from adjuvant anastrozole (A) for postmenopausal early breast cancer (PEBC). (Abstract #636) C. A. Lohrisch, D. McKenzie, P. Truong, D. Jesperson, K. A. Gelmon, S. Premji, H. F. Kennecke 370 Monday, June 6, 2011 1:00 PM - 5:00 PM GENERAL POSTER SESSION Breast Cancer—Triple-negative/Cytotoxics/Local Therapy Brd. 14A Predictors of recurrence among patients with breast cancer who achieved a pathological complete response (pCR) after neoadjuvant systemic chemotherapy. (Abstract #1036) M. Chavez-MacGregor, X. Lei, J. K. Litton, A. Melhem, E. A. Mittendorf, F. Meric-Bernstam, A. A. Sahin, V. Valero, G. N. Hortobagyi, A. M. GonzalezAngulo Brd. 14B Radiation and survival in women over 70 with T1 N0 M0 ER-negative breast cancer from 1990 –2007: A population-based analysis. (Abstract #1037) A. P. Wojcieszynski, X. Shen, M. V. Mishra, P. R. Anne, T. N. Showalter Brd. 14C Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study. (Abstract #1038) C. Liedtke, O. Gluz, F. Heitz, R. Wuerstlein, R. E. Kates, J. Tio, U. Nitz, A. Du Bois, T. N. Fehm, N. Harbeck Brd. 14D Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. (Abstract #1039) X. Lei, S. S. Dawood, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo Brd. 14E Multi-institutional evaluation of sentinel lymph node (SLN) examination by one-step nucleic acid amplification (OSNA) assay in breast cancer: Performance of metastases detection and prediction of additional nonsentinel lymph node (non-SLN) involvement. (Abstract #1040) N. Sato, K. Honma, S. Noguchi, Y. Tamaki, H. Tsuda, T. Kinoshita, S. Nakamura, K. Tsugawa, K. Suzuki, M. Tsujimoto, K. Yoshidome, F. Akiyama, T. Iwase, D. Takabatake, R. Nishimura, K. Taniyama, H. Kato, S. Umemura, Y. Tokuda, T. Kamio, OSNA Researchers’ Group Brd. 14F A multicenter randomized phase III trial of nonpegylated liposomeencapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line in locally advanced (LABC) or metastatic breast cancer (MBC). (Abstract #1041) V. Lorusso, F. Giotta, R. Bordonaro, E. Maiello, S. Del Prete, V. Gebbia, G. Filippelli, S. Pisconti, S. Cinieri, S. Romito, F. Riccardi, G. Cairo, V. E. Chiuri, M. Ciccarese, R. Forcignano, L. Petrucelli, V. Saracino, G. Colucci Brd. 14G Pathologic characteristics of second breast cancers (SBC) among women previously treated for ductal carcinoma in situ (DCIS) with breast conservation. (Abstract #1042) N. D. Arvold, R. S. Punglia, M. E. Hughes, W. Jiang, S. B. Edge, S. H. Javid, C. Laronga, J. C. Niland, R. L. Theriault, J. C. Weeks, Y. Wong, S. J. Lee, M. J. Hassett Brd. 14H Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness. (Abstract #1043) R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa, N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. Esserman Brd. 15A Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial. (Abstract #1044) S. Hegewisch-Becker, C. A. Lerchenmuller, A. Welt, T. Decker, M. Just, C. Steffens, A. Hipper, N. Marschner 371 MONDAY Location: Hall A Track(s): Breast Cancer Monday, June 6, 2011 MONDAY Brd. 15B Close or positive margins after mastectomy in early-stage, node-negative breast cancer: The association of tumor grade with local recurrence. (Abstract #1045) J. R. Hastings, S. Iganej, D. M. Bugoci, C. Huang Brd. 15C Prevalence and impact of correlative science in breast cancer phase II trials. (Abstract #1046) T. Zhang, E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, J. M. Peppercorn Brd. 15D Overall survival effect of lower chemotherapy dosing in extremely obese (BMI > 35) patients with breast cancer based on adjusted BSA. (Abstract #1047) P. Sharma, T. A. Samuel, J. C. Wells, E. Mebel, J. T. French, J. A. Crozier, S. W. Looney Brd. 15E Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer. (Abstract #1048) A. M. Vanderwalde, W. Ye, P. H. Frankel, D. G. Asuncion, R. D. Pezner, T. H. Luu, S. Shibata, L. A. Leong, K. A. Margolin, R. Morgan, M. Koczywas, W. A. Chow, P. Twardowski, J. Y. Wong, J. H. Doroshow, S. J. Forman, G. Somlo Brd. 15F Can preoperative dynamic contrast enhanced breast MRI predict extensive occult axillary lymph node metastases in patients with positive sentinel node biopsy? (Abstract #1049) C. R. Loiselle, P. R. Eby, J. N. Kim, K. E. Calhoun, K. H. Allison, V. K. Gadi, S. Peacock, B. Storer, D. A. Mankoff, S. C. Partridge, C. D. Lehman Brd. 15G Risk and health care costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. (Abstract #1050) D. Weycker, J. Edelsberg, A. Kartashov, R. Barron, G. H. Lyman Brd. 15H A randomized phase II study of pemetrexed-carboplatin and gemcitabinevinorelbine in patients with anthracycline- and taxane-pretreated advanced breast cancer. (Abstract #1051) D. Amadori, I. La Torre, E. M. Carrasco, S. Roesel, R. Labianca, V. MoreauDonnet, D. Desaiah, M. Martin Brd. 16A Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC). (Abstract #1052) R. Borson, W. G. Harker, J. E. Reeves, D. Drosick, J. T. Beck, S. J. Hager, W. L. Horvath, J. Bromund, H. Zeigler, D. Tai, D. A. Yardley Brd. 16B Locoregional recurrence after breast cancer surgery: A meta-analysis by molecular subtype. (Abstract #1053) A. J. Lowery, M. R. Kell, R. W. Glynn, M. J. Kerin, K. J. Sweeney Brd. 16C The effect of tetrathiomolybdate on endothelial progenitor cells in patients at high risk for breast cancer recurrence. (Abstract #1054) S. Jain, J. A. Cohen, M. M. Ward, J. O’Loughlin, M. Boeck, N. Wiener, E. Chuang, T. Cigler, A. Moore, D. Donovan, C. Lam, M. E. Cobham, S. E. Schneider, P. J. Christos, M. E. Lane, R. Baergen, V. Mittal, S. Rafii, L. T. Vahdat Brd. 16D Rechallenging taxanes in recurrent breast cancer in patients treated with (neo)adjuvant taxane-based therapy. (Abstract #1055) X. Guo, S. Loibl, M. Untch, V. Möbus, K. Schwedler, P. A. Fasching, J. Barinoff, F. Holms, C. Thomssen, D. Zahm, R. Kreienberg, M. Hauschild, H. Eidtmann, S. Tauchert, K. Mehta, G. Von Minckwitz, German Breast Group and AGO-B Study Group Brd. 16E Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC). (Abstract #1056) E. Munzone, E. Botteri, A. Sciandivasci, G. Curigliano, F. Nole, N. Rotmensz, M. Colleoni, G. Viale, A. Esposito, A. Luini, M. G. Mastropasqua, A. Goldhirsch Brd. 16F Clinical outcome of triple-negative primary breast cancer in older women: Comparison with their younger counterparts. (Abstract #1057) K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis 372 Brd. 16G 06-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer (TNBC). (Abstract #1058) C. Fumagalli, P. Possanzini, M. O. Biasi, M. Manzotti, M. Barberis, B. Bonanni, M. Barile, I. Feroce, G. Viale Brd. 16H SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). (Abstract #1059) B. Conrad, N. Harbeck, G. Von Minckwitz, M. Wuellner, M. Warm, K. Schwedler, B. Gerber, I. Schrader, H. Eidtmann, K. Mehta, S. Loibl, GBG/AGO-B Study Groups Brd. 17A The relationship between age and survival outcomes for eribulin in metastatic breast cancer. (Abstract #1060) C. Twelves, L. T. Vahdat, J. Cortes, J. Wanders, C. E. Dutcus, S. Seegobin, H. B. Muss Brd. 17B PARP1 in triple-negative breast cancer: Expression and therapeutic potential. (Abstract #1061) M. B. Cotter, A. Pierce, P. M. McGowan, S. F. Madden, L. Flanagan, C. Quinn, D. Evoy, J. Crown, E. McDermott, M. J. Duffy Brd. 17C ADAMs as new therapeutic targets for triple-negative breast cancer. (Abstract #1062) M. Mullooly, P. M. McGowan, S. Sukor, S. F. Madden, E. McDermott, J. Crown, N. O’Donovan, M. J. Duffy Brd. 17D Triple-negative breast cancer: The effect of guideline adherent adjuvant treatment on the cumulative survival. A retrospective multicenter cohort study of 3,658 patients. (Abstract #1063) L. Schwentner, R. Wolters, M. Wischnewsky, R. Kreienberg, A. Wöckel Brd. 17E Effect of neoadjuvant ixabepilone (Ixa) on cell cycle genes and on tumorinitiating cell (TIC) signature in breast cancer (BC). (Abstract #1064) H. Chang, C. E. Horak, P. Mukhopadhyay, C. Lowery, J. Baselga, J. A. Sparano Brd. 17F Breast conservation therapy: The influence of molecules and margins. (Abstract #1065) S. Demirci, G. Broadwater, L. B. Marks, R. Clough, L. R. Prosnitz Brd. 17G Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2negative breast cancer with exploratory oncotype DX assessments: A Sarah Cannon Research Institute phase II trial. (Abstract #1066) N. W. Peacock, D. A. Yardley, C. B. Hendricks, S. Y. Huh, S. L. Ketchum, C. Chao, C. Yoshizawa, M. Shastry, B. Strike, H. A. Burris III, J. D. Hainsworth Brd. 17H A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixeddose capecitabine in metastatic breast cancer (MBC). (Abstract #1067) R. M. Connolly, M. A. Rudek, H. L. Mc Leod, E. Garrett-Mayer, S. C. Jeter, L. A. Wright, V. Stearns, D. K. Armstrong, J. H. Fetting, S. P. Watkins, N. E. Davidson, A. C. Wolff Brd. 18A The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: Results of a prospective practice improvement study. (Abstract #1068) A. W. Peled, R. D. Foster, E. Garwood, C. A. Ewing, M. Alvarado, E. S. Hwang, L. Esserman Brd. 18B Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (Abstract #1069) F. Heitz, B. Sinn, S. Loibl, A. Du Bois, C. Jackisch, S. Kuemmel, C. Denkert, J. Barinoff, K. Mehta, G. Von Minckwitz, on behalf the GeparTrio trialists Brd. 18C The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer. (Abstract #1070) U. Ortmann, J. Salmen, P. G. Hepp, M. W. Beckmann, T. N. Fehm, H. Hindenburg, W. Lichtenegger, B. K. Rack, A. Schneeweiss, W. Janni 373 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 18D Clinical significance of time to relapse and the distinction between breast cancer recurrences and new primary tumors. (Abstract #1071) A. Patt, T. Li, M. Cristofanilli, G. M. Freedman, E. R. Sigurdson, R. J. Bleicher Brd. 18E Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial. (Abstract #1072) M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, M. Bulsara, on behalf of the TARGIT Trialists’ Group Brd. 18F Breast cancer carcinomatous meningitis: Differences in survival depending on biological subtype, performance status, and treatment methods. (Abstract #1073) A. M. Niwinska, H. Rudnicka, M. Murawska Brd. 18G Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A). (Abstract #1074) E. Muñoz-Couselo, J. M. Perez-Garcia, C. Saura, M. Vidal, M. Bellet Ezquerra, J. Balmaña, B. Graña, P. Gomez Pardo, L. De Mattos-Arruda, S. Di Cosimo, S. Muñoz, O. Vidal, B. Garcia Castro, R. Espallargas, V. Esteban, J. Tabernero, J. Baselga, J. Cortes Brd. 18H Phase II trial report of the new preoperative chemotherapy with S-1 and docetaxel for advanced breast cancer. (Abstract #1075) M. Nakagawa, M. Aoyama, M. Ikeda, M. Morimoto, H. Takechi, Y. Kawakami, K. Kennzaki, A. Tangoku Brd. 19A Breast cancer subtypes and outcome after local and regional relapse. (Abstract #1076) E. Montagna, V. Bagnardi, N. Rotmensz, G. Viale, G. Renne, G. Cancello, A. Balduzzi, E. Scarano, D. Pastrello, P. Veronesi, A. Luini, S. Zurrida, S. Monti, M. G. Mastropasqua, L. Bottiglieri, A. Goldhirsch, M. Colleoni Brd. 19B Is E-cadherin a useful surrogate marker to predict chemosensitivity of chemotherapy for triple-negative breast cancer? (Abstract #1077) S. Kashiwagi, M. Yashiro, T. Takashima, N. Aomatsu, H. Kawajiri, N. Onoda, B. Nakata, T. Ishikawa, K. Hirakawa Brd. 19C Survival of triple-negative and HER2-positive breast cancer by AJCC stage. (Abstract #1078) V. Caggiano, K. Bauer, C. Parise Brd. 19D Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC). (Abstract #1079) P. Klare, F. G. Foerster, M. Geberth, A. Schneeweiss, H. Tesch, S. Kuemmel, C. Schumacher, W. Hollburg, U. Soeling, M. Schmidt Brd. 19E Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC). (Abstract #1080) N. Harbeck, M. Kaufmann, F. Siedentopf, P. Dalivoust, M. Debled, N. J. Robert, J. O’Shaughnessy Brd. 19F Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC). (Abstract #1081) M. Oliveira, L. De Mattos-Arruda, G. Sánchez-Ollé, B. Graña, J. Cortes, J. M. Perez-Garcia, E. Muñoz-Consuelo, M. Vidal, M. Bellet, S. Di Cosimo, P. Gomez Pardo, J. Rodon Ahnert, J. Hernandez-Losa, A. Vivancos, L. Prudkin, C. Aura, V. Serra, J. Baselga, J. Tabernero, C. Saura Brd. 19G Roles of miRNAs in breast cancer stem cells, drug sensitivity, and spontaneous metastases in orthotopic human-in-mouse models. (Abstract #1082) H. Liu, J. Bockhorn, R. Dalton, M. Dolan, C. M. Perou, O. I. Olopade, M. F. Clarke, G. Greene 374 Brd. 19H Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (Abstract #1083) L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman, J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. Valero Brd. 20A Adjuvant chemotherapy in American and Italian patients with BRCA1/2associated breast cancer. (Abstract #1084) A. Cappetta, R. Nanda, C. Liao, D. Huo, L. F. Chen, G. Artioli, V. Zagonel, O. I. Olopade Brd. 20B Modeling the risk of secondary lung malignancy in patients treated with breast radiation therapy. (Abstract #1085) J. Ng, I. Shuryak, A. Xu, I. Deutsch, R. J. Burri, D. J. Brenner Brd. 20C Utility of breast MRI for patients with breast cancer scheduled for breast conserving surgery. (Abstract #1086) H. Shin, W. Han, H. Moon, C. Yom, S. Ahn, H. Kim, D. Noh Brd. 20D Comparison of lesion size between preoperative imaging and postoperative histopathology in unifocal breast cancer. (Abstract #1087) C. R. Abraham, B. Whiteside, M. Schuster, D. Jones, J. Pollard, L. MacFarlan, K. Hena, M. A. Hena Brd. 20E Repeat use of chemotherapy in metastatic breast cancer. (Abstract #1088) A. Im, A. Brufsky, J. G. Reeder, M. Q. Rosenzweig, S. Y. Jung Brd. 20F Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC). (Abstract #1089) S. Lee, Y. Park, E. Cho, Y. Ham, J. Seo, J. Ahn, Y. Im Brd. 20G Platinum-based chemotherapy in triple-negative breast cancer. (Abstract #1090) C. Villarreal-Garza, M. Clemons, F. Kassam, K. Enright, S. Verma, J. A. Myers, R. A. Dent Brd. 20H Is there any utility to frozen section or immunohistochemistry examination of the sentinel lymph node (SLN) in patients with ductal carcinoma in situ (DCIS)? (Abstract #1091) U. K. Ballehaninna, A. R. Reeves, R. S. Chamberlain Brd. 21A Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study. (Abstract #1092) E. L. Mayer, M. E. Scheulen, J. Beckman, H. Richly, A. Poli, P. Bhargava, A. Duarte, M. M. Cotreau, A. L. Strahs, M. N. Dickler Brd. 21B Incidence of anthracycline-induced cardiotoxicity in patients with breast cancer: A single center’s experience. (Abstract #1093) O. Nadeem, C. Rauwerdink, V. L. Beggs, D. D. Parr, A. T. Kono, G. N. Schwartz Brd. 21C Sunitinib as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow. (Abstract #1094) J. Li, M. E. Melisko, P. N. Munster, M. Pelayo, M. M. Moasser, A. J. Chien, J. Scott, L. Esserman, J. W. Park, H. S. Rugo Brd. 21E Prevalence of synchronous metastases of breast cancer depends both on tumor subtypes and tumor burden. (Abstract #1096) C. Boutros, C. Mazouni, M. Saghatchian, J. Domont, C. Balleyguier, C. Bourgier, M. Mathieu, M. Spielmann, S. Delaloge Brd. 21F Prognostic index for patients with brain metastases from breast cancer: A validation and refinement of the breast-specific graded prognostic assessment (GPA) index. (Abstract #1097) H. Ahn, S. Lee, J. Sohn, S. Park, Y. Ham, J. Seo, E. Cho, D. Nam, J. Lee, D. Choi, W. Park, S. Huh, Y. Park, J. Ahn, Y. Im Brd. 21G Basoluminal and luminal phenotypes in triple-negative breast cancer: Immunohistochemical profiling and survival. (Abstract #1098) H. Sinn, Z. Elsawaf, J. L. Bermejo, S. Aulmann, J. Rom, A. Schneeweiss 375 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 21H Outcomes of children exposed to chemotherapy in utero for breast cancer. (Abstract #1099) J. K. Litton, S. Hodge, D. Mattair, M. M. Ramirez, P. H. Morrow, A. M. Gonzalez-Angulo, C. M. Barnett, G. N. Hortobagyi, R. L. Theriault Brd. 22A Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors. (Abstract #1100) M. N. Dickler, B. P. Schneider, M. Volm, J. L. Speyer, Y. Novik, L. A. Callahan, C. H. Darby, J. Barth, G. L. Elfring, A. Ogden, A. Tiersten Brd. 22B Febrile neutropenia rates during docetaxel and cyclophosphamide (TC) adjuvant therapy in early breast cancer (EBC). (Abstract #1101) D. Kotasek Brd. 22C Magnetic resonance imaging (MRI) as compared to mammogram (MMG) in the evaluation of size, number of lesions, and nodal positivity in breast cancer (BrCa). (Abstract #1102) A. Korant, M. Kanaan, S. Sirop, H. Nuthakki, L. Lawrence, R. Hicks, D. Strahle, S. Nagpal, D. Wiese, S. Saha Brd. 22D TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triplenegative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial. (Abstract #1103) D. A. Yardley, J. D. Hainsworth, W. N. Harwin, S. A. Goble, B. R. Daniel, M. A. Ackerman, D. Shipley, D. R. Drosick, S. E. Hanson, P. L. Griner, H. A. Burris III Brd. 22E Increasing use of mastectomy with immediate reconstruction and contralateral prophylactic mastectomy in breast conservation candidates: A 14-year report from a comprehensive cancer center. (Abstract #1104) A. E. Dragun, J. Pan, E. C. Riley, B. B. Kruse, M. R. Wilson, S. Rai, D. Jain Brd. 22F Are we improving the outcomes of metastatic breast cancer (MBC)? A single academic institution experience. (Abstract #1105) A. Florescu, S. Giilck, C. Victor, U. Zurawska, D. A. Baribeau, S. Verma Brd. 22G Alterations in breast cancer resistance protein in human placentas exposed to chemotherapy. (Abstract #1106) M. G. Holland, A. McCampbell, J. K. Litton, R. L. Theriault, M. M. Ramirez Brd. 22H Oral etoposide monotherapy for Chinese patients with metastatic breast cancer: Efficacy and tolerance regardless of heavy prior therapy. (Abstract #1107) P. Yuan, B. Xu, F. Ma, J. Wang, Y. Fan Brd. 23A Comparison of indocyanine green (ICG) fluorescence imaging plus blue dye and blue dye alone in sentinel node navigation surgery (SNNS) for breast cancer. (Abstract #1108) A. Hirano, T. Shimizu, M. Kamimura, K. Ogura, N. Kim, Y. Setoguchi, F. Okubo, H. Inoue, R. Miyamoto, J. Kinoshita, K. Ogawa Brd. 23B Clinical outcome of triple-negative breast cancer with BRCA mutation in the context of dose-dense and or metronomic chemotherapy. (Abstract #1109) R. S. Mehta, C. Liu Brd. 23C Primary systemic therapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in locally advanced and metastatic triple-negative breast cancer. (Abstract #1110) M. Skrypnikova, M. Frolova, E. Ignatova, I. Pokataev, M. Stenina, S. Tjulandin Brd. 23D Prediction of the nonsentinel node metastasis in patients who received neoadjuvant chemotherapy for clinically axillary lymph node metastasis. (Abstract #1111) S. Lee, S. Y. Jung, S. W. Kim, H. S. Kang, I. Park, K. S. Lee, J. Ro, K. Ko, Y. Kwon, K. Shin, S. Kim 376 Brd. 23E First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis. (Abstract #1112) J. Salvador, A. Jaen, E. Ciruelos, M. Codes, M. Gil, A. Murias, A. Galan, J. De la Haba, C. Jara, J. L. Bayo, J. Baena, J. Casal, J. Mel, I. Blancas, E. Gonzalez, D. Perez, L. Manso Brd. 23F Paclitaxel-carboplatin (P-C) regimen for metastatic breast cancer (MBC): Single-institution retrospective evaluation. (Abstract #1113) M. Zambetti, G. Goisis, A. Moliterni, A. Marchianò, D. Scaramuzza, M. Carcangiu, G. Saibene, G. Mariani, G. V. Bianchi, P. Valagussa, L. Gianni Brd. 23G Poly (ADP-ribose) polymerase-1 (PARP) expression in triple-negative breast cancer. (Abstract #1114) P. Possanzini, M. O. Biasi, C. Fumagalli, M. Barberis, M. Barile, B. Bonanni, G. Viale Brd. 23H Lymphocyte infiltration (LI) and immunohistochemistry (IHC) classification of metastatic breast cancer (MBC) correlation with medical survival. (Abstract #1115) C. S. Yau, A. R. Trumbly, C. O. Ruud, V. O. Speight, C. Chisholm, J. Song Brd. 24A Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial. (Abstract #1116) J. H. Barton, K. C. Shih, E. Raefsky, D. W. Haines III, B. Strike, J. D. Hainsworth, H. A. Burris III, D. A. Yardley Brd. 24B Body mass index in breast cancer subtypes. (Abstract #1117) I. Petekkaya, C. Arslan, E. Dogan, M. Solak, Ö. Keskin, N. Kertmen, Y. Y. Ozisik, K. Altundag Brd. 24C Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers. (Abstract #1118) A. B. Zelnak, S. Harichand-Herdt, T. M. Styblo, M. Rizzo, S. G. Gabram, H. L. Bumpers, R. C. Hermann, J. Srinivasiah, F. M. Schnell, R. O’Regan Brd. 24D Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (nⴝ120). (Abstract #1119) Y. Ito, K. Aogi, N. Masuda, S. Ohno, T. Oda, H. Iwata, M. Kashiwaba, Y. Fujiwara, S. Kamigaki, T. Ueno, S. Takashima Brd. 24E Oral paricalcitol (19-nor-1,25-Dihydroxyvitamn D2) in women with metastatic breast cancer receiving taxanes or ixabepilone: A feasibility trial. (Abstract #1120) J. Lawrence, J. Lovelace, S. A. Akman, S. A. Melin, L. D. Case, G. Schwartz Brd. 24F What is the survival length from the late lines of treatment in metastatic breast cancer? (Abstract #1121) M. Mouret-Reynier, E. Planchat, E. Thivat, C. Abrial, C. Pomel, P. DubrayLongeras, H. Devaud, B. Nayl, A. Dillies, Q. Wang-Lopez, P. J. Chollet, H. Cure, J. Nabholtz, X. Durando Brd. 24G Validation study on the clinical usefulness of the ICG fluorescence method for detecting sentinel lymph node in early-stage breast cancer in comparison with the dye method. (Abstract #1122) T. Sugie, T. Sawada, N. Tagaya, T. Kinoshita, K. Yamagami, H. Suwa, K. Yoshimura, M. Sumi, M. Toi Brd. 24H Association of BRCA1 promoter methylation in triple-negative breast cancer (TNBC) with resistance to standard anthracyline-based adjuvant chemotherapy. (Abstract #1123) P. Sharma, B. F. Kimler, Y. A. Park, S. R. Stecklein, Q. J. Khan, B. K. Petroff, O. W. Tawfik, R. A. Jensen 377 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 25A A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: Three-year follow-up. (Abstract #1124) S. J. Kronowitz, W. Tereffe, K. Hunt, H. M. Kuerer, V. Valero, G. L. Robb, L. Feng, T. A. Buchholz Brd. 25B Final results of a phase II trial of trabectedin (T) in triple-negative, HER2positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). (Abstract #1125) K. L. Tedesco, J. L. Blum, A. Goncalves, J. Lubinski, C. R. Osborne, P. Lardelli, J. C. Tercero, A. Florez, F. A. Holmes, S. Delaloge Brd. 25C Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. (Abstract #1126) D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Zander, P. J. Stella, M. Melnik, E. S. Pavey, E. A. Perez Brd. 26A Retrospective analysis of the effect on overall-survival of radiotherapy and chemotherapy sequence as treatment for primary breast cancer. (Abstract #1127) E. H. Gort, S. G. Elias, O. Visser, P. H. Elkhuizen, S. C. Linn Brd. 26B The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): A systematic review and meta-analysis. (Abstract #1128) J. J. Biagi, M. Raphael, W. D. King, W. Kong, C. M. Booth, W. J. Mackillop Brd. 26C The other triple-negative breast cancer: Immunohistochemical and clinicopathological characterization of the claudin-low subtype. (Abstract #1129) D. Voduc, M. Cheang, A. Prat, X. He, S. Tyldesley, J. Snider, K. DeSchryver, S. Davies, M. J. Ellis, C. M. Perou, T. O. Nielsen Brd. 27A Effect of body mass index on survival outcome among women with earlystage, triple-negative breast cancer. (Abstract #1130) S. S. Dawood, X. Lei, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo Brd. 27B Significantly different costs of adjuvant chemotherapy regimens in the United States. (Abstract #1131) R. G. Chellappah, P. Ravdin Brd. 27C Neoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study. (Abstract #1132) L. Wang, J. Chen, Q. Yao Sr., J. Zhang, T. Wang, H. Wang, X. Zhou, Y. Huan, J. Wang Brd. 28A Neoadjuvant chemotherapy (NACT) in hormonal receptor-positive (HRⴙ) or triple-negative (TN), operable breast cancer (BC): A randomized study comparing standard to response–adapted sequence. (Abstract #1133) H. Cure, Q. Wang-Lopez, M. Mouret-Reynier, X. Durando, C. Jouannaud, J. Charpentier, J. Eymard, P. J. Chollet, C. Garbar, E. Brabencova, I. Raoelfils, F. Penault-Llorca, J. Nabholtz Brd. 28B Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in patients with breast cancer: A retrospective analysis. (Abstract #1134) N. Ngamphaiboon, P. P. Advani, T. L. O’Connor, F. O. Ademuyiwa, E. G. Levine, G. Riebandt, E. B. Kossoff Brd. 28C Phase II trial, open, single arm: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced, triple-negative breast cancer. (Abstract #1135) A. Alvarado Miranda, F. Lara Medina, C. Arce, N. Castañeda-Soto, C. Cano Blanco, J. Aguilar Ponce, E. Bargallo Rocha, V. Perez-Sanchez 378 Monday, June 6, 2011 1:00 PM - 5:00 PM GENERAL POSTER SESSION Leukemia, Myelodysplasia, and Transplantation Brd. 29A Correlation of RASGRP1:APTX expression assay with response to tipifarnib plus etoposide in elderly patients with newly diagnosed AML. (Abstract #6534) T. I. Vener, C. Derecho, S. Galkin, J. Greer, M. J. Levis, C. D. Gocke, S. Malek, J. F. Palma, M. Raponi, Y. Wang, J. J. Wright, J. E. Karp Brd. 29B Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). (Abstract #6535) T. H. Brummendorf, J. E. Cortes, H. Kantarjian, C. Gambacorti-Passerini, M. Baccarani, D. Kim, A. Zaritskey, J. Navarro, A. Rapoport, P. E. Dorlhiac-Llacer, J. Milone, M. Zanichelli, N. Besson, E. Leip, V. Kelly, H. J. Khoury Brd. 29C Tyrosine kinase inhibitors in BCR/ABL positive ALL . (Abstract #6536) A. T. Lopez-Enriquez Brd. 30A A phase II study with decitabine, low dose cytarabine, and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia, or acute myeloid leukemia in patients with significant comorbidities. (Abstract #6537) J. Butera, E. Winer, C. Wang, J. J. Castillo, A. G. Thomas, H. Safran, A. E. Mega, G. A. Colvin, B. Rathore, P. J. Quesenberry, Brown Oncology Group Brd. 30B Serum galactomannan (GM) assay for invasive aspergillosis (IA) in acute leukemia (AL) and hematopoietic stem cell transplantation (HSCT). (Abstract #6538) I. Ghosh, V. Raina, L. Kumar, A. Sharma, S. Bakhshi, S. Iqbal Brd. 30C Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia. (Abstract #6539) G. Nair, R. Karmali, S. A. Gregory, J. M. Shammo, H. C. Fung, A. Jimenez, P. Venugopal, M. L. Larson Brd. 31A Successful autologous hematopoietic stem cell (AHSC) mobilization with salvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dose chemotherapy (HDC) and AHSC transplantation (AHSCT) in relapsed malignancies: preliminary single center experience. (Abstract #6540) C. Kosmas, A. Athanasopoulos, P. Politis, T. Papachrysanthou, T. Daladimos, A. Papadaki, E. Panagiotidi, D. Moschovis, N. Ziras, A. Karabelis, N. Mylonakis Brd. 31B Results of employing a plerixafor dosing algorithm to mobilize hematopoietic stem cells in patients with multiple myeloma and lymphoma. (Abstract #6541) T. Bechtel, Y. A. Efebera, S. M. Devine, P. Elder Brd. 31C A meta-analysis of the complete remission ratio with replaced or refractory acute promyelocytic leukemia. (Abstract #6542) B. Jiang, Q. Gong, H. Watanabe, S. Zhu, J. Xie, Y. Ohashi Brd. 31D Prevention of mucositis with KGF in patients undergoing allogeneic stem cell transplantation. (Abstract #6543) J. D. Goldberg, J. Zheng, H. Castro-Malaspina, A. A. Jakubowski, G. Heller, M. R. Van Den Brink, M. Perales Brd. 31E FLT3 positive acute myeloid leukemia: Does timed sequential induction therapy influence outcome? (Abstract #6544) D. Rifai, M. L. Larson, M. C. Keller, P. Venugopal Brd. 31F High-dose melphalan on day 2 versus 1 before autologous stem cell transplantation for multiple myeloma. (Abstract #6545) K. Rakszawski, J. J. Drabick, N. G. Dolloff, J. M. Sivik, J. Malysz, D. Claxton, W. C. Ehmann, W. B. Rybka, G. Talamo 379 MONDAY Location: Hall A Track(s): Leukemia, Myelodysplasia, and Transplantation Monday, June 6, 2011 MONDAY Brd. 31G Targeting multiple signal pathways simultaneously might provide effective therapeutic strategies in acute myeloid leukemia . (Abstract #6546) H. Liu, E. Diaz-Flores, X. Poire, G. Koval, G. Malnassy, M. M. Le Beau, K. Shannon, O. Odenike, W. Stock Brd. 31H Immunosupressive properties of human placenta-derived mesenchymal stem cells on control of acute graft-versus-host disease in mice. (Abstract #6547) M. Jang, S. Oh, H. Kim, H. Shin, G. Kim, S. Chong, D. Oh, H. Chung Brd. 32A Second cancers after hematopoietic stem cell transplantation with total body irradiation conditioning regimen in hematologic disorders. (Abstract #6548) J. Kim, M. Chung, J. Lee, B. Choi, S. Chung Brd. 32B Study of oral clofarabine plus low-dose cytarabine in previously treated AML and high-risk MDS patients at least 60 years of age. (Abstract #6549) K. M. Smith, E. Estey, J. M. Pagel Brd. 32C Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure. (Abstract #6550) J. Shan, S. M. O’Brien, G. Garcia-Manero, S. Faderl, F. Ravandi, E. Jabbour, J. E. Cortes, H. Kantarjian Brd. 32D Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (Abstract #6551) B. Mistry, L. Gibiansky, Z. Hussein Brd. 32E Healthcare utilization and costs in patients with early onset myelodysplastic syndrome in a commercially insured population. (Abstract #6552) A. Powers, K. Stein, R. L. Knoth, M. Broder, E. Chang Brd. 32F Impact of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV. (Abstract #6553) A. Leitner, S. Saussele, C. Haferlach, G. Goehring, B. Schlegelberger, S. Jung-Munkwitz, U. Proetel, M. Lauseker, M. Pfirrmann, J. Hasford, A. Hochhaus, R. Hehlmann, German CML Study group Brd. 32G Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (TALL/LL). (Abstract #6554) A. Al-Ameri, D. A. Thomas, F. Ravandi, S. M. O’Brien, H. Kantarjian, G. Borthakur, T. M. Kadia, M. Kelly, R. Garris, S. Faderl Brd. 32H Survival differences in chronic myeloid leukemia by race in pre- and postimatinib era. (Abstract #6555) R. Mandal, D. M. Bolt, B. K. Shah Brd. 33A LeukemiaNet: A transnational model for cooperative leukemia research. (Abstract #6556) R. Hehlmann, B. Simonsson, M. Baccarani, D. Grimwade, J. Apperley, T. Barbui, M. C. Bene, T. Buchner, T. J. de Witte, R. Foà, C. Haferlach, M. Hallek, J. Hasford, A. Hochhaus, D. Hoelzer, P. Ljungman, D. Niederwieser, M. . Sanz, S. Saussele Brd. 33B Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. (Abstract #6557) A. Quintas-Cardama, J. E. Cortes, E. Jabbour, S. M. O’Brien, G. Garcia-Manero, J. Shan, F. Ravandi, S. Faderl, T. M. Kadia, G. Borthakur, H. Kantarjian Brd. 33C Lenalidomide following rituximab and fludarabine in untreated CLL. (Abstract #6558) C. S. Ujjani, S. Jamshed, K. Fitzpatrick, E. A. Gehan, J. Crawford, C. M. Broome, P. Cohen, C. Kessler, B. D. Cheson 380 Brd. 33D Intermediate-dose cyclophosphamide (1.5 Gm/M2) with G-CSF as the primary peripheral blood progenitor mobilization strategy: A single institution experience. (Abstract #6559) A. Padmanabhan, J. W. Hayslip, G. P. Monohan, S. D. Sutphin, H. Weiss, D. S. Howard Brd. 33E Relationship between age and healthcare utilization in patients with myelodysplastic syndrome receiving supportive care. (Abstract #6560) K. Stein, A. Powers, R. L. Knoth, M. Broder, E. Chang Brd. 33F Impact of combined lymphocyte and monocyte recovery on survival post myeloablative allogeneic hematopoietic stem cell transplant for acute leukemia. (Abstract #6561) M. Thoma, T. Huneke, L. DeCook, N. Johnson, R. Wiegand, M. R. Litzow, W. J. Hogan, L. F. Porrata, S. G. Holtan Brd. 33G An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia. (Abstract #6562) S. Hashmi, E. S. Rich, S. Basu, J. J. Maciejewski, S. Nathan, P. Venugopal, S. A. Gregory, H. C. Fung, J. M. Shammo Brd. 33H Survival after nonmyeloablative versus myeloablative allotransplantation for AML/MDS. (Abstract #6563) M. R. Khawaja, J. E. Schwartz, M. Yu, M. J. Robertson, G. H. Vance, S. Srivastava, L. L. Wood, R. Abonour, K. Cornetta, S. Farag, L. D. Cripe, R. P. Nelson Jr. Brd. 34A Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes. (Abstract #6564) A. P. Michelson, K. J. Kopecky, E. R. Koegle, J. E. Anderson, J. E. Godwin, S. H. Petersdorf, A. F. List, C. L. Willman, F. R. Appelbaum, J. P. Radich, M. K. Ganapathi, R. N. Ganapathi, A. Advani Brd. 34B Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for non-cutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. (Abstract #6565) A. Beitinjaneh, R. Saliba, G. Okoroji, A. M. Alousi, U. R. Popat, M. Korbling, P. Anderlini, M. Qazilbash, P. Kebriaei, C. Hosing, R. E. Champlin, I. F. Khouri Brd. 34C An evaluation of the risk/benefit ratio of low molecular weight heparin to reduce the high risk of venous thromboembolism in acute leukemia. (Abstract #6566) G. L. Simmons, B. E. Hillner, T. J. Smith Brd. 34D Therapy-related acute promyelocytic leukemia (t-APL): Observations on APL pathogenesis. (Abstract #6567) M. A. Elliott, L. Letendre, A. Tefferi, W. J. Hogan, C. C. Hook, R. Pruthi, S. H. Kaufmann, A. D. Pardanani, K. Begna, A. Ashrani, A. P. Wolanskyj, A. Al-Kali, M. R. Litzow Brd. 34E A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6568) H. Ghanem, H. Kantarjian, G. Garcia-Manero, F. Ravandi, S. Faderl, J. E. Cortes, A. Reyes, S. M. O’Brien, G. Borthakur, T. M. Kadia, J. A. Burger, M. Konopleva, E. Jabbour Brd. 34F Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blastic crisis: A retrospective analysis. (Abstract #6569) N. Thota, S. Gundeti, P. Coca, J. Srirambhatla, R. Parimkayala, V. Linga, S. Bheemnathi Hanuman, L. S. Maddali, R. Digumarti 381 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 34G Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Phⴙ) chronic myeloid leukemia in the chronic phase (CML-CP). (Abstract #6570) M. Botteman, J. Stephens, S. J. Snedecor, X. Ji, M. Hussein, J. Coombs Brd. 34H Interim PK analysis results of a phase IIa, open-label, randomized, pharmacokinetic comparative, cross-over studyof melphalan HCl for injection (Propylene Glycol-Free) and alkeran for injection formyeloablative conditioning in multiple myeloma patients undergoing autologous transplantation. (Abstract #6571) O. S. Aljitawi, S. Ganguly, S. H. Abhyankar, D. Robinson, R. Marks, J. Pipkin, J. McGuirk Brd. 35A Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Phⴙ) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective. (Abstract #6572) A. Ovanfors, J. Stephens, S. J. Snedecor, D. Patel, X. Ji, K. T. Carpiuc, J. Coombs, M. Botteman Brd. 35B Distinctions between adult T-cell leukemia-lymphoma (ATLL) secondary to human T-cell lymphotropic virus 1 (HTLV1) and peripheral T-cell lymphoma (TCL). (Abstract #6573) G. D. Ayalew, J. Yao, K. A. Killoran, K. Laveaux, C. A. Axiotis, A. S. Braverman Brd. 35C Phase II study of AZD2171 for the treatment of patients with acute myelogenous leukemia. (Abstract #6574) M. Juckett, B. LaPlant, P. J. Flynn, A. Jumonville, A. Moreno-Aspitia, C. Erlichman Brd. 35D Mediation of LA-4 lung epithelial cell injury by alloreactive donor T cells. (Abstract #6575) S. V. Radhakrishnan, T. Obermeier, G. Mueller, G. C. Hildebrandt Brd. 35E The diagnostic and prognostic implications of nucleated red blood cells in myelophthisis. (Abstract #6576) J. L. Schering, J. Munoz, E. Raybon, S. Hegab, A. S. Hanbali, P. Kuriakose Brd. 35F Vaginal bleeding in women with leukemia. (Abstract #6577) S. Ghazal, S. Barton, R. Boyajian, J. H. Antin, R. M. Stone, E. S. Ginsburg Brd. 35G TLI-ATG for nonmyeloablative stem cell transplant: A single center experience. (Abstract #6578) D. A. Wong, A. S. Steinberg, C. Bresee, A. M. Lopez, S. Lim, M. Lill Brd. 35H Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multiagent chemotherapy. (Abstract #6579) S. B. Patel, I. Gojo, M. Tidwell, Y. Ning, X. F. Zhao, E. A. Sausville, M. R. Baer Brd. 36A Effect of lenalidomide on antileukemia activity in vitro against adult T-cell leukemia (ATL) . (Abstract #6580) Y. Kitagawa, M. Matsuoka, S. Mitani Brd. 36B Relation of methylenetetrahydrofolate reductase C677T polymorphism to chronic myeloid leukemia in serbia. (Abstract #6581) R. N. Jankovic, K. Jakovljevic, M. Cavic, E. Malisic Brd. 36C Enhanced risk stratification in young and elderly patients treated with induction chemotherapy as well as in frail patients with AML. (Abstract #6582) S. Wilop, T. H. Brummendorf, M. Crysandt Brd. 36D UCBT with ATG in adult patients. (Abstract #6583) W. M. Linkesch, D. Strunk, W. Zinke-Cerwenka, H. Sill, P. Neumeister Brd. 36E Clinico-hematological characteristics and outcome assessment of chronic lymphocytic leukemia patients: A single institution study of 285 cases. (Abstract #6584) A. Gogia, A. Sharma, V. Raina, L. Kumar, R. Kumar, R. Gupta, S. Vishnubhatla 382 Brd. 36F Evaluation of the JAK2 V617F mutational status in coronary patients. (Abstract #6585) K. Gasser, A. Muendlein, N. Stark, T. Winder, P. Rein, C. H. Saely, K. Geiger, S. Geller-Rhomberg, B. L. Hartmann, B. Kohler, H. Drexel, A. Lang Brd. 36G Time from relapse after allogeneic stem cell transplantation (SCT) to donor leukocyte infusion (DLI) is longer, incidence of GVHD is higher, but survival is similar for recipients of unrelated DLI compared to matched sibling DLI. (Abstract #6586) A. Kumar, N. V. Frey, P. Vassilev, S. Goldstein, E. O. Hexner, A. W. Loren, R. Reshef, S. M. Luger, D. L. Porter, E. A. Stadtmauer Brd. 36H Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. (Abstract #6587) F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone, T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. Kantarjian Brd. 37A Comparison of cytarabine, mitoxantrone and CNDAC in vitro treatment of AML bone marrow and peripheral blood cells. (Abstract #6588) S. Jagan, L. A. Paganessi, S. Gezer, A. Rizman, D. Rifai, M. C. Keller, M. L. Larson, P. Venugopal, S. Frame, K. W. Christopherson II Brd. 37B Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients (pts) with chronic myeloid leukemia (CML). (Abstract #6589) M. Ulcickas Yood, S. A. Oliveria, I. Hirji, S. Phillips, M. J. Cziraky, C. C. Davis Brd. 37C Altered mitochondrial metabolism as a target in acute myeloid leukemia. (Abstract #6590) T. S. Pardee, D. A. Levitan, D. D. Hurd Brd. 37D LACE: A conditioning regimen for lymphoma patients undergoing autologous transplant. (Abstract #6591) R. Thippeswamy, L. Mathew, B. Bhosale, N. Kumar, S. Kannan, A. Joshi, V. Rangarajan, N. Khattry Brd. 37E The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients. (Abstract #6592) H. J. Lee, K. M. Wright, E. Kandeel, W. Tan, G. E. Wilding, L. Ford, S. N. Sait, A. W. Block, M. P. Barcos, P. L. McCarthy, C. E. Vigil, E. A. Griffiths, J. E. Thompson, E. S. Wang, P. K. Wallace, M. Wetzler Brd. 37F Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience. (Abstract #6593) A. Ganetsky, N. G. Adel, M. G. Frattini, P. G. Maslak, M. L. Heaney, J. G. Jurcic, M. S. Tallman Brd. 37G Prognostic factors of long-term survival in patients with acute myeloid leukemia after allogeneic or autologous stem cell transplantation. (Abstract #6594) L. Wang, C. Corona, X. Nie, L. Mejias, S. j. Hou, R. Mullaney, K. M. Ward, D. L. Topolsky, M. Styler, P. A. Crilley Brd. 37H Prevalence of venous thromboembolism (VTE) among patients (pts) with acute leukemia (AL) prior to treatment. (Abstract #6595) N. V. Luong, S. Faderl, H. Kantarjian, K. Vu Brd. 38A Relevance of PIG-A mutation in aplastic anemia and myelodysplastic syndromes. (Abstract #6596) J. J. Pu, R. Hu, G. Mukhina, R. A. Brodsky Brd. 38B Risk of progression to myelofibrosis and acute myeloid leukemia in patients with essential thrombocythemia and polycythemia vera with prior malignancy. (Abstract #6597) M. A. Cherry, H. Pham, H. Kantarjian, J. E. Cortes, S. Pierce, L. Zhou, S. Verstovsek 383 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 38C Retrospective analysis of prognostic factors associated with response and overall survival in patients with RAEB-t MDS treated with decitabine. (Abstract #6598) A. Malik, G. Garcia-Manero, M. Welch, H. Kantarjian, K. Stein, A. Teng, E. Jabbour Brd. 38D Genetic variation in vitamin D pathway and graft-versus-host disease risk after blood and marrow transplantation. (Abstract #6599) K. Robien, L. G. Strayer, T. E. DeFor, B. Thyagarajan, D. Lazovich, S. A. Cooley, J. A. Ross, K. S. Baker Brd. 38E Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes. (Abstract #6600) M. Cornelison, G. Garcia-Manero, J. E. Cortes, F. Ravandi, H. Kantarjian, K. Stein, A. Teng, E. Jabbour Brd. 38F Pharmacogenetic variants and outcomes after hematopoietic cell transplantation. (Abstract #6601) B. Thyagarajan, P. Jacobson, S. Jackson, S. Basu, D. J. Weisdorf, M. Gross, M. Arora Brd. 38G Chronic lymphocytic leukemia (CLL) patients at a VA medical center: Comorbidity and survival. (Abstract #6602) L. Soriano, S. Srinivas, M. Tufail, K. Kim, R. Paulin, V. T. Chang, B. Kasimis, M. L. Gonzalez Brd. 38H Role of topotecan, vinorelbine, thiotepa, and gemcitabine (TVTG) chemotheapy in relapsed/refractory adult acute leukemia: A single-institution retrospective analysis. (Abstract #6603) S. A. Srour, M. A. Cherry, E. Borders, H. Parekh, J. L. Holter, T. S. Herman, G. B. Selby Brd. 39A Model-based prediction of patient-specific residual disease levels for imatinib-treated chronic myeloid leukemia. (Abstract #6604) M. Loeffler, M. Horn, I. Glauche, M. C. Müller, A. Hochhaus, I. Roeder Brd. 39B Analysis of patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes. (Abstract #6605) P. Laneuville, M. Baccarani, J. E. Cortes, A. Hochhaus, H. Kantarjian, N. P. Shah, M. Bradley-Garelik, C. Zhu, K. Porkka Brd. 39C Disease management and treatment of chronic myeloid leukemia (CML): Experience from the patient (pt) perspective. (Abstract #6606) T. W. Victor, M. Talpaz, A. Buzyn, C. B. Lemoine, A. Moadel, E. Olavarria, S. Leighton, S. Gupta, I. Hirji, C. C. Davis Brd. 39D Validation of a transplant-related mortality (TRM) risk score for pediatric patients undergoing allogeneic haematopoietic stem cells transplantation. (Abstract #6607) P. Angelini, A. Gassas, I. Zaidman, J. Doyle, T. Schechter Brd. 39E Analysis of outcomes in relapsed/refractory acute promyelocytic leukemia (APL) patients (pts) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT). (Abstract #6608) N. Pemmaraju, F. Ravandi, G. Rondon, S. Giralt, J. Chen, S. Pierce, R. E. Champlin, M. De Lima, M. Qazilbash Brd. 39F Romiplostim for the treatment of amegakaryocytic thrombocytopenia secondary to remission-inducing immunomodulation in a patient with relapsing acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. (Abstract #6609) L. Volodin, V. K. Bhanderi, J. Shahan, C. Leary, G. Jean, J. Comeau, J. Cotelingam, G. C. Hildebrandt 384 Brd. 39G Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. (Abstract #6610) R. M. Scherber, A. C. Dueck, P. Johansson, T. Barbui, G. Barosi, A. M. Vannucchi, F. Passamonti, B. I. Andreasson, M. L. Ferarri, A. Rambaldi, J. Samuelsson, G. Birgegard, A. Tefferi, N. Maldonado, F. Sackmann, P. Muxi, D. Hernandez-Maraver, J. Kiladjian, R. A. Mesa Brd. 39H Leukemia regression by targeting c-Kit activity with pazopanib. (Abstract #6611) A. Trujillo, C. S. McGee, E. Gars, R. Bosse, A. Meacham, E. Wise, S. Bais, C. R. Cogle Brd. 40A Health-related quality of life (HRQoL) in newly diagnosed chronic phase chronic myelogenous leukemia (CP CML) patients (pts) treated with bosutinib (BOS) or imatinib (IM). (Abstract #6612) J. H. Lipton, P. C. Trask, D. Cella, L. Duvillie, C. Powell, M. V. Ramanan, Z. Maslyak, D. Kim Brd. 40B Investigation of thrombopoietin (TPO) function in primary chronic lymphocytic leukemia cells. (Abstract #6613) R. D. Loberg, S. Wang, S. D. Patterson, I. McCaffery Brd. 40C Association between chronic myeloid leukemia (CML) treatment responses and patient satisfaction, functioning, and quality of life (QOL): Patient survey results. (Abstract #6614) S. Goldberg, V. K. Bollu, R. Morlock, A. Niyazov, A. Guo, E. Jabbour Brd. 40D Open-label study evaluating change in chronic low-grade (LG) nonhematologic (heme) adverse events (AEs) in Philadelphia positive (Phⴙ) CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL). (Abstract #6615) J. E. Cortes, C. B. Miller, J. H. Lipton, L. Busque, L. P. Akard, J. Pinilla-Ibarz, S. Ericson, M. J. Mauro Brd. 40E Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML). (Abstract #6616) E. Q. Wu, A. Guerin, V. K. Bollu, A. Guo, M. Cloutier, D. Ponce de Leon Barido, S. Ericson, A. Quintas-Cardama Brd. 40F Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. (Abstract #6617) T. M. Kadia, G. Garcia-Manero, H. Kantarjian, N. Pemmaraju, K. Stein, A. Teng, J. E. Cortes Brd. 40G Intergroup study in elderly patients with AML to compare complete remission rate and overall survival after intermediate dose or low dose AraC. (Abstract #6618) T. Lange, D. Niederwieser, V. Hoffmann, M. Pfirrmann, G. Maschmeyer, T. Fischer, M. Herold, H. G. Sayer, C. Junghanss, R. Krahl, H. Al-Ali, W. Pönisch, V. Vucinic, G. Doelken, M. C. Sauerland, A. Heinecke, D. Hoelzer, R. Hehlmann, W. E. Berdel, T. Buchner Brd. 40H Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL. (Abstract #6619) D. D. Shepard, H. E. Kohrt, T. L. Rosenblat, J. G. Jurcic, J. H. Park, A. Goldman, J. S. Dalal, P. G. Maslak, A. A. Jakubowski, V. Klimek, E. Berman, S. Nand, S. E. Coutre, M. S. Tallman, H. P. Erba Brd. 41A Health-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinibresistant (IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloid leukemia (CP CML). (Abstract #6620) P. C. Trask, D. Cella, N. Besson, V. Kelly, T. Masszi, D. Kim 385 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 41B Secondary malignancies in essential thrombocythemia and polycythemia vera: A retrospective analysis of 437 patients from a single institution. (Abstract #6621) S. Pierce, M. A. Cherry, H. Pham, H. Kantarjian, A. Al-Ameri, J. E. Cortes, L. Zhou, S. Verstovsek Brd. 41C Incidence of cytogenetic (CG) abnormalities in acute myeloid leukemia (AML) in African American (AA) population. (Abstract #6622) R. Khillan, A. S. Braverman, C. A. Axiotis, R. Latif, G. S. Sidhu Brd. 41D Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. (Abstract #6623) J. M. Flynn, J. A. Jones, L. Andritsos, K. A. Blum, A. J. Johnson, J. Hessler, E. Wiley, N. A. Heerema, J. Poon, K. A. Small, Y. Jou, D. Zhang, P. Statkevich, M. R. Grever, R. Bannerji, J. C. Byrd Brd. 41E Modulation of nuclear factor-kb (NF-kb), IkB kinase (IKK), and inducible nitric oxide synthase (iNOS) via proinflammatory cytokines with adjuvant selenomethionine (Se-Met) in chronic myelogenous leukemia (CML) patients with imatinib mesylate (IM) overexpression of bcr-abl fusion protein. (Abstract #6624) E. McPherson, K. Patel, P. Tassy, J. Kleinfeld Brd. 41F Chronic myelomonocytic leukemia (CMML) associated with symptomatic pericardial effusion. (Abstract #6625) M. I. Ibrahim, P. G. Maslak, M. L. Heaney, M. S. George, R. J. Downey, M. S. Tallman Brd. 41G Cytomorphologic and clinical features of AML with translocation (8;16) mimicking APL. (Abstract #6626) S. Jhanwar, A. Diab, L. Zickl, G. A. Manji, J. Patel, O. I. Abdel-Wahab, J. G. Jurcic, P. G. Maslak, P. G. Steinherz, E. Paietta, J. Feldstein, R. L. Levine, M. S. Tallman Brd. 41H Chemotherapeutic drugs-induced apoptosis-related mRNAs in whole blood ex vivo as a new diagnostic markers for the prediction of clinical outcome of AML. (Abstract #6627) N. Usui, K. Mitani, T. Maeda, T. Sakura, N. Dobashi, F. Yagasaki, K. Obata, M. Mitsubashi, S. Miyawaki Brd. 42A Influence of type of antecedent disorder on outcome of therapy-related AML. (Abstract #6628) S. R. Mohan, P. Elson, M. E. Kalaycio, R. V. Tiu, A. S. Advani, E. A. Copelan, J. P. Maciejewski, M. A. Sekeres Brd. 42B A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. (Abstract #6629) F. R. Mauro, S. Ciolli, F. Di Raimondo, G. Del Poeta, F. Forconi, A. Cuneo, A. Cortellezzi, F. Nobile, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, L. Orsucci, M. Mura, A. Alietti, E. J. Runggaldier, E. Gamba, A. Guarini, R. Foa Brd. 42C Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents. (Abstract #6630) C. E. Vigil, W. Tan, G. E. Wilding, G. Garcia-Manero, E. S. Wang, M. Wetzler, A. F. List Brd. 42D Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. (Abstract #6631) S. E. Coutre, J. C. Byrd, R. R. Furman, J. R. Brown, D. M. Benson Jr., N. D. Wagner-Johnston, I. W. Flinn, B. S. Kahl, S. E. Spurgeon, B. J. Lannutti, H. K. Hsu, R. Ulrich, S. Peterman, L. Holes, L. L. Miller, A. S. Yu Brd. 42E Effects of eltrombopag on human cord blood hematopoietic stem cell/primitive progenitor cell expansion. (Abstract #6632) H. Sun, Y. Tsai, J. Liesveld, K. L. Dawson, C. L. Erickson-Miller, Y. Chen 386 Monday, June 6, 2011 1:00 PM - 5:00 PM GENERAL POSTER SESSION Lymphoma and Plasma Cell Disorders Brd. 43A Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients with aggressive CD20ⴙ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL. (Abstract #8029) M. Pfreundschuh, M. Ziepert, S. Zeynalova, E. Lengfelder, H. Steinhauer, M. R. Clemens, C. Nickenig, A. D. Ho, L. H. Truemper, M. Hoffmann, R. H. Mertelsmann, B. Metzner, H. Mergenthaler, V. Poeschel, N. Schmitz, M. Loeffler, German Non-Hodgkin Lymphoma Study Group (DSHNHL) Brd. 43B High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. (Abstract #8030) F. Samaniego, F. Hagemeister, P. Mclaughlin, L. W. Kwak, J. Romaguera, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, L. Lacerte, N. H. Fowler Brd. 43C Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). (Abstract #8031) R. W. Chen, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt, K. J. Savage, J. M. Connors, A. Engert, E. K. Larsen, D. A. Kennedy, E. L. Sievers, A. Younes Brd. 43D Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). (Abstract #8032) B. Pro, R. Advani, P. Brice, N. Bartlett, J. D. Rosenblatt, T. Illidge, J. Matous, R. Ramchandren, M. A. Fanale, J. M. Connors, Y. Yang, E. L. Sievers, D. A. Kennedy, A. R. Shustov Brd. 43E Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). (Abstract #8033) S. M. Horwitz, B. Coiffier, F. M. Foss, H. M. Prince, L. Sokol, M. Greenwood, D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. C. Pinter-Brown, S. Padmanabhan, A. R. Shustov, J. Nichols, J. Balser, S. Carroll, B. Pro Brd. 43F The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. (Abstract #8034) K. J. Savage, J. M. Connors, R. J. Klasa, P. Hoskins, T. N. Shenkier, R. D. Gascoyne, S. Bhimji, T. Pickles, F. Benard, D. Wilson, L. H. Sehn Brd. 43G Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496. (Abstract #8035) A. M. Evens, F. Hong, L. I. Gordon, R. I. Fisher, N. Bartlett, J. M. Connors, H. Wagner, M. K. Gospodarowicz, B. D. Cheson, R. Advani, B. S. Kahl, R. T. Hoppe, S. J. Horning Brd. 43H Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices. (Abstract #8036) A. K. Nooka, N. J. DeJoubner, C. Nabhan, X. Zhou, M. Taylor, M. Byrtek, T. P. Miller, J. W. Friedberg, A. D. Zelenetz, B. K. Link, J. R. Cerhan, H. Dillon, D. Levy, J. Hirata, C. Flowers Brd. 44A Long-term survival among Hodgkin lymphoma (HL) patients with gastrointestinal (GI) cancers: A population-based study. (Abstract #8037) P. Youn, H. Li, M. T. Milano, M. Stovall, L. S. Constine, L. B. Travis 387 MONDAY Location: Hall A Track(s): Lymphoma and Plasma Cell Disorders Monday, June 6, 2011 MONDAY Brd. 44B Aggressive craniofacial lymphoma in the prerituximab and rituximab era. (Abstract #8038) V. Poeschel, N. Murawski, B. Glass, S. Zeynalova, J. Fleckenstein, M. Ziepert, B. Kempf, M. Loeffler, N. Schmitz, M. Pfreundschuh, German Non-Hodgkin Lymphoma Study Group (DSHNHL) Brd. 44C Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). (Abstract #8039) Y. L. Kasamon, H. A. Jacene, L. J. Swinnen, L. Popplewell, B. K. Link, T. M. Habermann, J. M. Herman, R. J. Jones, R. F. Ambinder Brd. 44D The impact of high-intensity conditioning prior to allogeneic stem cell transplantation in patients with chemorefractory or relapsed T-cell lymphoma. (Abstract #8040) B. Glass, J. Hasenkamp, W. Jung, C. Wilhelm, G. Held, M. Nickelsen, M. Pfreundschuh, N. Schmitz, L. H. Truemper, G. Wulf Brd. 44E Patients’ versus physicians’ roles in detecting recurrent Hodgkin lymphoma. (Abstract #8041) A. Bestawros, L. Foltz, N. Srour, J. M. Connors Brd. 44F Multicenter analysis of more than 300 very elderly non-Hodgkin lymphoma (NHL) patients (pts): Impact of comorbidities and functional status on outcome. (Abstract #8042) C. Nabhan, S. M. Smith, I. B. Helenowski, E. E. Ramsdale, R. Karmali, B. M. Parsons, J. Feliciano, B. Hanson, S. E. Smith, J. M. Mckoy, A. Larsen, A. Hantel, S. A. Gregory, A. M. Evens Brd. 44G Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL). (Abstract #8043) B. M. William, F. R. Loberiza Jr., V. Whalen, P. J. Bierman, G. Bociek, J. Vose, J. O. Armitage Brd. 44H PET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of a retrospective study. (Abstract #8044) M. Hentrich, M. Berger, C. Hoffmann, J. Siehl, T. Wolf, M. Nickelsen, J. Rockstroh, D. Schuermann, A. Rieke, R. Schmidmaier, H. Knechten, M. Mueller, G. Fätkenheuer, R. Meyer, K. Arastéh, F. A. Mosthaf Sr., C. Wyen Brd. 45B Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT). (Abstract #8046) S. J. Harrison, A. K. Hsu, P. J. Neeson, A. Younes, A. Sureda, A. Engert, M. Li, P. Savage, R. Bugarini, C. Le Corre, D. E. Williams, J. D. Gallagher, A. Shen, D. Ritchie Brd. 45C Activity of anti-CD20-interferon-␣ fusion protein against human B-cell lymphomas. (Abstract #8047) G. Ngarmchamnanrith, R. E. Yamada, K. K. Steward, S. Khare, R. Sachdev, S. L. Morrison, J. Timmerman Brd. 45D Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trials and 9 years of post-approval safety data. (Abstract #8048) J. W. Kylstra, T. E. Witzig, M. Huang, C. E. Emmanouilides, A. Hagenbeek, G. F. Tidmarsh Brd. 45E Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study. (Abstract #8049) B. K. Link, T. P. Miller, M. Byrtek, J. R. Cerhan, A. D. Zelenetz, H. Dillon, C. Flowers, J. W. Friedberg 388 Brd. 45F The association between the GOELAMS MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or highdose therapy with autologous stem cell rescue (HDT/ASCT). (Abstract #8050) T. Feldman, A. R. Mato, T. Zielonka, S. D. Rowley, S. Goldberg, M. Donato, D. S. Siegel, K. Facchin, A. Campaiola, D. H. Vesole, C. Bejot, S. Stives, M. Curtin, M. Miller, H. Agress, D. Panush, P. Lizotte, P. Bhattacharyya, A. Pecora, A. Goy Brd. 45G A new predictive model based on age, pretreatment LDH, and post-therapy PET-CT in patients with MCL treated with dose-intensive strategies. (Abstract #8051) A. R. Mato, T. Feldman, T. Zielonka, S. Goldberg, S. D. Rowley, M. Donato, D. S. Siegel, D. H. Vesole, A. Campaiola, K. Facchin, S. Stives, C. Bejot, M. Curtin, M. Miller, H. Agress, D. Panush, P. Lizotte, A. Pecora, P. Bhattacharyya, A. Goy Brd. 45H Variation of hepatitis C virus genotype distribution between geographically related patients: A retrospective multicenter study. (Abstract #8052) H. A. Torres, M. Nevah-Rubin, B. J. Barnett, P. Mahale, D. P. Kontoyiannis, L. Mishra, M. Hassan, I. Raad Brd. 46A Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). (Abstract #8053) M. A. Rodriguez, J. Durand, A. B. Astrow, M. J. Bury, M. A. Fanale, F. B. Hagemeister Jr., X. Huang, P. McLaughlin, S. S. Neelapu, B. Pro, L. W. Kwak, L. Fayad, J. E. Romaguera, A. Younes, M. Fisch Brd. 46B Allograft versus non-allograft post-transplant lymphoproliferative disorder, characterization of two distinct subtypes as defined by presentation, histology, and outcome: A case series of 165 patients. (Abstract #8054) D. E. Tsai, I. S. Hagemann, J. J. Morrissette, R. Daber, D. Xu, S. J. Schuster, R. D. Bloom, V. N. Ahya, M. Jessup, G. A. Makar, S. Chen, R. Reshef Brd. 46C Identification of prognostic tumor markers in HIVⴙ diffuse large B-cell lymphoma (DLBCL). (Abstract #8055) C. Chao, M. Silverberg, D. I. Abrams, R. Haque, H. D. Zha, O. Martinez-Maza, M. McGuire, M. D. Chi, B. Castor, L. Xu, J. Said Brd. 46D Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/ relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. (Abstract #8056) M. Cotto, F. Cabanillas, G. Garcia-Manero, H. Yang, M. Bruno, O. A. Pavia, E. Rivera, I. Liboy, M. Tirado-Gomez Brd. 46E Prognostic significance of absolute lymphocyte count in patients with early-stage diffuse large B-cell lymphoma treated with RCHOP. (Abstract #8057) Y. Chae, Y. Lee, B. Kang, J. Moon, J. Kim, S. Sohn, D. Yang, J. Lee, T. Park Brd. 46F A phase II study of R-COMP14 in elderly patients with high-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high “life threat” impact cardiopathy. (Abstract #8058) G. Corazzelli, F. Frigeri, M. Arcamone, A. Lucania, G. Capobianco, M. Villa, F. Russo, S. Crisci, G. Marcacci, C. Becchimanzi, E. Morelli, F. Volzone, R. De Filippi, A. Pinto Brd. 46G Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). (Abstract #8059) C. A. Thompson, M. J. Maurer, C. Allmer, S. L. Slager, K. J. Yost, W. R. Macon, S. M. Ansell, D. J. Inwards, T. M. Habermann, B. K. Link, J. R. Cerhan Brd. 46H Differences in regulatory T cells (Tregs) in responding and non-responding patients with indolent B-cell or mantle cell lymphoma during treatment with lenalidomide and rituximab ⴞ dexamethasone. (Abstract #8060) N. Aqui, A. Gordon, Y. Xu, E. A. Chong, L. Leinbach, T. Ahmadi, S. Nasta, J. Svoboda, S. J. Schuster 389 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 MONDAY Brd. 47A Cell cycle effects of CDK 4/6 inhibitor PD 0332991 in diffuse large B-cell lymphoma cell lines in vitro. (Abstract #8061) H. A. Eradat, M. A. Eckardt, E. Dorfman, H. Hamidi, C. Ginther, R. S. Finn, G. Los, J. G. Christensen, S. De Vos, D. J. Slamon Brd. 47B Piracy of COX-2/PGE2/EP receptor pathway by Kaposi’s sarcoma associated herpes virus (KSHV): A potential Achilles’ heel of KSHV–related diseases. (Abstract #8062) A. G. Paul, N. Sharma-Walia, B. Chandran Brd. 47C Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma. (Abstract #8063) L. Aloj, L. D’Ambrosio, M. Aurilio, R. Marreno, D. Neri, H. D. Menssen, L. Giovannoni, F. Di Gennaro, C. Caraco, M. Arcamone, F. Frigeri, A. Pinto, S. Lastoria Brd. 47D Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the Stanford G5 Study. (Abstract #8064) R. Advani, S. J. Horning, E. Jonathan, S. Daadi, J. Allen, S. A. Rosenberg, R. T. Hoppe Brd. 47E Outcomes following involved field radiotherapy (IFRT) with or without rituximab in patients (Pts) with limited-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT versus PET. (Abstract #8065) J. N. Lukens, S. Nasta, E. Glatstein, J. P. Plastaras Brd. 47F Bendamustine and lenalidomide in relapsed/refractory lymphoid malignancies. (Abstract #8066) B. D. Cheson, C. S. Ujjani, E. A. Gehan, S. M. Karim, T. Goswami, J. Crawford Brd. 47G Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide. (Abstract #8067) J. Mikhael, V. Rajkumar, V. Roy, S. R. Hayman, R. Fonseca, K. Detweiler Short, B. LaPlant, K. M. Laumann, A. Dispenzieri, M. Lacy Brd. 47H Extramedullary disease (EMD): A common terminal pathway in multiple myeloma (MM) progression. (Abstract #8068) S. Z. Usmani, A. Mitchell, J. Szymonifka, J. D. Shaughnessy Jr., A. Hoering, Y. Alsayed, S. Waheed, B. Nair, J. Crowley, B. Barlogie Brd. 48A Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete response (sCR) following upfront autologous stem cell transplantation (SCT). (Abstract #8069) P. Kapoor, S. Kumar, A. Dispenzieri, M. Lacy, D. Dingli, S. R. Hayman, F. Buadi, P. R. Greipp, R. A. Kyle, S. V. Rajkumar, M. A. Gertz Brd. 48B Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial. (Abstract #8070) J. R. Berenson, O. Yellin, A. Bessudo, R. Boccia, S. Noga, D. Gravenor, D. Patel-Donnelly, R. S. Siegel, T. Kewalramani, E. J. Gorak, R. Swift, D. Bensen-Kennedy Brd. 48C Outcomes of a late second autologous hematopoietic stem cell transplant compared to nontransplantation salvage therapy in relapsed multiple myeloma after upfront transplant. (Abstract #8071) J. M. Azar, S. Abdelqader, R. Abonour, A. Suvannasankha, R. Tabbey, S. Farag Brd. 48D Impact of baseline characteristics on efficacy and safety after bortezomibbased induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study. (Abstract #8072) R. Niesvizky, I. W. Flinn, R. M. Rifkin, N. Gabrail, V. Charu, Y. Gaffar, R. Neuwirth, D. Corzo, J. Reeves 390 Brd. 48E Association of familial disease status with inferior treatment outcome in patients with Waldenstrom’s macroglobulinemia. (Abstract #8073) Z. R. Hunter, C. Hanzis, L. Ioakimidis, C. Tripsas, R. J. Manning, C. J. Patterson, P. Sheehy, B. Turnbull, S. P. Treon Brd. 48F Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. (Abstract #8074^) N. C. Munshi, S. Lee, S. Kambhampati, A. Mohiuddin, M. G. Rose, C. Behler, A. Han, Y. A. Efebera, A. Houranieh, M. T. Brophy, A. Zimelman, R. H. Prabhala, T. Grady, C. E. Klein, P. Mehta, T. G. Hayes, G. D. Roodman, A. Lichtenstein Brd. 48G A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. (Abstract #8075) J. F. San-Miguel, P. G. Richardson, O. Sezer, A. Guenther, D. S. Siegel, J. Blade, R. LeBlanc, H. J. Sutherland, M. Mateos, M. Gramatzki, K. M. Hazell, B. Bengoudifa, P. M. Bourquelot, K. C. Anderson Brd. 48H Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract #8076) S. Lonial, R. Vij, T. Facon, P. Moreau, X. Leleu, A. Mazumder, J. L. Kaufman, C. Westland, C. Tsao, A. K. Singhal, S. Jagannath Brd. 49A Prevalence of interleukin-6 receptor polymorphism in Castleman disease and association with increased soluble interleukin-6 receptor levels. (Abstract #8077) K. Stone, E. Woods, S. M. Szmania, O. Stephens, T. K. Garg, A. Moreno-Bost, B. Barlogie, J. D. Shaughnessy Jr., B. Hall, M. P. Reddy, F. Van Rhee Brd. 49B Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. (Abstract #8078) J. Endell, C. Samuelsson, R. Boxhammer, S. Strauss, S. Steidl Brd. 49C Evaluation of pretransplant variables predicting cardiomyopathy following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. (Abstract #8079) J. S. Bleeker, M. A. Gertz, P. A. Pellikka, F. Buadi, D. Dingli, A. Dispenzieri, S. R. Hayman, W. J. Hogan, S. Kumar, M. Lacy Brd. 49D Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial. (Abstract #8080) F. Buadi, M. Lacy, A. Dispenzieri, B. LaPlant, K. M. Laumann, G. S. Nowakowski, S. R. Hayman, K. Detweiler Short, D. Dingli, M. A. Gertz, P. R. Greipp, J. A. Lust, T. E. Witzig, S. R. Zeldenrust, S. J. Russell, V. Rajkumar, S. Kumar Brd. 49E The impact of frontline risk-adapted strategy on the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM): A population study in Singapore (SG). (Abstract #8081) D. C. Tan, K. H. Ong, L. P. Koh, S. S. Wong, M. T. Khin, L. H. Lee, Y. T. Goh, W. J. Chng Brd. 49F A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/ refractory (R/R) multiple myeloma (MM). (Abstract #8082) O. Yellin, J. R. Berenson, T. Kazamel, C. Chen, A. Cartmel, T. B. Woliver, M. S. Flam, E. N. Bravin, Y. Nassir, R. A. Vescio, R. Swift Brd. 49G Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival (OS) benefit associated with treatment with zoledronic acid (ZOL). (Abstract #8083) G. J. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child, P. Wu 391 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 Brd. 49H An evaluation of MIST 1 as an indicator of plasmacytic differentiation. (Abstract #8084) C. C. Yeung, J. Mills, J. Frater Brd. 50A Effect of NF-kB2 mutation on pathway activitation in the pathogenesis of B-cell lymphomas. (Abstract #8085) B. A. McCarthy, L. Yang, D. Liu, J. Ding, H. Ding Brd. 50B Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. (Abstract #8086) B. G. Durie, G. Morgan, J. F. San-Miguel, R. Z. Orlowski, S. Lonial, R. Niesvizky, Z. Yu, K. C. Anderson MONDAY 392 Monday, June 6, 2011 1:15 PM - 2:30 PM SPECIAL SESSION ASCO/Union for International Cancer Control (UICC) Joint Session: Breast Cancer Health Disparities—Challenges and Opportunities from an International Perspective Location: Hall B1 CME credit: 1.25 Track(s): Breast Cancer, International, Special Session Eduardo L. Cazap, MD—Co-Chair Latin American-Caribbean Society of Medical Oncology George W. Sledge Jr., MD—Co-Chair Indiana University Simon Cancer Center Larry Norton, MD Memorial Sloan-Kettering Cancer Center Developing a Strategy for Independent Breast Cancer Research Benjamin O. Anderson, MD University of Washington Controversies in Screening for Breast Cancer Mary K. Gospodarowicz, MD Princess Margaret Hospital and University of Toronto Role of Radiotherapy in Low-resource Scenarios MONDAY Gabriel N. Hortobagyi, MD University of Texas M. D. Anderson Cancer Center How to Treat Advanced Breast Cancer with Limited Resources 393 Monday, June 6, 2011 1:15 PM - 2:30 PM EDUCATION SESSIONS Challenges in Treating Children, Adolescents, and Adults with Benign and Malignant Vascular Tumors Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology Denise Adams, MD—Chair Cincinnati Children’s Hospital Multidisciplinary Strategies for the Treatment of Vascular Malformations and Tumors in Children Anthony Montag, MD The University of Chicago Medical Center The Pathology and Biology of Vascular Tumors in Children and Young Adults Steven J. Fishman, MD Children’s Hospital Boston The Role of the Surgeon in the Diagnosis and Management of Vascular Tumors Evolving Therapy of Hodgkin Lymphoma Location: S406 CME credit: 1.25 Track(s): Lymphoma and Plasma Cell Disorders, General Oncology Joseph M. Connors, MD—Chair British Columbia Cancer Agency Center for Lymphoid Cancer Advanced-stage Hodgkin Lymphoma Andreas Engert, MD University Hospital of Cologne Limited-stage Hodgkin Lymphoma Francisco J. Hernandez-Ilizaliturri, MD Roswell Park Cancer Institute New Therapies in Hodgkin Lymphoma MONDAY How to Advise the Patient with Early-stage Esophageal Carcinoma and Highgrade Dysplasia Arising in Barrett’s Esophagus: Endoluminal Therapies to Resection Location: Hall D2 CME credit: 1.25 Track(s): Gastrointestinal (Noncolorectal) Cancer Martin S. Karpeh Jr., MD—Chair Beth Israel Medical Center What Are the Surgical Options for High-grade Dysplasia and Carcinoma in Situ? Blair A. Jobe, MD University of Pittsburgh What Are the Endoluminal Therapies for High-grade Dysplasia or Carcinoma in Situ? 394 Monday, June 6, 2011 Myelodysplastic Disorders and Myeloproliferative Disorders: New Therapeutic Developments Location: E354a CME credit: 1.25 Track(s): Leukemia, Myelodysplasia, and Transplantation Alan F. List, MD—Chair H. Lee Moffitt Cancer Center & Research Institute Update of Therapy for Myelodysplastic Syndromes Pierre Fenaux, MD, PhD Hopital Avicenne The Biology and Prognostic Factors of Myelodysplastic Syndromes Srdan Verstovsek, MD, PhD University of Texas M. D. Anderson Cancer Center Myeloproliferative Disorders: JAK2 and Beyond Optimizing Data Collection for Clinical Trials to Support Clinically Relevant Decisions (eQuestions Session) Location: E353 CME credit: 1.25 Track(s): Clinical Trials Richard L. Schilsky, MD—Chair The University of Chicago Data Collection and Optimization in the Cooperative Group Setting Jeffrey S. Abrams, MD National Cancer Institute Challenges in the Coordination of Clinical Trials Ann T. Farrell, MD U.S. Food and Drug Administration FDA Recommendations for Sponsors on Data Collection for Cancer Clinical Trials MONDAY Peter C. Adamson, MD Children’s Hospital of Philadelphia Data Collection Standards to Establish Safety and Efficacy in Pediatric Clinical Trials 395 Monday, June 6, 2011 1:15 PM - 2:30 PM MEET THE PROFESSOR SESSIONS Non-oncogene Addiction to Stress: A Cancer Cell Fix Exploited for Cancer Therapy (M23)—Ticketed Session Location: E451b CME credit: 1.25 Track(s): Tumor Biology, Developmental Therapeutics Kapil N. Bhalla, MD University of Kansas Cancer Center Oncogene and Non-oncogene Addiction in Cancer Sex and the Survivor (M16)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Patient and Survivor Care Leslie R. Schover, PhD University of Texas M. D. Anderson Cancer Center MONDAY 396 Monday, June 6, 2011 1:15 PM - 2:45 PM CLINICAL SCIENCE SYMPOSIUM BRAF: From Biology to Patients Location: E354b CME credit: 1.5 Track(s): Melanoma/Skin Cancers Keith T. Flaherty, MD—Co-Chair Massachusetts General Hospital Richard Kefford, MD, PhD—Co-Chair Westmead Institute for Cancer Research Discussion 1:15 PM Levi A. Garraway, MD, PhD Dana-Farber Cancer Institute Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. (Abstract #8500) J. A. Jakob, R. L. Bassett Jr., C. S. Ng, A. J. Lazar, G. C. Alvarado, M. L. Rohlfs, J. Richard, J. E. Gershenwald, P. Hwu, K. B. Kim, M. A. Davies 1:45 PM Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). (Abstract #8501) K. L. Nathanson, A. Martin, R. Letrero, K. P. D’Andrea, S. O’Day, J. R. Infante, G. S. Falchook, M. Millward, C. M. Curtis Jr., B. Ma, R. C. Gagnon, P. F. Lebowitz, G. V. Long, R. F. Kefford 2:00 PM Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts). (Abstract #8502) G. A. McArthur, A. Ribas, P. B. Chapman, K. T. Flaherty, K. B. Kim, I. Puzanov, K. L. Nathanson, R. J. Lee, A. Koehler, O. Spleiss, G. Bollag, W. Wu, K. Trunzer, J. A. Sosman 2:15 PM Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (Abstract #CRA8503) J. R. Infante, G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford, J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long, H. A. Burris III, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet, K. Patel, P. F. Lebowitz, K. T. Flaherty MONDAY 1:30 PM Discussion 2:30 PM Reinhard Dummer, MD (Abstracts #8500 –CRA8503) University Hospital of Zurich 397 Monday, June 6, 2011 1:15 PM - 2:45 PM CLINICAL SCIENCE SYMPOSIUM Molecular Biomarkers in Neuro-oncology: Ready for Clinical Practice? Location: S100bc CME credit: 1.5 Track(s): Central Nervous System Tumors Markus Bredel, MD, PhD—Co-Chair University of Freiburg Rimas Vincas Lukas, MD—Co-Chair The University of Chicago Discussion 1:15 PM Martin J. Van Den Bent, MD Daniel den Hoed Cancer Center 1:30 PM RTOG 0525: Molecular correlates from randomized phase III trial of newly diagnosed glioblastoma. (Abstract #LBA2000) K. D. Aldape, M. Wang, E. P. Sulman, D. P. Cahill, M. Hegi, H. Colman, G. Jones, A. Chakravarti, M. P. Mehta, D. W. Andrews, L. Long, K. Diefes, L. Heathcock, R. Jenkins, C. J. Schultz, M. R. Gilbert 1:45 PM Impact of MGMT promoter methylation in glioblastoma of the elderly. (Abstract #2001) M. Weller, B. Hentschel, J. Felsberg, G. Schackert, M. Simon, O. Schnell, M. Westphal, W. Wick, T. Pietsch, M. Loeffler, G. Reifenberger, German Glioma Network 2:00 PM Predictive value of IDH1 mutation assessed by immunohistochemistry and DNA sequencing in WHO grade 3 oligodendrogliomas. (Abstract #2002) J. Frenel, C. Leux, D. Loussouarn, A. Le Loupp, F. Leclair, A. Von Deimling, M. Aumont, S. Martin, M. G. Denis, M. Campone 2:15 PM Prediction of glioblastoma outcome using combined analysis of MGMT protein expression and promoter methylation (Abstract #2003) A. Lai, S. Lalezari, A. P. Chou, A. Tran, O. E. Solis, J. A. Carrillo, W. Chen, P. S. Mischel, R. M. Green, P. L. Nghiemphu, L. M. Liau, H. Wang, R. M. Elashoff, T. F. Cloughesy, W. H. Yong MONDAY Discussion 2:30 PM Michael Prados, MD (Abstract #LBA2000 –2003) University of California, San Francisco 398 Monday, June 6, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Gastrointestinal (Noncolorectal) Cancer Display Time: 2:00 PM - 6:00 PM Display Location: E450b Discussion Time: 5:00 PM - 6:00 PM Discussion Location: Hall D1 CME credit: 1 Track(s): Gastrointestinal (Noncolorectal) Cancer Abby B. Siegel, MD, MS—Co-Chair Columbia University Gauri R. Varadhachary, MD—Co-Chair University of Texas M. D. Anderson Cancer Center Discussion 5:00 PM Alexandria T. Phan, MD (Abstracts #4008 – 4011) University of Texas M. D. Anderson Cancer Center Discussion 5:15 PM Ian Chau, MD (Abstracts #4012– 4019) The Royal Marsden Hospital Discussion 5:30 PM Eunice Lee Kwak, MD, PhD (Abstracts #4020 – 4027) Massachusetts General Hospital and Harvard Medical School Brd. 1 Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). (Abstract #4008) E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, P. Metrakos, D. Smith, A. Vinik, J. Chen, D. Hoersch, D. E. Castellano, H. F. Kennecke, J. Picus, G. Van Hazel, D. Lu, S. Patyna, R. C. Chao, E. Van Cutsem Brd. 2 Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3). (Abstract #4009) J. R. Strosberg, J. Lincy, R. E. Winkler, E. M. Wolin Brd. 3 Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. (Abstract #4010) M. H. Shah, C. Lombard-Bohas, T. Ito, E. M. Wolin, E. Van Cutsem, C. Sachs, R. E. Winkler, J. Lincy, T. J. Hobday, J. C. Yao Brd. 4 Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. (Abstract #4011) J. C. Yao, S. Ricci, R. E. Winkler, V. Jehl, M. E. Pavel Brd. 5 HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). (Abstract #4012) H. H. Yoon, Q. Shi, W. R. Sukov, A. E. Wiktor, M. Khan, C. A. Sattler, A. Grothey, T. Wu, R. B. Diasio, R. B. Jenkins, F. Sinicrope 399 MONDAY Discussion 5:45 PM Colin D. Weekes, MD, PhD (Abstracts #4028 –LBA4032) University of Colorado Cancer Center Monday, June 6, 2011 MONDAY Brd. 6 Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. (Abstract #4013) M. Terashima, A. Ochiai, K. Kitada, W. Ichikawa, I. Kurahashi, S. Sakuramoto, T. Fukagawa, T. Sano, H. Imamura, M. Sasako Brd. 7 Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis. (Abstract #4014) M. A. Shah, Y. Y. Janjigian, C. Pauligk, D. Werner, D. P. Kelsen, E. Jaeger, H. Altmannsberger, E. Robinson, L. H. Tang, V. V. Barbashina, S. Al-Batran Brd. 8 Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study. (Abstract #4015) D. A. Richards, D. M. Kocs, A. I. Spira, A. D. McCollum, K. A. Boehm, F. Zhan, L. Asmar Brd. 9 Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. (Abstract #4016) M. Fujii, Y. H. Kim, T. Satoh, H. Hosaka, T. Kim, A. Tsuji, M. Inokuchi, A. Takagane, S. Oh, K. Tanabe, T. Okuno, K. Chin, T. Ura, J. I. Lee, Y. Kakudo, K. Yamaguchi, S. Iijima, M. Takeuchi, H. Kim, T. Nakajima, Japan Clinical Cancer Research Organization and Korean Cancer Study Group Inter-Group Study Brd. 10 SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer. (Abstract #4017) A. Tsuburaya, K. Yoshida, M. Kobayashi, S. Yoshino, Y. Miyashita, S. Morita, K. Oba, M. E. Buyse, J. S. Macdonald, J. Sakamoto Brd. 11 Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. (Abstract #4018) E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti, D. A. Richards, H. Prenen, I. Steinberg, P. Rougier Brd. 12 A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. (Abstract #4019) J. Li, S. Qin, J. Xu, W. j. Guo, J. p. Xiong, Y. Bai, G. Sun, Y. Yang, L. Wang, N. Xu, Y. Cheng, W. Zhe-Hai, L. Zheng, M. Tao Brd. 13 Evaluation of putative prognostic tissue biomarkers in pancreatic ductal adenocarcinoma. (Abstract #4020) J. M. Winter, L. H. Tang, D. S. Klimstra, M. F. Brennan, E. M. O’Reilly, W. R. Jarnagin, P. J. Allen Brd. 14 Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912. (Abstract #4021) Y. Yamada, J. Mizusawa, A. Takashima, K. Nakamura, Y. Tsuji, Y. Suzuki, K. Amagai, K. Yamaguchi, K. Konishi, T. Yoshino, T. Denda, W. Koizumi, S. Ohkawa, H. Kawai, H. Kojima, H. Nishizaki, T. Nishina, A. Tsuji, H. Fukuda, N. Boku Brd. 15 Genome-wide interaction study of gemcitabine treatment and genotype on survival in pancreatic cancer. (Abstract #4022) R. R. McWilliams, W. R. Bamlet, M. Matsumoto, G. P. Kim, P. A. Burch, D. Grendahl, G. M. Petersen 400 Brd. 16 Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). (Abstract #4023) P. O. Bohanes, B. H. Goldman, L. P. Leichman, C. D. Blanke, S. Iqbal, C. R. Thomas Jr., C. L. Corless, K. G. Billingsley, K. D. Danenberg, W. Zhang, J. K. Benedetti, P. J. Gold, H. Lenz Brd. 17 Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression. (Abstract #4024) R. Maréchal, j. Bachet, J. R. Mackey, P. Demetter, K. Graham, A. Couvelard, M. Svrcek, A. Bardier, P. Hammel, A. Sauvanet, C. Louvet, F. Paye, P. Rougier, L. Hannoun, T. Andre, C. M. Dumontet, C. Cass, I. Salmon, J. Emile, J. Van Laethem Brd. 18 Comparing the classification precision and prognostic performance of an intrinsic gastric cancer signature with existing genomic signatures in six independent datasets. (Abstract #4025) I. B. Tan, H. Grabsch, H. Toh, J. Lee, A. Boussioutas, S. Y. Rha, J. A. Ajani, P. Tan Brd. 19 Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. (Abstract #4026) M. M. Javle, G. R. Varadhachary, D. R. Fogelman, R. T. Shroff, M. J. Overman, L. Ukegbu, B. N. Bekele, S. P. Kar, R. A. Wolff, J. L. Abbruzzese Brd. 20 Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). (Abstract #4027) J. A. Ajani, X. Wang, Y. Hayashi, D. Maru, J. Welsh, W. L. Hofstetter, J. H. Lee, M. S. Bhutani, A. Suzuki, D. A. Berry, J. Izzo Brd. 21 BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer. (Abstract #4028) A. Goncalves, F. Viret, E. François, L. Dahan, H. Perrier, R. Lamy, D. Re, R. Largillier, M. Gasmi, X. Tchiknavorian, O. Turrini, L. Moureau-Zabotto, J. Delpero, P. Viens Brd. 22 A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer. (Abstract #4029) Y. Omuro, T. Ikari, H. Ishii, M. Ozaka, M. Suyama, Y. Matsumura, T. Itoi, N. Egawa, S. Yano, K. Hanada, Y. Kimura, T. Ukita, Y. Ishida, M. Tani, S. Ohoka, Y. Hirose, S. Hijioka, R. Watanabe, T. Ikeda, T. Nakajima, Japan Clinical Cancer Research Organization Brd. 23 Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. (Abstract #4030) G. P. Kim, N. R. Foster, M. Salim, P. J. Flynn, D. F. Moore, R. Zon, R. B. Mowat, M. Wiesenfeld, A. E. McCullough, S. R. Alberts Brd. 24 Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). (Abstract #4031) B. M. Wolpin, E. M. O’Reilly, Y. Ko, L. S. Blaszkowsky, M. U. Rarick, C. S. Rocha Lima, P. S. Ritch, E. Chan, J. L. Spratlin, T. Macarulla, E. McWhirter, D. Pezet, M. Lichinitser, L. D. Roman, A. Hartford, L. Jackson, M. Vincent, L. M. Reyno, M. Hidalgo Brd. 25 Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma. (Abstract #LBA4032) H. Y. Lim, J. Lee, H. M. Chang, J. S. Kim, H. J. Choi, M. A. Lee, J. S. Jang, H. C. Jeung, J. H. Kang, H. W. Lee, D. Shin, H. J. Jang, J. M. Sun, S. H. Park, J. O. Park, Y. Park, W. K. Kang 401 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Health Services Research Display Time: 2:00 PM - 6:00 PM Display Location: S403 Discussion Time: 5:00 PM - 6:00 PM Discussion Location: S404 CME credit: 1 Track(s): Health Services Research Michael J. Hassett, MD, MPH—Co-Chair Dana-Farber Cancer Institute Scott Michael Gilbert, MD, MS—Co-Chair University of Florida Discussion 5:00 PM Scott David Ramsey, MD, PhD (Abstracts #6012– 6016) Fred Hutchinson Cancer Research Center Discussion 5:15 PM Jennifer J. Griggs, MD, MPH (Abstracts #6017– 6023) University of Michigan Discussion 5:30 PM Lynne I. Wagner, PhD (Abstracts #6024 – 6028) Northwestern University Discussion 5:45 PM Michael J. Hall, MD (Abstracts #6029 – 6036) Fox Chase Cancer Center MONDAY Brd. 1 Validation of specific chemotherapy drugs in Medicare data. (Abstract #6012) J. L. Lund, T. Sturmer, R. S. Sandler, H. K. Sanoff, L. C. Harlan, J. L. Warren Brd. 2 Changes in cancer survival by ethnicity between 1992–1996 and 2002–2006: Are survival disparities increasing or decreasing? (Abstract #6013) D. Pulte, T. Redaniel, H. Brenner, M. Jeffreys Brd. 3 High-cost imaging for managed care Medicare beneficiaries with cancer, 2001–2006. (Abstract #6014) E. T. Loggers, P. A. Fishman, M. C. Hornbrook, C. C. Greenberg, M. C. O’Keeffe-Rosetti, A. Ramaprasan, N. Q. Vanneman, E. H. Wagner, J. C. Weeks, D. P. Ritzwoller Brd. 4 Costs and trends in pancreatic cancer treatment: A population-based analysis. (Abstract #6015) C. B. O’Neill, C. L. Atoria, E. M. O’Reilly, J. LaFemina, E. B. Elkin Brd. 5 Costs of medical care after open or minimally-invasive prostate cancer surgery: A population-based analysis. (Abstract #6016) E. B. Elkin, W. T. Lowrance, B. Denton, J. N. Mirkin, J. A. Eastham Brd. 6 Different risk factors for mortality in younger and older women after breastconserving surgery. (Abstract #6017) G. G. Kimmick, F. Camacho, W. Hwang, H. B. Mackley, J. H. Stewart IV, R. T. Anderson Brd. 7 Associations between county-level surgeon density and colorectal cancer (CRC) mortality. (Abstract #6018) J. S. Albarrak, M. Y. Ho, W. Y. Cheung Brd. 8 Concordance with NCCN practice guidelines for local therapies as a measure of quality of care: Review of practice and identification of quality gaps. (Abstract #6019) V. Francescutti, N. L. Watroba, S. B. Edge 402 Brd. 9 Physicians characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. (Abstract #6020) J. D. Wright, A. I. Neugut, E. T. Wilde, D. Buono, J. Malin, W. Tsai, D. L. Hershman Brd. 10 Patient access to breast reconstruction after mastectomy and long-term outcomes. (Abstract #6021) M. Morrow, A. K. Alderman, S. T. Hawley, S. J. Katz Brd. 11 Timing in adjuvant chemotherapy (CTX) initiation among women with breast cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An analysis from the NCCN Outcomes Database. (Abstract #6022) J. L. Vandergrift, J. C. Niland, R. L. Theriault, S. B. Edge, Y. Wong, L. S. Loftus, T. M. Breslin, C. Hudis, S. H. Javid, H. S. Rugo, S. M. Silver, E. M. Lepisto, J. C. Weeks Brd. 12 The association of obesity, smoking, and access to oncology services with cancer mortality in the United States. (Abstract #6023) A. J. Hayanga, S. B. Zeliadt, D. E. Wood, L. M. Backhus Brd. 13 Early palliative care, depression, and survival in metastatic NSCLC. (Abstract #6024) W. F. Pirl, J. A. Greer, E. R. Gallagher, V. A. Jackson, I. T. Lennes, J. S. Temel Brd. 14 Fertility concerns in young women with breast cancer: Results from a prospective cohort study. (Abstract #6025) K. J. Ruddy, S. Gelber, R. M. Tamimi, E. S. Ginsburg, L. Schapira, S. E. Come, M. E. Meyer, E. P. Winer, A. H. Partridge Brd. 15 Discussions about end-of-life care planning between physicians and patients with stage IV lung or colorectal cancer. (Abstract #6026) J. W. Mack, A. Cronin, N. Taback, H. Huskamp, N. L. Keating, J. L. Malin, C. Earle, J. C. Weeks Brd. 16 Patient perspectives on a treatment plan and summary program in community oncology care. (Abstract #6027) V. S. Blinder, V. W. Norris, N. W. Peacock, J. J. Griggs, D. P. Harrington, A. Moore, R. L. Theriault, A. H. Partridge Brd. 17 Evaluation of an intervention to improve communication about phase I/II trials. (Abstract #6028) L. Fallowfield, I. Solis-Trapala, C. I. Langridge, V. A. Jenkins Brd. 18 Patients’ understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. (Abstract #6029) N. T. Brewer, C. M. Walko, W. K. Chiu, L. G. Dressler, A. Yuen, P. Rubin, O. A. Olajide, S. G. Moore, R. E. Raab, D. R. Carrizosa, S. W. Corso, G. Schwartz, J. M. Peppercorn, H. L. McLeod, L. A. Carey, W. J. Irvin Jr. Brd. 19 The balance between benefits and harms of molecular targeted agents. (Abstract #6030) S. Niraula, E. Amir, A. Ocana, B. Seruga, I. Tannock Brd. 20 Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program. (Abstract #6031) R. L. Yung, M. J. Hassett, K. Chen, F. C. Gesten, P. R. Roohan, F. P. Boscoe, A. H. Sinclair, M. J. Schymura, D. Schrag Brd. 21 Persistence with adjuvant hormonal therapy in older breast cancer survivors. (Abstract #6032) T. Hedin, C. Guo, A. Nattinger Brd. 22 Anthracycline adherence in older patients with breast cancer. (Abstract #6033) C. H. Barcenas, N. Zhang, H. Zhao, Z. Duan, G. N. Hortobagyi, S. H. Giordano Brd. 23 Racial disparities in chemotherapy for breast cancer: Are delays explained by hospital quality and volume? (Abstract #6034) R. A. Freedman, Y. He, N. L. Keating 403 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 Brd. 24 Preoperative breast MRI in early-stage breast cancer: A decision analysis. (Abstract #6035) P. Young, B. Kim, J. Malin Brd. 25 Abandoning oral oncolytic prescriptions at the pharmacy: Patient and health plan factors influencing adherence. (Abstract #6036) L. S. Schwartzberg, S. B. Streeter, N. Husain, M. Johnsrud MONDAY 404 Monday, June 6, 2011 2:00 PM - 6:00 PM POSTER DISCUSSION SESSION Lung Cancer—Metastatic/Non-small Cell Display Time: 2:00 PM - 6:00 PM Display Location: E450a Discussion Time: 5:00 PM - 6:00 PM Discussion Location: Hall D2 CME credit: 1 Track(s): Lung Cancer Shadia Ibrahim Jalal, MD—Co-Chair Indiana University Simon Cancer Center Robert Charles Doebele, MD, PhD—Co-Chair University of Colorado Denver Discussion 5:00 PM Kenneth John O’Byrne, MD (Abstracts #LBA7512–7518) St. James Hospital Discussion 5:15 PM Rebecca Suk Heist, MD (Abstracts #7519 –7523) Massachusetts General Hospital Cancer Center Discussion 5:30 PM Shirish M. Gadgeel, MD (Abstracts #7524 –7529) Karmanos Cancer Institute Brd. 1 An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #LBA7512) G. Scagliotti, I. Vynnychenko, Y. Ichinose, K. Park, K. Kubota, F. H. Blackhall, R. Pirker, R. Galiulin, T. E. Ciuleanu, O. Sydorenko, M. Dediu, Z. Papai-Szekely, N. Martinez Banaclocha, S. McCoy, B. Yao, Y. J. Hei, D. R. Spigel Brd. 2 A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study. (Abstract #7513) J. R. Molina, G. K. Dy, N. R. Foster, K. L. Allen Ziegler, A. Adjei, K. M. Rowland, M. Aubry, P. J. Flynn, S. J. Mandrekar, S. E. Schild, A. A. Adjei, North Central Cancer Treatment Group (NCCTG) Brd. 3 Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. (Abstract #7514) L. Crinò, D. Kim, G. J. Riely, P. A. Janne, F. H. Blackhall, D. R. Camidge, V. Hirsh, T. Mok, B. J. Solomon, K. Park, S. M. Gadgeel, R. Martins, J. Han, T. M. De Pas, A. Bottomley, A. Polli, J. Petersen, V. R. Tassell, A. T. Shaw Brd. 4 Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors. (Abstract #7515) D. Kim, J. Lee, H. S. Park, K. Kulig, T. M. Kim, S. Lee, Y. Jeon, D. H. Chung, D. S. Heo, W. Kim, Y. Bang Brd. 5 Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC). (Abstract #7516) G. J. Riely, S. N. Gettinger, R. G. Stoller, N. Y. Gabrail, G. K. Dy, G. J. Weiss, C. Tunkey, G. Skliris, S. Strychor, J. Dunbar, D. DeLucia, R. W. Ross, J. E. Gray 405 MONDAY Discussion 5:45 PM Fred R. Hirsch, MD (Abstracts #7530 –7536) University of Colorado Denver Monday, June 6, 2011 MONDAY Brd. 6 The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). (Abstract #7517) T. M. Ortiz, V. A. Joshi, S. Heon, M. Butaney, L. Chen, D. M. Jackman, D. J. Kwiatkowski, N. I. Lindeman, P. A. Janne, B. E. Johnson Brd. 7 SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. (Abstract #7518) L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, J. S. Temel, I. T. Lennes, E. Bast, B. A. Waltman, M. Lanuti, A. Muzikansky, M. Mino-Kenudson, A. J. Iafrate, D. R. Borger, D. Dias-Santagata, J. A. Engelman Brd. 8 Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. (Abstract #7519) A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, T. Nukiwa, North-East Japan Study Group Brd. 9 Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/ carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mutⴙ) advanced non-small cell lung cancer (NSCLC). (Abstract #7520) C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang, On behalf of the OPTIMAL investigators Brd. 10 IFCT-0504 trial: Mucinous (M) and non-mucinous (NM) cytological subtypes interaction effect in first-line treatment of advanced bronchioloalveolar carcinoma (BAC), by erlotinib (E) or carboplatin/paclitaxel (C/P). (Abstract #7521) J. Cadranel, R. Gervais, M. Wislez, P. Merle, D. Moro-Sibilot, V. Westeel, L. Bigay-Game, E. A. Quoix, S. Friard, F. Barlesi, M. Zaegel, L. Moreau, I. Monnet, J. Duhamel, G. Oliviero, P. J. Souquet, L. Thiberville, L. Baudrin, F. Morin, G. Zalcman, on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) Brd. 11 A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). (Abstract #7522) Y. Sun, Y. Shi, L. Zhang, X. Liu, C. Zhou, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Song, J. Feng, Y. Cheng, H. Zhang, Y. Wu, N. Xu, J. Zhou Brd. 12 An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib. (Abstract #7523) J. F. Hilton, L. Seymour, A. Le Maitre, D. Tu, F. A. Shepherd, P. A. Bradbury Brd. 13 A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G) (Abstract #7524) N. Yamamoto, N. Katakami, S. Atagi, T. Hida, K. Goto, T. Horai, A. Inoue, Y. Ichinose, K. Kobayashi, K. Takeda, K. Kiura, H. Saka, T. Tamura, I. Okamoto, N. Nogami, R. Morinaga, K. Nishio, Y. Seki, R. M. Lorence, M. Shahidi Brd. 14 Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. (Abstract #7525^) Y. Y. Janjigian, H. J. Groen, L. Horn, E. F. Smit, Y. Fu, F. Wang, M. Shahidi, L. J. Denis, W. Pao, V. A. Miller Brd. 15 A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC. (Abstract #7526) J. Von Pawel, Z. Papai-Szekely, N. Vinolas, C. Sederholm, M. Klima, D. Desaiah, M. I. Leschinger, C. Dittrich 406 Brd. 16 Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced stage non-small cell lung cancer (NSCLC). (Abstract #7527) S. S. Ramalingam, D. R. Spigel, M. Steins, J. A. Engelman, C. Schneider, S. Novello, W. E. Eberhardt, L. Crino, P. A. Janne, L. Liu, C. M. Brownstein, M. Reck Brd. 17 Apricot-l: Results of a biomarker-based phase II randomized placebocontrolled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. (Abstract #7528) B. J. Gitlitz, E. D. Bernstein, G. P. Keogh, E. S. Santos, G. A. Otterson, G. Milne, M. Syto, S. L. Zaknoen Brd. 18 Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small-cell lung cancer (NSCLC). (Abstract #7529) W. Yu, A. Pandita, E. Penuel, R. Raja, J. Zha, S. Mohan, R. D. Patel, R. Desai, L. Fu, A. Do, J. Mango, V. Parab, M. Lipkind, J. Huang, M. Lazarov, V. Ramakrishnan, L. C. Amler, A. C. Peterson, P. H. Patel, R. L. Yauch Brd. 19 Use of negative thyroid transcription factor (TTF-1) status to predict for negative epidermal growth factor receptor (EGFR) mutations (Mts) status with a high negative predictive value (NPV) in patients (pts) with adenocarcinomas (AC) of the lung. (Abstract #7530) N. Somaiah, E. Garrett-Mayer, X. Huang, A. E. Wahlquist, K. Danenberg, G. R. Simon Brd. 20 Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. (Abstract #7531) S. Yano, T. Yamada, S. Takeuchi, K. Tachibana, Y. Minami, M. Noguchi, F. R. Hirsch Brd. 21 An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type. (Abstract #7532) F. Wang, J. Wang, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang, M. Wu, Y. Wang, S. Wang, X. Liu Brd. 22 Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (Abstract #7533) D. Soulieres, J. Wolf, F. A. Shepherd, F. Cappuzzo, P. A. Bunn, R. S. Herbst, F. R. Hirsch, K. M. Kerr, T. Mitsudomi, M. S. Tsao, C. Yang, F. C. Richardson, B. Klughammer, B. Wacker, D. Sternberg, A. M. Davies Brd. 23 Comparison of high sensitive IHC, FISH, and RT-PCR direct sequencing for detection of ALK translocation in lung cancer. (Abstract #7534) T. Mitsudomi, K. Tomizawa, Y. Horio, T. Hida, Y. Yatabe Brd. 24 Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC). (Abstract #7535) B. H. Grønberg, M. Lund-Iversen, E. H. Strøm, O. Brustugun, H. Scott, Norwegian Lung Cancer Study Group Brd. 25 Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. (Abstract #7536) M. Joerger, S. A. Burgers, P. Baas, E. F. Smit, T. J. Haitjema, M. P. Bard, V. D. Doodeman, P. H. Smits, A. Vincent, A. Huitema, J. H. Beijnen, J. H. Schellens 407 MONDAY Monday, June 6, 2011 Monday, June 6, 2011 3:00 PM - 4:15 PM SPECIAL SESSION Why Isn’t Cancer Research More Successful? Location: E354b CME credit: 1.25 Track(s): Special Session Laurence H. Baker, DO—Chair University of Michigan You Reap What You Sow: Research Goals (Incremental versus Large Gains) and Practical Barriers Lee M. Ellis, MD University of Texas M. D. Anderson Cancer Center Challenges in Translating Success from the Lab to the Clinic: A Perspective on Our Current Infrastructure and Suggestions on Ways to Improve It Andrea Denicoff, RN, MSN, ANP National Cancer Institute Science of Patient Participation: Ethics, Decision-making Process, and Informed Consent MONDAY 408 Monday, June 6, 2011 3:00 PM - 4:15 PM EDUCATION SESSIONS From Minimalist Therapy to Bilateral Mastectomy: Controversies in Locoregional Management of Breast Cancer Location: Hall B1 CME credit: 1.25 Track(s): Breast Cancer Armando E. Giuliano, MD—Chair John Wayne Cancer Institute Overview and Evolution of Axillary Management: What to Do With Isolated Tumor Cells and When Do You Need to Dissect the Axilla? Julia R. White, MD Radiation Therapy Oncology Group and Medical College of Wisconsin What Are the Clinical Data Regarding Partial Breast and Other Novel Radiation Techniques and Schedules? Monica Morrow, MD Memorial Sloan-Kettering Cancer Center The Bilateral Mastectomy Epidemic Managing Electronic Education (eQuestions Session) Location: E353 CME credit: 1.25 Track(s): Professional Development, Practice Management and Information Technology Michael Fisch, MD, MPH—Chair University of Texas M. D. Anderson Cancer Center Mobile Applications for Professional and Patient Education Peter Ravdin, MD, PhD University of Texas M. D. Anderson Cancer Center Using ASCO and Non-ASCO Web-based Resources MONDAY David L. Graham, MD Carle Clinic Associates Professional and Social Networking Resources for Oncologists: Using Electronic Media to Improve Cancer Care Recent Advances in Non-small Cell Lung Cancer: Best of 2010 Basic and Clinical Research in Lung Cancer Location: Hall D2 CME credit: 1.25 Track(s): Lung Cancer, General Oncology Lawrence H. Einhorn, MD—Chair Indiana University Simon Cancer Center Best of 2010: In the Context of My Own Four Decades of Experience Pasi A. Janne, MD, PhD Dana-Farber Cancer Institute Best of 2010: Basic Research in Lung Cancer Gregory Peter Kalemkerian, MD University of Michigan Comprehensive Cancer Center Best of 2010: Lung Cancer Clinical Research 409 Monday, June 6, 2011 Update on Quality Improvement Initiatives in Oncology Location: S504 CME credit: 1.25 Track(s): Health Services Research, Practice Management and Information Technology Michael N. Neuss, MD—Chair Oncology/Hematology Care, Inc. Quality Oncology Practice Initiative (QOPI) and QOPI Certification Andrew Stewart, MA Commission on Cancer, American College of Surgeons American College of Surgeons Electronic Quality Improvement Packets (e-QuIP) Steven M. Asch, MD, MPH VA Greater Los Angeles Healthcare System The VA’s Cancer Quality Improvement Toolkits MONDAY 410 Monday, June 6, 2011 3:00 PM - 4:15 PM MEET THE PROFESSOR SESSION Update on the Treatment of Adolescents and Young Adults with Acute Lymphocytic Leukemia (M17)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and Transplantation MONDAY Stephen Hunger, MD University of Colorado Denver Health Science Center 411 Monday, June 6, 2011 3:00 PM - 6:00 PM ORAL ABSTRACT SESSION Cancer Prevention/Epidemiology Location: S100bc CME credit: 3 Track(s): Cancer Prevention/Epidemiology Michaela Jane Higgins, MD—Co-Chair Massachusetts General Hospital Dean E. Brenner, MD—Co-Chair University of Michigan Medical Center 3:00 PM Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2 Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR). (Abstract #1500) K. Phillips, R. L. Milne, M. A. Rookus, D. Goldgar, M. Friedlander, S. McLachlan, S. S. Buys, A. C. Antoniou, K. E. Birch, M. Terry, D. Easton, P. Weideman, M. B. Daly, N. Andrieu, E. M. John, M. Hooning, I. L. Andrulis, T. Caldes, H. Olsson, J. L. Hopper 3:15 PM Is hormone replacement therapy (HRT) following risk-reducing salpingooophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? (Abstract #1501) S. M. Domchek, T. Friebel, S. L. Neuhausen, H. T. Lynch, C. F. Singer, R. A. Eeles, C. Isaacs, N. M. Tung, P. A. Ganz, F. J. Couch, J. N. Weitzel, O. I. Olopade, W. S. Rubinstein, G. E. Tomlinson, G. C. Pichert, M. B. Daly, E. T. Matloff, D. G. Evans, J. E. Garber, T. R. Rebbeck, PROSE Consortium 3:30 PM Past use of hormone therapy and breast cancer risk. (Abstract #1502) W. Y. Chen, B. A. Rosner, S. E. Hankinson, Nurses’ Health Study Research Group Discussion 3:45 PM Lynn C. Hartmann, MD (Abstracts #1500 –1502) Mayo Clinic MONDAY 4:00 PM Metformin and breast cancer incidence in postmenopausal diabetic women in the Women’s Health Initiative (WHI). (Abstract #1503) R. T. Chlebowski, A. McTiernan, A. K. Aragaki, T. Rohan, J. Wactawski-Wende, E. Ipp, D. Euhus, V. G. Kaklamani, M. Vitolins, R. B. Wallace, S. Liu, M. J. Gunter, L. Phillips, H. Strickler, B. Howard 4:15 PM Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial. (Abstract #1504) L. Bordeleau, G. Dagenais, N. Yakubovich, S. Yusuf, J. Probstfield, M. Riddle, L. Ryden, L. Xu, J. Bosch, H. Gerstein 4:30 PM Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). (Abstract #1505) S. R. Land, N. Christian, D. L. Wickerham, J. P. Costantino, P. A. Ganz Discussion 4:45 PM Pamela Jean Goodwin, MD (Abstracts #1503–1505) Mount Sinai Hospital 5:00 PM DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. (Abstract #1506) P. Saintigny, J. Jelinek, C. R. Pickering, W. Lang, M. J. Frederick, L. Zhang, H. Ren, V. Papadimitrakopoulou, J. Lee, E. S. Kim, Y. H. Fan, A. K. El-Naggar, W. K. Hong, J. Myers, J. J. Issa, S. M. Lippman, L. Mao 5:15 PM Final results of a chemoprevention trial with enzastaurin in former smokers. (Abstract #1507) J. E. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen, D. Tai, G. Bepler 412 Monday, June 6, 2011 5:30 PM Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice. (Abstract #1508) H. A. Katki, W. K. Kinney, B. Fetterman, T. Lorey, N. E. Poitras, L. Cheung, F. Demuth, M. Schiffman, S. Wacholder, P. E. Castle MONDAY Discussion 5:45 PM Eva Szabo, MD (Abstracts #1506 –1507) National Cancer Institute 413 Monday, June 6, 2011 3:00 PM - 6:00 PM ORAL ABSTRACT SESSION Head and Neck Cancer Location: S406 CME credit: 3 Track(s): Head and Neck Cancer Ezra E. W. Cohen, MD—Co-Chair The University of Chicago David N. Hayes, MD, MPH—Co-Chair University of North Carolina at Chapel Hill 3:00 PM A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). (Abstract #5500) K. Ang, Q. Zhang, D. I. Rosenthal, P. Nguyen-Tan, E. J. Sherman, R. S. Weber, J. M. Galvin, D. L. Schwartz, A. K. El-Naggar, M. L. Gillison, R. Jordan, M. A. List, A. A. Konski, W. L. Thorstad, A. Trotti, J. J. Beitler, A. S. Garden, W. J. Spanos, S. Yom, R. S. Axelrod 3:15 PM Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. (Abstract #5501) J. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, C. Sire, D. De Raucourt, E. Bardet, C. Tuchais, P. Garaud, G. Calais Discussion 3:30 PM Ezra E. W. Cohen, MD (Abstracts #5500 –5501) The University of Chicago MONDAY 3:45 PM A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. (Abstract #5502) J. A. Sosa, R. Elisei, B. Jarzab, C. S. Bal, H. Koussis, A. W. Gramza, R. Ben-Yosef, B. J. Gitlitz, B. Haugen, S. M. Karandikar, F. R. Khuri, L. F. Licitra, S. C. Remick, S. Marur, C. Lu, F. G. Ondrey, S. Lu, J. Balkissoon 4:00 PM A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). (Abstract #5503) S. I. Sherman, B. Jarzab, M. E. Cabanillas, L. F. Licitra, F. Pacini, R. Martins, B. Robinson, D. Ball, J. McCaffrey, M. H. Shah, D. Bodenner, R. Allison, K. Newbold, R. Elisei, J. P. O’Brien, M. Schlumberger Discussion 4:15 PM Marcia S. Brose, MD, PhD (Abstracts #5502–5503) University of Pennsylvania 4:30 PM Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC). (Abstract #5504) J. N. Waldron, R. W. Gilbert, L. Eapen, A. Hammond, D. I. Hodson, A. Hendler, B. Perez-Ordonez, C. Gu, J. A. Julian, D. H. Julian, M. N. Levine Discussion 4:45 PM Randal S. Weber, MD (Abstract #5504) University of Texas M. D. Anderson Cancer Center 5:00 PM 414 Prediction of clinical outcome in patients with primary laryngeal carcinoma using gene expression profiling. (Abstract #5505) E. Fountzilas, N. Angouridakis, I. Karasmanis, R. M. Wirtz, A. G. Eleftheraki, E. Veltrup, K. Markou, A. Nikolaou, P. Konstantinopoulos, V. Kotoula, D. Spentzos, G. Fountzilas Monday, June 6, 2011 5:15 PM Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial. (Abstract #5506) A. M. Lim, D. Rischin, H. Cao, R. Fisher, G. A. McArthur, L. J. Peters, R. J. Young, Q. Le MONDAY Discussion 5:30 PM David N. Hayes, MD, MPH (Abstracts #5505–5506) University of North Carolina at Chapel Hill 415 Monday, June 6, 2011 3:00 PM - 6:00 PM ORAL ABSTRACT SESSION Sarcoma Location: E354a CME credit: 3 Track(s): Sarcoma Andrew J. Wagner, MD, PhD—Co-Chair Dana-Farber Cancer Institute Bruce Brockstein, MD—Co-Chair NorthShore University Health System 3:00 PM Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. (Abstract #10000) G. K. Schwartz, R. G. Maki, M. J. Ratain, S. D. Undevia, R. L. Jones, C. M. Rudin, L. L. Siu, B. Brockstein, D. Khayat, T. Gil, M. J. De Jonge, M. B. Sawyer, T. Evans, J. Medioni, P. J. O’Dwyer, C. Hartman, V. Poulart, I. B. Walters 3:15 PM An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). (Abstract #10001) S. Kummar, A. Strassberger, A. Monks, S. P. Ivy, I. B. Turkbey, P. L. Choyke, S. M. Steinberg, R. Simon, J. H. Doroshow, L. J. Helman, Developmental Therapeutics Clinical Group, National Cancer Institute 3:30 PM PALETTE: A randomized, double-blind, phase III trial of pazopanib versus (vs) placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG global network study (EORTC 62072). (Abstract #LBA10002) W. T. A. Van Der Graaf, J. Y. Blay, S. P. Chawla, D. W. Kim, B. Bui Nguyen, P. G. Casali, P. Schöffski, M. Aglietta, A. P. Staddon, Y. Beppu, A. Le Cesne, H. Gelderblom, I. R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge, M. Dewji, A. P. Dei Tos, and P. Hohenberger Discussion 3:45 PM Shreyaskumar Patel, MD (Abstracts #10000 –LBA10002) University of Texas M. D. Anderson Cancer Center MONDAY 4:00 PM Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma. (Abstract #10003) S. Schuetze, L. Zhao, R. Chugh, M. Zalupski, D. Thomas, D. R. Lucas, L. H. Baker 4:15 PM Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors. (Abstract #10004) P. Schoffski, D. Adkins, J. Blay, T. Gil, A. D. Elias, P. Rutkowski, G. K. Pennock, H. Youssoufian, N. J. Zojwalla, R. Willey, D. O. Grebennik 4:30 PM Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (Abstract #10005) S. P. Chawla, J. Blay, I. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, N. Penel, R. F. Riedel, B. Bui Nguyen, L. D. Cranmer, P. Reichardt, E. Bompas, Y. Song, R. Lee, J. E. Eid, J. Loewy, F. G. Haluska, P. F. Dodion, G. D. Demetri Discussion 4:45 PM Scott H. Okuno, MD (Abstracts #10003–10005) Mayo Clinic 5:00 PM 416 A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). (Abstract #10006) J. C. Trent, K. Wathen, M. von Mehren, B. L. Samuels, A. P. Staddon, E. Choy, J. E. Butrynski, R. Chugh, W. A. Chow, D. A. Rushing, C. A. Forscher, L. H. Baker, S. Schuetze, Sarcoma Alliance for Research through Collaboration Monday, June 6, 2011 5:15 PM A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). (Abstract #10007) S. George, M. von Mehren, M. C. Heinrich, Q. Wang, C. L. Corless, J. E. Butrynski, J. A. Morgan, A. J. Wagner, E. Choy, W. D. Tap, J. Manola, J. T. Yap, A. D. Van Den Abbeele, S. Solomon, J. A. Fletcher, G. D. Demetri 5:30 PM Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study. (Abstract #10007b) I. Ray-Coquard, J. Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, A. Beryozkina, F. Heil, R. Rueger, G. L. Nichols, and B. Bui Nguyen MONDAY Discussion 5:45 PM Jaap Verweij, MD, PhD (Abstracts #10006 –1007b) Erasmus University Medical Center 417 Monday, June 6, 2011 3:00 PM - 6:00 PM ORAL ABSTRACT SESSION Tumor Biology Location: S100a CME credit: 3 Track(s): Tumor Biology Robert Arthur Kratzke, MD—Co-Chair University of Minnesota Kapil N. Bhalla, MD—Co-Chair University of Kansas Cancer Center 3:00 PM Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. (Abstract #10500) E. Vakiani, M. Janakiraman, R. Shen, Z. Zeng, A. Cercek, N. E. Kemeny, A. Heguy, P. Paty, T. A. Chan, L. Saltz, M. R. Weiser, D. B. Solit 3:15 PM Exomic sequencing of pancreatic neuroendocrine tumors: Detection of alterations in chromatin remodeling and mTOR pathway genes. (Abstract #10501) L. A. Diaz, Y. Jiao, C. Shi, B. H. Edil, R. de Wilde, D. S. Klimstra, A. Maitra, L. H. Tang, A. L. Blackford, V. Velculescu, B. Vogelstein, K. W. Kinzler, R. H. Hruban, N. Papadopoulos 3:30 PM Tumor genomic profiling of FFPE samples by massively parallel sequencing. (Abstract #10502) N. Wagle, M. F. Berger, M. J. Davis, B. Blumenstiel, M. DeFelice, W. C. Hahn, M. Meyerson, S. B. Gabriel, L. E. MacConaill, L. A. Garraway Discussion 3:45 PM A. John Iafrate, MD, PhD (Abstracts #10500 –10502) Massachusetts General Hospital MONDAY 4:00 PM Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2ⴙ breast cancer in NCCTG N9831 trial. (Abstract #10503) M. M. Reinholz, A. C. Dueck, B. Chen, X. Geiger, A. E. McCullough, R. B. Jenkins, W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, G. W. Sledge Jr., L. Harris, J. Gralow, E. A. Perez 4:15 PM Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2ⴙ breast cancer in NCCTG adjuvant trial N9831. (Abstract #10504) E. A. Perez, A. C. Dueck, M. M. Reinholz, B. Chen, X. Geiger, R. B. Jenkins, W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, G. W. Sledge Jr., L. Harris, J. Gralow, A. E. McCullough 4:30 PM Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer. (Abstract #10505) S. C. Linn, E. H. Lips, P. M. Nederlof, L. F. Wessels, J. Wesseling, M. van de Vijver, E. De Vries, H. van Tinteren, J. Jonkers, M. Hauptmann, S. Rodenhuis, M. A. Vollebergh Discussion 4:45 PM Ana M. Gonzalez-Angulo, MD, MSc (Abstracts #10503–10505) University of Texas M. D. Anderson Cancer Center 5:00 PM 418 Detection of circulating miRNAs in serum from patients with breast cancer and their association with the presence of metastatic disease. (Abstract #10506) E. van Schooneveld, M. Wouters, I. Van der Auwera, D. Peeters, P. Huget, P. A. van Dam, P. B. Vermeulen, S. J. Van Laere, L. Y. Dirix, Translational Cancer Research Group Antwerp, GZA Hospitals Sint-Augustinus Monday, June 6, 2011 5:15 PM Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. (Abstract #10507) F. Janku, I. Garrido-Laguna, J. J. Wheler, D. S. Hong, A. Naing, G. S. Falchook, S. Fu, S. L. Moulder, R. Luthra, J. Lee, A. M. Tsimberidou, R. Kurzrock 5:30 PM Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. (Abstract #10508) A. B. Nixon, H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. Hurwitz MONDAY Discussion 5:45 PM David Paul Carbone, MD, PhD (Abstracts #10506 –10508) Vanderbilt-Ingram Cancer Center 419 Monday, June 6, 2011 4:45 PM - 6:00 PM EDUCATION SESSIONS Developing and Implementing More Informative Phase II Oncology Clinical Trials Location: Arie Crown Theater CME credit: 1.25 Track(s): Clinical Trials, Genitourinary Cancer, Lung Cancer David B. Solit, MD—Chair Memorial Sloan-Kettering Cancer Center How Do We Improve Phase II Trial Designs to Better Ensure Success in Phase III? Catherine M. Tangen, PhD Fred Hutchinson Cancer Research Center The Randomized Phase II Trial: Is it Useful in Predicting Results of Phase III Studies? Primo Lara, MD University of California, Davis Pitfalls in the Use of Progression-free Survival in Patients with Lung and Prostate Cancer Implementing an Electronic Health Record (EHR) in Different Practice Settings: Strategies for Success (eQuestions Session) Location: E353 CME credit: 1.25 Track(s): Practice Management and Information Technology, Professional Development William M. Jordan, DO—Chair The Center for Cancer and Blood Disorders EHR Implementation: Community Practice Perspective Nancy T. Sklarin, MD Memorial Sloan-Kettering Cancer Center EHR Implementation: Academic Practice Perspective Carolyn P. Hartley, MD Physician’s EHR The Practice EHR Implementation Team MONDAY To Transplant or Not to Transplant? Current Controversies in Transplantation for Pediatric Acute Leukemias Location: S504 CME credit: 1.25 Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and Transplantation Michael Pulsipher, MD—Chair University of Utah Chemotherapy versus Transplant for Pediatric Acute Lymphoblastic Leukemia Richard Aplenc, MD The Children’s Hospital of Philadelphia Chemotherapy versus Transplant for Pediatric Acute Myeloblastic Leukemia Saro Armenian, DO, MPH City of Hope Long-term Outcome of Children with Leukemia after Treatment with Stem Cell Transplant 420 Monday, June 6, 2011 Treating Genitourinary Malignancies (Prostate, Kidney, and Urothelial Cancers): The Latest and Greatest Location: Hall B1 CME credit: 1.25 Track(s): Genitourinary Cancer, Clinical Trials, General Oncology Gary R. MacVicar, MD—Chair Northwestern University Feinberg School of Medicine Advances in Prostate Cancer Therapeutics Christopher Sweeney, MBBS Dana-Farber Cancer Institute What’s New in Urothelial Cancer MONDAY Elisabeth I. Heath, MD Karmanos Cancer Institute Renal Cell Cancer Update 421 Monday, June 6, 2011 4:45 PM - 6:00 PM MEET THE PROFESSOR SESSION Finding the Best Job for You/Contract Negotiation (M18)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Professional Development, Practice Management and Information Technology Douglas W. Blayney, MD Stanford University MONDAY 422 Tuesday, June 7, 2011 7:30 AM - 9:00 AM HIGHLIGHTS OF THE DAY SESSION Highlights of the Day III Location: Hall D1 CME credit: 1.5 Track(s): Special Session, General Oncology Ronald Levy, MD—Chair Stanford University School of Medicine 7:30 AM Stephen K. L. Chia, MD British Columbia Cancer Agency Breast Cancer—Triple-negative/Cytotoxics/Local Therapy and Cancer Prevention/Epidemiology 7:50 AM A. Oliver Sartor, MD Tulane University School of Medicine Genitourinary (Prostate and Nonprostate) Cancer 8:10 AM Vassiliki Papadimitrakopoulou, MD University of Texas M. D. Anderson Cancer Center Head and Neck Cancer 8:25 AM Thomas J. Smith, MD Massey Cancer Center of Virginia Commonwealth University Patient and Survivor Care TUESDAY 8:40 AM Jean-Yves Blay, MD, PhD Centre Léon Bérard Sarcoma 423 Tuesday, June 7, 2011 8:00 AM - 9:15 AM EDUCATION SESSIONS How the Human Genome Project Will Help Us in the Clinic Location: S100a CME credit: 1.25 Track(s): Tumor Biology, Cancer Genetics, Developmental Therapeutics Todd Golub, MD—Chair Dana-Farber Cancer Institute Genomic Mutations Mediating Sensitivity and Resistance to Targeted Therapies Jordi Barretina, PhD Broad Institute of MIT and Harvard Exploiting Genomic Mutations and Pathway Analysis for the Rationale Development of Effective Therapeutics Joe W. Gray, PhD Oregon Health and Science University The Future of Genomics in Directing Personalized Cancer Therapy Targeting Angiogenesis in Breast Cancer: Where Do We Stand in 2011? Location: E354a CME credit: 1.25 Track(s): Breast Cancer, Tumor Biology Maura N. Dickler, MD—Chair Memorial Sloan-Kettering Cancer Center Antiangiogenic Therapy in Breast Cancer: The Current Status and Controversy Robert S. Kerbel, PhD Sunnybrook Research Institute Angiogenesis as a Target Daniel J. Sargent, PhD Mayo Clinic Appropriate Endpoints for Clinical Trials and Source of U.S. Food and Drug Administration/Oncologic Drugs Advisory Committee Controversy TUESDAY 424 Tuesday, June 7, 2011 8:00 AM - 9:15 AM MEET THE PROFESSOR SESSION Orthopedic Oncology for the Rest of Us (M19)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Sarcoma R. Lor Randall, MD Huntsman Cancer Institute, University of Utah TUESDAY Kristy Weber, MD The Johns Hopkins University School of Medicine 425 Tuesday, June 7, 2011 8:00 AM - 9:30 AM CLINICAL SCIENCE SYMPOSIUM Immune Correlates of Clinical Outcomes Location: E354b CME credit: 1.5 Track(s): Developmental Therapeutics Thomas Gajewski, MD, PhD—Chair The University of Chicago 8:00 AM Pharmacodynamic and predictive markers of ipilimumab on melanoma patients’ T cells. (Abstract #2503) J. S. Weber, B. Yu, M. Hall, D. Morelli, D. Yu, Y. Zhang, X. Zhao, A. Sarnaik, W. Wang Discussion 8:15 AM Thomas Gajewski, MD, PhD (Abstract #2503) The University of Chicago 8:30 AM Phase II cancer vaccination trial with multiple peptides derived from novel oncoantigens against advanced esophageal cancer. (Abstract #2504) K. Kono, H. Iinuma, Y. Akutsu, H. Tanaka, N. Hayashi, Y. Uchikado, T. Noguchi, H. Fujii, R. Fukushima, H. Matsubara, K. Hirakawa, H. Baba, S. Natsugoe, S. Kitano, K. Yoshida, T. Tsunoda, Y. Nakamura Discussion 8:45 AM Mary L. Disis, MD (Abstract #2504) University of Washington 9:00 AM Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. (Abstract #2505) M. K. Callahan, A. Yang, S. Tandon, Y. Xu, S. K. Subudhi, R. Roman, A. I. Heine, E. Pogoriler, D. Kuk, K. Panageas, J. D. Yuan, J. P. Allison, J. D. Wolchok Discussion 9:15 AM To be determined TUESDAY 426 Tuesday, June 7, 2011 8:00 AM - 11:00 AM ORAL ABSTRACT SESSION Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell Location: Arie Crown Theater CME credit: 3 Track(s): Lung Cancer Tom Stinchcombe, MD—Co-Chair University of North Carolina at Chapel Hill Wilfried Ernst Erich Eberhardt, MD—Co-Chair University Hospital–University Duisburg-Essen 8:00 AM Randomized phase III trial of amrubicin versus topotecan (Topo) as secondline treatment for small cell lung cancer (SCLC). (Abstract #7000) R. Jotte, J. Von Pawel, D. R. Spigel, M. A. Socinski, M. O’Brien, E. H. Paschold, J. Mezger, M. Steins, L. Bosquée, J. A. Bubis, K. Nackaerts, J. Trigo Perez, P. R. Clingan, W. Schuette, P. Lorigan, M. Reck, M. Domine, F. A. Shepherd, R. McNally, M. F. Renschler 8:15 AM A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). (Abstract #7001) C. J. Langer, I. Albert, P. Kovacs, L. Blakely, G. Pajkos, P. Petrov, A. Somfay, A. Szczesna, P. Zatloukal, A. Kazarnowicz, M. M. Moezi, M. T. Schreeder, J. Schnyder, M. S. Berger Discussion 8:30 AM Bonnie S. Glisson, MD (Abstracts #7000 –7001) University of Texas M. D. Anderson Cancer Center 8:45 AM Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT. (Abstract #7002) M. Kreuter, J. F. Vansteenkiste, J. R. Fischer, W. E. Eberhardt, H. Zabeck, J. Kollmeier, M. H. Serke, N. Frickhofen, M. Reck, W. Engel-Riedel, S. Neumann, M. Thomeer, C. Schumann, P. Deleyn, T. Graeter, G. Stamatis, I. Zuna, F. Griesinger, M. Thomas Discussion 9:00 AM Heather A. Wakelee, MD (Abstracts #7002) Stanford University School of Medicine 9:15 AM Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. (Abstract #7003) D. Harpole, K. V. Ballman, A. L. Oberg, G. Whiteley, R. Cerfolio, R. Keenan, D. R. Jones, T. A. D’Amico, J. Shrager, J. B. Putnam, American College of Surgeons Oncology Group 9:45 AM Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (Abstract #7004) S. Michiels, A. Mauguen, D. Fisher, S. Burdett, R. Paulus, S. J. Mandrekar, C. P. Belani, F. A. Shepherd, T. Eisen, H. Pang, L. Collette, C. Le Pechoux, J. Pignon, Surrogate Lung Project Collaborative Group 10:00 AM Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. (Abstract #7005) S. J. Mandrekar, Y. Qi, K. Allen-Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, D. R. Gandara, A. A. Adjei 427 TUESDAY Discussion 9:30 AM To be determined Tuesday, June 7, 2011 Discussion 10:15 AM Suzanne Eleanor Dahlberg, PhD (Abstracts #7004 –7005) Dana-Farber Cancer Institute 10:30 AM A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. (Abstract #7006) P. Baas, W. Buikhuisen, O. Dalesio, A. Vincent, N. Pavlakis, R. Van Klaveren, F. Schramel, F. Custers, H. Schouwink, S. A. Burgers Discussion 10:45 AM Rolf A. Stahel, MD (Abstract #7006) University Hospital Zurich TUESDAY 428 Tuesday, June 7, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Breast Cancer—HER2/ER Display Time: 8:00 AM - 12:00 PM Display Location: E450a Discussion Time: 11:30 AM - 12:30 PM Discussion Location: Arie Crown Theater CME credit: 1 Track(s): Breast Cancer Herve R. Bonnefoi, MD—Co-Chair Institut Bergonie Cancer Center Anne F. Schott, MD—Co-Chair University of Michigan Discussion 11:30 AM Jennifer J. Griggs, MD, MPH (Abstracts #512–520) University of Michigan Discussion 11:45 AM Charles L. Loprinzi, MD (Abstracts #521–526) Mayo Clinic Discussion 12:00 PM Herve R. Bonnefoi, MD (Abstracts #527–532) Institut Bergonie Cancer Center Brd. 1 Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. (Abstract #512) R. Segal, G. R. Pond, M. Vallis, M. Dion, K. I. Pritchard, J. A. Ligibel, M. N. Levine, P. J. Goodwin Brd. 2 Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. (Abstract #513) R. Yerushalmi, B. Dong, J. W. Chapman, P. E. Goss, M. N. Pollak, M. J. Burnell, V. H. Bramwell, M. N. Levine, K. I. Pritchard, T. J. Whelan, J. N. Ingle, W. Parulekar, L. E. Shepherd, K. A. Gelmon Brd. 3 Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. (Abstract #514) G. Pfeiler, R. Königsberg, B. Mlineritsch, H. Stoger, C. F. Singer, S. Poestlberger, G. G. Steger, M. Seifert, P. C. Dubsky, R. Jakesz, H. Samonigg, V. Bjelic-Radisic, R. Greil, C. Marth, C. Fesl, M. Gnant Brd. 4 Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment. (Abstract #515) G. Lunardi, L. Del Mastro, C. Bighin, G. Bisagni, P. Driol, O. Garrone, S. Giraudi, P. Marroni, P. Piccioli, R. Ponzone, M. Porpiglia, M. Venturini, Gruppo Italiano Mammella (GIM) Brd. 5 Bone mineral density (BMD) in participants (pts) of trial BIG 1–98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence. (Abstract #516) A. De Censi, Z. Sun, B. J. Thurlimann, C. McIntosh, A. Guerrieri-Gonzaga, A. Monnier, C. Tondini, M. Campone, L. Mauriac, K. Zaman, A. Schoenberger, K. N. Price, R. D. Gelber, A. Goldhirsch, A. S. Coates, S. P. Aebi, BIG 1–98 Collaborative and International Breast Cancer Study Groups 429 TUESDAY Discussion 12:15 PM Anne F. Schott, MD (Abstracts #533–536) University of Michigan Tuesday, June 7, 2011 TUESDAY Brd. 6 Bone effects of adjuvant tamoxifen (T), letrozole (L), or L ⴙ zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study. (Abstract #517) F. Perrone, C. Gallo, S. Lastoria, F. Nuzzo, A. Gravina, G. Landi, E. Rossi, C. Pacilio, V. Labonia, F. Di Rella, M. De Laurentiis, M. Piccirillo, M. Di Maio, P. Giordano, G. Daniele, G. De Feo, R. Fiore, S. Signoriello, G. Esposito, A. de Matteis Brd. 7 Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study. (Abstract #518) D. L. Hershman, A. M. Cheung, J. W. Chapman, J. N. Ingle, F. Ahmed, H. Hu, J. Scher, S. Leeson, C. Elliott, A. Le Maitre, L. E. Shepherd, P. E. Goss Brd. 8 A population-based assessment of the risk of fragility fracture associated with the use of adjuvant hormone therapy for early breast cancer in older women. (Abstract #519) K. Enright, M. E. Trudeau, N. Taback, M. K. Krzyzanowska Brd. 9 Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. (Abstract #520) M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, P. C. Dubsky, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil Brd. 10 Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays. (Abstract #521) A. Guerrero-Zotano, J. Gavila, E. Folkerd, B. Ortiz, T. Labrador, F. Martinez, A. Garcia, M. Climent, V. Guillem, M. Dowsett, A. Ruiz Brd. 11 Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1–98 trial. (Abstract #522) J. B. Huober, B. F. Cole, J. Wu, A. Giobbie-Hurder, M. Rabaglio, H. T. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, I. Lang, I. E. Smith, A. M. Wardley, K. N. Price, A. Goldhirsch, A. S. Coates, B. J. Thurlimann, BIG 1–98 Collaborative and International Breast Cancer Study Groups Brd. 12 Increased progression-free and overall survival in patients with breast cancer with menopausal symptoms or arthralgia/myalgia during adjuvant treatment with exemestane or tamoxifen: Results of the German TEAM trial. (Abstract #523) D. G. Kieback, P. Hadji, T. Menschik, A. Hasenburg, J. Tams, M. Ziller Brd. 13 Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy. (Abstract #524) R. A. Shelby, F. J. Keefe, S. N. Red, K. L. Blackwell, J. M. Peppercorn, P. K. Marcom, G. G. Kimmick Brd. 14 Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. (Abstract #525) V. Stearns, J. W. Chapman, C. X. Ma, M. J. Ellis, J. N. Ingle, K. I. Pritchard, G. T. Budd, M. Rabaglio, G. W. Sledge Jr., A. Le Maitre, J. Kundapur, L. E. Shepherd, P. E. Goss Brd. 15 24-month follow-up from the Patient’s Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer. (Abstract #526) H. Lück, P. Hadji, N. Harbeck, C. Jackisch, M. Blettner, M. Glados, J. Terhaag, R. Hackenberg, T. Goehler, S. Zaun, A. Rexrodt von Fircks, R. Kreienberg Brd. 16 TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2ⴙ metastatic breast cancer (MBC). (Abstract #527) N. U. Lin, I. A. Mayer, J. S. Najita, T. J. Hobday, C. I. Falkson, E. C. Dees, M. F. Rimawi, R. Nanda, R. S. Gelman, K. Josephs, A. Richardson, L. Flores, A. D. Van Den Abbeele, J. T. Yap, C. L. Arteaga, A. C. Wolff, I. E. Krop, E. P. Winer, Translational Breast Cancer Research Consortium 430 Tuesday, June 7, 2011 The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. (Abstract #528) I. E. Krop, L. Flores, J. S. Najita, I. A. Mayer, T. J. Hobday, C. I. Falkson, C. L. Arteaga, A. C. Wolff, E. C. Dees, M. F. Rimawi, R. Nanda, K. Josephs, N. U. Lin, E. P. Winer, Translational Breast Cancer Research Consortium Brd. 18 Response to neoadjuvant trastuzumab and chemotherapy in ERⴙ and ERHER2-positive breast cancers: Gene expression analysis. (Abstract #529) G. Bianchini, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. J. Vazquez Mazon, J. Baselga, L. Gianni Brd. 19 Validation of p95 as predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. (Abstract #530) S. Loibl, J. Bruey, G. Von Minckwitz, J. B. Huober, M. F. Press, S. Darb-Esfahani, C. Solbach, C. Denkert, H. Tesch, F. Holms, T. N. Fehm, K. Mehta, M. Untch Brd. 20 Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEVERLY2 study. (Abstract #531) P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. H. Roche, M. Pavlyuk, T. D. Bachelot, E. Charafe-Jauffret Brd. 21 Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. (Abstract #532) S. Bayraktar, A. M. Gonzalez-Angulo, X. Lei, A. Buzdar, V. Valero, A. Melhem, H. M. Kuerer, G. N. Hortobagyi, A. A. Sahin, F. Meric-Bernstam Brd. 22 Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III). (Abstract #533) M. S. Rosati, M. Di Seri, G. Baciarello, V. LO Russo, P. Grassi, L. Marchetti, S. Giovannoni, M. Basile, L. Frati Brd. 23 Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. (Abstract #534) A. M. Thompson, T. Iwamoto, L. Jordan, C. Purdie, S. E. Bray, L. Baker, G. Hardie, L. Pusztai, S. L. Moulder, J. A. Dewar, S. M. Hadad Brd. 24 Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma. (Abstract #535) D. Fumagalli, O. Metzger, I. Veys, A. Catteau, S. Michiels, H. Sandy, R. Salgado, S. K. Singhal, K. V. Saini, C. Galant, N. Galland, F. Bertucci, H. P. Peyro Saint Paul, M. J. Piccart-Gebhart, C. Sotiriou, D. Larsimont Brd. 25 A randomized controlled trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with breast carcinoma of high estrogen receptor content: Long-term results at 20 years of follow-up. (Abstract #536) S. J. Johnston, F. S. Kenny, B. M. Syed, J. F. Robertson, S. Pinder, L. Winterbottom, I. O. Ellis, R. W. Blamey, K. Cheung TUESDAY Brd. 17 431 Tuesday, June 7, 2011 8:00 AM - 12:30 PM POSTER DISCUSSION SESSION Genitourinary (Nonprostate) Cancer Display Time: 8:00 AM - 12:00 PM Display Location: E450b Discussion Time: 11:30 AM - 12:30 PM Discussion Location: E354a CME credit: 1 Track(s): Genitourinary Cancer Emmanuel S. Antonarakis, MD—Co-Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Scott E. Eggener, MD—Co-Chair The University of Chicago Discussion 11:30 AM Walter Michael Stadler, MD (Abstracts #4546 – 4552) The University of Chicago Discussion 11:45 AM Thomas Powles, MD (Abstracts #4553– 4560) St. Bartholomew’s Hospital Discussion 12:00 PM Christian K. Kollmannsberger, MD (Abstracts #4561– 4565) British Columbia Cancer Agency Discussion 12:15 PM Matt D. Galsky, MD (Abstracts #4566 – 4570) Tisch Cancer Institute, Mount Sinai Medical Center TUESDAY Brd. 1 BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-␣2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4546) B. Melichar, S. Bracarda, V. Matveev, I. Rusakov, A. Kaprin, A. Zyryanov, R. Janciauskiene, E. Fernebro, G. H. Mickisch, M. E. Gore, A. Schulze, S. Jethwa, V. Sneller, P. Mulders, J. Bellmunt, on behalf of the BEVLiN Investigators Brd. 2 Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. (Abstract #4547) R. J. Motzer, T. de La Motte Rouge, A. L. Harzstark, D. Michaelson, G. Liu, V. Gruenwald, A. Ingrosso, M. A. Tortorici, P. W. Bycott, S. Kim, B. I. Rini Brd. 3 Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. (Abstract #4548) J. R. Merchan, H. C. Pitot, R. Qin, G. Liu, T. R. Fitch, W. J. Maples, J. Picus, C. Erlichman Brd. 4 Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). (Abstract #4549) F. F. Kabbinavar, S. Srinivas, R. J. Hauke, R. J. Amato, W. B. Esteves, M. M. Cotreau, A. L. Strahs, P. Bhargava, M. N. Fishman Brd. 5 Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). (Abstract #4550) D. Nosov, P. Bhargava, W. B. Esteves, A. L. Strahs, O. N. Lipatov, O. O. Lyulko, A. O. Anischenko, R. T. Chacko, D. Doval, W. J. Slichenmyer Brd. 6 A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). (Abstract #4551) E. Angevin, V. Grünwald, A. Ravaud, D. E. Castellano, C. Lin, J. E. Gschwend, A. L. Harzstark, J. Chang, Y. Wang, M. M. Shi, B. J. Escudier 432 Brd. 7 A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: Results of a preplanned interim analysis of a prospective study. (Abstract #4552) L. Bergmann, U. Kube, M. Kindler, T. Koepke, G. Steiner, J. Janssen, S. Fries, P. Goebell, A. Jakob, T. Steiner, M. D. Staehler, F. Overkamp, M. Albrecht, C. Doehn Brd. 8 Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC). (Abstract #4553) Y. Liu, H. T. Tran, Y. Lin, A. Martin, A. J. Zurita, C. N. Sternberg, R. G. Amado, L. N. Pandite, J. Heymach, VEG105192 Team Brd. 9 Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials. (Abstract #4554) S. Patil, J. Manola, P. Elson, W. Bro, S. Negrier, B. Escudier, R. M. Bukowski, R. J. Motzer Brd. 10 The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). (Abstract #4555) M. Y. Al-Marrawi, B. I. Rini, L. C. Harshman, G. A. Bjarnason, L. Wood, U. N. Vaishampayan, M. J. MacKenzie, J. J. Knox, N. Agarwal, C. K. Kollmannsberger, M. Tan, S. Y. Rha, F. Donskov, S. A. North, T. K. Choueiri, D. Y. Heng, International mRCC Database Consortium Brd. 11 Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling. (Abstract #4556) V. J. Thodima, A. M. Molina, X. Jia, J. Zhang, M. E. Georges, S. Patil, V. E. Reuter, R. J. Motzer, R. S. Chaganti Brd. 12 Host-mediated changes in patients receiving antiangiogenic therapy for resected RCC. (Abstract #4557) R. S. Bhatt, J. Manola, A. J. Bullock, L. Zhang, N. B. Haas, M. Pins, M. B. Atkins, R. S. DiPaola Brd. 13 Association of germ-line SNPs with overall survival (OS) in pazopanibtreated patients (Pts) with advanced renal cell carcinoma (RCC). (Abstract #4558) C. Xu, N. Bing, H. A. Ball, C. N. Sternberg, I. D. Davis, Z. Xue, L. McCann, K. King, J. C. Whittaker, C. F. Spraggs, V. E. Mooser, L. N. Pandite Brd. 14 Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group. (Abstract #4559) J. Garcia-Donas, E. Esteban, L. J. Leandro-Garcı́a, D. E. Castellano, A. Gonzalez del Alba, M. Climent, J. A. Arranz, E. Gallardo, J. Puente, J. Bellmunt, B. Mellado, E. Martı́nez, F. Moreno, A. Font, M. Robledo, C. Rodriguez de Antona, Spanish Oncology GenitoUrinary Group (SOGUG) Brd. 15 External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy. (Abstract #4560) D. Y. Heng, W. Xie, L. C. Harshman, G. A. Bjarnason, U. N. Vaishampayan, J. Lebert, L. Wood, F. Donskov, M. Tan, S. Y. Rha, C. Wells, Y. Wang, C. K. Kollmannsberger, B. I. Rini, T. K. Choueiri, International mRCC Database Consortium Brd. 16 Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial. (Abstract #4561) P. S. Grimison, D. B. Thomson, M. R. Stockler, M. D. Chatfield, M. Friedlander, V. Gebski, A. L. Boland, B. B. Houghton, H. Gurney, M. Rosenthal, N. Singhal, G. Kichenadasse, S. S. Wong, C. R. Lewis, P. A. Vasey, G. C. Toner, Australian and New Zealand Urogenital and Prostate Cancer Trials Group 433 TUESDAY Tuesday, June 7, 2011 Tuesday, June 7, 2011 Brd. 17 Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants. (Abstract #4562) B. P. Mulherin, M. J. Brames, L. H. Einhorn Brd. 18 Reproduction rates prior to diagnosis of testicular cancer: Does the testicular dysgenesis syndrome exist? (Abstract #4563) M. Cvancarova, J. Oldenburg, M. Sprauten, H. Stensheim, S. D. Fossa Brd. 19 Association of single-nucleotide polymorphism (SNP) in the 5-alpha-reductase gene (SRD5A2) with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer (TC) survivors. (Abstract #4564) H. Boer, C. Meijer, J. D. Dijck-Brouwer, I. P. Kema, J. D. Lefrandt, N. Zwart, H. M. Boezen, A. J. Smit, J. A. Gietema Brd. 20 Evaluation of low-dose CT scans for surveillance in stage I testicular cancer. (Abstract #4565) P. W. Chung, M. O’Malley, M. A. Jewett, T. Panzarella, D. Hogg, M. J. Moore, P. Bedard, L. Anson-Cartwright, B. Tew-George, M. A. Haider, M. K. Gospodarowicz, P. R. Warde Brd. 21 Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC). (Abstract #4566) A. V. Balar, M. I. Milowsky, A. B. Apolo, I. Ostrovnaya, A. Iasonos, A. Trout, A. M. Regazzi, I. R. Garcia-Grossman, D. J. Gallagher, D. F. Bajorin Brd. 22 Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). (Abstract #4567) W. M. Stadler, D. J. Vaughn, G. Sonpavde, N. J. Vogelzang, S. T. Tagawa, D. P. Petrylak, P. J. Rosen, C. Lin, J. F. Mahoney, S. S. Modi, P. Lee, M. S. Ernstoff, W. Su, A. I. Spira, M. Ould Kaci, J. M. Watrous, T. Taube, R. Vinisko, C. Schloss, C. Zhao, M. A. Carducci Brd. 23 Identification of ALK gene alterations in urothelial carcinoma (UC). (Abstract #4568) J. Bellmunt, S. Selvarajah, S. Rodig, M. Salido, I. Costa, B. Bellosillo, L. Werner, C. Namgyal, F. A. Schutz, F. Pons, R. O’Brien, J. Barretina, S. Signoretti, M. Loda, J. Albanell, T. K. Choueiri, D. M. Berman, P. W. Kantoff, J. E. Rosenberg Brd. 24 Identification of a novel urothelial carcinoma (UC) biomarker of lethality. (Abstract #4569) J. E. Rosenberg, L. Werner, S. Selvarajah, B. Weir, M. M. Regan, S. J. Jacobus, D. M. Berman, F. A. Schutz, R. O’Brien, T. K. Choueiri, J. Barretina, S. Signoretti, M. Loda, E. A. Guancial, E. Gallardo, F. G. Rojo, J. Lloreta, W. C. Hahn, P. W. Kantoff, J. Bellmunt Brd. 25 Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. (Abstract #4570) K. M. Krajewski, R. Fougeray, T. K. Choueiri, F. Pons, F. A. Schutz, J. E. Rosenberg, Y. Salhi, J. Bellmunt TUESDAY 434 Tuesday, June 7, 2011 9:30 AM - 12:30 PM ORAL ABSTRACT SESSION Gastrointestinal (Noncolorectal) Cancer Location: Hall D1 CME credit: 3 Track(s): Gastrointestinal (Noncolorectal) Cancer Jennifer J. Knox, MD—Co-Chair Princess Margaret Hospital Andrea Wang-Gillam, MD, PhD—Co-Chair Washington University School of Medicine 9:30 AM Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). (Abstract #4000) A. Cheng, Y. Kang, D. Lin, J. Park, M. Kudo, S. Qin, M. Omata, S. W. Pitman Lowenthal, S. Lanzalone, L. Yang, M. Lechuga, E. Raymond, SUN1170 HCC Study Group 9:45 AM Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. (Abstract #4001) J. A. Marrero, R. Lencioni, M. Kudo, S. Ye, K. Nakajima, F. Cihon, A. P. Venook Discussion 10:00 AM Bert H. O’Neil, MD (Abstracts #4000 – 4001) University of North Carolina at Chapel Hill 10:15 AM Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial. (Abstract #LBA4002) Y. J. Bang, Y. W. Kim, H. K. Yang, H. C. Chung, Y. K. Park, K. W. Lee, K. H. Lee, Y. H. Kim, S. I. Noh, J. Ji, M. Johnston, F. Sirzen, and S. H. Noh 10:30 AM Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. (Abstract #4003) C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. Hollis, H. J. Mamon, R. Swanson, D. G. Haller, T. Dragovich, S. R. Alberts, G. A. Bjarnason, C. G. Willett, P. C. Enzinger, R. M. Goldberg, A. P. Venook, R. J. Mayer 10:45 AM A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). (Abstract #4004) S. Park, D. Lim, K. Park, S. Lee, S. Oh, H. Kwon, J. Kang, I. Hwang, J. Lee, J. Park, Y. Park, H. Lim, W. Kang 11:15 AM Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RTⴙ5FU-mitomycin versus RTⴙ5FU-cisplatin. (Abstract #4005) L. L. Gunderson, K. A. Winter, J. A. Ajani, J. E. Pedersen, A. B. Benson, C. R. Thomas Jr., R. J. Mayer, M. G. Haddock, T. A. Rich, C. G. Willett Discussion 11:30 AM Theodore S. Hong, MD (Abstract #4005) Massachusetts General Hospital 435 TUESDAY Discussion 11:00 AM Florian Lordick, MD (Abstracts #LBA4002– 4004) Klinikum Rechts der Isar, Technische Universitaet Muenchen Tuesday, June 7, 2011 11:45 AM Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. (Abstract #LBA4006) J. P. Neoptolemos, M. J. Moore, T. F. Cox, J. W. Valle, D. H. Palmer, A. Mcdonald, R. Carter, N. C. Tebbutt, C. Dervenis, D. Smith, B. Glimelius, F. Y. Coxon, F. Lacaine, M. R. Middleton, P. Ghaneh, C. Bassi, C. Halloran, A. Olah, C. L. Rawcliffe, and M. W. Büchler 12:00 PM Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (Abstract #4007) T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba, K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi, T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. Okusaka Discussion 12:15 PM Dan Laheru, MD (Abstracts #LBA4006 – 4007) The Johns Hopkins University School of Medicine TUESDAY 436 Tuesday, June 7, 2011 9:45 AM - 11:00 AM EDUCATION SESSIONS Biomarkers for Vascular Endothelial Growth Factor (VEGF)-targeted Agents Location: S100a CME credit: 1.25 Track(s): Tumor Biology Michael L. Maitland, MD, PhD—Chair The University of Chicago Hypertension Is a Biomarker for Vascular Endothelial Growth Factor (VEGF)-targeted Therapies Herbert Hurwitz, MD Duke University Medical Center Hypertension Is Not a Biomarker for VEGF-targeted Therapies Bryan P. Schneider, MD Indiana University School of Medicine Single-nucleotide Polymorphisms (SNPs) as Potential Predictive Biomarkers for VEGF-targeted Agents Emile E. Voest, MD, PhD University Medical Center Utrecht Novel Approaches to Identify Predictive Biomarkers for VEGF-targeted Therapies Effective Time Management for the Busy Oncologist Location: E353 CME credit: 1.25 Track(s): Professional Development, General Oncology, Practice Management and Information Technology Timothy Jerome Moynihan, MD—Chair Mayo Clinic What Is Effective Time Management? Martha P. Mims, MD, PhD Baylor College of Medicine Developing a Healthy Balance of Work and Home-life Duties David H. Johnson, MD University of Texas Southwestern Medical Center How to Protect “Protected Time”: Prioritizing Competing Responsibilities The Changing Face of Castration-resistant Prostate Cancer: Standard Therapy and New Targets Location: E354a CME credit: 1.25 Track(s): Genitourinary Cancer, Geriatric Oncology TUESDAY Kim N. Chi, MD—Chair British Columbia Cancer Agency Emerging Investigational Therapies in Castration-resistant Prostate Cancer Charles G. Drake, MD, PhD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Immunotherapy in Castration-resistant Prostate Cancer Thomas W. Flaig, MD University of Colorado Denver New Standards in the Medical Management of Castration-resistant Prostate Cancer 437 Tuesday, June 7, 2011 9:45 AM - 11:00 AM MEET THE PROFESSOR SESSION Non-melanoma Skin Cancer: Surgical Management of Aggressive Cases and Molecular Targeted Therapies (M24)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Head and Neck Cancer, Melanoma/Skin Cancers Randal S. Weber, MD University of Texas M. D. Anderson Cancer Center Surgical Management of Aggressive Squamous Cell Carcinoma of the Skin David G. Pfister, MD Memorial Sloan-Kettering Cancer Center Role of Molecularly Targeted Therapy in the Management of Non-melanoma Skin Cancer TUESDAY 438 Tuesday, June 7, 2011 9:45 AM - 11:15 AM CLINICAL SCIENCE SYMPOSIUM Emerging Issues in Comparative Effectiveness Research Location: S100bc CME credit: 1.5 Track(s): Health Services Research Sharon Hermes Giordano, MD, MPH—Chair University of Texas M. D. Anderson Cancer Center 9:45 AM Development of a guideline for including patient-reported outcomes in post-approval clinical trials of oncology drugs for comparative effectiveness research. (Abstract #6000) E. M. Basch, A. P. Abernethy, C. D. Mullins, M. R. Tiglao, S. R. Tunis 10:15 AM The relationship between cost, quality, and outcomes among women with breast cancer in SEER–Medicare. (Abstract #6001) M. J. Hassett, B. A. Neville, J. C. Weeks Discussion 10:30 AM Steven J. Katz, MD, MPH (Abstract #6001) University of Michigan Medical School 10:45 AM Utilization and costs of nonevidence-based antineoplastic agents in patients with metastatic colon cancer. (Abstract #6002) J. A. de Souza, B. N. Polite, S. Zhu, J. J. Dignam, N. J. Meropol, M. J. Ratain, L. N. Newcomer, G. C. Alexander TUESDAY Discussion 11:00 AM Marcelo Blaya, MD (Abstract #6002) Tulane University Health Sciences Center 439 Tuesday, June 7, 2011 11:30 AM - 12:45 PM EDUCATION SESSIONS Cancer Stem Cells as a Therapeutic Target: Fact or Fiction? Location: S100a CME credit: 1.25 Track(s): Tumor Biology, Developmental Therapeutics Max Wicha, MD—Chair University of Michigan Cancer Center Targeted Cancer Stem Cells: Is This Really the Answer? Michael Kahn, PhD University of Southern California Targeting Wnt-B-catenin Signaling in Cancer Stem Cells Joan Seoane, PhD Vall d’Hebron University Hospital, Institut d’Oncologia Targeting Signaling Pathways That Mediate Cancer Stem Cell Survival The Importance of Histology and Molecular Testing (EGFR and EML4-ALK) in the Initial Evaluation of Advanced Non-small Cell Lung Cancer Location: E354b CME credit: 1.25 Track(s): Lung Cancer Renato Martins, MD, MPH—Chair Seattle Cancer Care Alliance Epidermal Growth Factor Receptor Testing: Who, What, When, and How? David N. Hayes, MD, MPH University of North Carolina at Chapel Hill The Role of Histology in Managing Non-small Cell Lung Cancer Alice Tsang Shaw, MD, PhD Massachusetts General Hospital Cancer Center EML4-ALK Testing: Who, What, When, and How? TUESDAY 440 Tuesday, June 7, 2011 11:30 AM - 12:45 PM MEET THE PROFESSOR SESSION How to Develop a Successful Career in Health Services Research (M25)—Ticketed Session Location: E451a CME credit: 1.25 Track(s): Health Services Research, Professional Development TUESDAY Jane C. Weeks, MD, MSc Dana-Farber Cancer Institute 441
![Genistein [446-72-0] - Università degli Studi di Roma "Tor Vergata"](http://s1.studyres.com/store/data/001069358_1-826841ed5b5b39775155b3058987503a-150x150.png)
